
<html lang="en"     class="pb-page"  data-request-id="2f6f3637-67a3-4e98-88ee-d086455f836e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-5;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01180;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions" /></meta><meta name="dc.Creator" content="Minru  Liao" /></meta><meta name="dc.Creator" content="Jin  Zhang" /></meta><meta name="dc.Creator" content="Guan  Wang" /></meta><meta name="dc.Creator" content="Leiming  Wang" /></meta><meta name="dc.Creator" content="Jie  Liu" /></meta><meta name="dc.Creator" content="Liang  Ouyang" /></meta><meta name="dc.Creator" content="Bo  Liu" /></meta><meta name="dc.Description" content="Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but an effective targeted therapy has not been well-established so far. Considering the lack of effective targe..." /></meta><meta name="Description" content="Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but an effective targeted therapy has not been well-established so far. Considering the lack of effective targe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 2, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01180" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01180" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01180" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01180" /></link>
        
    
    

<title>Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01180" /></meta><meta property="og:title" content="Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0023.jpeg" /></meta><meta property="og:description" content="Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but an effective targeted therapy has not been well-established so far. Considering the lack of effective targets, where do we go next in the current TNBC drug development? A promising intervention for TNBC might lie in de novo small-molecule drugs that precisely target different molecular characteristics of TNBC. However, an ideal single-target drug discovery still faces a huge challenge. Alternatively, other new emerging strategies, such as dual-target drug, drug repurposing, and combination strategies, may provide new insight into the improvement of TNBC therapeutics. In this review, we focus on summarizing the current situation of a series of candidate small-molecule drugs in TNBC therapy, including single-target drugs, dual-target drugs, as well as drug repurposing and combination strategies that will together shed new light on the future directions targeting TNBC vulnerabilities with small-molecule drugs for future therapeutic purposes." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01180"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01180">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01180&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01180&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01180&amp;href=/doi/10.1021/acs.jmedchem.0c01180" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2382-2418</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01786" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01487" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Minru Liao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minru Liao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minru++Liao">Minru Liao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jin Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jin Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jin++Zhang">Jin Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guan Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guan++Wang">Guan Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leiming Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leiming Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518107, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leiming++Wang">Leiming Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jie Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Liu">Jie Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liang Ouyang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Ouyang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#c3acb6baa2ada4afaaa2ada483b0a0b6eda6a7b6eda0ad"><span class="__cf_email__" data-cfemail="a8c7ddd1c9c6cfc4c1c9c6cfe8dbcbdd86cdccdd86cbc6">[email protected]</span></a>. Phone/Fax: (+86)28-85164063.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Ouyang">Liang Ouyang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5537-8834" title="Orcid link">http://orcid.org/0000-0001-5537-8834</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Bo Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#95f9fce0f7faa7a1a5a5d5a4a3a6bbf6faf8"><span class="__cf_email__" data-cfemail="4b27223e2924797f7b7b0b7a7d7865282426">[email protected]</span></a>. Phone/Fax: (+86)28-85164063.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Liu">Bo Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3900-9486" title="Orcid link">http://orcid.org/0000-0003-3900-9486</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01180&amp;href=/doi/10.1021%2Facs.jmedchem.0c01180" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2382–2418</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 2, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 July 2020</li><li><span class="item_label"><b>Published</b> online</span>2 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01180</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2382%26pageCount%3D37%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMinru%2BLiao%252C%2BJin%2BZhang%252C%2BGuan%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D5%26contentID%3Dacs.jmedchem.0c01180%26title%3DSmall-Molecule%2BDrug%2BDiscovery%2Bin%2BTriple%2BNegative%2BBreast%2BCancer%253A%2BCurrent%2BSituation%2Band%2BFuture%2BDirections%26numPages%3D37%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2418%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01180"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2600</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01180" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Minru&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Jin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Guan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Leiming&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Ouyang&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2382-2418&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01180&quot;},&quot;abstract&quot;:&quot;Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but an effective targeted therapy has not been well-established so far. Considering the lack of effective targets, where do we go next in the current TNBC drug development? A promising intervention for TNBC might lie in de novo small-molecule drugs that precisely target different molecular characteristics of TNBC. However, an ideal single-target drug discovery still faces a huge challenge. Alternatively, other new emerging strategies, such as dual-target drug, drug repurposing, and combination strategies, may provide new insight into the improvement of TNBC therapeutics. In this review, we focus on summarizing the current situation of a series of candidate small-molecule drugs in TNBC therapy, including single-target drugs, dual-target drugs, as well as drug repurposing and combination strategies that will together shed new light on the future directions targeting TNBC vulnerabilities with small-molecule drugs for future the&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01180&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01180" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01180&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01180" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01180&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01180" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01180&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01180&amp;href=/doi/10.1021/acs.jmedchem.0c01180" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01180" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01180" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01180%26sid%3Dliteratum%253Aachs%26pmid%3D33650861%26genre%3Darticle%26aulast%3DLiao%26date%3D2021%26atitle%3DSmall-Molecule%2BDrug%2BDiscovery%2Bin%2BTriple%2BNegative%2BBreast%2BCancer%253A%2BCurrent%2BSituation%2Band%2BFuture%2BDirections%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D5%26spage%3D2382%26epage%3D2418%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/jmcmar.2021.64.issue-5/20210311/jmcmar.2021.64.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0023.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but an effective targeted therapy has not been well-established so far. Considering the lack of effective targets, where do we go next in the current TNBC drug development? A promising intervention for TNBC might lie in <i>de novo</i> small-molecule drugs that precisely target different molecular characteristics of TNBC. However, an ideal single-target drug discovery still faces a huge challenge. Alternatively, other new emerging strategies, such as dual-target drug, drug repurposing, and combination strategies, may provide new insight into the improvement of TNBC therapeutics. In this review, we focus on summarizing the current situation of a series of candidate small-molecule drugs in TNBC therapy, including single-target drugs, dual-target drugs, as well as drug repurposing and combination strategies that will together shed new light on the future directions targeting TNBC vulnerabilities with small-molecule drugs for future therapeutic purposes.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23514" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23514" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer (BC) is one of the three most familiar cancers in the world and in women. About 3.8 million women in the United States have a history of BC, including 268,600 new cases in 2019.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Based upon histopathological characteristics, breast cancer can be divided into five important clinical types by using molecular biology tools and gene expression profile.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In addition to gene expression patterns, unique clinical features can also describe these subtypes. Tumor classifications based upon ER: estrogen receptor, PR: progesterone receptor, or HER-2: human epidermal growth factor receptor-2 status are necessary for the evaluation and management of BC treatment.</div><div class="NLM_p">Triple negative breast cancer (TNBC), featured by the absence of ER, PR, and HER-2 expressions, is a specific type of BC with the poorest prognosis, which accounts for 15% of all breast cancers and 25% of all BC-related deaths.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> TNBC is well-known to have different clinical and biological characteristics from other subtypes. The expressions of ER, PR, and HER-2 are absent, the response to endocrine therapy and anti-HER-2 targeted therapy is poor, and there are limited therapeutic options compared with other subtypes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Owing to its high metastatic potential and intractability to endocrine therapy or chemotherapy, it still constitutes a huge clinical challenge.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Hitherto, some candidate small-molecule drugs, such as single-target drugs and repurposing drugs, have been emerging as a promising TNBC therapy. Especially for TNBC patients who are resistant to traditional therapies, by co-targeting different signaling pathways, other dual-target drugs and drug combinations have also made an important contribution to the treatment of TNBC.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p last">Thus, in this review, we summarize the molecular characteristics of TNBC subtypes and focus on highlighting some valuable advances on a series of targeted drug development strategies, such as single-target drugs, drug repurposing, dual-target drugs, drug combination strategies, and immunomodulators that would provide a new clue on developing more prospective targeted small-molecule drugs for future TNBC therapeutics.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  TNBC Subtypes and Molecular Characteristics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">According to its molecular heterogeneity, the classifications of TNBC need to be further understood. Based upon the genetic changes in the spectrum of different subsets of TNBC, individualized treatment, rather than general progress-specific treatment, has become an emerging therapeutic strategy in TNBC.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> A patient-centered treatment algorithm should follow the initial immunohistochemical characteristics of TNBC, so as to obtain a better objective response rate (ORR) for treatment.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> To achieve more accurate classifications of TNBC, from the cluster analysis of gene expression (GE) profiles, seven TNBC subtypes can be identified: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal-stem-like (MSL), luminal androgen receptor (LAR), and unclassified (UNS).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">As the tumors of patients with TNBC have a high genetic diversity, ranging from highly proliferative tumors to chemotherapy resistant tumors with low proliferation and lumen characteristics, the accurate classifications may contribute to potential biomarker identification and candidate drug discovery, so that the patients will receive a personalized targeted therapy, which depends on their different subtypes.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Here, we mainly focused on the characteristics of BL1, BL2, IM, M, MSL, and LAR subtypes of TNBC (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. TNBC subtypes, characteristics, and potential targeted drugs. Based on the gene-expression signatures and biological functions, TNBCs are classified as basal-like 1 TNBC (BL1), basal-like 2 TNBC (BL2), immunomodulatory TNBC (IM), mesenchymal-like TNBC (M), mesenchymal-stem-like TNBC (MSL), the luminal androgen receptor TNBC (LAR), and others. BL1 TNBCs are sensitive to PARP inhibitors; BL2 TNBCs are sensitive to MET and EGFR inhibitors; M TNBCs and MSL TNBCs are sensitive to PI3K/AKT inhibitors; IM TNBCs are sensitive to immunotherapy; LAR TNBCs are sensitive to AR antagonists and CDK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Subtypes and Brief Characteristics of TNBC</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">subtype</th><th class="colsep0 rowsep0" align="center" char=".">%</th><th class="colsep0 rowsep0" align="center">gene expression characteristics</th><th class="colsep0 rowsep0" align="center">small-molecule drug targeting therapy</th><th class="colsep0 rowsep0" align="center">compounds</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">basal-like 1 (BL1)</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="left">upregulation: cell cycle, DNA damage repair, PPAR1 gene, KRAS, NRAS, BRAF</td><td class="colsep0 rowsep0" align="left">PARP inhibitors, CDK inhibitors, MEK 1/2 inhibitors</td><td class="colsep0 rowsep0" align="left">Olaparib, Abemaciclib, E6201</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">downregulation: INPP4B</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">mutations: TP53, high copy number losses for TP53, BRCA1/2 and RB1 genes, high copy number gains for PPAR1 gene</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">clinical biomarker: Bcl-3, CTSS, BRCA</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">sensitive to chemotherapy</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">basal-like 2 (BL2)</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">upregulation: growth factor receptors (EGFR/MET/EPHA2/NGF), stem cell renewal, cell survival</td><td class="colsep0 rowsep0" align="left">EGFR inhibitors</td><td class="colsep0 rowsep0" align="left">Varlitinib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">downregulation: INPP4B, cell motility</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">immunomodulatory (IM)</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left">upregulation: immune cell signaling (CTLA4/PD1/PDL1/IL12/APC/NK/Th1/2/TNF)</td><td class="colsep0 rowsep0" align="left">immune checkpoint inhibitors, CSF-1R inhibitors</td><td class="colsep0 rowsep0" align="left">Atezolizumab, PLX3397</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">clinical biomarker: PD-L1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mesenchymal-like (M)</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left">upregulation: proliferation associated genes (CDK), EGFR, Notch 1/3/4, MET, IGF, mTOR, ECM, Rho, stem cell renewal, angiogenesis</td><td class="colsep0 rowsep0" align="left">CDK inhibitors, anti-angiogenic therapy</td><td class="colsep0 rowsep0" align="left">PHA-767491, Bevacizumab</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">downregulation: immune signaling, cell cycle, DNA damage repair</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mesenchymal-stem-like (MSL)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="left">upregulation: low-claudin, growth factor signaling (EGFR, TGF-β), Wnt/β-catenin, MET, STAT3, GPCR, mTOR, cell survival, cell motility, angiogenesis (PDGFR, VEGFR)</td><td class="colsep0 rowsep0" align="left">EGFR inhibitors, MET inhibitors, anti-angiogenic therapy</td><td class="colsep0 rowsep0" align="left">Salidroside, Protopheophorbide A, SKLB646</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">downregulation: proliferation associated genes</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">mutations: PIK3CA</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">luminal AR (LAR)</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">upregulation: androgen receptor, endocrine signaling, CK18, cell survival</td><td class="colsep0 rowsep0" align="left">AR inhibitors, HDAC inhibitors, PI3K/AKT inhibitors, CDK4/6 inhibitors</td><td class="colsep0 rowsep0" align="left">Enzalutamide, Bicalutamide, Entinostat, BAY80-6946</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">downregulation: estrogen receptor, cell motility, stem cell renewal</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">mutations: PIK3CA, AKT1, CDH1, KMT2C, NF1, PTEN and PIK3R1, ERBB2, CDKN2A</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unclassified (UNS)</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">mutations: ATR, BRCA2, CDKN2A, PTEN, FGFR 1, PDGFRB, TP53, CDKN2A, PI3KCA</td><td class="colsep0 rowsep0" align="left">PRL-3 inhibitors</td><td class="colsep0 rowsep0" align="left">AMPI-109</td></tr></tbody></table></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.1.  Basal-Like 1 (BL1) and Basal-Like 2 (BL2)</h3><div class="NLM_p last">The BL1 TNBC subtype is characterized by high level expression of cell-cycle-related genes, increased expression of deoxyribonucleic acid (DNA) damage response (DDR) genes, and the most sensitivity to chemotherapy.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> According to an open gene data set of 300 patients with TNBC receiving neoadjuvant chemotherapy, the BL1 subtype shows the largest pathological complete response (pCR) compared with the BL2 and LAR subtypes.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Moreover, Bcl-3 gene expression and high Cathepsin S (CTSS) expression is relative to the prognosis of patients with the BL1 subtype.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Bcl-3 gene knockout in BL1MDA-MB-468 cells induces G1/S phase arrest by increasing p27 expression and decreasing the protein and messenger ribonucleic acid (mRNA) expression of Skp2 and c-myc.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In addition, Bcl-3 can enhance the sensibility of TNBC cells to chemotherapeutic drugs.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.2.  Immunomodulatory TNBC (IM)</h3><div class="NLM_p last">The IM subtype has an abundant gene ontology (GO) in the process of immune cells.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The immune signaling gene in the IM subtype overlaps with that in medullary breast cancer, which is a rarely seen and distinctive type of TNBC in histology. Although it has a high histological grade, the prognosis is good.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Despite the relatively favorable outcome of the IM subtype, 6% of patients in this group recurred and metastasized within 5 years after operation. This subtype is featured by elevated immune cell signaling observed in the gene expression data, both clinical and omics features have confirmed that immune recognition is activated in the IM subtype, and, thus, the mechanisms by which these tumors achieve immune escape likely involves the recruitment of immune suppressive cells or the activation of immune checkpoint molecules, thereby providing a potential reason for using an immune checkpoint blockade as a therapeutic strategy.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.3.  Mesenchymal-Like TNBC (M) and Mesenchymal-Stem-Like TNBC (MSL)</h3><div class="NLM_p last">The MSL subtype and M subtype have similar biological processes, consisting of cell differentiation, motility, and growth pathway.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In the M subtype, a variety of changes occur in unique genes, which play a role in extracellular matrix (ECM) receptor interaction. The M subtype is mainly characterized by epithelial–mesenchymal transformation (EMT) and cancer stem cells (CSCs). Notch receptor 4 (NOTCH4) is implicated in TNBC progression and breast cancer stem cell (BCSC) control. Also, the NOTCH4-Snail family transcriptional repressor 2 (SNAI2/SLUG)-growth arrest-specific protein 1 (GAS1) pathway is a promising target for tumor therapy by surmounting stemness of mesenchymal-like breast cancer stem cells (ML-BCSCs) and by overcoming the metastasis and chemoresistance of TNBC.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The phosphatidylinositol-3-kinase (PI3K)/AKT (protein kinase B, PKB)/mammalian target of the rapamycin (mTOR) pathway is often disrupted, which increases the probability of targeting the axis.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Histone deacetylase inhibitors can sensitize at any rate part of the MSL subtype to aminoflavone (AF) by resuming aryl hydrocarbon receptor (AhR) reactivity to AF and activating ERα expression.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> It indicates that the combination of AF and histone deacetylase inhibitors has a certain antitumor effect on mesenchymal-like TNBC.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.4.  Luminal Androgen Receptor TNBC (LAR)</h3><div class="NLM_p">The LAR subtype is a positive subtype of androgen receptor expression in TNBC. Among the TNBC subtypes, the gene expression changes in the LAR group are the largest.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Expression of AR can be found in most TNBC and is related to a good survival rate. Breast tumors without AR expression led to a briefer disease-free interval (DFI) and more pessimistic overall survival (OS) than tumors with positive AR expression.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Thus, AR is a prognostic marker, which should be employed in conjunction with an evaluation procedure of ER, PR, and HER2 status to confirm the invasiveness of tumors, especially in African American (AA) women.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">In addition, patients with the LAR subtype had the lowest pCR response in all carboplatin containing regimens and were the group with the lowest proliferation rate (ki-675, 0% vs 27%, <i>P</i> = 0.002).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The LAR cell line exhibits unique sensitivity to bicalutamide, an AR antagonist. The second-generation AR inhibitors can inhibit the binding of androgen to the receptor by competitive inhibition and inhibit AR nuclear transport and the interaction between the AR and DNA, thereby exerting an antitumor effect. More recently, AR-positive patients in the early phase of TNBC have been reported to be cured with AR inhibitor supplementation, and it can be found to be safe and tolerable. In the late stages of AR-positive TNBC, a phase 2 clinical trial of AR inhibitors revealed a 33% clinical benefit rate (CBR, defined as confirmed complete response (CR), partial response, or stable disease).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">3.  Current Status of Candidate Small-Molecule Drugs in TNBC</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Small-molecule targeted therapy refers to the design of a corresponding therapeutic drug at a molecular level for a well-defined carcinogenic target, enabling binding to a target to cause tumor-cell-specific death. Small-molecule drugs have the advantages of a wide range of uses and mature theoretical foundations. The U.S. Food and Drug Administration (FDA) ratified 59 new drugs in total; 64% of these were small-molecule drugs in 2018.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> According to the statistics, small-molecule drugs account for 98% of the total drugs in common use and antitumor drugs account for 50%.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Unlike traditional cytotoxic drugs, most of the small-molecule targeted drugs are targeted at membrane receptors, components of the cell signaling pathway, cell cycle regulatory proteins, and some key proteins or factors involved in angiogenesis; these are relatively specific, less toxic to normal cells, result in lower resistance, have higher selectivity, and require a relatively lower dosage. As a part of the developments in TNBC, the targeted treatment of TNBC has gradually been emerging as a hot spot in TNBC therapy; therefore, many targeted drugs have entered the clinical trial stage (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Among them, we summarized 5 epidermal growth factor receptor (EGFR) inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>),<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25">(21−25)</a> 4 extracellular signal regulated kinase/extracellular signal regulated kinase (MEK/ERK) inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>),<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26−28)</a> 4 PI3K/AKT/mTOR inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>),<a onclick="showRef(event, 'ref3 ref29'); return false;" href="javascript:void(0);" class="ref ref3 ref29">(3,29)</a> 6 poly(ADP-ribose) polymerase (PARP) inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>),<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> 14 Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>),<a onclick="showRef(event, 'ref22 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref22 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44">(22,33−44)</a> 3 SRC inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>),<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45−47)</a> 2 Unc-51-like autophagy activating kinase 1 (ULK1) inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>),<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> 5 eukaryotic elongation factor 2 kinase (eEF2K) inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>),<a onclick="showRef(event, 'ref50 ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52 ref53 ref54">(50−54)</a> 3 bromodomain 4 (BRD4) inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>),<a onclick="showRef(event, 'ref55 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57">(55−57)</a> and another 40 kinase inhibitors that are currently used in clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>).<a onclick="showRef(event, 'ref58 ref59 ref60 ref61 ref62 ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86 ref87 ref88 ref89 ref90 ref91 ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60 ref61 ref62 ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86 ref87 ref88 ref89 ref90 ref91 ref92 ref93">(58−93)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Potential targeted small-molecule drugs and relevant signaling pathways in TNBC therapies. TNBCs are often characterized by excessive activation of growth factor pathways, such as EGFR, c-MET and VEGFR regulated PI3K-AKT-mTOR, Ras-Raf-MEK-ERK, SRC-STAT pathways and JAK-STATS signaling. These pathways play an important role in the proliferation and progression of TNBCs. In addition, PARP is overactivated and involved in DNA repair in response to environmental stress. Overexpression of CDKs and BRD4 also contributes to the progression of TNBC. Moreover, mTOR-related overexpression of eEF2K inhibits the extension of the polypeptide chain during protein synthesis to help the cell adapt to the adverse conditions of nutrition or energy deficiency. Of note, autophagy is also inhibited in TNBC. Thus, the corresponding small-molecule compounds are applied in targeted therapies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Chemical Structures of the EGFR Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Varlitinib</td><td class="colsep0 rowsep0" align="left">EGFR, HER1 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-468 (IC<sub>50</sub> = 0–10 μM), HCC1937 (IC<sub>50</sub> = 20 μM), HCC70 (IC<sub>50</sub> = 10–20 μM), Hs578T (IC<sub>50</sub> = 10–20 μM), MDA-MB-453 (IC<sub>50</sub> = 0–10 μM)</td><td class="colsep0 rowsep0" align="left">BL1, BL2, MSL, LAR</td><td class="colsep0 rowsep0" align="left">NCT02338245 (phase 2), NCT02396108 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Salidroside</td><td class="colsep0 rowsep0" align="left">EGFR, JAK2, STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 40 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">Cannabidiol (CBD)</td><td class="colsep0 rowsep0" align="left">EGFR inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 6 μM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">Cyclo (<span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-prolyl) peptide (CLP)</td><td class="colsep0 rowsep0" align="left">EGFR inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 73.4 μM), MDA-MB-468 (IC<sub>50</sub> = 67.42 μM)</td><td class="colsep0 rowsep0" align="left">MSL, BL1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">Vandetanib</td><td class="colsep0 rowsep0" align="left">EGFR, VEGFR2 inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 40 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Chemical Structures of the MEK/ERK Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">E6201</td><td class="colsep0 rowsep0" align="left">MEK1 inhibitor</td><td class="colsep0 rowsep0" align="left">BT20 (IC<sub>50</sub> = 10.14 μM), HCC70 (IC<sub>50</sub> = 8.79 μM), HCC1806 (IC<sub>50</sub> = 2.50 μM), HCC1937 (IC<sub>50</sub> = 3.73 μM), MDA-MB-231 (IC<sub>50</sub> = 0.25 μM), SUM149 (IC<sub>50</sub> = 0.21 μM), SUM159 (IC<sub>50</sub> = 2.36 μM)</td><td class="colsep0 rowsep0" align="left">BL1, BL2, MSL, UNS</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">Cobimetinib</td><td class="colsep0 rowsep0" align="left">MEK1 inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 4.2 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT03424005 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">Nifetepimine</td><td class="colsep0 rowsep0" align="left">MEK, ERK inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 50 μM</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">BL-EI001</td><td class="colsep0 rowsep0" align="left">ERK inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 5 μM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Chemical Structures of the PI3K/AKT/mTOR Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">Buparlisib</td><td class="colsep0 rowsep0" align="left">PI3K inhibitor</td><td class="colsep0 rowsep0" align="left">p110α (IC<sub>50</sub> = 52 nM), p110β (IC<sub>50</sub> = 166 nM), p110δ (IC<sub>50</sub> = 116 nM), p110γ (IC<sub>50</sub> = 262 nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01576666 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">BAY80-6946</td><td class="colsep0 rowsep0" align="left">PI3K inhibitor</td><td class="colsep0 rowsep0" align="left">TGI = 80%, <i>p</i> = 0.006</td><td class="colsep0 rowsep0" align="left">LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">MK-2206</td><td class="colsep0 rowsep0" align="left">AKT inhibitor</td><td class="colsep0 rowsep0" align="left">Akt1 (IC<sub>50</sub> = 5 nM), Akt2 (IC<sub>50</sub> = 12 nM), Akt3 (IC<sub>50</sub> = 65 nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01319539 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Everolimus</td><td class="colsep0 rowsep0" align="left">mTOR inhibitor</td><td class="colsep0 rowsep0" align="left">mTOR (IC<sub>50</sub> = 5–6 nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01931163 (phase 2), NCT02616848 (phase 1), NCT02456857 (phase 2), NCT02120469 (phase 1), NCT02890069 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Chemical Structures of the PARP Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">Talazoparib (TALA)</td><td class="colsep0 rowsep0" align="left">PARP 1, PARP 2 inhibitor</td><td class="colsep0 rowsep0" align="left">PARP-1 (<i>K</i><sub><i>i</i></sub> = 1.2 nM), PARP-2 (<i>K</i><sub><i>i</i></sub> = 0.87 nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02282345</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">Olaparib</td><td class="colsep0 rowsep0" align="left">PARP 1, PARP 2 inhibitor</td><td class="colsep0 rowsep0" align="left">PARP-1 (IC<sub>50</sub> = 5 nM), PARP-2 (IC<sub>50</sub> = 1 nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT03801369 (phase 2), NCT03167619 (phase 2), NCT03330847 (phase 2), NCT00707707 (phase 1), NCT03544125 (phase 1), NCT02227082 (phase 1), NCT02000622</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">Veliparib</td><td class="colsep0 rowsep0" align="left">PARP 1, PARP 2 inhibitor</td><td class="colsep0 rowsep0" align="left">PARP-1 (<i>K</i><sub><i>i</i></sub> = 5.2 nM), PARP-2 (<i>K</i><sub><i>i</i></sub> = 2.9 nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02158507 (none), NCT01145430 (phase 1), NCT02985658 (none), NCT02032277 (phase 3), NCT00576654 (phase 1), NCT01104259 (phase 1), NCT01306032 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">Rucaparib</td><td class="colsep0 rowsep0" align="left">PARP 1 inhibitor</td><td class="colsep0 rowsep0" align="left">PARP-1 (<i>K</i><sub><i>i</i></sub> = 1.4 nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT03992131 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">OL-1</td><td class="colsep0 rowsep0" align="left">PARP 1 inhibitor</td><td class="colsep0 rowsep0" align="left">PARP-1 (IC<sub>50</sub> = 0.079 ± 0.013 μM), MDA-MB-436 (IC<sub>50</sub> = 5 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Chemical Structures of the JAK/STAT3 Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">Ruxolitinib</td><td class="colsep0 rowsep0" align="left">JAK1, JAK 2 inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 3 μM</td><td class="colsep0 rowsep0" align="left">BL1</td><td class="colsep0 rowsep0" align="left">NCT01562873 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">ECN</td><td class="colsep0 rowsep0" align="left">JAK, STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 5 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">Eupalinolide J</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 3.21 ± 0.49 μM), MDA-MB-468 (IC<sub>50</sub> = 3.04 ± 0.68 μM)</td><td class="colsep0 rowsep0" align="left">MSL, BL1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">1,3-Dicaffeoylquinic acid (1,3-dcqa)</td><td class="colsep0 rowsep0" align="left">Jak, PI3K, Akt inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 81.85 ± 3.56 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">Alantolactone</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 15 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">Galiellalactone analogues 16</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-468 (IC<sub>50</sub> = 11.79 ± 0.74 μM), MDA-MB-231 (IC<sub>50</sub> = 12.14 ± 0.25 μM), BT-549 (IC<sub>50</sub> = 9.63 ± 0.24 μM)</td><td class="colsep0 rowsep0" align="left">BL1, M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">Galiellalactone analogues 17</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-468 (IC<sub>50</sub> = 7.91 ± 0.10 μM), MDA-MB-231 (IC<sub>50</sub> = 8.63 ± 0.09 μM), BT-549 (IC<sub>50</sub> = 6.61 ± 0.14 μM)</td><td class="colsep0 rowsep0" align="left">BL1, M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">FZU-03,010</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">HCC1806 (IC<sub>50</sub> = 7.0 μM)</td><td class="colsep0 rowsep0" align="left">BL2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">Niclosamide</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 0.625 μM)</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">Flubendazole</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 0.25 μM), Hs578T (IC<sub>50</sub> = 0.125 μM), BT-549 (IC<sub>50</sub> = 0.125 μM)</td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">Disulfiram (DSF)</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">4T1 (IC<sub>50</sub> = 0.25 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left">NCT03323346 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">Salinomycin</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 0.5–10 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">Isoharringtonine (IHT)</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">HCC1806 (IC<sub>50</sub> = 100 nM), HCC1937 (IC<sub>50</sub> = 500 nM)</td><td class="colsep0 rowsep0" align="left">BL1, BL2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Chemical Structures of the SRC Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">1j</td><td class="colsep0 rowsep0" align="left">SRC inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 11 nM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">BJ-2302</td><td class="colsep0 rowsep0" align="left">SRC inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 3.23 μM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">Dasatinib</td><td class="colsep0 rowsep0" align="left">Bcr-Abl, SRC inhibitor</td><td class="colsep0 rowsep0" align="left">SRC (IC<sub>50</sub> = 0.8 nM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left">NCT02720185 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Chemical Structures of the ULK1 Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">LYN-1604</td><td class="colsep0 rowsep0" align="left">ULK1 agonist</td><td class="colsep0 rowsep0" align="left">ULK1 (EC<sub>50</sub> = 18.94 nM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">Narciclasine</td><td class="colsep0 rowsep0" align="left">ULK1, AMPK agonist</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Chemical Structures of the eEF2K Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">TX-1918</td><td class="colsep0 rowsep0" align="left">eEF2K inhibitor</td><td class="colsep0 rowsep0" align="left">HCC1937 (IC<sub>50</sub> = 51.1 μM), BT549 (IC<sub>50</sub> = 27.5 μM)</td><td class="colsep0 rowsep0" align="left">BL1, M</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">Thymoquinone (TQ)</td><td class="colsep0 rowsep0" align="left">eEF2K inhibitor</td><td class="colsep0 rowsep0" align="left">eEF2K (IC<sub>50</sub> = 8.2 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">21l</td><td class="colsep0 rowsep0" align="left">eEF2K inhibitor</td><td class="colsep0 rowsep0" align="left">eEF2K (IC<sub>50</sub> = 5.5 ± 1.4 μM), MDA-MB-231 (IC<sub>50</sub> = 12.6 ± 1.8 μM), MDA-MB-436 (IC<sub>50</sub> = 19.8 ± 3.0 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">Cefatrizine</td><td class="colsep0 rowsep0" align="left">eEF2K inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-436 (IC<sub>50</sub> = 30 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">Fluoxetine</td><td class="colsep0 rowsep0" align="left">eEF2K inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 0.5 μM), MDA-MB-436 (IC<sub>50</sub> = 0.5 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Chemical Structures of the BRD4 Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">BETd-246</td><td class="colsep0 rowsep0" align="left">BRD inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">FL-411</td><td class="colsep0 rowsep0" align="left">BRD 4 inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 0.43 ± 0.09 μM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">JQ1</td><td class="colsep0 rowsep0" align="left">BET inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 0.5 μM</td><td class="colsep0 rowsep0" align="left">MSL, LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Chemical Structures of the Non-Key Targeted Small-Molecule Drugs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">L80</td><td class="colsep0 rowsep0" align="left">C-terminal HSP90 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 5 μM), BT549 (IC<sub>50</sub> = 15 μM), Hs578T (IC<sub>50</sub> = 5 μM)</td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">17-demethoxy recombinant protein (17-DR)</td><td class="colsep0 rowsep0" align="left">HSP90-ATPASE inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 74.9 μM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">17-DMAG (Alvespimycin)</td><td class="colsep0 rowsep0" align="left">HSP90 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 45.7 nM), BT549 (IC<sub>50</sub> = 17.1 nM), Hs578T (IC<sub>50</sub> = 8.4 nM)</td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">NTRC 0066-0</td><td class="colsep0 rowsep0" align="left">TTK inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 0.6 nM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">LCL161</td><td class="colsep0 rowsep0" align="left">IAP inhibitor</td><td class="colsep0 rowsep0" align="left">cIAP1 (IC<sub>50</sub> = 0.4 nM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left">NCT02890069 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">Berberine (BBR)</td><td class="colsep0 rowsep0" align="left">IL-8 inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 50 μM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">Palbociclib</td><td class="colsep0 rowsep0" align="left">CDK4/6 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (EC<sub>50</sub> = 0.3 ± 0.01 μM), HCC38 (EC<sub>50</sub> = 1.4 ± 0.05 μM), MDA-MB-468 (EC<sub>50</sub> = 5 ± 0.5 μM)</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">SL0101(1b)</td><td class="colsep0 rowsep0" align="left">RSK1/2 inhibitor</td><td class="colsep0 rowsep0" align="left">HCC70 (IC<sub>50</sub> = 15 μM), MDA-MB-231 (IC<sub>50</sub> = 3 μM)</td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Cl-amidine</td><td class="colsep0 rowsep0" align="left">PAD1 inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">Protopheophorbide A</td><td class="colsep0 rowsep0" align="left">c-Met inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 6.5 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">AEB071</td><td class="colsep0 rowsep0" align="left">pan-PKC inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">Tiplaxtinin</td><td class="colsep0 rowsep0" align="left">PAI1 inhibitor</td><td class="colsep0 rowsep0" align="left">IC = 5 μM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">TD19</td><td class="colsep0 rowsep0" align="left">SET inhibitor</td><td class="colsep0 rowsep0" align="left">IC = 3 μM</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">PD173074</td><td class="colsep0 rowsep0" align="left">FGFR inhibitor</td><td class="colsep0 rowsep0" align="left">SUM185PE (IC<sub>50</sub> = 20 nM)</td><td class="colsep0 rowsep0" align="left">LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">AMPI-109</td><td class="colsep0 rowsep0" align="left">PRL-3 inhibitor</td><td class="colsep0 rowsep0" align="left">IC = 100 nM</td><td class="colsep0 rowsep0" align="left">BL1, UNS</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">Bazedoxifene (TSE-424)</td><td class="colsep0 rowsep0" align="left">IL 6, glycoprotein 130 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 7.45 μM), MDA-MB-468 (IC<sub>50</sub> = 3.14 μM)</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">AZ505</td><td class="colsep0 rowsep0" align="left">SMYD2 inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 20 μM</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">Y29</td><td class="colsep0 rowsep0" align="left">PDGFR-β inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 0.73 ± 0.10 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">HJ-PI01</td><td class="colsep0 rowsep0" align="left">Pim-2 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 300 nM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">FL-1607</td><td class="colsep0 rowsep0" align="left">Fam20C inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-468 (IC<sub>50</sub> = 7.89 μM)</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left">Flubendazole</td><td class="colsep0 rowsep0" align="left">Atg4B agonist</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 0.5–1 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left">EPZ015666 (GSK3235025)</td><td class="colsep0 rowsep0" align="left">PRMT5 inhibitor</td><td class="colsep0 rowsep0" align="left">HCC38 (IC<sub>50</sub> = 5 μM), MDA-MB-453 (IC<sub>50</sub> = 1 μM), MDA-MB-468 (IC<sub>50</sub> = 60 μM)</td><td class="colsep0 rowsep0" align="left">BL1, LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left">Pyr3</td><td class="colsep0 rowsep0" align="left">TRPC3 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 1 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">AZD1208</td><td class="colsep0 rowsep0" align="left">PIM1 inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">Entinostat</td><td class="colsep0 rowsep0" align="left">HDAC inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 1 μM), Hs578T (IC<sub>50</sub> = 1 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left">NCT03361800 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left">ONC201 (TIC10)</td><td class="colsep0 rowsep0" align="left">TRAIL inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 10 μM)</td><td class="colsep0 rowsep0" align="left">MSL, UNS</td><td class="colsep0 rowsep0" align="left">NCT03394027 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">Telaglenastat (CB-839)</td><td class="colsep0 rowsep0" align="left">GLS1 inhibitor</td><td class="colsep0 rowsep0" align="left">HCC1806 (IC<sub>50</sub> = 100 nM), MDA-MB-231 (IC<sub>50</sub> = 50 nM)</td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left">NCT03875313 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">Nirogacestat</td><td class="colsep0 rowsep0" align="left">γ-secretase inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 6.2 nM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02299635 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left">CRT0066101</td><td class="colsep0 rowsep0" align="left">PRKD inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left">LDN192960</td><td class="colsep0 rowsep0" align="left">DYRK2 inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 13 nM</td><td class="colsep0 rowsep0" align="left">BL1, BL2, IM, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>75</b></td><td class="colsep0 rowsep0" align="left">S63845</td><td class="colsep0 rowsep0" align="left">MCL1 inhibitor</td><td class="colsep0 rowsep0" align="left">TNBC PDXs (IC<sub>50</sub> < 1 mM)</td><td class="colsep0 rowsep0" align="left">BL1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="left">PF06873600</td><td class="colsep0 rowsep0" align="left">CDK inhibitor</td><td class="colsep0 rowsep0" align="left">CDK2 (<i>K</i><sub><i>i</i></sub> = 0.09 nM), CDK4 (<i>K</i><sub><i>i</i></sub> = 0.13 nM), CDK6 (<i>K</i><sub><i>i</i></sub> = 0.16 nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT03519178 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>77</b></td><td class="colsep0 rowsep0" align="left">CYC065</td><td class="colsep0 rowsep0" align="left">CDK2, CDK9 inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left">Dinaciclib</td><td class="colsep0 rowsep0" align="left">CDK2 inhibitor</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 10 nM</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left">NCT01676753 (phase 1), NCT01624441 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="left">Flavopiridol</td><td class="colsep0 rowsep0" align="left">CDK1, CDK2, CDK4 inhibitor</td><td class="colsep0 rowsep0" align="left">CDK1 (IC<sub>50</sub> = 30 nM), CDK2 (IC<sub>50</sub> = 170 nM), CDK4 (IC<sub>50</sub> = 100 nM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b></td><td class="colsep0 rowsep0" align="left">Abemaciclib (ABE/LY2835219)</td><td class="colsep0 rowsep0" align="left">CDK4, CDK6 inhibitor</td><td class="colsep0 rowsep0" align="left">CDK4 (IC<sub>50</sub> = 2 nM), CDK6 (IC<sub>50</sub> = 10 nM)</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left">NCT03979508 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left">Ribociclib (RIBO)</td><td class="colsep0 rowsep0" align="left">CDK4, CDK6 inhibitor</td><td class="colsep0 rowsep0" align="left">CDK4 (IC<sub>50</sub> = 10 nM), CDK6 (IC<sub>50</sub> = 39 nM)</td><td class="colsep0 rowsep0" align="left">BL1</td><td class="colsep0 rowsep0" align="left">NCT03090165 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left">C1572</td><td class="colsep0 rowsep0" align="left">c-MYC inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>83</b></td><td class="colsep0 rowsep0" align="left">KEA1-97</td><td class="colsep0 rowsep0" align="left">activate apoptosis</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 10 μM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left">WX2-43</td><td class="colsep0 rowsep0" align="left">PRMT5-KLF4 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (EC<sub>50</sub> = 0.96 μM), MDA-MB-468 (EC<sub>50</sub> = 2.5 μM), MCF-7 (EC<sub>50</sub> = 0.77 μM), HCC1937 (EC<sub>50</sub> = 0.44 μM), HCC38 (EC<sub>50</sub> = 1.20 μM), MDA-MB-453 (EC<sub>50</sub> = 2.51 μM)</td><td class="colsep0 rowsep0" align="left">BL1, MSL, LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></td></tr></tbody></table></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">3.1.  Receptor Tyrosine Kinases (RTKs)</h3><div class="NLM_p">The tumor suppressor tyrosine phosphatase PTPN12 is often inactivated in TNBC, which causes the inhibition of a variety of RTKs, suggesting that PTPN12 deficiency leads to the abnormal activation of multiple RTKs and co-dependency on these receptors.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In contrast to single drugs, combined inhibitors targeting RTK receptors can induce TNBC cell apoptosis.</div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">3.1.1.  EGFR</h4><div class="NLM_p">ErbBs are typical RTKs that are found in the avian erythroblastosis virus and encode an abnormal form of human EGFR. Clinical studies have shown that the grave prognosis of TNBC is related to the overexpression of EGFR.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> In malignant tumors, the tumor microenvironment can produce EGFR ligands and subsequently activate EGFR. Another mode of activation is the EGFR mutation, which locks the receptor and causes sustained activation. About 80% of TNBC patients have been shown an increased expression of EGFR, and its gene amplification and overexpression account for about 1/4 and 3/4, respectively, indicating that the high expression may be related to poor prognosis. Other members of the EGFR family, including HER2, have been targeted by delivery of cytotoxic therapy. So far, EGFR has been regarded as a prospective therapeutic target in TNBC.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The overexpression of miR-361-5p may inhibit the EGFR/PI3K/AKT signaling pathway by targeting RQCD1 and inhibit TNBC progression.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">The two main treatments for EGFR rely on small-molecule EGFR tyrosine kinase inhibitors (EGFR-TKIs) and monoclonal antibodies (mAbs). Varieties of preclinical and clinical research have estimated the efficacy of EGFR-TKIs combined with traditional cytotoxic chemotherapy in the treatment of TNBC.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The combination of mAbs and EGFR-TKIs in TNBC can produce a synergistic antiproliferative effect by inhibiting the Ras/MAPK signaling pathway. The antiproliferative efficacy is related to cell cycle arrest and apoptosis.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> It is suggested that double targeting of EGFR with mAb and EGFR-TKI is a potential strategy for TNBC treatment.</div><div class="NLM_p">Additionally, varlitinib (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>1</b>), a potent and reversible EGFR small-molecule inhibitor, can reduce cell activity and induce apoptosis in the majority of TNBC.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><b>1</b> inhibited the migration, invasion, and mammosphere formation of TNBC cells and significantly inhibited the growth of mice bearing tumors through the inhibition of HER.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The EGFR/JAK2/STAT3 signaling pathway was involved in the salidroside-related regulation of the inhibition of the migration, invasion, and angiogenesis of TNBC cells (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>2</b>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Cannabidiol (CBD) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>3</b>) inhibited the EGF-induced activation of the EGFR pathway and the secretion of MMP2 and MMP9, showing that CBD inhibited the metastasis and growth of TNBC by inhibiting the EGF/EGFR pathway and tumor microenvironment regulation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Cyclo (<span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-prolyl) peptide (CLP) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>4</b>) was found to inhibit cell growth and migration of TNBC through EGFR and CD151 signaling pathways.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of <b>1</b>–<b>5</b> as EGFR inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">More recently, an immunohistochemical method has been used to analyze 187 primary TNBC clinical specimens to verify the targeted therapeutic effect of TKIs in TNBC.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> It is suggested that, <i>in vivo</i>, TKI inhibits the activation of downstream signaling molecules by targeting RON-ant-MET, inhibits the migration and proliferation of TNBC, and increases the apoptosis of TNBC.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> In the TNBC xenograft model, they significantly inhibited tumor growth and reduced tumor volume.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> It reveals that TKIs targeting RON and MET have strong drug development potential for the treatment of TNBC. Interestingly, a study showed that the interleukin 17E (IL-17E) receptor axis might be the basis of TNBC tolerance to EGFR inhibitors, suggesting that the inhibition of IL-17E receptor binding to EGFR inhibitors might ameliorate TNBC.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">3.1.2.  VEGFR</h4><div class="NLM_p">Vascular endothelial growth factor (VEGF) is an effective angiogenic factor. The signaling pathway initiated by the VEGFR family is mainly responsible for the stimulation of blood vessels, such as the formation of blood vessels and lymphatics. In TNBC, tumor has high microvessel density, which indicates that the development is related to angiogenesis. Angiogenesis leads to poor prognosis of TNBC, especially by promoting growth and metastasis. VEGF is one of the best regulatory factors of angiogenesis, which plays an important role in maintaining vascular survival.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> VEGF has been proven to drive malignant stem cells, which could therefore increase the activity of the tumor sphere and aldehyde dehydrogenase <i>in vitro</i> and in TNBC cell lines, both of which are indicators of stem cell function.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> TNBC has a higher VEGF level than non-TNBC through clinical data. TNBC with a high VEGF level may evade anti-angiogenesis by upregulating VEGF, thus promoting the self-renewal of CSCs after treatment.</div><div class="NLM_p last">Some VEGF inhibitors have achieved good results in the treatment of advanced tumors with single drug or combination chemotherapy. The reason for the development of such drugs is that the inhibition of the formation of new blood vessels can stop the supply of the necessary oxygen and nutrients to the tumor. The OS of <i>HER2</i>-positive and triple negative populations with vascular endothelial growth factor A (VEGFA) amplification was lower; ER+ or PR+ and HER2– patients with <i>VEGFA</i> amplification did not affect OS. The progression-free survival (PFS) and OS of patients with VEGFA amplification treated with bevacizumab was low.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> It is suggested that VEGFA amplification can be associated with poor prognosis in univariate analysis, especially in patients with HER2+ breast cancer or TNBC. In addition, vandetanib (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>5</b>), a VEGFR2 inhibitor with strong activity, exerted antitumor activity through a reduction in VEGFR gene expression, inhibition of angiogenesis, and induction of TNBC cell necrosis.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">3.2.  Mitogen-Activated Protein Kinases (MAPKs)</h3><div class="NLM_p">MAPKs are a type of serine/threonine protein kinases that are widespread in cells. TNBC usually has abnormal activity in the TAF/MAPK/ERK pathway.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> An increasing body of data have shown that the MAPK (RAS-RAF-MEK-ERK) pathway is a vital therapeutic target for TNBC. Thus, the use of MEK inhibitors and ERK inhibitors to inhibit the pathway is an attractive tactic for TNBC therapy.</div><div class="NLM_p">The protein expression of ERK-1 in TNBC tissues is higher than that in normal tissues, suggesting that the protein overexpression of ERK-1 may play a role in the development and malignant transformation of TNBC. ERK-1 is associated with the pathological stage, depth of invasion, and histological grade and is not related to lymph node metastasis or pathological tissue type, suggesting the overexpression of ERK-1 and the invasion of TNBC.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In patients with TNBC, the overall survival rate of patients with ERK-2-overexpressing tumors is lower than that of patients with ERK-2-underexpressing tumors.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> A MEK1 inhibitor E6201 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>6</b>) could reduce lung metastasis and phosphorylated ERK expression through the induction of apoptosis and G1 cell cycle arrest in a dose-dependent manner.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In the experimental metastasis and spontaneous metastasis experiments, <b>6</b> inhibited the growth of TNBC xenotransplantation, inhibited lung metastasis and improved the survival rate of mice, and exerted a dose-dependent inhibitory effect on TNBC cell colony formation, migration, and invasion.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> An ongoing clinical trial (National Clinical Trial (NCT) 03424005) shows that cobimetinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>7</b>), a selective MEK1 inhibitor, also has the potential to treat patients with metastatic or inoperable locally advanced TNBC. Also, the MEK/ERK inhibitor nifetepimine (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>8</b>) downregulates the MEK/ERK pathway in TNBC through the downregulation of pERK expression.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Interestingly, the ERK inhibitor BL-EI001 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>9</b>) has been found to induce apoptosis in mitochondria by targeting ERK <i>in vivo</i> and then induces apoptosis in TNBC cells.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Moreover, ERK1 and ERK5 play a key role in a variety of specific cancers. ERK5 affords a common alternative pathway to rescue cell proliferation when the ERK1 pathway is blocked. Thus, the dual-target inhibitor of ERK1/ERK5 might also be expected to overcome the compensatory mechanism of TNBC.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of <b>6</b>–<b>9</b> as MEK/ERK inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">3.3.  PI3K/AKT/mTOR</h3><div class="NLM_p">The PI3K family is a type of intracellular phosphatidylinositol kinase. The increase in PI3K activity is often associated with a variety of human cancers. AKT, also known as PKB, is the main downstream effector of PI3K. AKT3 has been proven to produce specific overexpression of DNA and mRNA expression in TNBC, which induces tumor growth, but does not promote invasion.</div><div class="NLM_p">The PI3K/AKT/mTOR pathway plays a vital role in tumor proliferation, metastasis, and vascular growth. The pathway is activated in BC, and its inhibition can induce cancer cell apoptosis. Compared with other types of breast cancer, the incidence of phosphatase and tensin homologue deleted on chromosome ten (PTEN) and PI3K mutations in TNBC is much higher.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Preclinical studies of TNBC have shown that AKT can activate the ER pathway, regardless of the effectiveness of estrogen.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> The poor prognosis of TNBC has been reported to be related to the activation of the PI3K/Akt/mTOR pathway.<a onclick="showRef(event, 'ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref108 ref109">(108,109)</a> Activation of the signaling pathways, such as the PI3K/PKB/mTOR target protein in mesenchymal and mesenchymal stem cell-like forms, targeting PI3K/AKT/mTOR may be a potential treatment strategy. A PI3K inhibitor buparlisib (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>10</b>) has been found to effectively induce the regression of TNBC tumors, especially in TNBC with drug target somatic distortion.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The PI3K inhibitor BAY80-6946 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>11</b>) is reported to have significant antitumor activity in PDX, which is ineffective against the AR antagonist.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In addition, the results of multiple clinical trials hold great promise for the treatment of TNBC with AKT inhibitor MK-2206 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>12</b>) and mTOR inhibitor everolimus (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <b>13</b>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of <b>10</b>–<b>13</b> as PI3K/AKT/mTOR inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Metaplastic breast cancer (MBC) is a highly aggressive triple negative breast cancer (TNBC), and MBC is more likely to metastasize and be drug-resistant.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> At present, little is known about the mechanisms of the occurrence and metastasis of MBC, and there are no specific guidelines for clinical treatment. Thus, new methods based on the molecular characteristics of tumors are urgently needed to treat MBC. The PI3K/Akt/mTOR pathway has been shown to be prone to high frequency changes in MBC patients. mTOR inhibitors combined with liposomal doxorubicin and VEGF monoclonal antibody inhibitors have significant long-term efficacy in the treatment of advanced metaplasia TNBC patients, suggesting that mTOR inhibitors may become a potential strategy for the treatment of MBC.<a onclick="showRef(event, 'ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref111 ref112">(111,112)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">3.4.  PARP</h3><div class="NLM_p">The breast cancer susceptibility genes (BRCA) is a tumor suppressor gene that can repair the broken double-strand DNA by homologous recombination. The detection of a BRCA gene mutation in some TNBC patients has indicated that PARP inhibitors can inhibit the repair of broken single-stranded DNA and BRCA mutants cannot induce homologous recombination to repair double-stranded DNA, resulting in a synthetic lethal effect on tumor cells.<a onclick="showRef(event, 'ref30 ref113'); return false;" href="javascript:void(0);" class="ref ref30 ref113">(30,113)</a> Therefore, BRCA gene mutations are sensitive to PARP inhibitors, which have a significant effect. Of note, patients with BRCA mutations can obtain a greater pathological remission rate and control toxicity only by using the PARP inhibitor talazoparib (TALA) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>14</b>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of <b>14</b>–<b>18</b> as PARP inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Currently, several potential PARP inhibitors for TNBC have been used in clinical progression containing <b>14</b>, olaparib (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>15</b>), veliparib (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>16</b>), and rucaparib (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>17</b>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In HER2-negative metastatic BC and BRCA mutation patients, <b>15</b> alone has a remarkable advantage on the standard treatment. In a randomized, open-label phase 3 trial, the median PFS of <b>15</b> monotherapy is prolonged, and the risk of disease progression or death is lower than that of the standard treatment.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> In addition, the inhibition of PARP by the inhibitor <b>15</b> and the activation of the STING-TBK1-IRF3 pathway related to the tumor microenvironment play a key role in the regulation of CD8 T cell recruitment and antitumor effects in BRCA1-deficient TNBC cells.<a onclick="showRef(event, 'ref31 ref115'); return false;" href="javascript:void(0);" class="ref ref31 ref115">(31,115)</a> In addition, a PARP1 inhibitor OL-1 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <b>18</b>) can inhibit cell proliferation (BRAC1 mutation) and cell migration closely related to cancer metastasis through the inhibition of the PARylation regulated by PARP1 in TNBC and shows significant antitumor effects in a TNBC xenotransplantation model, with no obvious toxicity.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">3.5.  JAK/STAT3</h3><div class="NLM_p">JAK, the Janus kinase, is a nonreceptor tyrosine protein kinase. Independently of PD-L1, activation of the JAK2/STAT3 pathway, as measured by phosphorylated STAT3 (pSTAT3), is related to BC metastasis and poor prognosis.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Targeted inhibition of JAK2/STAT3 signaling impairs tumor growth and metastasis, suggesting that the JAK2/STAT3 pathway might be an effective therapeutic target in TNBC.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Ruxolitinib (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>19</b>) is a JAK1/JAK2 selective inhibitor approved by the FDA for the therapy of myelofibrosis but has been recently shown to have a limited effect on tumor growth in a xenogeneic model because of concordant JAK1 inhibition.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Moreover, STAT3 has been reported to play a key role in the initiation, progression, metastasis, and immune escape of TNBC. Overexpression and structural activation of STAT3 are found in TNBC. Some STAT3 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>20</b>–<b>31</b>) have been developed and showed good antitumor activity in TNBC.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44">(34−44)</a> The compound ECN (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>20</b>), isolated from <i>Farfarae Flos</i>, can inhibit JAK-STAT3 by inhibiting the expression of STAT3, thereby strongly inducing TNBC cell apoptosis.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Eupalinolide J (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>21</b>), which is a typical natural Michael reaction acceptor (MRA), has an inhibitory effect on STAT3 and exerted underlying cytotoxicity in TNBC cells.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In addition, the 14–3–3 protein plays an important role in the occurrence and metastasis of breast cancer and may be a new drug target protein.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> 1,3-Dicaffeoylquinic acid (1,3-dcqa) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, <b>22</b>) combined with the 14–3–3 protein through the JAK/PI3K/AKT and Raf/ERK signaling pathways, promoting the expression of IL-6 and csf3 induced by CREB (crebbp, creb5), and inducing apoptosis through the Bad/Bax/caspase9 signaling pathway, preventing the proliferation and metastasis of TNBC, suggesting that <b>22</b> can inhibit the JAK pathway by targeting the 14–3–3 protein as a leading compound.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of <b>20</b>–<b>31</b> as JAK/STAT3 inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">3.6.  SRC</h3><div class="NLM_p">The SRC kinase, encoded by the sarcoma gene, is a specific protein kinase of tyrosine. The activation of STAT3 and its upstream regulator, SRC kinase, can improve the expression of HO-1, abolish the activation of the SRC/STAT3 pathway, and suppress the induction of HO-1 and autophagy, which increases the chemical sensitivity of TNBC cells.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Compound 1j (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, <b>32</b>) is reported to exert the strongest inhibition of SRC kinase and the strongest antitumor activity against the TNBC cell line.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Of note, the invasion and metastasis of TNBC are related to the lysosomal enzyme CTSS and gelatinase MMP-9.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> BJ-2302 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, <b>33</b>), a SRC inhibitor, is an upstream activator of two pathways responsible for the expression of CTSS and MMP-9 (PI3K/AKT and Ras/Raf/ERK).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><b>33</b> proved to effectively inhibit the invasion and metastasis of TNBC and strongly inhibits the proliferation and tumor growth of TNBC.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> C-SRC and syndecan binding protein (SDCBP) interact to regulate the G1/S of TNBC cells and promote the proliferation of tumor cells by promoting c-SRC phosphorylation of Tyr419.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Dasatinib (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, <b>34</b>) inhibited this phosphorylation and blocked the cell cycle process induced by SDCBP.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of <b>32</b>–<b>34</b> as SRC inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">3.7.  ULK1</h3><div class="NLM_p">ULK1 is the downstream protein kinase of PI3K-AKT-mTOR and acts as an autophagy initiator. The expression of ULK1 in tissue samples from TNBC by analysis of the histo-genomic map (the cancer genome atlas (TCGA)) and tissue microarray (TMA) shows that upregulation of ULK1 leads to autophagy-dependent apoptosis, inhibiting TNBC tumor growth, showing the therapeutic potential of targeted agonists of ULK1 in TNBC.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> A small molecule named LYN-1604 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, <b>35</b>) is found to target ULK1.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Through site-specific mutagenesis and biochemical detection, three amino acid residues are shown to be the keys to the ULK1 and <b>35</b> activation sites, and it is proven that the <b>35</b> induces tumor cell death by autophagy through ULK in TNBC. This process also involved the induction of cell death of some potential ULK1 interacting bodies (ATF3, RAD21, and Caspase-3) by <b>35</b>, attended by apoptosis and autophagy, which confirms the therapeutic potential of <b>35</b> in activating the ULK1 complex in TNBC.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> More recently, narciclasine (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, <b>36</b>) has been found to regulate the adenosine 5′-monophosphate-activated protein kinase (AMPK)-ULK1 signaling axis in the TNBC cells and promotes the autophagy-dependent apoptosis in a dose-dependent manner, significantly inhibiting the growth of TNBC tumors, demonstrating the potential of an activator of ULK1 in TNBC.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of <b>35</b> and <b>36</b> as ULK1 inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">3.8.  eEF2K</h3><div class="NLM_p">eEF2K belongs to the atypical protein kinase family of α-kinases. It is demonstrated that protein expression of eEF2K is highly upregulated in TNBC cells and TNBC patients, which is related to poor clinical outcomes and low patient survival.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Inhibition of the eEF2K signaling pathway has been shown to inhibit tumor proliferation, migration/invasion, and growth in TNBC.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> In downregulation of the expression of eEF2K in an orthotopic xenograft mouse model of TNBC tumors by systemic injection of liposome eEF2K small interfering RNA (siRNA), the results showed that the enhanced phosphorylation of eEF2 in the tumor inhibited the growth of TNBC tumor cells, induced TNBC tumor attenuation, and increased the sensitivity to adriamycin, a TNBC tumor chemotherapeutic drug.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The combined PTEN-p53 mutation accelerated the formation of TNBC.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Compared with PTEN or p53 single mutant tumors, the eEF2K inhibitor TX-1918 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <b>37</b>) has stronger effects on mouse and human PTEN/p53-deficient TNBC cells than PI3K/AKT/mTOR inhibitors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Sensitivity to eEF2K inhibition is related to AKT pathway activity. eEF2K monotherapy can inhibit the growth of PTEN/p53-deficient TNBC xenografts, which can effectively kill tumor cells in combination with adriamycin.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Recently, an effective small-molecule component of thyme (<i>Nigella sativa</i>), thymoquinone (TQ) (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <b>38</b>), has been shown to be an effective and safe effective eEF2K inhibitor in TNBC.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The authors demonstrated that <b>38</b> (20 and 100 mg/kg) is able to reduce the proliferation, colony formation, invasion, and migration of TNBC cell lines by inhibiting the mRNA and protein expression of eEF2K, the clinically related downstream targets, and inducing the inhibitory effect of tumor inhibitor miR-603 on NF-kB.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The system significantly inhibits the expression of eEF2K in a mouse tumor model.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> It proves that standard <b>38</b> drug therapy can be used as a targeted treatment tactic to inhibit the growth and progression of TNBC tumors. Moreover, an eEF2K inhibitor 21l (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <b>39</b>) could induce TNBC cell death and inhibit TNBC in a xenograft mouse model through the induction of apoptosis.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Another eEF2K inhibitor, cefatrizine (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <b>40</b>), is found to induce endoplasmic reticulum stress in TNBC with an antiproliferative activity.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The antidepressant drug fluoxetine (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, <b>41</b>), which also has eEF2K inhibitory effects, will be discussed in detail in the “drug repurposing” section later.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of <b>37</b>–<b>41</b> as eEF2K inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">3.9.  BRD4</h3><div class="NLM_p">The BRD4 protein is the most important functional protein in the bromodomain and extra-terminal (BET) family. The lack of targeted treatment for TNBC is still a concern. Recently, BET inhibitors showed significant antitumor activity against TNBC.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> BRD4 or BRD4-related pathways have been demonstrated to play a vital role in the occurrence and development of BC.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> BET inhibitors exerted strong antitumor activity in a mouse xenotransplantation model of human TNBC, with a mechanism mainly related to Bcl-xL and Jagged1/Notch 1. BET inhibitors can inhibit the expression of Bcl-2 or Bcl-xL, and myeloid cell leukemia 1 (MCL1) is also found to be a member of the Bcl-2 antiapoptosis family of proteins.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The second-generation BET inhibitor BETd-246 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, <b>42</b>) can induce the degradation of BET transcription factors, inhibit the growth of TNBC cells, and thus induce apoptosis.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> TNBC cells with MCL1 silenced by siRNA greatly enhanced the apoptosis-inducing effect of BET inhibitors, whereas the overexpression of MCL1 significantly reduced the apoptosis-inducing effect of BET inhibitors, indicating that MCL1 is the key target of apoptosis induced by BET inhibitors. Notably, BRD4 can regulate the expression and signaling pathways of ligand/receptor Jagged1/Notch 1 in patients with TNBC, and the expression of BRD4 and Jagged1 is positively correlated with the distant metastasis of TNBC. Selective knockout of BRD4 inhibited the activity of Notch 1 and the migration and invasion of breast cancer cells. BRD4 is shown to interact with AMPK, causing the downregulation of AMPK in breast cancer, and the BRD4 inhibitor can induce AMPK to regulate autophagy-related cell apoptosis.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> A BRD4 small-molecule inhibitor 9F (FL-411) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, <b>43</b>) has been discovered in TNBC.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> JQ1 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, <b>44</b>), a BET inhibitor, effectively inhibited the expression of AR-related targets by inducing apoptosis and cell cycle arrest, blocking the interaction between the AAA domains (a Walker-type ATPase domain with a second region of homology) of the ATPase family containing 2 proteins (ATAD2), BRD2, BRD4, and AR, and exerted an antitumor effect in AR-positive TNBC.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of <b>42</b>–<b>44</b> as BRD4 inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As mentioned above, we summarized 86 potential single-target drugs for the treatment of TNBC. These single-target drugs can be divided into 10 categories according to the main signaling pathways of the target: EGFR inhibitor <b>1</b>, MEK/ERK inhibitor <b>6</b>, PI3K/AKT/mTOR inhibitor <b>10</b>, PARP inhibitor <b>14</b>, JAK/STAT inhibitor <b>20</b>, SRC inhibitor <b>32</b>, ULK1 agonist <b>35</b>, eEF2K inhibitor <b>37</b>, BRD4 inhibitor <b>42</b>, and other pathway mechanisms (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>, <b>45</b>–<b>84</b>). The representative drugs of the above-mentioned signaling pathways have made great contributions in the treatment of TNBC. In addition to these small-molecule targeted drugs for the potential treatment of TNBC, there are also some noteworthy targets worthy of further studies. Beclin-1 plays an important role in breast cancer subtypes, and AFF3 is related to <i>BECN1</i> in breast cancer, which might be a potential therapeutic target.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> An effective G9a inhibitor is found to induce apoptosis of breast cancer cells through the p21 BIM signaling cascade, and it might have a potential for TNBC treatment in the near future.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In the past few decades, the discovery of TNBC drugs has greatly benefited from the use of small-molecule compounds to target cell apoptosis and other classic ways of cell death.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> More innovations such as proteolysis targeting chimeras (PROTAC) may provide a better rational use for small-molecule inhibitors or activators.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">4.  Dual-Target Drugs and Drug Combination Strategies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">At present, we have summarized 23 kinase specific inhibitors or activators for TNBC treatment in phase 1–3 clinical trials in the past 6 years.<a onclick="showRef(event, 'ref3 ref45 ref84 ref129 ref130 ref131 ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref3 ref45 ref84 ref129 ref130 ref131 ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139">(3,45,84,129−139)</a> However, the intrinsic mechanism of protein kinase may invalidate the use of single-target small-molecule drugs for patients with TNBC and lead to the corresponding resistance or compensatory mechanism of the target kinase in cancer treatment. Thus, the development of new strategies for dual-targeted drug discovery and drug combinations appears to be meaningful.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">4.1.  Dual-Target Drugs</h3><div class="NLM_p">Because of the heterogeneity of TNBC, the response rate of patients to single-target small-molecule drugs is relatively low.<a onclick="showRef(event, 'ref5 ref140'); return false;" href="javascript:void(0);" class="ref ref5 ref140">(5,140)</a> Therefore, the use of dual-target drugs can provide some advantages for patients with TNBC (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a> and <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>85</b>–<b>99</b>). For example, CYT387 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>91</b>) as a dual inhibitor of the TBK1/IKBK and JAK signaling pathways can simultaneously act on multiple pathological links and multiple pathogenesis of TNBC to produce a synergistic effect, so that the total effect is greater, thereby improving the efficacy of the drug.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a><b>32</b>, as an SRC/B-Raf/c-raf multikinase inhibitor, can better balance the relationship between multiple pathological factors of TNBC.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> At a relatively low blood concentration level, <b>32</b> can synergistically produce biological effects that require a high concentration of single-target drugs.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Moreover, <b>32</b> has the characteristics of weak affinity for biological targets, so it will not strongly inhibit or activate a drug target and so it can reduce the adverse reactions of drugs.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> PHA-767491, (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>96</b>) as a potent Dbf4-dependent kinase (DDK) (Cdc7-Dbf4)/cyclin-dependent kinases 9 (CDK9) inhibitor, can reduce drug resistance by simultaneously interfering with the main pathogenic target of TNBC and its compensatory signaling pathway.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of <b>85</b>–<b>99</b> as double/multiple targeted small-molecule drugs in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Double/Multiple Targeted Small-Molecule Drugs in TNBC</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">mechanism</th><th class="colsep0 rowsep0" align="center">activity</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="left">Lapatinib</td><td class="colsep0 rowsep0" align="left">EGFR, HER2 inhibitor</td><td class="colsep0 rowsep0" align="left">EGFR (IC<sub>50</sub> = 10.2 nM), ErbB-2 (IC<sub>50</sub> = 9.8 nM)</td><td class="colsep0 rowsep0" align="left">BL2</td><td class="colsep0 rowsep0" align="left">NCT02158507 (not applicable)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>86</b></td><td class="colsep0 rowsep0" align="left">Norcantharidin (NCTD)</td><td class="colsep0 rowsep0" align="left">ERK, AKT inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 21.83 μg/mL), MDA-MB-468 (IC<sub>50</sub> = 17.66 μg/mL), BT-549 (IC<sub>50</sub> = 12.83 μg/mL)</td><td class="colsep0 rowsep0" align="left">MSL, BL1, M</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>87</b></td><td class="colsep0 rowsep0" align="left">9d</td><td class="colsep0 rowsep0" align="left">Raf1, ERK inhibitor</td><td class="colsep0 rowsep0" align="left">Raf1 (IC<sub>50</sub> = 0.028 μM), ERK (IC<sub>50</sub> = 0.79 μM), MDA-MB-231 (IC<sub>50</sub> = 2.10 μM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>88</b></td><td class="colsep0 rowsep0" align="left">AZD2014 (Vistusertib)</td><td class="colsep0 rowsep0" align="left">mTORC1, mTORC2 inhibitor</td><td class="colsep0 rowsep0" align="left">TGI = 72%, <i>p</i> = 0.02</td><td class="colsep0 rowsep0" align="left">LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>89</b></td><td class="colsep0 rowsep0" align="left">PF-04691502</td><td class="colsep0 rowsep0" align="left">PI3K, mTOR inhibitor</td><td class="colsep0 rowsep0" align="left">TGI = 72%, <i>p</i> = 0.01</td><td class="colsep0 rowsep0" align="left">LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>90</b></td><td class="colsep0 rowsep0" align="left">Torin2</td><td class="colsep0 rowsep0" align="left">mTOR, PIKK inhibitor</td><td class="colsep0 rowsep0" align="left">HCC1806 (GR<sub>50</sub> = 0.01–0.1 μM), HCC70 (GR<sub>50</sub> = 0.01–0.1 μM)</td><td class="colsep0 rowsep0" align="left">BL2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>91</b></td><td class="colsep0 rowsep0" align="left">CYT387 (Momelotinib)</td><td class="colsep0 rowsep0" align="left">TBK1, IKBK, JAK inhibitor</td><td class="colsep0 rowsep0" align="left">HCC1187(IC<sub>50</sub> = 1–5 μM), MDA-MB-468 (IC<sub>50</sub> = 1–5 μM), MDA-MB-231 (IC<sub>50</sub> = 1–5 μM), HCC1143 (IC<sub>50</sub> = 5–10 μM), HCC70 (IC<sub>50</sub> = 10 μM)</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">1j</td><td class="colsep0 rowsep0" align="left">SRC, B-RAF, C-RAF inhibitor</td><td class="colsep0 rowsep0" align="left">SRC (IC<sub>50</sub> = 0.0009 μM), RAF (IC<sub>50</sub> = 0.092 μM), C-RAF (IC<sub>50</sub> = 0.027 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>92</b></td><td class="colsep0 rowsep0" align="left">SKLB646</td><td class="colsep0 rowsep0" align="left">SRC, VEGFR2, Raf inhibitor</td><td class="colsep0 rowsep0" align="left">SRC (IC<sub>50</sub> = 0.002 μM), VEGFR2 (IC<sub>50</sub> = 0.012 μM), B-RAF (IC<sub>50</sub> = 0.022 μM), C-RAF (IC<sub>50</sub> = 0.019 μM), MDA-MB-231 (IC<sub>50</sub> = 0.013 μM), MDA-MB-435 (IC<sub>50</sub> = 0.080 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>93</b></td><td class="colsep0 rowsep0" align="left">UM-164</td><td class="colsep0 rowsep0" align="left">c-SRC, p38 inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 6.1 nM), SUM149 (IC<sub>50</sub> = 230 nM), HCC1937 (IC<sub>50</sub> = 120 nM), Hs578t (IC<sub>50</sub> = 9.1 nM), MDA-MB-468 (IC<sub>50</sub> = 260 nM)</td><td class="colsep0 rowsep0" align="left">BL1, BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>94</b></td><td class="colsep0 rowsep0" align="left">13an</td><td class="colsep0 rowsep0" align="left">SRC, KDR, MAPK inhibitor</td><td class="colsep0 rowsep0" align="left">SRC (IC<sub>50</sub> = 0.003 μM), KDR (IC<sub>50</sub> = 0.032 μM), MDA-MB-231 (IC<sub>50</sub> = 0.030 ± 0.006 μM)</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MS645</td><td class="colsep0 rowsep0" align="left">BRD4, BrDs inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-231 (IC<sub>50</sub> = 10.3 nM), Hs578t (IC<sub>50</sub> = 4.1 nM), BT549 (IC<sub>50</sub> = 6.8 nM), HCC1806 (IC<sub>50</sub> = 19.0 nM), HCC38 (IC<sub>50</sub> = 15.0 nM)</td><td class="colsep0 rowsep0" align="left">BL1, BL2, M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>96</b></td><td class="colsep0 rowsep0" align="left">PHA-767491</td><td class="colsep0 rowsep0" align="left">DDK, CDK9 inhibitor</td><td class="colsep0 rowsep0" align="left">cdc7 (IC<sub>50</sub> = 10 nM), CDK9 (IC<sub>50</sub> = 34 nM)</td><td class="colsep0 rowsep0" align="left">M, MSL, LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>97</b></td><td class="colsep0 rowsep0" align="left">PF431396 (PF396)</td><td class="colsep0 rowsep0" align="left">PYK2, FAK inhibitor</td><td class="colsep0 rowsep0" align="left">MDA-MB-468 (IC<sub>50</sub> = 3.4 ± 0.2 μM), BT-20 (IC<sub>50</sub> = 6.2 ± 0.4 μM)</td><td class="colsep0 rowsep0" align="left">BL1, UNS</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>98</b></td><td class="colsep0 rowsep0" align="left">Foretinib</td><td class="colsep0 rowsep0" align="left">MET, KDR inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01147484 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>99</b></td><td class="colsep0 rowsep0" align="left">KW-2450</td><td class="colsep0 rowsep0" align="left">Aurora A, B kinase, IGF-IR inhibitor</td><td class="colsep0 rowsep0" align="left">Aurora A kinase (MDA-MB-468: IC<sub>50</sub> = 0.215 μM), Aurora B kinase (MDA-MB-468: IC<sub>50</sub> = 0.478 μM) (SUM149: IC<sub>50</sub> = 0.272 μM) (MDA-MB-231: IC<sub>50</sub> = 0.066 μM), IGF-IR (MDA-MB-468, SUM149: IC<sub>50</sub> < 0.002 μM)</td><td class="colsep0 rowsep0" align="left">BL1, BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></td></tr></tbody></table></div></div><div class="NLM_p">Norcantharidin (NCTD) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>86</b>), as a demethyl analogue of cantharidin, is reported to have the same antitumor effect as cantharidin, and with fewer side effects.<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a> The dual inhibitor of AKT and ERK, NCTD, effectively induces TNBC cell cycle arrest and cell senescence <i>in vitro</i>, which was accompanied by the decrease in phosphorylated AKT and ERK1/2 and an increase in p21 and p16.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Thus, NCTD is an underlying adjuvant treatment for TNBC. Moreover, a Raf1/ERK dual inhibitor 9d (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>87</b>) has been discovered to inhibit the proliferation of TNBC cells and induce apoptosis through the mitochondrial pathway.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> AZD2014 (an mTORC1/2 dual inhibitor) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>88</b>) and PF-04691502 (a PI3K/mTOR dual inhibitor) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>89</b>) exhibited significant antitumor activity in TNBC PDX, which is not sensitive to the AR antagonist.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In addition, the compound Torin2 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>90</b>) can prevent proliferation and induce cell death of PI3K-activated TNBC; reconstitution experiments and analysis of chemical analogues both show that its activity in TNBC is the result of co-inhibition of mTOR and other PIKKs, which affects multiple kinases involved in cell cycle S phase progression and cell cycle checkpoints, leading to single-stranded DNA accumulation, replication mutations, or mitotic failure and death.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> It is suggested that the therapeutic potential of TNBC for development of <b>90</b> analogues or existing mTOR combined with PIKK inhibitors.</div><div class="NLM_p">Recently, the JAK/STAT pathway has been reported to be particularly abundant in the IM subtypes of TNBC.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (IKBKE) is overexpressed in TNBC and activated nuclear factor kappa-B (NF-κB), STAT, and cytokine signaling in TNBC.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a><b>91</b>, a dual-target inhibitor of the TANK-binding kinase 1 (TBK1)/IKBKE and JAK signaling pathways, has been found to inhibit the activation of NF-κB and STAT in TNBC induced by IKBKE and block the expression of CC chemokine ligand-5 (CCL5) and IL-6, whereas the addition of CCL5 and IL-6 not only promotes the proliferation of tumor spheres but also promotes the proliferation and migration of endothelial cells.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a><b>91</b> can block cytokine signaling and affect the growth of TNBC cells and PDX driven by IKBKE.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Thus, IKBKE-related cytokine signaling can promote the immune-driven tumorigenicity of TNBC, suggesting the therapeutic potential of <b>91</b>.</div><div class="NLM_p">A series of 3-(phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>] pyrimidin-4-amine derivatives have been reported to be a new class of SRC inhibitors.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Compound <b>32</b> is discovered as a SRC/B-Raf/c-raf multikinase inhibitor and induces the apoptosis of tumor cells owing to a significant inhibition of SRC and MAPK signaling. In a TNBC xenograft mouse model, compound <b>32</b> continuously and completely inhibits tumor growth, with an inhibition rate of more than 100%, no obvious toxicity, and good pharmacokinetic characteristics.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In addition, <i>N</i>-(3-((4-amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo-pyrimidin-3-yl) ethynyl)-4-methylphenyl)-3-(trifluoromethyl) benzamide, called SKLB646 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>92</b>), has been reported to show quite high efficacy against SRC, VEGFR2, and Raf targets, can be found to inhibit tumor growth dose dependency, and significantly inhibits the invasion and migration of TNBC cells by inhibiting SRC and blocking MAPKs.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> In a model of experimental lung metastasis, compared with control, <b>34</b>, and paclitaxel treatment groups, the overall survival of the <b>92</b> treatment group is longer.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> These preclinical data suggest that <b>92</b> may be a prospective drug for the therapy of TNBC. Since DFG-out conformation inhibitors of c-SRC are shown to be superior to FDA-approved c-SRC inhibitors, they synthesized an analogue of <b>34</b>, termed UM-164 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>93</b>), that binds c-SRC and forces a DFG-out inactive conformation.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Investigation of the c-SRC/p38 dual inhibitor <b>93</b> showed that the inhibition of dual-target c-SRC/p38 is better than that of single c-SRC or p38.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> In the xenotransplantation model of TNBC, <b>93</b> significantly reduces tumor growth with limited toxicity <i>in vivo</i>.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> A SRC/kinase-insert domain receptor (KDR)/MAPK multikinase inhibitor obtained by structural optimization, 13an (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>94</b>), showed remarkable antitumor activity <i>in vivo</i> and <i>in vitro</i>, with good pharmacokinetic properties and low toxicity.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Additionally, MS645 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>95</b>), a dual BRD4/BRDs thienodiazepine-based inhibitor, provided space-limited tandem BRD inhibition and therefore continuously inhibiting BRD4 transcriptional activity to block TNBC proliferation.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Its potency is superior to monovalent BET inhibitors. The specific killing of tumor cells observed due to the lack of DDK has aroused people’s interest as a target of cancer treatment drugs.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The first DDK inhibitor was the pyrrolopyridinone molecule, <b>96</b>. It has demonstrated potent inhibition of DDK/CDK9 with strong antiproliferative activity against three TNBC cells by inducing cell cycle arrest. It is suggested that the dual inhibition of <b>96</b> on DDK and CDK9 is a potential strategy for TNBC which DDK is overexpressed and sensitive to apoptosis.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Proline-rich tyrosine kinase 2 (PYK2) is a common downstream effector of EGFR, CMET, and their crosstalk in some TNBC cells, the activated PYK2 existed mainly in basal breast cancer and is related to high expression of EGFR and activated ERK1/2, and FAK was often highly expressed in TNBC.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> PYK2 and FAK may be potential therapeutic targets for TNBC. The PYK2/FAK dual inhibitor PF431396 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>97</b>) reduces the growth of TNBC cells by 10–70% in clinical samples and database analysis, and the growth inhibition of basal-like cells is stronger than that of mesenchymal cells.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><div class="NLM_p last">Foretinib (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>98</b>) is an oral multikinase inhibitor of the MET, recepteur d’origine nantais (RON), anexelekto (AXL), and tyrosine kinase receptors with immunoglobulin and EGF homology domains receptors-2 (TIE-2) and VEGF receptors. A two-stage single-arm trial showed a CBR of 46% in the TNBC population, indicating that the MET/KDR dual-target inhibitor <b>98</b> has clinical activity as a single non-cytotoxic drug in TNBC.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> The cell-division-driven Aurora A and B mitotic kinases are overexpressed in various tumor types including TNBC with a high mitotic index.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> KW-2450 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>99</b>), a multikinase inhibitor of Aurora A/B kinases and insulin-like growth factor I receptor (IGF-IR), significantly inhibits the growth of TNBC xenografts through the tetraploid accumulation, apoptosis, or survival of octaploid (8N) cells.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">4.2.  Drug Combination</h3><div class="NLM_p">Compared with single therapy, combination therapy has great potential for improving curative effects, reducing drug toxicity, and overcoming drug resistance.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Although it has been recognized that combination therapy has a potential therapeutic effect on TNBC, only a few successful studies optimize TNBC treatment through manageable drug delivery strategy, thus improving the therapeutic effect and manageable toxicity.<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144,145)</a> Drug combination is a popular treatment for TNBC treatment.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Here, we mainly discussed some drug combination strategies (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>), including combination among small-molecule drugs,<a onclick="showRef(event, 'ref20 ref32 ref64 ref84 ref90 ref123 ref138 ref139 ref140 ref141 ref142 ref143 ref144 ref145 ref146 ref147 ref148 ref149 ref150 ref151 ref152 ref153 ref154 ref155 ref156 ref157 ref158 ref159 ref160 ref161 ref162 ref163 ref164 ref165 ref166 ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref20 ref32 ref64 ref84 ref90 ref123 ref138 ref139 ref140 ref141 ref142 ref143 ref144 ref145 ref146 ref147 ref148 ref149 ref150 ref151 ref152 ref153 ref154 ref155 ref156 ref157 ref158 ref159 ref160 ref161 ref162 ref163 ref164 ref165 ref166 ref167 ref168">(20,32,64,84,90,123,138−168)</a> combination of small-molecule drugs and chemotherapy,<a onclick="showRef(event, 'ref13 ref55 ref70 ref73 ref169 ref170 ref171 ref172 ref173 ref174 ref175 ref176 ref177 ref178 ref179 ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref13 ref55 ref70 ref73 ref169 ref170 ref171 ref172 ref173 ref174 ref175 ref176 ref177 ref178 ref179 ref180 ref181">(13,55,70,73,169−181)</a> combination of small-molecule drugs and antibody,<a onclick="showRef(event, 'ref177 ref182 ref183 ref184'); return false;" href="javascript:void(0);" class="ref ref177 ref182 ref183 ref184">(177,182−184)</a> and other combinations about small-molecule drugs.<a onclick="showRef(event, 'ref185 ref186 ref187 ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref185 ref186 ref187 ref188 ref189">(185−189)</a></div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. Combination of Targeted Small-Molecule Drugs in TNBC</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound 1 (name, target)</th><th class="colsep0 rowsep0" align="center">compound 2 (name, target)</th><th class="colsep0 rowsep0" align="center">compound 3 (name, target)</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>100</b> (Gefitinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>97</b> (PF431396, PYK2/FAK inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, UNS</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>101</b> (Erlotinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>102</b> (MGCD265, MET inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>101</b> (Erlotinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>102</b> (Crizotinib, MET inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b> (Lapatinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>16</b> (Veliparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02158507 (not applicable)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b> (Lapatinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>98</b> (Foretinib, MET/KDR inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b> (Lapatinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>96</b> (PHA-767491, DDK/CDK9 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>101</b> (Erlotinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>96</b> (PHA-767491, DDK/CDK9 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>100</b> (Gefitinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>96</b> (PHA-767491, DDK/CDK9 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>102</b> (Afatinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>34</b> (Dasatinib, SRC inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, BL2, M, MSL, IM, UNS</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b> (Selumetinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>104</b> (Ipatasertib, AKT inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, M, MSL, LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>105</b> (CY-9d, Raf/ERK inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>106</b> (AUY922, HSP90 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>107</b> (AZD6244, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>10</b> (Buparlisib, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>107</b> (AZD6244, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>108</b> (Pazopanib, PDGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>109</b> (AS703026, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>110</b> (SAR245409, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b> (E6201, MEK1 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>13</b> (Everolimus, mTOR 1 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b> (E6201, MEK1 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>51</b> (Palbociclib, CDK4/6 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>111</b> (Trametinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>111</b> (Trametinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>112</b> (Ponatinib, broad-spectrum tyrosine kinase inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IM</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>111</b> (Trametinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>91</b> (CYT387, TBK 1/IKBK + JAK inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b> (Selumetinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>113</b> (AZD-1480, JAK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left">PDGFR inhibitor</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>111</b> (Trametinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>44</b> (JQ1, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>111</b> (Trametinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>114</b> (I-BET151, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>109</b> (AS703026, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>69</b> (Entinostat, HDAC1/2/3 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>115</b> (PD0325901, MEK inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>116</b> (NVP-AEW541, IGF-1R inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>115</b> (PD0325901, MEK inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>117</b> (BKM120, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>115</b> (PD0325901, MEK inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>118</b> (KU0063794, mTORC1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>116</b> (NVP-AEW541, IGF-1R inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>118</b> (KU0063794, mTORC1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b> (Selumetinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>99</b> (KW-2450, Aurora A/B kinase + IGF-IR inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL, BL2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>119</b> (Taselisib, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>120</b> (Enzalutamide, AR inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02457910 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>121</b> (Alpelisib, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>120</b> (Enzalutamide, AR inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT03207529 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>122</b> (GSK2141795, AKT inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>111</b> (Trametinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01964924 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>123</b> (AZD5363, AKT inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02208375 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>104</b> (Ipatasertib, AKT inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>7</b> (Cobimetinib, MEK1 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01562275 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>124</b> (ARQ092, pan-AKT inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>125</b> (Anastrozole, aromatase inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02476955 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>126</b> (Rapamycin, mTOR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>127</b> (AEE788, EGFR/HER2 + VEGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>128</b> (Dactolisib, PI3K/mTOR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>13</b> (Everolimus, mTOR 1 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IM, MSL, LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b> (Everolimus, mTOR 1 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>14</b> (Talazoparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b> (Everolimus, mTOR 1 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>129</b> (Eribulin, microtubule inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02616848 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>88</b> (AZD2014, mTORC1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02208375 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>88</b> (AZD2014, mTORC1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>103</b> (Selumetinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02583542 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>130</b> (Temsirolimus, mTOR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>131</b> (Neratinib, tyrosine kinase inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02723877 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>132</b> (PQR309, PI3K/mTOR inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>129</b> (Eribulin, microtubule inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02723877 (phase 1/2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>133</b> (Suberoylanilide hydroxamic acid, HDAC inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b> (Veliparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>78</b> (Dinaciclib, CDK12 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, M, MSL, UNS</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>134</b> (Prexasertib, Chk1 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL, LAR</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>135</b> (Perifosine, UCHL3 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b> (Palbociclib, CDK4/6 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>119</b> (Taselisib, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT 02389842 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b> (Abemaciclib, CDK4/6 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>85</b> (Lapatinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, BL2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b> (Palbociclib, CDK4/6 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>121</b> (Alpelisib, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b> (Palbociclib, CDK4/6 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>136</b> (BEZ235, PI3K/mTORC1 + 2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b> (Palbociclib, CDK4/6 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>117</b> (BKM120, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>137</b> (Irinotecan, TOP1 inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>138</b> (VE-822, ATR inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b> (JQ1, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>139</b> (GSK525762A, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b> (JQ1, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>140</b> (ABT737, BCL-xL inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b> (JQ1, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>141</b> (CX-4945, CK2 inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b> (JQ1, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>142</b> (Phenothiazine, PP2A activator)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b> (JQ1, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>143</b> (Perphenazine, PP2A activator)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b> (JQ1, BET inhibitor)</td><td class="colsep0 rowsep0" align="left"><b>144</b> (GSK2801, BAZ2/BRD9 Bromodomain inhibitor)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b> (Lapatinib, EGFR inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT00075270 (phase 3)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>145</b> (Apatinib, VEGFR2 inhibitor)</td><td class="colsep0 rowsep0" align="left">Cisplatin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>123</b> (AZD5363, AKT inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02423603 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>104</b> (Ipatasertib, AKT inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02162719 (phase 2), NCT02301988 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>124</b> (ARQ092, pan-AKT inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left">Carboplatin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02476955 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>124</b> (ARQ092, pan-AKT inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02476955 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b> (MK-2206, AKT inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01042379 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b> (Buparlisib, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01572727 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b> (Everolimus, mTOR 1 inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT00499603 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b> (Dasatinib, SRC inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b> (Everolimus, mTOR 1 inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left">Cisplatin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT00930930 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>146</b> (Riluzole, mGluR1 inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b> (NTRC 0066-0, TTK inhibitor)</td><td class="colsep0 rowsep0" align="left">Docetaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b> (LCL161, IAP inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01617668 (phase 2)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b> (Nirogacestat, γ-secretase inhibitor)</td><td class="colsep0 rowsep0" align="left">Docetaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT01876251 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b> (Dinaciclib, CDK2 inhibitor)</td><td class="colsep0 rowsep0" align="left">Tamoxifen</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>147</b> (EPZ-6438, EZH2 inhibitor)</td><td class="colsep0 rowsep0" align="left">Tamoxifen</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>148</b> (LY2157299, TGF-βRI inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>149</b> (NVP-LDE225, Smo inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>150</b> (Metformin, STAT3 inhibitor)</td><td class="colsep0 rowsep0" align="left">Cisplatin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>151</b> (Digoxin, HIF1 inhibitor)</td><td class="colsep0 rowsep0" align="left">Carboplatin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>151</b> (Digoxin, HIF1 inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>152</b> (SB203580, p38 MAPK inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>153</b> (PF3644022, p38 regulated/activated kinase inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>154</b> (LY2228820, p38 inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b> (TD19, SET inhibitor)</td><td class="colsep0 rowsep0" align="left">Cisplatin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b> (Bazedoxifene, IL 6/glycoprotein 130 inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>155</b> (SC-60, SHP-1 agonist)</td><td class="colsep0 rowsep0" align="left">Docetaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>156</b> (INCB050465, PI3K inhibitor)</td><td class="colsep0 rowsep0" align="left">Pembrolizumab, anti-PD-1 antibody</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT02646748 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>130</b> (Temsirolimus, mTOR inhibitor)</td><td class="colsep0 rowsep0" align="left">Doxorubicin</td><td class="colsep0 rowsep0" align="left">Bevacizumab, anti-VEGF antibody</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left">NCT00761644 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b> (Everolimus, mTOR inhibitor)</td><td class="colsep0 rowsep0" align="left">Doxorubicin</td><td class="colsep0 rowsep0" align="left">Bevacizumab, anti-VEGF antibody</td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left">NCT00761644 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Carboplatin</td><td class="colsep0 rowsep0" align="left">Gemcitabine</td><td class="colsep0 rowsep0" align="left">Panitumumab, anti-EGFR antibody</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NCT00894504 (phase 2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>111</b> (Trametinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left">α-PD-1/α-PD-L1, anti-PD-1 antibody/anti-PD-L1 antibody</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b> (Selumetinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left">α-PD-1/α-PD-L1, anti-PD-1 antibody/anti-PD-L1 antibody</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b> (Olaparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left">IMMU-132, anti-Topo I antibody</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL1, BL2, MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b> (Talazoparib, PARP 1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left">IMMU-132, anti-Topo I antibody</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BL2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>157</b> (A-419259, SRC-family kinase inhibitor)</td><td class="colsep0 rowsep0" align="left">MOv18-IgG1, anti-FRα antibody</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>158</b> (Verteporfin, YAP inhibitor)</td><td class="colsep0 rowsep0" align="left">Paclitaxel</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b> (JQ1, BET inhibitor)</td><td class="colsep0 rowsep0" align="left">Polydopamine nanoparticles</td><td class="colsep0 rowsep0" align="left">Photothermal therapy</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b> (Selumetinib, MEK1/2 inhibitor)</td><td class="colsep0 rowsep0" align="left">Tumor Associated Macrophages</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>159</b> (YCW1, HDAC inhibitor)</td><td class="colsep0 rowsep0" align="left">Infrared Radiation</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>160</b> (Regorafenib. VEGFR1/2/3 + PDGFRβ + Kit + RET + Raf-1 inhibitor)</td><td class="colsep0 rowsep0" align="left">Radiotherapy</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a></td></tr></tbody></table></div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37">4.2.1.  Small-Molecule Drug Combination</h4><div class="NLM_p">EGFR is highly expressed in approximately 69% of TNBC cases, and the overexpression of EGFR is related to poor prognosis.<a onclick="showRef(event, 'ref190 ref191'); return false;" href="javascript:void(0);" class="ref ref190 ref191">(190,191)</a> Unfortunately, the treatment of EGFR inhibitors or EGFR monoclonal antibodies alone has mostly minor effects in TNBC.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> Therefore, the combined application of EGFR inhibitors and other kinase inhibitors has become a new potential treatment strategy for TNBC (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <b>100</b>–<b>102</b>). EGFR and PYK2/FAK have been reported to effectively inhibit the treatment of high expression basal patients TNBC in EGFR.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The synergistic effect of gefitinib (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <b>100</b>) combined with <b>97</b>, a dual inhibitor of PYK2/FAK, on TNBC cells was better than that of <b>100</b> or <b>97</b> single drug treatment and circumvented HER3-related resistance through the NEDD4-NDRG1 axis, further emphasizing the efficacy and potential clinical significance of EGFR-PYK2/FAK in TNBC.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The combination of the EGFR inhibitor erlotinib (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <b>101</b>) and the MET inhibitor MGCD265 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <b>102</b>) can effectively inhibit tumor growth and significantly reduce the variability in treatment response compared with single drug treatment.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> It is indicated that combined inhibition of Met and EGFR may be a promising treatment strategy for patients with TNBC.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of <b>100</b>–<b>102</b> related to EGFR inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The EGFR inhibitor lapatinib (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, <b>85</b>) combined with the PARP inhibitor <b>16</b> have antitumor effects in locally advanced/metastatic TNBC.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> The combination of EGFR inhibitor <b>85</b> and Met inhibitor <b>98</b> effectively reduces the survival rate of TNBC, leading to G2/M phase block and decreased pAKT.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> The number of invaders decreases, the ability to digest gelatin decreases, and the capacity for cell migration/invasion decreases. It is suggested that the combination of an EGFR inhibitor and Met inhibitor is more effective.</div><div class="NLM_p"><b>96</b>, a dual Cdc7-Dbf4 (DDK)/CDK9 inhibitor, is reported to be used together with a variety of EGFR-TKIs, including <b>85</b>, <b>100</b>, and <b>101</b>, to conquer the resistance of different TNBC cells to EGFR targeted therapy.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Compared with single inhibition, EGFR and DDK/CDK9 combined inhibition can reduce cell proliferation, apoptosis, cell cycle arrest, DNA replication inhibition, and CDK9-mediated transcription extension.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> RNA sequencing has revealed that the regulatory pathway of cell proliferation, transcription, and survival is significantly downregulated by EGFR-TKI and DDK/CDK9.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Moreover, the dual inhibition of <b>96</b> on DDK and CDK9 is a potential strategy to target TNBC against EGFR-TKIs. The combination of the EGFR inhibitor afatinib and the SRC inhibitor <b>34</b> can induce cell cycle arrest and inhibit pERK and pAKT, and the low baseline B-cell lymphoma 2 (BCL2) and mTOR are related to the synergistic growth inhibition of the combination of afatinib and <b>34</b>.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> In the model of TNBC xenotransplantation, combined therapy inhibits tumor growth, showing that <b>34</b> combined with afatinib has an underlying clinical effect on TNBC.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><div class="NLM_p">It is well-known that the MEK/ERK pathway can be activated in TNBC, providing a possible target for the intervention of TNBC. TNBC was very sensitive to MEK inhibition <i>in vivo</i> but, due to the reprogramming of the kinome, can exhibit drug resistance without combined treatment. Currently, combination strategies with MEK/ERK inhibitors are currently needed to improve efficacy (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>103</b>–<b>118</b>). The resistance of MEK inhibitors is due to the crosstalk between PI3K/AKT/mTOR and Raf/MEK/ERK signaling pathways. The combination of the MEK inhibitor selumetinib (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>103</b>) and the AKT inhibitor ipatasertib (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>104</b>) can reverse the resistance of MEK inhibitors.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Moreover, CDK inhibitors targeting the cell cycle can conquer the dual resistance of MEK and AKT inhibitors. For example, flavopiridol and dinaciclib, CDK inhibitors, can inhibit the proliferation of TNBC cells which are resistant to MEK inhibitors and AKT inhibitors.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of <b>103</b>–<b>118</b> related to MEK/ERK inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Heat Shock Protein 90 (HSP90) inhibitor CY-9d (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>105</b>) and Raf/ERK dual-target inhibitor AUY922 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>106</b>) have synergistic therapeutic and apoptosis-inducing effects on TNBC cells, with no significant toxicity.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> The combinations of a MEK inhibitor and PI3K inhibitor and a MEK inhibitor and PDGFR inhibitor were simple and reasonable. The combination of the MEK inhibitor AZD6244 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>107</b>) and the PI3K inhibitor buparisib or the PDGFR inhibitor pazopanib (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>108</b>) has synergistic effects on TNBC cells.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> The survival rate of TNBC was improved by the combination of the MEK inhibitor AS703026 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>109</b>) and the PI3K inhibitor SAR245409 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>110</b>), which reduced colony formation (<i>P</i> < 0.001) and migration invasion ability (<i>P</i> < 0.01) compared with the two drugs alone, and has a synergistic effect on the inhibition of proliferation (<i>P</i> < 0.001) .<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The combined antitumor effect of the MEK1 inhibitor <b>6</b> combined with the mTOR inhibitor <b>13</b> or the CDK4/6 inhibitor palbociclib (<b>51</b>) was observed in TNBC cells.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The MEK inhibitor trametinib (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>111</b>), the PARP inhibitor <b>15</b>, as well as the broad-spectrum tyrosine kinase inhibitor ponatinib (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>112</b>) have been reported to have synergistic cytotoxic binding reactions in the TNBC cell line DU-4475.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> The combination of <b>91</b>, a dual inhibitor of the TBK1/IKBK and JAK signaling pathways, and metinib, a MEK inhibitor, is particularly effective in the treatment of a TNBC invasive PDX model, which can inhibit tumor growth and angiogenesis.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> It reveals that the combined inhibition of TBK1/IKBKE, Jak, and MEK would be an effective treatment strategy.</div><div class="NLM_p">Interestingly, TNBC cells treated with diversified small-molecule inhibitors containing JAK2 displayed the upregulated expression of PDGFR β.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> In the nonanchored growth experiment, the TNBC cells induced by MEK1/2-JAK2 show resistant colonies. The triple blocking effect of the PDGFR β inhibitor imatinib, the JAK2 inhibitor AZD-1480 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>113</b>), and the MEK1/2 inhibitor <b>103</b> can completely eliminate the resistant colonies <i>in vitro</i>. Moreover, BRD4 bromodomain inhibitors <b>44</b> and I-BET151 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>114</b>) can overcome the resistance of the MEK inhibitor <b>111</b> and produce sustained growth inhibition in cells, xenografts, and isogenic mouse TNBC models.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> The main mechanism was that BRD4 bromodomain inhibitors can block the adaptive upregulation of PDGFRB, DDR1, FGFR2, and DDR1 induced by <b>111</b>, and the combined treatment increases BIM, indicating that a single drug cannot cause proapoptotic initiation. The combination of histone deacetylase (HDAC) inhibitor entinostat and the MEK inhibitor <b>109</b> inhibited tumor growth and TNBC cell growth.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div><div class="NLM_p">Combined application of the MEK inhibitor PD0325901 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>115</b>) and the IGF-1R inhibitor NVP-AEW541 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>116</b>), the PI3K inhibitor BKM120 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>117</b>), or the mTOR inhibitor KU0063794 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, <b>118</b>) and the combination of the IGF-1R inhibitor <b>116</b> and the mTOR inhibitor <b>118</b> show significant synergistic growth inhibition of TNBC cells.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Compared with single treatment, these two therapies increased cell apoptosis and cell cycle arrest and inhibit downstream molecules AKT or mTORC1 phosphorylation.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The treatment of the MEK inhibitor <b>103</b> combined with the multikinase inhibitor <b>99</b> observably decreases the 8N cell population and increases apoptosis compared with <b>99</b> treatment alone.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Indeed, this combined application results in a synergistic antitumor effect in TNBC xenografts. A clinical trial of <b>34</b> in a TNBC population has revealed that its curative effect is limited.</div><div class="NLM_p">Although PI3K/AKT/mTOR-targeted intervention can prolong survival rate, TNBC patients ultimately generate resistance to PI3K/AKT/mTOR inhibitors and lead to unsatisfactory results. At this time, alternative combination treatments for drug-resistant TNBC therapy have become necessary. At present, preclinical trials and clinical trials have proved that some combined strategies of PI3K/Akt/mTOR inhibitors are effective, providing a breakthrough point for drug resistance of the PI3K/Akt/mTOR pathway (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>119</b>–<b>132</b>). A phase 1 clinical trial (NCT 02389842) evaluated the effect of the PI3K inhibitor taselisib (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>119</b>) combined with the CDK4/6 inhibitor <b>51</b> in the treatment of metastatic breast cancer. In addition, there are some other clinical trials that have also proved that the PI3K/Akt/mTOR inhibitor combination strategy is promising, such as combination of the AR inhibitor enzalutamide (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>120</b>) and the PI3K inhibitor alpelisib (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>121</b>) in a phase 1 clinical trial (NCT 03207529), combination of the AKT inhibitor GSK2141795 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>122</b>) and the MEK1/2 inhibitor <b>111</b> in a phase 2 clinical trial (NCT 01964924), combination of the AKT inhibitor AZD5363 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>123</b>) and the PARP 1/2 inhibitor <b>15</b> in a phase 2 clinical trial (NCT 02208375), and combination of the pan-AKT inhibitor ARQ092 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>124</b>) and the aromatase inhibitor anastrozole (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>125</b>) in a phase 1 clinical trial (NCT 02476955). Rapalog therapy can release the negative feedback of mTOR from upstream kinases and activate compensatory pathways such as the MAPK/ERK and PI3K/AKT pathways, thus bypassing the inhibition of mTOR.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Also, rapamycin (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>126</b>), a selective mTOR inhibitor, combined with AEE788 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>127</b>), a multi-RTK (VEGFR and EGFR/HER2) inhibitor, can effectively inhibit the phosphorylation of mTOR and eukaryotic translation initiation factor 4E-binding protein (4EBP1), reduces the upregulation of cyclin D1 mediated by mTOR inhibition, maintains inhibition of the AKT and ERK pathways, and sensitizes TNBC cells to <b>126</b>.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Moreover, the combination of the PI3K/mTOR dual inhibitor dactolisib (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>128</b>) and the mTOR inhibitor <b>13</b> can enhance the cytotoxic effects in TNBC cell lines DU4475 and CAL-148 but only enhances the activity inhibition ability in the TNBC cell line MDA-MB-231, without any cumulative effect on cytotoxicity.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> The mTOR inhibitor <b>13</b> combined with the PARP inhibitor <b>14</b> can improve the effect compared with either drug alone. Also, the mTOR inhibitor is shown to inhibit HR repair and the synergy of PARP inhibitors by regulating the expression of SUV39 H1 in BRCA-proficient TNBCs.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> In clinical trials, the combination strategy of mtor inhibitors is often studied, such as combination of mTOR 1 inhibitor <b>13</b> and microtubule inhibitor eribulin (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>129</b>) in a phase 1 clinical trial (NCT 02616848), combination of mTOR inhibitor temsirolimus (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>130</b>) and tyrosine kinase inhibitor neratinib (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>131</b>) in a phase 1/2 clinical trial (NCT 02723877), and combination of mTOR inhibitor PQR309 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>132</b>) and microtubule inhibitor <b>129</b> in a phase 1/2 clinical trial (NCT 02723877).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of <b>119</b>–<b>132</b> related to PI3K/Akt/mTOR inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PARP inhibitors in combination with chemotherapy or radiotherapy can kill human cancer cells more effectively than PARP inhibitors alone.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Therefore, there is an imperative demand to develop new therapies of PARP inhibitors combined with molecular targeted drugs to overcome TNBC resistance to chemotherapy (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, <b>133</b>–<b>135</b>). The PARP inhibitor <b>15</b> combined with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, <b>133</b>) inhibited the growth of TNBC cells expressing functional PTEN by downregulating the proliferation, increasing apoptosis, autophagy death, and accumulating DNA damage; it also has an antitumor effect in a TNBC xenotransplantation model.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> In Myc-driven TNBC cells, Myc blockade combined with PARP inhibition produced synthetic lethality.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> In BRCA mutant TNBC cells, the ruthenium(II) polypyridyl complex (RPC) metal intercalation agent Ru-PIP combined with the PARP inhibitor <b>15</b> can enhance G2/M cell cycle arrest and apoptosis and decrease cell viability, without damaging DNA double-strand break (DSB) compared with PARP inhibitor monotherapy, and is not easy to cause a large number of cytotoxic and potential genotoxic DSB damage.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of <b>133</b>–<b>135</b> related to PARP inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dinaciclib, a CDK 1/2/5/9 inhibitor, has a strong inhibitory effect on the transcription regulator CDK12 of HR. In BRCA mutant TNBC cells and PDXs, dinacilib can ablate the restored HR and reversed resistance to <b>16</b>, a PARP inhibitor, enhances the response of the sensitive model of the PARP inhibitor, and transformed tumor growth inhibition into persistent degeneration.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> The expression of RAD51 in TNBC is higher than that in normal breast tissue, and expression of RAD51 and CHEK1 in BC is positively relevant.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> The combination of the checkpoint kinase 1 (CHK1) inhibitor prexasertib (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, <b>134</b>) and PARP inhibitor <b>15</b> has a synergistic effect in TNBC cells, with increased DNA strand breaks, phosphorylated form of H2AX histone variant (γ-H2AX) lesions, and mitosis compared with single drug therapy.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> The reasonable combination of <b>134</b> and <b>15</b> may provide an additional mechanistic insight for improving the prognosis of TNBC. Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCHL3) may act as a deubiquitinating enzyme by deubiquitinating RAD51, thus increasing the recruitment of RAD51 to the site of DNA damage and enhancing DNA repair.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Perifosine (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, <b>135</b>), an inhibitor of UCHL3, is reported to reduce the activity of RAD51 by inducing the RAD51 ubiquitination and blocking the interaction of BRCA2–RAD51, consequently reducing the repair of DNA double-strand breaks mediated by homologous recombination (HR).<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> The inhibitor of UCHL3, <b>135</b>, enhanced growth inhibition in TNBC cells induced by <b>15</b>, and <b>135</b> combined with <b>15</b> demonstrated synergistic antitumor activity in TNBC xenotransplantation.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></div><div class="NLM_p">In clinical trials, inhibition of CDK4/6 is an effective treatment strategy for ER-positive BC (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). However, TNBC is a molecular heterogeneous disease with negative ER expression and has shown resistance to single-drug CDK4/6 inhibition. TNBC with PIK3CA mutation was reported to be sensitive to CDK4/6 inhibition.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> The double blockade of PI3Kα and CDK4/6 has synergistic effects on a variety of wild-type TNBC models.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> PI3Kα and CDK4/6 could block the cell cycle processes, DNA damage response, and immune regulation of TNBC and might be a novel treatment for TNBC.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> The death effector domain DNA-binding protein (DEDD) with death domain is overexpressed by more than 60% in TNBC, and the overexpression of DEDD made TNBC susceptible to cell cycle inhibition.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The combination therapy of the CDK4/6 inhibitor abemaciclib and the EGFR inhibitor <b>85</b> showed a DEDD-dependent sensitivity.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> A CDK4/6 inhibitor <b>51</b>, by inhibiting the PI3K/mTOR and CDK4/6/Rb/Myc signaling pathways, sequentially combined with the PI3K/mTOR inhibitors <b>122</b> or BEZ235 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>, <b>136</b>) or <b>117</b> produced synergistic antiproliferation and pro-apoptosis effects in TNBC cells.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of <b>136</b> related to CDK4/6 inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the above hot target combination strategy, there are some other target combination strategies that are also effective in the treatment of TNBC (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>137</b>–<b>144</b>). The topoisomerase I (TOP1) inhibitor captures the TOP1 cleavage complex, which causes DNA double-strand breaks (DSB) and homologous recombination (HR) repairs. Given that a significant percentage of TNBCs have HR-mediated repair defects (BRCAness), TNBCs may respond to TOP1 inhibitors. The antitumor effect of the TOP1 inhibitor irinotecan (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>137</b>) was detected in some TNBC PDXs.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The ATR inhibitor VE-822 (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>138</b>) promoted the sensitivity of <b>137</b> to SLFN11-negative PDXs and eliminated <b>137</b>-induced CHK1 phosphorylation.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The combined effect of <b>137</b> with ataxia telangiectasia and the Rad3-related protein (ATR) inhibitor <b>138</b> is verified in SLFN11-negative PDX.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The BET inhibitors <b>44</b> or GSK525762A (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>139</b>) could induce a dose-dependent reduction in BRCA1 and RAD51 levels, prevent homologous recombination-mediated DNA damage repair, and produce a BRCAness phenotype in TNBC cells.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> The BET inhibitors <b>44</b> or <b>139</b> can make TNBC BRCA1 wild-type cells sensitive to the PARP inhibitor <b>15</b> and trigger synthetic lethality when used in combination.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> The MET inhibitor <b>44</b> combined with the Bcl-xL inhibitor ABT737 (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>140</b>) or the CK2 inhibitor CX-4945 (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>141</b>) have significant synergistic effects in TNBC cells.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The PP2A activator phenothiazine (PTZ) (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>142</b>) and the PP2A activator perphenazine (PPZ) (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>143</b>) or the BAZ2/BRD9 bromodomain inhibitor GSK2801 (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <b>144</b>) combined with the BET inhibitor <b>44</b> can block BRD2-driven transcription, thereby inducing TNBC cell apoptosis.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structures of <b>137</b>–<b>144</b> related to some other target inhibitors or activators in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38">4.2.2.  Combination of Chemotherapy and Small-Molecule Drugs</h4><div class="NLM_p">Cytotoxic chemotherapy, such as with taxanes, is initially effective in most patients with metastatic TNBC. The recurrence of metastatic tumors is characterized by rapid proliferation of drug-resistant cancer accompanied by high mortality. Chemotherapy alone does not lead to significant improvement and often leads to drug resistance. Currently, evidence is mounting to show that the combination of chemotherapy and small-molecule drugs has a significant effect on the treatment of TNBC (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>145</b>–<b>155</b>).</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of <b>145</b>–<b>155</b> related to chemotherapy in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Apatinib (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>145</b>), an inhibitor of VEGFR2, can enhance the antitumor effect of cisplatin on TNBC cells by inhibiting the levels of p-VEGFR2, p-AKT, and p-mTOR.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> It is suggested that the combination of apatinib and cisplatin may be a potential approach in the treatment of TNBC, in addition to demonstrating direct antiproliferative activity. The efficacy and safety of an AKT inhibitor, AZD5363 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, <b>123</b>), have been reported in combination with paclitaxel for the treatment of transferable TNBC (pAKT study).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> It is shown that <b>123</b> combined with paclitaxel extended PFS and OS in the first-line therapy of metastatic TNBC. The benefit of the AKT1/PTEN signaling pathway mutation subgroup <b>123</b> is more pronounced. The AKT inhibitor <b>104</b> combined with paclitaxel as the first-line treatment of locally advanced or metastatic TNBC in a double-blind, placebo-controlled, randomized phase 2 clinical trial (LOTUS study) showed that patients treated with the <b>104</b> combination can benefit from an extended OS of approximately 5 months.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div><div class="NLM_p">The mTOR inhibitor <b>13</b> can synergistically enhance taxane-induced BC cytotoxicity <i>in vitro</i> and <i>in vivo</i>. A phase 2 study randomized patients with primary TNBC into T-FEC (paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide) and TR-FEC (paclitaxel and <b>13</b>) treatments.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> In the TR-FEC group, <b>13</b> can downregulate mTOR signaling, and the addition of <b>13</b> to paclitaxel is well tolerated, suggesting that paclitaxel combined with <b>13</b> has a certain effect in the treatment of TNBC. The aggressive phenotype of TNBC is partly due to the presence of breast cancer stem cells (BCSCs).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Therefore, targeting BCSCs is an important way to overcome the failure of TNBC chemotherapy. Interestingly, the combination of the SRC inhibitor <b>34</b> and paclitaxel can not only reduce the number of BCSCs and the ability to form spheres of paclitaxel-resistant TNBC cells but also decrease the cell viability and tumor growth.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> These data indicate that <b>34</b> is a prospective anti-BCSC drug which can be used in combination with paclitaxel to conquer TNBC resistance.</div><div class="NLM_p">Riluzole (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>146</b>) has the function of a metabotropic glutamate receptor subtype1 (mGluR1) inhibitor and reduced cell proliferation and tumor growth.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> All tested TNBC cells have been found to have a synergistic response to <b>146</b> and paclitaxel, which strongly suggested the effectiveness of this combined treatment strategy in TNBC, especially in those patients with tumor resistance to paclitaxel.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a><b>146</b> combined with paclitaxel inhibited the proliferation, invasion, and colony formation of TNBC, suggesting that the combination of <b>146</b> and paclitaxel plays a role in the systemic treatment of TNBC.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The combined application of the truncated thymidine kinase (TTK) inhibitor NTRC 0066-0 and the therapeutic dose of docetaxel doubled the survival rate of TNBC mouse models, can prolong tumor remission time, and has no toxic side effects.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Only the combined administration of two compounds can achieve a therapeutic effect, indicating that the TTK inhibitor NTRC 0066-0 has a synergistic effect <i>in vivo</i> with docetaxel.</div><div class="NLM_p">More recently, a study randomly assigned 209 patients with TNBC localization (1:1) to a combination group treated with LCL161 orally and paclitaxel intravenously or the control group treated with paclitaxel alone.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> The 12-week follow-up results have shown that the combination group is higher than that of the control group (38.2% vs 17.2%), which is statistically significant. It is suggested that LCL161 can enhance the efficacy of paclitaxel and provide a new targeted therapy for TNBC patients. To determine whether the combination therapy of dinaciclib, a CDK2 inhibitor, or epz-6438 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>147</b>), an enhancer of zeste homologue 2 (EZH2) inhibitors, and tamoxifen is effective.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> The combination of dinaciclib or <b>147</b> and tamoxifen can significantly inhibit tumor growth in TNBC tumor-bearing mice, and the survival rate of TNBC tumor-bearing mice is significantly improved, with a significant reduction in distant lung metastasis. LY2157299 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>148</b>), a TGF-β I inhibitor, can reduce CSC amplification and transcription of IL-8 induced by paclitaxel.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> The treatment of TNBC xenografts with <b>148</b> prevents tumor reconstruction after paclitaxel treatment.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> It is suggested that the combination of a TGF-β inhibitor and anticancer chemotherapy has potential in patients with TNBC. The combination of paclitaxel with NVP-LDE225 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>149</b>) or bevacizumab, a smoothened (SMO) inhibitor, is tested in mice bearing TNBC.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> The combination of <b>149</b> and paclitaxel may provide a good sustained inhibition of the proliferation of TNBC cells and vascular endothelial cells. Cisplatin combined with metformin (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>150</b>) is more effective than cisplatin alone in reducing TNBC cell viability and metastasis.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> The chemotherapy drugs carboplatin or paclitaxel combined with the hypoxia inducible factor-1 (HIF1) inhibitor digoxin (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>151</b>) and the chemotherapy drug paclitaxel combined with the p38 inhibitors SB203580 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>152</b>), PF3644022 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>153</b>), or LY2228820 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>154</b>) blocked BCSC enrichment and improved the outcome of TNBC.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> It is suggested that chemotherapy combined with p38 inhibitors can improve the survival rate of patients.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> The SET inhibitor TD19 combined with cisplatin enhanced apoptosis of TNBC cells by inducing PARP cleavage.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p last">Bazedoxifene, an IL-6/glycoprotein 130 inhibitor, combined with paclitaxel, has an inhibitory effect on TNBC cell viability, colony formation, and cell migration <i>in vitro</i> and induced more apoptosis, leading to remarkable inhibitory effects on TNBC tumor growth <i>in vivo</i>.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The SRC homologous region 2 domain containing phosphatase-1 (SHP-1) could inhibit cancer by dephosphorylating the oncogene kinase. STAT3, the main target of SHP-1, is highly activated in TNBC.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> SC-60 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>155</b>), an activator of SHP-1, combined with docetaxel, synergized the antitumor effect of TNBC cells through the SHP-1/STAT3 pathway and shows significant antitumor effects in a TNBC xenotransplantation model.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> It is indicated that SHP-1/p-STAT3 is a target for the combination treatment with an SHP-1 agonist and the chemotherapy drug docetaxel, which may be a feasible therapeutic strategy.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39">4.2.3.  Combination of Antibodies and Small-Molecule Drugs</h4><div class="NLM_p">Multiple clinical studies have found that the combined strategy of immunotherapy and small-molecule drugs is more effective in the treatment of TNBC compared with monotherapy (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>, <b>156</b> and <b>157</b>). Several TNBC patients are treated with doxorubicin liposome, bevacizumab, <b>130</b> (DAT) or doxorubicin liposome, bevacizumab, or <b>13</b> (DAE), DAT combined with DAE have significant activity, indicating that the abnormal PI3K pathway is related to the improvement of the objective response rate.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The combined use of the Top I inhibitor IMMU-132 antibody and the PARP inhibitors <b>14</b> or <b>15</b> can significantly improve antitumor effects compared with monotherapy in TNBC mutant mice.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> In mice carrying wild-type TNBC tumors, the combined application of IMMU-132 and <b>15</b> has significant antitumor effects and survival benefits compared with monotherapy, and this combination is well swallowed.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> In clinical trials, there are also some research on the combination strategy of antibodies and small-molecule drugs, such as combination of PI3K inhibitor INCB050465 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>, <b>156</b>) and anti-PD-1 antibody pembrolizumab in a phase 1 clinical trial (NCT 02646748). FRα is found to be highly expressed in invasive basal-like subtype TNBC and residual diseases after neoadjuvant chemotherapy, and the risk of recurrence is high.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> The combination of an anti-FRα antibody (MOv18-IgG1) and the SRC inhibitor A-419259 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>, <b>157</b>) can observably inhibit the growth of TNBC.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of <b>156</b> and <b>157</b> related to other treatment methods in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the classic combination treatment strategies above, we also summarized some combination strategies of small-molecule drugs combined with other treatment methods (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>, <b>158</b>–<b>160</b>),<a onclick="showRef(event, 'ref185 ref186 ref187 ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref185 ref186 ref187 ref188 ref189">(185−189)</a> such as combination of YAP inhibitor verteporfin (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>, <b>158</b>) and paclitaxel via nanoparticle packaging,<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> combination of HDAC inhibitor YCW1 (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>, <b>159</b>) and infrared radiation therapy,<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> and combination of VEGFR inhibitor regorafenib (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>, <b>160</b>) and radiotherapy.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structures of <b>158</b>–<b>160</b> related to EGFR inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">5.  Drug Repurposing</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58562" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58562" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Recently, repurposing of existing drugs to cure new diseases has become a paradigm to expedite drug discovery and development; as the safety information for existing drugs is fully recorded, the cost of clinical trials can be greatly reduced. TNBC, as a subtype of breast cancer with obvious molecular heterogeneity, a high metastasis potential, and strong resistance to endocrine therapy and chemotherapy, has the poorest prognosis. Clinical trials for TNBC often have a high failure rate, and targeted therapeutic drugs for TNBC have rarely been approved by the FDA. Therefore, drug repurposing is a prospective strategy for the therapy of TNBC. We summarized some small-molecule drugs which were potential candidates for repurposing in TNBC therapy (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a>).<a onclick="showRef(event, 'ref40 ref54 ref123 ref179 ref180 ref196 ref197 ref198 ref199'); return false;" href="javascript:void(0);" class="ref ref40 ref54 ref123 ref179 ref180 ref196 ref197 ref198 ref199">(40,54,123,179,180,196−199)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures of <b>161</b>–<b>165</b> for drug repurposing in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl14"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 14. Drug Repurposing in TNBC</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name in the literature</th><th class="colsep0 rowsep0" align="center">original indication</th><th class="colsep0 rowsep0" align="center">TNBC subtype</th><th class="colsep0 rowsep0" align="center">mechanism of treating TNBC</th><th class="colsep0 rowsep0" align="center">clinical trial identifier</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">Fluoxetine</td><td class="colsep0 rowsep0" align="left">Depression</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left">eEF2K inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>142</b></td><td class="colsep0 rowsep0" align="left">Phenothiazine (PTZ)</td><td class="colsep0 rowsep0" align="left">Pesticide</td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left">PP2A activator</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>143</b></td><td class="colsep0 rowsep0" align="left">Perphenazine (PPZ)</td><td class="colsep0 rowsep0" align="left">Acute and chronic schizophrenia</td><td class="colsep0 rowsep0" align="left">BL2, MSL</td><td class="colsep0 rowsep0" align="left">PP2A activator</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>151</b></td><td class="colsep0 rowsep0" align="left">Digoxin</td><td class="colsep0 rowsep0" align="left">Congestive heart failure</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left">HIF1 inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">Niclosamide</td><td class="colsep0 rowsep0" align="left">Cestode infection</td><td class="colsep0 rowsep0" align="left">BL1, MSL</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>150</b></td><td class="colsep0 rowsep0" align="left">Metformin</td><td class="colsep0 rowsep0" align="left">Diabetes</td><td class="colsep0 rowsep0" align="left">MSL</td><td class="colsep0 rowsep0" align="left">STAT3 inhibitor</td><td class="colsep0 rowsep0" align="left">NCT01650506 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>161</b></td><td class="colsep0 rowsep0" align="left">Flucytosine</td><td class="colsep0 rowsep0" align="left">Candida and/or Cryptococcus</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Other antifungal</td><td class="colsep0 rowsep0" align="left">NCT02576665 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>162</b></td><td class="colsep0 rowsep0" align="left">Indomethacin</td><td class="colsep0 rowsep0" align="left">Analgesia</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cyclooxygenase inhibitor</td><td class="colsep0 rowsep0" align="left">NCT02950259 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>163</b></td><td class="colsep0 rowsep0" align="left">Omeprazole</td><td class="colsep0 rowsep0" align="left">Antacid</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ATPase inhibitor</td><td class="colsep0 rowsep0" align="left">NCT02950259 (phase 1)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>164</b></td><td class="colsep0 rowsep0" align="left">Ritonavir</td><td class="colsep0 rowsep0" align="left">Antiretroviral</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HIV protease inhibitor</td><td class="colsep0 rowsep0" align="left">NCT01009437 (phase 1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>165</b></td><td class="colsep0 rowsep0" align="left">Zoledronic acid</td><td class="colsep0 rowsep0" align="left">Osteoporosis</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Bone resorption inhibitor</td><td class="colsep0 rowsep0" align="left">NCT02595138 (phase 3)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref198 ref199'); return false;" href="javascript:void(0);" class="ref ref198 ref199">(198,199)</a></td></tr></tbody></table></div></div><div class="NLM_p"><b>41</b>, once used mainly for the treatment of depression, has been found to induce autophagic cell death through the activation of the AMPK-mTOR-ULK complex axis and the inhibition of eEF2K, and exerts remarkable antiproliferative effects on TNBC.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> However, the adverse reactions of <b>41</b> are also key challenges, mainly including “serotonin syndrome”, cardiovascular complications, extrapyramidal side effects (such as sedentary insufficiency, dyskinesia, and Parkinson’s syndrome), and the increased risk of suicide.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> In addition, the combination of low-dose <b>41</b> and the existing TNBC treatment has been reported to provide some advantages. First, it can reduce psychological distress, and second, it can induce invasive TNBC tumor cell death, which provides a new idea for the treatment of TNBC patients with depression.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> The inactivation of the protein phosphatase 2A (PP2A) phosphatase tumor suppressor gene usually occurred in breast cancer and was related to treatment resistance.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> A PP2A activator <b>142</b>, once used mainly as a pesticide, combined with a BET inhibitor <b>44</b>, overcame BET bromodomain inhibitor (BBI) resistance in TNBC. It has also been observed that PP2A activator <b>143</b>, once used mainly for the treatment of acute and chronic schizophrenia, combined with the MET inhibitor <b>44</b>, has a significant synergistic effect in TNBC cells.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> However, some studies have indicated that clinicians should be highly alert to the damage of PTZ caused by histamine accumulation and long-term inflammatory response caused by increasing histamine levels.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Besides, the extrapyramidal system (EPS) dysfunction caused by long-term administration and a high dose of <b>143</b> should also be kept in mind.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> Cytotoxic chemotherapy can reduce tumor volume, but owing to the persistence of BCSCs, which are resistant to chemotherapy, it leaves residual disease, which is most likely a critical component of tumor metastasis and tumor recurrence. Regulation of the HIF-1-dependent MAPK signaling pathway is shown to contribute to BCSC enrichment induced by chemotherapy.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a><b>151</b>, which was used to treat congestive heart failure, is reported to block BCSC enrichment and improve TNBC prognosis through inhibition of the HIF1 pathway.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> However, it is worth noting that <b>151</b> may cross-react with antitumor drugs, leading to acquired drug-induced short QT syndrome (SQTS), which can be solved after gastric lavage and atropine injection.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a><b>27</b>, which has been used mainly in cestode infection, is found to inhibit Bcl-2 and STAT3 and induces reactive oxygen species (ROS), in combination with radiotherapy, increases the production of ROS, and thus induces apoptosis in TNBC.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Due to the low absorption efficiency of nicolosamide in human intestine, it is necessary to modify the drug to promote its application in the treatment of cancer.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a><b>150</b>, as a typical diabetes drug, has recently become a research hotspot for drug repurposing.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Cisplatin combined with <b>150</b> is more effective than cisplatin alone in reducing TNBC cell viability and metastasis.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a><b>150</b> enhanced the antitumor effect of cisplatin through downregulation of the expression of RAD51, which is a potential novel target for TNBC treatment.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> For the safety of TNBC patients, it is very important to determine the most suitable dose of <b>150</b>, and the concentration of <b>150</b> (5 mM) used in the above study seems to be appropriate.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Although many candidate drugs in the TNBC treatment database have generated preclinical evidence, only a few of them have been tested in clinical trials. Clinical studies have demonstrated a noteworthy benefit in advanced TNBC women using beta blockers (BBs) when compared to not users about PFS but not in OS.<a onclick="showRef(event, 'ref205 ref206 ref207'); return false;" href="javascript:void(0);" class="ref ref205 ref206 ref207">(205−207)</a> Omeprazole can produce a promising rate in BBs, which is well tolerated and had no known grade 3/4 toxicity.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> With other repurposing drugs for TNBC neoadjuvant chemotherapy, such as <b>150</b>, zoledronic acid, NSAIDs, and statins, no noteworthy survival outcome can be acquired.<a onclick="showRef(event, 'ref198 ref199 ref209 ref210 ref211'); return false;" href="javascript:void(0);" class="ref ref198 ref199 ref209 ref210 ref211">(198,199,209−211)</a> BBs are the more prospective repurposing drugs; however, accumulating evidence suggests that other NSAIDs still require further evaluation for TNBC therapy.</div><div class="NLM_p last">Moreover, some repurposing drugs in clinical trials are also reported, including flucytosine, indomethacin, omeprazole, ritonavir, and zoledronic acid (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>, <b>161</b>–<b>165</b>).<a onclick="showRef(event, 'ref196 ref197 ref198 ref199'); return false;" href="javascript:void(0);" class="ref ref196 ref197 ref198 ref199">(196−199)</a> In addition, a powerful tool has been reported to be used for giving the chance to research whether non-antitumor drugs might be resultful in cancer therapy, repurposing drugs in oncology database (ReDO), collecting with favorable retrospective clinical trials or preclinical evidence is not enough to provide a compelling case; however, large-scale retrospective cohort research should be necessary to assess their efficacy.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> As mentioned above, drug repurposing has achieved early results in the treatment of TNBC. However, several key challenges have been identified, such as adverse reactions and drug interactions. These obstacles should be overcome to prevent and treat TNBC more effectively. Thus, it is necessary to further examine the broad antitumor activities of these drugs in patients with TNBC to develop therapeutic methods.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">6.  Immunomodulators of TNBC</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer immunotherapy can remodel the host immune system to destroy tumor cells and has been becoming a promising avenue for the treatment of TNBC. PD-1 restricts autoimmunity by inhibiting effector T lymphocytes and is activated by immunosuppressive PD-L1. TNBC often overexpresses PD-L1, which is highly mutagenic. Accumulating evidence has indicated that PD-L1 expression is present in 20% of TNBC, indicating that the checkpoint protein may be an underlying therapeutic target.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> PD-L1/2 ligands expressed by TNBC cells can bind to the PD-1 receptor to inactivate T cells, thus avoiding immune-system-mediated damage. The PD-L1 expression is positively correlated with the presence of tumor infiltrating lymphocytes and with the highest expression in TNBC subtypes. Activation of the Ras-MAPK pathway may promote the immune escape of TNBC, whereas the combination of the MEK inhibitors <b>111</b> or <b>103</b> and the anti-PD-1 antibody/anti-PD-L1 antibody α-PD-L1 or α-PD-1 enhanced the antitumor immune response of a TNBC mouse model.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a></div><div class="NLM_p">Cowpea mosaic virus (CPMV) combined with low-dose cyclophosphamide (CPA) <i>in vivo</i> has recently been reported to have a significant synergistic effect on TNBC mice tumors.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> Combined treatment can reduce the growth of primary and distant tumors, decrease lung metastasis, and increase the survival rate.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> CPMV combined with CPA can also increase secretion of several cytokines, activate antigen-presenting cells, increase the abundance of tumor infiltrating T cells, and reverse the immunosuppressive effect.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> The potential of pseudopterosin has been reported as a new immunomodulator in TNBC and therefore plays a key role by inhibiting NF-κB and blocking subsequent cytokine secretion.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> When GRα expression decreases, the antiproliferative effect of pseudopterosin is significantly inhibited.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> As an effective immunomodulator, pseudopterosin is regarded as an underlying strategy in TNBC.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a></div><div class="NLM_p last">Immunotherapy with checkpoint inhibitors has shown therapeutic potential, but as a drug for advanced TNBCs, the response rate is very low. The increase in TIL is associated with an increase in overall survival and a higher response rate.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> Further research on new prospective combination of chemotherapy and immunotherapy, and chemotherapy-sensitive tumor biomarkers of TNBC, is essential to provide patients with immunotherapy combination on the basis of predictive chemotherapy-sensitive tumor biomarkers.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> The combination with PARP inhibitors or specific chemotherapy may be a promising strategy for TNBC immunotherapy.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">7.  Conclusions and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Triple negative breast cancer (TNBC) is well-known as the worst prognosis subtype of breast cancer (BC), and it is not sensitive to common endocrine therapy and chemotherapy. Hitherto, the most promising area for small-molecule drug discovery has been taking advantage of the personalized concept that precisely targeting different molecular characteristics of TNBC subtypes, which may be further explained as a specific cancer-selective overexpression, mutations and even modifications can result in an acquired vulnerability that in turn can be targeted. The classifications of TNBC may be utilized as a prognostic or predictive means for better individualized therapies in patients theoretically. Moreover, strong predictive biomarkers are needed to promote the clinical prognosis of TNBC patients and expedite clinical progress.</div><div class="NLM_p">While such rapid development is so exciting, an inherent limitation of single-target drug discovery is the susceptibility of TNBC to drug resistance. When such cancer cells become resistant to targeted drug therapy, it may result in some new vulnerabilities that should be targeted by another drug. Thus, an emerging avenue that avoids this problem is developing the combination drug strategies, including dual-target drug (designing one drug that can simultaneously hit two targets), and drug combination strategies. Moreover, repurposing drugs have been recently used for potential TNBC therapy, which is the reuse of some existing drugs already approved for non-oncology diseases, as candidate antitumor drugs. However, for most therapies that include dual targets and combined applications, it can be expected that, after a long period of treatment, these candidate small-molecule drugs will eventually become resistant and reduce their therapeutic effects. At this time, we need to keep pace with the times and combine with different fields of science and technology to solve the problem of drug resistance. More recently, accumulating data have provided a therapeutic strategy for designing a few CRISPR-mediated targeted therapies on the clinical resistance of TNBC. Targeted activation of PTEN which is mediated by CRISPR will offer a totally new strategy that has been refractory to TNBC treatment.</div><div class="NLM_p last">In conclusion, we summarized 16 candidate small-molecule drugs targeting different TNBC subtypes (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), 86 candidate single-target drugs, 16 candidate dual-target drugs, 101 combination drugs, 10 repurposing drugs, and immunomodulators. Our research into small-molecule drugs is in its ascendancy, with new potential drugs constantly emerging, bringing a new hope to many patients with TNBC; therefore, they have been becoming a key area of targeted drug discovery. With the continued development of small-molecule drugs with their higher efficacy, which induce low resistance and fewer side effects, as well as research into new drug combinations, it is believed that more novel “magic bullets” will be ultimately utilized to precisely target or co-target TNBC vulnerabilities for therapeutic purposes.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01180" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Ouyang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5537-8834" title="Orcid link">http://orcid.org/0000-0001-5537-8834</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#09667c7068676e656068676e497a6a7c276c6d7c276a67"><span class="__cf_email__" data-cfemail="452a303c242b22292c242b22053626306b2021306b262b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3900-9486" title="Orcid link">http://orcid.org/0000-0003-3900-9486</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fc9095899e93cec8ccccbccdcacfd29f9391"><span class="__cf_email__" data-cfemail="0965607c6b663b3d393949383f3a276a6664">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minru Liao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guan Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leiming Wang</span> - <span class="hlFld-Affiliation affiliation">The
Institute of Chemical Biology, Shenzhen
Bay Laboratory, Shenzhen 518107, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Liu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.L., J.Z., G.W.: These authors contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Minru Liao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=BIO-d7e8707-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Minru Liao</b> received her bachelor’s degree in clinical pharmacy from China Medical University in 2019. She is an undergraduate student at State Key Laboratory of Biotherapy and Cancer Center of West China Hospital in Sichuan University. Her research interest focuses on autophagic target identification and drug repurposing in triple negative breast cancer.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Jin Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=BIO-d7e8712-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jin Zhang</b> received her Ph.D. degree in medicinal chemistry from Shenyang Pharmaceutical University in 2017. She is an assistant professor at State Key Laboratory of Biotherapy and Cancer Center of West China Hospital in Sichuan University. Her research interest focuses on target identification and molecular mechanisms in triple negative breast cancer.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Guan Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=BIO-d7e8717-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Guan Wang</b> received his Ph.D. degree in pharmacy from Shenyang Pharmaceutical University in 2017. Then, he joined the faculty of State Key Laboratory of Biotherapy and Cancer Center of West China Hospital at Sichuan University as an assistant professor. His research interests are targeted drug design and discovery and bioinformatics methodology.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Leiming Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=BIO-d7e8722-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Leiming Wang</b> received his Ph.D. degree in Biomedical Sciences at Shanghai Institutes for Biological Sciences in 2011. He took his postdoctoral training in 2013 at Baylor College of Medicine and joined Shenzhen Bay Laboratory as an Investigator in 2020. His major research interests include targeted therapy and small-molecule drug development for treatment of cancer and metabolism diseases.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Jie Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=BIO-d7e8727-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jie Liu</b> received his Ph.D. degree in organic chemistry from School of Chemistry, Sichuan University, in 2009. In 2012, he began his academic career at the State Key Lab of Biotherapy of West China Hospital in Sichuan University as a professor. His research interest focuses on targeted small-molecule drug design and discovery in cancer.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Liang Ouyang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=BIO-d7e8732-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Liang Ouyang</b> received his Ph.D. degree in medicinal chemistry from West China School of Pharmacy, Sichuan University, in 2010. In 2012, he began his academic career at the State Key Lab of Biotherapy of West China Hospital in Sichuan University as a professor. His research interests include identification of novel drug targets in cell death and structure-based discovery of small-molecule and peptide drugs.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Bo Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=BIO-d7e8737-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Bo Liu</b> received his Ph.D. degree in Bioinformatics (drug design) from School of Life Sciences, Sichuan University, in 2010. In 2012, he joined the faculty of State Key Lab of Biotherapy of West China Hospital in Sichuan University as a professor. His research interests include autophagic target identification and structure-based drug discovery in breast cancer and Parkinson’s disease.</p></figure></div><div class="ack" id="ACK-d7e8750-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Prof. Shengyong Yang, Prof. Canhua Huang, and Prof. Heng Xu (Sichuan University) for their helpful discussions on this work. We also thank Elsevier Language Editing Services (No. 331566771) for further improvement of this manuscript. This work was supported by grants from National Science and Technology Major Project of the Ministry of Science and Technology of China (No. 2018ZX09735005), National Natural Science Foundation of China (Grant No. 81922064, Grant No. 81673455, Grant No. 81803365, and Grant No. 81873939), and Post-Doctor Research Project (Grant No. 2018M643510).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">4EBP1</td><td class="NLM_def"><p class="first last">eukaryotic translation initiation factor 4E-binding protein</p></td></tr><tr><td class="NLM_term">γ-H2AX</td><td class="NLM_def"><p class="first last">phosphorylated form of H2AX histone variant</p></td></tr><tr><td class="NLM_term">AA</td><td class="NLM_def"><p class="first last">African American</p></td></tr><tr><td class="NLM_term">ACD</td><td class="NLM_def"><p class="first last">autophagic cell death</p></td></tr><tr><td class="NLM_term">ACS</td><td class="NLM_def"><p class="first last">American Cancer Society</p></td></tr><tr><td class="NLM_term">AF</td><td class="NLM_def"><p class="first last">aminoflavone</p></td></tr><tr><td class="NLM_term">AhR</td><td class="NLM_def"><p class="first last">aryl hydrocarbon receptor</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">adenosine 5′-monophosphate-activated protein kinase</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">androgen receptor</p></td></tr><tr><td class="NLM_term">ASCO</td><td class="NLM_def"><p class="first last">American Society of Clinical Oncology</p></td></tr><tr><td class="NLM_term">Atg101</td><td class="NLM_def"><p class="first last">autophagy-associated protein 101</p></td></tr><tr><td class="NLM_term">ATR</td><td class="NLM_def"><p class="first last">ataxia telangiectasia and the Rad3-related protein</p></td></tr><tr><td class="NLM_term">AXL</td><td class="NLM_def"><p class="first last">Anexelekto</p></td></tr><tr><td class="NLM_term">BBI</td><td class="NLM_def"><p class="first last">BET bromodomain inhibitor</p></td></tr><tr><td class="NLM_term">BB</td><td class="NLM_def"><p class="first last">beta blocker</p></td></tr><tr><td class="NLM_term">BC</td><td class="NLM_def"><p class="first last">breast cancer</p></td></tr><tr><td class="NLM_term">BCL2</td><td class="NLM_def"><p class="first last">B-cell lymphoma 2</p></td></tr><tr><td class="NLM_term">BCSC</td><td class="NLM_def"><p class="first last">breast cancer stem cell</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extra-terminal</p></td></tr><tr><td class="NLM_term">BL1/2</td><td class="NLM_def"><p class="first last">basal-like 1/2</p></td></tr><tr><td class="NLM_term">BLIS</td><td class="NLM_def"><p class="first last">basal-like immune-suppressed</p></td></tr><tr><td class="NLM_term">BRCA</td><td class="NLM_def"><p class="first last">breast cancer susceptibility gene</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">bromodomain 4</p></td></tr><tr><td class="NLM_term">CBD</td><td class="NLM_def"><p class="first last">cannabidiol</p></td></tr><tr><td class="NLM_term">CBR</td><td class="NLM_def"><p class="first last">clinical benefit rate</p></td></tr><tr><td class="NLM_term">CCL5</td><td class="NLM_def"><p class="first last">CC chemokine ligand-5</p></td></tr><tr><td class="NLM_term">CDK9</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase 9</p></td></tr><tr><td class="NLM_term">CHK1</td><td class="NLM_def"><p class="first last">checkpoint kinase 1</p></td></tr><tr><td class="NLM_term">CLP</td><td class="NLM_def"><p class="first last">cyclo (<span class="smallcaps smallerCapital">l</span>-leucyl-<span class="smallcaps smallerCapital">l</span>-Pr olyl) peptide</p></td></tr><tr><td class="NLM_term">CPA</td><td class="NLM_def"><p class="first last">cyclophosphamide</p></td></tr><tr><td class="NLM_term">CPMV</td><td class="NLM_def"><p class="first last">cowpea mosaic virus</p></td></tr><tr><td class="NLM_term">CR</td><td class="NLM_def"><p class="first last">complete response</p></td></tr><tr><td class="NLM_term">CSC</td><td class="NLM_def"><p class="first last">cancer stem cell</p></td></tr><tr><td class="NLM_term">CTSS</td><td class="NLM_def"><p class="first last">cathepsin S</p></td></tr><tr><td class="NLM_term">DDK</td><td class="NLM_def"><p class="first last">Dbf4-dependent kinase</p></td></tr><tr><td class="NLM_term">DDR</td><td class="NLM_def"><p class="first last">DNA damage response</p></td></tr><tr><td class="NLM_term">DEDD</td><td class="NLM_def"><p class="first last">death effector domain DNA-binging protein</p></td></tr><tr><td class="NLM_term">DFI</td><td class="NLM_def"><p class="first last">shorter disease-free interval</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">DSB</td><td class="NLM_def"><p class="first last">double-strand breaks</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">eEF2</td><td class="NLM_def"><p class="first last">eukaryotic elongation factor 2</p></td></tr><tr><td class="NLM_term">eEF2K</td><td class="NLM_def"><p class="first last">eukaryotic elongation factor 2 kinase</p></td></tr><tr><td class="NLM_term">EF-2</td><td class="NLM_def"><p class="first last">elongation factor 2</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR-TKI</td><td class="NLM_def"><p class="first last">EGFR tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transformation</p></td></tr><tr><td class="NLM_term">EphA2</td><td class="NLM_def"><p class="first last">epithelial cell kinase</p></td></tr><tr><td class="NLM_term">EPS</td><td class="NLM_def"><p class="first last">extrapyramidal system</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">ERK1/2</td><td class="NLM_def"><p class="first last">extracellular signal regulated kinase 1/2</p></td></tr><tr><td class="NLM_term">EZH2</td><td class="NLM_def"><p class="first last">enhancer of zeste homologue 2</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FIP200</td><td class="NLM_def"><p class="first last">focal adhesion kinase family interacting protein of 200 kDa</p></td></tr><tr><td class="NLM_term">GAS1</td><td class="NLM_def"><p class="first last">growth-arrest-specific protein 1</p></td></tr><tr><td class="NLM_term">GE</td><td class="NLM_def"><p class="first last">gene expression</p></td></tr><tr><td class="NLM_term">GO</td><td class="NLM_def"><p class="first last">gene ontology</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine triphosphate</p></td></tr><tr><td class="NLM_term">HER-2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor-2</p></td></tr><tr><td class="NLM_term">HIF1</td><td class="NLM_def"><p class="first last">hypoxia inducible factor-1</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">homologous recombination</p></td></tr><tr><td class="NLM_term">HRD</td><td class="NLM_def"><p class="first last">homologous recombination defect</p></td></tr><tr><td class="NLM_term">HSP90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">ICI</td><td class="NLM_def"><p class="first last">immune checkpoint inhibitor</p></td></tr><tr><td class="NLM_term">IGF-IR</td><td class="NLM_def"><p class="first last">insulin-like growth factor I receptor</p></td></tr><tr><td class="NLM_term">IHC</td><td class="NLM_def"><p class="first last">immunohistochemical</p></td></tr><tr><td class="NLM_term">IKBKE</td><td class="NLM_def"><p class="first last">inhibitor of kappa light polypeptide gene enhancer in B-cell, kinase epsilon</p></td></tr><tr><td class="NLM_term">IL-17E</td><td class="NLM_def"><p class="first last">interleukin 17E</p></td></tr><tr><td class="NLM_term">IM</td><td class="NLM_def"><p class="first last">immunomodulatory</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">LAR</td><td class="NLM_def"><p class="first last">luminal androgen receptor</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">mesenchymal</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">mAtg13</td><td class="NLM_def"><p class="first last">autophagy-associated protein 13</p></td></tr><tr><td class="NLM_term">MCL1</td><td class="NLM_def"><p class="first last">myeloid cell leukemia 1</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated extracellular signal regulated kinase</p></td></tr><tr><td class="NLM_term">MES</td><td class="NLM_def"><p class="first last">mesenchymal-like</p></td></tr><tr><td class="NLM_term">MET</td><td class="NLM_def"><p class="first last">mesenchymal to epithelial transition factor</p></td></tr><tr><td class="NLM_term">mGluR1</td><td class="NLM_def"><p class="first last">metabotropic glutamate receptor subtype 1</p></td></tr><tr><td class="NLM_term">ML-BCSCs</td><td class="NLM_def"><p class="first last">mesenchymal-like breast cancer stem cells</p></td></tr><tr><td class="NLM_term">MRA</td><td class="NLM_def"><p class="first last">michael reaction acceptor</p></td></tr><tr><td class="NLM_term">mRNA</td><td class="NLM_def"><p class="first last">messenger ribonucleic acid</p></td></tr><tr><td class="NLM_term">MSL</td><td class="NLM_def"><p class="first last">mesenchymal; mesenchymal-stem-like</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">mTORC1/2</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin complex 1/complex 2</p></td></tr><tr><td class="NLM_term">NACT</td><td class="NLM_def"><p class="first last">neoadjuvant and chemotherapy</p></td></tr><tr><td class="NLM_term">NCT</td><td class="NLM_def"><p class="first last">national clinical trial</p></td></tr><tr><td class="NLM_term">NCTD</td><td class="NLM_def"><p class="first last">norcantharidin</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor kappa-B</p></td></tr><tr><td class="NLM_term">NGF</td><td class="NLM_def"><p class="first last">nerve growth factor</p></td></tr><tr><td class="NLM_term">NOTCH4</td><td class="NLM_def"><p class="first last">Notch receptor 4</p></td></tr><tr><td class="NLM_term">ORR</td><td class="NLM_def"><p class="first last">objective response rate</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">pCR</td><td class="NLM_def"><p class="first last">pathological complete response</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed death receptor 1</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet derived growth factor</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed death ligand protein</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient derived xenograft</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression-free survival rate</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-kinase</p></td></tr><tr><td class="NLM_term">PIK3CA</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-kinase catalyzed subunit alpha</p></td></tr><tr><td class="NLM_term">PIK3R1</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-kinase; phosphoinositide-3-kinase, regulatory subunit 1</p></td></tr><tr><td class="NLM_term">PKB</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">PP2A</td><td class="NLM_def"><p class="first last">protein phosphatase 2A</p></td></tr><tr><td class="NLM_term">PPZ</td><td class="NLM_def"><p class="first last">perphenazine</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimeras</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue deleted on chromosome ten</p></td></tr><tr><td class="NLM_term">PTZ</td><td class="NLM_def"><p class="first last">phenothiazine</p></td></tr><tr><td class="NLM_term">PYK2</td><td class="NLM_def"><p class="first last">proline-rich tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">ReDO</td><td class="NLM_def"><p class="first last">Repurposing Drugs in Oncology database</p></td></tr><tr><td class="NLM_term">RON</td><td class="NLM_def"><p class="first last">Recepteur d’Origine Nantais</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAHA</td><td class="NLM_def"><p class="first last">suberoylanilide hydroxamic acid</p></td></tr><tr><td class="NLM_term">SDCBP</td><td class="NLM_def"><p class="first last">syndecan binding protein</p></td></tr><tr><td class="NLM_term">Ser/Thr</td><td class="NLM_def"><p class="first last">serine/threonine</p></td></tr><tr><td class="NLM_term">SH2</td><td class="NLM_def"><p class="first last">SRC homologous region 2</p></td></tr><tr><td class="NLM_term">SHP-1</td><td class="NLM_def"><p class="first last">SRC homologous region 2 domain containing phosphatase-1</p></td></tr><tr><td class="NLM_term">SLUG/SNAI2</td><td class="NLM_def"><p class="first last">snail family transcriptional repressor 2</p></td></tr><tr><td class="NLM_term">SMO</td><td class="NLM_def"><p class="first last">smoothened</p></td></tr><tr><td class="NLM_term">SQTS</td><td class="NLM_def"><p class="first last">short QT syndrome</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">TALA</td><td class="NLM_def"><p class="first last">talazoparib</p></td></tr><tr><td class="NLM_term">TBK1</td><td class="NLM_def"><p class="first last">TANK-binding kinase 1</p></td></tr><tr><td class="NLM_term">TCGA</td><td class="NLM_def"><p class="first last">the cancer genome atlas</p></td></tr><tr><td class="NLM_term">TGF-β</td><td class="NLM_def"><p class="first last">transforming growth factor-β</p></td></tr><tr><td class="NLM_term">TIE-2</td><td class="NLM_def"><p class="first last">tyrosine kinase receptors with immunoglobulin and EGF homology domains receptors-2</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">TMA</td><td class="NLM_def"><p class="first last">tissue microarray</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple negative breast cancer</p></td></tr><tr><td class="NLM_term">TOP1</td><td class="NLM_def"><p class="first last">topoisomerase I</p></td></tr><tr><td class="NLM_term">TQ</td><td class="NLM_def"><p class="first last">thymoquinone</p></td></tr><tr><td class="NLM_term">TTK</td><td class="NLM_def"><p class="first last">truncated thymidine kinase</p></td></tr><tr><td class="NLM_term">UCHL3</td><td class="NLM_def"><p class="first last">ubiquitin carboxyl-terminal hydrolase isozyme L3</p></td></tr><tr><td class="NLM_term">ULK1</td><td class="NLM_def"><p class="first last">Unc-51-like autophagy activating kinase 1</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">VEGFA</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor A</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">vs</td><td class="NLM_def"><p class="first last">versus</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 217 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2019</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.3322/caac.21551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3322%2Fcaac.21551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30620402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3cnptFCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=7-34&issue=1&author=R.+Siegelauthor=K.+Millerauthor=A.+Jemal&title=Cancer+statistics%2C+2019&doi=10.3322%2Fcaac.21551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2019</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data, available through 2016, were collected by the National Center for Health Statistics.  In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States.  Over the past decade of data, the cancer incidence rate (2006-2015) was stable in women and declined by approximately 2% per year in men, whereas the cancer death rate (2007-2016) declined annually by 1.4% and 1.8%, respectively.  The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.  Although the racial gap in cancer mortality is slowly narrowing, socioeconomic inequalities are widening, with the most notable gaps for the most preventable cancers.  For example, compared with the most affluent counties, mortality rates in the poorest counties were 2-fold higher for cervical cancer and 40% higher for male lung and liver cancers during 2012-2016.  Some states are home to both the wealthiest and the poorest counties, suggesting the opportunity for more equitable dissemination of effective cancer prevention, early detection, and treatment strategies.  A broader application of existing cancer control knowledge with an emphasis on disadvantaged groups would undoubtedly accelerate progress against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBHJFurk9wJJp6t8nS6Nc3fW6udTcc2ebYke5L3lS2qbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnptFCntA%253D%253D&md5=02ba708e57d7573ebe0649182325b52c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21551%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202019%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2019%26volume%3D69%26issue%3D1%26spage%3D7%26epage%3D34%26doi%3D10.3322%2Fcaac.21551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, J. S.</span></span> <span> </span><span class="NLM_article-title">Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers</span>. <i>Histol Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.14670/HH-27.1481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.14670%2FHH-27.1481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23018247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FgslertA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=1481-1493&issue=11&author=J.+Choiauthor=W.+H.+Jungauthor=J.+S.+Koo&title=Clinicopathologic+features+of+molecular+subtypes+of+triple+negative+breast+cancer+based+on+immunohistochemical+markers&doi=10.14670%2FHH-27.1481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers</span></div><div class="casAuthors">Choi Junjeong; Jung Woo-Hee; Koo Ja Seung</div><div class="citationInfo"><span class="NLM_cas:title">Histology and histopathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1481-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This study was performed to identify molecular subtypes of triple negative breast carcinoma (TNBC) based on immunohistochemical markers.  We prepared a tissue microarray from TNBC specimens of 122 patients and performed immunohistochemical staining for cytokeratin (CK) 5/6, epidermal growth factor receptor (EGFR), claudin 3, claudin 4, claudin 7, E-cadherin, androgen receptor (AR), and gammma-glutamyltransferase (GGT1).  Based on immunoreactivity, tumors were classified into basal-like (CK5/6 positive and/or EGFR positive), molecular apocrine (AR positive and/or GGT1 positive), claudin low (claudin 3, claudin 4, claudin 7 negative and/or E-cadherin negative), mixed (tumors belonging to two or more subtypes), and null (tumors not matching any other subtypes).  The TNBC specimens of 122 patients included 27 basal-like (22.1%), 28 claudin low (23.0%), 12 molecular apocrine (9.8%), 23 mixed (18.9%) and 32 null (26.2%) subtype tumors.  The molecular apocrine subtype showed the highest percentage of apocrine differentiation and the lowest Ki-67 labeling index (p<0.001 and p=0.040, respectively).  In univariate analysis, tumor cell discohesiveness was related with shorter disease free survival (DFS) and overall survival (OS) (p=0.005, and 0.002, respectively).  In multivariate analysis, tumor cell discohesiveness was related with shorter OS and CK5/6 positivity (p=0.018), and claudin 7 positivity (p=0.019) was related with shorter DFS.  In conclusion, using immunohistochemical staining for CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, AR, and GGT1, we categorized TNBC into a basal-like subtype, a claudin low subtype, a molecular apocrine subtype, a mixed subtype showing characteristics of two different subtypes, and a null subtype not belonging to any of the subtypes identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPkKQj8k6B0V1C8OJBvdfbfW6udTcc2ebYke5L3lS2qbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FgslertA%253D%253D&md5=45e4fea9e43fe6c32d993994f2c76034</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.14670%2FHH-27.1481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-27.1481%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DW.%2BH.%26aulast%3DKoo%26aufirst%3DJ.%2BS.%26atitle%3DClinicopathologic%2520features%2520of%2520molecular%2520subtypes%2520of%2520triple%2520negative%2520breast%2520cancer%2520based%2520on%2520immunohistochemical%2520markers%26jtitle%3DHistol%2520Histopathol.%26date%3D2012%26volume%3D27%26issue%3D11%26spage%3D1481%26epage%3D1493%26doi%3D10.14670%2FHH-27.1481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coussy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavigne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botty, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bataillon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montaudon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painsec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chateau-Joubert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laetitia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemlali, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melaabi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinebretiere, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieche, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, E.</span></span> <span> </span><span class="NLM_article-title">Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1531</span>– <span class="NLM_lpage">1543</span>, <span class="refDoi"> DOI: 10.7150/thno.36182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.7150%2Fthno.36182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32042320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslalurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1531-1543&issue=4&author=F.+Coussyauthor=M.+Lavigneauthor=L.+de+Koningauthor=R.+E.+Bottyauthor=F.+Nematiauthor=A.+Naguezauthor=G.+Bataillonauthor=B.+Ouineauthor=A.+Dahmaniauthor=E.+Montaudonauthor=P.+Painsecauthor=S.+Chateau-Joubertauthor=F.+Laetitiaauthor=T.+Larcherauthor=S.+Vacherauthor=W.+Chemlaliauthor=A.+Briauxauthor=S.+Melaabiauthor=A.+V.+Salomonauthor=J.+M.+Guinebretiereauthor=I.+Biecheauthor=E.+Marangoni&title=Response+to+mTOR+and+PI3K+inhibitors+in+enzalutamide-resistant+luminal+androgen+receptor+triple-negative+breast+cancer+patient-derived+xenografts&doi=10.7150%2Fthno.36182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts</span></div><div class="casAuthors">Coussy, Florence; Lavigne, Marion; de Koning, Leanne; El Botty, Rania; Nemati, Fariba; Naguez, Adnan; Bataillon, Guillaume; Ouine, Berengere; Dahmani, Ahmed; Montaudon, Elodie; Painsec, Pierre; Chateau-Joubert, Sophie; Laetitia, Fuhrmann; Larcher, Thibaut; Vacher, Sophie; Chemlali, Walid; Briaux, Adrien; Melaabi, Samia; Salomon, Anne Vincent; Guinebretiere, Jean Marc; Bieche, Ivan; Marangoni, Elisabetta</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1531-1543</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Luminal androgen receptor (LAR) breast cancer accounts for 10% of all triple-neg. breast cancers (TNBC).  Anti-androgen therapy for this subtype is in development, but yields only partial clin. benefits.  In this study, we aimed to characterize the genomic alterations of LAR TNBC, to analyze activation of the PI3K signaling pathway and to compare the response to PI3K pathway inhibitors with that to anti-androgen therapy in patient-derived xenografts (PDX) of LAR TNBC.  Four LAR PDX models were identified, on the basis of their transcriptomic profiles, in a cohort of 57 PDX models of TNBC.  The expression of AR-related genes, basal and luminal cytokeratins and EMT genes was analyzed by RT-PCR and IHC.  AKT1 and PIK3CA mutations were identified by targeted NGS, and activation of the PI3K pathway was analyzed with a reverse-phase protein array.  Three LAR PDXs with a PIK3CA or AKT1 mutation were treated with the AR inhibitor enzalutamide, a PI3K inhibitor, a dual PI3K-mTOR inhibitor and a mTORC1-mTORC2 inhibitor.  Finally, we screened a clin. cohort of 329 TNBC for PIK3CA and AKT1 hotspot mutations.  LAR TNBC PDXs were significantly enriched in PIK3CA and AKT1 mutations, and had higher levels of luminal-androgen-like gene expression and a higher PI3K pathway protein activation score than other TNBC subtypes.  Immunohistochem. anal. revealed strong expression of the luminal cytokeratin CK18 and AR in three LAR PDX models.  We found that mTOR and PI3K inhibitors had marked antitumor activity in vivo in PDX harboring genomic alterations of PIK3CA and AKT1 genes that did not respond to the AR antagonist enzalutamide.  PIK3CA mutations were detected in more than one third of AR+TNBC from patients (38%), and only 10% of AR-neg. TNBC.  Our results for Patient derived xenografts models of LAR TNBC resistant to enzalutamide indicate that Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha and AKT1 are potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrV3HvZF6NXLVg90H21EOLACvtfcHk0lgzeXNk8FSqPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslalurrJ&md5=7f3198d25ee7a8bd95bab1b85bb95651</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.7150%2Fthno.36182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.36182%26sid%3Dliteratum%253Aachs%26aulast%3DCoussy%26aufirst%3DF.%26aulast%3DLavigne%26aufirst%3DM.%26aulast%3Dde%2BKoning%26aufirst%3DL.%26aulast%3DBotty%26aufirst%3DR.%2BE.%26aulast%3DNemati%26aufirst%3DF.%26aulast%3DNaguez%26aufirst%3DA.%26aulast%3DBataillon%26aufirst%3DG.%26aulast%3DOuine%26aufirst%3DB.%26aulast%3DDahmani%26aufirst%3DA.%26aulast%3DMontaudon%26aufirst%3DE.%26aulast%3DPainsec%26aufirst%3DP.%26aulast%3DChateau-Joubert%26aufirst%3DS.%26aulast%3DLaetitia%26aufirst%3DF.%26aulast%3DLarcher%26aufirst%3DT.%26aulast%3DVacher%26aufirst%3DS.%26aulast%3DChemlali%26aufirst%3DW.%26aulast%3DBriaux%26aufirst%3DA.%26aulast%3DMelaabi%26aufirst%3DS.%26aulast%3DSalomon%26aufirst%3DA.%2BV.%26aulast%3DGuinebretiere%26aufirst%3DJ.%2BM.%26aulast%3DBieche%26aufirst%3DI.%26aulast%3DMarangoni%26aufirst%3DE.%26atitle%3DResponse%2520to%2520mTOR%2520and%2520PI3K%2520inhibitors%2520in%2520enzalutamide-resistant%2520luminal%2520androgen%2520receptor%2520triple-negative%2520breast%2520cancer%2520patient-derived%2520xenografts%26jtitle%3DTheranostics%26date%3D2020%26volume%3D10%26issue%3D4%26spage%3D1531%26epage%3D1543%26doi%3D10.7150%2Fthno.36182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamidi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, C.</span></span> <span> </span><span class="NLM_article-title">Unraveling the genomic-epigenomic interaction landscape in triple negative and non-triple negative breast cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1559</span>, <span class="refDoi"> DOI: 10.3390/cancers12061559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers12061559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVehtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1559&issue=6&author=J.+Wuauthor=T.+Mamidiauthor=L.+Zhangauthor=C.+Hicks&title=Unraveling+the+genomic-epigenomic+interaction+landscape+in+triple+negative+and+non-triple+negative+breast+cancer&doi=10.3390%2Fcancers12061559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling the genomic-epigenomic interaction landscape in triple negative and non-triple negative breast cancer</span></div><div class="casAuthors">Wu, Jiande; Mamidi, Tarun Karthik Kumar; Zhang, Lu; Hicks, Chindo</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1559</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Background: The recent surge of next generation sequencing of breast cancer genomes has enabled development of comprehensive catalogues of somatic mutations and expanded the mol. classification of subtypes of breast cancer.  However, somatic mutations and gene expression data have not been leveraged and integrated with epigenomic data to unravel the genomic-epigenomic interaction landscape of triple neg. breast cancer (TNBC) and non-triple neg. breast cancer (non-TNBC).  Methods: We performed integrative data anal. combining somatic mutation, epigenomic and gene expression data from The Cancer Genome Atlas (TCGA) to unravel the possible oncogenic interactions between genomic and epigenomic variation in TNBC and non-TNBC.  We hypothesized that within breast cancers, there are differences in somatic mutation, DNA methylation and gene expression signatures between TNBC and non-TNBC.  We further hypothesized that genomic and epigenomic alterations affect gene regulatory networks and signaling pathways driving the two types of breast cancer.  Results: The investigation revealed somatic mutated, epigenomic and gene expression signatures unique to TNBC and non-TNBC and signatures distinguishing the two types of breast cancer.  In addn., the investigation revealed mol. networks and signaling pathways enriched for somatic mutations and epigenomic changes unique to each type of breast cancer.  The most significant pathways for TNBC were: retinal biosynthesis, BAG2, LXR/RXR, EIF2 and P2Y purigenic receptor signaling pathways.  The most significant pathways for non-TNBC were: UVB-induced MAPK, PCP, Apelin endothelial, Endoplasmatic reticulum stress and mechanisms of viral exit from host signaling Pathways.  Conclusion: The investigation revealed integrated genomic, epigenomic and gene expression signatures and signing pathways unique to TNBC and non-TNBC, and a gene signature distinguishing the two types of breast cancer.  The study demonstrates that integrative anal. of multi-omics data is a powerful approach for unravelling the genomic-epigenomic interaction landscape in TNBC and non-TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4luZIYXkCjbVg90H21EOLACvtfcHk0lgaEqyKafOAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVehtb7M&md5=14b8bfa51f35b3d29feb8d8d47fa534b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fcancers12061559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12061559%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DMamidi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHicks%26aufirst%3DC.%26atitle%3DUnraveling%2520the%2520genomic-epigenomic%2520interaction%2520landscape%2520in%2520triple%2520negative%2520and%2520non-triple%2520negative%2520breast%2520cancer%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D1559%26doi%3D10.3390%2Fcancers12061559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschraegen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaklamani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span> <span> </span><span class="NLM_article-title">Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1038/s41422-020-0375-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41422-020-0375-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32719455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsV2mtbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=178-186&author=Y.+Jiangauthor=Y.+Liuauthor=Y.+Xiaoauthor=X.+Huauthor=L.+Jiangauthor=W.+Zuoauthor=D.+Maauthor=J.+Dingauthor=X.+Zhuauthor=J.+Zouauthor=C.+Verschraegenauthor=D.+Stoverauthor=V.+Kaklamaniauthor=Z.+Wangauthor=Z.+Shao&title=Molecular+subtyping+and+genomic+profiling+expand+precision+medicine+in+refractory+metastatic+triple-negative+breast+cancer%3A+the+FUTURE+trial&doi=10.1038%2Fs41422-020-0375-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer</span></div><div class="casAuthors">Jiang, Yi-Zhou; Liu, Yin; Xiao, Yi; Hu, Xin; Jiang, Lin; Zuo, Wen-Jia; Ma, Ding; Ding, Jiahan; Zhu, Xiaoyu; Zou, Jianjun; Verschraegen, Claire; Stover, Daniel G.; Kaklamani, Virginia; Wang, Zhong-Hua; Shao, Zhi-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-186</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Here, we conducted the FUTURE trial (ClinicalTrials.gov identifier: NCT03805399), a phase Ib/II subtyping-based and genomic biomarker-guided umbrella trial, to evaluate the efficacy of these targets.  Patients with refractory metastatic TNBC were enrolled and stratified by TNBC subtypes and genomic biomarkers, and assigned to one of these seven arms: (A) pyrotinib with capecitabine, (B) androgen receptor inhibitor with CDK4/6 inhibitor, (C) anti PD-1 with nab-paclitaxel, (D) PARP inhibitor included, (E) and (F) anti-VEGFR included, or (G) mTOR inhibitor with nab-paclitaxel.  The primary end point was the objective response rate (ORR).  We enrolled 69 refractory metastatic TNBC patients with a median of three previous lines of therapy (range, 1-8).  Objective response was achieved in 20 (29.0%, 95% confidence interval (CI): 18.7%-41.2%) of the 69 intention-to-treat (ITT) patients.  Our results showed that immunotherapy (arm C), in particular, achieved the highest ORR (52.6%, 95% CI: 28.9%-75.6%) in the ITT population.  Somatic mutations of TOP2A and CD8 immunohistochem. score may have the potential to predict immunotherapy response in the immunomodulatory subtype of TNBC.  In conclusion, the phase Ib/II FUTURE trial suggested a new concept for TNBC treatment, demonstrating the clin. benefit of subtyping-based targeted therapy for refractory metastatic TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2XujAnABJsLVg90H21EOLACvtfcHk0lgaEqyKafOAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsV2mtbjM&md5=2421cb15b37f5747f032543589dddb1b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-0375-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-0375-9%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZuo%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DVerschraegen%26aufirst%3DC.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DKaklamani%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DShao%26aufirst%3DZ.%26atitle%3DMolecular%2520subtyping%2520and%2520genomic%2520profiling%2520expand%2520precision%2520medicine%2520in%2520refractory%2520metastatic%2520triple-negative%2520breast%2520cancer%253A%2520the%2520FUTURE%2520trial%26jtitle%3DCell%2520Res.%26date%3D2021%26volume%3D31%26spage%3D178%26epage%3D186%26doi%3D10.1038%2Fs41422-020-0375-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2750</span>– <span class="NLM_lpage">2767</span>, <span class="refDoi"> DOI: 10.1172/JCI45014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1172%2FJCI45014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21633166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2750-2767&issue=7&author=B.+D.+Lehmannauthor=J.+A.+Bauerauthor=X.+Chenauthor=M.+E.+Sandersauthor=A.+B.+Chakravarthyauthor=Y.+Shyrauthor=J.+A.+Pietenpol&title=Identification+of+human+triple-negative+breast+cancer+subtypes+and+preclinical+models+for+selection+of+targeted+therapies&doi=10.1172%2FJCI45014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span></div><div class="casAuthors">Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2750-2767</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify mol.-based therapies.  In this study, we analyzed gene expression (GE) profiles from 21 breast cancer data sets and identified 587 TNBC cases.  Cluster anal. identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype.  Further, GE anal. allowed us to identify TNBC cell line models representative of these subtypes.  Predicted "driver" signaling pathways were pharmacol. targeted in these cell line models as proof of concept that anal. of distinct GE signatures can inform therapy selection.  BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin.  M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor).  The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling.  LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist).  These data may be useful in biomarker selection, drug discovery, and clin. trial design that will enable alignment of TNBC patients to appropriate targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhoQQUFogW7Vg90H21EOLACvtfcHk0lgaEqyKafOAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D&md5=c3681c79e0b972f16f6d5a5ecdc99fec</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2FJCI45014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45014%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DBauer%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DChakravarthy%26aufirst%3DA.%2BB.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520human%2520triple-negative%2520breast%2520cancer%2520subtypes%2520and%2520preclinical%2520models%2520for%2520selection%2520of%2520targeted%2520therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26issue%3D7%26spage%3D2750%26epage%3D2767%26doi%3D10.1172%2FJCI45014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bareche, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatiadis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftimos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotiriou, C.</span></span> <span> </span><span class="NLM_article-title">Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">902</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdy024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29365031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1MvjvVWltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=895-902&issue=4&author=Y.+Barecheauthor=D.+Venetauthor=M.+Ignatiadisauthor=P.+Aftimosauthor=M.+Piccartauthor=F.+Rotheauthor=C.+Sotiriou&title=Unravelling+triple-negative+breast+cancer+molecular+heterogeneity+using+an+integrative+multiomic+analysis&doi=10.1093%2Fannonc%2Fmdy024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis</span></div><div class="casAuthors">Bareche Y; Venet D; Rothe F; Ignatiadis M; Aftimos P; Piccart M; Sotiriou C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-902</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple-negative breast cancers (TNBCs) reporting, at least six different molecular subtypes of TNBC namely Basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL) and luminal androgen receptor (LAR).  However, little is known regarding the potential driving molecular events within each subtype, their difference in survival and response to therapy.  Further insight into the underlying genomic alterations is therefore needed.  Patients and methods:  This study was carried out using copy-number aberrations, somatic mutations and gene expression data derived from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas.  TNBC samples (n = 550) were classified according to Lehmann's molecular subtypes using the TNBCtype online subtyping tool (http://cbc.mc.vanderbilt.edu/tnbc/).  Results:  Each subtype showed significant clinic-pathological characteristic differences.  Using a multivariate model, IM subtype showed to be associated with a better prognosis (HR = 0.68; CI = 0.46-0.99; P = 0.043) whereas LAR subtype was associated with a worst prognosis (HR = 1.47; CI = 1.0-2.14; P = 0.046).  BL1 subtype was found to be most genomically instable subtype with high TP53 mutation (92%) and copy-number deletion in genes involved in DNA repair mechanism (BRCA2, MDM2, PTEN, RB1 and TP53).  LAR tumours were associated with higher mutational burden with significantly enriched mutations in PI3KCA (55%), AKT1 (13%) and CDH1 (13%) genes.  M and MSL subtypes were associated with higher signature score for angiogenesis.  Finally, IM showed high expression levels of immune signatures and check-point inhibitor genes such as PD1, PDL1 and CTLA4.  Conclusion:  Our findings highlight for the first time the substantial genomic heterogeneity that characterize TNBC molecular subtypes, allowing for a better understanding of the disease biology as well as the identification of several candidate targets paving novel approaches for the development of anticancer therapeutics for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFAwKX5MVwZa_dlEzl_fBafW6udTcc2eYBKRmmED13Cbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvjvVWltA%253D%253D&md5=b9932f82899e488739ab272e989b9e32</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy024%26sid%3Dliteratum%253Aachs%26aulast%3DBareche%26aufirst%3DY.%26aulast%3DVenet%26aufirst%3DD.%26aulast%3DIgnatiadis%26aufirst%3DM.%26aulast%3DAftimos%26aufirst%3DP.%26aulast%3DPiccart%26aufirst%3DM.%26aulast%3DRothe%26aufirst%3DF.%26aulast%3DSotiriou%26aufirst%3DC.%26atitle%3DUnravelling%2520triple-negative%2520breast%2520cancer%2520molecular%2520heterogeneity%2520using%2520an%2520integrative%2520multiomic%2520analysis%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D4%26spage%3D895%26epage%3D902%26doi%3D10.1093%2Fannonc%2Fmdy024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovanovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span> <span> </span><span class="NLM_article-title">Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e0157368</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0157368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0157368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27310713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOqtr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0157368&issue=6&author=B.+D.+Lehmannauthor=B.+Jovanovicauthor=X.+Chenauthor=M.+V.+Estradaauthor=K.+N.+Johnsonauthor=Y.+Shyrauthor=H.+L.+Mosesauthor=M.+E.+Sandersauthor=J.+A.+Pietenpol&title=Refinement+of+triple-negative+breast+cancer+molecular+subtypes%3A+implications+for+neoadjuvant+chemotherapy+selection&doi=10.1371%2Fjournal.pone.0157368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection</span></div><div class="casAuthors">Lehmann, Brian D.; Jovanovic, Bojana; Chen, Xi; Estrada, Monica V.; Johnson, Kimberly N.; Shyr, Yu; Moses, Harold L.; Sanders, Melinda E.; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0157368/1-e0157368/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct mol. subtypes by gene expression profiling.  Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival.  Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients.  Previously, we developed an approach to identify six mol. subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to std.-of-care chemotherapy.  Given the complexity of the varying histol. landscape of tumor specimens, we used histopathol. quantification and laser-capture microdissection to det. that transcripts in the previously described immunomodulatory (IM) and mesenchymal stem-like (MSL) subtypes were contributed from infiltrating lymphocytes and tumor-assocd. stromal cells, resp.  Therefore, we refined TNBC mol. subtypes from six (TNBCtype) into four (TNBCtype-4) tumor-specific subtypes (BL1, BL2, M and LAR) and demonstrate differences in diagnosis age, grade, local and distant disease progression and histopathol.  Using five publicly available, neoadjuvant chemotherapy breast cancer gene expression datasets, we retrospectively evaluated chemotherapy response of over 300 TNBC patients from pretreatment biopsies subtyped using either the intrinsic (PAM50) or TNBCtype approaches.  Combined anal. of TNBC patients demonstrated that TNBC subtypes significantly differ in response to similar neoadjuvant chemotherapy with 41% of BL1 patients achieving a pathol. complete response compared to 18% for BL2 and 29% for LAR with 95% confidence intervals (CIs; [33, 51], [9, 28], [17, 41], resp.).  Collectively, we provide pre-clin. data that could inform clin. trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of mol. TNBC subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjbtsOOP5UtLVg90H21EOLACvtfcHk0lj--yw1N_cX2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOqtr3P&md5=62dddc464beb0b81b34c325e787c698d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0157368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0157368%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DJovanovic%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DEstrada%26aufirst%3DM.%2BV.%26aulast%3DJohnson%26aufirst%3DK.%2BN.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DMoses%26aufirst%3DH.%2BL.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DRefinement%2520of%2520triple-negative%2520breast%2520cancer%2520molecular%2520subtypes%253A%2520implications%2520for%2520neoadjuvant%2520chemotherapy%2520selection%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D6%26spage%3De0157368%26doi%3D10.1371%2Fjournal.pone.0157368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells</span>. <i>Acta Bioch Bioph Sin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1093/abbs/gmy117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fabbs%2Fgmy117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30289427" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=1141-1149&issue=11&author=J.+Huoauthor=X.+Chenauthor=H.+Zhangauthor=Y.+Huauthor=Y.+Jiangauthor=S.+Liuauthor=X.+Zhang&title=Bcl-3+promotes+proliferation+and+chemosensitivity+in+BL1+subtype+of+TNBC+cells&doi=10.1093%2Fabbs%2Fgmy117"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fabbs%2Fgmy117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fabbs%252Fgmy117%26sid%3Dliteratum%253Aachs%26aulast%3DHuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DBcl-3%2520promotes%2520proliferation%2520and%2520chemosensitivity%2520in%2520BL1%2520subtype%2520of%2520TNBC%2520cells%26jtitle%3DActa%2520Bioch%2520Bioph%2520Sin.%26date%3D2018%26volume%3D50%26issue%3D11%26spage%3D1141%26epage%3D1149%26doi%3D10.1093%2Fabbs%2Fgmy117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charafe-Jauffret, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamessier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelaide, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houvenaeghel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maraninchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span> <span> </span><span class="NLM_article-title">Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4644</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-06-0031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=16651414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvF2ksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4636-4644&issue=9&author=F.+Bertucciauthor=P.+Finettiauthor=N.+Cerveraauthor=E.+Charafe-Jauffretauthor=E.+Mamessierauthor=J.+Adelaideauthor=S.+Debonoauthor=G.+Houvenaeghelauthor=D.+Maraninchiauthor=P.+Viensauthor=C.+Charpinauthor=J.+Jacquemierauthor=D.+Birnbaum&title=Gene+expression+profiling+shows+medullary+breast+cancer+is+a+subgroup+of+basal+breast+cancers&doi=10.1158%2F0008-5472.CAN-06-0031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers</span></div><div class="casAuthors">Bertucci, Francois; Finetti, Pascal; Cervera, Nathalie; Charafe-Jauffret, Emmanuelle; Mamessier, Emilie; Adelaide, Jose; Debono, Stephane; Houvenaeghel, Gilles; Maraninchi, Dominique; Viens, Patrice; Charpin, Colette; Jacquemier, Jocelyne; Birnbaum, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4636-4644</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Medullary breast cancer (MBC) is a rare but enigmatic pathol. type of breast cancer.  Despite features of aggressiveness, MBC is assocd. with a favorable prognosis.  Morphol. diagnosis remains difficult in many cases.  Very little is known about the mol. alterations involved in MBC.  Notably, it is not clear whether MBC and ductal breast cancer (DBC) represent molecularly distinct entities and what genes/proteins might account for their differences.  Using whole-genome oligonucleotide microarrays, we compared gene expression profiles of 22 MBCs and 44 grade III DBCs.  We show that MBCs are less heterogeneous than DBCs.  Whereas different mol. subtypes (luminal A, luminal B, basal, ERBB2-overexpressing, and normal-like) exist in DBCs, 95% MBCs display a basal profile, similar to that of basal DBCs.  Supervised anal. identified gene expression signatures that discriminated MBCs from DBCs.  Discriminator genes are assocd. with various cellular processes related to MBC features, in particular immune reaction and apoptosis.  As compared with MBCs, basal DBCs overexpress genes involved in smooth muscle cell differentiation, suggesting that MBCs are a distinct subgroup of basal breast cancer with limited myoepithelial differentiation.  Finally, MBCs overexpress a series of genes located on the 12p13 and 6p21 chromosomal regions known to contain pluripotency genes.  Our results contribute to a better understanding of MBC and of mammary oncogenesis in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgy5b76s3ICrVg90H21EOLACvtfcHk0lid8-WWTkATkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvF2ksb4%253D&md5=6db0341b38ea8bf331849e6d3eb5fbd2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0031%26sid%3Dliteratum%253Aachs%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DFinetti%26aufirst%3DP.%26aulast%3DCervera%26aufirst%3DN.%26aulast%3DCharafe-Jauffret%26aufirst%3DE.%26aulast%3DMamessier%26aufirst%3DE.%26aulast%3DAdelaide%26aufirst%3DJ.%26aulast%3DDebono%26aufirst%3DS.%26aulast%3DHouvenaeghel%26aufirst%3DG.%26aulast%3DMaraninchi%26aufirst%3DD.%26aulast%3DViens%26aufirst%3DP.%26aulast%3DCharpin%26aufirst%3DC.%26aulast%3DJacquemier%26aufirst%3DJ.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DGene%2520expression%2520profiling%2520shows%2520medullary%2520breast%2520cancer%2520is%2520a%2520subgroup%2520of%2520basal%2520breast%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D9%26spage%3D4636%26epage%3D4644%26doi%3D10.1158%2F0008-5472.CAN-06-0031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A.</span></span> <span> </span><span class="NLM_article-title">Robust enumeration of cell subsets from tissue expression profiles</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1038/nmeth.3337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fnmeth.3337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25822800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVOgu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=453-457&issue=5&author=A.+Newmanauthor=C.+Liuauthor=M.+Greenauthor=A.+Gentlesauthor=W.+Fengauthor=Y.+Xuauthor=C.+Hoangauthor=M.+Diehnauthor=A.+Alizadeh&title=Robust+enumeration+of+cell+subsets+from+tissue+expression+profiles&doi=10.1038%2Fnmeth.3337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Robust enumeration of cell subsets from tissue expression profiles</span></div><div class="casAuthors">Newman, Aaron M.; Liu, Chih Long; Green, Michael R.; Gentles, Andrew J.; Feng, Weiguo; Xu, Yue; Hoang, Chuong D.; Diehn, Maximilian; Alizadeh, Ash A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">453-457</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We introduce CIBERSORT, a method for characterizing cell compn. of complex tissues from their gene expression profiles.  When applied to enumeration of hematopoietic subsets in RNA mixts. from fresh, frozen and fixed tissues, including solid tumors, CIBERSORT outperformed other methods with respect to noise, unknown mixt. content and closely related cell types.  CIBERSORT should enable large-scale anal. of RNA mixts. for cellular biomarkers and therapeutic targets (http://cibersort.stanford.edu/).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE-GiX_cz7kbVg90H21EOLACvtfcHk0lid8-WWTkATkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVOgu7Y%253D&md5=8824a5271d4dfdd8b2aaee5210cb14f6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.3337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.3337%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DGentles%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHoang%26aufirst%3DC.%26aulast%3DDiehn%26aufirst%3DM.%26aulast%3DAlizadeh%26aufirst%3DA.%26atitle%3DRobust%2520enumeration%2520of%2520cell%2520subsets%2520from%2520tissue%2520expression%2520profiles%26jtitle%3DNat.%2520Methods%26date%3D2015%26volume%3D12%26issue%3D5%26spage%3D453%26epage%3D457%26doi%3D10.1038%2Fnmeth.3337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2405</span>– <span class="NLM_lpage">2421</span>, <span class="refDoi"> DOI: 10.7150/thno.38875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.7150%2Fthno.38875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32104513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKltrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=2405-2421&issue=5&author=L.+Zhouauthor=D.+Wangauthor=D.+Shengauthor=J.+Xuauthor=W.+Chenauthor=Y.+Qinauthor=R.+Duauthor=X.+Yangauthor=X.+Heauthor=N.+Xieauthor=S.+Liuauthor=L.+Zhang&title=NOTCH4+maintains+quiescent+mesenchymal-like+breast+cancer+stem+cells+via+transcriptionally+activating+SLUG+and+GAS1+in+triple-negative+breast+cancer&doi=10.7150%2Fthno.38875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer</span></div><div class="casAuthors">Zhou, Lei; Wang, Dong; Sheng, Dandan; Xu, Jiahui; Chen, Weilong; Qin, Yuanyuan; Du, Ruikai; Yang, Xiaoli; He, Xueyan; Xie, Ni; Liu, Suling; Zhang, Lixing</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2405-2421</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A NOTCH4 receptor has been implicated in triple-neg. breast cancer (TNBC) development and breast cancer stem cell (BCSC) regulation.  However, the potential of NOTCH4 as a BCSC marker and the underlying mechanisms remain unclear.  In this study, we detd. the expression and activation of NOTCH4 in breast cancer cell lines and tumor samples by qRT-PCR, western blotting and immunohistochem.  Subsequently, in vitro and in vivo serial diln. expts. were performed to demonstrate the application of NOTCH4 as an efficient mesenchymal-like (ML)-BCSC marker in TNBC.  Stable overexpression of activated NOTCH4 and knockdown cell lines were established using lentivirus.  The RNA-seq and qRT-PCR were employed to reveal the downstream effectors of NOTCH4, followed by dual-luciferase reporter and chromatin immunopptn. assays to identify the genuine binding sites of NOTCH4 on SLUG and GAS1 promoters.  Transwell assay, mammosphere formation and chemoresistance expts. were performed to det. the effects of SLUG, GAS1 and NOTCH4 on the mesenchymal-like characteristics of TNBC cells.  Survival anal. was used to study the relation of NOTCH4, SLUG and GAS1 with prognosis of breast cancer.  The NOTCH4 is aberrantly highly expressed and activated in TNBC, which contributes to the maintenance of ML-BCSCs.  Furthermore, NOTCH4 shows significantly higher efficiency in labeling ML-BCSCs than the currently commonly used CD24-CD44+ marker.  Mechanistically, NOTCH4 transcriptionally upregulates SLUG and GAS1 to promote EMT and quiescence in TNBC, resp.  The effects of NOTCH4 can be mimicked by simultaneous overexpression of SLUG and GAS1.  Moreover, SLUG is also involved in harnessing GAS1, a known tumor suppressor gene, via its anti-apoptotic function.  Our findings reveal that the NOTCH4-SLUG-GAS1 circuit serves as a potential target for tumor intervention by overcoming stemness of ML-BCSCs and by conquering the lethal chemoresistance and metastasis of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdUU_Aj5mbp7Vg90H21EOLACvtfcHk0lid8-WWTkATkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKltrjI&md5=809ffcfe31621b13f6111a55bb8f98f1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.7150%2Fthno.38875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.38875%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DNOTCH4%2520maintains%2520quiescent%2520mesenchymal-like%2520breast%2520cancer%2520stem%2520cells%2520via%2520transcriptionally%2520activating%2520SLUG%2520and%2520GAS1%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DTheranostics%26date%3D2020%26volume%3D10%26issue%3D5%26spage%3D2405%26epage%3D2421%26doi%3D10.7150%2Fthno.38875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basho, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbrich, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarracin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-MacGregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. L.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S. L.</span></span> <span> </span><span class="NLM_article-title">Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2016.5281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1001%2Fjamaoncol.2016.5281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27893038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhtVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=509-515&issue=4&author=R.+K.+Bashoauthor=M.+Gilcreaseauthor=R.+K.+Murthyauthor=T.+Helgasonauthor=D.+D.+Karpauthor=F.+Meric-Bernstamauthor=K.+R.+Hessauthor=S.+M.+Herbrichauthor=V.+Valeroauthor=C.+Albarracinauthor=J.+K.+Littonauthor=M.+Chavez-MacGregorauthor=N.+K.+Ibrahimauthor=J.+L.+Murrayauthor=K.+B.+Koenigauthor=D.+Hongauthor=V.+Subbiahauthor=R.+Kurzrockauthor=F.+Jankuauthor=S.+L.+Moulder&title=Targeting+the+PI3K%2FAKT%2FmTOR+pathway+for+the+treatment+of+mesenchymal+triple-negative+breast+cancer%3A+evidence+from+a+phase+1+trial+of+mTOR+inhibition+in+combination+with+liposomal+doxorubicin+and+bevacizumab&doi=10.1001%2Fjamaoncol.2016.5281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab</span></div><div class="casAuthors">Basho Reva K; Gilcrease Michael; Albarracin Constance; Murthy Rashmi K; Valero Vicente; Litton Jennifer K; Ibrahim Nuhad K; Murray James L 3rd; Koenig Kimberly B; Helgason Thorunn; Karp Daniel D; Hong David; Subbiah Vivek; Janku Filip; Meric-Bernstam Funda; Hess Kenneth R; Herbrich Shelley M; Chavez-MacGregor Mariana; Kurzrock Razelle; Moulder Stacy L</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-515</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response.  Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy.  While assays to identify mesenchymal TNBC are under development, metaplastic breast cancer serves as a clinically identifiable surrogate to evaluate potential regimens for mesenchymal TNBC.  Objective:  To assess safety and efficacy of mammalian target of rapamycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with advanced metaplastic TNBC.  Design, Setting, and Participants:  Phase 1 study with dose escalation and dose expansion at the University of Texas MD Anderson Cancer Center of patients with advanced metaplastic TNBC.  Patients were enrolled from April 16, 2009, to November 4, 2014, and followed for outcomes with a cutoff date of November 1, 2015, for data analysis.  Interventions:  Liposomal doxorubicin, bevacizumab, and the mTOR inhibitors temsirolimus or everolimus using 21-day cycles.  Main Outcomes and Measures:  Safety and response.  When available, archived tissue was evaluated for aberrations in the PI3K pathway.  Results:  Fifty-two women with metaplastic TNBC (median age, 58 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE) (N = 13).  The objective response rate was 21% (complete response = 4 [8%]; partial response = 7 [13%]) and 10 (19%) patients had stable disease for at least 6 months, for a clinical benefit rate of 40%.  Tissue was available for testing in 43 patients, and 32 (74%) had a PI3K pathway aberration.  Presence of PI3K pathway aberration was associated with a significant improvement in objective response rate (31% vs 0%; P = .04) but not clinical benefit rate (44% vs 45%; P > .99).  Conclusions and Relevance:  Using metaplastic TNBC as a surrogate for mesenchymal TNBC, DAT and DAE had notable activity in mesenchymal TNBC.  Objective response was limited to patients with PI3K pathway aberration.  A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTatjZ_QtxszUbxh97K6Vt6fW6udTcc2eabxt9SRD4867ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhtVSjsQ%253D%253D&md5=10ca11d3bfc1e167136b282120d58a7b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2016.5281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2016.5281%26sid%3Dliteratum%253Aachs%26aulast%3DBasho%26aufirst%3DR.%2BK.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DMurthy%26aufirst%3DR.%2BK.%26aulast%3DHelgason%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DD.%2BD.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHess%26aufirst%3DK.%2BR.%26aulast%3DHerbrich%26aufirst%3DS.%2BM.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DAlbarracin%26aufirst%3DC.%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DChavez-MacGregor%26aufirst%3DM.%26aulast%3DIbrahim%26aufirst%3DN.%2BK.%26aulast%3DMurray%26aufirst%3DJ.%2BL.%26aulast%3DKoenig%26aufirst%3DK.%2BB.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DMoulder%26aufirst%3DS.%2BL.%26atitle%3DTargeting%2520the%2520PI3K%252FAKT%252FmTOR%2520pathway%2520for%2520the%2520treatment%2520of%2520mesenchymal%2520triple-negative%2520breast%2520cancer%253A%2520evidence%2520from%2520a%2520phase%25201%2520trial%2520of%2520mTOR%2520inhibition%2520in%2520combination%2520with%2520liposomal%2520doxorubicin%2520and%2520bevacizumab%26jtitle%3DJAMA%2520Oncol.%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D509%26epage%3D515%26doi%3D10.1001%2Fjamaoncol.2016.5281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e74525</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0074525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0074525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24058584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSqs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e74525&issue=9&author=K.+Starkauthor=A.+Burgerauthor=J.+Wuauthor=P.+Sheltonauthor=L.+Polinauthor=J.+Li&title=Reactivation+of+estrogen+receptor+%CE%B1+by+vorinostat+sensitizes+mesenchymal-like+triple-negative+breast+cancer+to+aminoflavone%2C+a+ligand+of+the+aryl+hydrocarbon+receptor&doi=10.1371%2Fjournal.pone.0074525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor</span></div><div class="casAuthors">Stark, Karri; Burger, Angelika; Wu, Jianmei; Shelton, Phillip; Polin, Lisa; Li, Jing</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e74525</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Objective: Aminoflavone (AF) acts as a ligand of the aryl hydrocarbon receptor (AhR).  Expression of estrogen receptor α (ERα) and AhR-mediated transcriptional induction of CYP1A1 can sensitize breast cancer cells to AF.  The objective of this study was to investigate the combined antitumor effect of AF and the histone deacetylase inhibitor vorinostat for treating mesenchymal-like triple-neg. breast cancer (TNBC) as well as the underlying mechanisms of such treatment.  Methods: In vitro antiproliferative activity of AFP464 (AF prodrug) in breast cancer cell lines was evaluated by MTS assay.  In vitro, the combined effect of AFP464 and vorinostat on cell proliferation was assessed by the Chou-Talalay method.  In vivo, antitumor activity of AFP464, given alone and in combination with vorinostat, was studied using TNBC xenograft models.  Knockdown of ERα was performed using specific, small-interfering RNA.  Western blot, quant. RT-PCR, immunofluorescence, and immunohistochem. staining were performed to study the mechanisms underlying the combined antitumor effect.  Results: Luminal and basal A subtype breast cancer cell lines were sensitive to AFP464, whereas basal B subtype or mesenchymal-like TNBC cells were resistant.  Vorinostat sensitized mesenchymal-like TNBC MDA-MB-231 and Hs578T cells to AFP464.  It also potentiated the antitumor activity of AFP464 in a xenograft model using MDA-MB-231 cells.  In vitro and in vivo mechanistic studies suggested that vorinostat reactivated ERα expression and restored AhR-mediated transcriptional induction of CYP1A1.  Conclusion: The response of breast cancer cells to AF or AFP464 was assocd. with their gene expression profile.  Vorinostat sensitized mesenchymal-like TNBC to AF, at least in part, by reactivating ERα expression and restoring the responsiveness of AhR to AF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRTL2W5a8iS7Vg90H21EOLACvtfcHk0lj9YIDk8LKe0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSqs7bO&md5=fdb6e31997a867828b56f8496d639bdc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0074525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0074525%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DK.%26aulast%3DBurger%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DP.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DReactivation%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520by%2520vorinostat%2520sensitizes%2520mesenchymal-like%2520triple-negative%2520breast%2520cancer%2520to%2520aminoflavone%252C%2520a%2520ligand%2520of%2520the%2520aryl%2520hydrocarbon%2520receptor%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D9%26spage%3De74525%26doi%3D10.1371%2Fjournal.pone.0074525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span> <span> </span><span class="NLM_article-title">Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">406</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1007/s12032-011-9832-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs12032-011-9832-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21264529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2jurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=406-410&issue=2&author=J.+Heauthor=R.+Pengauthor=Z.+Yuanauthor=S.+Wangauthor=J.+Pengauthor=G.+Linauthor=X.+Jiangauthor=T.+Qin&title=Prognostic+value+of+androgen+receptor+expression+in+operable+triple-negative+breast+cancer%3A+a+retrospective+analysis+based+on+a+tissue+microarray&doi=10.1007%2Fs12032-011-9832-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray</span></div><div class="casAuthors">He, Jiehua; Peng, Roujun; Yuan, Zhongyu; Wang, Shusen; Peng, Jiewen; Lin, Guinan; Jiang, Xiaomei; Qin, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Medical Oncology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">406-410</span>CODEN:
                <span class="NLM_cas:coden">MONCEZ</span>;
        ISSN:<span class="NLM_cas:issn">1357-0560</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The aim of this study is to analyze the prognostic value of androgen receptor (AR) expression for patients with triple-neg. breast cancer (TNBC).  Clin. data of these patients were collected and analyzed, and immunohistochem. staining for AR was performed on tissue microarrays of operable breast cancer from 287 patients with TNBC, who were treated at Sun Yat-sen University Cancer Center from Jan. 1995 to Dec. 2008.  AR expression was found in 25.8% of the cases with TNBC.  TNBC patients with AR neg. have a higher proportion of pos. lymph node.  A significant correlation was found between AR expression and disease-free survival (DFS) and overall survival (OS).  Univariated anal. indicated that AR expression had a significant prognostic value in TNBC patients, whereas multivariate anal. indicated that AR was a significant independent prognostic factor of DFS (P = 0.032) in all patients.  Our results suggested that AR was a favorable prognostic factor of DFS and OS in patients with TNBC.  Therefore, TNBC may be further divided into two subtypes according to AR status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2OlUt8Go-5bVg90H21EOLACvtfcHk0lj9YIDk8LKe0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2jurs%253D&md5=62b1ffd49245aa6f3983b3fb319e4f72</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs12032-011-9832-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-011-9832-0%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DQin%26aufirst%3DT.%26atitle%3DPrognostic%2520value%2520of%2520androgen%2520receptor%2520expression%2520in%2520operable%2520triple-negative%2520breast%2520cancer%253A%2520a%2520retrospective%2520analysis%2520based%2520on%2520a%2520tissue%2520microarray%26jtitle%3DMed.%2520Oncol.%26date%3D2012%26volume%3D29%26issue%3D2%26spage%3D406%26epage%3D410%26doi%3D10.1007%2Fs12032-011-9832-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z. M.</span></span> <span> </span><span class="NLM_article-title">Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2106</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">27</span>),  <span class="NLM_fpage">41285</span>– <span class="NLM_lpage">41293</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.9778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.9778" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2106&pages=41285-41293&issue=27&author=H.+S.+Jiangauthor=X.+Y.+Kuangauthor=W.+L.+Sunauthor=Y.+Xuauthor=Y.+Z.+Zhengauthor=Y.+R.+Liuauthor=G.+T.+Langauthor=F.+Qiaoauthor=X.+Huauthor=Z.+M.+Shao&title=Androgen+receptor+expression+predicts+different+clinical+outcomes+for+breast+cancer+patients+stratified+by+hormone+receptor+status&doi=10.18632%2Foncotarget.9778"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.9778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.9778%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DH.%2BS.%26aulast%3DKuang%26aufirst%3DX.%2BY.%26aulast%3DSun%26aufirst%3DW.%2BL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%2BZ.%26aulast%3DLiu%26aufirst%3DY.%2BR.%26aulast%3DLang%26aufirst%3DG.%2BT.%26aulast%3DQiao%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DZ.%2BM.%26atitle%3DAndrogen%2520receptor%2520expression%2520predicts%2520different%2520clinical%2520outcomes%2520for%2520breast%2520cancer%2520patients%2520stratified%2520by%2520hormone%2520receptor%2520status%26jtitle%3DOncotarget%26date%3D2106%26volume%3D7%26issue%3D27%26spage%3D41285%26epage%3D41293%26doi%3D10.18632%2Foncotarget.9778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colomb, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grizzle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, C.</span></span> <span> </span><span class="NLM_article-title">AR negative triple negative or ″quadruple negative″ breast cancers in African American women have an enriched basal and immune signature</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e0196909</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0196909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0196909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29912871" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e0196909&issue=6&author=M.+Davisauthor=S.+Tripathiauthor=R.+Hughleyauthor=Q.+Heauthor=S.+Baeauthor=B.+Karanamauthor=R.+Martiniauthor=L.+Newmanauthor=W.+Colombauthor=W.+Grizzleauthor=C.+Yates&title=AR+negative+triple+negative+or+%E2%80%B3quadruple+negative%E2%80%B3+breast+cancers+in+African+American+women+have+an+enriched+basal+and+immune+signature&doi=10.1371%2Fjournal.pone.0196909"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0196909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0196909%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%26aulast%3DTripathi%26aufirst%3DS.%26aulast%3DHughley%26aufirst%3DR.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DBae%26aufirst%3DS.%26aulast%3DKaranam%26aufirst%3DB.%26aulast%3DMartini%26aufirst%3DR.%26aulast%3DNewman%26aufirst%3DL.%26aulast%3DColomb%26aufirst%3DW.%26aulast%3DGrizzle%26aufirst%3DW.%26aulast%3DYates%26aufirst%3DC.%26atitle%3DAR%2520negative%2520triple%2520negative%2520or%2520%25E2%2580%25B3quadruple%2520negative%25E2%2580%25B3%2520breast%2520cancers%2520in%2520African%2520American%2520women%2520have%2520an%2520enriched%2520basal%2520and%2520immune%2520signature%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3De0196909%26doi%3D10.1371%2Fjournal.pone.0196909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burden, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. J.</span></span> <span> </span><span class="NLM_article-title">A novel role for cathepsin s as a potential biomarker in triple negative breast cancer</span>. <i>J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span>,  <span class="NLM_fpage">3980273</span>, <span class="refDoi"> DOI: 10.1155/2019/3980273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1155%2F2019%2F3980273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31346333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MvhtlOrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=3980273&author=R.+D.+A.+Wilkinsonauthor=R.+E.+Burdenauthor=S.+H.+McDowellauthor=D.+G.+McArtauthor=S.+McQuaidauthor=V.+Binghamauthor=R.+Williamsauthor=O.+T.+Coxauthor=R.+O%E2%80%99Connorauthor=N.+McCabeauthor=R.+D.+Kennedyauthor=N.+E.+Buckleyauthor=C.+J.+Scott&title=A+novel+role+for+cathepsin+s+as+a+potential+biomarker+in+triple+negative+breast+cancer&doi=10.1155%2F2019%2F3980273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer</span></div><div class="casAuthors">Wilkinson Richard D A; McDowell Sara H; McArt Darragh G; Williams Rich; McCabe Nuala; Kennedy Richard D; Scott Christopher J; Burden Roberta E; Buckley Niamh E; McQuaid Stephen; Bingham Victoria; Cox Orla T; O'Connor Rosemary; McCabe Nuala; Kennedy Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3980273</span>
        ISSN:<span class="NLM_cas:issn">1687-8450</span>.
    </div><div class="casAbstract">Cathepsin S (CTSS) has previously been implicated in a number of cancer types, where it is associated with poor clinical features and outcome.  To date, patient outcome in breast cancer has not been examined with respect to this protease.  Here, we carried out immunohistochemical (IHC) staining of CTSS using a breast cancer tissue microarray in patients who received adjuvant therapy.  We scored CTSS expression in the epithelial and stromal compartments and evaluated the association of CTSS expression with matched clinical outcome data.  We observed differences in outcome based on CTSS expression, with stromal-derived CTSS expression correlating with a poor outcome and epithelial CTSS expression associated with an improved outcome.  Further subtype characterisation revealed high epithelial CTSS expression in TNBC patients with improved outcome, which remained consistent across two independent TMA cohorts.  Further in silico gene expression analysis, using both in-house and publicly available datasets, confirmed these observations and suggested high CTSS expression may also be beneficial to outcome in ER-/HER2+ cancer.  Furthermore, high CTSS expression was associated with the BL1 Lehmann subgroup, which is characterised by defects in DNA damage repair pathways and correlates with improved outcome.  Finally, analysis of matching IHC analysis reveals an increased M1 (tumour destructive) polarisation in macrophage in patients exhibiting high epithelial CTSS expression.  In conclusion, our observations suggest epithelial CTSS expression may be prognostic of improved outcome in TNBC.  Improved outcome observed with HER2+ at the gene expression level furthermore suggests CTSS may be prognostic of improved outcome in ER- cancers as a whole.  Lastly, from the context of these patients receiving adjuvant therapy and as a result of its association with BL1 subgroup CTSS may be elevated in patients with defects in DNA damage repair pathways, indicating it may be predictive of tumour sensitivity to DNA damaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqORQ4PrRF0BFwe7cAcrfPfW6udTcc2eaZPu4VgrOja7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvhtlOrsw%253D%253D&md5=12ed5d8a82e0fecb9a369c5989aae711</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1155%2F2019%2F3980273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2019%252F3980273%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DR.%2BD.%2BA.%26aulast%3DBurden%26aufirst%3DR.%2BE.%26aulast%3DMcDowell%26aufirst%3DS.%2BH.%26aulast%3DMcArt%26aufirst%3DD.%2BG.%26aulast%3DMcQuaid%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DV.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DCox%26aufirst%3DO.%2BT.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DKennedy%26aufirst%3DR.%2BD.%26aulast%3DBuckley%26aufirst%3DN.%2BE.%26aulast%3DScott%26aufirst%3DC.%2BJ.%26atitle%3DA%2520novel%2520role%2520for%2520cathepsin%2520s%2520as%2520a%2520potential%2520biomarker%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Oncol.%26date%3D2019%26volume%3D2019%26spage%3D3980273%26doi%3D10.1155%2F2019%2F3980273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traina, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yardley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eakle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradishar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gucalp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Estevez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudeau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudor, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.71.3495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2016.71.3495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29373071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1amtr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=884-890&issue=9&author=T.+A.+Trainaauthor=K.+Millerauthor=D.+A.+Yardleyauthor=J.+Eakleauthor=L.+S.+Schwartzbergauthor=J.+O%E2%80%99Shaughnessyauthor=W.+Gradisharauthor=P.+Schmidauthor=E.+Winerauthor=C.+Kellyauthor=R.+Nandaauthor=A.+Gucalpauthor=A.+Awadaauthor=L.+Garcia-Estevezauthor=M.+E.+Trudeauauthor=J.+Steinbergauthor=H.+Uppalauthor=I.+C.+Tudorauthor=A.+Petersonauthor=J.+Cortes&title=Enzalutamide+for+the+treatment+of+androgen+receptor-expressing+triple-negative+breast+cancer&doi=10.1200%2FJCO.2016.71.3495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer</span></div><div class="casAuthors">Traina, Tiffany A.; Miller, Kathy; Yardley, Denise A.; Eakle, Janice; Schwartzberg, Lee S.; O'Shaughnessy, Joyce; Gradishar, William; Schmid, Peter; Winer, Eric; Kelly, Catherine; Nanda, Rita; Gucalp, Ayca; Awada, Ahmad; Garcia-Estevez, Laura; Trudeau, Maureen E.; Steinberg, Joyce; Uppal, Hirdesh; Tudor, Iulia Cristina; Peterson, Amy; Cortes, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">884-890</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Studies suggest that a subset of patients with triple-neg. breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor.  This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-pos. TNBC.  Patients and Methods Tumors were tested for AR with an immunohistochem. assay optimized for breast cancer; nuclear AR staining > 0% was considered pos.  Patients received enzalutamide 160 mg once per day until disease progression.  The primary end point was clin. benefit rate (CBR) at 16 wk.  Secondary end points included CBR at 24wk, progression-free survival, and safety.  End points were analyzed in all enrolled patients (the intent-to-treat [ITT] population) and in patients with one or more postbaseline assessment whose tumor expressed ≥ 10% nuclear AR (the evaluable subgroup).  Results Of 118 patients enrolled, 78 were evaluable.  CBR at 16 wk was 25% (95% CI, 17% to 33%) in the ITT population and 33% (95% CI, 23% to 45%) in the evaluable subgroup.  Median progression-free survival was 2.9 mo (95% CI, 1.9 to 3.7 mo) in the ITT population and 3.3 mo (95% CI, 1.9 to 4.1 mo) in the evaluable subgroup.  Median overall survival was 12.7 mo (95% CI, 8.5 mo to not yet reached) in the ITT population and 17.6 mo (95% CI, 11.6 mo to not yet reached) in the evaluable subgroup.  Fatigue was the only treatment-related grade 3 or higher adverse event with an incidence of > 2%.  Conclusion Enzalutamide demonstrated clin. activity and was well tolerated in patients with advanced AR-pos. TNBC.  Adverse events related to enzalutamide were consistent with its known safety profile.  This study supports addnl. development of enzalutamide in advanced TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXhl3xaKaC4LVg90H21EOLACvtfcHk0lipzIh9N5YL1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1amtr%252FP&md5=5ac1d1563e9ffcadb63644dab880f9bd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.71.3495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.71.3495%26sid%3Dliteratum%253Aachs%26aulast%3DTraina%26aufirst%3DT.%2BA.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DEakle%26aufirst%3DJ.%26aulast%3DSchwartzberg%26aufirst%3DL.%2BS.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DGradishar%26aufirst%3DW.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DKelly%26aufirst%3DC.%26aulast%3DNanda%26aufirst%3DR.%26aulast%3DGucalp%26aufirst%3DA.%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DGarcia-Estevez%26aufirst%3DL.%26aulast%3DTrudeau%26aufirst%3DM.%2BE.%26aulast%3DSteinberg%26aufirst%3DJ.%26aulast%3DUppal%26aufirst%3DH.%26aulast%3DTudor%26aufirst%3DI.%2BC.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DEnzalutamide%2520for%2520the%2520treatment%2520of%2520androgen%2520receptor-expressing%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D9%26spage%3D884%26epage%3D890%26doi%3D10.1200%2FJCO.2016.71.3495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebied, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper-DeHoff, R.</span></span> <span> </span><span class="NLM_article-title">New drug approvals in 2018 - another record year!</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1016/j.amjmed.2019.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.amjmed.2019.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30853471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3cbitlOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2019&pages=1038-1043&issue=9&author=A.+Ebiedauthor=J.+Naauthor=R.+Cooper-DeHoff&title=New+drug+approvals+in+2018+-+another+record+year%21&doi=10.1016%2Fj.amjmed.2019.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">New Drug Approvals in 2018 - Another Record Year!</span></div><div class="casAuthors">Ebied Alex M; Na Juri; Cooper-DeHoff Rhonda M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1038-1043</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In 2018, the US Food and Drug Administration approved 59 novel drugs.  This all-time record was due primarily to the expedited review pathways; 43 of the 59 (73%) novel drug approvals were designated in an expedited review pathway, and 34 of the 59 (58%) were approved for treatment of rare diseases.  A review of these novel drugs is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtcAMHF8dFLKe0F5ixvZgXfW6udTcc2ebz1qEfzRPgz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbitlOitw%253D%253D&md5=3bacfd49accb4dbe5ce0769f3c83d142</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2019.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2019.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DEbied%26aufirst%3DA.%26aulast%3DNa%26aufirst%3DJ.%26aulast%3DCooper-DeHoff%26aufirst%3DR.%26atitle%3DNew%2520drug%2520approvals%2520in%25202018%2520-%2520another%2520record%2520year%2521%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2019%26volume%3D132%26issue%3D9%26spage%3D1038%26epage%3D1043%26doi%3D10.1016%2Fj.amjmed.2019.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. M.</span></span> <span> </span><span class="NLM_article-title">Varlitinib downregulates HER/ERK signaling and induces apoptosis in triple negative breast cancer cells</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.3390/cancers11010105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers11010105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKgsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=105&issue=1&author=C.+Y.+Liuauthor=P.+Y.+Chuauthor=C.+T.+Huangauthor=J.+L.+Chenauthor=H.+P.+Yangauthor=W.+L.+Wangauthor=K.+Y.+Lauauthor=C.+H.+Leeauthor=T.+Y.+Lanauthor=T.+T.+Huangauthor=P.+H.+Linauthor=M.+S.+Daiauthor=L.+M.+Tseng&title=Varlitinib+downregulates+HER%2FERK+signaling+and+induces+apoptosis+in+triple+negative+breast+cancer+cells&doi=10.3390%2Fcancers11010105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Varlitinib downregulates HER/ERK signaling and induces apoptosis in triple negative breast cancer cells</span></div><div class="casAuthors">Liu, Chun-Yu; Chu, Pei-Yi; Huang, Chun-Teng; Chen, Ji-Lin; Yang, Hsiu-Ping; Wang, Wan-Lun; Lau, Ka-Yi; Lee, Chia-Han; Lan, Tien-Yun; Huang, Tzu-Ting; Lin, Po-Han; Dai, Ming-Shen; Tseng, Ling-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a complex disease assocd. with the aggressive phenotype and poor prognosis.  TNBC harbors heterogeneous mol. subtypes with no approved specific targeted therapy.  It has been reported that HER receptors are overexpressed in breast cancer including TNBC.  In this study, we evaluated the efficacy of varlitinib, a reversible small mol. pan-HER inhibitor in TNBC.  Our results showed that varlitinib reduced cell viability and induced cell apoptosis in most TNBC cell lines but not in MDA-MB-231 cells.  MEK and ERK inhibition overcame resistance to varlitinib in MDA-MB-231 cells.  Varlitinib inhibited HER signaling which led to inhibition of migration, invasion and mammosphere formation of TNBC cells as well as significant suppression of tumor growth of MDA-MB-468 xenograft mouse model.  In summary, these results suggest that HER signaling plays an important role in TNBC progression and that pan-HER inhibition is potentially an effective treatment for TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou9HLm9WN94bVg90H21EOLACvtfcHk0lipzIh9N5YL1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKgsL7K&md5=0019c6f1f80f329bd3b2c62c3839646a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fcancers11010105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11010105%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DH.%2BP.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DLau%26aufirst%3DK.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DLan%26aufirst%3DT.%2BY.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DLin%26aufirst%3DP.%2BH.%26aulast%3DDai%26aufirst%3DM.%2BS.%26aulast%3DTseng%26aufirst%3DL.%2BM.%26atitle%3DVarlitinib%2520downregulates%2520HER%252FERK%2520signaling%2520and%2520induces%2520apoptosis%2520in%2520triple%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D1%26spage%3D105%26doi%3D10.3390%2Fcancers11010105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. M.</span></span> <span> </span><span class="NLM_article-title">Salidroside inhibits migration, invasion and angiogenesis of MDAMB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.3892/ijo.2018.4430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3892%2Fijo.2018.4430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29901185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=877-885&issue=2&author=D.+Y.+Kangauthor=N.+Spauthor=D.+H.+Kimauthor=Y.+H.+Joungauthor=H.+G.+Leeauthor=Y.+M.+Parkauthor=Y.+M.+Yang&title=Salidroside+inhibits+migration%2C+invasion+and+angiogenesis+of+MDAMB+231+TNBC+cells+by+regulating+EGFR%2FJak2%2FSTAT3+signaling+via+MMP2&doi=10.3892%2Fijo.2018.4430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Salidroside inhibits migration, invasion and angiogenesis of MDA-MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2</span></div><div class="casAuthors">Kang, Dong Young; Sp, Nipin; Kim, Doh Hoon; Joung, Youn Hee; Lee, Hyo Gun; Park, Young Min; Yang, Young Mok</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">877-885</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The major hallmarks of tumor progression are angiogenesis, migration and metastasis.  Among the components of Rhodiola rosea, salidroside (p-hydroxyphenethyl-β-dglucoside) is one of the most potent, and is present in all Rhodiola species.  The present study aimed to analyze how salidroside affects major factors involved in breast cancer, and to elucidate its ability to inhibit angiogenesis and invasion.  Signal transducer and activator of transcription 3 (STAT3) is a marker for tumor angiogenesis and migration, which interacts with matrix metalloproteinases (MMPs).  Specifically, MMPs act as a downstream target for STAT3.  Using western blotting and reverse transcription-quant. polymerase chain reaction anal., the present study demonstrated that treatment of MDA-MB 231 triple-neg. breast cancer (TNBC) cells with salidroside led to inhibition of invasion and migration markers, and of STAT3 signaling.  Furthermore, in vitro angiogenesis analyses in human umbilical vein endothelial cells confirmed the anti-angiogenic activity of salidroside.  An electrophoretic mobility shift assay also demonstrated that salidroside may inhibit the DNA-binding activity of STAT3, preventing STAT3 from binding to a novel binding site of the MMP2 gene promoter.  In conclusion, the present results demonstrated that salidroside may downregulate the STAT3 signaling pathway, and inhibit cell viability, migration and invasion through MMPs in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK7dsZ9hKGhbVg90H21EOLACvtfcHk0liYKM8LGpdg2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCrtrs%253D&md5=674c95b736f01112367f4e5605781945</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3892%2Fijo.2018.4430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2018.4430%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DD.%2BY.%26aulast%3DSp%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DJoung%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BG.%26aulast%3DPark%26aufirst%3DY.%2BM.%26aulast%3DYang%26aufirst%3DY.%2BM.%26atitle%3DSalidroside%2520inhibits%2520migration%252C%2520invasion%2520and%2520angiogenesis%2520of%2520MDAMB%2520231%2520TNBC%2520cells%2520by%2520regulating%2520EGFR%252FJak2%252FSTAT3%2520signaling%2520via%2520MMP2%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2018%26volume%3D53%26issue%3D2%26spage%3D877%26epage%3D885%26doi%3D10.3892%2Fijo.2018.4430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elbaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasser, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahirwar, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oghumu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoskar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shilo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, W. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganju, R. K.</span></span> <span> </span><span class="NLM_article-title">Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">906</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2014.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.molonc.2014.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25660577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVaktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=906-919&issue=4&author=M.+Elbazauthor=M.+W.+Nasserauthor=J.+Raviauthor=N.+A.+Waniauthor=D.+K.+Ahirwarauthor=H.+Zhaoauthor=S.+Oghumuauthor=A.+R.+Satoskarauthor=K.+Shiloauthor=W.+E.+Carsonauthor=R.+K.+Ganju&title=Modulation+of+the+tumor+microenvironment+and+inhibition+of+EGF%2FEGFR+pathway%3A+novel+anti-tumor+mechanisms+of+Cannabidiol+in+breast+cancer&doi=10.1016%2Fj.molonc.2014.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer</span></div><div class="casAuthors">Elbaz, Mohamad; Nasser, Mohd W.; Ravi, Janani; Wani, Nissar A.; Ahirwar, Dinesh K.; Zhao, Helong; Oghumu, Steve; Satoskar, Abhay R.; Shilo, Konstantin; Carson, Wiliam E., III; Ganju, Ramesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">906-919</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The anti-tumor role and mechanisms of Cannabidiol (CBD), a non-psychotropic cannabinoid compd., are not well studied esp. in triple-neg. breast cancer (TNBC).  In the present study, we analyzed CBD's anti-tumorigenic activity against highly aggressive breast cancer cell lines including TNBC subtype.  We show here -for the first time-that CBD significantly inhibits epidermal growth factor (EGF)-induced proliferation and chemotaxis of breast cancer cells.  Further studies revealed that CBD inhibits EGF-induced activation of EGFR, ERK, AKT and NF-kB signaling pathways as well as MMP2 and MMP9 secretion.  In addn., we demonstrated that CBD inhibits tumor growth and metastasis in different mouse model systems.  Anal. of mol. mechanisms revealed that CBD significantly inhibits the recruitment of tumor-assocd. macrophages in primary tumor stroma and secondary lung metastases.  Similarly, our in vitro studies showed a significant redn. in the no. of migrated RAW 264.7 cells towards the conditioned medium of CBD-treated cancer cells.  The conditioned medium of CBD-treated cancer cells also showed lower levels of GM-CSF and CCL3 cytokines which are important for macrophage recruitment and activation.  In summary, our study shows -for the first time-that CBD inhibits breast cancer growth and metastasis through novel mechanisms by inhibiting EGF/EGFR signaling and modulating the tumor microenvironment.  These results also indicate that CBD can be used as a novel therapeutic option to inhibit growth and metastasis of highly aggressive breast cancer subtypes including TNBC, which currently have limited therapeutic options and are assocd. with poor prognosis and low survival rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0OvPnACYBYrVg90H21EOLACvtfcHk0liYKM8LGpdg2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVaktbg%253D&md5=20fc63b1ce328066e37db731b7998cbe</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DElbaz%26aufirst%3DM.%26aulast%3DNasser%26aufirst%3DM.%2BW.%26aulast%3DRavi%26aufirst%3DJ.%26aulast%3DWani%26aufirst%3DN.%2BA.%26aulast%3DAhirwar%26aufirst%3DD.%2BK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DOghumu%26aufirst%3DS.%26aulast%3DSatoskar%26aufirst%3DA.%2BR.%26aulast%3DShilo%26aufirst%3DK.%26aulast%3DCarson%26aufirst%3DW.%2BE.%26aulast%3DGanju%26aufirst%3DR.%2BK.%26atitle%3DModulation%2520of%2520the%2520tumor%2520microenvironment%2520and%2520inhibition%2520of%2520EGF%252FEGFR%2520pathway%253A%2520novel%2520anti-tumor%2520mechanisms%2520of%2520Cannabidiol%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26issue%3D4%26spage%3D906%26epage%3D919%26doi%3D10.1016%2Fj.molonc.2014.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kgk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">G, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malla, R. R.</span></span> <span> </span><span class="NLM_article-title">Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">108872</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2019.108872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.cbi.2019.108872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31669320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVyht7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2020&pages=108872&author=D.+Kgkauthor=S.+Kumariauthor=S.+Gauthor=R.+R.+Malla&title=Marine+natural+compound+cyclo%28L-leucyl-L-prolyl%29+peptide+inhibits+migration+of+triple+negative+breast+cancer+cells+by+disrupting+interaction+of+CD151+and+EGFR+signaling&doi=10.1016%2Fj.cbi.2019.108872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling</span></div><div class="casAuthors">Kgk, Deepak; Kumari, Seema; G, Shailender; Malla, Rama Rao</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108872</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Cyclo (L-Leucyl-L-Prolyl) peptide/CLP is a marine natural metabolite and well recognized as an antimicrobial and antioxidant agent with limited studies on anticancer activity.  The current study aims to det. the effect of CLP on migration and growth of triple neg. breast cancer cell lines.  The anti-growth potential was evaluated by MTT, BrdU and TUNEL assays; DNA damage by γH2AX and Dead green assays; antimigration activity by Boyden chamber invasion and wound healing assays.  Interaction of CLP with CD151 was resolved by PatchDock.  Effect of CLP on the expression of transmembrane CD151 was evaluated by cell-based ELISA assay.  The interaction between CD151 and EGFR was predicted by using FireDoc Web server.  Impact of CLP on the interaction of CD151 with EGFR was evaluated by co-immunopptn. assay.  The effect of CLP on the cell cycle and its controlling proteins was detd. by Western blotting.  CLP reduced the viability of MDA-MB-231 and MDA-MB-468 TNBC cell lines but not human breast healthy epithelial cell line (MCF-12A) similar to eribulin, std.  CLP also inhibited proliferation; cell cycle and migration.  It induced DNA strand breaks, DNA damage, and cell death.  It showed the most favorable interactions with CD151 in in silico docking and significantly reduced the expression of membrane-bound CD151 proteins.  FireDoc Web study predicted the assocn. between CD151 and EGFR with -29.13 kcal/mol of binding energy.  CLP reduced the interaction of CD151 with EGFR along with the expression of cyclin D, CDK4, PAK, RAC1, and P27kiP1.  This study concludes that CLP suppresses growth and migration by attenuating cell cycle of TNBC cell lines via EGFR and CD151 signaling.  Thus, exploring the EGFR and CD151 signaling pathway targeted by CLP may provide a new approach in the treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpygt4HuDzKWLVg90H21EOLACvtfcHk0liYKM8LGpdg2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVyht7jL&md5=77ea188a2cf955c11807dbad924f4c4c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2019.108872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2019.108872%26sid%3Dliteratum%253Aachs%26aulast%3DKgk%26aufirst%3DD.%26aulast%3DKumari%26aufirst%3DS.%26aulast%3DG%26aufirst%3DS.%26aulast%3DMalla%26aufirst%3DR.%2BR.%26atitle%3DMarine%2520natural%2520compound%2520cyclo%2528L-leucyl-L-prolyl%2529%2520peptide%2520inhibits%2520migration%2520of%2520triple%2520negative%2520breast%2520cancer%2520cells%2520by%2520disrupting%2520interaction%2520of%2520CD151%2520and%2520EGFR%2520signaling%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2020%26volume%3D315%26spage%3D108872%26doi%3D10.1016%2Fj.cbi.2019.108872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatem, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labiod, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chateau-Joubert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Plater, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Botty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servely, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieche, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, E.</span></span> <span> </span><span class="NLM_article-title">Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2510</span>– <span class="NLM_lpage">2521</span>, <span class="refDoi"> DOI: 10.1002/ijc.29974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fijc.29974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26686064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFyksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=2510-2521&issue=10&author=R.+Hatemauthor=D.+Labiodauthor=S.+Chateau-Joubertauthor=L.+de+Platerauthor=R.+El+Bottyauthor=S.+Vacherauthor=F.+Boninauthor=J.+L.+Servelyauthor=V.+Dierasauthor=I.+Biecheauthor=E.+Marangoni&title=Vandetanib+as+a+potential+new+treatment+for+estrogen+receptor-negative+breast+cancers&doi=10.1002%2Fijc.29974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers</span></div><div class="casAuthors">Hatem, Rana; Labiod, Dalila; Chateau-Joubert, Sophie; de Plater, Ludmilla; El Botty, Rania; Vacher, Sophie; Bonin, Florian; Servely, Jean-Luc; Dieras, Veronique; Bieche, Ivan; Marangoni, Elisabetta</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2510-2521</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase RET is implicated in the progression of luminal breast cancers (BC) but its role in estrogen receptor (ER) neg. tumors is unknown.  Here we investigated the expression of RET in breast cancer patients tumors and patient-derived xenografts (PDX) and evaluated the therapeutic potential of Vandetanib, a tyrosin kinase inhibitor with strong activity against RET, EGFR and VEGFR2, in ER neg. breast cancer PDX.  The RT-PCR anal. of RET expression in breast tumors of 446 patients and 57 PDX, showed elevated levels of RET in ER+ and HER2+ subtypes and in a small subgroup of triple-neg. breast cancers (TNBC).  The activity of Vandetanib was tested in vivo in three PDX models of TNBC and one model of HER2+ BC with different expression levels of RET and EGFR.  Vandetanib induced tumor regression in PDX models with high expression of RET or EGFR.  The effect was assocd. with inhibition of RET/EGFR phosphorylation and MAP kinase pathway and increased necrosis.  In a PDX model with no expression of RET nor EGFR, Vandetanib slowed tumor growth without inducing tumor regression.  In addn., treatment by Vandetanib decreased expression of murine Vegf receptors and the endothelial marker Cd31 in the four PDX models tested, suggesting inhibition of tumor vascularization.  In summary, these preclin. results suggest that Vandetanib treatment could be useful for patients with ER neg. breast cancers overexpressing Vandetanib's main targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIK0aqhEtPYLVg90H21EOLACvtfcHk0liecaLnFV4hyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFyksQ%253D%253D&md5=c6c68e2f13043046f24ce9b23314230d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fijc.29974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29974%26sid%3Dliteratum%253Aachs%26aulast%3DHatem%26aufirst%3DR.%26aulast%3DLabiod%26aufirst%3DD.%26aulast%3DChateau-Joubert%26aufirst%3DS.%26aulast%3Dde%2BPlater%26aufirst%3DL.%26aulast%3DEl%2BBotty%26aufirst%3DR.%26aulast%3DVacher%26aufirst%3DS.%26aulast%3DBonin%26aufirst%3DF.%26aulast%3DServely%26aufirst%3DJ.%2BL.%26aulast%3DDieras%26aufirst%3DV.%26aulast%3DBieche%26aufirst%3DI.%26aulast%3DMarangoni%26aufirst%3DE.%26atitle%3DVandetanib%2520as%2520a%2520potential%2520new%2520treatment%2520for%2520estrogen%2520receptor-negative%2520breast%2520cancers%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2016%26volume%3D138%26issue%3D10%26spage%3D2510%26epage%3D2521%26doi%3D10.1002%2Fijc.29974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1007/s10549-019-05166-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-019-05166-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30826934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWnt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2019&pages=339-351&issue=2&author=J.+Leeauthor=B.+Limauthor=T.+Pearsonauthor=K.+Choiauthor=J.+A.+Fusonauthor=C.+Bartholomeuszauthor=L.+J.+Paradisoauthor=T.+Myersauthor=D.+Tripathyauthor=N.+T.+Ueno&title=Anti-tumor+and+anti-metastasis+efficacy+of+E6201%2C+a+MEK1+inhibitor%2C+in+preclinical+models+of+triple-negative+breast+cancer&doi=10.1007%2Fs10549-019-05166-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer</span></div><div class="casAuthors">Lee, Jangsoon; Lim, Bora; Pearson, Troy; Choi, Kuicheon; Fuson, Jon A.; Bartholomeusz, Chandra; Paradiso, Linda J.; Myers, Thomas; Tripathy, Debu; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-351</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Triple-neg. breast cancer (TNBC) lacks the receptor targets estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, and thus, it does not respond to receptor-targeted treatments.  TNBC has higher recurrence, metastasis, and mortality rates than other subtypes of breast cancer.  Mounting data suggest that the MAPK (also known as RAS-RAF-MEK-ERK) pathway is an important therapeutic target in TNBC.  Methods: To evaluate anti-tumor and anti-metastasis efficacy of E6201, we used cell proliferation assay, soft agar assay, cell cycle assay, Annexin V staining assay, immunoblotting anal., immunohistochem., migration assay, invasion assay, mammary fat pad xenograft, and exptl. and spontaneous metastasis xenograft models.  We also evaluated the anti-tumor efficacy of E6201 plus CDK4/6 inhibitor, mTOR inhibitor, or ATR inhibitor.  Results: E6201 inhibited TNBC cell colony formation, migration, and invasion in a dose-dependent manner.  E6201 induced G1 cell cycle arrest and apoptosis.  E6201 inhibited TNBC xenograft growth and inhibited TNBC lung metastasis and improved mouse survival in exptl. metastasis and spontaneous metastasis assays.  Immunohistochem. staining demonstrated that E6201 decreased the metastatic burden in the lung and decreased phosphorylated ERK expression in a dose-dependent manner.  Combination of E6201 with CDK4/6 inhibitor or mTOR inhibitor enhanced E6201's in vitro anti-tumor efficacy.  Conclusion: These results indicate that E6201 exhibits anti-tumor efficacy against TNBC in vitro and anti-metastasis efficacy against TNBC in vivo.  These results provide a rationale for further clin. development of E6201 as a MAPK-pathway-targeted therapy for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM2oQkV2aX27Vg90H21EOLACvtfcHk0liecaLnFV4hyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWnt7vK&md5=f667ee90f0b3dbcf62a76ab138b90c8f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs10549-019-05166-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-019-05166-3%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DPearson%26aufirst%3DT.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DFuson%26aufirst%3DJ.%2BA.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DParadiso%26aufirst%3DL.%2BJ.%26aulast%3DMyers%26aufirst%3DT.%26aulast%3DTripathy%26aufirst%3DD.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DAnti-tumor%2520and%2520anti-metastasis%2520efficacy%2520of%2520E6201%252C%2520a%2520MEK1%2520inhibitor%252C%2520in%2520preclinical%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2019%26volume%3D175%26issue%3D2%26spage%3D339%26epage%3D351%26doi%3D10.1007%2Fs10549-019-05166-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putatunda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, P. C.</span></span> <span> </span><span class="NLM_article-title">Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3936</span>– <span class="NLM_lpage">3949</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.594028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1074%2Fjbc.M114.594028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25527500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=3936-3949&issue=7&author=S.+Ghoshauthor=A.+Adhikaryauthor=S.+Chakrabortyauthor=P.+Bhattacharjeeauthor=M.+Mazumderauthor=S.+Putatundaauthor=M.+Gorainauthor=A.+Chakrabortyauthor=G.+C.+Kunduauthor=T.+Dasauthor=P.+C.+Sen&title=Cross-talk+between+endoplasmic+reticulum+%28ER%29+stress+and+the+MEK%2FERK+pathway+potentiates+apoptosis+in+human+triple+negative+breast+carcinoma+cells%3A+role+of+a+dihydropyrimidone%2C+nifetepimine&doi=10.1074%2Fjbc.M114.594028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK Pathway Potentiates Apoptosis in Human Triple Negative Breast Carcinoma Cells</span></div><div class="casAuthors">Ghosh, Swatilekha; Adhikary, Arghya; Chakraborty, Supriya; Bhattacharjee, Pushpak; Mazumder, Minakshi; Putatunda, Salil; Gorain, Mahadeo; Chakraborty, Arijit; Kundu, Gopal C.; Das, Tanya; Sen, Parimal C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3936-3949</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Triple neg. breast cancers (TNBC) are among the most aggressive and therapy-resistant breast tumors and currently possess almost no mol. targets for therapeutic options in this horizon.  In the present study we discerned the mol. mechanisms of potential interaction between the endoplasmic reticulum (ER) stress response and the MEK/ERK pathway in inducing apoptosis in TNBC cells.  Here we obsd. that induction of ER stress alone was not sufficient to trigger significant apoptosis but simultaneous inhibition of the MEK/ERK pathway enhanced ER stress-induced apoptosis via a caspase-dependent mechanism.  Our study also demonstrated nifetepimine, a dihydropyrimidone deriv. as a potent anti-cancer agent in TNBC cells.  Nifetepimine down-regulated the MEK/ERK pathway in MDAMB-231 and MDAMB-468 cells and resulted in blockage of ER stress-mediated GRP78 up-regulation.  Detailed mechanistic studies also revealed that nifetepimine by down-regulating pERK expression also declined the promoter binding activity of TFII-I to the GRP78 promoter and in turn regulated GRP78 transcription.  Studies further extended to in vivo Swiss albino and SCID mice models also revalidated the anti-carcinogenic property of nifetepimine.  Thus our findings cumulatively suggest that nifetepimine couples two distinct signaling pathways to induce the apoptotic death cascade in TNBC cells and raises the possibility for the use of nifetepimine as a potent anti-cancer agent with strong immune-restoring properties for therapeutic intervention for this group of cancer bearers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiuRnGB-DU-LVg90H21EOLACvtfcHk0liecaLnFV4hyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGqt70%253D&md5=d88a156eae32d9e35128a2334efab4db</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.594028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.594028%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DAdhikary%26aufirst%3DA.%26aulast%3DChakraborty%26aufirst%3DS.%26aulast%3DBhattacharjee%26aufirst%3DP.%26aulast%3DMazumder%26aufirst%3DM.%26aulast%3DPutatunda%26aufirst%3DS.%26aulast%3DGorain%26aufirst%3DM.%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DKundu%26aufirst%3DG.%2BC.%26aulast%3DDas%26aufirst%3DT.%26aulast%3DSen%26aufirst%3DP.%2BC.%26atitle%3DCross-talk%2520between%2520endoplasmic%2520reticulum%2520%2528ER%2529%2520stress%2520and%2520the%2520MEK%252FERK%2520pathway%2520potentiates%2520apoptosis%2520in%2520human%2520triple%2520negative%2520breast%2520carcinoma%2520cells%253A%2520role%2520of%2520a%2520dihydropyrimidone%252C%2520nifetepimine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26issue%3D7%26spage%3D3936%26epage%3D3949%26doi%3D10.1074%2Fjbc.M114.594028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">6762</span>– <span class="NLM_lpage">6775</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.3105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25742792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnht1Skug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6762-6775&issue=9&author=B.+Liuauthor=L.+Fuauthor=C.+Zhangauthor=L.+Zhangauthor=Y.+Zhangauthor=L.+Ouyangauthor=G.+Heauthor=J.+Huang&title=Computational+design%2C+chemical+synthesis%2C+and+biological+evaluation+of+a+novel+ERK+inhibitor+%28BL-EI001%29+with+apoptosis-inducing+mechanisms+in+breast+cancer&doi=10.18632%2Foncotarget.3105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer</span></div><div class="casAuthors">Liu Bo; Fu Leilei; Zhang Yonghui; Ouyang Liang; He Gu; Zhang Cui; Zhang Lan; Huang Jian; Zhang Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6762-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Extracellular signal-regulated kinase1/2 (ERK1/2) plays a crucial role in the resistance of apoptosis in carcinogenesis; however, its targeted small-molecule inhibitors still remain to be discovered.  Thus, in this study, we computationally and experimentally screened a series of small-molecule inhibitors targeting ERK toward different types of human breast cancer cells.  Subsequently, we synthesized some candidate ERK inhibitors, identified a novel ERK inhibitor (BL-EI001) with anti-proliferative activities, and analyzed the BL-EI001/ERK complex.  Moreover, we found that BL-EI001 induced breast cancer cell apoptosis via mitochondrial pathway but independent on Ras/Raf/MEK pathway.  In addition, we carried out proteomics analyses for exploring some possible BL-EI001-induced apoptotic pathways, and further found that BL-EI001-induced apoptosis affected ERK phosphorylation in breast cancer.  Further, we found that BL-EI001 bear anti-tumor activities without remarkable toxicities, and also induced mitochondrial apoptosis by targeting ERK in vivo.  Taken together, these results demonstrate that in silico design and experimental discovery of a synthesized small-molecule ERK inhibitor (BL-EI001)as a potential novel apoptosis-inducing drug in the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAcldmGJtbSv9pSBfyDvp7fW6udTcc2eZUW7NR3OGqAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnht1Skug%253D%253D&md5=f2431958417d2dd62c77664ec3e88604</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3105%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DComputational%2520design%252C%2520chemical%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520%2528BL-EI001%2529%2520with%2520apoptosis-inducing%2520mechanisms%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D9%26spage%3D6762%26epage%3D6775%26doi%3D10.18632%2Foncotarget.3105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karreth, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdal, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elemento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Identifying and targeting sporadic oncogenic genetic aberrations in mouse models of triple-negative breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F2159-8290.CD-17-0679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29203461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVCitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=354-369&issue=3&author=H.+Liuauthor=C.+J.+Murphyauthor=F.+A.+Karrethauthor=K.+B.+Emdalauthor=F.+M.+Whiteauthor=O.+Elementoauthor=A.+Tokerauthor=G.+M.+Wulfauthor=L.+C.+Cantley&title=Identifying+and+targeting+sporadic+oncogenic+genetic+aberrations+in+mouse+models+of+triple-negative+breast+cancer&doi=10.1158%2F2159-8290.CD-17-0679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Liu, Hui; Murphy, Charles J.; Karreth, Florian A.; Emdal, Kristina B.; White, Forest M.; Elemento, Olivier; Toker, Alex; Wulf, Gerburg M.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">354-369</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBC) are genetically characterized by aberrations in TP53 and a low rate of activating point mutations in common oncogenes, rendering it challenging in applying targeted therapies.  We performed whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to identify somatic genetic alterations in mouse models of TNBCs driven by loss of Trp53 alone or in combination with Brca1.  Amplifications or translocations that resulted in elevated oncoprotein expression or oncoprotein-contg. fusions, resp., as well as frameshift mutations of tumor suppressors were identified in approx. 50% of the tumors evaluated.  Although the spectrum of sporadic genetic alterations was diverse, the majority had in common the ability to activate the MAPK/PI3K pathways.  Importantly, we demonstrated that approved or exptl. drugs efficiently induce tumor regression specifically in tumors harboring somatic aberrations of the drug target.  Our study suggests that the combination of WES and RNA-seq on human TNBC will lead to the identification of actionable therapeutic targets for precision medicine-guided TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO61D4LP9UArVg90H21EOLACvtfcHk0lg7FGkv2tIe-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVCitrw%253D&md5=1d0157d39a71c84293034decc0ea1a7b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0679%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMurphy%26aufirst%3DC.%2BJ.%26aulast%3DKarreth%26aufirst%3DF.%2BA.%26aulast%3DEmdal%26aufirst%3DK.%2BB.%26aulast%3DWhite%26aufirst%3DF.%2BM.%26aulast%3DElemento%26aufirst%3DO.%26aulast%3DToker%26aufirst%3DA.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DIdentifying%2520and%2520targeting%2520sporadic%2520oncogenic%2520genetic%2520aberrations%2520in%2520mouse%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D3%26spage%3D354%26epage%3D369%26doi%3D10.1158%2F2159-8290.CD-17-0679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scoggins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrada, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcenas, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damodaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSnyder, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewster, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz-Gomez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arun, B.</span></span> <span> </span><span class="NLM_article-title">Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">508</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2018.36.15_suppl.508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=508&issue=15_suppl&author=J.+K.+Littonauthor=M.+Scogginsauthor=K.+R.+Hessauthor=B.+Adradaauthor=C.+H.+Barcenasauthor=R.+K.+Murthyauthor=S.+Damodaranauthor=S.+M.+DeSnyderauthor=A.+M.+Brewsterauthor=A.+M.+Thompsonauthor=G.+J.+Whitmanauthor=N.+K.+Ibrahimauthor=S.+L.+Moulderauthor=J.+Schwartz-Gomezauthor=E.+A.+Mittendorfauthor=B.+Arun&title=Neoadjuvant+talazoparib+%28TALA%29+for+operable+breast+cancer+patients+with+a+BRCA+mutation+%28BRCA%2B%29&doi=10.1200%2FJCO.2018.36.15_suppl.508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.508%26sid%3Dliteratum%253Aachs%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DScoggins%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DK.%2BR.%26aulast%3DAdrada%26aufirst%3DB.%26aulast%3DBarcenas%26aufirst%3DC.%2BH.%26aulast%3DMurthy%26aufirst%3DR.%2BK.%26aulast%3DDamodaran%26aufirst%3DS.%26aulast%3DDeSnyder%26aufirst%3DS.%2BM.%26aulast%3DBrewster%26aufirst%3DA.%2BM.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DWhitman%26aufirst%3DG.%2BJ.%26aulast%3DIbrahim%26aufirst%3DN.%2BK.%26aulast%3DMoulder%26aufirst%3DS.%2BL.%26aulast%3DSchwartz-Gomez%26aufirst%3DJ.%26aulast%3DMittendorf%26aufirst%3DE.%2BA.%26aulast%3DArun%26aufirst%3DB.%26atitle%3DNeoadjuvant%2520talazoparib%2520%2528TALA%2529%2520for%2520operable%2520breast%2520cancer%2520patients%2520with%2520a%2520BRCA%2520mutation%2520%2528BRCA%252B%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D15_suppl%26spage%3D508%26doi%3D10.1200%2FJCO.2018.36.15_suppl.508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pantelidou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonzogni, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Oliveria
Taveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrillon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheney, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitor efficacy depends on CD8 T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-1218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F2159-8290.CD-18-1218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31015319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FosVGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=722-737&issue=6&author=C.+Pantelidouauthor=O.+Sonzogniauthor=M.+De+Oliveria%0ATaveiraauthor=A.+K.+Mehtaauthor=A.+Kothariauthor=D.+Wangauthor=T.+Visalauthor=M.+K.+Liauthor=J.+Pintoauthor=J.+A.+Castrillonauthor=E.+M.+Cheneyauthor=P.+Bouwmanauthor=J.+Jonkersauthor=S.+Rottenbergauthor=J.+L.+Guerrieroauthor=G.+M.+Wulfauthor=G.+I.+Shapiro&title=PARP+inhibitor+efficacy+depends+on+CD8+T-cell+recruitment+via+intratumoral+STING+pathway+activation+in+BRCA-deficient+models+of+triple-negative+breast+cancer&doi=10.1158%2F2159-8290.CD-18-1218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Pantelidou Constantia; Kothari Aditi; Visal Tanvi; Shapiro Geoffrey I; Sonzogni Olmo; De Oliveria Taveira Mateus; Wang Dan; Li Michelle K; Pinto Jocelin; Wulf Gerburg M; De Oliveria Taveira Mateus; Mehta Anita K; Castrillon Jessica A; Cheney Emily M; Guerriero Jennifer L; Wang Dan; Bouwman Peter; Jonkers Jos; Rottenberg Sven; Rottenberg Sven; Shapiro Geoffrey I</div><div class="citationInfo"><span class="NLM_cas:title">Cancer discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-737</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied.  Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC).  We demonstrate that the PARP inhibitor olaparib induces CD8(+) T-cell infiltration and activation in vivo, and that CD8(+) T-cell depletion severely compromises antitumor efficacy.  Olaparib-induced T-cell recruitment is mediated through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-deficient compared with HR-proficient TNBC cells and in vivo models.  CRISPR-mediated knockout of STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish olaparib-induced T-cell infiltration in vivo.  These findings elucidate an additional mechanism of action of PARP inhibitors and provide a rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC.  SIGNIFICANCE: This work demonstrates cross-talk between PARP inhibition and the tumor microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that governs CD8(+) T-cell recruitment and antitumor efficacy.  The data provide insight into the mechanism of action of PARP inhibitors in BRCA-associated breast cancer.This article is highlighted in the In This Issue feature, p. 681.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxbdzw73c18b0AGQpJZWpJfW6udTcc2eYLZHrff-AjXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FosVGhsw%253D%253D&md5=d8487d03a3349df3daf16105de1e4ff9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-1218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-1218%26sid%3Dliteratum%253Aachs%26aulast%3DPantelidou%26aufirst%3DC.%26aulast%3DSonzogni%26aufirst%3DO.%26aulast%3DDe%2BOliveria%2BTaveira%26aufirst%3DM.%26aulast%3DMehta%26aufirst%3DA.%2BK.%26aulast%3DKothari%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DVisal%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DM.%2BK.%26aulast%3DPinto%26aufirst%3DJ.%26aulast%3DCastrillon%26aufirst%3DJ.%2BA.%26aulast%3DCheney%26aufirst%3DE.%2BM.%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DGuerriero%26aufirst%3DJ.%2BL.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DPARP%2520inhibitor%2520efficacy%2520depends%2520on%2520CD8%2520T-cell%2520recruitment%2520via%2520intratumoral%2520STING%2520pathway%2520activation%2520in%2520BRCA-deficient%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D6%26spage%3D722%26epage%3D737%26doi%3D10.1158%2F2159-8290.CD-18-1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1038/s41598-016-0007-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41598-016-0007-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28442756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1crhtFChsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=3&issue=1&author=L.+Fuauthor=S.+Wangauthor=X.+Wangauthor=P.+Wangauthor=Y.+Zhengauthor=D.+Yaoauthor=M.+Guoauthor=L.+Zhangauthor=L.+Ouyang&title=Crystal+structure-based+discovery+of+a+novel+synthesized+PARP1+inhibitor+%28OL-1%29+with+apoptosis-inducing+mechanisms+in+triple-negative+breast+cancer&doi=10.1038%2Fs41598-016-0007-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer</span></div><div class="casAuthors">Fu Leilei; Wang Shuya; Wang Xuan; Wang Peiqi; Zheng Yaxin; Yao Dahong; Guo Mingrui; Zhang Lan; Ouyang Liang; Wang Shuya; Wang Peiqi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conserved enzyme focused on the self-repair of cellular DNA damage.  Until now, numbers of PARP inhibitors have been reported and used for breast cancer therapy in recent years, especially in TNBC.  However, developing a new type PARP inhibitor with distinctive skeleton is alternatively promising strategy for TNBC therapy.  In this study, based on co-crystallization studies and pharmacophore-docking-based virtual screening, we discovered a series of dihydrodibenzo[b,e]-oxepin compounds as PARP1 inhibitors.  Lead optimization result in the identification of compound OL-1 (2-(11-(3-(dimethylamino)propylidene)-6,11- dihydrodibenzo[b,e]oxepin )-2-yl)acetohydrazide), which has a novel chemical scaffold and unique binding interaction with PARP1 protein.  OL-1 demonstrated excellent potency (inhibiting PARP1 enzyme activity with IC50 = 0.079 μM), as well as inhibiting PARP-modulated PARylation and cell proliferation in MDA-MB-436 cells (BRAC1 mutation).  In addition, OL-1 also inhibited cell migration that closely related to cancer metastasis and displayed remarkable anti-tumor efficacy in MDA-MB-436 xenograft model without apparent toxicities.  These findings highlight a new small-molecule PAPR1 inhibitor (OL-1) that has the potential to impact future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCGXnCF2P3vK91pGlMMoT5fW6udTcc2ebg2Aa1JwPDt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhtFChsw%253D%253D&md5=b84954d1577a0b753255501f3e26408a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41598-016-0007-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-016-0007-2%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DCrystal%2520structure-based%2520discovery%2520of%2520a%2520novel%2520synthesized%2520PARP1%2520inhibitor%2520%2528OL-1%2529%2520with%2520apoptosis-inducing%2520mechanisms%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D1%26spage%3D3%26doi%3D10.1038%2Fs41598-016-0007-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span> <span> </span><span class="NLM_article-title">A sesquiterpenoid from Farfarae Flos induces apoptosis of MDA-MB-231 human breast cancer cells through inhibition of JAK–STAT3 signaling</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">278</span>, <span class="refDoi"> DOI: 10.3390/biom9070278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fbiom9070278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1eitLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=278&issue=7&author=H.+Jangauthor=H.+Koauthor=K.+Songauthor=S.+Y.+Kim&title=A+sesquiterpenoid+from+Farfarae+Flos+induces+apoptosis+of+MDA-MB-231+human+breast+cancer+cells+through+inhibition+of+JAK%E2%80%93STAT3+signaling&doi=10.3390%2Fbiom9070278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A sesquiterpenoid from farfarae flos induces apoptosis of MDA-MB-231 human breast cancer cells through inhibition of JAK-STAT3 signaling</span></div><div class="casAuthors">Jang, Hyeri; Ko, Hyejin; Song, Kwangho; Kim, Yeong Shik</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">278pp.</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBCs) are hard-to-treat breast tumors with poor prognosis, which need to be treated by chemotherapy.  Signal transducer and activator of transcription 3 (STAT3) is a transcription factor involved in proliferation, metastasis, and invasion of cancer cells.  Therefore, research on searching for promising compds. with metab. that suppress phosphorylation or transcription of STAT3 in TNBC cells is important.  Farfarae Flos is well known as a traditional medicine for treating inflammation.  However, few studies have shown that sesquiterpenoids from Farfarae Flos have an anticancer effect.  In this study, efficient sepn. methods and an MTT assay were conducted to isolate an anticancer compd. from Farfarae Flos against TNBC MDA-MB-231 cells.  Here, 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone (ECN), a compd. isolated from Farfarae Flos showed a potent cytotoxic effect on MDA-MB-231 cells.  ECN inhibited JAK-STAT3 signaling and suppressed the expression of STAT3 target genes.  In addn., ECN induced apoptosis through both extrinsic and intrinsic pathways.  Furthermore, we investigated that ECN inhibited the growth of tumors by i.p. administration in mice injected with MDA-MB-231 cells.  Therefore, ECN can be an effective chemotherapeutic agent for breast cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsry_6SkgatLVg90H21EOLACvtfcHk0lgawJ-QO7-mZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1eitLvL&md5=806f6a1964b0e031747f3b5072c945a2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3390%2Fbiom9070278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom9070278%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DH.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BY.%26atitle%3DA%2520sesquiterpenoid%2520from%2520Farfarae%2520Flos%2520induces%2520apoptosis%2520of%2520MDA-MB-231%2520human%2520breast%2520cancer%2520cells%2520through%2520inhibition%2520of%2520JAK%25E2%2580%2593STAT3%2520signaling%26jtitle%3DBiomolecules%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D278%26doi%3D10.3390%2Fbiom9070278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. J.</span></span> <span> </span><span class="NLM_article-title">Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer</span>. <i>Nat. Prod. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1080/14786419.2017.1396596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1080%2F14786419.2017.1396596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29086600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCmtL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=477-485&issue=4&author=B.+Yangauthor=J.+W.+Shenauthor=D.+H.+Zhouauthor=Y.+P.+Zhaoauthor=W.+Q.+Wangauthor=Y.+Zhuauthor=H.+J.+Zhao&title=Precise+discovery+of+a+STAT3+inhibitor+from+Eupatorium+lindleyanum+and+evaluation+of+its+activity+of+anti-triple-negative+breast+cancer&doi=10.1080%2F14786419.2017.1396596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer</span></div><div class="casAuthors">Yang, Bo; Shen, Jia Wei; Zhou, Dong Heng; Zhao, Ya Ping; Wang, Wei Qian; Zhu, Ying; Zhao, Hua Jun</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">NPRAAT</span>;
        ISSN:<span class="NLM_cas:issn">1478-6419</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Michael reaction acceptors (MRAs) are a class of active compds.  There is a great prospect to screen STAT3 inhibitors from Eupatorium lindleyanum, furthermore, to discover lead compds. for anti-triple-neg. breast cancer (TNBC).  In this study, glutathione (GSH) was employed, and a UPLC-MS screening method was developed to discover MRAs.  We screened MRAs which can inhibit STAT3 using a STAT3-dependent reporter system.  Six sesquiterpene lactones, including a new compd. Eupalinolide O, together with five known compds., Eupalinolide I, Eupalinolide K, Eupalinolide H, Eupalinolide J and Eupalinolide G were isolated.  Eupalinolide J was identified as MRA that decreased luciferase activity of STAT3.  Preliminary activity assessment showed that Eupalinolide J could inhibit the viability of TNBC cell lines.  We demonstrated that Eupalinolide J, which is a natural typical MRA, has a notable inhibition of STAT3 activity and a potential cytotoxic activity against TNBC cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_5-tBUv0LNbVg90H21EOLACvtfcHk0lgawJ-QO7-mZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCmtL7P&md5=29d3f06881a4ce1259778e6d1dbd188c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F14786419.2017.1396596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14786419.2017.1396596%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DJ.%2BW.%26aulast%3DZhou%26aufirst%3DD.%2BH.%26aulast%3DZhao%26aufirst%3DY.%2BP.%26aulast%3DWang%26aufirst%3DW.%2BQ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%2BJ.%26atitle%3DPrecise%2520discovery%2520of%2520a%2520STAT3%2520inhibitor%2520from%2520Eupatorium%2520lindleyanum%2520and%2520evaluation%2520of%2520its%2520activity%2520of%2520anti-triple-negative%2520breast%2520cancer%26jtitle%3DNat.%2520Prod.%2520Res.%26date%3D2019%26volume%3D33%26issue%3D4%26spage%3D477%26epage%3D485%26doi%3D10.1080%2F14786419.2017.1396596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, A.</span></span> <span> </span><span class="NLM_article-title">Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.3892/or.2018.6805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3892%2For.2018.6805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30365081" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=437-446&issue=1&author=W.+Liauthor=H.+Yangauthor=X.+Liauthor=L.+Hanauthor=N.+Xuauthor=A.+Shi&title=Signaling+pathway+inhibitors+target+breast+cancer+stem+cells+in+triple-negative+breast+cancer&doi=10.3892%2For.2018.6805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3892%2For.2018.6805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2018.6805%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DN.%26aulast%3DShi%26aufirst%3DA.%26atitle%3DSignaling%2520pathway%2520inhibitors%2520target%2520breast%2520cancer%2520stem%2520cells%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncol.%2520Rep.%26date%3D2018%26volume%3D41%26issue%3D1%26spage%3D437%26epage%3D446%26doi%3D10.3892%2For.2018.6805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span> <span> </span><span class="NLM_article-title">1,3-Dicaffeoylquinic acid targeting 14–3-3 tau suppresses human breast cancer cell proliferation and metastasis through IL6/JAK2/PI3K pathway</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">113752</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.113752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.bcp.2019.113752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31836387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKrs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2020&pages=113752&author=Y.+Zhouauthor=X.+Fuauthor=Y.+Guanauthor=M.+Gongauthor=K.+Heauthor=B.+Huang&title=1%2C3-Dicaffeoylquinic+acid+targeting+14%E2%80%933-3+tau+suppresses+human+breast+cancer+cell+proliferation+and+metastasis+through+IL6%2FJAK2%2FPI3K+pathway&doi=10.1016%2Fj.bcp.2019.113752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">1,3-Dicaffeoylquinic acid targeting 14-3-3 tau suppresses human breast cancer cell proliferation and metastasis through IL6/JAK2/PI3K pathway</span></div><div class="casAuthors">Zhou, Yuhang; Fu, Xiang; Guan, Yanqing; Gong, Mengting; He, Kan; Huang, Bei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113752</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">14-3-3τ Plays a crit. role in tumorigenesis and metastasis of breast cancer and can be used as new drug target protein.  Dicaffeoylquinic acids (DCQAs), natural products, have antioxidant, antimicrobial, and anti-inflammatory activities.  In this study, the anticancer effects of DCQAs on breast cancer cells MCF-7, MDA-MB-231 cell lines and mechanism in triple neg. breast cancer (TNBC) were investigated.  First, we screened for DCQAs that could bind to 14-3-3τ and had a significant inhibitory effect on breast cancer cells.  MTT, colony formation, transwell migration, and flow cytometric assays revealed that 1,3-DCQA was the best one of 14-3-3τ binding protein from DCQAs against breast cancer cell proliferation and metastasis but safe for normal cells.  Through mol. docking simulation, overexpression and knockdown assays, we confirmed that 14-3-3τ was one of 1,3-DCQA target protein.  Eukaryotic transcriptome sequencing and western blot anal. demonstrated that 1,3-DCQA binds to 14-3-3τ to prevent breast cancer proliferation and metastasis via Jak/PI3K/Akt and Raf/ERK pathway, which promote IL6 and CSF3 expression raised by CREB (CREBBP, CREB5) and induced cell apoptosis via Bad/Bax/caspase 9 signaling pathway.  Our results provided evidence that 1,3-DCQA can be used as a novel lead compd. against breast cancer by inhibition of 14-3-3 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPvK3pKH9A87Vg90H21EOLACvtfcHk0ljz1wXoiYpQaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKrs7zN&md5=0db5cc960c92a4a78cc616cb5a5ef1c0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.113752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.113752%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DB.%26atitle%3D1%252C3-Dicaffeoylquinic%2520acid%2520targeting%252014%25E2%2580%25933-3%2520tau%2520suppresses%2520human%2520breast%2520cancer%2520cell%2520proliferation%2520and%2520metastasis%2520through%2520IL6%252FJAK2%252FPI3K%2520pathway%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D172%26spage%3D113752%26doi%3D10.1016%2Fj.bcp.2019.113752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span> <span> </span><span class="NLM_article-title">Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>357</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2014.11.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2014.11.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25434800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVeis7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2015&pages=393-403&issue=1&author=J.+Chunauthor=R.+J.+Liauthor=M.+S.+Chengauthor=Y.+S.+Kim&title=Alantolactone+selectively+suppresses+STAT3+activation+and+exhibits+potent+anticancer+activity+in+MDA-MB-231+cells&doi=10.1016%2Fj.canlet.2014.11.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells</span></div><div class="casAuthors">Chun, Jaemoo; Li, Rui-Juan; Cheng, Mao-Sheng; Kim, Yeong Shik</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">393-403</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The important goal of cancer drug discovery is to develop therapeutic agents that are effective, safe, and affordable.  In the present study, we demonstrated that alantolactone, which is a sesquiterpene lactone, has potential activity against triple-neg. breast cancer MDA-MB-231 cells by suppressing the signal transducer and activator of transcription 3 (STAT3) signaling pathway.  Alantolactone effectively suppressed both constitutive and inducible STAT3 activation at tyrosine 705.  Alantolactone decreased STAT3 translocation to the nucleus, its DNA-binding, and STAT3 target gene expression.  Alantolactone significantly inhibits STAT3 activation with a marginal effect on MAPKs and on NF-κB transcription; however, this effect is not mediated by inhibiting STAT3 upstream kinases.  Although SHP-1, SHP-2, and PTEN, which are protein tyrosine phosphatases (PTPs), were not affected by alantolactone, the treatment with a PTP inhibitor reversed the alantolactone-induced suppression of STAT3 activation, indicating that PTP plays an important role in the action of alantolactone.  Finally, alantolactone treatment resulted in the inhibition of migration, invasion, adhesion, and colony formation.  The in vivo administration of alantolactone inhibited the growth of human breast xenograft tumors.  These results provide preclin. evidence to continue the development of alantolactone as a STAT3 inhibitor and as a potential therapeutic agent against breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNY-D5XCgfH7Vg90H21EOLACvtfcHk0ljz1wXoiYpQaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVeis7%252FK&md5=c904bccd5ba1ec5ae07b8e2941903e8a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.11.049%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DR.%2BJ.%26aulast%3DCheng%26aufirst%3DM.%2BS.%26aulast%3DKim%26aufirst%3DY.%2BS.%26atitle%3DAlantolactone%2520selectively%2520suppresses%2520STAT3%2520activation%2520and%2520exhibits%2520potent%2520anticancer%2520activity%2520in%2520MDA-MB-231%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2015%26volume%3D357%26issue%3D1%26spage%3D393%26epage%3D403%26doi%3D10.1016%2Fj.canlet.2014.11.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span> <span> </span><span class="NLM_article-title">Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5032</span>– <span class="NLM_lpage">5040</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.bmc.2017.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28705432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5032-5040&issue=19&author=H.+S.+Kimauthor=T.+Kimauthor=H.+Koauthor=J.+Leeauthor=Y.+S.+Kimauthor=Y.+G.+Suh&title=Identification+of+galiellalactone-based+novel+STAT3-selective+inhibitors+with+cytotoxic+activities+against+triple-negative+breast+cancer+cell+lines&doi=10.1016%2Fj.bmc.2017.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines</span></div><div class="casAuthors">Kim, Hyun Su; Kim, Taewoo; Ko, Hyejin; Lee, Jeeyeon; Kim, Yeong Shik; Suh, Young-Ger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5032-5040</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is phosphorylated in breast cancer cells, particularly triple-neg. breast cancers (TNBCs).  Therefore, the inhibition of constitutive phosphorylated STAT3 is a promising therapeutic for TNBC treatment.  Recently, a series of novel STAT3 inhibitors based on natural (-)-galiellalactone have been identified to inhibit STAT3 phosphorylation at the Tyr705 residue.  Interestingly, the truncation of the cyclohexene moiety of (-)-galiellalactone to [3.3] bicyclic lactone as a pharmacophoric core produced improved cytotoxic effects against TNBCs.  The potent analogs 16 and 17, identified from a STAT3-mediated luciferase reporter assay, selectively inhibited the STAT3 signaling pathway without affecting STAT1 or STAT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBskRR7L612rVg90H21EOLACvtfcHk0ljz1wXoiYpQaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtbbE&md5=ddb78941b45c15c1a33bd7e6ded6269b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26atitle%3DIdentification%2520of%2520galiellalactone-based%2520novel%2520STAT3-selective%2520inhibitors%2520with%2520cytotoxic%2520activities%2520against%2520triple-negative%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D19%26spage%3D5032%26epage%3D5040%26doi%3D10.1016%2Fj.bmc.2017.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span> <span> </span><span class="NLM_article-title">Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells</span>. <i>Acta Biochim. Biophys. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1093/abbs/gmx012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fabbs%2Fgmx012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28338932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2hsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=367-373&issue=4&author=W.+Liauthor=H.+Zhangauthor=M.+Nieauthor=Y.+Tianauthor=X.+Chenauthor=C.+Chenauthor=H.+Chenauthor=R.+Liu&title=Ursolic+acid+derivative+FZU-03%2C010+inhibits+STAT3+and+induces+cell+cycle+arrest+and+apoptosis+in+renal+and+breast+cancer+cells&doi=10.1093%2Fabbs%2Fgmx012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells</span></div><div class="casAuthors">Li, Wei; Zhang, Hongxiu; Nie, Mingxiu; Tian, Yanlei; Chen, Xu; Chen, Ceshi; Chen, Haijun; Liu, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Acta Biochimica et Biophysica Sinica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-373</span>CODEN:
                <span class="NLM_cas:coden">ABBSC2</span>;
        ISSN:<span class="NLM_cas:issn">1672-9145</span>.
    
            (<span class="NLM_cas:orgname">ABBS Editorial Office</span>)
        </div><div class="casAbstract">Advanced renal cell carcinoma and triple neg. breast cancer (TNBC) are malignancies without effective therapeutics currently.  Ursolic acid (UA) has been previously reported to have anti-cancer effects in multiple solid tumors.  In order to develop more potent anti-cancer reagents, FZU-03,010 based on the chem. structure of UA were synthesized.  The results demonstrated that, compared with UA, FZU-03,010 could suppress renal cancer cell 786-0 and TNBC cell HCC1806 cell viability more potently.  Furthermore, FZU-03,010 could induce G1 cell cycle arrest and cell apoptosis more efficiently than UA.  FZU-03,010 could also inhibit signal transducer and activator of transcription 3 activation, induce the expression of cell cycle-dependent kinase inhibitors (p21 and p27) and promote cell apoptosis.  In conclusion, our results suggest that the UA deriv. FZU-03,010 is more potent in inhibiting cancer cell survival, and FZU-03,010 has the potential to be developed as a therapeutic for renal cell cancers and TNBCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKG__Y3r8G7Vg90H21EOLACvtfcHk0liEm8r0K7hR0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2hsLnK&md5=a0b88e8e5612763db5c44dd6db89e1ce</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fabbs%2Fgmx012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fabbs%252Fgmx012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DNie%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26atitle%3DUrsolic%2520acid%2520derivative%2520FZU-03%252C010%2520inhibits%2520STAT3%2520and%2520induces%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%2520in%2520renal%2520and%2520breast%2520cancer%2520cells%26jtitle%3DActa%2520Biochim.%2520Biophys.%2520Sin.%26date%3D2017%26volume%3D49%26issue%3D4%26spage%3D367%26epage%3D373%26doi%3D10.1093%2Fabbs%2Fgmx012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span> <span> </span><span class="NLM_article-title">Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">5292</span>– <span class="NLM_lpage">5304</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0340-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41388-018-0340-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29855616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKqsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=5292-5304&issue=39&author=L.+Luauthor=J.+Dongauthor=L.+Wangauthor=Q.+Xiaauthor=D.+Zhangauthor=H.+Kimauthor=T.+Yinauthor=S.+Fanauthor=Q.+Shen&title=Activation+of+STAT3+and+Bcl-2+and+reduction+of+reactive+oxygen+species+%28ROS%29+promote+radioresistance+in+breast+cancer+and+overcome+of+radioresistance+with+niclosamide&doi=10.1038%2Fs41388-018-0340-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide</span></div><div class="casAuthors">Lu, Lu; Dong, Jiali; Wang, Lili; Xia, Qing; Zhang, Dan; Kim, Hyejin; Yin, Tao; Fan, Saijun; Shen, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5292-5304</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Radiotherapy significantly improves the therapeutic outcomes and survival of breast cancer patients.  However, the acquired resistance to this therapeutic modality is a major clin. challenge.  Here we show that ionizing irradn. (IR)-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) at the Tyr705 residue and the induction of reactive oxygen species (ROS) in wild-type and radioresistant MDA-MB-231 and MDA-MB-468 triple-neg. breast cancer (TNBC) cell lines.  Comparing with radiosensitive parental TNBC cells, significantly low levels of ROS and higher protein levels of phospho-STAT3 and Bcl-2 were obsd. in TNBC cells with acquired radioresistance.  Moreover, knockdown of STAT3 by shRNA sensitized the TNBC cells to IR.  Niclosamide, a potent inhibitor of STAT3, overcame the radioresistance in TNBC cells via inhibition of STAT3 and Bcl-2 and induction of ROS.  In combination with radiation, niclosamide treatment resulted in significant increase of ROS generation and induction of apoptosis in parental and radioresistant TNBC cells in vitro and TNBC xenograft tumors in vivo.  These findings demonstrate that activation of STAT3 and Bcl-2 and redn. of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors.  Our findings suggest that niclosamide in combination with irradn. may offer an effective alternative approach for restoring the sensitivity of radioresistant TNBC cells to IR for improved therapeutic efficacy and outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-x7437dw8-bVg90H21EOLACvtfcHk0liEm8r0K7hR0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKqsr%252FP&md5=e56a599ccdc45378434c4af1d8d3a9e7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0340-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0340-y%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DQ.%26atitle%3DActivation%2520of%2520STAT3%2520and%2520Bcl-2%2520and%2520reduction%2520of%2520reactive%2520oxygen%2520species%2520%2528ROS%2529%2520promote%2520radioresistance%2520in%2520breast%2520cancer%2520and%2520overcome%2520of%2520radioresistance%2520with%2520niclosamide%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26issue%3D39%26spage%3D5292%26epage%3D5304%26doi%3D10.1038%2Fs41388-018-0340-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span> <span> </span><span class="NLM_article-title">Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1993</span>, <span class="refDoi"> DOI: 10.1002/ijc.31585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fijc.31585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29744876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1978-1993&issue=8&author=E.+Ohauthor=Y.+J.+Kimauthor=H.+Anauthor=D.+Sungauthor=T.+M.+Choauthor=L.+Farrandauthor=S.+Jangauthor=J.+H.+Seoauthor=J.+Y.+Kim&title=Flubendazole+elicits+anti-metastatic+effects+in+triple-negative+breast+cancer+via+STAT3+inhibition&doi=10.1002%2Fijc.31585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition</span></div><div class="casAuthors">Oh, Eunhye; Kim, Yoon-Jae; An, Hyunsook; Sung, Daeil; Cho, Tae-Min; Farrand, Lee; Jang, Seojin; Seo, Jae Hong; Kim, Ji Young</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1978-1993</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Tumor metastasis remains the cause of 90% of cancer-related deaths.  Cancer stem cells (CSC) are thought to be responsible for the aggressive and metastatic nature of triple-neg. breast cancers (TNBC), and new therapeutic strategies are being devised to target them.  Flubendazole (FLU) is a widely used anthelmintic agent that also exhibits anticancer activity in several cancer types.  The aim of this study was to characterize the mechanism of action of FLU on breast cancer stem cell (BCSC)-like properties and metastasis in TNBC.  FLU treatment caused a significant induction of apoptosis, accompanied by G2/M phase accumulation, caspase-3/-7 activation and the dysregulation of STAT3 activation in TNBC cells.  The latter phenomenon was assocd. with impairment of cancer stem-like traits, concomitant with a redn. in the CD24low/CD44high, CD24high/CD49fhigh subpopulation, ALDH1 activity and mammosphere formation.  The BCSC-enriched populations exhibited enhanced metastasis with higher STAT3 activation, while FLU administration inhibited tumor growth, angiogenesis and lung and liver metastasis, coinciding with decreased MMP-2 and MMP-9 levels in circulating blood.  FLU kills not only rapid proliferating tumor cells but also effectively eradicates BCSC-like cells in vitro and in vivo.  Our findings warrant further investigation of FLU as a treatment for metastatic TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcep7SDrwIbVg90H21EOLACvtfcHk0liEm8r0K7hR0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrs7zO&md5=0c3d558e8a902a9b9c1063d614c66924</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fijc.31585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.31585%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DAn%26aufirst%3DH.%26aulast%3DSung%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DT.%2BM.%26aulast%3DFarrand%26aufirst%3DL.%26aulast%3DJang%26aufirst%3DS.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26atitle%3DFlubendazole%2520elicits%2520anti-metastatic%2520effects%2520in%2520triple-negative%2520breast%2520cancer%2520via%2520STAT3%2520inhibition%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2018%26volume%3D143%26issue%3D8%26spage%3D1978%26epage%3D1993%26doi%3D10.1002%2Fijc.31585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span> <span> </span><span class="NLM_article-title">Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>486</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1076</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.03.164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.bbrc.2017.03.164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28373070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Wiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2017&pages=1069-1076&issue=4&author=Y.+J.+Kimauthor=J.+Y.+Kimauthor=N.+Leeauthor=E.+Ohauthor=D.+Sungauthor=T.+M.+Choauthor=J.+H.+Seo&title=Disulfiram+suppresses+cancer+stem-like+properties+and+STAT3+signaling+in+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.bbrc.2017.03.164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells</span></div><div class="casAuthors">Kim, Yoon-Jae; Kim, Ji Young; Lee, Nahyun; Oh, Eunhye; Sung, Daeil; Cho, Tae-Min; Seo, Jae Hong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1069-1076</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the presence of copper (Cu), disulfiram (DSF) suppresses properties assocd. with cancer stem cells (CSCs) in breast cancer, but the mechanism of action is poorly understood.  In the present study, we obsd. that DSF/Cu treatment induced apoptosis, mediated by caspase-3 activation in triple-neg. breast cancer (TNBC) cells.  DSF/Cu treatment also specifically targeted CSC-like cell populations, marked by the inhibition of ALDH1 activity, the suppression of CD44+/CD24-and CD49f+/CD24 + subpopulations, and the subsequent impairment of mammosphere formation.  These effects were functionally assocd. with a significant impact on the STAT3 signaling pathway, characterized by the downregulation of phospho-STAT3, cyclin D1 and survivin.  In an MDA-MB-231-derived xenograft model, DSF administration significantly downregulated ALDH1A1, CD44 and phospho-STAT3 levels.  These findings show for the first time that DSF suppresses stem-like properties in TNBC by targeting the STAT3 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopLNEFRU2reLVg90H21EOLACvtfcHk0li2r7tGAH9RRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Wiu7o%253D&md5=46e45ab442b22d2d821773ef2457394f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.03.164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.03.164%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DOh%26aufirst%3DE.%26aulast%3DSung%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DT.%2BM.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26atitle%3DDisulfiram%2520suppresses%2520cancer%2520stem-like%2520properties%2520and%2520STAT3%2520signaling%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D486%26issue%3D4%26spage%3D1069%26epage%3D1076%26doi%3D10.1016%2Fj.bbrc.2017.03.164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span> <span> </span><span class="NLM_article-title">Salinomycin promotes anoikis and decreases the CD44+/CD24-stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e0141919</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0141919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0141919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26528725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWnsbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0141919&issue=11&author=H.+Anauthor=J.+Y.+Kimauthor=E.+Ohauthor=N.+Leeauthor=Y.+Choauthor=J.+H.+Seo&title=Salinomycin+promotes+anoikis+and+decreases+the+CD44%2B%2FCD24-stem-like+population+via+inhibition+of+STAT3+activation+in+MDA-MB-231+cells&doi=10.1371%2Fjournal.pone.0141919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Salinomycin promotes anoikis and decreases the CD44+/CD24- stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells</span></div><div class="casAuthors">An, Hyunsook; Kim, Ji Young; Oh, Eunhye; Lee, Nahyun; Cho, Youngkwan; Seo, Jae Hong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0141919/1-e0141919/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is an aggressive tumor subtype with an enriched CD44+/CD24- stem-like population.  Salinomycin is an antibiotic that has been shown to target cancer stem cells (CSC); however, the mechanisms of action involved have not been well characterized.  The objective of the present study was to investigate the effect of salinomycin on cell death, migration, and invasion, as well as CSC-like properties in MDA-MB-231 breast cancer cells.  Salinomycin significantly induced anoikis-sensitivity, accompanied by caspase-3 and caspase-8 activation and PARP cleavage, during anchorage-independent growth.  Salinomycin treatment also caused a marked suppression of cell migration and invasion with concomitant downregulation of MMP-9 and MMP-2 mRNA levels.  Notably, salinomycin inhibited the formation of mammospheres and effectively reduced the CD44+/CD24- stem-like population during anchorage-independent growth.  These observations were assocd. with the inhibition of STAT3 phosphorylation (Tyr705).  Furthermore, interleukin-6 (IL-6)-induced STAT3 activation was strongly suppressed by salinomycin challenge.  These findings support the notion that salinomycin may be potentially efficacious for targeting breast cancer stem-like cells through the inhibition of STAT3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhzRJ-nQx-Y7Vg90H21EOLACvtfcHk0li2r7tGAH9RRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWnsbrP&md5=1c540cc74031a0f2a56c008aa6667587</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0141919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0141919%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DOh%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DCho%26aufirst%3DY.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26atitle%3DSalinomycin%2520promotes%2520anoikis%2520and%2520decreases%2520the%2520CD44%252B%252FCD24-stem-like%2520population%2520via%2520inhibition%2520of%2520STAT3%2520activation%2520in%2520MDA-MB-231%2520cells%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D11%26spage%3De0141919%26doi%3D10.1371%2Fjournal.pone.0141919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, B.</span></span> <span> </span><span class="NLM_article-title">Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2018.04.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.biopha.2018.04.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29679903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosFOqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=435-442&author=W.+Chenauthor=H.+Wangauthor=M.+Chengauthor=L.+Niauthor=L.+Zouauthor=Q.+Yangauthor=X.+Caiauthor=B.+Jiao&title=Isoharringtonine+inhibits+breast+cancer+stem-like+properties+and+STAT3+signaling&doi=10.1016%2Fj.biopha.2018.04.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling</span></div><div class="casAuthors">Chen, Wei; Wang, Hui; Cheng, Mei; Ni, Ling; Zou, Li; Yang, Qin; Cai, Xianghai; Jiao, Baowei</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">435-442</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Breast cancer stem cells (BCSCs) contribute to breast cancer progression, relapse, and treatment resistance.  Identification of the natural inhibitory components of BCSCs is therefore crit. for clin. treatment.  Here, we investigated whether isoharringtonine (IHT) had inhibitory effects on BCSCs in breast cancer cell lines.  HCC1806, HCC1937, and MCF7 cells were treated with IHT.  The proliferation and the migration of cells were detected by MTS assay and wound healing migration assay, resp.  The proportions of BCSCs were detd. by flow cytometry and tumor sphere formation assay.  Using real-time quant. polymerase chain reaction (qRT-PCR) and Western blotting, the expression of Nanog and activation of STAT3 were detected, resp.  Results showed that IHT inhibited the proliferation of HCC1806, HCC1937, and MCF-7 cells, and suppressed the migration of HCC1806 and HCC1937 cells in a dose-dependent manner.  IHT treatment decreased the proportion of BCSCs in MCF-7, HCC1806, and HCC1937 cells.  In addn., the mRNA level of Nanong was significantly downregulated after IHT treatment.  We also found an inhibitory effect of IHT on STAT3 activation.  IHT inhibited the proliferation, migration, and BCSC proportion of breast cancer cell lines via inhibition of the STAT3/Nanong pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7IX4O_m5MbVg90H21EOLACvtfcHk0li2r7tGAH9RRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosFOqsro%253D&md5=f667b28c35cf51cda6a52095a2c90c0f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.04.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.04.076%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DJiao%26aufirst%3DB.%26atitle%3DIsoharringtonine%2520inhibits%2520breast%2520cancer%2520stem-like%2520properties%2520and%2520STAT3%2520signaling%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2018%26volume%3D103%26spage%3D435%26epage%3D442%26doi%3D10.1016%2Fj.biopha.2018.04.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and structure–activity relationship studies of 3-(phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as a new class of Src inhibitors with potent activities in models of triple negative breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3957</span>– <span class="NLM_lpage">3974</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVaksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3957-3974&issue=9&author=C.+H.+Zhangauthor=M.+W.+Zhengauthor=Y.+P.+Liauthor=X.+D.+Linauthor=M.+Huangauthor=L.+Zhongauthor=G.+B.+Liauthor=R.+J.+Zhangauthor=W.+T.+Linauthor=Y.+Jiaoauthor=X.+A.+Wuauthor=J.+Yangauthor=R.+Xiangauthor=L.+J.+Chenauthor=Y.+L.+Zhaoauthor=W.+Chengauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Design%2C+Synthesis%2C+and+structure%E2%80%93activity+relationship+studies+of+3-%28phenylethynyl%29-1h-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-amine+derivatives+as+a+new+class+of+Src+inhibitors+with+potent+activities+in+models+of+triple+negative+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer</span></div><div class="casAuthors">Zhang, Chun-Hui; Zheng, Ming-Wu; Li, Ya-Ping; Lin, Xing-Dong; Huang, Mei; Zhong, Lei; Li, Guo-Bo; Zhang, Rong-Jie; Lin, Wan-Ting; Jiao, Yan; Wu, Xiao-Ai; Yang, Jiao; Xiang, Rong; Chen, Li-Juan; Zhao, Ying-Lan; Cheng, Wei; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3957-3974</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivs. were designed and synthesized.  Structure-activity relationship (SAR) anal. of these compds. led to the discovery of compd. 1j (I), which showed the highest inhibitory potency against the Src kinase and the most potent antiviability activity against the typical TNBC cell line MDA-MB-231 among all the synthesized compds.  Further kinase inhibition assays showed that compd. 1j was a multikinase inhibitor and potently inhibited Src (IC50 = 0.0009 μM) and MAPK signaling protein kinases B-RAF and C-RAF.  In an MDA-MB-231 xenograft mouse model, a once-daily dose of compd. 1j at 30 mg/kg for 18 days completely suppressed the tumor growth with a tumor inhibition rate larger than 100% without obvious toxicity.  It also displayed good pharmacokinetic properties in a preliminary pharmacokinetic assay.  Western blot and immunohistochem. assays revealed that compd. 1j significantly inhibited Src and MAPK signaling and markedly induced apoptosis in tumor tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvXJluk6Zz57Vg90H21EOLACvtfcHk0ljz9iUluJg6Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVaksbg%253D&md5=a15a90d306d54efac683cc373940cde4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00270%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DZheng%26aufirst%3DM.%2BW.%26aulast%3DLi%26aufirst%3DY.%2BP.%26aulast%3DLin%26aufirst%3DX.%2BD.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DZhang%26aufirst%3DR.%2BJ.%26aulast%3DLin%26aufirst%3DW.%2BT.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%2BJ.%26aulast%3DZhao%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520studies%2520of%25203-%2528phenylethynyl%2529-1h-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2520derivatives%2520as%2520a%2520new%2520class%2520of%2520Src%2520inhibitors%2520with%2520potent%2520activities%2520in%2520models%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D9%26spage%3D3957%26epage%3D3974%26doi%3D10.1021%2Facs.jmedchem.5b00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banskota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, B. S.</span></span> <span> </span><span class="NLM_article-title">Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">118</span>, <span class="refDoi"> DOI: 10.1038/s12276-018-0135-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs12276-018-0135-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=118&issue=9&author=J.+Gautamauthor=S.+Banskotaauthor=H.+Leeauthor=Y.+J.+Leeauthor=Y.+H.+Jeonauthor=J.+A.+Kimauthor=B.+S.+Jeong&title=Down-regulation+of+cathepsin+S+and+matrix+metalloproteinase-9+via+Src%2C+a+non-receptor+tyrosine+kinase%2C+suppresses+triple-negative+breast+cancer+growth+and+metastasis&doi=10.1038%2Fs12276-018-0135-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs12276-018-0135-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-018-0135-9%26sid%3Dliteratum%253Aachs%26aulast%3DGautam%26aufirst%3DJ.%26aulast%3DBanskota%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DJeon%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BA.%26aulast%3DJeong%26aufirst%3DB.%2BS.%26atitle%3DDown-regulation%2520of%2520cathepsin%2520S%2520and%2520matrix%2520metalloproteinase-9%2520via%2520Src%252C%2520a%2520non-receptor%2520tyrosine%2520kinase%252C%2520suppresses%2520triple-negative%2520breast%2520cancer%2520growth%2520and%2520metastasis%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2018%26volume%3D50%26issue%3D9%26spage%3D118%26doi%3D10.1038%2Fs12276-018-0135-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e0171169</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0171169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0171169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28141839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslSgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0171169&issue=1&author=X.+L.+Qianauthor=J.+Zhangauthor=P.+Z.+Liauthor=R.+G.+Langauthor=W.+D.+Liauthor=H.+Sunauthor=F.+F.+Liuauthor=X.+J.+Guoauthor=F.+Guauthor=L.+Fu&title=Dasatinib+inhibits+c-src+phosphorylation+and+prevents+the+proliferation+of+Triple-Negative+Breast+Cancer+%28TNBC%29+cells+which+overexpress+Syndecan-Binding+Protein+%28SDCBP%29&doi=10.1371%2Fjournal.pone.0171169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-negative breast cancer (TNBC) cells which overexpress syndecan-binding protein (SDCBP)</span></div><div class="casAuthors">Qian, Xiao-Long; Zhang, Jun; Li, Pei-Ze; Lang, Rong-Gang; Li, Wei-Dong; Sun, Hui; Liu, Fang-Fang; Guo, Xiao-Jing; Gu, Feng; Fu, Li</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0171169/1-e0171169/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Triple neg. breast cancer (TNBC) progresses rapidly but lacks effective targeted therapies.  Our previous study showed that downregulating syndecan-binding protein (SDCBP) in TNBC inhibits the proliferation of TNBC cells.  Dasatinib is a new small-mol. inhibitor of c-src phosphorylation.  The aim of this study was to investigate if SDCBP is a potential marker to indicate whether a TNBC is suitable for dasatinib therapy.  This study applied coimmunopptn. to identify the interaction between SDCBP and c-src in TNBC cell lines.  In addn., immunohistochem. was used to investigate SDCBP and tyrosine-419 phosphorylated c-src (p-c-src-Y419) expression in TNBC tissues.  SDCBP-overexpressing MDAMB-231 cells were then constructed to evaluate the effects of dasatinib on SDCBP-induced TNBC progression in vitro and tumor formation in nude mice.  We found wild-type SDCBP interacted with c-src and promoted the phosphorylation of c-src; this phosphorylation was completely blocked by dasatinib.  SDCBP lacking the PDZ domain had no such effect.  Among the 52 consecutive random TNBC cases examd., the expression of SDCBP was consistent with that of p-c-src-Y419, and pos. correlated with histol. grading or Ki-67 levels.  SDCBP overexpression significantly accelerated the proliferation and cell cycle progression of the TNBC cell line MDA-MB-231; these effects were prevented by dasatinib treatment.  However, the subsequent inhibition of p27 expression partially restored the proliferation and viability of the TNBC cells.  The results of this study suggest that SDCBP interacts with c-src, regulates G1/S in TNBC cells, and enhances tumor cell proliferation by promoting the tyrosine phosphorylation of c-src at residue 419.  Dasatinib inhibits such phosphorylation and blocks SDCBP-induced cell cycle progression.  Therefore, SDCBP might be an important marker for identifying TNBC cases that are suitable for dasatinib therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsa7ofiHy617Vg90H21EOLACvtfcHk0lhmY5_G_pFSzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslSgtL0%253D&md5=d2b76d94744be08f00e3454973961363</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0171169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0171169%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DX.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%2BZ.%26aulast%3DLang%26aufirst%3DR.%2BG.%26aulast%3DLi%26aufirst%3DW.%2BD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%2BF.%26aulast%3DGuo%26aufirst%3DX.%2BJ.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DDasatinib%2520inhibits%2520c-src%2520phosphorylation%2520and%2520prevents%2520the%2520proliferation%2520of%2520Triple-Negative%2520Breast%2520Cancer%2520%2528TNBC%2529%2520cells%2520which%2520overexpress%2520Syndecan-Binding%2520Protein%2520%2528SDCBP%2529%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3De0171169%26doi%3D10.1371%2Fjournal.pone.0171169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2687</span>– <span class="NLM_lpage">2701</span>, <span class="refDoi"> DOI: 10.1039/C6SC05368H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC6SC05368H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28553505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlChtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2687-2701&issue=4&author=L.+Zhangauthor=L.+Fuauthor=S.+Zhangauthor=J.+Zhangauthor=Y.+Zhaoauthor=Y.+Zhengauthor=G.+Heauthor=S.+Yangauthor=L.+Ouyangauthor=B.+Liu&title=Discovery+of+a+small+molecule+targeting+ULK1-modulated+cell+death+of+triple+negative+breast+cancer+in+vitro+and+in+vivo&doi=10.1039%2FC6SC05368H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo</span></div><div class="casAuthors">Zhang, Lan; Fu, Leilei; Zhang, Shouyue; Zhang, Jin; Zhao, Yuqian; Zheng, Yaxin; He, Gu; Yang, Shengyong; Ouyang, Liang; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2687-2701</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">UNC-51-like kinase 1 (ULK1) is well-known to initiate autophagy, and the downregulation of ULK1 has been found in most breast cancer tissues.  Thus, the activation of ULK1-modulated autophagy could be a promising strategy for breast cancer therapy.  In this study, we found that ULK1 was remarkably downregulated in breast cancer tissue samples by The Cancer Genome Atlas (TCGA) anal. and tissue microarray (TMA) anal., esp. in triple neg. breast cancer (TNBC).  To design a ULK1 agonist, we integrated in silico screening and chem. synthesis to acquire a series of small mol. candidates.  After rounds of kinase and anti-proliferative activity screening, we discovered the small mol., LYN-1604, to be the best candidate for a ULK1 agonist.  Addnl., we identified that three amino acid residues (LYS50, LEU53, and TYR89) were key to the activation site of LYN-1604 and ULK1 by site-directed mutagenesis and biochem. assays.  Subsequently, we demonstrated that LYN-1604 could induce cell death, assocd. with autophagy by the ULK complex (ULK1-mATG13-FIP200-ATG101) in MDA-MB-231 cells.  To further explore LYN-1604-induced autophagic mechanisms, we found some potential ULK1 interactors, such as ATF3, RAD21, and caspase3, by performing comparative microarray anal.  Intriguingly, we found that LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.  Moreover, we demonstrated that LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo; thus making this ULK1 agonist a novel potential small-mol. drug candidate for future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqilhZpiddfcbVg90H21EOLACvtfcHk0lhmY5_G_pFSzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlChtg%253D%253D&md5=6c40089843a8fbcdbb5ee60e0547dc7c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1039%2FC6SC05368H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6SC05368H%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520a%2520small%2520molecule%2520targeting%2520ULK1-modulated%2520cell%2520death%2520of%2520triple%2520negative%2520breast%2520cancer%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DChem.%2520Sci.%26date%3D2017%26volume%3D8%26issue%3D4%26spage%3D2687%26epage%3D2701%26doi%3D10.1039%2FC6SC05368H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span> <span> </span><span class="NLM_article-title">Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e12518</span>, <span class="refDoi"> DOI: 10.1111/cpr.12518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1111%2Fcpr.12518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30152053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSrtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=e12518&issue=6&author=C.+Caoauthor=W.+Huangauthor=N.+Zhangauthor=F.+Wuauthor=T.+Xuauthor=X.+Panauthor=C.+Pengauthor=B.+Han&title=Narciclasine+induces+autophagy-dependent+apoptosis+in+triple-negative+breast+cancer+cells+by+regulating+the+AMPK-ULK1+axis&doi=10.1111%2Fcpr.12518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis</span></div><div class="casAuthors">Cao, Chuan; Huang, Wei; Zhang, Nan; Wu, Fengbo; Xu, Ting; Pan, Xiaoli; Peng, Cheng; Han, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Proliferation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e12518/1-e12518/11</span>CODEN:
                <span class="NLM_cas:coden">CPROEM</span>;
        ISSN:<span class="NLM_cas:issn">0960-7722</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : Autophagy and apoptosis are major types of eukaryotic programmed cell death, and regulating these processes holds promise for treating cancers.  In this study, we explored the regulation mechanisms of narciclasine to autophagy and apoptosis processes in triple-neg. breast cancer.  Materials and Methods : Effects of narciclasine on proliferation, apoptosis, and autophagy of HCC-1937 and MDA-MB-231 triple-neg. breast cancer (TNBC) cells were assessed using transmission electronic microscopy, flow cytometry following staining with Annexin V-FITC and propidium iodide, RNA sequencing, real-time PCR, and Western blotting.  The ability of narciclasine to inhibit growth of human HCC1937 TNBC xenografts in mice was assessed, and potential mechanisms of inhibition were explored using immunohistochem.  Results : Narciclasine inhibited TNBC cell proliferation and induced autophagy-dependent apoptosis in a dose-dependent manner.  These apoptotic effects could be reversed using autophagy inhibitors, including an AMPK inhibitor and ULK1 siRNA.  Consistent with these in vitro results, narciclasine significantly inhibited TNBC tumor growth in mice by upregulating autophagy-dependent apoptosis.  Conclusions : Our findings suggest that narciclasine regulates the AMPK-ULK1 signalling axis to promote autophagy-dependent apoptosis, demonstrating therapeutic potential against TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozM94BFEehS7Vg90H21EOLACvtfcHk0lhmY5_G_pFSzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSrtLbM&md5=0b59dbfd4b6f5394f107d40915cb372f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fcpr.12518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcpr.12518%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DB.%26atitle%3DNarciclasine%2520induces%2520autophagy-dependent%2520apoptosis%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520by%2520regulating%2520the%2520AMPK-ULK1%2520axis%26jtitle%3DCell%2520Proliferation%26date%3D2018%26volume%3D51%26issue%3D6%26spage%3De12518%26doi%3D10.1111%2Fcpr.12518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voisin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacksenhaus, E.</span></span> <span> </span><span class="NLM_article-title">Combined deletion of PTEN and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1542</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.15252/emmm.201404402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.15252%2Femmm.201404402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25330770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVamur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1542-1560&issue=12&author=J.+C.+Liuauthor=V.+Voisinauthor=S.+Wangauthor=D.+Y.+Wangauthor=R.+A.+Jonesauthor=A.+Dattiauthor=D.+Uehlingauthor=R.+Al-awarauthor=S.+E.+Eganauthor=G.+D.+Baderauthor=M.+Tsaoauthor=T.+W.+Makauthor=E.+Zacksenhaus&title=Combined+deletion+of+PTEN+and+p53+in+mammary+epithelium+accelerates+triple-negative+breast+cancer+with+dependency+on+eEF2K&doi=10.15252%2Femmm.201404402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K</span></div><div class="casAuthors">Liu, Jeff C.; Voisin, Veronique; Wang, Sharon; Wang, Dong-Yu; Jones, Robert A.; Datti, Alessandro; Uehling, David; Al-Awar, Rima; Egan, Sean E.; Bader, Gary D.; Tsao, Ming; Mak, Tak W.; Zacksenhaus, Eldad</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1542-1560</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The tumor suppressors Pten and p53 are frequently lost in breast cancer, yet the consequences of their combined inactivation are poorly understood.  Here, we show that mammary-specific deletion of Pten via WAP-Cre, which targets alveolar progenitors, induced tumors with shortened latency compared to those induced by MMTV-Cre, which targets basal/luminal progenitors.  Combined Pten-p53 mutations accelerated formation of claudin-low, triple-neg.-like breast cancer (TNBC) that exhibited hyper-activated AKT signaling and more mesenchymal features relative to Pten or p53 single-mutant tumors.  Twenty-four genes that were significantly and differentially expressed between WAP-Cre:Pten/p53 and MMTV-Cre:Pten/p53 tumors predicted poor survival for claudin-low patients.  Kinome screens identified eukaryotic elongation factor-2 kinase (eEF2K) inhibitors as more potent than PI3K/AKT/mTOR inhibitors on both mouse and human Pten/p53-deficient TNBC cells.  Sensitivity to eEF2K inhibition correlated with AKT pathway activity. eEF2K monotherapy suppressed growth of Pten/p53-deficient TNBC xenografts in vivo and cooperated with doxorubicin to efficiently kill tumor cells in vitro.  Our results identify a prognostic signature for claudin-low patients and provide a rationale for using eEF2K inhibitors for treatment of TNBC with elevated AKT signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTmlzPz8bEO7Vg90H21EOLACvtfcHk0ljchOVOR5rFhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVamur7E&md5=a801dcd1402ccf33157a65d432678ace</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.15252%2Femmm.201404402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201404402%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DVoisin%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DD.%2BY.%26aulast%3DJones%26aufirst%3DR.%2BA.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DUehling%26aufirst%3DD.%26aulast%3DAl-awar%26aufirst%3DR.%26aulast%3DEgan%26aufirst%3DS.%2BE.%26aulast%3DBader%26aufirst%3DG.%2BD.%26aulast%3DTsao%26aufirst%3DM.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DZacksenhaus%26aufirst%3DE.%26atitle%3DCombined%2520deletion%2520of%2520PTEN%2520and%2520p53%2520in%2520mammary%2520epithelium%2520accelerates%2520triple-negative%2520breast%2520cancer%2520with%2520dependency%2520on%2520eEF2K%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26issue%3D12%26spage%3D1542%26epage%3D1560%26doi%3D10.15252%2Femmm.201404402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhlis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1007/s10549-018-4847-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-018-4847-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29971628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yksLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2018&pages=593-605&issue=3&author=N.+Kabilauthor=R.+Bayraktarauthor=N.+Kahramanauthor=H.+A.+Mokhlisauthor=G.+A.+Calinauthor=G.+Lopez-Beresteinauthor=B.+Ozpolat&title=Thymoquinone+inhibits+cell+proliferation%2C+migration%2C+and+invasion+by+regulating+the+elongation+factor+2+kinase+%28eEF-2K%29+signaling+axis+in+triple-negative+breast+cancer&doi=10.1007%2Fs10549-018-4847-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer</span></div><div class="casAuthors">Kabil, Nashwa; Bayraktar, Recep; Kahraman, Nermin; Mokhlis, Hamada A.; Calin, George A.; Lopez-Berestein, Gabriel; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">593-605</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background/purpose: Triple-neg. breast cancer (TNBC) is the most aggressive and chemoresistant subtype of breast cancer.  Therefore, new mol. targets and treatments need to be developed to improve poor patient prognosis and survival.  We have previously shown that eukaryotic elongation factor 2 kinase (eEF-2K) is highly expressed in TNBC cells, is assocd. with poor patient survival and prognosis, and promotes cell proliferation, migration, and invasion.  In vivo targeting of eEF-2K significantly reduces the tumor growth of orthotopic TNBC xenograft mouse models, suggesting that eEF-2K may serve as a potential novel therapeutic target.  Methods/results: In the current study, we identified thymoquinone (TQ), an active ingredient of Nigella sativa, as a potential safe and effective eEF-2K inhibitor in TNBC.  We demonstrated for the first time that TQ inhibits the protein and mRNA expression of eEF-2K, as well as the clin. relevant downstream targets, including Src/FAK and Akt, and induces the tumor suppressor miR-603, in response to NF-kB inhibition.  This effect was assocd. with a significant decrease in the proliferation, colony formation, migration, and invasion of TNBC cells.  Furthermore, systemic in vivo injection of TQ (20 and 100 mg/kg) significantly reduced the growth of MDA-MB-231 tumors and inhibited the eEF-2K expression in an orthotopic tumor model in mice.  Conclusion: Our study provides first evidence that TQ treatment inhibits cell proliferation, migration/invasion, and tumor growth, in part through the inhibition of eEF-2K signaling in TNBC.  Thus, our findings suggest that systemic TQ treatment may be used as a targeted therapeutic strategy for the inhibition of eEF-2K in TNBC tumor growth and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8kyxIVXtRLVg90H21EOLACvtfcHk0ljchOVOR5rFhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yksLbL&md5=0bbf638cfefa85c33f9c4bc4f8c492c8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs10549-018-4847-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-018-4847-2%26sid%3Dliteratum%253Aachs%26aulast%3DKabil%26aufirst%3DN.%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DMokhlis%26aufirst%3DH.%2BA.%26aulast%3DCalin%26aufirst%3DG.%2BA.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DThymoquinone%2520inhibits%2520cell%2520proliferation%252C%2520migration%252C%2520and%2520invasion%2520by%2520regulating%2520the%2520elongation%2520factor%25202%2520kinase%2520%2528eEF-2K%2529%2520signaling%2520axis%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2018%26volume%3D171%26issue%3D3%26spage%3D593%26epage%3D605%26doi%3D10.1007%2Fs10549-018-4847-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ejmech.2017.11.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29202403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=402-418&author=Y.+Guoauthor=Y.+Zhaoauthor=G.+Wangauthor=Y.+Chenauthor=Y.+Jiangauthor=L.+Ouyangauthor=B.+Liu&title=Design%2C+synthesis+and+structure-activity+relationship+of+a+focused+library+of+%CE%B2-phenylalanine+derivatives+as+novel+eEF2K+inhibitors+with+apoptosis-inducing+mechanisms+in+breast+cancer&doi=10.1016%2Fj.ejmech.2017.11.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer</span></div><div class="casAuthors">Guo, Yongzhi; Zhao, Yuqian; Wang, Guan; Chen, Yi; Jiang, Yingnan; Ouyang, Liang; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">402-418</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase.  EEF2K has been recently reported to be highly activated or over-expressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target.  In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivs. with assessment of inhibition activity against eEF2K and cytotoxicity.  After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (I) with best eEF2K enzymic activity (IC50 of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC50 of 12.6 μM, MDA-MB-436 cells, IC50 of 19.8 μM).  Moreover, we found that I could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells.  Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo.  These results suggested that I inhibited tumor growth by apoptosis in the xenograft mouse model of breast cancer (MDA-MB-231 and MDA-MB-436).  Collectively, our results demonstrate a novel small-mol. inhibitor targeting eEF2K with mechanism of apoptosis and a therapeutic potential in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHKgIUg85n1LVg90H21EOLACvtfcHk0ljchOVOR5rFhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FM&md5=d5017cf0b61bbd2cc2962d3ded11dda3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.065%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DDesign%252C%2520synthesis%2520and%2520structure-activity%2520relationship%2520of%2520a%2520focused%2520library%2520of%2520%25CE%25B2-phenylalanine%2520derivatives%2520as%2520novel%2520eEF2K%2520inhibitors%2520with%2520apoptosis-inducing%2520mechanisms%2520in%2520breast%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D402%26epage%3D418%26doi%3D10.1016%2Fj.ejmech.2017.11.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span> <span> </span><span class="NLM_article-title">Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1039/C5MB00848D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC5MB00848D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26776155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=729-736&issue=3&author=Z.+Yaoauthor=J.+Liauthor=Z.+Liuauthor=L.+Zhengauthor=N.+Fanauthor=Y.+Zhangauthor=N.+Jiaauthor=J.+Lvauthor=N.+Liuauthor=X.+Zhuauthor=J.+Duauthor=C.+Lvauthor=F.+Xieauthor=Y.+Liuauthor=X.+Wangauthor=Z.+Feiauthor=C.+Gao&title=Integrative+bioinformatics+and+proteomics-based+discovery+of+an+eEF2K+inhibitor+%28cefatrizine%29+with+ER+stress+modulation+in+breast+cancer+cells&doi=10.1039%2FC5MB00848D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells</span></div><div class="casAuthors">Yao, Zhiqiang; Li, Juntang; Liu, Zhongyu; Zheng, Lu; Fan, Naijun; Zhang, Ying; Jia, Nan; Lv, Jingjing; Liu, Ningning; Zhu, Xiaoshan; Du, Jiangbo; Lv, Ci; Xie, Feng; Liu, Yigang; Wang, Xingke; Fei, Zhou; Gao, Chunfang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">729-736</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF2K), a unique calcium/calmodulin-dependent protein kinase, is well known to regulate apoptosis, autophagy and ER stress in many types of human cancers.  Therefore, eEF2K would be regarded as a promising therapeutic target; however, the eEF2K-regulated mechanism and its targeted inhibitor still remain to be discovered in cancer.  Herein, we constructed a protein-protein interaction (PPI) network of eEF2K and achieved an eEF2K-regulated ER stress subnetwork by bioinformatics prediction.  Then, we found that the differential protein expressions involved in ER stress in the context of si-eEF2K-treated MCF-7 and MDA-MB-436 cells by iTRAQ-based analyses, resp.  Integrated into these aforementioned results, we constructed a core eEF2K-regulated ER stress subnetwork in breast cancer cells.  Subsequently, we screened a series of candidate compds. targeting eEF2K and discovered a novel eEF2K inhibitor (cefatrizine) with an anti-proliferative activity toward breast cancer cells.  Moreover, we found that cefatrizine induced ER stress in both MCF-7 and MDA-MB-436 cells.  Interestingly, we demonstrated that the mechanism of cefatrizine-induced ER stress was in good agreement with our bioinformatics and proteomics-based results.  In conclusion, these results demonstrate that a novel eEF2K inhibitor (cefatrizine) induces ER stress in breast cancer cells by integrating bioinformatics prediction, proteomics analyses and exptl. validation, which would provide a clue for exploring more mechanisms of eEF2K and its targeted inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDQPIGrQ6947Vg90H21EOLACvtfcHk0ljyCc9CqILJcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGhuw%253D%253D&md5=84c2bbd60d8c71479e98f426db5fbb5b</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1039%2FC5MB00848D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MB00848D%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DN.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFei%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DC.%26atitle%3DIntegrative%2520bioinformatics%2520and%2520proteomics-based%2520discovery%2520of%2520an%2520eEF2K%2520inhibitor%2520%2528cefatrizine%2529%2520with%2520ER%2520stress%2520modulation%2520in%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520BioSyst.%26date%3D2016%26volume%3D12%26issue%3D3%26spage%3D729%26epage%3D736%26doi%3D10.1039%2FC5MB00848D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e12402</span>, <span class="refDoi"> DOI: 10.1111/cpr.12402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1111%2Fcpr.12402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29094413" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=e12402&issue=2&author=D.+Sunauthor=L.+Zhuauthor=Y.+Zhaoauthor=Y.+Jiangauthor=L.+Chenauthor=Y.+Yuauthor=L.+Ouyang&title=Fluoxetine+induces+autophagic+cell+death+via+eEF2K-AMPK-mTOR-ULK+complex+axis+in+triple+negative+breast+cancer&doi=10.1111%2Fcpr.12402"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fcpr.12402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcpr.12402%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DFluoxetine%2520induces%2520autophagic%2520cell%2520death%2520via%2520eEF2K-AMPK-mTOR-ULK%2520complex%2520axis%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DCell%2520Proliferation%26date%3D2018%26volume%3D51%26issue%3D2%26spage%3De12402%26doi%3D10.1111%2Fcpr.12402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeted degradation of BET proteins in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2476</span>– <span class="NLM_lpage">2487</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-2622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-16-2622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28209615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFakurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2476-2487&issue=9&author=L.+Baiauthor=B.+Zhouauthor=C.+Y.+Yangauthor=J.+Jiauthor=D.+McEachernauthor=S.+Przybranowskiauthor=H.+Jiangauthor=J.+Huauthor=F.+Xuauthor=Y.+Zhaoauthor=L.+Liuauthor=E.+Fernandez-Salasauthor=J.+Xuauthor=Y.+Douauthor=B.+Wenauthor=D.+Sunauthor=J.+Meagherauthor=J.+Stuckeyauthor=D.+F.+Hayesauthor=S.+Liauthor=M.+J.+Ellisauthor=S.+Wang&title=Targeted+degradation+of+BET+proteins+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-16-2622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Bai, Longchuan; Zhou, Bing; Yang, Chao-Yie; Ji, Jiao; McEachern, Donna; Przybranowski, Sally; Jiang, Hui; Hu, Jiantao; Xu, Fuming; Zhao, Yujun; Liu, Liu; Fernandez-Salas, Ester; Xu, Jing; Dou, Yali; Wen, Bo; Sun, Duxin; Meagher, Jennifer; Stuckey, Jeanne; Hayes, Daniel F.; Li, Shunqiang; Ellis, Matthew J.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2476-2487</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBC) remain clin. challenging with a lack of options for targeted therapy.  In this study, we report the development of a second-generation BET protein degrader, BETd-246, which exhibits superior selectivity, potency, and antitumor activity.  In human TNBC cells, BETd-246 induced degrdn. of BET proteins at low nanomolar concns. within 1 h of exposure, resulting in robust growth inhibition and apoptosis.  BETd-246 was more potent and effective in TNBC cells than its parental BET inhibitor compd. BETi-211.  RNA-seq anal. revealed predominant downregulation of a large no. of genes involved in proliferation and apoptosis in cells treated with BETd-246, as compared with BETi-211 treatment that upregulated and downregulated a similar no. of genes.  Functional investigations identified the MCL1 gene as a crit. downstream effector for BET degraders, which synergized with small-mol. inhibitors of BCL-xL in triggering apoptosis.  In multiple murine xenograft models of human breast cancer, BETd-246 and a further optimized analog BETd-260 effectively depleted BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules.  Overall, our findings show that targeting BET proteins for degrdn. represents an effective therapeutic strategy for TNBC treatment.  Cancer Res; 77(9); 2476-87. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8M1VaSNIBCLVg90H21EOLACvtfcHk0ljyCc9CqILJcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFakurg%253D&md5=84c0e0b23e61a5503f8d88385cc88ae5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-2622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-2622%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDou%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DMeagher%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeted%2520degradation%2520of%2520BET%2520proteins%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D9%26spage%3D2476%26epage%3D2487%26doi%3D10.1158%2F0008-5472.CAN-16-2622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small-molecule bromodomain-containing protein 4 (BRD4) inhibitor that induces AMP-Activated protein kinase-modulated autophagy-associated cell death in breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">9990</span>– <span class="NLM_lpage">10012</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00275</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00275" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOitrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9990-10012&issue=24&author=L.+Ouyangauthor=L.+Zhangauthor=J.+Liuauthor=L.+Fuauthor=D.+Yaoauthor=Y.+Zhaoauthor=S.+Zhangauthor=G.+Wangauthor=G.+Heauthor=B.+Liu&title=Discovery+of+a+small-molecule+bromodomain-containing+protein+4+%28BRD4%29+inhibitor+that+induces+AMP-Activated+protein+kinase-modulated+autophagy-associated+cell+death+in+breast+cancer&doi=10.1021%2Facs.jmedchem.7b00275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer</span></div><div class="casAuthors">Ouyang, Liang; Zhang, Lan; Liu, Jie; Fu, Leilei; Yao, Dahong; Zhao, Yuqian; Zhang, Shouyue; Wang, Guan; He, Gu; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9990-10012</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Upon the basis of The Cancer Genome Atlas (TCGA) data set, the authors identified that several autophagy-related proteins such as AMP-activated protein kinase (AMPK) were remarkably downregulated in breast cancer.  Combined with coimmunopptn. assay, the authors demonstrated that BRD4 might interact with AMPK.  After analyses of the pharmacophore and WPF interaction optimization, the authors designed a small-mol. inhibitor of BRD4, 9f (FL-411 (2-(4-hydroxy-3,5-dimethylphenyl)-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one)) which was validated by cocrystal structure with BD1 of BRD4.  Subsequently, 9f was discovered to induce ATG5-dependent autophagy-assocd. cell death (ACD) by blocking BRD4-AMPK interaction and thus activating AMPK-mTOR-ULK1-modulated autophagic pathway in breast cancer cells.  Interestingly, the iTRAQ-based proteomics analyses revealed that 9f induced ACD pathways involved in HMGB1, VDAC1/2, and eEF2.  Moreover, 9f displayed a therapeutic potential on both breast cancer xenograft mouse and zebrafish models.  Together, these results demonstrate that a novel small-mol. inhibitor of BRD4 induces BRD4-AMPK-modulated ACD in breast cancer, which may provide a candidate drug for future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Ocrq2wyy6bVg90H21EOLACvtfcHk0lhGyZMcxfiS2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOitrvF&md5=ac15f7e108511ea207f2c2fcd299b4e5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00275%26sid%3Dliteratum%253Aachs%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520a%2520small-molecule%2520bromodomain-containing%2520protein%25204%2520%2528BRD4%2529%2520inhibitor%2520that%2520induces%2520AMP-Activated%2520protein%2520kinase-modulated%2520autophagy-associated%2520cell%2520death%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D24%26spage%3D9990%26epage%3D10012%26doi%3D10.1021%2Facs.jmedchem.7b00275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13305</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-49366-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41598-019-49366-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31527644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MrpsVejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=13305&issue=1&author=I.+H.+Parkauthor=H.+N.+Yangauthor=S.+Y.+Jeonauthor=J.+A.+Hwangauthor=M.+K.+Kimauthor=S.+Y.+Kongauthor=S.+H.+Shimauthor=K.+S.+Lee&title=Anti-tumor+activity+of+BET+inhibitors+in+androgen-receptor-expressing+triple-negative+breast+cancer&doi=10.1038%2Fs41598-019-49366-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer</span></div><div class="casAuthors">Park In Hae; Yang Han Na; Jeon Su Yeon; Kim Min Kyeong; Kong Sun-Young; Shim Sung Hoon; Park In Hae; Shim Sung Hoon; Lee Keun Seok; Hwang Jung-Ah; Kong Sun-Young; Kong Sun-Young</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is a heterogeneous disease comprising several subtypes.  Androgen-receptor (AR) signaling has been targeted by several investigational agents in luminal AR subtype TNBCs.  Bromodomain (BRD) and extra-terminal motif (BET) protein inhibitors have been shown to attenuate AR signaling in metastatic castration-resistant prostate cancer and to overcome enzalutamide resistance.  We demonstrated potent anti-tumor effects of the BET inhibitor JQ1 against AR-positive TNBC cell lines using cell viability and cell cycle analysis.  To reveal the mechanisms of JQ1 effects, multiplex gene expression analysis and immunoblotting assays were used.  We examined in vivo effects of JQ1 in a xenograft model of AR expressing TNBC.  JQ1 exhibited its anti-proliferative activity by inducing apoptosis and cell cycle arrest.  JQ1 activity was not mediated by MYC downregulation.  Instead, JQ1 blocked the interactions among the ATPase-family AAA-domain-containing 2 protein (ATAD2), BRD2, BRD4, and AR; effectively suppressing the expression of AR associated targets.  In addition, JQ1 showed significant anti-tumor activity in vivo in TNBC xenograft mouse models as a monotherapy and in combination with anti-AR therapy.  Taken together, our results showed that the BET inhibitor JQ1 is a promising therapeutic agent for the treatment of AR-positive TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4GG7aPDCwMhBrI9DTGjC0fW6udTcc2ebX0eBezAfBj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrpsVejtg%253D%253D&md5=f2786099b09c8d89ca85bcf79a2a9239</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-49366-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-49366-9%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BH.%26aulast%3DYang%26aufirst%3DH.%2BN.%26aulast%3DJeon%26aufirst%3DS.%2BY.%26aulast%3DHwang%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DKong%26aufirst%3DS.%2BY.%26aulast%3DShim%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DAnti-tumor%2520activity%2520of%2520BET%2520inhibitors%2520in%2520androgen-receptor-expressing%2520triple-negative%2520breast%2520cancer%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D13305%26doi%3D10.1038%2Fs41598-019-49366-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span> <span> </span><span class="NLM_article-title">C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2019.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30703411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFWmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2019&pages=141-153&author=T.+M.+Choauthor=J.+Y.+Kimauthor=Y.+J.+Kimauthor=D.+Sungauthor=E.+Ohauthor=S.+Jangauthor=L.+Farrandauthor=V.+H.+Hoangauthor=C.+T.+Nguyenauthor=J.+Annauthor=J.+Leeauthor=J.+H.+Seo&title=C-terminal+HSP90+inhibitor+L80+elicits+anti-metastatic+effects+in+triple-negative+breast+cancer+via+STAT3+inhibition&doi=10.1016%2Fj.canlet.2019.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition</span></div><div class="casAuthors">Cho, Tae-Min; Kim, Ji Young; Kim, Yoon-Jae; Sung, Daeil; Oh, Eunhye; Jang, Seojin; Farrand, Lee; Hoang, Van-Hai; Nguyen, Cong-Truong; Ann, Jihyae; Lee, Jeewoo; Seo, Jae Hong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">141-153</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is an aggressive heterogeneous disease with a divergent profile.  It has an earlier tendency to form metastases and is assocd. with poor clin. outcomes due to the limited treatment options available.  Heat-shock protein (HSP90) represents a potential treatment target as it promotes tumor progression and metastasis by modulating the maturation and stabilization of signal transduction proteins.  We sought to investigate the efficacy of the C-terminal HSP90 inhibitor L80 on cell proliferation, breast cancer stem cell (BCSC)-like properties, tumor growth and metastasis.  L80 suppressed cell viability and concomitantly inhibited AKT/MEK/ERK/JAK2/STAT3 signaling in TNBC cells but did not induce cytotoxicity in normal cells.  L80 effectively targeted BCSC-like traits, together with significant redns. in the CD44high/CD24low-population, ALDH1 activity and mammosphere forming-ability.  In support of the in vitro observations, L80 administration caused significant impairment in tumor growth, angiogenesis and distant metastases in an orthotopic allograft model with BCSC-enriched cells in vivo.  These phenomena were assocd. with the suppression of BCSC-like characteristics and STAT3 dysfunction.  Our findings highlight properties of the L80 compd. that may be useful in suppressing metastatic TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrybhXQe-U6ubVg90H21EOLACvtfcHk0lhGyZMcxfiS2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFWmsrk%253D&md5=e966bb533d6bf4d9fe583dd6a8cd0dd8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DSung%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DE.%26aulast%3DJang%26aufirst%3DS.%26aulast%3DFarrand%26aufirst%3DL.%26aulast%3DHoang%26aufirst%3DV.%2BH.%26aulast%3DNguyen%26aufirst%3DC.%2BT.%26aulast%3DAnn%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26atitle%3DC-terminal%2520HSP90%2520inhibitor%2520L80%2520elicits%2520anti-metastatic%2520effects%2520in%2520triple-negative%2520breast%2520cancer%2520via%2520STAT3%2520inhibition%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D447%26spage%3D141%26epage%3D153%26doi%3D10.1016%2Fj.canlet.2019.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells</span>. <i>J. Microbiol. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">914</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.4014/jmb.1311.11052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.4014%2Fjmb.1311.11052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24705874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKrsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=914-920&issue=7&author=Q.+Zhaoauthor=C.+Z.+Wuauthor=J.+K.+Leeauthor=S.+R.+Zhaoauthor=H.+M.+Liauthor=Q.+Huoauthor=T.+Maauthor=J.+Zhangauthor=Y.+S.+Hongauthor=H.+Liu&title=Anticancer+effects+of+the+Hsp90+inhibitor+17-demethoxy-reblastatin+in+human+breast+cancer+MDA-MB-231+cells&doi=10.4014%2Fjmb.1311.11052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells</span></div><div class="casAuthors">Zhao, Qing; Wu, Cheng-Zhu; Lee, Jae Kyoung; Zhao, Su-Rong; Li, Hong-Mei; Huo, Qiang; Ma, Tao; Zhang, Jin; Hong, Young-Soo; Liu, Hao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology and Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">914-920</span>CODEN:
                <span class="NLM_cas:coden">JOMBES</span>;
        ISSN:<span class="NLM_cas:issn">1017-7825</span>.
    
            (<span class="NLM_cas:orgname">Korean Society for Microbiology and Biotechnology</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) possesses a higher rate of distant recurrence and a poorer prognosis than other breast cancer subtypes.  Interestingly, most of the heat shock protein 90 (Hsp90) client proteins are oncoproteins, and some are closely related to unfavorable factors of TNBC patients.  17-Demethoxy-reblastatin (17-DR), a novel non-benzoquinone-type geldanamycin analog, exhibited potent Hsp90 ATPase inhibition activity.  In this study, the anticancer effects of 17-DR on TNBC MDA-MB-231 cells were investigated.  These results showed that 17-DR inhibited cell proliferation, induced apoptosis, and suppressed cell invasion and migration in the MDA-MB-231 cells.  Down-regulation of the key Hsp90-dependent tumor-driving mols., such as RIP1 and MMP-9, by 17-DR may be related to these effects.  Taken together, our results suggest that 17-DR has potential as a therapeutic agent for the treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ2qsHTUpUM7Vg90H21EOLACvtfcHk0livtdtrlUY5yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKrsLjN&md5=6cf2c55bc6f53572cefbf855380ceb08</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.4014%2Fjmb.1311.11052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4014%252Fjmb.1311.11052%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DC.%2BZ.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DZhao%26aufirst%3DS.%2BR.%26aulast%3DLi%26aufirst%3DH.%2BM.%26aulast%3DHuo%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DAnticancer%2520effects%2520of%2520the%2520Hsp90%2520inhibitor%252017-demethoxy-reblastatin%2520in%2520human%2520breast%2520cancer%2520MDA-MB-231%2520cells%26jtitle%3DJ.%2520Microbiol.%2520Biotechnol.%26date%3D2014%26volume%3D24%26issue%3D7%26spage%3D914%26epage%3D920%26doi%3D10.4014%2Fjmb.1311.11052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiery, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Targeting HSP90-HDAC6 regulating network implicates precision treatment of breast cancer</span>. <i>Int. J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.7150/ijbs.18834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.7150%2Fijbs.18834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28529458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1crpsl2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=505-517&issue=4&author=S.+Yuauthor=X.+Caiauthor=C.+Wuauthor=Y.+Liuauthor=J.+Zhangauthor=X.+Gongauthor=X.+Wangauthor=X.+Wuauthor=T.+Zhuauthor=L.+Moauthor=J.+Guauthor=Z.+Yuauthor=J.+Chenauthor=J.+P.+Thieryauthor=R.+Chaiauthor=L.+Chen&title=Targeting+HSP90-HDAC6+regulating+network+implicates+precision+treatment+of+breast+cancer&doi=10.7150%2Fijbs.18834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer</span></div><div class="casAuthors">Yu Shiyi; Cai Xiuxiu; Wu Chenxi; Liu Yan; Zhang Jun; Gong Xue; Wang Xin; Chen Liming; Yu Shiyi; Cai Xiuxiu; Wu Chenxi; Liu Yan; Zhang Jun; Gong Xue; Wang Xin; Chai Renjie; Chen Liming; Wu Xiaoli; Zhu Tao; Mo Lin; Gu Jun; Yu Zhenghong; Chen Jinfei; Chen Jinfei; Thiery Jean Paul; Thiery Jean Paul; Thiery Jean Paul; Chai Renjie; Chai Renjie</div><div class="citationInfo"><span class="NLM_cas:title">International journal of biological sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-517</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Breast cancer is the leading cause of women death.  Heat shock protein 90 (HSP90) and Histone deacetylase 6 (HDAC6) are promising anti-cancer drug targets.  However, it's still unclear the applicability of anti-HSP90 and anti-HDAC6 strategies in precision treatment of breast cancer.  In current study, we found that triple negative breast cancer (TNBC) cells, compared to T47D, an ERα+ breast cancer cell line, exhibited 7~40 times lower IC50 values, stronger cell cycle perturbation, increased cell apoptosis and stronger inhibition of cell migration upon 17-DMAG treatment, while T47D, compared to TNBC cells, expressed higher HDAC6 and showed stronger anti-cancer response upon treatment of Tubacin.  Mechanically, 17-DMAG treatment inhibited a complex network consists at least ERK, AKT, and Hippo pathway in TNBC cells, and higher expression of HDAC6 inhibited HSP90 activity via deacetylating HSP90.  Furthermore, we found higher HDAC6 expression level in tamoxifen-resistance T47D than that in T47D, and Tubacin treatment suppressed the growth of tamoxifen-resistant cells in vivo.  Our data suggested that anti-HSP90 and anti-HDAC6 are promising strategies to treat TNBC and ERα+ breast cancers respectively, and anti-HDAC6 can be considered during treatment of tamoxifen-resistance breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSX8r12aXIDwoxhnOQkIHOxfW6udTcc2eaNn1F620Lcnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crpsl2htQ%253D%253D&md5=9911639d19fd6bb643944844cdacdf33</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.7150%2Fijbs.18834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijbs.18834%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMo%26aufirst%3DL.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DThiery%26aufirst%3DJ.%2BP.%26aulast%3DChai%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DTargeting%2520HSP90-HDAC6%2520regulating%2520network%2520implicates%2520precision%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Biol.%2520Sci.%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D505%26epage%3D517%26doi%3D10.7150%2Fijbs.18834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omerzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterrenburg, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Roos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doornmalen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kops, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, R. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2180</span>– <span class="NLM_lpage">2192</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdv293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26153498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhsVCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2180-2192&issue=10&author=A.+R.+Maiaauthor=J.+de+Manauthor=U.+Boonauthor=A.+Janssenauthor=J.+Y.+Songauthor=M.+Omerzuauthor=J.+G.+Sterrenburgauthor=M.+B.+Prinsenauthor=N.+Willemsen-Seegersauthor=J.+A.+de+Roosauthor=A.+M.+van+Doornmalenauthor=J.+C.+Uitdehaagauthor=G.+J.+Kopsauthor=J.+Jonkersauthor=R.+C.+Buijsmanauthor=G.+J.+Zamanauthor=R.+H.+Medema&title=Inhibition+of+the+spindle+assembly+checkpoint+kinase+TTK+enhances+the+efficacy+of+docetaxel+in+a+triple-negative+breast+cancer+model&doi=10.1093%2Fannonc%2Fmdv293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model</span></div><div class="casAuthors">Maia A R R; Janssen A; de Man J; Sterrenburg J G; Prinsen M B W; Willemsen-Seegers N; de Roos J A D M; van Doornmalen A M; Uitdehaag J C M; Buijsman R C; Zaman G J R; Boon U; Song J-Y; Omerzu M; Kops G J P L; Jonkers J; Medema R H</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2180-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancers (TNBC) are considered the most aggressive type of breast cancer, for which no targeted therapy exists at the moment.  These tumors are characterized by having a high degree of chromosome instability and often overexpress the spindle assembly checkpoint kinase TTK.  To explore the potential of TTK inhibition as a targeted therapy in TNBC, we developed a highly potent and selective small molecule inhibitor of TTK, NTRC 0066-0.  RESULTS AND CONCLUSIONS:  The compound is characterized by long residence time on the target and inhibits the proliferation of a wide variety of human cancer cell lines with potency in the same range as marketed cytotoxic agents.  In cell lines and in mice, NTRC 0066-0 inhibits the phosphorylation of a TTK substrate and induces chromosome missegregation.  NTRC 0066-0 inhibits tumor growth in MDA-MB-231 xenografts as a single agent after oral application.  To address the effect of the inhibitor in breast cancer, we used a well-defined mouse model that spontaneously develops breast tumors that share key morphologic and molecular features with human TNBC.  Our studies show that combination of NTRC 0066-0 with a therapeutic dose of docetaxel resulted in doubling of mouse survival and extended tumor remission, without toxicity.  Furthermore, we observed that treatment efficacy is only achieved upon co-administration of the two compounds, which suggests a synergistic in vivo effect.  Therefore, we propose TTK inhibition as a novel therapeutic target for neoadjuvant therapy in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQW4bdSIlyWFQ8IxFYvehhofW6udTcc2eaNn1F620Lcnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhsVCrtg%253D%253D&md5=579aa33d6fd0de70b6c68ae86d8316c0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv293%26sid%3Dliteratum%253Aachs%26aulast%3DMaia%26aufirst%3DA.%2BR.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DBoon%26aufirst%3DU.%26aulast%3DJanssen%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DOmerzu%26aufirst%3DM.%26aulast%3DSterrenburg%26aufirst%3DJ.%2BG.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%2BA.%26aulast%3Dvan%2BDoornmalen%26aufirst%3DA.%2BM.%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%26aulast%3DKops%26aufirst%3DG.%2BJ.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26aulast%3DMedema%26aufirst%3DR.%2BH.%26atitle%3DInhibition%2520of%2520the%2520spindle%2520assembly%2520checkpoint%2520kinase%2520TTK%2520enhances%2520the%2520efficacy%2520of%2520docetaxel%2520in%2520a%2520triple-negative%2520breast%2520cancer%2520model%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26issue%3D10%26spage%3D2180%26epage%3D2192%26doi%3D10.1093%2Fannonc%2Fmdv293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kümmel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes
Castan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Borrego, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín
Martorell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail-Khan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I.</span></span> <span> </span><span class="NLM_article-title">1977 Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC)</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">S326</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)30925-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2FS0959-8049%2816%2930925-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=S326&author=A.+Bardiaauthor=J.+S.+Cameronauthor=K.+Venkatesanauthor=D.+Robinsonauthor=D.+Porterauthor=S.+B.+Kimauthor=M.+Partonauthor=S.+K%C3%BCmmelauthor=L.+G.+Estevezauthor=C.+S.+Huangauthor=J.+Cortes%0ACastanauthor=M.+Ruiz-Borregoauthor=M.+Telliauthor=P.+Mart%C3%ADn%0AMartorellauthor=R.+Lopezauthor=J.+T.+Beckauthor=R.+Ismail-Khanauthor=S.+C.+Chenauthor=S.+Hurvitzauthor=I.+Mayer&title=1977+Synergy+of+LCL161%2C+an+antagonist+of+inhibitor+of+apoptosis+proteins+%28IAPs%29%2C+with+paclitaxel+in+a+gene+expression+signature-enriched+cohort+of+triple-negative+breast+cancer+%28TNBC%29&doi=10.1016%2FS0959-8049%2816%2930925-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2930925-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252930925-X%26sid%3Dliteratum%253Aachs%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DJ.%2BS.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DParton%26aufirst%3DM.%26aulast%3DK%25C3%25BCmmel%26aufirst%3DS.%26aulast%3DEstevez%26aufirst%3DL.%2BG.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DCortes%2BCastan%26aufirst%3DJ.%26aulast%3DRuiz-Borrego%26aufirst%3DM.%26aulast%3DTelli%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn%2BMartorell%26aufirst%3DP.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DIsmail-Khan%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DHurvitz%26aufirst%3DS.%26aulast%3DMayer%26aufirst%3DI.%26atitle%3D1977%2520Synergy%2520of%2520LCL161%252C%2520an%2520antagonist%2520of%2520inhibitor%2520of%2520apoptosis%2520proteins%2520%2528IAPs%2529%252C%2520with%2520paclitaxel%2520in%2520a%2520gene%2520expression%2520signature-enriched%2520cohort%2520of%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2015%26volume%3D51%26spage%3DS326%26doi%3D10.1016%2FS0959-8049%2816%2930925-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span> <span> </span><span class="NLM_article-title">Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells</span>. <i>Phytomedicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.phymed.2018.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.phymed.2018.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30466991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKrs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=43-49&author=S.+Kimauthor=D.+Youauthor=Y.+Jeongauthor=J.+Yuauthor=S.+W.+Kimauthor=S.+J.+Namauthor=J.+E.+Lee&title=Berberine+down-regulates+IL-8+expression+through+inhibition+of+the+EGFR%2FMEK%2FERK+pathway+in+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.phymed.2018.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells</span></div><div class="casAuthors">Kim, Sangmin; You, Daeun; Jeong, Yisun; Yu, Jonghan; Kim, Seok Won; Nam, Seok Jin; Lee, Jeong Eon</div><div class="citationInfo"><span class="NLM_cas:title">Phytomedicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-49</span>CODEN:
                <span class="NLM_cas:coden">PYTOEY</span>;
        ISSN:<span class="NLM_cas:issn">0944-7113</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Interleukin-8 (IL-8) expression is assocd. with metastasis in a variety of cancer cells.  Here, we investigated the regulatory mechanism of IL-8 expression as well as the pharmacol. effect of berberine (BBR) on IL-8 expression in triple-neg. breast cancer (TNBC) cells.  The clin. value of IL-8 was analyzed by from a public database [Kaplan-Meier plotter database.  IL-8 mRNA and protein expression was analyzed by real-time PCR and ELISA, resp.  Cell invasion was analyzed by Boyden chamber assay.  Tumor cell growth was analyzed by colony forming assay.  Clin., we obsd. that breast cancer patients with highly expressed IL-8 are assocd. with poor outcomes in areas such as relapse-free, overall, and distant metastasis-free survival.  We showed that IL-8 expression is higher in TNBC cells than in non-TNBC cells.  In addn., the rates of cell invasion were significantly increased by IL-8 treatment.  These IL-8 levels were decreased by EGFR (Neratinib and Afatinib) and MEK (PD98059) inhibitors in TNBC cells.  Finally, we obsd. that BBR dramatically suppresses IL-8 expression.  In addn., BBR also inhibited cell invasiveness and anchorage-independent growth.  Interestingly, our results showed that BBR down-regulates EGFR protein expression and dose-dependently inhibits MEK and ERK phosphorylation.  Here, we demonstrate that BBR may be a promising drug to suppress cell invasiveness and growth of TNBC through IL-8-related mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6d3y0KdS15LVg90H21EOLACvtfcHk0lgUGQd9snHjBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKrs7vP&md5=5c682d102500aaa5210aa0cccb57a349</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.phymed.2018.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phymed.2018.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DNam%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26atitle%3DBerberine%2520down-regulates%2520IL-8%2520expression%2520through%2520inhibition%2520of%2520the%2520EGFR%252FMEK%252FERK%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DPhytomedicine%26date%3D2018%26volume%3D50%26spage%3D43%26epage%3D49%26doi%3D10.1016%2Fj.phymed.2018.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cretella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumarola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Monica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digiacomo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazzoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Generali, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronini, P. G.</span></span> <span> </span><span class="NLM_article-title">The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">72</span>, <span class="refDoi"> DOI: 10.1186/s13046-018-0741-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13046-018-0741-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29587820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1egtL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=72&issue=1&author=D.+Cretellaauthor=A.+Ravelliauthor=C.+Fumarolaauthor=S.+La+Monicaauthor=G.+Digiacomoauthor=A.+Cavazzoniauthor=R.+Alfieriauthor=A.+Biondiauthor=D.+Generaliauthor=M.+Bonelliauthor=P.+G.+Petronini&title=The+anti-tumor+efficacy+of+CDK4%2F6+inhibition+is+enhanced+by+the+combination+with+PI3K%2FAKT%2FmTOR+inhibitors+through+impairment+of+glucose+metabolism+in+TNBC+cells&doi=10.1186%2Fs13046-018-0741-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells</span></div><div class="casAuthors">Cretella, Daniele; Ravelli, Andrea; Fumarola, Claudia; Monica, Silvia La; Digiacomo, Graziana; Cavazzoni, Andrea; Alfieri, Roberta; Biondi, Alessandra; Generali, Daniele; Bonelli, Mara; Petronini, Pier Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72/1-72/12</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Cell cycle regulators have gain attention as potential targets for anticancer therapy.  Palbociclib is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), which coordinate the G1-S transition.  Palbociclib is currently approved for the treatment of hormone receptor pos., HER2-neg. advanced breast cancer (BC) in assocn. with letrozole or fulvestrant.  In contrast, its efficacy in triple neg. BC (TNBC), either alone or in combined therapies, has not been fully investigated to date.  Methods: Here we evaluated the potential of combining palbociclib with PI3K/mTOR inhibitors in Rb-proficient TNBC cells comparing different schedules of treatment: simultaneous, sequential, or sequential combined treatment (pre-incubation with palbociclib followed by exposure to both palbociclib and PI3K/mTOR inhibitors).  We assessed the effects on cell proliferation, cell death, and cell cycle distribution, and looked at the impact of such treatments on glucose metab.  Results: Palbociclib exerted cytostatic effects in Rb-pos. TNBC cells, inducing a reversible blockade in G0/G1 cell cycle phase assocd. with down-regulation of CDK6, Rb, and c-myc expression and/or activity.  Palbociclib treatment induced AKT signaling, providing a rationale for its combination with PI3K/mTOR inhibitors.  The simultaneous or sequential treatment resulted in an additive inhibition of cell proliferation.  On the other hand, the sequential combined treatment in which palbociclib was maintained also during exposure to PI3K/mTOR inhibitors gave rise to synergistic anti-proliferative and pro-apoptotic effects, by inhibiting both CDK4/6/Rb/myc and PI3K/ mTOR signaling.  Interestingly, the inhibition of the Rb/E2F/myc axis mediated by palbociclib resulted in a significant down-regulation of glucose metab.; most importantly, these inhibitory effects were enhanced by the combination of palbociclib with BYL719 (specific inhibitor of the p110α PI3K-subunit), which promoted a stronger inhibition of GLUT-1 glucose transporter expression, glucose uptake and consumption in comparison with individual treatments, under both normoxic and hypoxic conditions.  Conclusions: Combination of palbociclib with PI3K/mTOR inhibitors may represent a promising therapeutic option for the treatment of Rb-proficient TNBC, with the sequential combined schedule showing a superior efficacy over the other schedules.  In addn. our results demonstrate that the impairment of glucose metab. may contribute to the anti-tumor activity of such drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry9YJWakzPCbVg90H21EOLACvtfcHk0lgUGQd9snHjBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1egtL3M&md5=a957f93b7ae278b8017d16d8042885de</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0741-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0741-3%26sid%3Dliteratum%253Aachs%26aulast%3DCretella%26aufirst%3DD.%26aulast%3DRavelli%26aufirst%3DA.%26aulast%3DFumarola%26aufirst%3DC.%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DDigiacomo%26aufirst%3DG.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DGenerali%26aufirst%3DD.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26atitle%3DThe%2520anti-tumor%2520efficacy%2520of%2520CDK4%252F6%2520inhibition%2520is%2520enhanced%2520by%2520the%2520combination%2520with%2520PI3K%252FAKT%252FmTOR%2520inhibitors%2520through%2520impairment%2520of%2520glucose%2520metabolism%2520in%2520TNBC%2520cells%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26issue%3D1%26spage%3D72%26doi%3D10.1186%2Fs13046-018-0741-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwik, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowder, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannigan, D. A.</span></span> <span> </span><span class="NLM_article-title">Development of a RSK inhibitor as a novel therapy for triple-negative breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2598</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-16-0106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27528706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVOqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2598-2608&issue=11&author=K.+A.+Ludwikauthor=J.+P.+Campbellauthor=M.+Liauthor=Y.+Liauthor=Z.+M.+Sanduskyauthor=L.+Pasicauthor=M.+E.+Sowderauthor=D.+R.+Breninauthor=J.+A.+Pietenpolauthor=G.+A.+Dohertyauthor=D.+A.+Lannigan&title=Development+of+a+RSK+inhibitor+as+a+novel+therapy+for+triple-negative+breast+cancer&doi=10.1158%2F1535-7163.MCT-16-0106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a RSK inhibitor as a novel therapy for triple-negative breast cancer</span></div><div class="casAuthors">Ludwik, Katarzyna A.; Campbell, J. Preston; Li, Mingzong; Li, Yu; Sandusky, Zachary M.; Pasic, Lejla; Sowder, Miranda E.; Brenin, David R.; Pietenpol, Jennifer A.; O'Doherty, George A.; Lannigan, Deborah A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2598-2608</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metastatic breast cancer is an incurable disease and identification of novel therapeutic opportunities is vital.  Triple-neg. breast cancer (TNBC) frequently metastasizes and high levels of activated p90RSK (RSK), a downstream MEK-ERK1/2 effector, are found in TNBC.  We demonstrate, using direct pharmacol. and genetic inhibition of RSK1/2, that these kinases contribute to the TNBC metastatic process in vivo.  Kinase profiling showed that RSK1 and RSK2 are the predominant kinases targeted by the new inhibitor, which is based on the natural product SL0101.  Further evidence for selectivity was provided by the observations that silencing RSK1 and RSK2 eliminated the ability of the analog to further inhibit survival or proliferation of a TNBC cell line.  In vivo, the new deriv. was as effective as the FDA-approved MEK inhibitor trametinib in reducing the establishment of metastatic foci.  Importantly, inhibition of RSK1/2 did not result in activation of AKT, which is known to limit the efficacy of MEK inhibitors in the clinic.  Our results demonstrate that RSK is a major contributor to the TNBC metastatic program and provide preclin. proof-of-concept for the efficacy of the novel SL0101 analog in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm1jJkBc1CfrVg90H21EOLACvtfcHk0li9p87FwsfjQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVOqsL8%253D&md5=3f4020911c09d843ecbfbdae4fe61bb9</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0106%26sid%3Dliteratum%253Aachs%26aulast%3DLudwik%26aufirst%3DK.%2BA.%26aulast%3DCampbell%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSandusky%26aufirst%3DZ.%2BM.%26aulast%3DPasic%26aufirst%3DL.%26aulast%3DSowder%26aufirst%3DM.%2BE.%26aulast%3DBrenin%26aufirst%3DD.%2BR.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26aulast%3DDoherty%26aufirst%3DG.%2BA.%26aulast%3DLannigan%26aufirst%3DD.%2BA.%26atitle%3DDevelopment%2520of%2520a%2520RSK%2520inhibitor%2520as%2520a%2520novel%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D2598%26epage%3D2608%26doi%3D10.1158%2F1535-7163.MCT-16-0106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coonrod, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2017.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28844713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVSlsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2017&pages=30-41&author=H.+Qinauthor=X.+Liuauthor=F.+Liauthor=L.+Miaoauthor=T.+Liauthor=B.+Xuauthor=X.+Anauthor=A.+Muthauthor=P.+R.+Thompsonauthor=S.+A.+Coonrodauthor=X.+Zhang&title=PAD1+promotes+epithelial-mesenchymal+transition+and+metastasis+in+triple-negative+breast+cancer+cells+by+regulating+MEK1-ERK1%2F2-MMP2+signaling&doi=10.1016%2Fj.canlet.2017.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling</span></div><div class="casAuthors">Qin, Hao; Liu, Xiaoqiu; Li, Fujun; Miao, Lixia; Li, Tingting; Xu, Boqun; An, Xiaofei; Muth, Aaron; Thompson, Paul R.; Coonrod, Scott A.; Zhang, Xuesen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-41</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Peptidylargininedeiminase 1 (PAD1) catalyzes protein for citrullination, and this activity has been linked to the epidermal cornification.  However, a role for PAD1 in tumorigenesis, including breast cancers has not been previously explored.  Here we first showed that PAD1 is overexpressed in human triple neg. breast cancer (TNBC).  In cultured cells and xenograft mouse models, PAD1 depletion or inhibition reduced cell proliferation, suppressed epithelial-mesenchymal transition, and prevented metastasis of MDA-MB-231 cells.  These changes were correlated with a dramatic decrease in MMP2/9 expression.  Furthermore, ERK1/2 and P38 MAPK signaling pathways are activated upon PAD1 silencing.  Treatment with MEK1/2 inhibitor in PAD1 knockdown cells significantly recovered MMP2 expression, while inhibiting P38 activation only slightly elevated MMP9 levels.  We then showed that PAD1 interacts with and citrullinates MEK1 thereby disrupting MEK1-catalyzed ERK1/2 phosphorylation, thus leading to the MMP2 overexpression.  Collectively, our data indicate that PAD1 appears to promote tumorigenesis by regulating MEK1-ERK1/2-MMP2 signaling in TNBC.  These results also raise the possibility that PAD1 may function as an important new biomarker for TNBC tumors and suggest that PAD1-specific inhibitors could potentially be utilized to treat metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF9YlUyw_CZ7Vg90H21EOLACvtfcHk0li9p87FwsfjQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVSlsb7N&md5=c3366e717e7496f57bffabb8d23475b1</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DAn%26aufirst%3DX.%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DP.%2BR.%26aulast%3DCoonrod%26aufirst%3DS.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DPAD1%2520promotes%2520epithelial-mesenchymal%2520transition%2520and%2520metastasis%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520by%2520regulating%2520MEK1-ERK1%252F2-MMP2%2520signaling%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D409%26spage%3D30%26epage%3D41%26doi%3D10.1016%2Fj.canlet.2017.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Souid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsayed, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohyeldin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddique, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Sayed, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essafi-Benkhadir, K.</span></span> <span> </span><span class="NLM_article-title">131-Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal-epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1002/mc.22874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fmc.22874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29978911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1507-1524&issue=11&author=S.+Souidauthor=H.+E.+Elsayedauthor=H.+Y.+Ebrahimauthor=M.+M.+Mohyeldinauthor=A.+B.+Siddiqueauthor=H.+Karouiauthor=K.+A.+El+Sayedauthor=K.+Essafi-Benkhadir&title=131-Oxophorbine+protopheophorbide+A+from+Ziziphus+lotus+as+a+novel+mesenchymal-epithelial+transition+factor+receptor+inhibitory+lead+for+the+control+of+breast+tumor+growth+in+vitro+and+in+vivo&doi=10.1002%2Fmc.22874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">131-Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal-epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo</span></div><div class="casAuthors">Souid, Soumaya; Elsayed, Heba E.; Ebrahim, Hassan Y.; Mohyeldin, Mohamed M.; Siddique, Abu Bakar; Karoui, Habib; El Sayed, Khalid A.; Essafi-Benkhadir, Khadija</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1507-1524</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The failure of chemotherapy esp. in triple neg. breast cancer (TNBC) patients has been correlated with the overexpression of the mesenchymal-epithelial transition factor (c-Met) receptor.  Thus, the hepatocyte growth factor (HGF)/c-Met signaling axis has gained considerable attention as a valid mol. target for breast cancer therapy.  This study reports for the first time the discovery of the 131-oxophorbines pheophorbide A and protopheophorbide A along with chlorophyllide A from Ziziphus lotus, an edible typical Tunisian plant, as the potent antiproliferative compds. against the human breast cancer cells MDA-MB-231 and MCF-7.  In silico, this compd. targeted the kinase domain of multiple c-Met crystal structures.  It potently inhibited the kinase domain phosphorylation of wild and mutant c-Met in Z-LYTE kinase assay.  Protopheophorbide A inhibited HGF-induced downstream c-Met-dependent cell proliferation, survival, adhesion and migration through RAF/MEK/ERK and PI3K/PTEN/AKT signaling pathways modulation, ROS generation and activation of JNK and p38 pathways.  Importantly, treatment with protopheophorbide A significantly inhibited the MDA-MB-231 tumor growth in vivo.  Our results suggest that protopheophorbide A could be a novel c-Met inhibitory lead with promise to control c-Met/HGF-dependent breast malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOzfJbfSHQTbVg90H21EOLACvtfcHk0li9p87FwsfjQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsrnI&md5=9dc0761a41bd3fd958748124cdaa758e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fmc.22874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.22874%26sid%3Dliteratum%253Aachs%26aulast%3DSouid%26aufirst%3DS.%26aulast%3DElsayed%26aufirst%3DH.%2BE.%26aulast%3DEbrahim%26aufirst%3DH.%2BY.%26aulast%3DMohyeldin%26aufirst%3DM.%2BM.%26aulast%3DSiddique%26aufirst%3DA.%2BB.%26aulast%3DKaroui%26aufirst%3DH.%26aulast%3DEl%2BSayed%26aufirst%3DK.%2BA.%26aulast%3DEssafi-Benkhadir%26aufirst%3DK.%26atitle%3D131-Oxophorbine%2520protopheophorbide%2520A%2520from%2520Ziziphus%2520lotus%2520as%2520a%2520novel%2520mesenchymal-epithelial%2520transition%2520factor%2520receptor%2520inhibitory%2520lead%2520for%2520the%2520control%2520of%2520breast%2520tumor%2520growth%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Carcinog.%26date%3D2018%26volume%3D57%26issue%3D11%26spage%3D1507%26epage%3D1524%26doi%3D10.1002%2Fmc.22874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byerly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halstead-Nussloch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsyv, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, H. Y.</span></span> <span> </span><span class="NLM_article-title">PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>, <span class="refDoi"> DOI: 10.1186/s13058-016-0749-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-016-0749-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27663795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGks7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=95&issue=1&author=J.+Byerlyauthor=G.+Halstead-Nusslochauthor=K.+Itoauthor=I.+Katsyvauthor=H.+Y.+Irie&title=PRKCQ+promotes+oncogenic+growth+and+anoikis+resistance+of+a+subset+of+triple-negative+breast+cancer+cells&doi=10.1186%2Fs13058-016-0749-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells</span></div><div class="casAuthors">Byerly, Jessica; Halstead-Nussloch, Gwyneth; Ito, Koichi; Katsyv, Igor; Irie, Hanna Y.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95/1-95/11</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The protein kinase C (PKC) family comprises distinct classes of proteins, many of which are implicated in diverse cellular functions.  Protein tyrosine kinase C theta isoform (PRKCQ)/PKCθ, a member of the novel PKC family, may have a distinct isoform-specific role in breast cancer.  PKCθ is preferentially expressed in triple-neg. breast cancer (TNBC) compared to other breast tumor subtypes.  We hypothesized that PRKCQ/PKCθ critically regulates growth and survival of a subset of TNBC cells.  Methods: To elucidate the role of PRKCQ/PKCθ in regulating growth and anoikis resistance, we used both gain and loss of function to modulate expression of PRKCQ.  We enhanced expression of PKCθ (kinase-active or inactive) in non-transformed breast epithelial cells (MCF-10A) and assessed effects on epidermal growth factor (EGF)-independent growth, anoikis, and migration.  We downregulated expression of PKCθ in TNBC cells, and detd. effects on in vitro and in vivo growth and survival.  TNBC cells were also treated with a small mol. inhibitor to assess requirement for PKCθ kinase activity in the growth of TNBC cells.  Results: PRKCQ/PKCθ can promote oncogenic phenotypes when expressed in non-transformed MCF-10A mammary epithelial cells; PRKCQ/PKCθ enhances anchorage-independent survival, growth-factor-independent proliferation, and migration.  PKCθ expression promotes retinoblastoma (Rb) phosphorylation and cell-cycle progression under growth factor-deprived conditions that typically induce cell-cycle arrest of MCF-10A breast epithelial cells.  Proliferation and Rb phosphorylation are dependent on PKCθ-stimulated extracellular signal-related kinase (Erk)/mitogen-activated protein kinase (MAPK) activity.  Enhanced Erk/MAPK activity is dependent on the kinase activity of PKCθ, as overexpression of kinase-inactive PKCθ does not stimulate Erk/MAPK or Rb phosphorylation or promote growth-factor-independent proliferation.  Downregulation of PRKCQ/PKCθ in TNBC cells enhances anoikis, inhibits growth in 3-D Matrigel cultures, and impairs triple-neg. tumor xenograft growth.  AEB071, an inhibitor of PKCθ kinase activity, also inhibits growth and invasive branching of TNBC cells in 3-D cultures, further supporting a role for PKCθ kinase activity in triple-neg. cancer cell growth.  Conclusions: Enhanced PRKCQ/PKCθ expression can promote growth-factor-independent growth, anoikis resistance, and migration.  PRKCQ critically regulates growth and survival of a subset of TNBC.  Inhibition of PKCθ kinase activity may be an attractive therapeutic approach for TNBC, a subtype in need of improved targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotMxHI_ruRt7Vg90H21EOLACvtfcHk0lhagxIsI0BW1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGks7vP&md5=9bf31c044b4b8aedb311dcf9da49ea20</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1186%2Fs13058-016-0749-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-016-0749-6%26sid%3Dliteratum%253Aachs%26aulast%3DByerly%26aufirst%3DJ.%26aulast%3DHalstead-Nussloch%26aufirst%3DG.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DKatsyv%26aufirst%3DI.%26aulast%3DIrie%26aufirst%3DH.%2BY.%26atitle%3DPRKCQ%2520promotes%2520oncogenic%2520growth%2520and%2520anoikis%2520resistance%2520of%2520a%2520subset%2520of%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26issue%3D1%26spage%3D95%26doi%3D10.1186%2Fs13058-016-0749-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschhaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qyli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajendran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinosa, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luker, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luker, G. D.</span></span> <span> </span><span class="NLM_article-title">Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1142</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-18-0836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1541-7786.MCR-18-0836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30718260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVeks77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=1142-1154&issue=5&author=B.+A.+Humphriesauthor=J.+M.+Buschhausauthor=Y.-C.+Chenauthor=H.+R.+Haleyauthor=T.+Qyliauthor=B.+Chiangauthor=N.+Shenauthor=S.+Rajendranauthor=A.+Cutterauthor=Y.-H.+Chengauthor=Y.-T.+Chenauthor=J.+Congauthor=P.+C.+Spinosaauthor=E.+Yoonauthor=K.+E.+Lukerauthor=G.+D.+Luker&title=Plasminogen+activator+inhibitor+1+%28PAI1%29+promotes+actin+cytoskeleton+reorganization+and+glycolytic+metabolism+in+triple-negative+breast+cancer&doi=10.1158%2F1541-7786.MCR-18-0836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer</span></div><div class="casAuthors">Humphries, Brock A.; Buschhaus, Johanna M.; Chen, Yu-Chih; Haley, Henry R.; Qyli, Tonela; Chiang, Benjamin; Shen, Nathan; Rajendran, Shrila; Cutter, Alyssa; Cheng, Yu-Heng; Chen, Yu-Ting; Cong, Jason; Spinosa, Phillip C.; Yoon, Euisik; Luker, Kathryn E.; Luker, Gary D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1142-1154</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here we show that increased PAI1 drives rearrangement of the actin cytoskeleton, mitochondrial fragmentation, and glycolytic metab. in triple-neg. breast cancer (TNBC) cells.  In two-dimensional environments, both stable expression of PAI1 and treatment with recombinant PAI1 increased migration, which could be blocked with the specific inhibitor tiplaxtinin.  PAI1 also promoted invasion into the extracellular matrix from coculture spheroids with human mammary fibroblasts in fibrin gels.  Elevated cellular PAI1 enhanced cytoskeletal features assocd. with migration, actin-rich migratory structures, and reduced actin stress fibers.  In orthotopic tumor xenografts, we discovered that TNBC cells with elevated PAI1 show collagen fibers aligned perpendicular to the tumor margin, an established marker of invasive breast tumors.  Further studies revealed that PAI1 activates ERK signaling, a central regulator of motility, and promotes mitochondrial fragmentation.  Consistent with known effects of mitochondrial fragmentation on metab., fluorescence lifetime imaging microscopy of endogenous NADH showed that PAI1 promotes glycolysis in cell-based assays, orthotopic tumor xenografts, and lung metastases.  Together, these data demonstrate for the first time that PAI1 regulates cancer cell metab. and suggest targeting metab. to block motility and tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQKupxh_tLoLVg90H21EOLACvtfcHk0lhagxIsI0BW1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVeks77E&md5=3af3739f0e48e693246a54500d56cae6</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-18-0836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-18-0836%26sid%3Dliteratum%253Aachs%26aulast%3DHumphries%26aufirst%3DB.%2BA.%26aulast%3DBuschhaus%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DY.-C.%26aulast%3DHaley%26aufirst%3DH.%2BR.%26aulast%3DQyli%26aufirst%3DT.%26aulast%3DChiang%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DN.%26aulast%3DRajendran%26aufirst%3DS.%26aulast%3DCutter%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DY.-H.%26aulast%3DChen%26aufirst%3DY.-T.%26aulast%3DCong%26aufirst%3DJ.%26aulast%3DSpinosa%26aufirst%3DP.%2BC.%26aulast%3DYoon%26aufirst%3DE.%26aulast%3DLuker%26aufirst%3DK.%2BE.%26aulast%3DLuker%26aufirst%3DG.%2BD.%26atitle%3DPlasminogen%2520activator%2520inhibitor%25201%2520%2528PAI1%2529%2520promotes%2520actin%2520cytoskeleton%2520reorganization%2520and%2520glycolytic%2520metabolism%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D5%26spage%3D1142%26epage%3D1154%26doi%3D10.1158%2F1541-7786.MCR-18-0836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2018.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ebiom.2018.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30651219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3cjit1Wksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=263-275&author=C.+Y.+Liuauthor=T.+T.+Huangauthor=Y.+T.+Chenauthor=J.+L.+Chenauthor=P.+Y.+Chuauthor=C.+T.+Huangauthor=W.+L.+Wangauthor=K.+Y.+Lauauthor=M.+S.+Daiauthor=C.+W.+Shiauauthor=L.+M.+Tseng&title=Targeting+SET+to+restore+PP2A+activity+disrupts+an+oncogenic+CIP2A-feedforward+loop+and+impairs+triple+negative+breast+cancer+progression&doi=10.1016%2Fj.ebiom.2018.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression</span></div><div class="casAuthors">Liu Chun-Yu; Huang Tzu-Ting; Chen Ji-Lin; Chen Yi-Ting; Lau Ka-Yi; Chu Pei-Yi; Huang Chun-Teng; Wang Wan-Lun; Dai Ming-Shen; Shiau Chung-Wai; Tseng Ling-Ming</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263-275</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancer (TNBC) remains difficult to be targeted.  SET and cancerous inhibitor of protein phosphatase 2A (CIP2A) are intrinsic protein-interacting inhibitors of protein phosphatase 2A (PP2A) and frequently overexpressed in cancers, whereas reactivating PP2A activity has been postulated as an anti-cancer strategy.  Here we explored this strategy in TNBC.  METHODS:  Data from The Cancer Genome Atlas (TCGA) database was analyzed.  TNBC cell lines were used for in vitro studies.  Cell viability was examined by MTT assay.  The apoptotic cells were examined by flow cytometry and Western blot.  A SET-PP2A protein-protein interaction antagonist TD19 was used to disrupt signal transduction.  In vivo efficacy of TD19 was tested in MDA-MB-468-xenografted animal model.  FINDINGS:  TCGA data revealed upregulation of SET and CIP2A and positive correlation of these two gene expressions in TNBC tumors.  Ectopic SET or CIP2A increased cell viability, migration, and invasion of TNBC cells.  Notably ERK inhibition increased PP2A activity.  ERK activation is known crucial for Elk-1 activity, a transcriptional factor regulating CIP2A expression, we hypothesized an oncogenic feedforward loop consisting of pERK/pElk-1/CIP2A/PP2A.  This loop was validated by knockdown of PP2A and ectopic expression of Elk-1, showing reciprocal changes in loop members.  In addition, ectopic expression of SET increased pAkt, pERK, pElk-1 and CIP2A expressions, suggesting a positive linkage between SET and CIP2A signaling.  Moreover, TD19 disrupted this CIP2A-feedforward loop by restoring PP2A activity, demonstrating in vitro and in vivo anti-cancer activity.  Mechanistically, TD19 downregulated CIP2A mRNA via inhibiting pERK-mediated Elk-1 nuclear translocation thereby decreased Elk-1 binding to the CIP2A promoter.  INTERPRETATION:  These findings suggested that a novel oncogenic CIP2A-feedforward loop contributes to TNBC progression and targeting SET to disrupt this oncogenic CIP2A loop showed therapeutic potential in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxAmj6DAngMZNiNltV31zlfW6udTcc2eZoIJ9W_gTqsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjit1Wksg%253D%253D&md5=03b080b2050c976220e2466b807398a5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2018.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2018.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DChen%26aufirst%3DJ.%2BL.%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DLau%26aufirst%3DK.%2BY.%26aulast%3DDai%26aufirst%3DM.%2BS.%26aulast%3DShiau%26aufirst%3DC.%2BW.%26aulast%3DTseng%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520SET%2520to%2520restore%2520PP2A%2520activity%2520disrupts%2520an%2520oncogenic%2520CIP2A-feedforward%2520loop%2520and%2520impairs%2520triple%2520negative%2520breast%2520cancer%2520progression%26jtitle%3DEBioMedicine%26date%3D2019%26volume%3D40%26spage%3D263%26epage%3D275%26doi%3D10.1016%2Fj.ebiom.2018.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span> <span> </span><span class="NLM_article-title">FGFR3 signaling and function in triple negative breast cancer</span>. <i>Cell Commun. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.1186/s12964-019-0486-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs12964-019-0486-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31987043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVGiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=13&issue=1&author=N.+J.+Chewauthor=E.+V.+Nguyenauthor=S.-P.+Suauthor=K.+Novyauthor=H.+C.+Chanauthor=L.+K.+Nguyenauthor=J.+Luuauthor=K.+J.+Simpsonauthor=R.+S.+Leeauthor=R.+J.+Daly&title=FGFR3+signaling+and+function+in+triple+negative+breast+cancer&doi=10.1186%2Fs12964-019-0486-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR3 signaling and function in triple negative breast cancer</span></div><div class="casAuthors">Chew, Nicole J.; Nguyen, Elizabeth V.; Su, Shih-Ping; Novy, Karel; Chan, Howard C.; Nguyen, Lan K.; Luu, Jennii; Simpson, Kaylene J.; Lee, Rachel S.; Daly, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Communication and Signaling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13</span>CODEN:
                <span class="NLM_cas:coden">CCSEC6</span>;
        ISSN:<span class="NLM_cas:issn">1478-811X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">High FGFR3 expression and phosphorylation were detected in SUM185PE cells, which harbor a FGFR3-TACC3 gene fusion.  Low FGFR3 phosphorylation was detected in CAL51, MFM-223 and MDA-MB-231 cells.  In SUM185PE cells, the FGFR3-TACC3 fusion protein contributed the majority of phosphorylated FGFR3, and largely localized to the cytoplasm and plasma membrane, with staining at the mitotic spindle in a small subset of cells.  Knockdown of the FGFR3-TACC3 fusion and wildtype FGFR3 in SUM185PE cells decreased FRS2, AKT and ERK phosphorylation, and induced cell death.  Knockdown of wildtype FGFR3 resulted in only a trend for decreased proliferation.  PD173074 significantly decreased FRS2, AKT and ERK activation, and reduced SUM185PE cell proliferation.  Cyclin A and pRb were also decreased in the presence of PD173074, while cleaved PARP was increased, indicating cell cycle arrest in G1 phase and apoptosis.  Knockdown of FGFR3 in CAL51, MFM-223 and MDA-MB-231 cells had no significant effect on cell proliferation.  Interrogation of public datasets revealed that increased FGFR3 expression in breast cancer was significantly assocd. with reduced overall survival, and that potentially oncogenic FGFR3 alterations (eg mutation and amplification) occur in the TNBC/basal, luminal A and luminal B subtypes, but are rare.  These results indicate that targeting FGFR3 may represent a therapeutic option for TNBC, but only for patients with oncogenic FGFR3 alterations, such as the FGFR3-TACC3 fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTYd7FrDSY2LVg90H21EOLACvtfcHk0ljMtfYzvlisUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVGiuro%253D&md5=772fa1a7760de1c2227b6f30092491cf</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1186%2Fs12964-019-0486-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12964-019-0486-4%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DN.%2BJ.%26aulast%3DNguyen%26aufirst%3DE.%2BV.%26aulast%3DSu%26aufirst%3DS.-P.%26aulast%3DNovy%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DH.%2BC.%26aulast%3DNguyen%26aufirst%3DL.%2BK.%26aulast%3DLuu%26aufirst%3DJ.%26aulast%3DSimpson%26aufirst%3DK.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BS.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DFGFR3%2520signaling%2520and%2520function%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DCell%2520Commun.%2520Signaling%26date%3D2020%26volume%3D18%26issue%3D1%26spage%3D13%26doi%3D10.1186%2Fs12964-019-0486-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gari, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGala, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucia, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. R.</span></span> <span> </span><span class="NLM_article-title">PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2016.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27452906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eju7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2016&pages=505-512&issue=2&author=H.+H.+Gariauthor=G.+D.+DeGalaauthor=R.+Rayauthor=M.+S.+Luciaauthor=J.+R.+Lambert&title=PRL-3+engages+the+focal+adhesion+pathway+in+triple-negative+breast+cancer+cells+to+alter+actin+structure+and+substrate+adhesion+properties+critical+for+cell+migration+and+invasion&doi=10.1016%2Fj.canlet.2016.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion</span></div><div class="casAuthors">Gari, Hamid H.; DeGala, Gregory D.; Ray, Rahul; Lucia, M. Scott; Lambert, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">505-512</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBCs) are among the most aggressive cancers characterized by a high propensity to invade, metastasize and relapse.  We previously reported that the TNBC-specific inhibitor, AMPI-109, significantly impairs the ability of TNBC cells to migrate and invade by reducing levels of the metastasis-promoting phosphatase, PRL-3.  Here, we examd. the mechanisms by which AMPI-109 and loss of PRL-3 impede cell migration and invasion.  AMPI-109 treatment or knock down of PRL-3 expression were assocd. with deactivation of Src and ERK signaling and concomitant downregulation of RhoA and Rac1/2/3 GTPase protein levels.  These cellular changes led to rearranged filamentous actin networks necessary for cell migration and invasion.  Conversely, overexpression of PRL-3 promoted TNBC cell invasion by upregulating matrix metalloproteinase 10, which resulted in increased TNBC cell adherence to, and degrdn. of, the major basement membrane component laminin.  Our data demonstrate that PRL-3 engages the focal adhesion pathway in TNBC cells as a key mechanism for promoting TNBC cell migration and invasion.  Collectively, these data suggest that blocking PRL-3 activity may be an effective method for reducing the metastatic potential of TNBC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGookcrOakjR7LVg90H21EOLACvtfcHk0ljMtfYzvlisUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eju7%252FK&md5=33ecc31aad335837607772f742dc5ce9</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DGari%26aufirst%3DH.%2BH.%26aulast%3DDeGala%26aufirst%3DG.%2BD.%26aulast%3DRay%26aufirst%3DR.%26aulast%3DLucia%26aufirst%3DM.%2BS.%26aulast%3DLambert%26aufirst%3DJ.%2BR.%26atitle%3DPRL-3%2520engages%2520the%2520focal%2520adhesion%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520to%2520alter%2520actin%2520structure%2520and%2520substrate%2520adhesion%2520properties%2520critical%2520for%2520cell%2520migration%2520and%2520invasion%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D380%26issue%3D2%26spage%3D505%26epage%3D512%26doi%3D10.1016%2Fj.canlet.2016.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.01.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2019.01.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30707920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2qur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2019&pages=11-19&author=S.+Fuauthor=X.+Chenauthor=H.+W.+Loauthor=J.+Lin&title=Combined+bazedoxifene+and+paclitaxel+treatments+inhibit+cell+viability%2C+cell+migration%2C+colony+formation%2C+and+tumor+growth+and+induce+apoptosis+in+breast+cancer&doi=10.1016%2Fj.canlet.2019.01.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer</span></div><div class="casAuthors">Fu, Shengling; Chen, Xiang; Lo, Hui-Wen; Lin, Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Breast cancer, esp. triple-neg. breast cancer (TNBC), has limited treatment options.  We repurposed the FDA-approved drug bazedoxifene as a novel inhibitor of interleukin 6/glycoprotein 130 signaling.  In this study, we investigated the inhibitory effects of bazedoxifene alone or in combination with paclitaxel on several estrogen receptor pos. and TNBC cells.  Bazedoxifene inhibited the cell viability of these cells, as well as tumor growth of TNBC cells in a xenograft tumor model.  Furthermore, bazedoxifene combined with paclitaxel exhibited more potent inhibition of cell viability, colony formation, and cell migration and induced more apoptosis in vitro, and generated stronger inhibition of tumor growth of TNBC in vivo than either drug alone.  Western blotting showed that bazedoxifene inhibited estrogen receptor pos. breast cancer cells by suppressing the expression of estrogen receptor, Cyclin D1, p-P70S6K, Survivin, c-Myc, and Bcl-2, and bazedoxifene inhibited TNBC cells by inhibiting the expression of phosphorylated STAT3 (Tyr705), Cyclin D1, p-P70S6K, c-Myc, p-AKT (Ser473) and p-ERK 1/2 (T202/Y204) without changing the expression of total STAT3.  When combined with paclitaxel, bazedoxifene may be a potential small mol. for the treatment of both estrogen receptor pos. and triple-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrxFrVJz_HPLVg90H21EOLACvtfcHk0lj3fTTeqEBAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2qur8%253D&md5=94beee09dca36656ea9b922b0aba0d16</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.01.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.01.026%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLo%26aufirst%3DH.%2BW.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DCombined%2520bazedoxifene%2520and%2520paclitaxel%2520treatments%2520inhibit%2520cell%2520viability%252C%2520cell%2520migration%252C%2520colony%2520formation%252C%2520and%2520tumor%2520growth%2520and%2520induce%2520apoptosis%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D448%26spage%3D11%26epage%3D19%26doi%3D10.1016%2Fj.canlet.2019.01.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvet, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godwin, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">326</span>, <span class="refDoi"> DOI: 10.1038/s41419-018-0347-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41419-018-0347-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29487338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1MrlvF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=326&issue=3&author=L.+X.+Liauthor=J.+X.+Zhouauthor=J.+P.+Calvetauthor=A.+K.+Godwinauthor=R.+A.+Jensenauthor=X.+Li&title=Lysine+methyltransferase+SMYD2+promotes+triple+negative+breast+cancer+progression&doi=10.1038%2Fs41419-018-0347-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression</span></div><div class="casAuthors">Li Linda Xiaoyan; Zhou Julie Xia; Li Xiaogang; Calvet James P; Li Xiaogang; Calvet James P; Li Xiaogang; Godwin Andrew K; Jensen Roy A</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">326</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We identified SMYD2, a SMYD (SET and MYND domain) family protein with lysine methyltransferase activity, as a novel breast cancer oncogene.  SMYD2 was expressed at significantly higher levels in breast cancer cell lines and in breast tumor tissues.  Silencing of SMYD2 by RNAi in triple-negative breast cancer (TNBC) cell lines or inhibition of SMYD2 with its specific inhibitor, AZ505, significantly reduced tumor growth in vivo.  SMYD2 executes this activity via methylation and activation of its novel non-histone substrates, including STAT3 and the p65 subunit of NF-κB, leading to increased TNBC cell proliferation and survival.  There are cross-talk and synergistic effects among SMYD2, STAT3, and NF-κB in TNBC cells, in that STAT3 can contribute to the modification of NF-κB p65 subunit post-translationally by recruitment of SMYD2, whereas the p65 subunit of NF-κB can also contribute to the modification of STAT3 post-translationally by recruitment of SMYD2, leading to methylation and activation of STAT3 and p65 in these cells.  The expression of SMYD2 can be upregulated by IL-6-STAT3 and TNFα-NF-κB signaling, which integrates epigenetic regulation to inflammation in TNBC development.  In addition, we have identified a novel SMYD2 transcriptional target gene, PTPN13, which links SMYD2 to other known breast cancer associated signaling pathways, including ERK, mTOR, and Akt signaling via PTPN13 mediated phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3Ul-MwFVF_Wx8TEN9K18QfW6udTcc2eaFGG8lY0GDuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrlvF2rtg%253D%253D&md5=fc4f3435b5090f2631b9e595ad319d45</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-0347-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-0347-x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%2BX.%26aulast%3DZhou%26aufirst%3DJ.%2BX.%26aulast%3DCalvet%26aufirst%3DJ.%2BP.%26aulast%3DGodwin%26aufirst%3DA.%2BK.%26aulast%3DJensen%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DLysine%2520methyltransferase%2520SMYD2%2520promotes%2520triple%2520negative%2520breast%2520cancer%2520progression%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D326%26doi%3D10.1038%2Fs41419-018-0347-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ejmech.2017.08.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28923383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=155-171&author=D.+Yaoauthor=Y.+Zhouauthor=L.+Zhuauthor=L.+Ouyangauthor=J.+Zhangauthor=Y.+Jiangauthor=Y.+Zhaoauthor=D.+Sunauthor=S.+Yangauthor=Y.+Yuauthor=J.+Wang&title=Design%2C+synthesis+and+structure-activity+relationship+studies+of+a+focused+library+of+pyrimidine+moiety+with+anti-proliferative+and+anti-metastasis+activities+in+triple+negative+breast+cancer&doi=10.1016%2Fj.ejmech.2017.08.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer</span></div><div class="casAuthors">Yao, Dahong; Zhou, Yuxin; Zhu, Lingjuan; Ouyang, Liang; Zhang, Jin; Jiang, Yingnan; Zhao, Yuqian; Sun, Dejuan; Yang, Shilin; Yu, Yang; Wang, Jinhui</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-171</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this study, based on the structural features of type II kinase inhibitors, a focused library of 41 pyrimidine derivs. possessing potent anti-proliferative activity was designed and synthesized, Y29 showed the most potent activity against MDA-MB-231 cells.  Subsequently, target prediction, homol. modeling, mol. docking, dynamics simulation and detn. of enzymic activity was carried out.  The results suggested that PDGFR-β was its potential target.  In vitro expts. revealed that Y29 attenuated metastasis by PDGFR-β inhibition-induced autophagy and could enhance autophagy-related cell death through AKT-MAPK feedback loop in MDA-MB-231 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQIVq8UJHpX7Vg90H21EOLACvtfcHk0lj3fTTeqEBAfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsLvI&md5=50571d1957b99e2de04fa9d747c20276</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.067%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520a%2520focused%2520library%2520of%2520pyrimidine%2520moiety%2520with%2520anti-proliferative%2520and%2520anti-metastasis%2520activities%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D140%26spage%3D155%26epage%3D171%26doi%3D10.1016%2Fj.ejmech.2017.08.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. H.</span></span> <span> </span><span class="NLM_article-title">Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1250</span>, <span class="refDoi"> DOI: 10.1038/aps.2016.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Faps.2016.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27397540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCgsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1237-1250&issue=9&author=Y.+Q.+Zhaoauthor=Y.+Q.+Yinauthor=J.+Liuauthor=G.+H.+Wangauthor=J.+Huangauthor=L.+J.+Zhuauthor=J.+H.+Wang&title=Characterization+of+HJ-PI01+as+a+novel+Pim-2+inhibitor+that+induces+apoptosis+and+autophagic+cell+death+in+triple-negative+human+breast+cancer&doi=10.1038%2Faps.2016.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer</span></div><div class="casAuthors">Zhao, Yu-qian; Yin, Yi-qiong; Liu, Jie; Wang, Gui-hua; Huang, Jian; Zhu, Ling-juan; Wang, Jin-hui</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1237-1250</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: Pim-2 is a short-lived serine/threonine kinase, which plays a key role in metastasis of breast cancer through persistent activation of STAT3.  Although the crystal structure of Pim-2 has been reported, but thus far no specific Pim-2-targeted compds. have been reported.  In this study, we identified a novel Pim-2 inhibitor, HJ-PI01, by in silico anal. and exptl. validation.  Methods: The protein-protein interaction (PPI) network, chem. synthesis, mol. docking, and mol. dynamics (MD) simulations were used to design and discover the new Pim-2 inhibitor HJ-PI01.  The anti-tumor effects of HJ-PI01 were evaluated in human breast MDA-MB-231, MDA-MB-468, MDA-MB-436, MCF-7 cells in vitro and in MDA-MB-231 xenograft mice, which were treated with HJ-PI01 (40 mg·kg-1·d-1, ig) with or without lienal polypeptide (50 mg·kg-1·d-1, i.p.) for 10 d.  The apoptosis/autophage-inducing mechanisms of HJ-PI01 were elucidated using Western blots, immunoblots, flow cytometry, transmission electron microscopy and fluorescence microscopy.  Results: Based on the PrePPI network, the potential partners interacting with Pim-2 in regulating apoptosis (160 protein pairs) and autophagy (47 protein pairs) were identified.  Based on the structural characteristics of Pim-2, a total of 15 compds. (HJ-PI01 to HJ-P015) were synthesized, which showed moderate or remarkable anti-proliferative potency in the human breast cancer cell lines tested.  The most effective compd. HJ-PI01 exerted a robust inhibition on MDA-MB-231 cells compared with chlorpromazine and the pan-Pim inhibitor PI003.  Mol. dynamics (MD) simulation revealed that HJ-PI01 had a good binding score with Pim-2.  Moreover, HJ-PI01 (300 nmol/L) induced death receptor-dependent and mitochondrial apoptosis as well as autophagic death in MDA-MB-231 cells.  In MDA-MB-231 xenograft mice, administration of HJ-PI01 remarkably inhibited the tumor growth and induced tumor cell apoptosis in vivo.  Co-administration of HJ-PI01 with lienal polypeptide could improve the anti-tumor activity of HJ-PI01 and reduce its toxicity.  Conclusion: The newly synthesized compd., HJ-PI01, can induce death receptor/mitochondrial apoptosis and autophagic cell death by targeting Pim-2 in human breast cancer cells in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdehhYe3J3SLVg90H21EOLACvtfcHk0lithPqxUGE7_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCgsbrF&md5=033fe94bf83b0cf1bf72edd7ade9ed72</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Faps.2016.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2016.60%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BQ.%26aulast%3DYin%26aufirst%3DY.%2BQ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%2BH.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26atitle%3DCharacterization%2520of%2520HJ-PI01%2520as%2520a%2520novel%2520Pim-2%2520inhibitor%2520that%2520induces%2520apoptosis%2520and%2520autophagic%2520cell%2520death%2520in%2520triple-negative%2520human%2520breast%2520cancer%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2016%26volume%3D37%26issue%3D9%26spage%3D1237%26epage%3D1250%26doi%3D10.1038%2Faps.2016.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Systematic network-based discovery of a Fam20C inhibitor (FL-1607) with apoptosis modulation in triple-negative breast cancer</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2108</span>– <span class="NLM_lpage">2118</span>, <span class="refDoi"> DOI: 10.1039/C6MB00111D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC6MB00111D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27113542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=2108-2118&issue=7&author=Z.+Qinauthor=P.+Wangauthor=X.+Liauthor=S.+Zhangauthor=M.+Tianauthor=Y.+Daiauthor=L.+Fu&title=Systematic+network-based+discovery+of+a+Fam20C+inhibitor+%28FL-1607%29+with+apoptosis+modulation+in+triple-negative+breast+cancer&doi=10.1039%2FC6MB00111D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic network-based discovery of a Fam20C inhibitor (FL-1607) with apoptosis modulation in triple-negative breast cancer</span></div><div class="casAuthors">Qin, Ziyi; Wang, Peiqi; Li, Xinyi; Zhang, Shouyue; Tian, Mao; Dai, Yi; Fu, Leilei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2108-2118</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Family with sequence similarity 20, member C (Fam20C) is a physiol. Golgi casein kinase that phosphorylates multiple secreted proteins.  Recently, it has been reported that Fam20C can be identified as a novel kinase target for therapeutic development.  Thus, inhibition of Fam20C will be a potential therapeutic strategy to prevent tumor cell progression and metastasis.  In our study, based upon the systems-biol. network, mol. modeling and mol. dynamics (MD) simulations, we discovered a novel Fam20C inhibitor (FL-1607) with potent anti-proliferative effects on triple-neg. breast cancer (TNBC) cells.  Subsequently, we found that this Fam20C inhibitor could induce apoptosis and inhibit cell migration in MDA-MB-468 cells.  Together, these findings would provide a new clue to the exploration of more novel Fam20C inhibitors for future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoKtN51oN0lbVg90H21EOLACvtfcHk0lithPqxUGE7_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKqu70%253D&md5=96dfd65f2ea8eda5af05a329639249ed</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1039%2FC6MB00111D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MB00111D%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DSystematic%2520network-based%2520discovery%2520of%2520a%2520Fam20C%2520inhibitor%2520%2528FL-1607%2529%2520with%2520apoptosis%2520modulation%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520BioSyst.%26date%3D2016%26volume%3D12%26issue%3D7%26spage%3D2108%26epage%3D2118%26doi%3D10.1039%2FC6MB00111D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2860</span>– <span class="NLM_lpage">2866</span>, <span class="refDoi"> DOI: 10.1039/C5MB00466G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC5MB00466G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26299935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWlt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=2860-2866&issue=11&author=L.+Zhangauthor=M.+Guoauthor=J.+Liauthor=Y.+Zhengauthor=S.+Zhangauthor=T.+Xieauthor=B.+Liu&title=Systems+biology-based+discovery+of+a+potential+Atg4B+agonist+%28Flubendazole%29+that+induces+autophagy+in+breast+cancer&doi=10.1039%2FC5MB00466G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer</span></div><div class="casAuthors">Zhang, Lan; Guo, Mingrui; Li, Jing; Zheng, Yaxin; Zhang, Shouyue; Xie, Tao; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2860-2866</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The aim of this study was to explore the autophagy-related protein 4B(ATG4B) and its targeted candidate agonist in triple-neg. breast cancer (TNBC) therapy.  In this study, the identification of Atg4B as a novel breast cancer target for screening candidate small mol. agonists was performed by phylogenetic anal., network construction, mol. modeling, mol. docking and mol. dynamics (MD) simulation.  In vitro, MTT assay, electron microscopy, western blot and ROS measurement were used for validating the efficacy of the candidate compds.  We used the phylogenetic anal. of Atg4B and constructed their protein-protein interaction (PPI) network.  Also, we screened target compds. of Atg4 proteins from Drugbank and ZINC.  Flubendazole was validated for its anti-proliferative efficacy in MDA-MB-231 cells.  Further MD simulation results supported the stable interaction between Flubendazole and Atg4B.  Moreover, Flubendazole induced autophagy and increased ROS prodn.  In conclusion, in silico anal. and exptl. validation together demonstrate that Flubendazole can target Atg4B in MDA-MB-231 cells and induce autophagy, which may shed light on the exploration of this compd. as a potential new Atg4B targeted drug for future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4pY16N3ASc7Vg90H21EOLACvtfcHk0lithPqxUGE7_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWlt73O&md5=f1e946be8d60619445e25a70fde2f7b8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1039%2FC5MB00466G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MB00466G%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DSystems%2520biology-based%2520discovery%2520of%2520a%2520potential%2520Atg4B%2520agonist%2520%2528Flubendazole%2529%2520that%2520induces%2520autophagy%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520BioSyst.%26date%3D2015%26volume%3D11%26issue%3D11%26spage%3D2860%26epage%3D2866%26doi%3D10.1039%2FC5MB00466G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vinet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maire, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monchecourt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Némati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesage, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescure, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meseure, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigaill, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Nery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman-Roman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, T.</span></span> <span> </span><span class="NLM_article-title">Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2414</span>– <span class="NLM_lpage">2428</span>, <span class="refDoi"> DOI: 10.1002/cam4.2114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fcam4.2114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30957988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVygsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=2414-2428&issue=5&author=M.+Vinetauthor=S.+Sureshauthor=V.+Maireauthor=C.+Monchecourtauthor=F.+N%C3%A9matiauthor=L.+Lesageauthor=F.+Pierreauthor=M.+Yeauthor=A.+Lescureauthor=A.+Brissonauthor=D.+Meseureauthor=A.+Nicolasauthor=G.+Rigaillauthor=E.+Marangoniauthor=E.+Del+Neryauthor=S.+Roman-Romanauthor=T.+Dubois&title=Protein+arginine+methyltransferase+5%3A+A+novel+therapeutic+target+for+triple-negative+breast+cancers&doi=10.1002%2Fcam4.2114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers</span></div><div class="casAuthors">Vinet, Mathilde; Suresh, Samyuktha; Maire, Virginie; Monchecourt, Clarisse; Nemati, Fariba; Lesage, Laetitia; Pierre, Fabienne; Ye, Mengliang; Lescure, Auriane; Brisson, Amelie; Meseure, Didier; Nicolas, Andre; Rigaill, Guillem; Marangoni, Elisabetta; Del Nery, Elaine; Roman-Roman, Sergio; Dubois, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2414-2428</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">TNBC is a highly heterogeneous and aggressive breast cancer subtype assocd. with high relapse rates, and for which no targeted therapy yet exists.  Protein arginine methyltransferase 5 (PRMT5), an enzyme which catalyzes the methylation of arginines on histone and non-histone proteins, has recently emerged as a putative target for cancer therapy.  Potent and specific PRMT5 inhibitors have been developed, but the therapeutic efficacy of PRMT5 targeting in TNBC has not yet been demonstrated.  Here, we examine the expression of PRMT5 in a human breast cancer cohort obtained from the Institut Curie, and evaluate the therapeutic potential of pharmacol. inhibition of PRMT5 in TNBC.  We find that PRMT5 mRNA and protein are expressed at comparable levels in TNBC, luminal breast tumors, and healthy mammary tissues.  However, immunohistochem. analyzes reveal that PRMT5 is differentially localized in TNBC compared to other breast cancer subtypes and to normal breast tissues.  PRMT5 is heterogeneously expressed in TNBC and high PRMT5 expression correlates with poor prognosis within this breast cancer subtype.  Using the small-mol. inhibitor EPZ015666, we show that PRMT5 inhibition impairs cell proliferation in a subset of TNBC cell lines.  PRMT5 inhibition triggers apoptosis, regulates cell cycle progression and decreases mammosphere formation.  Furthermore, EPZ015666 administration to a patient-derived xenograft model of TNBC significantly deters tumor progression.  Finally, we reveal potentiation between EGFR and PRMT5 targeting, suggestive of a beneficial combination therapy.  Our findings highlight a distinctive subcellular localization of PRMT5 in TNBC, and uphold PRMT5 targeting, alone or in combination, as a relevant treatment strategy for a subset of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDMfM3UVd7aLVg90H21EOLACvtfcHk0lgtXek9vFyemg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVygsbbN&md5=4a0496027be8d085828ba4bfa98531f6</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1002%2Fcam4.2114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.2114%26sid%3Dliteratum%253Aachs%26aulast%3DVinet%26aufirst%3DM.%26aulast%3DSuresh%26aufirst%3DS.%26aulast%3DMaire%26aufirst%3DV.%26aulast%3DMonchecourt%26aufirst%3DC.%26aulast%3DN%25C3%25A9mati%26aufirst%3DF.%26aulast%3DLesage%26aufirst%3DL.%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DLescure%26aufirst%3DA.%26aulast%3DBrisson%26aufirst%3DA.%26aulast%3DMeseure%26aufirst%3DD.%26aulast%3DNicolas%26aufirst%3DA.%26aulast%3DRigaill%26aufirst%3DG.%26aulast%3DMarangoni%26aufirst%3DE.%26aulast%3DDel%2BNery%26aufirst%3DE.%26aulast%3DRoman-Roman%26aufirst%3DS.%26aulast%3DDubois%26aufirst%3DT.%26atitle%3DProtein%2520arginine%2520methyltransferase%25205%253A%2520A%2520novel%2520therapeutic%2520target%2520for%2520triple-negative%2520breast%2520cancers%26jtitle%3DCancer%2520Med.%26date%3D2019%26volume%3D8%26issue%3D5%26spage%3D2414%26epage%3D2428%26doi%3D10.1002%2Fcam4.2114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, S. Y.</span></span> <span> </span><span class="NLM_article-title">TRPC3 regulates the proliferation and apoptosis resistance of triple negative breast cancer cells through the TRPC3/RASA4/MAPK pathway</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">558</span>, <span class="refDoi"> DOI: 10.3390/cancers11040558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers11040558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlKk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=558&issue=4&author=Y.+Wangauthor=Y.+X.+Qiauthor=Z.+Qiauthor=S.+Y.+Tsang&title=TRPC3+regulates+the+proliferation+and+apoptosis+resistance+of+triple+negative+breast+cancer+cells+through+the+TRPC3%2FRASA4%2FMAPK+pathway&doi=10.3390%2Fcancers11040558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">TRPC3 regulates the proliferation and apoptosis resistance of triple negative breast cancer cells through the TRPC3/RASA4/MAPK pathway</span></div><div class="casAuthors">Wang, Yan; Qi, Yan-Xiang; Qi, Zenghua; Tsang, Suk-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">558</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Currently, there is no effective mol.-based therapy for triple-neg. breast cancer (TNBC).  Canonical transient receptor potential isoform 3 (TRPC3) was previously shown to be upregulated in breast cancer biopsy tissues when compared to normal breast tissues.  However, the biol. role of TRPC3 in breast cancer still remains to be elucidated.  In this study, subcellular fractionation followed byWestern blot and immunocytochem. showed that TRPC3 was over-expressed on the plasma membrane of TNBC line MDA-MB-231 when compared to an estrogen receptor-pos. cell line MCF-7.  TRPC3 blocker Pyr3 and dominant neg. of TRPC3 attenuated proliferation, induced apoptosis and sensitized cell death to chemotherapeutic agents in MDA-MB-231 as measured by proliferation assays.  Interestingly, Ras GTPase-activating protein 4 (RASA4), a Ca2+-promoted Ras-MAPK pathway suppressor, was found to be located on the plasma membrane of MDA-MB-231.  Blocking TRPC3 decreased the amt. of RASA4 located on the plasma membrane, with concomitant activation of MAPK pathways.  Our results suggest that, in TNBC MDA-MB-231 cells, Ca2+ influx through TRPC3 channel sustains the presence of RASA4 on the plasma membrane where it inhibits the Ras-MAPK pathway, leading to proliferation and apoptosis resistance.  Our study reveals the novel TRPC3-RASA4-MAPK signaling cascade in TNBC cells and suggests that TRPC3 may be exploited as a potential therapeutic target for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg5SkGYp4s7rVg90H21EOLACvtfcHk0lgtXek9vFyemg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlKk&md5=eb4e31ee71c1287f1429e9eb94f1bb7e</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.3390%2Fcancers11040558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11040558%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%2BX.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DTsang%26aufirst%3DS.%2BY.%26atitle%3DTRPC3%2520regulates%2520the%2520proliferation%2520and%2520apoptosis%2520resistance%2520of%2520triple%2520negative%2520breast%2520cancer%2520cells%2520through%2520the%2520TRPC3%252FRASA4%252FMAPK%2520pathway%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D4%26spage%3D558%26doi%3D10.3390%2Fcancers11040558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">PIM1: a promising target in patients with triple-negative breast cancer</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">142</span>, <span class="refDoi"> DOI: 10.1007/s12032-017-0998-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs12032-017-0998-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28721678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1cjovFKgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=142&issue=8&author=W.+Zhaoauthor=R.+Qiuauthor=P.+Liauthor=J.+Yang&title=PIM1%3A+a+promising+target+in+patients+with+triple-negative+breast+cancer&doi=10.1007%2Fs12032-017-0998-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">PIM1: a promising target in patients with triple-negative breast cancer</span></div><div class="casAuthors">Zhao Wen; Qiu RuiYue; Li Pan; Yang Jin</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">142</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancers (TNBCs) have poor prognosis, and chemotherapy remains the mainstay of therapy because of lack of discovered possible target.  MYC were found overexpressed in TNBCs compared with other subtypes and especially in those resistant to chemotherapy, but the inhibition has been challenging to achieve.  Recently, the cooperation of PIM1 and MYC was identified involved in cell proliferation, migration and apoptosis of TNBCs, which has been reported in hematological malignancy and prostatic cancer.  Inhibition of PIM1 can promote the apoptosis of tumor cells and enhance sensitivity to chemotherapy.  Notably, PIM1-null mice develop normally and are fertile, suggesting the side effects can be tolerated.  Thus, PIM1 may be a promising target in TNBCs and further investigation, both in vivo and in vitro, needs to be carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrLLHJPYqPm9bHMBt0mMIXfW6udTcc2eaOAGBwd__2S7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjovFKgsw%253D%253D&md5=f6943a0de1f0b867bc16dc99abf70c48</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs12032-017-0998-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-017-0998-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DPIM1%253A%2520a%2520promising%2520target%2520in%2520patients%2520with%2520triple-negative%2520breast%2520cancer%26jtitle%3DMed.%2520Oncol.%26date%3D2017%26volume%3D34%26issue%3D8%26spage%3D142%26doi%3D10.1007%2Fs12032-017-0998-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schech, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1857</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-14-0778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26037781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1yrs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1848-1857&issue=8&author=A.+Schechauthor=A.+Kaziauthor=S.+Yuauthor=P.+Shahauthor=G.+Sabnis&title=Histone+deacetylase+inhibitor+entinostat+inhibits+tumor-initiating+cells+in+triple-negative+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-14-0778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells</span></div><div class="casAuthors">Schech, Amanda; Kazi, Armina; Yu, Stephen; Shah, Preeti; Sabnis, Gauri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1857</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mortality following breast cancer diagnosis is mainly due to the development of distant metastasis.  To escape from the primary site, tumor cells undergo the epithelial-to-mesenchymal transition (EMT), which helps them acquire a more motile and invasive phenotype.  In our previous study, we showed that class I selective HDAC inhibitor entinostat reverses the EMT phenotype through reversal of epigenetic repression of E-cadherin.  Recent evidence suggests that a subset of cells within a breast tumor may drive the metastatic outgrowth following escape from the primary site.  These cells, termed tumor-initiating cells (TIC), represent a great threat to overall prognosis.  They are crit. in terms of drug resistance and tumor initiation at metastatic sites.  Acquisition of EMT traits has also been shown to impart TIC phenotype to the cells, making EMT a "dual-threat" for prognosis.  In the current study, we show that entinostat treatment can reduce the percentage of TIC cells from triple-neg. breast cancer (TNBC) cells.  Entinostat treatment was able to reduce the CD44high/CD24low cell population, ALDH-1 activity, as well as protein and mRNA expression of known TIC markers such as Bmi-1, Nanog, and Oct-4.  Next, we inoculated MDA-MB-231 cells transfected with firefly luciferase (231/Luc) in mammary fat pad of NSG mice.  The mice were then treated with entinostat (2.5 mg/kg/d), and tumor development and formation of metastasis were assessed by bioluminescence imaging.  Treatment with entinostat significantly reduced tumor formation at the primary site as well as lung metastasis.  As such, entinostat may help prevent development of distant metastasis.  Mol Cancer Ther; 14(8); 1848-57. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRu0jMR4ckFrVg90H21EOLACvtfcHk0li6-yRN6AAesQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1yrs7vF&md5=0a68c2c5bdfd03939c216a59987fc8bd</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0778%26sid%3Dliteratum%253Aachs%26aulast%3DSchech%26aufirst%3DA.%26aulast%3DKazi%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DSabnis%26aufirst%3DG.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520entinostat%2520inhibits%2520tumor-initiating%2520cells%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D8%26spage%3D1848%26epage%3D1857%26doi%3D10.1158%2F1535-7163.MCT-14-0778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ralff, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, C. L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küçükkase, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oster, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span> <span> </span><span class="NLM_article-title">ONC201 demonstrates antitumor effects in both triple-negative and non–triple-negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-17-0121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28424227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSms7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1290-1298&issue=7&author=M.+D.+Ralffauthor=C.+L.+B.+Klineauthor=O.+C.+K%C3%BC%C3%A7%C3%BCkkaseauthor=J.+Wagnerauthor=B.+Limauthor=D.+T.+Dickerauthor=V.+V.+Prabhuauthor=W.+Osterauthor=W.+S.+El-Deiry&title=ONC201+demonstrates+antitumor+effects+in+both+triple-negative+and+non%E2%80%93triple-negative+breast+cancers+through+TRAIL-dependent+and+TRAIL-independent+mechanisms&doi=10.1158%2F1535-7163.MCT-17-0121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms</span></div><div class="casAuthors">Ralff, Marie D.; Kline, Christina L. B.; Kucukkase, Ozan C.; Wagner, Jessica; Lim, Bora; Dicker, David T.; Prabhu, Varun V.; Oster, Wolfgang; El-Deiry, Wafik S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1290-1298</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Breast cancer is a major cause of cancer-related death.  TNF-related apoptosis-inducing ligand (TRAIL) has been of interest as a cancer therapeutic, but only a subset of triple-neg. breast cancers (TNBC) is sensitive to TRAIL.  The small-mol. ONC201 induces expression of TRAIL and its receptor DR5.  ONC201 has entered clin. trials in advanced cancers.  Here, we show that ONC201 is efficacious against both TNBC and non-TNBC cells (n = 13).  A subset of TNBC and non-TNBC cells succumbs to ONC201-induced cell death.  In 2 of 8 TNBC cell lines, ONC201 treatment induces caspase-8 cleavage and cell death that is blocked by TRAIL-neutralizing antibody RIK2.  The proapoptotic effect of ONC201 translates to in vivo efficacy in the MDA-MB-468 xenograft model.  In most TNBC lines tested (6/8), ONC201 has an antiproliferative effect but does not induce apoptosis.  ONC201 decreases cyclin D1 expression and causes an accumulation of cells in the G1 phase of the cell cycle. pRb expression is assocd. with sensitivity to the antiproliferative effects of ONC201, and the compd. synergizes with taxanes in less sensitive cells.  All non-TNBC cells (n = 5) are growth inhibited following ONC201 treatment, and unlike what has been obsd. with TRAIL, a subset (n = 2) shows PARP cleavage.  In these cells, cell death induced by ONC201 is TRAIL independent.  Our data demonstrate that ONC201 has potent antiproliferative and proapoptotic effects in a broad range of breast cancer subtypes, through TRAIL-dependent and TRAIL-independent mechanisms.  These findings develop a preclin. rationale for developing ONC201 as a single agent and/or in combination with approved therapies in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp033TAP6-qX7Vg90H21EOLACvtfcHk0li6-yRN6AAesQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSms7rI&md5=551c67303e5d5066e20424f04c329cfc</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0121%26sid%3Dliteratum%253Aachs%26aulast%3DRalff%26aufirst%3DM.%2BD.%26aulast%3DKline%26aufirst%3DC.%2BL.%2BB.%26aulast%3DK%25C3%25BC%25C3%25A7%25C3%25BCkkase%26aufirst%3DO.%2BC.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DDicker%26aufirst%3DD.%2BT.%26aulast%3DPrabhu%26aufirst%3DV.%2BV.%26aulast%3DOster%26aufirst%3DW.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26atitle%3DONC201%2520demonstrates%2520antitumor%2520effects%2520in%2520both%2520triple-negative%2520and%2520non%25E2%2580%2593triple-negative%2520breast%2520cancers%2520through%2520TRAIL-dependent%2520and%2520TRAIL-independent%2520mechanisms%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D7%26spage%3D1290%26epage%3D1298%26doi%3D10.1158%2F1535-7163.MCT-17-0121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Adorno, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2687</span>– <span class="NLM_lpage">2699</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-15-0096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26443806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2687-2699&issue=12&author=K.+Kaiauthor=K.+Kondoauthor=X.+Wangauthor=X.+Xieauthor=M.+K.+Pitnerauthor=M.+E.+Reyesauthor=A.+M.+Torres-Adornoauthor=H.+Masudaauthor=G.+N.+Hortobagyiauthor=C.+Bartholomeuszauthor=H.+Sayaauthor=D.+Tripathyauthor=S.+Senauthor=N.+T.+Ueno&title=Antitumor+activity+of+KW-2450+against+triple-negative+breast+cancer+by+inhibiting+Aurora+A+and+B+kinases&doi=10.1158%2F1535-7163.MCT-15-0096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases</span></div><div class="casAuthors">Kai, Kazuharu; Kondo, Kimie; Wang, Xiaoping; Xie, Xuemei; Pitner, Mary K.; Reyes, Monica E.; Torres-Adorno, Angie M.; Masuda, Hiroko; Hortobagyi, Gabriel N.; Bartholomeusz, Chandra; Saya, Hideyuki; Tripathy, Debu; Sen, Subrata; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2687-2699</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Currently, no targeted drug is available for triple-neg. breast cancer (TNBC), an aggressive breast cancer that does not express estrogen receptor, progesterone receptor, or HER2.  TNBC has high mitotic activity, and, because Aurora A and B mitotic kinases drive cell division and are overexpressed in tumors with a high mitotic index, we hypothesized that inhibiting Aurora A and B produces a significant antitumor effect in TNBC.  We tested this hypothesis by detg. the antitumor effects of KW-2450, a multikinase inhibitor of both Aurora A and B kinases.  We obsd. significant inhibitory activities of KW-2450 on cell viability, apoptosis, colony formation in agar, and mammosphere formation in TNBC cells.  The growth of TNBC xenografts was significantly inhibited with KW-2450.  In cell-cycle anal., KW-2450 induced tetraploid accumulation followed by apoptosis or surviving octaploid (8N) cells, depending on dose.  These phenotypes resembled those of Aurora B knockdown and complete pharmaceutical inhibition of Aurora A.  We demonstrated that 8N cells resulting from KW-2450 treatment depended on the activation of mitogen-activated protein kinase kinase (MEK) for their survival.  When treated with the MEK inhibitor selumetinib combined with KW-2450, compared with KW-2450 alone, the 8N cell population was significantly reduced and apoptosis was increased.  Indeed, this combination showed synergistic antitumor effect in SUM149 TNBC xenografts.  Collectively, Aurora A and B inhibition had a significant antitumor effect against TNBC, and this antitumor effect was maximized by the combination of selumetinib with Aurora A and B inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKPTT0DmSbt7Vg90H21EOLACvtfcHk0li6-yRN6AAesQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7zO&md5=238da6cf846e04783c879008c719af38</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0096%26sid%3Dliteratum%253Aachs%26aulast%3DKai%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DPitner%26aufirst%3DM.%2BK.%26aulast%3DReyes%26aufirst%3DM.%2BE.%26aulast%3DTorres-Adorno%26aufirst%3DA.%2BM.%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DSaya%26aufirst%3DH.%26aulast%3DTripathy%26aufirst%3DD.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DAntitumor%2520activity%2520of%2520KW-2450%2520against%2520triple-negative%2520breast%2520cancer%2520by%2520inhibiting%2520Aurora%2520A%2520and%2520B%2520kinases%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D12%26spage%3D2687%26epage%3D2699%26doi%3D10.1158%2F1535-7163.MCT-15-0096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. M.</span></span> <span> </span><span class="NLM_article-title">The role and mechanism of CRT0066101 as an effective drug for treatment of triple-negative breast cancer</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.33594/000000027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.33594%2F000000027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30845378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2019&pages=382-396&issue=3&author=Y.+Liuauthor=Y.+Z.+Wangauthor=S.+Y.+Yuauthor=Y.+H.+Zhouauthor=X.+X.+Maauthor=Q.+Suauthor=L.+Anauthor=F.+F.+Wangauthor=A.+H.+Shiauthor=J.+Z.+Zhangauthor=L.+M.+Chen&title=The+role+and+mechanism+of+CRT0066101+as+an+effective+drug+for+treatment+of+triple-negative+breast+cancer&doi=10.33594%2F000000027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The role and mechanism of CRT0066101 as an effective drug for treatment of triple-negative breast cancer</span></div><div class="casAuthors">Liu, Yan; Wang, Yuzhi; Yu, Shiyi; Zhou, Yehui; Ma, Xinxing; Su, Qian; An, Li; Wang, Feifei; Shi, Aihua; Zhang, Jingzhong; Chen, Liming</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology & Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-396</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1421-9778</span>.
    
            (<span class="NLM_cas:orgname">Cell Physiol Biochem Press GmbH & Co. KG</span>)
        </div><div class="casAbstract">Breast cancer is clin. classified into three main subtypes: estrogen receptor-pos. (ER+) breast cancer, human epidermal growth factor receptor 2-pos. (HER2+) breast cancer, and triple-neg. breast cancer (TNBC).  Without specific targeted therapies, patients with TNBC have poorer prognosis compared with those with ER+ and HER2+ breast cancer.  Protein kinase D (PRKD) family members play crucial roles in cancer progression.  CRT0066101, a PRKD inhibitor, has been reported to have anticancer activity in many cancer types.  Nevertheless, the role and mechanism of CRT0066101 in TNBC have not been well investigated.  The expression level of PRKDs was analyzed in breast cancer samples and breast cancer cell lines.  The effects of inhibiting PRKD activity with CRT0066101 on TNBC cell proliferation, cell cycle, apoptosis, and tumor growth were studied by Cell Counting Kit-8 assay, cell cycle assay, propidium iodide/annexin-V assay, and a xenograft mouse model, resp.  To uncover the mol. mechanism of CRT0066101 in TNBC, comparative phosphoproteomic anal. using iTRAQ was employed.  We found that PRKD2 and PRKD3 were preferentially expressed in breast cancers.  Immunohistochem. confirmed the overexpression of PRKD2 and PRKD3 in TNBC.  CRT0066101, which inhibited the activity of PRKDs, dramatically inhibited proliferation, increased apoptosis and the G1-phase population of TNBC cells in vitro, and reduced breast tumor vol. in vivo.  Comparative phosphoproteomic anal. between breast cancer cells with and without CRT0066101 treatment revealed that the anti-breast cancer effects involved regulation of a complex network contg. multiple enriched pathways and several hub-nodes contributing to multiple cancer-related processes, thus explaining the described effects of CRT0066101 on TNBC in vitro and in vivo.  Finally, we validated several targets of PRKD inhibition by treatment with CRT0066101 and small interfering RNAs against PRKD2 and PRKD3 (siPRKD2 and siPRKD3), including p-MYC(T58/S62), p-MAPK1/3(T202/Y204), p-AKT(S473), p-YAP(S127), and p-CDC2(T14).  PRKD inhibitor CRT0066101 exhibits anti-TNBC effects via modulating a phosphor-signaling network and inhibiting the phosphorylation of many cancer-driving factors, including MYC, MAPK1/3, AKT, YAP, and CDC2, providing insight into the important roles as well as the mol. mechanism of CRT0066101 as an effective drug for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok-uxzZIbTWLVg90H21EOLACvtfcHk0lgTGw5tr-yYvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7rN&md5=2990f3ec5227f50c68b56d18dd00995f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.33594%2F000000027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.33594%252F000000027%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%2BZ.%26aulast%3DYu%26aufirst%3DS.%2BY.%26aulast%3DZhou%26aufirst%3DY.%2BH.%26aulast%3DMa%26aufirst%3DX.%2BX.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DAn%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%2BF.%26aulast%3DShi%26aufirst%3DA.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BZ.%26aulast%3DChen%26aufirst%3DL.%2BM.%26atitle%3DThe%2520role%2520and%2520mechanism%2520of%2520CRT0066101%2520as%2520an%2520effective%2520drug%2520for%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2019%26volume%3D52%26issue%3D3%26spage%3D382%26epage%3D396%26doi%3D10.33594%2F000000027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sah, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Vega, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span> <span> </span><span class="NLM_article-title">Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">49</span>),  <span class="NLM_fpage">24881</span>– <span class="NLM_lpage">24891</span>, <span class="refDoi"> DOI: 10.1073/pnas.1912033116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1912033116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31754034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlejsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=24881-24891&issue=49&author=S.+Banerjeeauthor=T.+Weiauthor=J.+Wangauthor=J.+J.+Leeauthor=H.+L.+Gutierrezauthor=O.+Chapmanauthor=S.+E.+Wileyauthor=J.+E.+Mayfieldauthor=V.+Tandonauthor=E.+F.+Juarezauthor=L.+Chavezauthor=R.+Liangauthor=R.+L.+Sahauthor=C.+Costelloauthor=J.+P.+Mesirovauthor=L.+de+la+Vegaauthor=K.+L.+Cooperauthor=J.+E.+Dixonauthor=J.+Xiaoauthor=X.+Lei&title=Inhibition+of+dual-specificity+tyrosine+phosphorylation-regulated+kinase+2+perturbs+26S+proteasome-addicted+neoplastic+progression&doi=10.1073%2Fpnas.1912033116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression</span></div><div class="casAuthors">Banerjee, Sourav; Wei, Tiantian; Wang, Jue; Lee, Jenna J.; Gutierrez, Haydee L.; Chapman, Owen; Wiley, Sandra E.; Mayfield, Joshua E.; Tandon, Vasudha; Juarez, Edwin F.; Chavez, Lukas; Liang, Ruqi; Sah, Robert L.; Costello, Caitlin; Mesirov, Jill P.; de la Vega, Laureano; Cooper, Kimberly L.; Dixon, Jack E.; Xiao, Junyu; Lei, Xiaoguang</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">24881-24891</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dependence on the 26S proteasome is an Achilles heel for triple-neg. breast cancer (TNBC) and multiple myeloma (MM).  The therapeutic proteasome inhibitor, bortezomib, successfully targets MM but often leads to drug-resistant disease relapse and fails in breast cancer.  Here we show that a 26S proteasome-regulating kinase, DYRK2, is a therapeutic target for both MM and TNBC.  Genome editing or small-mol. mediated inhibition of DYRK2 significantly reduces 26S proteasome activity, bypasses bortezomib resistance, and dramatically delays in vivo tumor growth in MM and TNBC thereby promoting survival.  We further characterized the ability of LDN192960, a potent and selective DYRK2-inhibitor, to alleviate tumor burden in vivo.  The drug docks into the active site of DYRK2 and partially inhibits all 3 core peptidase activities of the proteasome.  Our results suggest that targeting 26S proteasome regulators will pave the way for therapeutic strategies in MM and TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXwWbK63rK7Vg90H21EOLACvtfcHk0lgTGw5tr-yYvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlejsLnM&md5=6d4c0199cf151357dd70279de8044308</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1912033116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1912033116%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DGutierrez%26aufirst%3DH.%2BL.%26aulast%3DChapman%26aufirst%3DO.%26aulast%3DWiley%26aufirst%3DS.%2BE.%26aulast%3DMayfield%26aufirst%3DJ.%2BE.%26aulast%3DTandon%26aufirst%3DV.%26aulast%3DJuarez%26aufirst%3DE.%2BF.%26aulast%3DChavez%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DR.%26aulast%3DSah%26aufirst%3DR.%2BL.%26aulast%3DCostello%26aufirst%3DC.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3Dde%2Bla%2BVega%26aufirst%3DL.%26aulast%3DCooper%26aufirst%3DK.%2BL.%26aulast%3DDixon%26aufirst%3DJ.%2BE.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DX.%26atitle%3DInhibition%2520of%2520dual-specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%25202%2520perturbs%252026S%2520proteasome-addicted%2520neoplastic%2520progression%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26issue%3D49%26spage%3D24881%26epage%3D24891%26doi%3D10.1073%2Fpnas.1912033116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillant, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragno, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanrion, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gräsel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalaoui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geneste, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visvader, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, G. J.</span></span> <span> </span><span class="NLM_article-title">Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">401</span>),  <span class="NLM_fpage">eaam7049</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aam7049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1126%2Fscitranslmed.aam7049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28768804" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaam7049&issue=401&author=D.+Merinoauthor=J.+R.+Whittleauthor=F.+Vaillantauthor=A.+Serranoauthor=J.+N.+Gongauthor=G.+Ginerauthor=A.+L.+Maragnoauthor=M.+Chanrionauthor=E.+Schneiderauthor=B.+Palauthor=X.+Liauthor=G.+Dewsonauthor=J.+Gr%C3%A4selauthor=K.+Liuauthor=N.+Lalaouiauthor=D.+Segalauthor=M.+J.+Heroldauthor=D.+C.+S.+Huangauthor=G.+K.+Smythauthor=O.+Genesteauthor=G.+Lesseneauthor=J.+E.+Visvaderauthor=G.+J.+Lindeman&title=Synergistic+action+of+the+MCL-1+inhibitor+S63845+with+current+therapies+in+preclinical+models+of+triple-negative+and+HER2-amplified+breast+cancer&doi=10.1126%2Fscitranslmed.aam7049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aam7049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aam7049%26sid%3Dliteratum%253Aachs%26aulast%3DMerino%26aufirst%3DD.%26aulast%3DWhittle%26aufirst%3DJ.%2BR.%26aulast%3DVaillant%26aufirst%3DF.%26aulast%3DSerrano%26aufirst%3DA.%26aulast%3DGong%26aufirst%3DJ.%2BN.%26aulast%3DGiner%26aufirst%3DG.%26aulast%3DMaragno%26aufirst%3DA.%2BL.%26aulast%3DChanrion%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DE.%26aulast%3DPal%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDewson%26aufirst%3DG.%26aulast%3DGr%25C3%25A4sel%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLalaoui%26aufirst%3DN.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DSmyth%26aufirst%3DG.%2BK.%26aulast%3DGeneste%26aufirst%3DO.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DVisvader%26aufirst%3DJ.%2BE.%26aulast%3DLindeman%26aufirst%3DG.%2BJ.%26atitle%3DSynergistic%2520action%2520of%2520the%2520MCL-1%2520inhibitor%2520S63845%2520with%2520current%2520therapies%2520in%2520preclinical%2520models%2520of%2520triple-negative%2520and%2520HER2-amplified%2520breast%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26issue%3D401%26spage%3Deaam7049%26doi%3D10.1126%2Fscitranslmed.aam7049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lind, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeruss, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1453</span>– <span class="NLM_lpage">1464</span>, <span class="refDoi"> DOI: 10.1080/15384101.2017.1338988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1080%2F15384101.2017.1338988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28678584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1SlsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1453-1464&issue=15&author=A.+L.+Thomasauthor=H.+Lindauthor=A.+Hongauthor=D.+Dokicauthor=K.+Oppatauthor=E.+Rosenthalauthor=A.+Guoauthor=A.+Thomasauthor=R.+Hamdenauthor=J.+S.+Jeruss&title=Inhibition+of+CDK-mediated+Smad3+phosphorylation+reduces+the+Pin1-Smad3+interaction+and+aggressiveness+of+triple+negative+breast+cancer+cells&doi=10.1080%2F15384101.2017.1338988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells</span></div><div class="casAuthors">Thomas, Alexandra L.; Lind, Hanne; Hong, Angela; Dokic, Danijela; Oppat, Kailey; Rosenthal, Elana; Guo, Amina; Thomas, Aaron; Hamden, Randala; Jeruss, Jacqueline S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1453-1464</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Triple neg. breast cancer (TNBC) is a highly aggressive breast cancer subtype that lacks effective targeted therapies.  Although TNBC is not defined by specific therapeutic targets, a subset of patients have tumors that overexpress cyclins.  High cyclin D/E expression catalyzes CDK4/2 activity.  In turn, CDK4/2 can non-canonically phosphorylate Smad3, a key TGFβ signaling intermediate, and this phosphorylation has been assocd. with the shift from tumor-suppressive to oncogenic TGFβ pathway action in breast oncogenesis.  Addnl., CDK-mediated Smad3 phosphorylation facilitates an interaction between Smad3 and Pin1, a cis-trans isomerase that is also overexpressed in aggressive breast cancers.  Treatment with CYC065, a CDK2/9 inhibitor, decreased non-canonical Smad3 phosphorylation and inhibited the Pin1-Smad3 interaction.  We hypothesized that the interaction of Pin1 and Smad3, facilitated by CDK-mediated Smad3 phosphorylation, promotes TNBC cell aggressiveness.  Inhibition of the Pin1-Smad3 interaction in TNBC cell lines, through depletion of Pin1 or CYC065 treatment, resulted in decreased cell migration/invasion and impeded the EMT program.  Inhibition of CDK-mediated phosphorylation of Smad3 by mutagenesis also decreased cell migration, underscoring the importance of non-canonical CDK2 phosphorylation of Smad3 to enable cell motility.  Pin1 depletion restored Smad3 protein levels and tumor-suppressive activity, suggesting that the Pin1-Smad3 interaction has a neg. impact on canonical Smad3 action.  Collectively, the data show that the Pin1-Smad3 interaction, facilitated by CDK-mediated Smad3 phosphorylation, is assocd. with oncogenic TGFβ signaling and breast cancer progression.  Inhibition of this interaction with CYC065 treatment may provide an important therapeutic option for TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrohturOI71vrVg90H21EOLACvtfcHk0lisElZiZzXLJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1SlsrrF&md5=4bd60987630499ce0b336e33bbd9fdea</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F15384101.2017.1338988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2017.1338988%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DLind%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DA.%26aulast%3DDokic%26aufirst%3DD.%26aulast%3DOppat%26aufirst%3DK.%26aulast%3DRosenthal%26aufirst%3DE.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DHamden%26aufirst%3DR.%26aulast%3DJeruss%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520CDK-mediated%2520Smad3%2520phosphorylation%2520reduces%2520the%2520Pin1-Smad3%2520interaction%2520and%2520aggressiveness%2520of%2520triple%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DCell%2520Cycle%26date%3D2017%26volume%3D16%26issue%3D15%26spage%3D1453%26epage%3D1464%26doi%3D10.1080%2F15384101.2017.1338988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Noord, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Water, B.</span></span> <span> </span><span class="NLM_article-title">An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13308</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-49809-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41598-019-49809-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31527768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MrpsVChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=13308&issue=1&author=V.+E.+van%0Ader+Noordauthor=R.+P.+McLaughlinauthor=M.+Smidauthor=J.+A.+Foekensauthor=J.+W.+M.+Martensauthor=Y.+Zhangauthor=B.+van+de+Water&title=An+increased+cell+cycle+gene+network+determines+MEK+and+Akt+inhibitor+double+resistance+in+triple-negative+breast+cancer&doi=10.1038%2Fs41598-019-49809-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer</span></div><div class="casAuthors">van der Noord Vera E; McLaughlin Ronan P; Zhang Yinghui; van de Water Bob; Smid Marcel; Foekens John A; Martens John W M</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13308</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor clinical prognosis and limited targeted treatment strategies.  Kinase inhibitor screening of a panel of 20 TNBC cell lines uncovered three critical TNBC subgroups: 1) sensitive to only MEK inhibitors; 2) sensitive to only Akt inhibitors; 3) resistant to both MEK/Akt inhibitors.  Using genomic, transcriptomic and proteomic datasets of these TNBC cell lines we unravelled molecular features associated with the MEK and Akt drug resistance.  MEK inhibitor-resistant TNBC cell lines were discriminated from Akt inhibitor-resistant lines by the presence of PIK3CA/PIK3R1/PTEN mutations, high p-Akt and low p-MEK levels, yet these features could not distinguish double-resistant cells.  Gene set enrichment analyses of transcriptomic and proteomic data of the MEK and Akt inhibitor response groups revealed a set of cell cycle-related genes associated with the double-resistant phenotype; these genes were overexpressed in a subset of breast cancer patients.  CDK inhibitors targeting the cell cycle programme could overcome the Akt and MEK inhibitor double-resistance.  In conclusion, we uncovered molecular features and alternative treatment strategies for TNBC that are double-resistant to Akt and MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEIuE118wd3kBuFdjgVNKSfW6udTcc2eZzdMQlLF7RDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrpsVChug%253D%253D&md5=83fe2e7e98acb8e95d3c126ed17bf682</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-49809-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-49809-3%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BNoord%26aufirst%3DV.%2BE.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BP.%26aulast%3DSmid%26aufirst%3DM.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DMartens%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3Dvan%2Bde%2BWater%26aufirst%3DB.%26atitle%3DAn%2520increased%2520cell%2520cycle%2520gene%2520network%2520determines%2520MEK%2520and%2520Akt%2520inhibitor%2520double%2520resistance%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D13308%26doi%3D10.1038%2Fs41598-019-49809-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guldner, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnepp, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Host, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlepage, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakshatri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2860</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-10743-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41467-019-10743-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31253784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MzitF2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2860&issue=1&author=Y.+Niauthor=K.+R.+Schmidtauthor=B.+A.+Wernerauthor=J.+K.+Koenigauthor=I.+H.+Guldnerauthor=P.+M.+Schneppauthor=X.+Tanauthor=L.+Jiangauthor=M.+Hostauthor=L.+Sunauthor=E.+N.+Howeauthor=J.+Wuauthor=L.+E.+Littlepageauthor=H.+Nakshatriauthor=S.+Zhang&title=Death+effector+domain-containing+protein+induces+vulnerability+to+cell+cycle+inhibition+in+triple-negative+breast+cancer&doi=10.1038%2Fs41467-019-10743-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer</span></div><div class="casAuthors">Ni Yingjia; Schmidt Keon R; Werner Barnes A; Koenig Jenna K; Guldner Ian H; Schnepp Patricia M; Tan Xuejuan; Jiang Lan; Host Misha; Sun Longhua; Howe Erin N; Zhang Siyuan; Ni Yingjia; Schmidt Keon R; Werner Barnes A; Koenig Jenna K; Guldner Ian H; Schnepp Patricia M; Tan Xuejuan; Jiang Lan; Host Misha; Sun Longhua; Howe Erin N; Wu Junmin; Littlepage Laurie E; Zhang Siyuan; Wu Junmin; Littlepage Laurie E; Zhang Siyuan; Littlepage Laurie E; Nakshatri Harikrishna; Zhang Siyuan; Nakshatri Harikrishna</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2860</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most clinically challenging subtype of breast cancer.  In this study, we reveal that Death Effector Domain-containing DNA-binding protein (DEDD), which is overexpressed in > 60% of TNBCs, drives a mitogen-independent G1/S cell cycle transition through cytoplasm localization.  The gain of cytosolic DEDD enhances cyclin D1 expression by interacting with heat shock 71 kDa protein 8 (HSC70).  Concurrently, DEDD interacts with Rb family proteins and promotes their proteasome-mediated degradation.  DEDD overexpression renders TNBCs vulnerable to cell cycle inhibition.  Patients with TNBC have been excluded from CDK 4/6 inhibitor clinical trials due to the perceived high frequency of Rb-loss in TNBCs.  Interestingly, our study demonstrated that, irrespective of Rb status, TNBCs with DEDD overexpression exhibit a DEDD-dependent vulnerability to combinatorial treatment with CDK4/6 inhibitor and EGFR inhibitor in vitro and in vivo.  Thus, our study provided a rationale for the clinical application of CDK4/6 inhibitor combinatorial regimens for patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxAinuUQmJ7mLFM_lbR1VmfW6udTcc2eZzdMQlLF7RDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzitF2gsw%253D%253D&md5=62a15d6691dd464b37c0dc7e04504083</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-10743-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-10743-7%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DY.%26aulast%3DSchmidt%26aufirst%3DK.%2BR.%26aulast%3DWerner%26aufirst%3DB.%2BA.%26aulast%3DKoenig%26aufirst%3DJ.%2BK.%26aulast%3DGuldner%26aufirst%3DI.%2BH.%26aulast%3DSchnepp%26aufirst%3DP.%2BM.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DHost%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DHowe%26aufirst%3DE.%2BN.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLittlepage%26aufirst%3DL.%2BE.%26aulast%3DNakshatri%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DDeath%2520effector%2520domain-containing%2520protein%2520induces%2520vulnerability%2520to%2520cell%2520cycle%2520inhibition%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D2860%26doi%3D10.1038%2Fs41467-019-10743-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethier, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tew, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. Y.</span></span> <span> </span><span class="NLM_article-title">MYC inhibition depletes cancer stem-like cells in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6641</span>– <span class="NLM_lpage">6650</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-3452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-16-3452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28951456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6641-6650&issue=23&author=A.+Yangauthor=S.+Qinauthor=B.+A.+Schulteauthor=S.+P.+Ethierauthor=K.+D.+Tewauthor=G.+Y.+Wang&title=MYC+inhibition+depletes+cancer+stem-like+cells+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-16-3452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Yang, Aimin; Qin, Shenghui; Schulte, Bradley A.; Ethier, Stephen P.; Tew, Kenneth D.; Wang, Gavin Y.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6641-6650</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is mounting evidence that cancer stem-like cells (CSC) are selectively enriched in residual tumors after anticancer therapies, which may account for tumor recurrence and metastasis by regenerating new tumors.  Thus, there is a crit. need to develop new therapeutic agents that can effectively eliminate drug-resistant CSCs and improve the efficacy of cancer therapy.  Here, we report that Triptolide (C1572), a small-mol. natural product, selectively depletes CSCs in a dose-dependent fashion in human triple-neg. breast cancer (TNBC) cell lines.  Nanomolar concns. of C1572 markedly reduced c-MYC (MYC) protein levels via a proteasome-dependent mechanism.  Silencing MYC expression phenocopied the CSC depletion effects of C1572 and induced senescence in TNBC cells.  Limited diln. assays revealed that ex vivo treatment of TNBC cells with C1572 reduced CSC levels by 28-fold.  In mouse xenograft models of human TNBC, administration of C1572 suppressed tumor growth and depleted CSCs in a manner correlated with diminished MYC expression in residual tumor tissues.  Together, these new findings provide a preclin. proof of concept defining C1572 as a promising therapeutic agent to eradicate CSCs for drug-resistant TNBC treatment.  Cancer Res; 77(23); 6641-50. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_SrzHLvV6MLVg90H21EOLACvtfcHk0limPnd6TneLvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsb7J&md5=5cf6cd4c22f30fc6638da4f2a9f10500</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-3452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-3452%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DA.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DSchulte%26aufirst%3DB.%2BA.%26aulast%3DEthier%26aufirst%3DS.%2BP.%26aulast%3DTew%26aufirst%3DK.%2BD.%26aulast%3DWang%26aufirst%3DG.%2BY.%26atitle%3DMYC%2520inhibition%2520depletes%2520cancer%2520stem-like%2520cells%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D23%26spage%3D6641%26epage%3D6650%26doi%3D10.1158%2F0008-5472.CAN-16-3452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzmann, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomics-enabled covalent ligand screening reveals a thioredoxin-caspase 3 interaction disruptor that impairs breast cancer pathogenicity</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2522</span>– <span class="NLM_lpage">2528</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00711</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00711" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKmurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2522-2528&issue=10&author=K.+E.+Andersonauthor=M.+Toauthor=J.+A.+Olzmannauthor=D.+K.+Nomura&title=Chemoproteomics-enabled+covalent+ligand+screening+reveals+a+thioredoxin-caspase+3+interaction+disruptor+that+impairs+breast+cancer+pathogenicity&doi=10.1021%2Facschembio.7b00711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity</span></div><div class="casAuthors">Anderson, Kimberly E.; To, Milton; Olzmann, James A.; Nomura, Daniel K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2522-2528</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Covalent ligand discovery is a promising strategy to develop small-mol. effectors against therapeutic targets.  Recent studies have shown that dichlorotriazines are promising reactive scaffolds that preferentially react with lysines.  Here, we have synthesized a series of dichlorotriazine-based covalent ligands and have screened this library to reveal small mols. that impair triple-neg. breast cancer cell survival.  Upon identifying a lead hit from this screen KEA1-97, we used activity-based protein profiling (ABPP)-based chemoproteomic platforms to identify that this compd. targets lysine 72 of thioredoxin-a site previously shown to be important in protein interactions with caspase 3 to inhibit caspase 3 activity and suppress apoptosis.  We show that KEA1-97 disrupts the interaction of thioredoxin with caspase 3, activates caspases, and induces apoptosis without affecting thioredoxin activity.  Moreover, KEA1-97 impairs in vivo breast tumor xenograft growth.  Our study showcases how the screening of covalent ligands can be coupled with ABPP platforms to identify unique anticancer lead and target pairs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3VpILz2ADVbVg90H21EOLACvtfcHk0limPnd6TneLvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKmurvF&md5=d428a05bb7d1fc5500fbdbf6ab214326</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00711%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DTo%26aufirst%3DM.%26aulast%3DOlzmann%26aufirst%3DJ.%2BA.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26atitle%3DChemoproteomics-enabled%2520covalent%2520ligand%2520screening%2520reveals%2520a%2520thioredoxin-caspase%25203%2520interaction%2520disruptor%2520that%2520impairs%2520breast%2520cancer%2520pathogenicity%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26issue%3D10%26spage%3D2522%26epage%3D2528%26doi%3D10.1021%2Facschembio.7b00711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradishar, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span> <span> </span><span class="NLM_article-title">A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2019.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ebiom.2019.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31101597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ntVCjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=98-111&author=Z.+Zhouauthor=Z.+Fengauthor=D.+Huauthor=P.+Yangauthor=M.+Gurauthor=I.+Baharauthor=M.+Cristofanilliauthor=W.+J.+Gradisharauthor=X.+Q.+Xieauthor=Y.+Wan&title=A+novel+small-molecule+antagonizes+PRMT5-mediated+KLF4+methylation+for+targeted+therapy&doi=10.1016%2Fj.ebiom.2019.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy</span></div><div class="casAuthors">Zhou Zhuan; Feng Zhiwei; Yang Peng; Hu Dong; Gur Mert; Bahar Ivet; Cristofanilli Massimo; Gradishar William J; Xie Xiang-Qun; Wan Yong</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-111</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple negative breast cancers (TNBCs) have a poor prognosis and are not amenable to endocrine- or HER2-targeted therapies.  The malignant and invasive feature of TNBCs is correlated with its high cancer stem cell population.  Recent results from us and others have unveiled an oncogenic role for the PRMT5-KLF4 axis in regulating tumor progression by orchestrating the stemness in mammary tumor cell as well as genome stability.  Methylation of KLF4 by PRMT5 leads to KLF4 stabilization, resulting in promoting mitogenesis.  METHODS:  We have developed a small molecule inhibitor, WX2-43, that specifically intercepts the interaction between PRMT5 and KLF4, thereby enhancing KLF4 degradation.  FINDINGS:  Results from our characterization demonstrate that WX2-43 binds to the region between amino acids L400-M500 on PRMT5.  Degradation of KLF4 down-regulates KLF4-mediated genes transcription.  We have characterized the potent effect for WX2-43 in inhibiting PRMT5-KLF4 binding that, in turns, suppresses tumor progression and induces tumor cell death in both TNBC cultured-cell and animal models.  INTERPRETATION:  WX2-43-mediated inhibition of KLF4 methylation by PRMT5 could be a potential strategy for anti-TNBC treatment.  FUND: This work was supported, in whole or in part, by National Institutes of Health grants CA202963 and CA202948 (Wan), R21HL109654 (Xie), P30DA035778 (Xie and Bahar) and P41GM103712 (Bahar).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdQsNVpjLaH5Pq5LRczm8ffW6udTcc2eYVzJexpRKe0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ntVCjsQ%253D%253D&md5=71776296f85255c2bd3412bbe9fe2b10</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2019.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2019.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DGur%26aufirst%3DM.%26aulast%3DBahar%26aufirst%3DI.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DGradishar%26aufirst%3DW.%2BJ.%26aulast%3DXie%26aufirst%3DX.%2BQ.%26aulast%3DWan%26aufirst%3DY.%26atitle%3DA%2520novel%2520small-molecule%2520antagonizes%2520PRMT5-mediated%2520KLF4%2520methylation%2520for%2520targeted%2520therapy%26jtitle%3DEBioMedicine%26date%3D2019%26volume%3D44%26spage%3D98%26epage%3D111%26doi%3D10.1016%2Fj.ebiom.2019.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrolecki, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-Vidana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orellana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renwick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsonis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrulle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtarge, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimawi, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, T. F.</span></span> <span> </span><span class="NLM_article-title">Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1038/nm.4507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fnm.4507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29578538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvFKnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=505-511&issue=4&author=A.+Nairauthor=H.+C.+Chungauthor=T.+Sunauthor=S.+Tyagiauthor=L.+E.+Dobroleckiauthor=R.+Dominguez-Vidanaauthor=S.+J.+Kurleyauthor=M.+Orellanaauthor=A.+Renwickauthor=D.+M.+Henkeauthor=P.+Katsonisauthor=E.+Schmittauthor=D.+W.+Chanauthor=H.+Liauthor=S.+Maoauthor=I.+Petrovicauthor=C.+J.+Creightonauthor=C.+Gutierrezauthor=J.+Dubrulleauthor=F.+Stossiauthor=J.+W.+Tynerauthor=O.+Lichtargeauthor=C.+Y.+Linauthor=B.+Zhangauthor=K.+L.+Scottauthor=S.+G.+Hilsenbeckauthor=J.+Sunauthor=X.+Yuauthor=C.+K.+Osborneauthor=R.+Schiffauthor=J.+G.+Christensenauthor=D.+J.+Shieldsauthor=M.+F.+Rimawiauthor=M.+J.+Ellisauthor=C.+A.+Shawauthor=M.+T.+Lewisauthor=T.+F.+Westbrook&title=Combinatorial+inhibition+of+PTPN12-regulated+receptors+leads+to+a+broadly+effective+therapeutic+strategy+in+triple-negative+breast+cancer&doi=10.1038%2Fnm.4507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer</span></div><div class="casAuthors">Nair, Amritha; Chung, Hsiang-Ching; Sun, Tingting; Tyagi, Siddhartha; Dobrolecki, Lacey E.; Dominguez-Vidana, Rocio; Kurley, Sarah J.; Orellana, Mayra; Renwick, Alexander; Henke, David M.; Katsonis, Panagiotis; Schmitt, Earlene; Chan, Doug W.; Li, Hui; Mao, Sufeng; Petrovic, Ivana; Creighton, Chad J.; Gutierrez, Carolina; Dubrulle, Julien; Stossi, Fabio; Tyner, Jeffrey W.; Lichtarge, Olivier; Lin, Charles Y.; Zhang, Bing; Scott, Kenneth L.; Hilsenbeck, Susan G.; Sun, Jinpeng; Yu, Xiao; Osborne, C. Kent; Schiff, Rachel; Christensen, James G.; Shields, David J.; Rimawi, Mothaffar F.; Ellis, Matthew J.; Shaw, Chad A.; Lewis, Michael T.; Westbrook, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-511</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is an aggressive subtype of breast cancer diagnosed in more than 200,000 women each year and is recalcitrant to targeted therapies.  Although TNBCs harbor multiple hyperactive receptor tyrosine kinases (RTKs), RTK inhibitors have been largely ineffective in TNBC patients thus far.  We developed a broadly effective therapeutic strategy for TNBC that is based on combined inhibition of receptors that share the neg. regulator PTPN12.  Previously, we and others identified the tyrosine phosphatase PTPN12 as a tumor suppressor that is frequently inactivated in TNBC.  PTPN12 restrains several RTKs, suggesting that PTPN12 deficiency leads to aberrant activation of multiple RTKs and a co-dependency on these receptors.  This in turn leads to the therapeutic hypothesis that PTPN12-deficient TNBCs may be responsive to combined RTK inhibition.  However, the repertoire of RTKs that are restrained by PTPN12 in human cells has not been systematically explored.  By methodically identifying the suite of RTK substrates (MET, PDGFRβ, EGFR, and others) inhibited by PTPN12, we rationalized a combination RTK-inhibitor therapy that induced potent tumor regression across heterogeneous models of TNBC.  Orthogonal approaches revealed that PTPN12 was recruited to and inhibited these receptors after ligand stimulation, thereby serving as a feedback mechanism to limit receptor signaling.  Cancer-assocd. mutation of PTPN12 or reduced PTPN12 protein levels diminished this feedback mechanism, leading to aberrant activity of these receptors.  Restoring PTPN12 protein levels restrained signaling from RTKs, including PDGFRβ and MET, and impaired TNBC survival.  In contrast with single agents, combined inhibitors targeting the PDGFRβ and MET receptors induced the apoptosis in TNBC cells in vitro and in vivo.  This therapeutic strategy resulted in tumor regressions in chemo-refractory patient-derived TNBC models.  Notably, response correlated with PTPN12 deficiency, suggesting that impaired receptor feedback may establish a combined addiction to these proto-oncogenic receptors.  Taken together, our data provide a rationale for combining RTK inhibitors in TNBC and other malignancies that lack receptor-activating mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE5kB8_e753LVg90H21EOLACvtfcHk0ljwD4GD5cTkcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvFKnu7k%253D&md5=eff751e8524a226313d512aa4ff63e51</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnm.4507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4507%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DH.%2BC.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DDobrolecki%26aufirst%3DL.%2BE.%26aulast%3DDominguez-Vidana%26aufirst%3DR.%26aulast%3DKurley%26aufirst%3DS.%2BJ.%26aulast%3DOrellana%26aufirst%3DM.%26aulast%3DRenwick%26aufirst%3DA.%26aulast%3DHenke%26aufirst%3DD.%2BM.%26aulast%3DKatsonis%26aufirst%3DP.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DD.%2BW.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DPetrovic%26aufirst%3DI.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DGutierrez%26aufirst%3DC.%26aulast%3DDubrulle%26aufirst%3DJ.%26aulast%3DStossi%26aufirst%3DF.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLichtarge%26aufirst%3DO.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DK.%2BL.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DShields%26aufirst%3DD.%2BJ.%26aulast%3DRimawi%26aufirst%3DM.%2BF.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DShaw%26aufirst%3DC.%2BA.%26aulast%3DLewis%26aufirst%3DM.%2BT.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26atitle%3DCombinatorial%2520inhibition%2520of%2520PTPN12-regulated%2520receptors%2520leads%2520to%2520a%2520broadly%2520effective%2520therapeutic%2520strategy%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D4%26spage%3D505%26epage%3D511%26doi%3D10.1038%2Fnm.4507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1007/s11523-013-0300-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs11523-013-0300-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24233638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2c7ms1Cgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=349-357&issue=4&author=M.+Zhangauthor=X.+Zhangauthor=S.+Zhaoauthor=Y.+Wangauthor=W.+Diauthor=G.+Zhaoauthor=M.+Yangauthor=Q.+Zhang&title=Prognostic+value+of+survivin+and+EGFR+protein+expression+in+triple-negative+breast+cancer+%28TNBC%29+patients&doi=10.1007%2Fs11523-013-0300-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic value of survivin and EGFR protein expression  in triple-negative breast cancer (TNBC) patients</span></div><div class="casAuthors">Zhang Minghui; Zhang Xiaosan; Zhao Shu; Wang Yan; Di Wenyu; Zhao Gangling; Yang Maopeng; Zhang Qingyuan</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">349-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is a particular type of breast cancer which is characterized by its biological aggressiveness, worse prognosis, and lack of prognostic markers or therapeutic targets in contrast with hormonal receptor-positive and human epidermal growth factor receptor 2-positive (HER2+) breast cancers.  We aimed to evaluate survivin and epidermal growth factor receptor (EGFR) expression and their prognostic value and determine their relationships with the clinicopathological parameters of TNBC.  A total of 136 patients who had undergone a resection of primary TNBC were enrolled at the Third Affiliated Hospital of Harbin Medical University from March 2003 to September 2005.  Expression of ER, PR, HER2, EGFR, and survivin was assessed by immunohistochemistry.  The association of TNBC and other clinicopathological variables and the prognostic value of survivin and EGFR expression were evaluated.  Survivin was expressed in 62 (45.6 %) cases and EGFR was expressed in 82 (60.3 %) cases.  Survivin expression was associated with menopausal status (P = 0.011), tumor size (P = 0.037), and lymph node status (P = 0.001).  EGFR expression was associated with menopausal status (P = 0.029), lymph node status (P = 0.004), P53 expression (P = 0.001), Ki-67 expression (P = 0.028), and lymphatic vascular invasion (P = 0.037).  A multivariate analysis demonstrated that tumor size (hazard ratio (HR) 1.587, 95 % confidence interval (CI) 1.081-2.330, P = 0.018 for disease-free survival (DFS); HR 1.606, 95%CI 1.096-2.354, P = 0.015 for overall survival (OS)), lymph node status (HR 2.873, 95%CI 1.544-5.344, P = 0.001 for DFS; HR 2.915, 95%CI 1.553-5.471, P = 0.001 for OS), tumor grade (HR 1.914, 95%CI 1.218-3.007, P = 0.005 for DFS; HR 1.983, 95%CI 1.228-3.203, P = 0.005 for OS), EGFR (HR 3.008, 95%CI 1.331-6.792, P = 0.008 for DFS; HR 3.151, 95%CI 1.374-7.226, P = 0.007 for OS), and survivin (HR 1.573, 95%CI 1.087-2.277, P = 0.016 for DFS; HR 1.607, 95%CI 1.088-2.374, P = 0.017 for OS) were of prognostic significance for disease-free and overall survival.  We draw a conclusion from the present study that survivin and EGFR expression are useful prognostic markers of TNBC and might be useful for molecular targeting therapy of TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQllMhUDJ_GNoUSrryheKE6fW6udTcc2eZ7tW6fhkYGlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7ms1Cgug%253D%253D&md5=1cc1119c318e8033b50ee7aa1c88809b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1007%2Fs11523-013-0300-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-013-0300-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DPrognostic%2520value%2520of%2520survivin%2520and%2520EGFR%2520protein%2520expression%2520in%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%2520patients%26jtitle%3DTarget%2520Oncol.%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3D349%26epage%3D357%26doi%3D10.1007%2Fs11523-013-0300-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antignani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnovsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, D.</span></span> <span> </span><span class="NLM_article-title">Targeting a cancer-specific epitope of the epidermal growth factor receptor in triple-negative breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">djw028</span>, <span class="refDoi"> DOI: 10.1093/jnci/djw028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fjnci%2Fdjw028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=djw028&issue=8&author=N.+Simonauthor=A.+Antignaniauthor=R.+Sarnovskyauthor=S.+M.+Hewittauthor=D.+FitzGerald&title=Targeting+a+cancer-specific+epitope+of+the+epidermal+growth+factor+receptor+in+triple-negative+breast+cancer&doi=10.1093%2Fjnci%2Fdjw028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjw028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjw028%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DN.%26aulast%3DAntignani%26aufirst%3DA.%26aulast%3DSarnovsky%26aufirst%3DR.%26aulast%3DHewitt%26aufirst%3DS.%2BM.%26aulast%3DFitzGerald%26aufirst%3DD.%26atitle%3DTargeting%2520a%2520cancer-specific%2520epitope%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2016%26volume%3D108%26issue%3D8%26spage%3Ddjw028%26doi%3D10.1093%2Fjnci%2Fdjw028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span> <span> </span><span class="NLM_article-title">Overexpression of miR-361–5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway</span>. <i>Bosnian J. Basic Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.17305/bjbms.2018.3399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.17305%2Fbjbms.2018.3399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29924958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWmu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=52-59&issue=1&author=J.+Hanauthor=J.+Yuauthor=Y.+Daiauthor=J.+Liauthor=M.+Guoauthor=J.+Songauthor=X.+Zhou&title=Overexpression+of+miR-361%E2%80%935p+in+triple-negative+breast+cancer+%28TNBC%29+inhibits+migration+and+invasion+by+targeting+RQCD1+and+inhibiting+the+EGFR%2FPI3K%2FAkt+pathway&doi=10.17305%2Fbjbms.2018.3399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway</span></div><div class="casAuthors">Han, Jianjun; Yu, Jingjing; Dai, Yu'na; Li, Jumei; Guo, Meiyan; Song, Jingzhen; Zhou, Xuefeng</div><div class="citationInfo"><span class="NLM_cas:title">Bosnian Journal of Basic Medical Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-59</span>CODEN:
                <span class="NLM_cas:coden">BJBMAF</span>;
        ISSN:<span class="NLM_cas:issn">1840-4812</span>.
    
            (<span class="NLM_cas:orgname">Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the leading cause of cancer-related death in women.  Previous studies indicated that miR-361-5p was downregulated in breast cancer, however, the exact effect of miR-361-5p on TNBC requires further investigation.  In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC.  The expression of miR-361-5p and RQCD1 was detd. by quant. reverse transcription PCR (qRT-PCR) and/or western blot in TNBC and the adjacent tissues. miR-361-5p mimics were constructed and transfected to TNBC cell line MDA-MB-231.  Cells were divided into three groups: blank control group, miRNA mimic neg. control (NC) group, and miR-361-5p mimics group.  Expression of miR-361-5p, mRNA and protein expression of PI3K, Akt, EGFR, phosphorylated (p)-EGFR/PI3K/Akt, and protein expression of RQCD1 and matrix metallopeptidase 9 (MMP-9) in MDA-MB-231 were measured by qRT-PCR/western blot after transfection.  Cell viability was detd. by CCK-8 assay.  Cell migration and invasion ability were evaluated by scratch and transwell assay, resp. miR-361-5p target gene was detd. by bioinformatics anal. and luciferase reporter assay.  RQCD1 was identified as a target of miR-361-5p by TargetScan and confirmed by luciferase reporter assay.  Downregulated miR-361-5p and upregulated RQCD1 were obsd. in TNBC tissues.  Expression of EGFR, PI3K, Akt and MMP-9 was inhibited in cells treated with miR-361-5p mimics.  Transfection of miR-361-5p mimics also inhibited the phosphorylation of EGFR, PI3K, and Akt.  Suppressed cell viability, migration, and invasion was found in miR-361-5p mimics groups.  Our results indicated that overexpression of miR-361-5p might act as a suppressor in TNBC by targeting RQCD1 to inhibit the EGFR/PI3K/Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_wKBf3lfEGLVg90H21EOLACvtfcHk0lg-haMYsmV-Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWmu7bJ&md5=ed011a587d7f8afa35cf06f4cd255f08</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.17305%2Fbjbms.2018.3399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17305%252Fbjbms.2018.3399%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DX.%26atitle%3DOverexpression%2520of%2520miR-361%25E2%2580%25935p%2520in%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%2520inhibits%2520migration%2520and%2520invasion%2520by%2520targeting%2520RQCD1%2520and%2520inhibiting%2520the%2520EGFR%252FPI3K%252FAkt%2520pathway%26jtitle%3DBosnian%2520J.%2520Basic%2520Med.%2520Sci.%26date%3D2019%26volume%3D19%26issue%3D1%26spage%3D52%26epage%3D59%26doi%3D10.17305%2Fbjbms.2018.3399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Guerrab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamdad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubel, C.</span></span> <span> </span><span class="NLM_article-title">Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">73618</span>– <span class="NLM_lpage">73637</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.12037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27655662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2svivVyjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=73618-73637&issue=45&author=A.+El%0AGuerrabauthor=M.+Bamdadauthor=F.+Kwiatkowskiauthor=Y.+Bignonauthor=F.+Penault-Llorcaauthor=C.+Aubel&title=Anti-EGFR+monoclonal+antibodies+and+EGFR+tyrosine+kinase+inhibitors+as+combination+therapy+for+triple-negative+breast+cancer&doi=10.18632%2Foncotarget.12037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer</span></div><div class="casAuthors">El Guerrab Abderrahim; Kwiatkowski Fabrice; Bignon Yves-Jean; Penault-Llorca Frederique; Aubel Corinne; El Guerrab Abderrahim; Bamdad Mahchid; Bignon Yves-Jean; Penault-Llorca Frederique; Aubel Corinne; Bamdad Mahchid</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">73618-73637</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is characterized by overexpression of epidermal growth factor receptor (EGFR) and activation of its downstream signaling pathways.  Dual targeting of EGFR using one monoclonal antibody (mAb; cetuximab or panitumumab) and one tyrosine kinase inhibitor (EGFR-TKI; gefitinib or erlotinib) is a potential therapeutic approach.  We investigated the effect of these therapies in EGFR-expressing TNBC cell lines that do or do not harbor the main activating mutations of EGFR pathways.  Cell lines were sensitive to EGFR-TKIs, whereas mAbs were active only in MDA-MB-468 (EGFR amplification) and SUM-1315 (KRAS and PTEN wild-type) cells.  MDA-MB-231 (KRAS mutated) and HCC-1937 (PTEN deletion) cells were resistant to mAbs.  The combined treatment resulted in a synergistic effect on cell proliferation and superior inhibition of the RAS/MAPK signaling pathway in mAb-sensitive cells.  The anti-proliferative effect was associated with G1 cell cycle arrest followed by apoptosis.  Sensitivity to therapies was characterized by induction of positive regulators and inactivation of negative regulators of cell cycle.  These results suggest that dual EGFR inhibition might result in an enhanced antitumor effect in a subgroup of TNBC.  The status of EGFR, KRAS and PTEN could be used as a molecular marker for predicting the response to this therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcxR9XiFsCPFWTCLT8lX9SfW6udTcc2eaGJ5qs19quvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svivVyjtw%253D%253D&md5=41bc12650451f8b0d57e659dbb4ebe98</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12037%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BGuerrab%26aufirst%3DA.%26aulast%3DBamdad%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DF.%26aulast%3DBignon%26aufirst%3DY.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DAubel%26aufirst%3DC.%26atitle%3DAnti-EGFR%2520monoclonal%2520antibodies%2520and%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520as%2520combination%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D45%26spage%3D73618%26epage%3D73637%26doi%3D10.18632%2Foncotarget.12037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H. P.</span></span> <span> </span><span class="NLM_article-title">RON and MET co-overexpression are significant pathological characteristics of poor survival and therapeutic targets of tyrosine kinase inhibitors in triple-negative breast cancer</span>. <i>Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.4143/crt.2019.726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.4143%2Fcrt.2019.726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32324988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2ms73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2020&pages=973-986&issue=3&author=T.+H.+Wengauthor=M.+Y.+Yaoauthor=X.+M.+Xuauthor=C.+Y.+Huauthor=S.+H.+Yaoauthor=Y.+Z.+Liuauthor=Z.+G.+Wuauthor=T.+M.+Tangauthor=P.+F.+Fuauthor=M.+H.+Wangauthor=H.+P.+Yao&title=RON+and+MET+co-overexpression+are+significant+pathological+characteristics+of+poor+survival+and+therapeutic+targets+of+tyrosine+kinase+inhibitors+in+triple-negative+breast+cancer&doi=10.4143%2Fcrt.2019.726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">RON and MET co-overexpression are significant pathological characteristics of poor survival and therapeutic targets of tyrosine kinase inhibitors in triple-negative breast cancer</span></div><div class="casAuthors">Weng, Tian-Hao; Yao, Min-Ya; Xu, Xiang-Ming; Hu, Chen-Yu; Yao, Shu-Hao; Liu, Yi-Zhi; Wu, Zhi-Gang; Tang, Tao-Ming; Fu, Pei-Fen; Wang, Ming-Hai; Yao, Hang-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">973-986</span>CODEN:
                <span class="NLM_cas:coden">CRTAC2</span>;
        ISSN:<span class="NLM_cas:issn">2005-9256</span>.
    
            (<span class="NLM_cas:orgname">Korean Cancer Association</span>)
        </div><div class="casAbstract">Purpose Triple-neg. breast cancer (TNBC) is highly malignant and has poor prognosis and a high mortality rate.  The lack of effective therapy has spurred our investigation of new targets for treating this malignant cancer.  Here,we identified RON (macrophage-stimulating 1 receptor) and MET (MET proto-oncogene, receptor tyrosine kinase) as a prognostic biomarker and therapeutic targets for potential TNBC treatment.  Materials and Methods We analyzed RON and MET expression in 187 primary TNBC clin. samples with immunohistochem.  We validated the targeted therapeutic effects of RON and MET in TNBC using three tyrosine kinase inhibitors (TKIs): BMS-777607, INCB28060, and tivantinib.  The preclin. therapeutic efficacy of the TKIs was mainly estd. using a TNBC xenograft model.  Results Patients with TNBC had widespread, abnormal expression of RON and MET.  There was RON overexpression, MET overexpression, and RON and MET co-overexpression in 63 (33.7%), 63 (33.7%), and 43 cases (23.0%), resp., which had poor prognosis and short survival.  In vivo, the TKI targeting RON ant MET inhibited the activation of the downstream signaling mols., inhibited TNBC cell migration and proliferation, and increased TNBC cell apoptosis; in the xenograft model, they significantly inhibited tumor growth and shrank tumor vols.  The TKI targeting RON and Met, such as BMS-777607 and tivantinib, yielded stronger anti-tumor effects than INCB28060.  Conclusion RON and MET co-overexpression can be significant pathol. characteristics in TNBC for poor prognosis.  TKIs targeting RON and MET have stronger drug development potential for treating TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJjnYNhm_OLVg90H21EOLACvtfcHk0lg-haMYsmV-Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2ms73E&md5=3e26c76abb461440735bc820771a5ff8</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2019.726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2019.726%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DT.%2BH.%26aulast%3DYao%26aufirst%3DM.%2BY.%26aulast%3DXu%26aufirst%3DX.%2BM.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DYao%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DY.%2BZ.%26aulast%3DWu%26aufirst%3DZ.%2BG.%26aulast%3DTang%26aufirst%3DT.%2BM.%26aulast%3DFu%26aufirst%3DP.%2BF.%26aulast%3DWang%26aufirst%3DM.%2BH.%26aulast%3DYao%26aufirst%3DH.%2BP.%26atitle%3DRON%2520and%2520MET%2520co-overexpression%2520are%2520significant%2520pathological%2520characteristics%2520of%2520poor%2520survival%2520and%2520therapeutic%2520targets%2520of%2520tyrosine%2520kinase%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2020%26volume%3D52%26issue%3D3%26spage%3D973%26epage%3D986%26doi%3D10.4143%2Fcrt.2019.726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrouche, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cure, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuselier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonicelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Daccak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensussan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giustiniani, J.</span></span> <span> </span><span class="NLM_article-title">IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">53350</span>– <span class="NLM_lpage">53361</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.10804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27462789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ksl2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=53350-53361&issue=33&author=Y.+Merroucheauthor=J.+Fabreauthor=H.+Cureauthor=C.+Garbarauthor=C.+Fuselierauthor=J.+Bastidauthor=F.+Antonicelliauthor=R.+Al-Daccakauthor=A.+Bensussanauthor=J.+Giustiniani&title=IL-17E+synergizes+with+EGF+and+confers+in+vitro+resistance+to+EGFR-targeted+therapies+in+TNBC+cells&doi=10.18632%2Foncotarget.10804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells</span></div><div class="casAuthors">Merrouche Yacine; Fabre Joseph; Garbar Christian; Fuselier Camille; Giustiniani Jerome; Merrouche Yacine; Fabre Joseph; Garbar Christian; Fuselier Camille; Antonicelli Frank; Giustiniani Jerome; Cure Herve; Cure Herve; Bastid Jeremy; Bensussan Armand; Al-Daccak Reem; Bensussan Armand; Al-Daccak Reem; Bensussan Armand</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">53350-53361</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Estrogen receptor-, progesterone receptor- and HER2-negative breast cancers, also known as triple-negative breast cancers (TNBCs), have poor prognoses and are refractory to current therapeutic agents, including epidermal growth factor receptor (EGFR) inhibitors.  Resistance to anti-EGFR therapeutic agents is often associated with sustained kinase phosphorylation, which promotes EGFR activation and translocation to the nucleus and prevents these agents from acting on their targets.  The mechanisms underlying this resistance have not been fully elucidated.  In addition, the IL-17E receptor is overexpressed in TNBC tumors and is associated with a poor prognosis.  We have previously reported that IL-17E promotes TNBC resistance to anti-mitotic therapies.  Here, we investigated whether IL-17E promotes TNBC resistance to anti-EGFR therapeutic agents by exploring the link between the IL-17E/IL-17E receptor axis and EGF signaling.  We found that IL-17E, similarly to EGF, activates the EGFR in TNBC cells that are resistant to EGFR inhibitors.  It also activates the PYK-2, Src and STAT3 kinases, which are essential for EGFR activation and nuclear translocation.  IL-17E binds its specific receptor, IL-17RA/IL17RB, on these TNBC cells and synergizes with the EGF signaling pathway, thereby inducing Src-dependent EGFR transactivation and pSTAT3 and pEGFR translocation to the nucleus.  Collectively, our data indicate that the IL-17E/IL-17E receptor axis may underlie TNBC resistance to EGFR inhibitors and suggest that inhibiting IL-17E or its receptor in combination with EGFR inhibitor administration may improve TNBC management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRs0_2DtmXYlMGsG_HTXYFfW6udTcc2ea20fznp1Py57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ksl2ktg%253D%253D&md5=31a10425d0c90669ac4e093f27c64e49</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10804%26sid%3Dliteratum%253Aachs%26aulast%3DMerrouche%26aufirst%3DY.%26aulast%3DFabre%26aufirst%3DJ.%26aulast%3DCure%26aufirst%3DH.%26aulast%3DGarbar%26aufirst%3DC.%26aulast%3DFuselier%26aufirst%3DC.%26aulast%3DBastid%26aufirst%3DJ.%26aulast%3DAntonicelli%26aufirst%3DF.%26aulast%3DAl-Daccak%26aufirst%3DR.%26aulast%3DBensussan%26aufirst%3DA.%26aulast%3DGiustiniani%26aufirst%3DJ.%26atitle%3DIL-17E%2520synergizes%2520with%2520EGF%2520and%2520confers%2520in%2520vitro%2520resistance%2520to%2520EGFR-targeted%2520therapies%2520in%2520TNBC%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D33%26spage%3D53350%26epage%3D53361%26doi%3D10.18632%2Foncotarget.10804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells</span>. <i>Cell Biol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1007/s10565-018-09458-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10565-018-09458-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30612216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=361-371&issue=4&author=F.+Jiangauthor=Y.+Liauthor=L.+Siauthor=Z.+Zhangauthor=Z.+Li&title=Interaction+of+EZH2+and+P65+is+involved+in+the+arsenic+trioxide-induced+anti-angiogenesis+in+human+triple-negative+breast+cancer+cells&doi=10.1007%2Fs10565-018-09458-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells</span></div><div class="casAuthors">Jiang, Fei; Li, Yuan; Si, Lu; Zhang, Zengli; Li, Zhong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology and Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">361-371</span>CODEN:
                <span class="NLM_cas:coden">CBTOE2</span>;
        ISSN:<span class="NLM_cas:issn">0742-2091</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Breast cancer (BC) is the most common female malignancy in the world.  Triple-neg. breast cancer (TNBC) is a subtype of BC characterized by the lack of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor-2 (HER-2), resulting in the limited therapeutic options.  Due to the aggressive behaviors at early stage, TNBC exhibits poorer outcomes compared to other BC subtypes.  Hematogenous metastasis, which spreads cancerous cells to lungs and/or bones, plays a pivotal role in the progression of TNBC.  Therefore, it is of great importance to study the anti-angiogenesis regulation mechanism for finding new treatment options for TNBC.  Arsenic trioxide (ATO) exhibits anti-cancer effect on solid tumors, including TNBC.  However, the roles and the mol. mechanism of ATO in the anti-angiogenesis of TNBC remain less well documented.  Our data showed that ATO restrained the expression and secretion of vascular endothelial growth factor (VEGF) and impaired the angiogenic ability in TNBC cells.  In addn., ATO suppressed the angiogenic ability in TNBC by inhibiting the interaction of the enhancer of zeste homolog 2 (EZH2) with p65, downregulating the nuclear factor-κB (NF-κB) activity, hence contributing to the regulation of IL-6/Stat3 signaling pathway.  All of our findings would help to better understand the mechanism of ATO anti-angiogenesis in TNBC, thus highlighting the therapeutic potential of ATO in TNBC by targeting angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBSVEJ5vAAKLVg90H21EOLACvtfcHk0ljfrgLXwdnJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVCjt7vJ&md5=ab00ede90b610b8036f3df6d7c3cd155</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1007%2Fs10565-018-09458-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10565-018-09458-0%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DInteraction%2520of%2520EZH2%2520and%2520P65%2520is%2520involved%2520in%2520the%2520arsenic%2520trioxide-induced%2520anti-angiogenesis%2520in%2520human%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DCell%2520Biol.%2520Toxicol.%26date%3D2019%26volume%3D35%26issue%3D4%26spage%3D361%26epage%3D371%26doi%3D10.1007%2Fs10565-018-09458-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drews-Elger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzam, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picon-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ashry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, J. M.</span></span> <span> </span><span class="NLM_article-title">VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3107</span>– <span class="NLM_lpage">3119</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fonc.2014.257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25151964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSqtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=3107-3119&issue=24&author=D.+Zhaoauthor=C.+Panauthor=J.+Sunauthor=C.+Gilbertauthor=K.+Drews-Elgerauthor=D.+J.+Azzamauthor=M.+Picon-Ruizauthor=M.+Kimauthor=W.+Ullmerauthor=D.+El-Ashryauthor=C.+J.+Creightonauthor=J.+M.+Slingerland&title=VEGF+drives+cancer-initiating+stem+cells+through+VEGFR-2%2FStat3+signaling+to+upregulate+Myc+and+Sox2&doi=10.1038%2Fonc.2014.257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2</span></div><div class="casAuthors">Zhao, D.; Pan, C.; Sun, J.; Gilbert, C.; Drews-Elger, K.; Azzam, D. J.; Picon-Ruiz, M.; Kim, M.; Ullmer, W.; El-Ashry, D.; Creighton, C. J.; Slingerland, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3107-3119</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor-A (VEGF), a potent angiogenic factor, is also implicated in self-renewal in several normal tissue types.  VEGF has been shown to drive malignant stem cells but mechanisms thereof and tumor types affected are not fully characterized.  Here, we show VEGF promotes breast and lung cancer stem cell (CSC) self-renewal via VEGF receptor-2 (VEGFR-2)/STAT3-mediated upregulation of Myc and Sox2.  VEGF increased tumor spheres and aldehyde dehydrogenase activity, both proxies for stem cell function in vitro, in triple-neg. breast cancer (TNBC) lines and dissocd. primary cancers, and in lung cancer lines.  VEGF exposure before injection increased breast cancer-initiating cell abundance in vivo yielding increased orthotopic tumors, and increased metastasis from orthotopic primaries and following tail vein injection without further VEGF treatment.  VEGF rapidly stimulated VEGFR-2/JAK2/STAT3 binding and activated STAT3 to bind MYC and SOX2 promoters and induce their expression.  VEGFR-2 knockdown or inhibition abrogated VEGF-mediated STAT3 activation, MYC and SOX2 induction and sphere formation.  Notably, knockdown of either STAT3, MYC or SOX2 impaired VEGF-upregulation of pSTAT3, MYC and SOX2 expression and sphere formation.  Each transcription factor, once upregulated, appears to promote sustained activation of the others, creating a feed-forward loop to drive self-renewal.  Thus, in addn. to angiogenic effects, VEGF promotes tumor-initiating cell self-renewal through VEGFR-2/STAT3 signaling.  Anal. of primary breast and lung cancers (>1300 each) showed high VEGF expression, was prognostic of poor outcome and strongly assocd. with STAT3 and MYC expression, supporting the link between VEGF and CSC self-renewal.  High-VEGF tumors may be most likely to escape anti-angiogenics by upregulating VEGF, driving CSC self-renewal to re-populate post-treatment.  Our work highlights the need to better define VEGF-driven cancer subsets and supports further investigation of combined therapeutic blockade of VEGF or VEGFR-2 and JAK2/STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJaiaQtHeeBbVg90H21EOLACvtfcHk0ljfrgLXwdnJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSqtb%252FJ&md5=be3d066b7f65a8a7ed1c1d0d9ebc05a1</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.257%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DC.%26aulast%3DDrews-Elger%26aufirst%3DK.%26aulast%3DAzzam%26aufirst%3DD.%2BJ.%26aulast%3DPicon-Ruiz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DUllmer%26aufirst%3DW.%26aulast%3DEl-Ashry%26aufirst%3DD.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DSlingerland%26aufirst%3DJ.%2BM.%26atitle%3DVEGF%2520drives%2520cancer-initiating%2520stem%2520cells%2520through%2520VEGFR-2%252FStat3%2520signaling%2520to%2520upregulate%2520Myc%2520and%2520Sox2%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26issue%3D24%26spage%3D3107%26epage%3D3119%26doi%3D10.1038%2Fonc.2014.257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vance, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gralow, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickler, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobleigh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkier, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vang
Nielsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sledge, G. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparano, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badve, S. S.</span></span> <span> </span><span class="NLM_article-title">Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1289</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-12-3029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23340303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFektLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1281-1289&issue=5&author=B.+P.+Schneiderauthor=R.+J.+Grayauthor=M.+Radovichauthor=F.+Shenauthor=G.+Vanceauthor=L.+Liauthor=G.+Jiangauthor=K.+D.+Millerauthor=J.+R.+Gralowauthor=M.+N.+Dicklerauthor=M.+A.+Cobleighauthor=E.+A.+Perezauthor=T.+N.+Shenkierauthor=K.+Vang%0ANielsenauthor=S.+Mullerauthor=A.+Thorauthor=G.+W.+Sledgeauthor=J.+A.+Sparanoauthor=N.+E.+Davidsonauthor=S.+S.+Badve&title=Prognostic+and+predictive+value+of+tumor+vascular+endothelial+growth+factor+gene+amplification+in+metastatic+breast+cancer+treated+with+paclitaxel+with+and+without+bevacizumab%3B+results+from+ECOG+2100+trial&doi=10.1158%2F1078-0432.CCR-12-3029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial</span></div><div class="casAuthors">Schneider, Bryan P.; Gray, Robert J.; Radovich, Milan; Shen, Fei; Vance, Gail; Li, Lang; Jiang, Guanglong; Miller, Kathy D.; Gralow, Julie R.; Dickler, Maura N.; Cobleigh, Melody A.; Perez, Edith A.; Shenkier, Tamara N.; Vang Nielsen, Kirsten; Mueller, Sven; Thor, Ann; Sledge, George W., Jr.; Sparano, Joseph A.; Davidson, Nancy E.; Badve, Sunil S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1281-1289</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Clin. validated biomarkers for anti-angiogenesis agents are not available.  We have previously reported assocns. between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100.  The assocns. between tumor VEGFA amplification and outcome are evaluated here.  Exptl. Design: E2100 was a phase III trial comparing paclitaxel with or without bevacizumab for patients with metastatic breast cancer.  FISH to assess gene amplification status for VEGFA was conducted on paraffin-embedded tumors from 363 patients in E2100.  Evaluation for assocn. between amplification status and outcomes was conducted.  Results: Estrogen receptor (ER)+ or progesterone receptor (PR)+ tumors were less likely to have VEGFA amplification than ER/PR- tumors (P = 0.020).  VEGFA amplification was assocd. with worse OS (20.2 vs. 25.3 mo; P = 0.013) in univariate anal. with a trend for worse OS in multivariate anal. (P = 0.08).  There was a significant interaction between VEGFA amplification, hormone receptor status, and study arm.  Patients with VEGFA amplification and triple-neg. breast cancers (TNBC) or HER2 amplification had inferior OS (P = 0.047); amplification did not affect OS for those who were ER+ or PR+ and HER2-.  Those who received bevacizumab with VEGFA amplification had inferior progression-free survival (PFS; P = 0.010) and OS (P = 0.042); no assocn. was seen in the control arm.  Test for interaction between study arm and VEGFA amplification with OS was not significant.  Conclusion: VEGFA amplification in univariate anal. was assocd. with poor outcomes; this was particularly prominent in HER2+ or TNBCs.  Addnl. studies are necessary to confirm the trend for poor OS seen on multivariate anal. for patients treated with bevacizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmAv75J8R6PLVg90H21EOLACvtfcHk0liLQp_gOt6p8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFektLY%253D&md5=1e9d79073d36e3e96d900e2f9fe06cba</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3029%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DB.%2BP.%26aulast%3DGray%26aufirst%3DR.%2BJ.%26aulast%3DRadovich%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DVance%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DGralow%26aufirst%3DJ.%2BR.%26aulast%3DDickler%26aufirst%3DM.%2BN.%26aulast%3DCobleigh%26aufirst%3DM.%2BA.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DShenkier%26aufirst%3DT.%2BN.%26aulast%3DVang%2BNielsen%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DThor%26aufirst%3DA.%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DSparano%26aufirst%3DJ.%2BA.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DBadve%26aufirst%3DS.%2BS.%26atitle%3DPrognostic%2520and%2520predictive%2520value%2520of%2520tumor%2520vascular%2520endothelial%2520growth%2520factor%2520gene%2520amplification%2520in%2520metastatic%2520breast%2520cancer%2520treated%2520with%2520paclitaxel%2520with%2520and%2520without%2520bevacizumab%253B%2520results%2520from%2520ECOG%25202100%2520trial%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D5%26spage%3D1281%26epage%3D1289%26doi%3D10.1158%2F1078-0432.CCR-12-3029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoforides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aitelli, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izatt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacioru, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakarya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Vega, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billings, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salhia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousses, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J. D.</span></span> <span> </span><span class="NLM_article-title">Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-12-0781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23171949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVamug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=104-116&issue=1&author=D.+W.+Craigauthor=J.+A.+O%E2%80%99Shaughnessyauthor=J.+A.+Kieferauthor=J.+Aldrichauthor=S.+Sinariauthor=T.+M.+Mosesauthor=S.+Wongauthor=J.+Dinhauthor=A.+Christoforidesauthor=J.+L.+Blumauthor=C.+L.+Aitelliauthor=C.+R.+Osborneauthor=T.+Izattauthor=A.+Kurdogluauthor=A.+Bakerauthor=J.+Koemanauthor=C.+Barbacioruauthor=O.+Sakaryaauthor=F.+M.+De+La+Vegaauthor=A.+Siddiquiauthor=L.+Hoangauthor=P.+R.+Billingsauthor=B.+Salhiaauthor=A.+W.+Tolcherauthor=J.+M.+Trentauthor=S.+Moussesauthor=D.+Von+Hoffauthor=J.+D.+Carpten&title=Genome+and+transcriptome+sequencing+in+prospective+metastatic+triple-negative+breast+cancer+uncovers+therapeutic+vulnerabilities&doi=10.1158%2F1535-7163.MCT-12-0781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities</span></div><div class="casAuthors">Craig, David W.; O'Shaughnessy, Joyce A.; Kiefer, Jeffrey A.; Aldrich, Jessica; Sinari, Shripad; Moses, Tracy M.; Wong, Shukmei; Dinh, Jennifer; Christoforides, Alexis; Blum, Joanne L.; Aitelli, Cristi L.; Osborne, Cynthia R.; Izatt, Tyler; Kurdoglu, Ahmet; Baker, Angela; Koeman, Julie; Barbacioru, Catalin; Sakarya, Onur; De La Vega, Francisco M.; Siddiqui, Asim; Hoang, Linh; Billings, Paul R.; Salhia, Bodour; Tolcher, Anthony W.; Trent, Jeffrey M.; Mousses, Spyro; Von Hoff, Daniel; Carpten, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-116</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2.  Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor prognosis with median survival of one year.  Here, we present initial analyses of whole genome and transcriptome sequencing data from 14 prospective mTNBC.  We have cataloged the collection of somatic genomic alterations in these advanced tumors, particularly those that may inform targeted therapies.  Genes mutated in multiple tumors included TP53, LRP1B, HERC1, CDH5, RB1, and NF1.  Notable genes involved in focal structural events were CTNNA1, PTEN, FBXW7, BRCA2, WT1, FGFR1, KRAS, HRAS, ARAF, BRAF, and PGCP.  Homozygous deletion of CTNNA1 was detected in 2 of 6 African Americans.  RNA sequencing revealed consistent overexpression of the FOXM1 gene when tumor gene expression was compared with nonmalignant breast samples.  Using an outlier anal. of gene expression comparing one cancer with all the others, we detected expression patterns unique to each patient's tumor.  Integrative DNA/RNA anal. provided evidence for deregulation of mutated genes, including the monoallelic expression of TP53 mutations.  Finally, mol. alterations in several cancers supported targeted therapeutic intervention on clin. trials with known inhibitors, particularly for alterations in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways.  In conclusion, whole genome and transcriptome profiling of mTNBC have provided insights into somatic events occurring in this difficult to treat cancer.  These genomic data have guided patients to investigational treatment trials and provide hypotheses for future trials in this irremediable cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-JLQZ9xmALVg90H21EOLACvtfcHk0liLQp_gOt6p8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVamug%253D%253D&md5=0cc86f6a13750602c4663ad034e9ff71</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0781%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DD.%2BW.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%2BA.%26aulast%3DKiefer%26aufirst%3DJ.%2BA.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DSinari%26aufirst%3DS.%26aulast%3DMoses%26aufirst%3DT.%2BM.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DDinh%26aufirst%3DJ.%26aulast%3DChristoforides%26aufirst%3DA.%26aulast%3DBlum%26aufirst%3DJ.%2BL.%26aulast%3DAitelli%26aufirst%3DC.%2BL.%26aulast%3DOsborne%26aufirst%3DC.%2BR.%26aulast%3DIzatt%26aufirst%3DT.%26aulast%3DKurdoglu%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DA.%26aulast%3DKoeman%26aufirst%3DJ.%26aulast%3DBarbacioru%26aufirst%3DC.%26aulast%3DSakarya%26aufirst%3DO.%26aulast%3DDe%2BLa%2BVega%26aufirst%3DF.%2BM.%26aulast%3DSiddiqui%26aufirst%3DA.%26aulast%3DHoang%26aufirst%3DL.%26aulast%3DBillings%26aufirst%3DP.%2BR.%26aulast%3DSalhia%26aufirst%3DB.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DTrent%26aufirst%3DJ.%2BM.%26aulast%3DMousses%26aufirst%3DS.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26atitle%3DGenome%2520and%2520transcriptome%2520sequencing%2520in%2520prospective%2520metastatic%2520triple-negative%2520breast%2520cancer%2520uncovers%2520therapeutic%2520vulnerabilities%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26issue%3D1%26spage%3D104%26epage%3D116%26doi%3D10.1158%2F1535-7163.MCT-12-0781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y. Q.</span></span> <span> </span><span class="NLM_article-title">Expression and significance of ERK-1 and p27 in human breast cancer</span>. <i>J. Mod. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>, (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2496</span>– <span class="NLM_lpage">2498</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=2496-2498&issue=11&author=J.+Y.+Qinauthor=L.+Wangauthor=L.+H.+Niuauthor=L.+M.+Liauthor=Y.+Q.+Su&title=Expression+and+significance+of+ERK-1+and+p27+in+human+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNiu%26aufirst%3DL.%2BH.%26aulast%3DLi%26aufirst%3DL.%2BM.%26aulast%3DSu%26aufirst%3DY.%2BQ.%26atitle%3DExpression%2520and%2520significance%2520of%2520ERK-1%2520and%2520p27%2520in%2520human%2520breast%2520cancer%26jtitle%3DJ.%2520Mod.%2520Oncol.%26date%3D2013%26issue%3D11%26spage%3D2496%26epage%3D2498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalezangulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2011-0377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1634%2Ftheoncologist.2011-0377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=22584435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=766-774&issue=6&author=C.+Bartholomeuszauthor=A.+Gonzalezanguloauthor=L.+Pingauthor=N.+Hayashiauthor=G.+N.+Hortobagyiauthor=N.+T.+Ueno&title=High+ERK+protein+expression+levels+correlate+with+shorter+survival+in+triple-negative+breast+cancer&doi=10.1634%2Ftheoncologist.2011-0377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">High ERK protein expression levels correlate with shorter survival in triple-breast cancer patients</span></div><div class="casAuthors">Bartholomeusz, Chandra; Gonzalez-Angulo, Ana M.; Liu, Ping; Hayashi, Naoki; Lluch, Ana; Ferrer-Lozano, Jaime; Hortobagyi, Gabriel N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">766-774</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) signaling pathway is known to be activated in triple-neg. breast cancer (TNBC).  Extracellular signal-related kinase (ERK), a member of the MAPK pathway, promotes cell proliferation, angiogenesis, cell differentiation, and cell survival.  To assess the prognostic impact of ERK in TNBC patients, relative quantities of ERK (ERK-2 and pMAPK) and direct targets of the ERK pathway (MAPK/ERK kinase 1, phospho-enriched protein in astrocytes [PEA]-15, phosphorylated (p)PEA-15, tuberous sclerosis protein 2, p70S6 kinase, and p27) were measured using reverse-phase protein arrays in tumor tissue from patients with TNBC (n = 97) and non-TNBC (n = 223).  Protein levels in patients with TNBC were correlated with clin. and tumor characteristics and outcome.  The median age of patients with TNBC was 55 years (range, 27-86 years).  Disease stage was I in 21%, II in 60%, and III in 20% of the patients.  In a multivariate anal., among patients with TNBC, those with ERK-2-overexpressing tumors had a lower overall survival rate than those with low ERK-2-expressing tumors (hazard ratio [HR], 2.76; 95% confidence interval [CI], 1.19-6.41).  However, high pMAPK levels were assocd. with a significantly higher relapse-free survival rate (HR, 0.66; 95% CI, 0.46-0.95).  In conclusion, ERK-2 and pMAPK are valuable prognostic markers in TNBC.  Further studies are justified to elucidate ERK's role in TNBC tumorigenicity and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG-QY4WCoyHLVg90H21EOLACvtfcHk0lgELQ0zrFLUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrsLbE&md5=adcaa0a1a5fb7605f88051b531dc2448</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2011-0377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2011-0377%26sid%3Dliteratum%253Aachs%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DGonzalezangulo%26aufirst%3DA.%26aulast%3DPing%26aufirst%3DL.%26aulast%3DHayashi%26aufirst%3DN.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DHigh%2520ERK%2520protein%2520expression%2520levels%2520correlate%2520with%2520shorter%2520survival%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncologist%26date%3D2012%26volume%3D17%26issue%3D6%26spage%3D766%26epage%3D774%26doi%3D10.1634%2Ftheoncologist.2011-0377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor types</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3976</span>– <span class="NLM_lpage">3995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01896</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01896" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFOku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3976-3995&issue=8&author=G.+Wangauthor=Y.+Zhaoauthor=Y.+Liuauthor=D.+Sunauthor=Y.+Zhenauthor=J.+Liuauthor=L.+Fuauthor=L.+Zhangauthor=L.+Ouyang&title=Discovery+of+a+novel+dual-target+inhibitor+of+ERK1+and+ERK5+that+induces+regulated+cell+death+to+overcome+compensatory+mechanism+in+specific+tumor+types&doi=10.1021%2Facs.jmedchem.9b01896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types</span></div><div class="casAuthors">Wang, Guan; Zhao, Yuqian; Liu, Yao; Sun, Dejuan; Zhen, Yongqi; Liu, Jie; Fu, Leilei; Zhang, Lan; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3976-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ERK1 and ERK5 are proposed to have pivotal roles in several types of cancer.  Under some circumstance, ERK5 may provide a common bypass route, which rescues proliferation upon abrogation of ERK1 signaling.  Thus, we accurately classified the tumor types from The Cancer Genome Atlas (TCGA) based on the expression levels of ERK1 and ERK5.  We proposed a novel therapeutic strategy to overcome the above-mentioned compensatory mechanism in specific tumor types by co-targeting both ERK1 and ERK5.  On the basis of the idea of overcoming ERK5 compensation mechanism, 22ac (ADTL-EI1712) as the first selective dual-target inhibitor of ERK1 and ERK5 was discovered to have potent antitumor effects in vitro and in vivo.  Interestingly, this compd. was found to induce regulated cell death accompanied by autophagy in MKN-74 cells.  Taken together, our results warrant the potential of this dual-target inhibitor as a new candidate drug that conquers compensatory mechanism in certain tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlxVBmkLH7mrVg90H21EOLACvtfcHk0lgELQ0zrFLUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFOku7c%253D&md5=a39e2b19b4e97ba739e78f2453335714</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01896%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520dual-target%2520inhibitor%2520of%2520ERK1%2520and%2520ERK5%2520that%2520induces%2520regulated%2520cell%2520death%2520to%2520overcome%2520compensatory%2520mechanism%2520in%2520specific%2520tumor%2520types%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D8%26spage%3D3976%26epage%3D3995%26doi%3D10.1021%2Facs.jmedchem.9b01896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizwanullah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, K.</span></span> <span> </span><span class="NLM_article-title">PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2181</span>– <span class="NLM_lpage">2191</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.drudis.2019.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31520748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWju7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2181-2191&issue=11&author=M.+Khanauthor=V.+Jainauthor=M.+Rizwanullahauthor=J.+Ahmadauthor=K.+Jain&title=PI3K%2FAKT%2FmTOR+pathway+inhibitors+in+triple-negative+breast+cancer%3A+a+review+on+drug+discovery+and+future+challenges&doi=10.1016%2Fj.drudis.2019.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges</span></div><div class="casAuthors">Khan, Mohammad A.; Jain, Vineet K.; Rizwanullah, Md.; Ahmad, Javed; Jain, Keerti</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2181-2191</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is a highly malignant subtype of breast cancer assocd. with poor prognosis.  Although conventional chemotherapy regimens have shown some effectiveness in early TNBC cases, the outcome in advanced stages is poor.  The PI3K/AKT/mTOR pathway is one of the important and active pathways involved in chemoresistance and survival of TNBC.  This pathway is speculated to play an important part in malignant transformation and has been considered as a potential mol. target for the design of therapeutic agents to treat TNBC.  This review discusses the potentials and drug discovery perspectives of PI3K/AKT/mTOR as a therapeutic target for effective management of TNBC with anticipated challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4h1LPJcV0U7Vg90H21EOLACvtfcHk0lgELQ0zrFLUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWju7rF&md5=dbde097d9af193befbd393d8b62a9136</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DJain%26aufirst%3DV.%26aulast%3DRizwanullah%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DJ.%26aulast%3DJain%26aufirst%3DK.%26atitle%3DPI3K%252FAKT%252FmTOR%2520pathway%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%253A%2520a%2520review%2520on%2520drug%2520discovery%2520and%2520future%2520challenges%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26issue%3D11%26spage%3D2181%26epage%3D2191%26doi%3D10.1016%2Fj.drudis.2019.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarracin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-MacGregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mtor inhibition in combination with liposomal doxorubicin and bevacizumab</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2016.5281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1001%2Fjamaoncol.2016.5281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27893038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhtVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=509-515&issue=4&author=R.+Bashoauthor=M.+Gilcreaseauthor=R.+Murthyauthor=T.+Helgasonauthor=D.+Karpauthor=F.+Meric-Bernstamauthor=K.+Hessauthor=S.+Herbrichauthor=V.+Valeroauthor=C.+Albarracinauthor=J.+Littonauthor=M.+Chavez-MacGregorauthor=N.+Ibrahimauthor=J.+Murrayauthor=K.+Koenigauthor=D.+Hongauthor=V.+Subbiahauthor=R.+Kurzrockauthor=F.+Jankuauthor=S.+Moulder&title=Targeting+the+PI3K%2FAKT%2FmTOR+pathway+for+the+treatment+of+mesenchymal+triple-negative+breast+cancer%3A+evidence+from+a+phase+1+trial+of+mtor+inhibition+in+combination+with+liposomal+doxorubicin+and+bevacizumab&doi=10.1001%2Fjamaoncol.2016.5281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab</span></div><div class="casAuthors">Basho Reva K; Gilcrease Michael; Albarracin Constance; Murthy Rashmi K; Valero Vicente; Litton Jennifer K; Ibrahim Nuhad K; Murray James L 3rd; Koenig Kimberly B; Helgason Thorunn; Karp Daniel D; Hong David; Subbiah Vivek; Janku Filip; Meric-Bernstam Funda; Hess Kenneth R; Herbrich Shelley M; Chavez-MacGregor Mariana; Kurzrock Razelle; Moulder Stacy L</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-515</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response.  Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy.  While assays to identify mesenchymal TNBC are under development, metaplastic breast cancer serves as a clinically identifiable surrogate to evaluate potential regimens for mesenchymal TNBC.  Objective:  To assess safety and efficacy of mammalian target of rapamycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with advanced metaplastic TNBC.  Design, Setting, and Participants:  Phase 1 study with dose escalation and dose expansion at the University of Texas MD Anderson Cancer Center of patients with advanced metaplastic TNBC.  Patients were enrolled from April 16, 2009, to November 4, 2014, and followed for outcomes with a cutoff date of November 1, 2015, for data analysis.  Interventions:  Liposomal doxorubicin, bevacizumab, and the mTOR inhibitors temsirolimus or everolimus using 21-day cycles.  Main Outcomes and Measures:  Safety and response.  When available, archived tissue was evaluated for aberrations in the PI3K pathway.  Results:  Fifty-two women with metaplastic TNBC (median age, 58 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE) (N = 13).  The objective response rate was 21% (complete response = 4 [8%]; partial response = 7 [13%]) and 10 (19%) patients had stable disease for at least 6 months, for a clinical benefit rate of 40%.  Tissue was available for testing in 43 patients, and 32 (74%) had a PI3K pathway aberration.  Presence of PI3K pathway aberration was associated with a significant improvement in objective response rate (31% vs 0%; P = .04) but not clinical benefit rate (44% vs 45%; P > .99).  Conclusions and Relevance:  Using metaplastic TNBC as a surrogate for mesenchymal TNBC, DAT and DAE had notable activity in mesenchymal TNBC.  Objective response was limited to patients with PI3K pathway aberration.  A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTatjZ_QtxszUbxh97K6Vt6fW6udTcc2eauwk0nN-H_fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhtVSjsQ%253D%253D&md5=10ca11d3bfc1e167136b282120d58a7b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2016.5281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2016.5281%26sid%3Dliteratum%253Aachs%26aulast%3DBasho%26aufirst%3DR.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DMurthy%26aufirst%3DR.%26aulast%3DHelgason%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DD.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHess%26aufirst%3DK.%26aulast%3DHerbrich%26aufirst%3DS.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DAlbarracin%26aufirst%3DC.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DChavez-MacGregor%26aufirst%3DM.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DKoenig%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DMoulder%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520PI3K%252FAKT%252FmTOR%2520pathway%2520for%2520the%2520treatment%2520of%2520mesenchymal%2520triple-negative%2520breast%2520cancer%253A%2520evidence%2520from%2520a%2520phase%25201%2520trial%2520of%2520mtor%2520inhibition%2520in%2520combination%2520with%2520liposomal%2520doxorubicin%2520and%2520bevacizumab%26jtitle%3DJAMA%2520Oncol.%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D509%26epage%3D515%26doi%3D10.1001%2Fjamaoncol.2016.5281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">González-Martínez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Mies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero-Barrio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios-Berraquero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-García, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios, J.</span></span> <span> </span><span class="NLM_article-title">Molecular features of metaplastic breast carcinoma: an infrequent subtype of triple negative breast carcinoma</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1832</span>, <span class="refDoi"> DOI: 10.3390/cancers12071832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers12071832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKms7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1832&issue=7&author=S.+Gonz%C3%A1lez-Mart%C3%ADnezauthor=B.+P%C3%A9rez-Miesauthor=I.+Carretero-Barrioauthor=M.+Palacios-Berraqueroauthor=J.+Perez-Garc%C3%ADaauthor=J.+Cort%C3%A9sauthor=J.+Palacios&title=Molecular+features+of+metaplastic+breast+carcinoma%3A+an+infrequent+subtype+of+triple+negative+breast+carcinoma&doi=10.3390%2Fcancers12071832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular features of metaplastic breast carcinoma: An infrequent subtype of triple negative breast carcinoma</span></div><div class="casAuthors">Gonzalez-Martinez, Silvia; Perez-Mies, Belen; Carretero-Barrio, Irene; Palacios-Berraquero, Maria Luisa; Perez-Garcia, Jose; Cortes, Javier; Palacios, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1832</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent invasive carcinomas that display differentiation of the neoplastic epithelium towards squamous cells and/or mesenchymal-type elements.  Most MBC have a triple neg. phenotype and poor prognosis.  Thus, MBC have worse survival rates than other invasive breast carcinomas, including other triple neg. breast carcinomas (TNBC).  In this study, we reviewed the mol. features of MBC, pointing out the differences among subtypes.  The most frequently mutated genes in MBC were TP53 and PIK3CA.  Addnl., mutations in the other genes of the PI3K/AKT pathway indicated its importance in the pathogenesis of MBC.  Regarding copy no. variations (CNVs), MYC was the most frequently amplified gene, and the most frequent gene loss affected the CDKN2A/CDKN2B locus.  Furthermore, the pattern of mutations and CNVs of MBC differed from those reported in other TNBC.  However, the mol. profile of MBC was not homogeneous among histol. subtypes, being the alterations in the PI3K pathway most frequent in spindle cell carcinomas.  Transcriptomic studies have demonstrated an epithelial to mesenchymal program activation and the enrichment of stemness genes in most MBC.  In addn., current studies are attempting to define the immune microenvironment of these tumors.  In conclusion, due to specific mol. features, MBC have a different clin. behavior from other types of TNBC, being more resistant to std. chemotherapy.  For this reason, new therapeutic approaches based on tumor mol. characteristics are needed to treat MBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosthQ8DLljKbVg90H21EOLACvtfcHk0liz7uO1YBo17Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKms7rP&md5=9fe24d62bdaa0176f9cf5e95ae4c039b</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.3390%2Fcancers12071832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12071832%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Mart%25C3%25ADnez%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez-Mies%26aufirst%3DB.%26aulast%3DCarretero-Barrio%26aufirst%3DI.%26aulast%3DPalacios-Berraquero%26aufirst%3DM.%26aulast%3DPerez-Garc%25C3%25ADa%26aufirst%3DJ.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26aulast%3DPalacios%26aufirst%3DJ.%26atitle%3DMolecular%2520features%2520of%2520metaplastic%2520breast%2520carcinoma%253A%2520an%2520infrequent%2520subtype%2520of%2520triple%2520negative%2520breast%2520carcinoma%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26issue%3D7%26spage%3D1832%26doi%3D10.3390%2Fcancers12071832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarracin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1346</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdv163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25878190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2MjksVWnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=1346-1352&issue=7&author=S.+Moulderauthor=T.+Helgasonauthor=F.+Jankuauthor=J.+Whelerauthor=J.+Moroneyauthor=D.+Booserauthor=C.+Albarracinauthor=P.+Morrowauthor=J.+Atkinsauthor=K.+Koenigauthor=M.+Gilcreaseauthor=R.+Kurzrock&title=Inhibition+of+the+phosphoinositide+3-kinase+pathway+for+the+treatment+of+patients+with+metastatic+metaplastic+breast+cancer&doi=10.1093%2Fannonc%2Fmdv163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer</span></div><div class="casAuthors">Moulder S; Helgason T; Janku F; Wheler J; Moroney J; Atkins J; Booser D; Morrow P K; Koenig K; Albarracin C; Gilcrease M; Kurzrock R</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1346-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor phosphoinositide 3-kinase (PI3kinase) alterations; thus, therapy with mTor inhibitors may demonstrate activity.  PATIENTS AND METHODS:  Patients with mesenchymal/MpBC treated with temsirolimus-based regimens were evaluated.  Mutational analyses [polymerase chain reaction (PCR)-based DNA sequencing method, mass spectrometric detection (Sequenom MassARRAY), or next-generation sequencing] as well as loss of phosphatase and tensin homolog (PTEN) (immunohistochemistry) were performed (archived tissue when available).  RESULTS:  Twenty-three patients (one of whom was on two separate trials) were treated using temsirolimus-containing regimens: temsirolimus alone (n = 1 patient) or combined with the following: liposomal doxorubicin and bevacizumab (DAT, n = 18); liposomal doxorubicin (DT, n = 1); paclitaxel and bevacizumab (TAT, n = 2); paclitaxel (TT, n = 1); carboplatin and bevacizumab (CAT, n = 1).  Response rate [complete response (CR) + partial response (PR)] was 25% across all regimens; 32% in the anthracycline-based regimens [DAT and DT (CR = 2, PR = 4; N = 19)].  An additional two patients achieved stable disease (SD) ≥6 months [total SD ≥6 months/CR/PR = 8 (33%)].  Molecular aberrations in the PI3K pathway were common: PIK3CA mutation = 6/15 (40%), PTEN mutation = 3/11 (27%), and PTEN loss = 2/11 (18%).  A point mutation in the NF2 gene (K159fs*16; NF2 alterations can activate mTor) was found in one patient who attained CR (3+ years).  Of the eight patients who achieved SD ≥6 months/CR/PR, all 4 patients with available tissue had a molecular aberration that activate the PIK3CA/Akt/mTOR axis: PIK3CA mutation = 2; PTEN loss = 1; NF2 aberration = 1.  CONCLUSIONS:  DAT has activity in MpBCs including complete CRs.  Molecular aberrations that can activate the PI3 K/Akt/mTOR axis are common in MpBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB_xIuv3BuABFwe7cAcrfPfW6udTcc2eZSBwSBk0SxE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjksVWnuw%253D%253D&md5=20467882c60bc34839680e80102bbd47</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv163%26sid%3Dliteratum%253Aachs%26aulast%3DMoulder%26aufirst%3DS.%26aulast%3DHelgason%26aufirst%3DT.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DWheler%26aufirst%3DJ.%26aulast%3DMoroney%26aufirst%3DJ.%26aulast%3DBooser%26aufirst%3DD.%26aulast%3DAlbarracin%26aufirst%3DC.%26aulast%3DMorrow%26aufirst%3DP.%26aulast%3DAtkins%26aufirst%3DJ.%26aulast%3DKoenig%26aufirst%3DK.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520metastatic%2520metaplastic%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26issue%3D7%26spage%3D1346%26epage%3D1352%26doi%3D10.1093%2Fannonc%2Fmdv163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarracin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-MacGregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span> <span> </span><span class="NLM_article-title">Comparative effectiveness of an mTOR-based systemic therapy regimen in advanced, metaplastic and nonmetaplastic triple-negative breast cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1300</span>– <span class="NLM_lpage">1309</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2017-0498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1634%2Ftheoncologist.2017-0498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30139837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=1300-1309&issue=11&author=R.+Bashoauthor=C.+Yamauthor=M.+Gilcreaseauthor=R.+Murthyauthor=T.+Helgasonauthor=D.+Karpauthor=F.+Meric-Bernstamauthor=K.+Hessauthor=V.+Valeroauthor=C.+Albarracinauthor=J.+Littonauthor=M.+Chavez-MacGregorauthor=D.+Hongauthor=R.+Kurzrockauthor=G.+Hortobagyiauthor=F.+Jankuauthor=S.+Moulder&title=Comparative+effectiveness+of+an+mTOR-based+systemic+therapy+regimen+in+advanced%2C+metaplastic+and+nonmetaplastic+triple-negative+breast+cancer&doi=10.1634%2Ftheoncologist.2017-0498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer</span></div><div class="casAuthors">Basho, Reva K.; Yam, Clinton; Gilcrease, Michael; Murthy, Rashmi K.; Helgason, Thorunn; Karp, Daniel D.; Meric-Bernstam, Funda; Hess, Kenneth R.; Valero, Vicente; Albarracin, Constance; Litton, Jennifer K.; Chavez-MacGregor, Mariana; Hong, David; Kurzrock, Razelle; Hortobagyi, Gabriel N.; Janku, Filip; Moulder, Stacy L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1300-1309</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1549-490X</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Background : Triple-neg. breast cancer (TNBC) is a heterogeneous disease with subtypes having different "targetable" mol. aberrations.  To det. if tumor subtype influences prognosis, we compared treatment outcomes of patients with MpBC with those of patients with nonmetaplastic TNBC receiving an mTOR-based systemic therapy regimen.  Patients and Methods : Patients with advanced MpBC and nonmetaplastic TNBC were treated at our institution from Apr. 16, 2009, through Nov. 4, 2014, using mTOR inhibition (temsirolimus or everolimus) with liposomal doxorubicin and bevacizumab (DAT/DAE).  Multivariable models were adjusted for all covariates.  Results : Fourteen patients with nonmetaplastic TNBC and 59 patients with advanced MpBC were treated with DAT/DAE.  Median PFS for the nonmetaplastic TNBC and MpBC patients was 2.5 mo and 4.8 mo, resp.  MpBC remained significantly assocd. with improved OS on multivariable anal. (p < .0001).  Conclusion : In our study, DAT/DAE appeared to be more effective in MpBC compared with nonmetaplastic TNBC.  These data support patient selection for targeted therapy in TNBC.  Patients with advanced MpBC treated with an mTOR-based systemic therapy regimen had better long-term outcomes compared with patients with nonmetaplastic triple-neg. breast cancer treated with the same regimen, suggesting that metaplastic histol. may predict benefit from agents targeting the PI3K/Akt/mTOR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAqAHhPuirGLVg90H21EOLACvtfcHk0likEBmaeFZt1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKnu7s%253D&md5=ec560680485f71f6e46f005922c4c2f8</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2017-0498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2017-0498%26sid%3Dliteratum%253Aachs%26aulast%3DBasho%26aufirst%3DR.%26aulast%3DYam%26aufirst%3DC.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DMurthy%26aufirst%3DR.%26aulast%3DHelgason%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DD.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHess%26aufirst%3DK.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DAlbarracin%26aufirst%3DC.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DChavez-MacGregor%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DMoulder%26aufirst%3DS.%26atitle%3DComparative%2520effectiveness%2520of%2520an%2520mTOR-based%2520systemic%2520therapy%2520regimen%2520in%2520advanced%252C%2520metaplastic%2520and%2520nonmetaplastic%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncologist%26date%3D2018%26volume%3D23%26issue%3D11%26spage%3D1300%26epage%3D1309%26doi%3D10.1634%2Ftheoncologist.2017-0498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Couch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godwin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankratz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olswold, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slettedahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidugli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janni, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantopoulou, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fostira, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vratimos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountzilas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelttari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapper, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durcan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilarski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevanlinna, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yannoukakos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasching, P.</span></span> <span> </span><span class="NLM_article-title">Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.57.1414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2014.57.1414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25452441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Glsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=304-311&issue=4&author=F.+Couchauthor=S.+Hartauthor=P.+Sharmaauthor=A.+Tolandauthor=X.+Wangauthor=P.+Mironauthor=J.+Olsonauthor=A.+Godwinauthor=V.+Pankratzauthor=C.+Olswoldauthor=S.+Slettedahlauthor=E.+Hallbergauthor=L.+Guidugliauthor=J.+Davilaauthor=M.+Beckmannauthor=W.+Janniauthor=B.+Rackauthor=A.+Ekiciauthor=D.+Slamonauthor=I.+Konstantopoulouauthor=F.+Fostiraauthor=A.+Vratimosauthor=G.+Fountzilasauthor=L.+Pelttariauthor=W.+Tapperauthor=L.+Durcanauthor=S.+Crossauthor=R.+Pilarskiauthor=C.+Shapiroauthor=J.+Klempauthor=S.+Yaoauthor=J.+Garberauthor=A.+Coxauthor=H.+Brauchauthor=C.+Ambrosoneauthor=H.+Nevanlinnaauthor=D.+Yannoukakosauthor=S.+Slagerauthor=C.+Vachonauthor=D.+Ecclesauthor=P.+Fasching&title=Inherited+mutations+in+17+breast+cancer+susceptibility+genes+among+a+large+triple-negative+breast+cancer+cohort+unselected+for+family+history+of+breast+cancer&doi=10.1200%2FJCO.2014.57.1414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer</span></div><div class="casAuthors">Couch, Fergus J.; Hart, Steven N.; Sharma, Priyanka; Toland, Amanda Ewart; Wang, Xianshu; Miron, Penelope; Olson, Janet E.; Godwin, Andrew K.; Pankratz, V. Shane; Olswold, Curtis; Slettedahl, Seth; Hallberg, Emily; Guidugli, Lucia; Davila, Jaime I.; Beckmann, Matthias W.; Janni, Wolfgang; Rack, Brigitte; Ekici, Arif B.; Slamon, Dennis J.; Konstantopoulou, Irene; Fostira, Florentia; Vratimos, Athanassios; Fountzilas, George; Pelttari, Liisa M.; Tapper, William J.; Durcan, Lorraine; Cross, Simon S.; Pilarski, Robert; Shapiro, Charles L.; Klemp, Jennifer; Yao, Song; Garber, Judy; Cox, Angela; Brauch, Hiltrud; Ambrosone, Christine; Nevanlinna, Heli; Yannoukakos, Drakoulis; Slager, Susan L.; Vachon, Celine M.; Eccles, Diana M.; Fasching, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-311</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing of patients.  We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-neg. breast cancer (TNBC) unselected for family history of breast or ovarian cancer to det. the utility of germline genetic testing for those with TNBC.  Patients and Methods Patients with TNBC (N = 1,824) unselected for family history of breast or ovarian cancer were recruited through 12 studies, and germline DNA was sequenced to identify mutations.  Results Deleterious mutations were identified in 14.6% of all patients.  Of these, 11.2% had mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes.  Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority obsd. in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%).  Patients with TNBC with mutations were diagnosed at an earlier age (P < .001) and had higher-grade tumors (P = .01) than those without mutations.  Conclusion Deleterious mutations in predisposition genes are present at high frequency in patients with TNBC unselected for family history of cancer.  Mutation prevalence ests. suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2.  Although mutations in other predisposition genes are obsd. among patients with TNBC, better cancer risk ests. are needed before these mutations are used for clin. risk assessment in relatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozoxGL1DDjHLVg90H21EOLACvtfcHk0likEBmaeFZt1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Glsr8%253D&md5=696dff86c2a17d15869cd2729b395cd4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.57.1414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.57.1414%26sid%3Dliteratum%253Aachs%26aulast%3DCouch%26aufirst%3DF.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DToland%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMiron%26aufirst%3DP.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DGodwin%26aufirst%3DA.%26aulast%3DPankratz%26aufirst%3DV.%26aulast%3DOlswold%26aufirst%3DC.%26aulast%3DSlettedahl%26aufirst%3DS.%26aulast%3DHallberg%26aufirst%3DE.%26aulast%3DGuidugli%26aufirst%3DL.%26aulast%3DDavila%26aufirst%3DJ.%26aulast%3DBeckmann%26aufirst%3DM.%26aulast%3DJanni%26aufirst%3DW.%26aulast%3DRack%26aufirst%3DB.%26aulast%3DEkici%26aufirst%3DA.%26aulast%3DSlamon%26aufirst%3DD.%26aulast%3DKonstantopoulou%26aufirst%3DI.%26aulast%3DFostira%26aufirst%3DF.%26aulast%3DVratimos%26aufirst%3DA.%26aulast%3DFountzilas%26aufirst%3DG.%26aulast%3DPelttari%26aufirst%3DL.%26aulast%3DTapper%26aufirst%3DW.%26aulast%3DDurcan%26aufirst%3DL.%26aulast%3DCross%26aufirst%3DS.%26aulast%3DPilarski%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DC.%26aulast%3DKlemp%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DGarber%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DA.%26aulast%3DBrauch%26aufirst%3DH.%26aulast%3DAmbrosone%26aufirst%3DC.%26aulast%3DNevanlinna%26aufirst%3DH.%26aulast%3DYannoukakos%26aufirst%3DD.%26aulast%3DSlager%26aufirst%3DS.%26aulast%3DVachon%26aufirst%3DC.%26aulast%3DEccles%26aufirst%3DD.%26aulast%3DFasching%26aufirst%3DP.%26atitle%3DInherited%2520mutations%2520in%252017%2520breast%2520cancer%2520susceptibility%2520genes%2520among%2520a%2520large%2520triple-negative%2520breast%2520cancer%2520cohort%2520unselected%2520for%2520family%2520history%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D4%26spage%3D304%26epage%3D311%26doi%3D10.1200%2FJCO.2014.57.1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senkus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaloge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goessl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runswick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, P.</span></span> <span> </span><span class="NLM_article-title">Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1056%2FNEJMoa1706450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28578601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=523-533&issue=6&author=M.+Robsonauthor=S.+A.+Imauthor=E.+Senkusauthor=B.+Xuauthor=S.+M.+Domchekauthor=N.+Masudaauthor=S.+Delalogeauthor=W.+Liauthor=N.+Tungauthor=A.+Armstrongauthor=W.+Wuauthor=C.+Goesslauthor=S.+Runswickauthor=P.+Conte&title=Olaparib+for+metastatic+breast+cancer+in+patients+with+a+germline+BRCA+mutation&doi=10.1056%2FNEJMoa1706450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</span></div><div class="casAuthors">Robson, Mark; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Tung, Nadine; Armstrong, Anne; Wu, Wenting; Goessl, Carsten; Runswick, Sarah; Conte, Pierfranco</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">523-533</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Olaparib is an oral poly(ADP-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.  We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with std. therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (HER2)-neg. metastatic breast cancer who had received no more than two previous chemotherapy regimens for metastatic disease.  Patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets (300 mg twice daily) or std. therapy with single-agent chemotherapy of the physician's choice (capecitabine, eribulin, or vinorelbine in 21-day cycles).  The primary end point was progression-free survival, which was assessed by blinded independent central review and was analyzed on an intention-to-treat basis. results Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive std. therapy.  Median progression-free survival was significantly longer in the olaparib group than in the std.-therapy group (7.0 mo vs. 4.2 mo; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).  The response rate was 59.9% in the olaparib group and 28.8% in the std.-therapy group.  The rate of grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the std.-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, resp.  Among patients with HER2-neg. metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over std. therapy; median progression-free survival was 2.8 mo longer and the risk of disease progression or death was 42% lower with olaparib monotherapy than with std. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMXxR-ZN4IGrVg90H21EOLACvtfcHk0lgXyBenMKBuEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbN&md5=7c8c62182a717c16c5762443fb3f6d5d</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706450%26sid%3Dliteratum%253Aachs%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DSenkus%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTung%26aufirst%3DN.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DGoessl%26aufirst%3DC.%26aulast%3DRunswick%26aufirst%3DS.%26aulast%3DConte%26aufirst%3DP.%26atitle%3DOlaparib%2520for%2520metastatic%2520breast%2520cancer%2520in%2520patients%2520with%2520a%2520germline%2520BRCA%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D6%26spage%3D523%26epage%3D533%26doi%3D10.1056%2FNEJMoa1706450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okuma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonemori, K.</span></span> <span> </span><span class="NLM_article-title">BRCA gene mutations and poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1026</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1007/978-981-10-6020-5_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2F978-981-10-6020-5_13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29282689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCns7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1026&publication_year=2017&pages=271-286&author=H.+Okumaauthor=K.+Yonemori&title=BRCA+gene+mutations+and+poly%28ADP-ribose%29+polymerase+inhibitors+in+triple-negative+breast+cancer&doi=10.1007%2F978-981-10-6020-5_13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">BRCA gene mutations and poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer</span></div><div class="casAuthors">Okuma, Hitomi Sumiyoshi; Yonemori, Kan</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1026</span>
        (<span class="NLM_cas:issue">Translational Research in Breast Cancer</span>),
    <span class="NLM_cas:pages">271-286</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Breast cancer is the most common cancer in women worldwide.  Treatment is chosen according to its hormone receptor status and human epidermal growth factor receptor 2 (HER2) status.  Among the four main clin. set subtypes, hormone receptor-neg./HER2-neg. subtype, also called triple-neg. subtype (TNBC), is the most aggressive type with limited choices of therapy.  However, recent research has provided important new insights into effective treatments for this subtype.  One mol. target that has gained attention is the BRCA gene.  BRCA proteins are involved in the maintenance of genomic integrity, therefore playing an important role as a "caretaker" DNA repair protein.  Approx. 5% of all breast cancer patients are BRCA mutation carriers, and among the patients with BRCA mutations, 57.1% have the clin. TNBC subtype, showing a high assocn. between BRCA mutations and TNBCs.  When cells lack either BRCA1 or BRCA2, all types of homol.-directed repairs are compromised, and poly(ADP-ribose) (PAR) polymerase (PARP) acts as a backup system to maintain the genome, consequently making the cells highly sensitive to PARP1 inhibitors.  PARP inhibitors have shown promising activity in preclin. and early clin. trials, and today, phase III trials are ongoing.  In this chapter, we discuss the mechanism and the role of PARP inhibitors in BRCA-mutated breast cancers and further elaborate the clin. potential of PARP inhibitors as well as their barriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ9T0ZyRJavbVg90H21EOLACvtfcHk0lgXyBenMKBuEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCns7vO&md5=aa55e62f4f2d0061a97bb425743f12be</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1007%2F978-981-10-6020-5_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-981-10-6020-5_13%26sid%3Dliteratum%253Aachs%26aulast%3DOkuma%26aufirst%3DH.%26aulast%3DYonemori%26aufirst%3DK.%26atitle%3DBRCA%2520gene%2520mutations%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D1026%26spage%3D271%26epage%3D286%26doi%3D10.1007%2F978-981-10-6020-5_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marotta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almendro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marusyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipitsin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schemme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloushtain-Qimron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessarabova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolskaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, K.</span></span> <span> </span><span class="NLM_article-title">The JAK2/STAT3 signaling pathway is required for growth of CD44<sup>+</sup>CD24<sup>–</sup> stem cell-like breast cancer cells in human tumors</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2723</span>– <span class="NLM_lpage">2735</span>, <span class="refDoi"> DOI: 10.1172/JCI44745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1172%2FJCI44745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21633165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2723-2735&issue=7&author=L.+Marottaauthor=V.+Almendroauthor=A.+Marusykauthor=M.+Shipitsinauthor=J.+Schemmeauthor=S.+Walkerauthor=N.+Bloushtain-Qimronauthor=J.+Kimauthor=S.+Choudhuryauthor=R.+Maruyamaauthor=Z.+Wuauthor=M.+G%C3%B6nenauthor=L.+Mulveyauthor=M.+Bessarabovaauthor=S.+Huhauthor=S.+Silverauthor=S.+Kimauthor=S.+Parkauthor=H.+Leeauthor=K.+Andersonauthor=A.+Richardsonauthor=T.+Nikolskayaauthor=Y.+Nikolskyauthor=X.+Liuauthor=D.+Rootauthor=W.+Hahnauthor=D.+Frankauthor=K.+Polyak&title=The+JAK2%2FSTAT3+signaling+pathway+is+required+for+growth+of+CD44%2BCD24%E2%80%93+stem+cell-like+breast+cancer+cells+in+human+tumors&doi=10.1172%2FJCI44745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors</span></div><div class="casAuthors">Marotta, Lauren L. C.; Almendro, Vanessa; Marusyk, Andriy; Shipitsin, Michail; Schemme, Janina; Walker, Sarah R.; Bloushtain-Qimron, Noga; Kim, Jessica J.; Choudhury, Sibgat A.; Maruyama, Reo; Wu, Zhenhua; Gonen, Mithat; Mulvey, Laura A.; Bessarabova, Marina O.; Huh, Sung Jin; Silver, Serena J.; Kim, So Young; Park, So Yeon; Lee, Hee Eun; Anderson, Karen S.; Richardson, Andrea L.; Nikolskaya, Tatiana; Nikolsky, Yuri; Liu, X. Shirley; Root, David E.; Hahn, William C.; Frank, David A.; Polyak, Kornelia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2723-2735</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Intratumor heterogeneity is a major clin. problem because tumor cell subtypes display variable sensitivity to therapeutics and may play different roles in progression.  We previously characterized 2 cell populations in human breast tumors with distinct properties: CD44+CD24- cells that have stem cell-like characteristics, and CD44-CD24+ cells that resemble more differentiated breast cancer cells.  Here we identified 15 genes required for cell growth or proliferation in CD44+CD24- human breast cancer cells in a large-scale loss-of-function screen and found that inhibition of several of these (IL6, PTGIS, HAS1, CXCL3, and PFKFB3) reduced Stat3 activation.  We found that the IL-6/JAK2/Stat3 pathway was preferentially active in CD44+CD24- breast cancer cells compared with other tumor cell types, and inhibition of JAK2 decreased their no. and blocked growth of xenografts.  Our results highlight the differences between distinct breast cancer cell types and identify targets such as JAK2 and Stat3 that may lead to more specific and effective breast cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQqJMwVplyerVg90H21EOLACvtfcHk0lgmxvYtD-p7mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgurc%253D&md5=572bfdae3d883384eca4888540698458</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1172%2FJCI44745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI44745%26sid%3Dliteratum%253Aachs%26aulast%3DMarotta%26aufirst%3DL.%26aulast%3DAlmendro%26aufirst%3DV.%26aulast%3DMarusyk%26aufirst%3DA.%26aulast%3DShipitsin%26aufirst%3DM.%26aulast%3DSchemme%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DBloushtain-Qimron%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChoudhury%26aufirst%3DS.%26aulast%3DMaruyama%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DG%25C3%25B6nen%26aufirst%3DM.%26aulast%3DMulvey%26aufirst%3DL.%26aulast%3DBessarabova%26aufirst%3DM.%26aulast%3DHuh%26aufirst%3DS.%26aulast%3DSilver%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DNikolskaya%26aufirst%3DT.%26aulast%3DNikolsky%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRoot%26aufirst%3DD.%26aulast%3DHahn%26aufirst%3DW.%26aulast%3DFrank%26aufirst%3DD.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DThe%2520JAK2%252FSTAT3%2520signaling%2520pathway%2520is%2520required%2520for%2520growth%2520of%2520CD44%252BCD24%25E2%2580%2593%2520stem%2520cell-like%2520breast%2520cancer%2520cells%2520in%2520human%2520tumors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26issue%3D7%26spage%3D2723%26epage%3D2735%26doi%3D10.1172%2FJCI44745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweardy, D. J.</span></span> <span> </span><span class="NLM_article-title">Targeting STAT3 in cancer therapy</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1097/00001813-200507000-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1097%2F00001813-200507000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=15930886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Glurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=601-607&issue=6&author=N.+Jingauthor=D.+J.+Tweardy&title=Targeting+STAT3+in+cancer+therapy&doi=10.1097%2F00001813-200507000-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Stat3 in cancer therapy</span></div><div class="casAuthors">Jing, Naijie; Tweardy, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-607</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Stat3 is constitutively activated in many human cancers where it functions as a crit. mediator of oncogenic signaling through transcriptional activation of genes encoding apoptosis inhibitors (e.g. Bcl-xL, Mcl-1 and survivin), cell-cycle regulators (e.g. cyclin D1 and c-Myc) and inducers of angiogenesis (e.g. vascular endothelial growth factor).  This article reviews several approaches that have been pursued for targeting Stat3 in cancer therapy including antisense strategies, tyrosine kinase inhibition, decoy phosphopeptides, decoy duplex oligonucleotides and G-quartet oligodeoxynucleotides (GQ-ODN).  The GQ-ODN strategy is reviewed in somewhat greater detail than the others because it includes a novel system that effectively delivers drug into cells and tissues, addresses successfully the issue of specificity of targeting Stat3 vs. Stat1, and has demonstrated efficacy in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLZy2Lwe8ObVg90H21EOLACvtfcHk0lgmxvYtD-p7mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Glurg%253D&md5=3d6cc9c9427a6a53a103bfb367457e12</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1097%2F00001813-200507000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200507000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DN.%26aulast%3DTweardy%26aufirst%3DD.%2BJ.%26atitle%3DTargeting%2520STAT3%2520in%2520cancer%2520therapy%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2005%26volume%3D16%26issue%3D6%26spage%3D601%26epage%3D607%26doi%3D10.1097%2F00001813-200507000-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aodengqimuge</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span> <span> </span><span class="NLM_article-title">Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1032</span>, <span class="refDoi"> DOI: 10.1111/cas.12712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1111%2Fcas.12712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26041409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKgsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2015&pages=1023-1032&issue=8&author=Q.+Tanauthor=H.+Wangauthor=Y.+Huauthor=M.+Huauthor=X.+Liauthor=+Aodengqimugeauthor=Y.+Maauthor=C.+Weiauthor=L.+Song&title=Src%2FSTAT3-dependent+heme+oxygenase-1+induction+mediates+chemoresistance+of+breast+cancer+cells+to+doxorubicin+by+promoting+autophagy&doi=10.1111%2Fcas.12712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy</span></div><div class="casAuthors">Tan, Qixing; Wang, Hongli; Hu, Yongliang; Hu, Meiru; Li, Xiaoguang; Aodengqimuge; Ma, Yuanfang; Wei, Changyuan; Song, Lun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1023-1032</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Chemotherapeutic resistance in breast cancer, whether acquired or intrinsic, remains a major clin. obstacle.  Thus, increasing tumor cell sensitivity to chemotherapeutic agents will be helpful in improving the clin. management of breast cancer.  In the present study, we found an induction of HO-1 expression in doxorubicin (DOX)-treated MDA-MB-231 human breast adenocarcinoma cells, which showed insensitivity to DOX treatment.  Knockdown HO-1 expression dramatically upregulated the incidence of MDA-MB-231 cell death under DOX treatment, indicating that HO-1 functions as a crit. contributor to drug resistance in MDA-MB-231 cells.  We further obsd. that DOX exposure induced a cytoprotective autophagic flux in MDA-MB-231 cells, which was dependent on HO-1 induction.  Moreover, upregulation of HO-1 expression required the activation of both signal transducer and activator of transcription (STAT)3 and its upstream regulator, protein kinase Src.  Abrogating Src/STAT3 pathway activation attenuated HO-1 and autophagy induction, thus increasing the chemosensitivity of MDA-MB-231 cells.  Therefore, we conclude that Src/STAT3-dependent HO-1 induction protects MDA-MB-231 breast cancer cells from DOX-induced death through promoting autophagy.  In the following study, we further demonstrated the contribution of Src/STAT3/HO-1/autophagy pathway activation to DOX resistance in another breast cancer cell line, MDA-MB-468, which bears a similar phenotype to MDA-MB-231 cells.  Therefore, activation of Src/STAT3/HO-1/autophagy signaling pathway might play a general role in protecting certain subtypes of breast cancer cells from DOX-induced cytotoxicity.  Targeting this signaling event may provide a potential approach for overcoming DOX resistance in breast cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5JMVyHxsU6LVg90H21EOLACvtfcHk0lgmxvYtD-p7mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKgsLjE&md5=fcde40487289be2840e579ce043245a2</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1111%2Fcas.12712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12712%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DAodengqimuge%26aulast%3DMa%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DL.%26atitle%3DSrc%252FSTAT3-dependent%2520heme%2520oxygenase-1%2520induction%2520mediates%2520chemoresistance%2520of%2520breast%2520cancer%2520cells%2520to%2520doxorubicin%2520by%2520promoting%2520autophagy%26jtitle%3DCancer%2520Sci.%26date%3D2015%26volume%3D106%26issue%3D8%26spage%3D1023%26epage%3D1032%26doi%3D10.1111%2Fcas.12712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1080/15548627.2017.1283470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1080%2F15548627.2017.1283470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28165887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFKjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=777-778&issue=4&author=L.+Ouyangauthor=L.+Zhangauthor=L.+Fuauthor=B.+Liu&title=A+small-molecule+activator+induces+ULK1-modulating+autophagy-associated+cell+death+in+triple+negative+breast+cancer&doi=10.1080%2F15548627.2017.1283470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer</span></div><div class="casAuthors">Ouyang, Liang; Zhang, Lan; Fu, Leilei; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">777-778</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8635</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">ULK1 (unc-51 like autophagy activating kinase 1) is well known to be required to initiate the macroautophagy/autophagy process, and thus activation of ULK1-modulating autophagy/autophagy-assocd. cell death (ACD) may be a possible therapeutic strategy in triple neg. breast cancer (TNBC).  Here, our integrated The Cancer Genome Atlas (TCGA) data set, tissue microarray-based analyses and multiple biol. evaluations together demonstrate a new small-mol. activator of ULK1 for better understanding of how ULK1, the mammalian homolog of yeast Atg1, as a potential drug target can regulate ACD by the ULK complex (ULK1-ATG13-RB1CC1/FIP200-ATG101), as well as other possible ULK1 interactors, including ATF3, RAD21 and CASP3/caspase3 in TNBC.  Moreover, such new inspiring findings may help us discover that this activator of ULK1 (LYN-1604) with its anti-tumor activity and ACD-modulating mechanisms can be further exploited as a small-mol. candidate drug for future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEYz4amkfwXrVg90H21EOLACvtfcHk0lh5RUTLMryDxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFKjsbY%253D&md5=011ed979ea170fc6a8f54252ac641de1</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1080%2F15548627.2017.1283470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15548627.2017.1283470%26sid%3Dliteratum%253Aachs%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DA%2520small-molecule%2520activator%2520induces%2520ULK1-modulating%2520autophagy-associated%2520cell%2520death%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DAutophagy%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D777%26epage%3D778%26doi%3D10.1080%2F15548627.2017.1283470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanlikilicer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguztuzun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulasli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">11641</span>– <span class="NLM_lpage">11658</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.14264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28036267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1c7gs1eisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=11641-11658&issue=7&author=R.+Bayraktarauthor=M.+Pichlerauthor=P.+Kanlikilicerauthor=C.+Ivanauthor=E.+Bayraktarauthor=N.+Kahramanauthor=B.+Aslanauthor=S.+Oguztuzunauthor=M.+Ulasliauthor=A.+Arslanauthor=G.+Calinauthor=G.+Lopez-Beresteinauthor=B.+Ozpolat&title=MicroRNA+603+acts+as+a+tumor+suppressor+and+inhibits+triple-negative+breast+cancer+tumorigenesis+by+targeting+elongation+factor+2+kinase&doi=10.18632%2Foncotarget.14264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase</span></div><div class="casAuthors">Bayraktar Recep; Kanlikilicer Pinar; Ivan Cristina; Bayraktar Emine; Kahraman Nermin; Aslan Burcu; Calin George; Lopez-Berestein Gabriel; Ozpolat Bulent; Bayraktar Recep; Bayraktar Emine; Ulasli Mustafa; Arslan Ahmet; Pichler Martin; Ivan Cristina; Calin George; Lopez-Berestein Gabriel; Ozpolat Bulent; Oguztuzun Serpil</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">11641-11658</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by the absence of defined molecular targets, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and is associated with high rates of relapse and distant metastasis despite surgery and adjuvant chemotherapy.  The lack of effective targeted therapies for TNBC represents an unmet therapeutic challenge.  Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical calcium/calmodulin-dependent serine/threonine kinase that promotes TNBC tumorigenesis, progression, and drug resistance, representing a potential novel molecular target.  However, the mechanisms regulating eEF2K expression are unknown.  Here, we report that eEF2K protein expression is highly up-regulated in TNBC cells and patient tumors and it is associated with poor patient survival and clinical outcome.  We found that loss/reduced expression of miR-603 leads to eEF2K overexpression in TNBC cell lines.  Its expression results in inhibition of eEF2K by directly targeting the 3-UTR and the inhibition of tumor cell growth, migration and invasion in TNBC.  In vivo therapeutic gene delivery of miR-603 into TNBC xenograft mouse models by systemic administration of miR-603-nanoparticles led to a significant inhibition of eEF2K expression and tumor growth, which was associated with decreased activity of the downstream targets of eEF2K, including Src, Akt, cyclin D1 and c-myc.  Our findings suggest that miR-603 functions as a tumor suppressor and loss of miR-603 expression leads to increase in eEF2K expression and contributes to the growth, invasion, and progression of TNBC.  Taken together, our data suggest that miR-603-based gene therapy is a potential strategy against TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-_T1YwZchiaNc3HjJRoFAfW6udTcc2eY4-mk2ZRp1BLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7gs1eisA%253D%253D&md5=629328be6dd8244a4b8183d7c0b1bf18</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14264%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DPichler%26aufirst%3DM.%26aulast%3DKanlikilicer%26aufirst%3DP.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DAslan%26aufirst%3DB.%26aulast%3DOguztuzun%26aufirst%3DS.%26aulast%3DUlasli%26aufirst%3DM.%26aulast%3DArslan%26aufirst%3DA.%26aulast%3DCalin%26aufirst%3DG.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DMicroRNA%2520603%2520acts%2520as%2520a%2520tumor%2520suppressor%2520and%2520inhibits%2520triple-negative%2520breast%2520cancer%2520tumorigenesis%2520by%2520targeting%2520elongation%2520factor%25202%2520kinase%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D7%26spage%3D11641%26epage%3D11658%26doi%3D10.18632%2Foncotarget.14264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akcakanat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span> <span> </span><span class="NLM_article-title">Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">R138</span>, <span class="refDoi"> DOI: 10.1186/bcr3343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fbcr3343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23102376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslyqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=R138&issue=5&author=F.+Meric-Bernstamauthor=H.+Chenauthor=A.+Akcakanatauthor=K.+A.+Doauthor=A.+Lluchauthor=B.+T.+Hennessyauthor=G.+N.+Hortobagyiauthor=G.+B.+Millsauthor=A.+Gonzalez-Angulo&title=Aberrations+in+translational+regulation+are+associated+with+poor+prognosis+in+hormone+receptor-positive+breast+cancer&doi=10.1186%2Fbcr3343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer</span></div><div class="casAuthors">Meric-Bernstam, Funda; Chen, Huiqin; Akcakanat, Argun; Do, Kim-Anh; Lluch, Ana; Hennessy, Bryan T.; Hortobagyi, Gabriel N.; Mills, Gordon B.; Gonzalez-Angulo, Ana Maria</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">R138</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: Translation initiation is activated in cancer through increase in eukaryotic initiation factor 4E (eIF4E), eIF4G, phosphorylated eIF4E-binding protein (p4E-BP1) and phosphorylated ribosomal protein S6 (pS6), and decreased programmed cell death protein 4 (pdcd4), a translational inhibitor.  Further, translation elongation is deregulated though alterations in eukaryotic elongation factor 2 (eEF2) and eEF2 kinase (eEF2K).  We sought to det. the assocn. of these translational aberrations with clin.-pathol. factors and survival outcomes in hormone receptor-pos. breast cancer.  Methods: Primary tumors were collected from 190 patients with Stage I to III hormone receptor-pos. breast cancer.  Expression of eIF4E, eIF4G, 4E-BP1, p4E-BP1 T37/46, p4E-BP1 S65, p4E-BP1 T70, S6, pS6 S235/236, pS6 S240/244, pdcd4, eEF2 and eEF2K was assessed by reverse phase protein arrays.  Univariable and multivariable analyses for recurrence-free survival (RFS) and overall survival (OS) were performed.  Results: High eEF2, S6, pS6 S240/244, p4E-BP1 T70, and low pdcd4 were significantly assocd. with node positivity.  Median follow-up for living patients was 96 mo.  High p4E-BP1 T36/47, p4E-BP1 S65, p4E-BP1 T70 and 4E-BP1 were assocd. with worse RFS.  High p4E-BP1 T70 and pS6 S235/236, and low pdcd4, were assocd. with worse OS.  In multivariable anal., in addn. to pos. nodes, p4E-BP1 S65 remained a significant predictor of RFS (HR = 1.62, 95% CI = 1.13-2.31; P = 0.008).  In addn. to age, pS6 S235/236 (HR = 1.73, 95% CI = 1.03-2.90, P = 0.039), eEF2K (HR = 2.19, 95% CI = 1.35-3.56, P = 0.002) and pdcd4 (HR = 0.42, 95% CI = 0.25-0.70, P = 0.001) were assocd. with OS.  Conclusions: Increased pS6, p4E-BP1, eEF2K and decreased pdcd4 are assocd. with poor prognosis in hormone receptor-pos. breast cancer, suggesting their role as prognostic markers and therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-rWwQTSYn97Vg90H21EOLACvtfcHk0lh5RUTLMryDxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslyqs7o%253D&md5=ab7e221e04951266a2bce6a1874c1ae8</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1186%2Fbcr3343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr3343%26sid%3Dliteratum%253Aachs%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DAkcakanat%26aufirst%3DA.%26aulast%3DDo%26aufirst%3DK.%2BA.%26aulast%3DLluch%26aufirst%3DA.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26atitle%3DAberrations%2520in%2520translational%2520regulation%2520are%2520associated%2520with%2520poor%2520prognosis%2520in%2520hormone%2520receptor-positive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2012%26volume%3D14%26issue%3D5%26spage%3DR138%26doi%3D10.1186%2Fbcr3343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells</span>. <i>Cell Stress Chaperones</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1007/s12192-014-0545-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs12192-014-0545-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25248493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Ohsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=217-220&issue=2&author=H.+Zhuauthor=X.+Yangauthor=J.+Liuauthor=L.+Zhouauthor=C.+Zhangauthor=L.+Xuauthor=Q.+Qinauthor=L.+Zhanauthor=J.+Luauthor=H.+Chengauthor=X.+Sun&title=Eukaryotic+elongation+factor+2+kinase+confers+tolerance+to+stress+conditions+in+cancer+cells&doi=10.1007%2Fs12192-014-0545-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells</span></div><div class="casAuthors">Zhu, Hongcheng; Yang, Xi; Liu, Jia; Zhou, Lu; Zhang, Chi; Xu, Liping; Qin, Qin; Zhan, Liangliang; Lu, Jing; Cheng, Hongyan; Sun, Xinchen</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stress & Chaperones</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-220</span>CODEN:
                <span class="NLM_cas:coden">CSCHFG</span>;
        ISSN:<span class="NLM_cas:issn">1355-8145</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Eukaryotic elongation factor 2 (eEF2) is a member of the GTP-binding translation elongation factor family that is essential for protein synthesis.  EEF2 kinase (eEF2K) is a structurally and functionally unique protein kinase in the calmodulin-mediated signaling pathway.  EEF2K phosphorylates eEF2, thereby inhibiting eEF2 function under stressful conditions.  EEF2K regulates numerous processes, such as protein synthesis, cell cycle progression, and induction of autophagy and apoptosis in cancer cells.  This review will demonstrate the mechanisms underlying eEF2K activity in cancer cells under different stresses, such as nutrient deprivation, hypoxia, and DNA damage via eEF2 regulation.  In vivo, in vitro, and clin. studies indicated that eEF2K may be a novel biomarker and therapeutic target for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3kybEFmecs7Vg90H21EOLACvtfcHk0lgrVq-69gfNrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Ohsr3L&md5=aafe80b35665d94527be0adc7fd3d1c0</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1007%2Fs12192-014-0545-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12192-014-0545-0%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DX.%26atitle%3DEukaryotic%2520elongation%2520factor%25202%2520kinase%2520confers%2520tolerance%2520to%2520stress%2520conditions%2520in%2520cancer%2520cells%26jtitle%3DCell%2520Stress%2520Chaperones%26date%3D2015%26volume%3D20%26issue%3D2%26spage%3D217%26epage%3D220%26doi%3D10.1007%2Fs12192-014-0545-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witwicki, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabassum, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekram, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, K.</span></span> <span> </span><span class="NLM_article-title">Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>529</i></span> (<span class="NLM_issue">7586</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1038/nature16508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fnature16508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26735014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1Gmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=413-417&issue=7586&author=S.+Shuauthor=C.+Y.+Linauthor=H.+H.+Heauthor=R.+M.+Witwickiauthor=D.+P.+Tabassumauthor=J.+M.+Robertsauthor=M.+Janiszewskaauthor=S.+J.+Huhauthor=Y.+Liangauthor=J.+Ryanauthor=E.+Dohertyauthor=H.+Mohammedauthor=H.+Guoauthor=D.+G.+Stoverauthor=M.+B.+Ekramauthor=J.+Brownauthor=C.+D%E2%80%99Santosauthor=I.+E.+Kropauthor=D.+Dillonauthor=M.+McKeownauthor=C.+Ottauthor=J.+Qiauthor=M.+Niauthor=P.+K.+Raoauthor=M.+Duarteauthor=S.+Y.+Wuauthor=C.+M.+Chiangauthor=L.+Andersauthor=R.+A.+Youngauthor=E.+Winerauthor=A.+Letaiauthor=W.+T.+Barryauthor=J.+S.+Carrollauthor=H.+Longauthor=M.+Brownauthor=X.+S.+Liuauthor=C.+A.+Meyerauthor=J.+E.+Bradnerauthor=K.+Polyak&title=Response+and+resistance+to+BET+bromodomain+inhibitors+in+triple-negative+breast+cancer&doi=10.1038%2Fnature16508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer</span></div><div class="casAuthors">Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Tabassum, Doris P.; Roberts, Justin M.; Janiszewska, Michalina; Huh, Sung Jin; Liang, Yi; Ryan, Jeremy; Doherty, Ernest; Mohammed, Hisham; Guo, Hao; Stover, Daniel G.; Ekram, Muhammad B.; Peluffo, Guillermo; Brown, Jonathan; D'Santos, Clive; Krop, Ian E.; Dillon, Deborah; McKeown, Michael; Ott, Christopher; Qi, Jun; Ni, Min; Rao, Prakash K.; Duarte, Melissa; Wu, Shwu-Yuan; Chiang, Cheng-Ming; Anders, Lars; Young, Richard A.; Winer, Eric P.; Letai, Antony; Barry, William T.; Carroll, Jason S.; Long, Henry W.; Brown, Myles; Shirley Liu, X.; Meyer, Clifford A.; Bradner, James E.; Polyak, Kornelia</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">413-417</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a heterogeneous and clin. aggressive disease for which there is no targeted therapy.  BET bromodomain inhibitors, which have shown efficacy in several models of cancer, have not been evaluated in TNBC.  These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs.  Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clin. investigation and further motivation to understand mechanisms of resistance.  In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation.  BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner.  Proteomic studies of resistant TNBC identify strong assocn. with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase.  Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clin. drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZu5A85pdQDbVg90H21EOLACvtfcHk0lgrVq-69gfNrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1Gmtw%253D%253D&md5=50a03861d9156ee6e344e95c5f5361b9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnature16508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16508%26sid%3Dliteratum%253Aachs%26aulast%3DShu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DHe%26aufirst%3DH.%2BH.%26aulast%3DWitwicki%26aufirst%3DR.%2BM.%26aulast%3DTabassum%26aufirst%3DD.%2BP.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DJaniszewska%26aufirst%3DM.%26aulast%3DHuh%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DRyan%26aufirst%3DJ.%26aulast%3DDoherty%26aufirst%3DE.%26aulast%3DMohammed%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DEkram%26aufirst%3DM.%2BB.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Santos%26aufirst%3DC.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DDillon%26aufirst%3DD.%26aulast%3DMcKeown%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DP.%2BK.%26aulast%3DDuarte%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DChiang%26aufirst%3DC.%2BM.%26aulast%3DAnders%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DBarry%26aufirst%3DW.%2BT.%26aulast%3DCarroll%26aufirst%3DJ.%2BS.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DMeyer%26aufirst%3DC.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DResponse%2520and%2520resistance%2520to%2520BET%2520bromodomain%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DNature%26date%3D2016%26volume%3D529%26issue%3D7586%26spage%3D413%26epage%3D417%26doi%3D10.1038%2Fnature16508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrieu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strissel, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, G. V.</span></span> <span> </span><span class="NLM_article-title">BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6555</span>– <span class="NLM_lpage">6567</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-0559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-16-0559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27651315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCjt73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=6555-6567&issue=22&author=G.+Andrieuauthor=A.+H.+Tranauthor=K.+J.+Strisselauthor=G.+V.+Denis&title=BRD4+Regulates+Breast+Cancer+Dissemination+through+Jagged1%2FNotch1+Signaling&doi=10.1158%2F0008-5472.CAN-16-0559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling</span></div><div class="casAuthors">Andrieu, Guillaume; Tran, Anna H.; Strissel, Katherine J.; Denis, Gerald V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6555-6567</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The bromodomain and extraterminal (BET) proteins are epigenetic "readers" of acetylated histones in chromatin and have been identified as promising therapeutic targets in diverse cancers.  However, it remains unclear how individual family members participate in cancer progression and small mol. inhibitors such as JQ1 can target functionally independent BET proteins.  Here, we report a signaling pathway involving BRD4 and the ligand/receptor pair Jagged1/Notch1 that sustains triple-neg. breast cancer migration and invasion.  BRD4, but not BRD2 or BRD3, regulated Jagged1 expression and Notch1 signaling.  BRD4-selective knockdown suppressed Notch1 activity and impeded breast cancer migration and invasion.  BRD4 was required for IL6-stimulated, Notch1-induced migration and invasion, coupling microenvironment inflammation with cancer propagation.  Moreover, in patients, BRD4 and Jagged1 expression pos. correlated with the presence of distant metastases.  These results identify a BRD4/Jagged1/Notch1 signaling pathway that is crit. for dissemination of triple-neg. breast cancer.  Cancer Res; 76(22); 6555-67. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Mrq6xjdRILVg90H21EOLACvtfcHk0lgrVq-69gfNrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCjt73F&md5=319d1cd2436dbf65cc2ef00732aa26f7</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-0559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-0559%26sid%3Dliteratum%253Aachs%26aulast%3DAndrieu%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DA.%2BH.%26aulast%3DStrissel%26aufirst%3DK.%2BJ.%26aulast%3DDenis%26aufirst%3DG.%2BV.%26atitle%3DBRD4%2520Regulates%2520Breast%2520Cancer%2520Dissemination%2520through%2520Jagged1%252FNotch1%2520Signaling%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D22%26spage%3D6555%26epage%3D6567%26doi%3D10.1158%2F0008-5472.CAN-16-0559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span> <span> </span><span class="NLM_article-title">Integrating multiple omics data for the discovery of potential Beclin-1 interactions in breast cancer</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">999</span>, <span class="refDoi"> DOI: 10.1039/C6MB00653A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC6MB00653A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28401970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Khsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=991-999&issue=5&author=Y.+Chenauthor=X.+Wangauthor=G.+Wangauthor=Z.+Liauthor=J.+Wangauthor=L.+Huangauthor=Z.+Qinauthor=X.+Yuanauthor=Z.+Chengauthor=S.+Zhangauthor=Y.+Yinauthor=J.+He&title=Integrating+multiple+omics+data+for+the+discovery+of+potential+Beclin-1+interactions+in+breast+cancer&doi=10.1039%2FC6MB00653A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating multiple omics data for the discovery of potential Beclin-1 interactions in breast cancer</span></div><div class="casAuthors">Chen, Yi; Wang, Xuan; Wang, Guan; Li, Zhaozhi; Wang, Jinjin; Huang, Lingyu; Qin, Ziyi; Yuan, Xiang; Cheng, Zhong; Zhang, Shu; Yin, Yiqiong; He, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">991-999</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Breast cancer has been reported as one of the most frequently diagnosed malignant diseases and the leading cause of cancer death in women all around the world.  Furthermore, this complicated cancer is divided into multiple subtypes which present different clin. symptoms and need correspondingly directed therapy.  We took BECN1, a core gene in autophagy performing a tumor inhibitory effect, as a starting point.  The study in this paper aims to identify genes related to breast cancer and its multiple subtypes by integrating multiple omics data using the least abs. shrinkage and selection operator (LASSO), which is a statistical method that can integrate more than two types of omics data.  All the data is obtained from The Cancer Genome Atlas (TCGA) platform which stores clin. and mol. tumor data.  The model constructed is based on three kinds of data including mRNA-gene expression with a dependent variable level, DNA methylation and copy no. alterations as independent variables.  Finally, we propose four subnets of four subtypes of breast cancer, and consider as a result of microarray anal. that AFF3 is assocd. with BECN1 in breast cancer, and may be a potential therapeutic target.  This finding may provide some potential targeted therapeutics for the four different subtypes of breast cancer at the genetic level.  In conclusion, finding out the major role Beclin-1 plays in breast cancer subtypes is of great value.  The results obtained are instructive for further research and may provide excellent results in clin. applications, as well as testing in animal expts., and may also indicate a new method to perform bioinformatics anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGQ8V8nTMe-LVg90H21EOLACvtfcHk0lhLWcHdEhx0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Khsrk%253D&md5=70431f1b7ef1e624bb231a66bf30e532</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2FC6MB00653A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MB00653A%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26atitle%3DIntegrating%2520multiple%2520omics%2520data%2520for%2520the%2520discovery%2520of%2520potential%2520Beclin-1%2520interactions%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520BioSyst.%26date%3D2017%26volume%3D13%26issue%3D5%26spage%3D991%26epage%3D999%26doi%3D10.1039%2FC6MB00653A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of benzimidazole derivatives as the G9a histone methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.bioorg.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28460359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFCjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2017&pages=168-181&author=J.+Zhangauthor=D.+Yaoauthor=Y.+Jiangauthor=J.+Huangauthor=S.+Yangauthor=J.+Wang&title=Synthesis+and+biological+evaluation+of+benzimidazole+derivatives+as+the+G9a+histone+methyltransferase+inhibitors+that+induce+autophagy+and+apoptosis+of+breast+cancer+cells&doi=10.1016%2Fj.bioorg.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells</span></div><div class="casAuthors">Zhang, Jin; Yao, Dahong; Jiang, Yingnan; Huang, Jian; Yang, Shilin; Wang, Jinhui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">168-181</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G9a (also known as KMT1C or EHMT2) is initially identified as a H3K9 methyltransferase that specifically mono- and dimethylates 'Lys 9' of histone H3 (H3K9me1 and H3K9me2, resp.) in euchromatin.  It is overexpressed in various human cancers and employed as a promising target in cancer therapy.  The authors discovered a benzoxazole scaffold through virtual high-throughput screening, and designed, synthesized 24 derivs. and investigated for inhibition of G9a.  After several rounds of kinase and anti-proliferative activity screening, the authors discovered a potent G9a antagonist (GA001) with an IC50 value of 1.32 μM that could induce autophagy via AMPK in MCF7 cells.  In addn., the authors found high concn. of GA001 could induce apoptosis via p21-Bim signal cascades in MCF7 cells.  The authors' results highlight a new approach for the development of a novel drug targeting G9a with a potential to induce autophagy and apoptosis for future breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvEhWsr0H7QbVg90H21EOLACvtfcHk0lhLWcHdEhx0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFCjur4%253D&md5=1a8ffbf3cf110bbee8cc01bf80cb853d</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520benzimidazole%2520derivatives%2520as%2520the%2520G9a%2520histone%2520methyltransferase%2520inhibitors%2520that%2520induce%2520autophagy%2520and%2520apoptosis%2520of%2520breast%2520cancer%2520cells%26jtitle%3DBioorg.%2520Chem.%26date%3D2017%26volume%3D72%26spage%3D168%26epage%3D181%26doi%3D10.1016%2Fj.bioorg.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1002/med.21398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fmed.21398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27357603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ltVamsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=983-1035&issue=6&author=B.+Keauthor=M.+Tianauthor=J.+Liauthor=B.+Liuauthor=G.+He&title=Targeting+programmed+cell+death+using+small-molecule+compounds+to+improve+potential+cancer+therapy&doi=10.1002%2Fmed.21398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy</span></div><div class="casAuthors">Ke Bowen; Tian Mao; Li Jingjing; Liu Bo; He Gu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">983-1035</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Evasion of cell death is one of the hallmarks of cancer cells, beginning with long-established apoptosis and extending to other new forms of cell death.  An elaboration of cell death pathways thus will contribute to a better understanding of cancer pathogenesis and therapeutics.  With the recent substantial biochemical and genetic explorations of cell death subroutines, their classification has switched from primarily morphological to more molecular definitions.  According to their measurable biochemical features and intricate mechanisms, cell death subroutines can be divided into apoptosis, autophagic cell death, mitotic catastrophe, necroptosis, parthanatos, ferroptosis, pyroptosis, pyronecrosis, anoikis, cornification, entosis, and NETosis.  Supportive evidence has gradually revealed the prime molecular mechanisms of each subroutine and thus providing series of possible targets in cancer therapy, while the intricate relationships between different cell death subroutines still remain to be clarified.  Over the past decades, cancer drug discovery has significantly benefited from the use of small-molecule compounds to target classical modalities of cell death such as apoptosis, while newly identified cell death subroutines has also emerging their potential for cancer drug discovery in recent years.  In this review, we comprehensively focus on summarizing 12 cell death subroutines and discussing their corresponding small-molecule compounds in potential cancer therapy.  Together, these inspiring findings may provide more evidence to fill in the gaps between cell death subroutines and small-molecule compounds to better develop novel cancer therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhPsvIEAjUsGBAiYWy6n3SfW6udTcc2ebl9sC4m5kJM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ltVamsA%253D%253D&md5=3fc5de00cb2c9a65b378d0358dfd3f5e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fmed.21398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21398%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DB.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DTargeting%2520programmed%2520cell%2520death%2520using%2520small-molecule%2520compounds%2520to%2520improve%2520potential%2520cancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2016%26volume%3D36%26issue%3D6%26spage%3D983%26epage%3D1035%26doi%3D10.1002%2Fmed.21398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Targeting autophagy-related protein kinases for potential therapeutic purpose</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2019.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.apsb.2019.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32322463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnslWjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=569-581&author=H.+Xiangauthor=J.+Zhangauthor=C.+Linauthor=L.+Zhangauthor=B.+Liuauthor=L.+Ouyang&title=Targeting+autophagy-related+protein+kinases+for+potential+therapeutic+purpose&doi=10.1016%2Fj.apsb.2019.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting autophagy-related protein kinases for potential therapeutic purpose</span></div><div class="casAuthors">Xiang, Honggang; Zhang, Jifa; Lin, Congcong; Zhang, Lan; Liu, Bo; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">569-581</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Autophagy, defined as a scavenging process of protein aggregates and damaged organelles mediated by lysosomes, plays a significant role in the quality control of macromols. and organelles.  Since protein kinases are integral to the autophagy process, it is critically important to understand the role of kinases in autophagic regulation.  At present, intervention of autophagic processes by small-mol. modulators targeting specific kinases has becoming a reasonable and prevalent strategy for treating several varieties of human disease, esp. cancer.  In this review, we describe the role of some autophagy-related kinase targets and kinase-mediated phosphorylation mechanisms in autophagy regulation.  We also summarize the small-mol. kinase inhibitors/activators of these targets, high-lighting the opportunities of these new therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUZ5eGWVZ5RbVg90H21EOLACvtfcHk0liUieRE3RxQiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnslWjug%253D%253D&md5=277da77a9145fb63c521c5babf333e9b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DTargeting%2520autophagy-related%2520protein%2520kinases%2520for%2520potential%2520therapeutic%2520purpose%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D569%26epage%3D581%26doi%3D10.1016%2Fj.apsb.2019.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, G.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2019.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30742942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1Clsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2019&pages=94-104&author=Q.+Heauthor=S.+Xueauthor=Y.+Tanauthor=L.+Zhangauthor=Q.+Shaoauthor=L.+Xingauthor=Y.+Liauthor=T.+Xiangauthor=X.+Luoauthor=G.+Ren&title=Dual+inhibition+of+Akt+and+ERK+signaling+induces+cell+senescence+in+triple-negative+breast+cancer&doi=10.1016%2Fj.canlet.2019.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer</span></div><div class="casAuthors">He, Qiang; Xue, Shuyin; Tan, Yiqing; Zhang, Ling; Shao, Qing; Xing, Lei; Li, Yunhai; Xiang, Tingxiu; Luo, Xinrong; Ren, Guosheng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-104</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activated Akt and ERK signaling pathways are closely related to breast cancer progression, and Akt or ERK inhibition induces cell senescence.  However, the crosstalk between the Akt and ERK signaling pathways in cell senescence and how to simultaneously suppress Akt and ERK signaling in triple-neg. breast cancer (TNBC) are undefined.  In this study, we found that norcantharidin (NCTD) effectively induced cell senescence and cell cycle arrest in TNBC in vitro, which was accompanied by a decline in phosphorylated Akt and ERK1/2 and a rise in p21 and p16.  The inhibitors LY294002 and U0126 imitated the effect of NCTD when these two inhibitors were combined regardless of crosstalk between these two signaling pathways.  In addn., NCTD inhibited the growth of xenografts via downregulation of phosphorylated Akt and ERK1/2 and upregulation of p21 in vivo.  However, NCTD upregulated the level of sol. signaling factors of the senescence-assocd. secretory phenotype (SASP) in a NF-κB-independent manner.  Collectively, these findings demonstrate that NCTD induced cell senescence and cell cycle arrest mainly by simultaneously blocking Akt and ERK signaling in TNBC, suggesting that NCTD may be used as a potential adjuvant therapy in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCyKsXlTOVZLVg90H21EOLACvtfcHk0liUieRE3RxQiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1Clsbo%253D&md5=22793342d13431bd800588b9ec09545c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DXue%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DQ.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DT.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DG.%26atitle%3DDual%2520inhibition%2520of%2520Akt%2520and%2520ERK%2520signaling%2520induces%2520cell%2520senescence%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D448%26spage%3D94%26epage%3D104%26doi%3D10.1016%2Fj.canlet.2019.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ejmech.2016.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27839788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=997-1011&author=Y.+Chenauthor=Y.+Zhengauthor=Q.+Jiangauthor=F.+Qinauthor=Y.+Zhangauthor=L.+Fuauthor=G.+He&title=Integrated+bioinformatics%2C+computational+and+experimental+methods+to+discover+novel+Raf%2Fextracellular-signal+regulated+kinase+%28ERK%29+dual+inhibitors+against+breast+cancer+cells&doi=10.1016%2Fj.ejmech.2016.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells</span></div><div class="casAuthors">Chen, Yin; Zheng, Yaxin; Jiang, Qinglin; Qin, Feifei; Zhang, Yonghui; Fu, Leilei; He, Gu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">997-1011</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Beginning with our previously reported ERK inhibitor BL-EI001, we found Raf1 to be an important regulator in the ERK interactive network, and then we designed and synthesized a novel series of Raf1/ERK dual inhibitors against human breast cancers through integrative computational, synthetic and biol. screening methods.  Moreover, we found that compd. 9d suppressed the proliferation of breast cancer cell lines and induced cellular apoptosis via a mitochondrial pathway with only partial dependence on Raf1 and ERK.  Our results suggest that an integrative method including in silico design, chem. synthesis, biol. screening and bioinformatics anal. could be an attractive strategy for the discovery of multi-target inhibitors against breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMI2OafaPJvbVg90H21EOLACvtfcHk0liUieRE3RxQiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3P&md5=23515e24b2f67b319f99fc28ab6c617a</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DQin%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DIntegrated%2520bioinformatics%252C%2520computational%2520and%2520experimental%2520methods%2520to%2520discover%2520novel%2520Raf%252Fextracellular-signal%2520regulated%2520kinase%2520%2528ERK%2529%2520dual%2520inhibitors%2520against%2520breast%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D997%26epage%3D1011%26doi%3D10.1016%2Fj.ejmech.2016.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niepel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivakumaren, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yapp, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorger, P. K.</span></span> <span> </span><span class="NLM_article-title">Torin2 exploits replication and checkpoint vulnerabilities to cause death of PI3K-activated triple-negative breast cancer cells</span>. <i>Cell Syst.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.cels.2019.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.cels.2019.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31812693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFeiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=66-81&issue=1&author=S.+S.+Chopraauthor=A.+Jenneyauthor=A.+Palmerauthor=M.+Niepelauthor=M.+Chungauthor=C.+Millsauthor=S.+C.+Sivakumarenauthor=Q.+Liuauthor=J.-Y.+Chenauthor=C.+Yappauthor=J.+M.+Asaraauthor=N.+S.+Grayauthor=P.+K.+Sorger&title=Torin2+exploits+replication+and+checkpoint+vulnerabilities+to+cause+death+of+PI3K-activated+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.cels.2019.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells</span></div><div class="casAuthors">Chopra, Sameer S.; Jenney, Anne; Palmer, Adam; Niepel, Mario; Chung, Mirra; Mills, Caitlin; Sivakumaren, Sindhu Carmen; Liu, Qingsong; Chen, Jia-Yun; Yapp, Clarence; Asara, John M.; Gray, Nathanael S.; Sorger, Peter K.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Systems</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-81.e11</span>CODEN:
                <span class="NLM_cas:coden">CSEYA4</span>;
        ISSN:<span class="NLM_cas:issn">2405-4712</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clin. successes are rare.  As a result, many cancers with high PI3K pathway activity, such as triple-neg. breast cancer (TNBC), are treated primarily with chemotherapy.  By systematically analyzing responses of TNBC cells to a diverse collection of PI3K pathway inhibitors, we find that one drug, Torin2, is unusually effective because it inhibits both mTOR and other PI3K-like kinases (PIKKs).  In contrast to mTOR-selective inhibitors, Torin2 exploits dependencies on several kinases for S-phase progression and cell-cycle checkpoints, thereby causing accumulation of single-stranded DNA and death by replication catastrophe or mitotic failure.  Thus, Torin2 and its chem. analogs represent a mechanistically distinct class of PI3K pathway inhibitors that are uniquely cytotoxic to TNBC cells.  This insight could be translated therapeutically by further developing Torin2 analogs or combinations of existing mTOR and PIKK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEVxEZJ8wcgrVg90H21EOLACvtfcHk0lhW5AgxbyhaOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFeiu78%253D&md5=5137380fdfa6a7c45d531b70de377b42</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.cels.2019.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cels.2019.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DChopra%26aufirst%3DS.%2BS.%26aulast%3DJenney%26aufirst%3DA.%26aulast%3DPalmer%26aufirst%3DA.%26aulast%3DNiepel%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DSivakumaren%26aufirst%3DS.%2BC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DJ.-Y.%26aulast%3DYapp%26aufirst%3DC.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSorger%26aufirst%3DP.%2BK.%26atitle%3DTorin2%2520exploits%2520replication%2520and%2520checkpoint%2520vulnerabilities%2520to%2520cause%2520death%2520of%2520PI3K-activated%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DCell%2520Syst.%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D66%26epage%3D81%26doi%3D10.1016%2Fj.cels.2019.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, T. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohoon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W. E.</span></span> <span> </span><span class="NLM_article-title">Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5411</span>– <span class="NLM_lpage">5423</span>, <span class="refDoi"> DOI: 10.1172/JCI75661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1172%2FJCI75661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25365225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2M3lt1artg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=5411-5423&issue=12&author=T.+U.+Barbieauthor=G.+Alexeauthor=A.+R.+Arefauthor=S.+Liauthor=Z.+Zhuauthor=X.+Zhangauthor=Y.+Imamuraauthor=T.+C.+Thaiauthor=Y.+Huangauthor=M.+Bowdenauthor=J.+Herndonauthor=T.+J.+Cohoonauthor=T.+Flemingauthor=P.+Tamayoauthor=J.+P.+Mesirovauthor=S.+Oginoauthor=K.+K.+Wongauthor=M.+J.+Ellisauthor=W.+C.+Hahnauthor=D.+A.+Barbieauthor=W.+E.+Gillanders&title=Targeting+an+IKBKE+cytokine+network+impairs+triple-negative+breast+cancer+growth&doi=10.1172%2FJCI75661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth</span></div><div class="casAuthors">Barbie Thanh U; Alexe Gabriela; Aref Amir R; Li Shunqiang; Zhu Zehua; Zhang Xiuli; Imamura Yu; Thai Tran C; Huang Ying; Bowden Michaela; Herndon John; Cohoon Travis J; Fleming Timothy; Tamayo Pablo; Mesirov Jill P; Ogino Shuji; Wong Kwok-Kin; Ellis Matthew J; Hahn William C; Barbie David A; Gillanders William E</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5411-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancers (TNBCs) are a heterogeneous set of cancers that are defined by the absence of hormone receptor expression and HER2 amplification.  Here, we found that inducible IκB kinase-related (IKK-related) kinase IKBKE expression and JAK/STAT pathway activation compose a cytokine signaling network in the immune-activated subset of TNBC.  We found that treatment of cultured IKBKE-driven breast cancer cells with CYT387, a potent inhibitor of TBK1/IKBKE and JAK signaling, impairs proliferation, while inhibition of JAK alone does not.  CYT387 treatment inhibited activation of both NF-κB and STAT and disrupted expression of the protumorigenic cytokines CCL5 and IL-6 in these IKBKE-driven breast cancer cells.  Moreover, in 3D culture models, the addition of CCL5 and IL-6 to the media not only promoted tumor spheroid dispersal but also stimulated proliferation and migration of endothelial cells.  Interruption of cytokine signaling by CYT387 in vivo impaired the growth of an IKBKE-driven TNBC cell line and patient-derived xenografts (PDXs).  A combination of CYT387 therapy with a MEK inhibitor was particularly effective, abrogating tumor growth and angiogenesis in an aggressive PDX model of TNBC.  Together, these findings reveal that IKBKE-associated cytokine signaling promotes tumorigenicity of immune-driven TNBC and identify a potential therapeutic strategy using clinically available compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1IkpC-K_EokBuFdjgVNKSfW6udTcc2eaE0L0Px1aTu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3lt1artg%253D%253D&md5=064d796c65d142b84f5c72c7330c5ea6</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1172%2FJCI75661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI75661%26sid%3Dliteratum%253Aachs%26aulast%3DBarbie%26aufirst%3DT.%2BU.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DThai%26aufirst%3DT.%2BC.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DBowden%26aufirst%3DM.%26aulast%3DHerndon%26aufirst%3DJ.%26aulast%3DCohoon%26aufirst%3DT.%2BJ.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DGillanders%26aufirst%3DW.%2BE.%26atitle%3DTargeting%2520an%2520IKBKE%2520cytokine%2520network%2520impairs%2520triple-negative%2520breast%2520cancer%2520growth%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26issue%3D12%26spage%3D5411%26epage%3D5423%26doi%3D10.1172%2FJCI75661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of a novel orally available SRC/Raf/VEGFR2 inhibitor, SKLB646, in the treatment of triple-negative breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-15-0501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26721945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCmsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=366-378&issue=3&author=M.+W.+Zhengauthor=C.+H.+Zhangauthor=K.+Chenauthor=M.+Huangauthor=Y.+P.+Liauthor=W.+T.+Linauthor=R.+J.+Zhangauthor=L.+Zhongauthor=R.+Xiangauthor=L.+L.+Liauthor=X.+Y.+Liuauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Preclinical+evaluation+of+a+novel+orally+available+SRC%2FRaf%2FVEGFR2+inhibitor%2C+SKLB646%2C+in+the+treatment+of+triple-negative+breast+cancer&doi=10.1158%2F1535-7163.MCT-15-0501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Zheng, Ming-Wu; Zhang, Chun-Hui; Chen, Kai; Huang, Mei; Li, Ya-Ping; Lin, Wan-Ting; Zhang, Rong-Jie; Zhong, Lei; Xiang, Rong; Li, Lin-Li; Liu, Xin-Yu; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">366-378</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most aggressive and deadly breast cancer subtype.  To date, chemotherapy is the only systemic therapy and prognosis remains poor.  Herein, we report the preclin. evaluation of SKLB646 in the treatment of TNBC; SKLB646 is a novel multiple kinase inhibitor developed by us recently.  This compd. potently inhibited SRC and VEGFR2 with IC50 values of 0.002 μmol/L and 0.012 μmol/L, resp.  It also considerably inhibited B-Raf and C-Raf with IC50 values of 0.022 and 0.019 μmol/L, resp.  It exhibited significant antiproliferation and antiviability activities against TNBC cell lines.  Studies of mechanism of action indicated that SKLB646 inhibited the activation of SRC signaling and blocked the MAPK signaling through inhibiting the Raf kinases.  Interestingly, SKLB646 dose dependently downregulated the expression of Fra1, a transcriptional factor that plays a crit. role in the epithelial-to-mesenchymal transition.  In addn., SKLB646 could inhibit HUVEC proliferation, migration, and invasion.  It effectively blocked the formation of intersegmental vessels in zebrafish embryos and displayed considerable antiangiogenic effects in the tumor-induced neovascularization zebrafish model.  In TNBC xenograft models, SKLB646 suppressed the tumor growth in a dose-dependent manner.  Moreover, SKLB646 could remarkably inhibit TNBC cell migration and invasion in vitro.  Furthermore, in an exptl. lung metastasis model, the overall survival time of groups treated with SKLB646 was much longer compared with the control-, dasatinib-, and paclitaxel-treated groups.  In a preliminary pharmacokinetic study, SKLB646 showed good pharmacokinetic properties.  Taken together, the preclin. data show that SKLB646 could be a promising lead compd. for the treatment of TNBC.  Mol Cancer Ther; 15(3); 366-78. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodSEWSFArBprVg90H21EOLACvtfcHk0lhW5AgxbyhaOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCmsL8%253D&md5=5503431d68d044995a94faa8948f27ba</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0501%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DM.%2BW.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%2BP.%26aulast%3DLin%26aufirst%3DW.%2BT.%26aulast%3DZhang%26aufirst%3DR.%2BJ.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DPreclinical%2520evaluation%2520of%2520a%2520novel%2520orally%2520available%2520SRC%252FRaf%252FVEGFR2%2520inhibitor%252C%2520SKLB646%252C%2520in%2520the%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D3%26spage%3D366%26epage%3D378%26doi%3D10.1158%2F1535-7163.MCT-15-0501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phadke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachacz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziubinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwarcinski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidwell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merajver, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M.</span></span> <span> </span><span class="NLM_article-title">In vivoretraction: UM-164: A potent c-Src/p38 kinase inhibitor with activity against triple-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1777</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-20-0653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-20-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32238414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB38zgtVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=1777&issue=7&author=R.+Gilaniauthor=S.+Phadkeauthor=L.+Baoauthor=E.+Lachaczauthor=M.+Dziubinskiauthor=K.+Brandvoldauthor=M.+Steffeyauthor=F.+Kwarcinskiauthor=C.+Graveelauthor=K.+Kidwellauthor=S.+Merajverauthor=M.+Soellner&title=In+vivoretraction%3A+UM-164%3A+A+potent+c-Src%2Fp38+kinase+inhibitor+with+activity+against+triple-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-20-0653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Retraction: UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer</span></div><div class="casAuthors">Gilani Rabia A; Phadke Sameer; Bao Li Wei; Lachacz Eric J; Dziubinski Michele L; Brandvold Kristoffer R; Steffey Michael E; Kwarcinski Frank E; Graveel Carrie R; Kidwell Kelley M; Merajver Sofia D; Soellner Matthew B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1777</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSV37Rg-SVp0WPgL4LrC-0VfW6udTcc2ebk97fwL6cOwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zgtVCltQ%253D%253D&md5=86237cdc504a8d60506d61b53bed3dc8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-20-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-20-0653%26sid%3Dliteratum%253Aachs%26aulast%3DGilani%26aufirst%3DR.%26aulast%3DPhadke%26aufirst%3DS.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DLachacz%26aufirst%3DE.%26aulast%3DDziubinski%26aufirst%3DM.%26aulast%3DBrandvold%26aufirst%3DK.%26aulast%3DSteffey%26aufirst%3DM.%26aulast%3DKwarcinski%26aufirst%3DF.%26aulast%3DGraveel%26aufirst%3DC.%26aulast%3DKidwell%26aufirst%3DK.%26aulast%3DMerajver%26aufirst%3DS.%26aulast%3DSoellner%26aufirst%3DM.%26atitle%3DIn%2520vivoretraction%253A%2520UM-164%253A%2520A%2520potent%2520c-Src%252Fp38%2520kinase%2520inhibitor%2520with%2520activity%2520against%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26issue%3D7%26spage%3D1777%26doi%3D10.1158%2F1078-0432.CCR-20-0653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">From lead to drug candidate: optimization of 3-(phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as agents for the treatment of triple negative breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9788</span>– <span class="NLM_lpage">9805</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00943</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00943" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9788-9805&issue=21&author=C.+H.+Zhangauthor=K.+Chenauthor=Y.+Jiaoauthor=L.+L.+Liauthor=Y.+P.+Liauthor=R.+J.+Zhangauthor=M.+W.+Zhengauthor=L.+Zhongauthor=S.+Z.+Huangauthor=C.+L.+Songauthor=W.+T.+Linauthor=J.+Yangauthor=R.+Xiangauthor=B.+Pengauthor=J.+H.+Hanauthor=G.+W.+Luauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=From+lead+to+drug+candidate%3A+optimization+of+3-%28phenylethynyl%29-1h-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-amine+derivatives+as+agents+for+the+treatment+of+triple+negative+breast+cancer&doi=10.1021%2Facs.jmedchem.6b00943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer</span></div><div class="casAuthors">Zhang, Chun-Hui; Chen, Kai; Jiao, Yan; Li, Lin-Li; Li, Ya-Ping; Zhang, Rong-Jie; Zheng, Ming-Wu; Zhong, Lei; Huang, Shen-Zhen; Song, Chun-Li; Lin, Wan-Ting; Yang, Jiao; Xiang, Rong; Peng, Bing; Han, Jun-Hong; Lu, Guang-Wen; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9788-9805</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compd. I, which showed high potency in the treatment of triple neg. breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity.  A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivs. were synthesized.  In vitro cell-based phenotypic screening together with in vivo assays and structure-activity relationship (SAR) studies finally led to the discovery of N-(3-((4-amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (II). II is a multikinase inhibitor, which potently inhibited Src (IC50 = 0.003 μM), KDR (IC50 = 0.032 μM), and several kinases involved in the MAPK signal transduction.  This compd. showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity.  Mechanisms of action of anti-TNBC were also investigated.  Collectively, the data obtained in this study indicate that II could be a promising drug candidate for the treatment of TNBC and hence merits further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGfeoJEAklBLVg90H21EOLACvtfcHk0linUH_KuUvexQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7vL&md5=074c0b21b8f61237497d21254cb5e423</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00943%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DY.%2BP.%26aulast%3DZhang%26aufirst%3DR.%2BJ.%26aulast%3DZheng%26aufirst%3DM.%2BW.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DS.%2BZ.%26aulast%3DSong%26aufirst%3DC.%2BL.%26aulast%3DLin%26aufirst%3DW.%2BT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DJ.%2BH.%26aulast%3DLu%26aufirst%3DG.%2BW.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DFrom%2520lead%2520to%2520drug%2520candidate%253A%2520optimization%2520of%25203-%2528phenylethynyl%2529-1h-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2520derivatives%2520as%2520agents%2520for%2520the%2520treatment%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D21%26spage%3D9788%26epage%3D9805%26doi%3D10.1021%2Facs.jmedchem.6b00943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meslamani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K. l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M. M.</span></span> <span> </span><span class="NLM_article-title">Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">7949</span>– <span class="NLM_lpage">7954</span>, <span class="refDoi"> DOI: 10.1073/pnas.1720000115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1720000115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30012592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOmurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=7949-7954&issue=31&author=C.+Renauthor=G.+Zhangauthor=F.+Hanauthor=S.+Fuauthor=Y.+Caoauthor=F.+Zhangauthor=Q.+Zhangauthor=J.+Meslamaniauthor=Y.+Xuauthor=D.+Jiauthor=L.+Caoauthor=Q.+Zhouauthor=K.+l.+Cheungauthor=R.+Sharmaauthor=N.+Babaultauthor=Z.+Yiauthor=W.+Zhangauthor=M.+J.+Walshauthor=L.+Zengauthor=M.+M.+Zhou&title=Spatially+constrained+tandem+bromodomain+inhibition+bolsters+sustained+repression+of+BRD4+transcriptional+activity+for+TNBC+cell+growth&doi=10.1073%2Fpnas.1720000115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth</span></div><div class="casAuthors">Ren, Chunyan; Zhang, Guangtao; Han, Fangbin; Fu, Shibo; Cao, Yingdi; Zhang, Fan; Zhang, Qiang; Meslamani, Jamel; Xub, Yaoyao; Ji, Donglei; Cao, Lingling; Zhou, Qian; Cheung, Ka-Lung; Sharma, Rajal; Babault, Nicolas; Yic, Zhengzi; Zhang, Weijia; Walsh, Martin J.; Zeng, Lei; Zhou, Ming-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">7949-7954</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The importance of BET protein BRD4 in gene transcription is well recognized through the study of chem. modulation of its characteristic tandem bromodomain (BrD) binding to lysine-acetylated histones and transcription factors.  However, while monovalent inhibition of BRD4 by BET BrD inhibitors such as JQ1 blocks growth of hematopoietic cancers, it is much less effective generally in solid tumors.  Here, we report a thienodiazepine-based bivalent BrD inhibitor, MS645, that affords spatially constrained tandem BrD inhibition and consequently sustained repression of BRD4 transcriptional activity in blocking proliferation of solid-tumor cells including a panel of triple-neg. breast cancer (TNBC) cells.  MS645 blocks BRD4 binding to transcription enhancer/mediator proteins MED1 and YY1 with potency superior to monovalent BET inhibitors, resulting in down-regulation of proinflammatory cytokines and genes for cell-cycle control and DNA damage repair that are largely unaffected by monovalent BrD inhibition.  Our study suggests a therapeutic strategy to maximally control BRD4 activity for rapid growth of solid-tumor TNBC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrg_KdQUQCjbVg90H21EOLACvtfcHk0liDELuXmz6wlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOmurrI&md5=7b0d3b8bc61ff57c100ac2bf875e8586</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1720000115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1720000115%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMeslamani%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DD.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DCheung%26aufirst%3DK.%2Bl.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DBabault%26aufirst%3DN.%26aulast%3DYi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWalsh%26aufirst%3DM.%2BJ.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DM.%2BM.%26atitle%3DSpatially%2520constrained%2520tandem%2520bromodomain%2520inhibition%2520bolsters%2520sustained%2520repression%2520of%2520BRD4%2520transcriptional%2520activity%2520for%2520TNBC%2520cell%2520growth%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D31%26spage%3D7949%26epage%3D7954%26doi%3D10.1073%2Fpnas.1720000115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasi, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soon, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreich, M.</span></span> <span> </span><span class="NLM_article-title">The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e113300</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0113300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0113300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25412417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2htrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e113300&issue=11&author=N.+K.+Sasiauthor=K.+Tiwariauthor=F.+F.+Soonauthor=D.+Bonteauthor=T.+Wangauthor=K.+Melcherauthor=H.+E.+Xuauthor=M.+Weinreich&title=The+potent+Cdc7-Dbf4+%28DDK%29+kinase+inhibitor+XL413+has+limited+activity+in+many+cancer+cell+lines+and+discovery+of+potential+new+DDK+inhibitor+scaffolds&doi=10.1371%2Fjournal.pone.0113300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds</span></div><div class="casAuthors">Sasi, Nanda Kumar; Tiwari, Kanchan; Soon, Fen-Fen; Bonte, Dorine; Wang, Tong; Melcher, Karsten; Xu, H. Eric; Weinreich, Michael</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e113300/1-e113300/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cdc7-Dbf4 kinase or DDK (Dbf4-dependent kinase) is required to initiate DNA replication by phosphorylating and activating the replicative Mcm2-7 DNA helicase.  DDK is overexpressed in many tumor cells and is an emerging chemotherapeutic target since DDK inhibition causes apoptosis of diverse cancer cell types but not of normal cells.  PHA-767491 and XL413 are among a no. of potent DDK inhibitors with low nanomolar IC50 values against the purified kinase.  Although XL413 is highly selective for DDK, its activity has not been extensively characterized on cell lines.  We measured anti-proliferative and apoptotic effects of XL413 on a panel of tumor cell lines compared to PHA-767491, whose activity is well characterized.  Both compds. were effective biochem. DDK inhibitors but surprisingly, their activities in cell lines were highly divergent.  Unlike PHA-767491, XL413 had significant anti-proliferative activity against only one of the ten cell lines tested.  Since XL413 did not effectively inhibit DDK in multiple cell lines, this compd. likely has limited bioavailability.  To identify potential leads for addnl. DDK inhibitors, we also tested the cross-reactivity of ∼400 known kinase inhibitors against DDK using a DDK thermal stability shift assay (TSA).  We identified 11 compds. that significantly stabilized DDK.  Several inhibited DDK with comparable potency to PHA-767491, including Chk1 and PKR kinase inhibitors, but had divergent chem. scaffolds from known DDK inhibitors.  Taken together, these data show that several well-known kinase inhibitors cross-react with DDK and also highlight the opportunity to design addnl. specific, biol. active DDK inhibitors for use as chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPt1UTrCoCKLVg90H21EOLACvtfcHk0liDELuXmz6wlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2htrnN&md5=3bf109d9e597319c787a9f947667c021</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0113300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0113300%26sid%3Dliteratum%253Aachs%26aulast%3DSasi%26aufirst%3DN.%2BK.%26aulast%3DTiwari%26aufirst%3DK.%26aulast%3DSoon%26aufirst%3DF.%2BF.%26aulast%3DBonte%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DH.%2BE.%26aulast%3DWeinreich%26aufirst%3DM.%26atitle%3DThe%2520potent%2520Cdc7-Dbf4%2520%2528DDK%2529%2520kinase%2520inhibitor%2520XL413%2520has%2520limited%2520activity%2520in%2520many%2520cancer%2520cell%2520lines%2520and%2520discovery%2520of%2520potential%2520new%2520DDK%2520inhibitor%2520scaffolds%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D11%26spage%3De113300%26doi%3D10.1371%2Fjournal.pone.0113300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panayotopoulou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selitrennik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtrich, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lev, S.</span></span> <span> </span><span class="NLM_article-title">Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-1797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-16-1797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27793840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=86-99&issue=1&author=N.+Vermaauthor=A.+K.+Mullerauthor=C.+Kothariauthor=E.+Panayotopoulouauthor=A.+Kedanauthor=M.+Selitrennikauthor=G.+B.+Millsauthor=L.+K.+Nguyenauthor=S.+Shinauthor=T.+Karnauthor=U.+Holtrichauthor=S.+Lev&title=Targeting+of+PYK2+synergizes+with+EGFR+antagonists+in+basal-like+TNBC+and+circumvents+HER3-associated+resistance+via+the+NEDD4-NDRG1+axis&doi=10.1158%2F0008-5472.CAN-16-1797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis</span></div><div class="casAuthors">Verma, Nandini; Muller, Anna-Katharina; Kothari, Charu; Panayotopoulou, Effrosini; Kedan, Amir; Selitrennik, Michael; Mills, Gordon B.; Nguyen, Lan K.; Shin, Sungyoung; Karn, Thomas; Holtrich, Uwe; Lev, Sima</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-99</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly aggressive, heterogeneous disease with poor prognosis and no effective targeted therapies.  EGFR is highly expressed in basal-like TNBC and is considered as a potential therapeutic target.  However, EGFR targeting exerts only marginal clin. benefits, possibly due to activation of compensatory signaling pathways, which are frequently assocd. with HER3 upregulation.  Here we show that concomitant targeting of EGFR and the nonreceptor tyrosine kinases PYK2/FAK synergistically inhibits the proliferation of basal-like TNBC cells in vitro and attenuates tumor growth in a mouse xenograft model.  Dual targeting of EGFR and PYK2/FAK inhibited complementary key growth and survival pathways mediated by AKT, S6K, STAT3, and ERK1/2 activation.  PYK2 inhibition also abrogated HER3 upregulation in response to EGFR antagonists, thereby circumventing HER3-assocd. drug resistance.  Mechanistically, PYK2 inhibition facilitated the proteasomal degrdn. of HER3 while inducing upregulation of NDRG1 (N-myc downstream regulated 1 gene).  NDRG1 enhanced the interaction of HER3 with the ubiquitin ligase NEDD4, while PYK2, which interacts with NEDD4 and HER3, interfered with NEDD4-HER3 binding, suggesting that the PYK2-NDRG1-NEDD4 circuit has a crit. role in receptor degrdn., drug response, and resistance mechanism.  Our studies offer a preclin. proof of concept for a strategy of cotargeting the EGFR and PYK2/FAK kinases to improve TNBC therapy.  Cancer Res; 77(1); 86-99. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFyqnUMLlVh7Vg90H21EOLACvtfcHk0liDELuXmz6wlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSn&md5=aed20fd02e56aad146d254b81fedd96d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-1797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-1797%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DA.%2BK.%26aulast%3DKothari%26aufirst%3DC.%26aulast%3DPanayotopoulou%26aufirst%3DE.%26aulast%3DKedan%26aufirst%3DA.%26aulast%3DSelitrennik%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DNguyen%26aufirst%3DL.%2BK.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DKarn%26aufirst%3DT.%26aulast%3DHoltrich%26aufirst%3DU.%26aulast%3DLev%26aufirst%3DS.%26atitle%3DTargeting%2520of%2520PYK2%2520synergizes%2520with%2520EGFR%2520antagonists%2520in%2520basal-like%2520TNBC%2520and%2520circumvents%2520HER3-associated%2520resistance%2520via%2520the%2520NEDD4-NDRG1%2520axis%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D1%26spage%3D86%26epage%3D99%26doi%3D10.1158%2F0008-5472.CAN-16-1797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rayson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupichuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhesy-Thind, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prady, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludkovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonomi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagerman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, P.</span></span> <span> </span><span class="NLM_article-title">Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1007/s10549-016-3812-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-016-3812-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27116183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XotF2lsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=109-116&issue=1&author=D.+Raysonauthor=S.+Lupichukauthor=K.+Potvinauthor=S.+Dentauthor=T.+Shenkierauthor=S.+Dhesy-Thindauthor=S.+L.+Ellardauthor=C.+Pradyauthor=M.+Salimauthor=P.+Farmerauthor=G.+Alloauthor=M.+S.+Tsaoauthor=A.+Allanauthor=O.+Ludkovskiauthor=M.+Bonomiauthor=D.+Tuauthor=L.+Hagermanauthor=R.+Goodwinauthor=E.+Eisenhauerauthor=P.+Bradbury&title=Canadian+Cancer+Trials+Group+IND197%3A+a+phase+II+study+of+foretinib+in+patients+with+estrogen+receptor%2C+progesterone+receptor%2C+and+human+epidermal+growth+factor+receptor+2-negative+recurrent+or+metastatic+breast+cancer&doi=10.1007%2Fs10549-016-3812-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer</span></div><div class="casAuthors">Rayson, Daniel; Lupichuk, Sasha; Potvin, Kylea; Dent, Susan; Shenkier, Tamara; Dhesy-Thind, Sukhbinder; Ellard, Susan L.; Prady, Catherine; Salim, Muhammad; Farmer, Patricia; Allo, Ghasson; Tsao, Ming-Sound; Allan, Alison; Ludkovski, Olga; Bonomi, Maria; Tu, Dongsheng; Hagerman, Linda; Goodwin, Rachel; Eisenhauer, Elizabeth; Bradbury, Penelope</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-116</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In murine models, overexpression of the MET receptor transgene induces tumors with human basal gene expression characteristics supporting MET inhibition as a treatment strategy for triple-neg. breast cancer (TNBC).  Foretinib is an oral multi-kinase inhibitor of MET, RON, AXL, TIE-2, and VEGF receptors with anti-tumor activity in advanced HCC and papillary renal cell cancer.  Patients with centrally reviewed primary TNBC and 0-1 prior regimens for metastatic disease received daily foretinib 60 mg po in a 2-stage single-arm trial.  Primary endpoints were objective response and early progression rates per RECIST 1.1.  In stage 2, correlative studies of MET, PTEN, EGFR, and p53 on archival and fresh tumor specimens were performed along with enumeration of CTCs. 45 patients were enrolled with 37 patients having response evaluable and centrally confirmed primary TNBC (cTNBC).  There were 2 partial responses (ITT 4.7 % response evaluable cTNBC 5.4 %) with a median duration of 4.4 mo (range 3.7-5 m) and 15 patients had stable disease (ITT 33 %, response evaluable cTNBC 40.5 %) with a median duration of 5.4 mo (range 2.3-9.7 m).  The most common toxicities (all grades/grade 3) were nausea (64/4 %), fatigue (60/4 %), hypertension (58/49 %), and diarrhea (40/7 %).  Six serious adverse events were considered possibly related to foretinib and 4 patients went off study due to adverse events.  There was no correlation between MET positivity and response nor between response and PTEN, EGFR, p53, or MET expression in CTCs.  Although CCTG IND 197 did not meet its primary endpoint, the observation of a clin. benefit rate of 46 % in this cTNBC population suggests that foretinib may have clin. activity as a single, non-cytotoxic agent in TNBC (ClinicalTrials.gov no., NCT01147484).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC4vs0yv27lLVg90H21EOLACvtfcHk0lh33EIwsPiZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotF2lsb0%253D&md5=011afe463c72f862f27e20f7649787e4</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs10549-016-3812-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-016-3812-1%26sid%3Dliteratum%253Aachs%26aulast%3DRayson%26aufirst%3DD.%26aulast%3DLupichuk%26aufirst%3DS.%26aulast%3DPotvin%26aufirst%3DK.%26aulast%3DDent%26aufirst%3DS.%26aulast%3DShenkier%26aufirst%3DT.%26aulast%3DDhesy-Thind%26aufirst%3DS.%26aulast%3DEllard%26aufirst%3DS.%2BL.%26aulast%3DPrady%26aufirst%3DC.%26aulast%3DSalim%26aufirst%3DM.%26aulast%3DFarmer%26aufirst%3DP.%26aulast%3DAllo%26aufirst%3DG.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26aulast%3DAllan%26aufirst%3DA.%26aulast%3DLudkovski%26aufirst%3DO.%26aulast%3DBonomi%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DHagerman%26aufirst%3DL.%26aulast%3DGoodwin%26aufirst%3DR.%26aulast%3DEisenhauer%26aufirst%3DE.%26aulast%3DBradbury%26aufirst%3DP.%26atitle%3DCanadian%2520Cancer%2520Trials%2520Group%2520IND197%253A%2520a%2520phase%2520II%2520study%2520of%2520foretinib%2520in%2520patients%2520with%2520estrogen%2520receptor%252C%2520progesterone%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-negative%2520recurrent%2520or%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2016%26volume%3D157%26issue%3D1%26spage%3D109%26epage%3D116%26doi%3D10.1007%2Fs10549-016-3812-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, T.</span></span> <span> </span><span class="NLM_article-title">Targeted therapies for triple-negative breast cancer</span>. <i>Curr. Treat Option On.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">82</span>, <span class="refDoi"> DOI: 10.1007/s11864-019-0682-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs11864-019-0682-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31754897" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=82&issue=11&author=T.+Lyons&title=Targeted+therapies+for+triple-negative+breast+cancer&doi=10.1007%2Fs11864-019-0682-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1007%2Fs11864-019-0682-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11864-019-0682-x%26sid%3Dliteratum%253Aachs%26aulast%3DLyons%26aufirst%3DT.%26atitle%3DTargeted%2520therapies%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DCurr.%2520Treat%2520Option%2520On.%26date%3D2019%26volume%3D20%26issue%3D11%26spage%3D82%26doi%3D10.1007%2Fs11864-019-0682-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. S.</span></span> <span> </span><span class="NLM_article-title">Medical uses of mylabris in ancient China and recent studies</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/0378-8741(89)90062-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2F0378-8741%2889%2990062-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=2689797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADyaK3cXptFSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1989&pages=147-162&issue=2&author=G.+S.+Wang&title=Medical+uses+of+mylabris+in+ancient+China+and+recent+studies&doi=10.1016%2F0378-8741%2889%2990062-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Medical uses of Mylabris in ancient China and recent studies</span></div><div class="casAuthors">Wang, Guangsheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-62</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    </div><div class="casAbstract">A review with 56 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtR_mIS1cynLVg90H21EOLACvtfcHk0lh33EIwsPiZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXptFSitg%253D%253D&md5=ac51dbf89c0fbb622bb0939b7d4a9f27</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2F0378-8741%2889%2990062-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-8741%252889%252990062-7%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%2BS.%26atitle%3DMedical%2520uses%2520of%2520mylabris%2520in%2520ancient%2520China%2520and%2520recent%2520studies%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D1989%26volume%3D26%26issue%3D2%26spage%3D147%26epage%3D162%26doi%3D10.1016%2F0378-8741%2889%2990062-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, M.</span></span> <span> </span><span class="NLM_article-title">Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>217</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2004.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2004.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=15596295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKksbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2005&pages=43-52&issue=1&author=S.+Kokauthor=S.+Chengauthor=C.+Hongauthor=J.+Leeauthor=S.+Linauthor=Y.+Kuoauthor=C.+Chiangauthor=M.+Kuo&title=Norcantharidin-induced+apoptosis+in+oral+cancer+cells+is+associated+with+an+increase+of+proapoptotic+to+antiapoptotic+protein+ratio&doi=10.1016%2Fj.canlet.2004.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio</span></div><div class="casAuthors">Kok, Sang-Heng; Cheng, Shih-Jung; Hong, Chi-Yuan; Lee, Jang-Jaer; Lin, Sze-Kwan; Kuo, Ying-Shiung; Chiang, Chun-Pin; Kuo, Mark Yen-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-52</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Norcantharidin (NCTD), the demethylated analog of cantharidin, was used to treat human cancers in China since 1984.  It was recently found to be capable of inducing apoptosis in human colon carcinoma, hepatoma and glioblastoma cells by way of an elusive mechanism.  In this study, the authors demonstrated that NCTD also induces apoptosis in human oral cancer cell lines SAS (p53 wild-type phenotype) and Ca9-22 (p53 mutant) as evidenced by nuclear condensation, TUNEL labeling, DNA fragmentation and cleavage of PARP.  Apoptosis induced by NCTD was both dose- and time-dependent.  The authors found NCTD did not induce Fas and FasL, implying that it activated other apoptosis pathways.  The authors' data showed that NCTD caused accumulation of cytosolic cytochrome c and activation of caspase-9, suggesting that apoptosis occurred via the mitochondria mediated pathway.  NCTD enhanced the expression of Bax in SAS cells consistent with their p53 status.  Moreover, the authors showed that NCTD downregulated the expression of Bcl-2 in Ca9-22 and Bcl-XL in SAS.  The authors' results suggest that NCTD-induced apoptosis in oral cancer cells may be mediated by an increase in the ratios of proapoptotic to antiapoptotic proteins.  Since oral cancer cells with mutant p53 or elevated Bcl-XL levels showed resistance to multiple chemotherapeutic agents, NCTD may overcome the chemoresistance of these cells and provide potential new avenues for treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh0t5WMeg_eLVg90H21EOLACvtfcHk0lh33EIwsPiZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKksbfJ&md5=505b03d726bd7a687c2daacc4a0d8dd2</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DKok%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DKuo%26aufirst%3DY.%26aulast%3DChiang%26aufirst%3DC.%26aulast%3DKuo%26aufirst%3DM.%26atitle%3DNorcantharidin-induced%2520apoptosis%2520in%2520oral%2520cancer%2520cells%2520is%2520associated%2520with%2520an%2520increase%2520of%2520proapoptotic%2520to%2520antiapoptotic%2520protein%2520ratio%26jtitle%3DCancer%2520Lett.%26date%3D2005%26volume%3D217%26issue%3D1%26spage%3D43%26epage%3D52%26doi%3D10.1016%2Fj.canlet.2004.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shreeram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blow, J. J.</span></span> <span> </span><span class="NLM_article-title">Cell type-specific responses of human cells to inhibition of replication licensing</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">6624</span>– <span class="NLM_lpage">6632</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fsj.onc.1205910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=12242660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFenu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6624-6632&issue=43&author=S.+Shreeramauthor=A.+Sparksauthor=D.+P.+Laneauthor=J.+J.+Blow&title=Cell+type-specific+responses+of+human+cells+to+inhibition+of+replication+licensing&doi=10.1038%2Fsj.onc.1205910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Cell type-specific responses of human cells to inhibition of replication licensing</span></div><div class="casAuthors">Shreeram, S.; Sparks, Alison; Lane, David P.; Blow, J. Julian</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">6624-6632</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Replication origins are licensed' for a single initiation event by loading Mcm2-7 complexes during late mitosis and G1.  Licensing is blocked at other cell cycle stages by the activity of cyclin-dependent kinases and a small protein called geminin.  Here, we describe the effects of over-expressing a non-degradable form of geminin in various cell lines.  Geminin expression reduced the quantity of Mcm2 bound to chromatin and blocked cell proliferation.  U2OS (p53+/Rb+) cells showed an early S phase arrest with high cyclin E and undetectable cyclin A levels, consistent with the activation of an intra-S checkpoint.  Saos2 (p53-/Rb-) cells showed an accumulation of cells in late S and G2/M with approx. normal levels of cyclin A, consistent with loss of this intra-S phase checkpoint.  Geminin also induced apoptosis in both these cell lines.  In contrast, IMR90 primary fibroblasts over-expressing geminin arrested in G1 with reduced cyclin E levels and no detectable apoptosis.  A licensing checkpoint' may therefore act in primary cells to prevent passage into S phase in the absence of sufficient origin licensing.  These results suggest that inhibition of the licensing system may cause cancer-specific cell killing and therefore represent a novel anti-cancer target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDBIPPuuHsBrVg90H21EOLACvtfcHk0lhMhL0R2ueLow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFenu7k%253D&md5=ed31520729a8704bcc3b904099b79361</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205910%26sid%3Dliteratum%253Aachs%26aulast%3DShreeram%26aufirst%3DS.%26aulast%3DSparks%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DBlow%26aufirst%3DJ.%2BJ.%26atitle%3DCell%2520type-specific%2520responses%2520of%2520human%2520cells%2520to%2520inhibition%2520of%2520replication%2520licensing%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26issue%3D43%26spage%3D6624%26epage%3D6632%26doi%3D10.1038%2Fsj.onc.1205910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igrejas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodeiro, C.</span></span> <span> </span><span class="NLM_article-title">An overview of the effective combination therapies for the treatment of breast cancer</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2016.04.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.biomaterials.2016.04.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27162073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFyitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2016&pages=34-50&author=C.+N%C3%BA%C3%B1ezauthor=J.+Capeloauthor=G.+Igrejasauthor=A.+Alfonsoauthor=L.+Botanaauthor=C.+Lodeiro&title=An+overview+of+the+effective+combination+therapies+for+the+treatment+of+breast+cancer&doi=10.1016%2Fj.biomaterials.2016.04.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of the effective combination therapies for the treatment of breast cancer</span></div><div class="casAuthors">Nunez, Cristina; Capelo, Jose Luis; Igrejas, Gilberto; Alfonso, Amparo; Botana, Luis M.; Lodeiro, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34-50</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Breast cancer (BC) is generally classified based on the receptors overexpressed on the cell nucleus, which include hormone receptors such as progesterone (PR) and estrogen (ER), and HER2.  Triple-neg. breast cancer (TNBC) is a type of cancer that lacks any of these three types of receptor proteins (ER/PR/HER2).  Tumor cells exhibit drug resistant phenotypes that decrease the efficacy of chemotherapeutic treatments.  Generally, drug resistance has a genetic basis that is caused by an abnormal gene expression, nevertheless, there are several types of drug resistance: efflux pumps reducing the cellular concn. of the drug, alterations in membrane lipids that reduce cellular uptake, increased or altered drug targets, metabolic alteration of the drug, inhibition of apoptosis, repair of the damaged DNA, and alteration of the cell cycle checkpoints.  The use of "combination therapy" is recognized as an efficient soln. to treat human diseases, in particular, breast cancer.  In this review, the authors give examples of different nanocarriers used to co-deliver multiple therapeutics (chemotherapeutic agent and nucleic acid) to drug-resistant tumor cells, and lastly, the authors give the recommendations for the future directions for the co-delivery treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPqDJbJcwJ7bVg90H21EOLACvtfcHk0lhMhL0R2ueLow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFyitr0%253D&md5=29b20c53e6e5937e67cb8ca892558f42</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2016.04.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2016.04.027%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DC.%26aulast%3DCapelo%26aufirst%3DJ.%26aulast%3DIgrejas%26aufirst%3DG.%26aulast%3DAlfonso%26aufirst%3DA.%26aulast%3DBotana%26aufirst%3DL.%26aulast%3DLodeiro%26aufirst%3DC.%26atitle%3DAn%2520overview%2520of%2520the%2520effective%2520combination%2520therapies%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DBiomaterials%26date%3D2016%26volume%3D97%26spage%3D34%26epage%3D50%26doi%3D10.1016%2Fj.biomaterials.2016.04.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djamgoz, M.</span></span> <span> </span><span class="NLM_article-title">Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2017.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ctrv.2017.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29202431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvValtbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=110-122&author=A.+Leeauthor=M.+Djamgoz&title=Triple+negative+breast+cancer%3A+Emerging+therapeutic+modalities+and+novel+combination+therapies&doi=10.1016%2Fj.ctrv.2017.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies</span></div><div class="casAuthors">Lee, Alice; Djamgoz, Mustafa B. A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">110-122</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Triple neg. breast cancer (TNBC) is a complex and aggressive subtype of breast cancer which lacks estrogen receptors, progesterone receptors and HER2 amplification, thereby making it difficult to target therapeutically.  In addn., TNBC has the highest rates of metastatic disease and the poorest overall survival of all breast cancer subtypes.  Resultantly, development of targeted therapies for TNBC is urgently needed.  Recent efforts aimed at mol. characterization of TNBCs have revealed various emerging therapeutic targets including PARP1, receptor and non-receptor tyrosine kinases, immune-checkpoints, androgen receptor and epigenetic proteins.  Key successes include that of the PARP inhibitor, olaparib, which prolonged progression-free survival in a trial of BRCA-mutated breast cancer and for which clin. approval (in this setting) appears imminent.  Nevertheless, the heterogeneity of TNBC has limited the clin. benefits of many trialled therapies in 'unselected' patients.  Further, drug resistance develops following use of many targeted monotherapies due to upregulation of compensatory signalling pathways.  In this review, we evaluate the current status of investigational targeted treatments and present evidence for the role of novel biomarkers and combination therapies in increasing response rates and circumventing drug-induced resistance.  Addnl., we discuss promising novel targets in metastatic TNBC identified through preclin. and/or epidemiol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraUe6qPPRyzbVg90H21EOLACvtfcHk0lhLtNgDiW3wBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvValtbnK&md5=738b63405e3d6c1a3541982a6987a2dd</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2017.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2017.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DA.%26aulast%3DDjamgoz%26aufirst%3DM.%26atitle%3DTriple%2520negative%2520breast%2520cancer%253A%2520Emerging%2520therapeutic%2520modalities%2520and%2520novel%2520combination%2520therapies%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2018%26volume%3D62%26spage%3D110%26epage%3D122%26doi%3D10.1016%2Fj.ctrv.2017.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linklater, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovar, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essenburg, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madaj, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnik, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkaya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maroun, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveel, C. R.</span></span> <span> </span><span class="NLM_article-title">Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">69903</span>– <span class="NLM_lpage">69915</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.12065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27655711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2svivVymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=69903-69915&issue=43&author=E.+S.+Linklaterauthor=E.+A.+Tovarauthor=C.+J.+Essenburgauthor=L.+Turnerauthor=Z.+Madajauthor=M.+E.+Winnauthor=M.+K.+Melnikauthor=H.+Korkayaauthor=C.+R.+Marounauthor=J.+G.+Christensenauthor=M.+R.+Steensmaauthor=J.+L.+Boernerauthor=C.+R.+Graveel&title=Targeting+MET+and+EGFR+crosstalk+signaling+in+triple-negative+breast+cancers&doi=10.18632%2Foncotarget.12065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers</span></div><div class="casAuthors">Linklater Erik S; Tovar Elizabeth A; Essenburg Curt J; Steensma Matthew R; Graveel Carrie R; Turner Lisa; Madaj Zachary; Winn Mary E; Melnik Marianne K; Steensma Matthew R; Melnik Marianne K; Melnik Marianne K; Steensma Matthew R; Korkaya Hasan; Maroun Christiane R; Christensen James G; Maroun Christiane R; Boerner Julie L</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">69903-69915</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is a vital need for improved therapeutic strategies that are effective in both primary and metastatic triple-negative breast cancer (TNBC).  Current treatment options for TNBC patients are restricted to chemotherapy; however tyrosine kinases are promising druggable targets due to their high expression in multiple TNBC subtypes.  Since coexpression of receptor tyrosine kinases (RTKs) can promote signaling crosstalk and cell survival in the presence of kinase inhibitors, it is likely that multiple RTKs will need to be inhibited to enhance therapeutic benefit and prevent resistance.  The MET and EGFR receptors are actionable targets due to their high expression in TNBC; however crosstalk between MET and EGFR has been implicated in therapeutic resistance to single agent use of MET or EGFR inhibitors in several cancer types.  Therefore it is likely that dual inhibition of MET and EGFR is required to prevent crosstalk signaling and acquired resistance.  In this study, we evaluated the heterogeneity of MET and EGFR expression and activation in primary and metastatic TNBC tumorgrafts and determined the efficacy of MET (MGCD265 or crizotinib) and/or EGFR (erlotinib) inhibition against TNBC progression.  Here we demonstrate that combined MET and EGFR inhibition with either MGCD265 and erlotinib treatment or crizotinib and erlotinib treatment were highly effective at abrogating tumor growth and significantly decreased the variability in treatment response compared to monotherapy.  These results advance our understanding of the RTK signaling architecture in TNBC and demonstrate that combined MET and EGFR inhibition may be a promising therapeutic strategy for TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcxR9XiFsCPOdfST00W0BcfW6udTcc2eZrWf-J6eFBzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svivVymsg%253D%253D&md5=e2fa57381f2fc7914598ec763f2aa70c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12065%26sid%3Dliteratum%253Aachs%26aulast%3DLinklater%26aufirst%3DE.%2BS.%26aulast%3DTovar%26aufirst%3DE.%2BA.%26aulast%3DEssenburg%26aufirst%3DC.%2BJ.%26aulast%3DTurner%26aufirst%3DL.%26aulast%3DMadaj%26aufirst%3DZ.%26aulast%3DWinn%26aufirst%3DM.%2BE.%26aulast%3DMelnik%26aufirst%3DM.%2BK.%26aulast%3DKorkaya%26aufirst%3DH.%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSteensma%26aufirst%3DM.%2BR.%26aulast%3DBoerner%26aufirst%3DJ.%2BL.%26aulast%3DGraveel%26aufirst%3DC.%2BR.%26atitle%3DTargeting%2520MET%2520and%2520EGFR%2520crosstalk%2520signaling%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D43%26spage%3D69903%26epage%3D69915%26doi%3D10.18632%2Foncotarget.12065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stringer-Reasor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caterinicchia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forero-Torres, A.</span></span> <span> </span><span class="NLM_article-title">An open label, pilot study of veliparib (ABT-888) and lapatinib in patients with metastatic, triple negative (ER, PR, and HER-2 negative) breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">1095</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.1095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2018.36.15_suppl.1095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1095-1095&issue=15_suppl&author=E.+M.+Stringer-Reasorauthor=E.+S.+H.+Yangauthor=J.+E.+Mayauthor=V.+Caterinicchiaauthor=Y.+Liauthor=A.+Forero-Torres&title=An+open+label%2C+pilot+study+of+veliparib+%28ABT-888%29+and+lapatinib+in+patients+with+metastatic%2C+triple+negative+%28ER%2C+PR%2C+and+HER-2+negative%29+breast+cancer&doi=10.1200%2FJCO.2018.36.15_suppl.1095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.1095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.1095%26sid%3Dliteratum%253Aachs%26aulast%3DStringer-Reasor%26aufirst%3DE.%2BM.%26aulast%3DYang%26aufirst%3DE.%2BS.%2BH.%26aulast%3DMay%26aufirst%3DJ.%2BE.%26aulast%3DCaterinicchia%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DForero-Torres%26aufirst%3DA.%26atitle%3DAn%2520open%2520label%252C%2520pilot%2520study%2520of%2520veliparib%2520%2528ABT-888%2529%2520and%2520lapatinib%2520in%2520patients%2520with%2520metastatic%252C%2520triple%2520negative%2520%2528ER%252C%2520PR%252C%2520and%2520HER-2%2520negative%2529%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D15_suppl%26spage%3D1095%26epage%3D1095%26doi%3D10.1200%2FJCO.2018.36.15_suppl.1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simiczyjew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dratkiewicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Troys, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ampe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Styczen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, D.</span></span> <span> </span><span class="NLM_article-title">Combination of EGFR inhibitor lapatinib and MET inhibitor foretinib inhibits migration of triple negative breast cancer cell lines</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">335</span>, <span class="refDoi"> DOI: 10.3390/cancers10090335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers10090335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyhtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=335&issue=9&author=A.+Simiczyjewauthor=E.+Dratkiewiczauthor=M.+Van+Troysauthor=C.+Ampeauthor=I.+Styczenauthor=D.+Nowak&title=Combination+of+EGFR+inhibitor+lapatinib+and+MET+inhibitor+foretinib+inhibits+migration+of+triple+negative+breast+cancer+cell+lines&doi=10.3390%2Fcancers10090335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of EGFR inhibitor lapatinib and MET inhibitor foretinib inhibits migration of triple negative breast cancer cell lines</span></div><div class="casAuthors">Simiczyjew, Aleksandra; Dratkiewicz, Ewelina; Van Troys, Marleen; Ampe, Christophe; Styczen, Ilona; Nowak, Dorota</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">335/1-335/17</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them.  Promising therapeutic targets are the hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR), which expression is frequently elevated in TNBC.  Inhibitors of these receptors used as monotherapy are often ineffective.  Due to that, we studied the efficacy of combined therapy targeting MET and EGFR simultaneously.  Two TNBC cell lines were treated with lapatinib (a dual EGFR and HER2 inhibitor), foretinib (a MET inhibitor), or a combination of the two.  After the inhibitors treatment, we verified the cell viability (XTT assay), distribution of the cell cycle phases, the activation of signaling pathways (Western blotting), distribution of invadopodia, fluorescent gelatin digestion (immunofluorescence), and the invasion capacity of cells.  A combination of foretinib and lapatinib effectively reduced the viability of examd. cells, led to G2/M arrest and redn. of pAKT.  There was also a decreasein no. of invadopodia formed by cells, their ability to digest gelatin and redn. of cells migration/invasion capacity.  Therapy targeting of both EGFR and MET receptors was much more effective against tested cells than monotherapy.  We selected a combination of drugs that could be successfully used against this breast cancer subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmOczbGv2Zh7Vg90H21EOLACvtfcHk0lhLtNgDiW3wBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyhtrbJ&md5=119835585685be125ad663e0218718c3</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.3390%2Fcancers10090335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers10090335%26sid%3Dliteratum%253Aachs%26aulast%3DSimiczyjew%26aufirst%3DA.%26aulast%3DDratkiewicz%26aufirst%3DE.%26aulast%3DVan%2BTroys%26aufirst%3DM.%26aulast%3DAmpe%26aufirst%3DC.%26aulast%3DStyczen%26aufirst%3DI.%26aulast%3DNowak%26aufirst%3DD.%26atitle%3DCombination%2520of%2520EGFR%2520inhibitor%2520lapatinib%2520and%2520MET%2520inhibitor%2520foretinib%2520inhibits%2520migration%2520of%2520triple%2520negative%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DCancers%26date%3D2018%26volume%3D10%26issue%3D9%26spage%3D335%26doi%3D10.3390%2Fcancers10090335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noord, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Water, B.</span></span> <span> </span><span class="NLM_article-title">A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">77</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1161-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-019-1161-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31262335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MzjtVCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=77&issue=1&author=R.+P.+McLaughlinauthor=J.+Heauthor=V.+E.+van+der+Noordauthor=J.+Redelauthor=J.+A.+Foekensauthor=J.+W.+M.+Martensauthor=M.+Smidauthor=Y.+Zhangauthor=B.+van+de+Water&title=A+kinase+inhibitor+screen+identifies+a+dual+cdc7%2FCDK9+inhibitor+to+sensitise+triple-negative+breast+cancer+to+EGFR-targeted+therapy&doi=10.1186%2Fs13058-019-1161-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy</span></div><div class="casAuthors">McLaughlin Ronan P; He Jichao; van der Noord Vera E; Redel Jevin; Zhang Yinghui; van de Water Bob; Foekens John A; Martens John W M; Smid Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge.  Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signalling pathways in TNBC, resistance to EGFR-tyrosine kinase inhibitors (TKIs) remains endemic.  Therefore, the identification of targeted agents, which synergise with current therapeutic options, is paramount.  METHODS:  Compound-based, high-throughput, proliferation screening was used to profile the response of TNBC cell lines to EGFR-TKIs, western blotting and siRNA transfection being used to examine the effect of inhibitors on EGFR-mediated signal transduction and cellular dependence on such pathways, respectively.  A kinase inhibitor combination screen was used to identify compounds that synergised with EGFR-TKIs in TNBC, utilising sulphorhodamine B (SRB) assay as read-out for proliferation.  The impact of drug combinations on cell cycle arrest, apoptosis and signal transduction was assessed using flow cytometry, automated live-cell imaging and western blotting, respectively.  RNA sequencing was employed to unravel transcriptomic changes elicited by this synergistic combination and to permit identification of the signalling networks most sensitive to co-inhibition.  RESULTS:  We demonstrate that a dual cdc7/CDK9 inhibitor, PHA-767491, synergises with multiple EGFR-TKIs (lapatinib, erlotinib and gefitinib) to overcome resistance to EGFR-targeted therapy in various TNBC cell lines.  Combined inhibition of EGFR and cdc7/CDK9 resulted in reduced cell proliferation, accompanied by induction of apoptosis, G2-M cell cycle arrest, inhibition of DNA replication and abrogation of CDK9-mediated transcriptional elongation, in contrast to mono-inhibition.  Moreover, high expression of cdc7 and RNA polymerase II Subunit A (POLR2A), the direct target of CDK9, is significantly correlated with poor metastasis-free survival in a cohort of breast cancer patients.  RNA sequencing revealed marked downregulation of pathways governing proliferation, transcription and cell survival in TNBC cells treated with the combination of an EGFR-TKI and a dual cdc7/CDK9 inhibitor.  A number of genes enriched in these downregulated pathways are associated with poor metastasis-free survival in TNBC.  CONCLUSIONS:  Our results highlight that dual inhibition of cdc7 and CDK9 by PHA-767491 is a potential strategy for targeting TNBC resistant to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvKxW8FVhTbg20zIbnCCI3fW6udTcc2eYGHIT3snSucbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzjtVCmtg%253D%253D&md5=832bb81fafa9e5645e4b842285e054fc</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1161-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1161-9%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DR.%2BP.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BNoord%26aufirst%3DV.%2BE.%26aulast%3DRedel%26aufirst%3DJ.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DMartens%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DSmid%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3Dvan%2Bde%2BWater%26aufirst%3DB.%26atitle%3DA%2520kinase%2520inhibitor%2520screen%2520identifies%2520a%2520dual%2520cdc7%252FCDK9%2520inhibitor%2520to%2520sensitise%2520triple-negative%2520breast%2520cancer%2520to%2520EGFR-targeted%2520therapy%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D77%26doi%3D10.1186%2Fs13058-019-1161-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canonici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eustace, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crown, J.</span></span> <span> </span><span class="NLM_article-title">Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer</span>. <i>Ther Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1177/1758835919897546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1177%2F1758835919897546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1-16&author=A.+Canoniciauthor=A.+L.+Browneauthor=M.+F.+K.+Ibrahimauthor=K.+P.+Fanningauthor=S.+Rocheauthor=N.+T.+Conlonauthor=F.+O%E2%80%99Neillauthor=J.+Meillerauthor=M.+Cremonaauthor=C.+Morganauthor=B.+T.+Hennessyauthor=A.+J.+Eustaceauthor=F.+Solcaauthor=N.+O%E2%80%99Donovanauthor=J.+Crown&title=Combined+targeting+EGFR+and+SRC+as+a+potential+novel+therapeutic+approach+for+the+treatment+of+triple+negative+breast+cancer&doi=10.1177%2F1758835919897546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1177%2F1758835919897546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758835919897546%26sid%3Dliteratum%253Aachs%26aulast%3DCanonici%26aufirst%3DA.%26aulast%3DBrowne%26aufirst%3DA.%2BL.%26aulast%3DIbrahim%26aufirst%3DM.%2BF.%2BK.%26aulast%3DFanning%26aufirst%3DK.%2BP.%26aulast%3DRoche%26aufirst%3DS.%26aulast%3DConlon%26aufirst%3DN.%2BT.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DF.%26aulast%3DMeiller%26aufirst%3DJ.%26aulast%3DCremona%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DEustace%26aufirst%3DA.%2BJ.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26aulast%3DCrown%26aufirst%3DJ.%26atitle%3DCombined%2520targeting%2520EGFR%2520and%2520SRC%2520as%2520a%2520potential%2520novel%2520therapeutic%2520approach%2520for%2520the%2520treatment%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DTher%2520Adv.%2520Med.%2520Oncol.%26date%3D2020%26volume%3D12%26spage%3D1%26epage%3D16%26doi%3D10.1177%2F1758835919897546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">61</span>),  <span class="NLM_fpage">104193</span>– <span class="NLM_lpage">104205</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.22119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.22119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29262632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzjs1egsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=104193-104205&issue=61&author=Y.+Chenauthor=X.+Wangauthor=C.+Caoauthor=X.+Wangauthor=S.+Liangauthor=C.+Pengauthor=L.+Fuauthor=G.+He&title=Inhibition+of+HSP90+sensitizes+a+novel+Raf%2FERK+dual+inhibitor+CY-9d+in+triple-negative+breast+cancer+cells&doi=10.18632%2Foncotarget.22119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells</span></div><div class="casAuthors">Chen Yujuan; Wang Xiaoyun; Wang Xiaodong; Liang Shufang; Fu Leilei; He Gu; Cao Chuan; Peng Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">61</span>),
    <span class="NLM_cas:pages">104193-104205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Raf and extracellular signal-regulated kinases (ERK) are both important therapeutic targets in the mitogen-activated protein kinase (MAPK) pathway, and play crucial roles in the apoptosis resistance of breast cancer cells.  In the present study, cytotoxic and apoptosis-inducing activities of the Raf/ERK dual inhibitor CY-9d were found to be restricted in triple negative breast cancer (TNBC) cells compared with ER/PR-positive cells.  Based on the analysis of differentially expressed proteins using a quantitative proteomic iTRAQ method and bioinformatics analysis, HSP90 was found to identify as a potential mediator between Raf and ERK in TNBC cells.  Western blotting and RNA interference suggested that down-regulated IQGAP1 can attenuate the routine Raf/MEK/ERK cascade and recruit HSP90 as a bypass pathway.  Simultaneous treatment with the HSP90 inhibitor and CY-9d at sub-therapeutic doses was found to produce synergistic therapeutic and apoptosis-inducing effects in TNBC cells.  Moreover, CY-9d was also found to suppress breast cancer growth, inhibit the activation of Raf/ERK, and induce mitochondrial apoptosis in vivo without remarkable toxicity.  These results support the combination of HSP90 and Raf/ERK inhibitors as a potential target therapeutic strategy with enhanced tumor growth suppression, downstream pathway blockade, and greater induction of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ7MGLt-1wSC-bLEOO4dYpfW6udTcc2eYGHIT3snSucbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzjs1egsg%253D%253D&md5=639905f07dc04ba69fada4057d8671fb</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.22119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.22119%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520HSP90%2520sensitizes%2520a%2520novel%2520Raf%252FERK%2520dual%2520inhibitor%2520CY-9d%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D61%26spage%3D104193%26epage%3D104205%26doi%3D10.18632%2Foncotarget.22119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Swearingen, A. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambade, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevill, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bash, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mounsey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitz, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, C. K.</span></span> <span> </span><span class="NLM_article-title">Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nox052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fneuonc%2Fnox052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28486691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2ktbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1481-1493&issue=11&author=A.+E.+D.+Van+Swearingenauthor=M.+J.+Sambadeauthor=M.+B.+Siegelauthor=S.+Sudauthor=R.+S.+McNeillauthor=S.+M.+Bevillauthor=X.+Chenauthor=R.+E.+Bashauthor=L.+Mounseyauthor=B.+T.+Golitzauthor=C.+Santosauthor=A.+Dealauthor=J.+S.+Parkerauthor=N.+Rashidauthor=C.+R.+Millerauthor=G.+L.+Johnsonauthor=C.+K.+Anders&title=Combined+kinase+inhibitors+of+MEK1%2F2+and+either+PI3K+or+PDGFR+are+efficacious+in+intracranial+triple-negative+breast+cancer&doi=10.1093%2Fneuonc%2Fnox052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Combined kinase inhibitors of mek1/2 and either pi3k or pdgfr are efficacious in intracranial triple-negative breast cancer</span></div><div class="casAuthors">Van Swearingen, Amanda E. D.; Sambade, Maria J.; Siegel, Marni B.; Sud, Shivani; McNeill, Robert S.; Bevill, Samantha M.; Chen, Xin; Bash, Ryan E.; Mounsey, Louisa; Golitz, Brian T.; Santos, Charlene; Deal, Allison; Parker, Joel S.; Rashid, Naim; Miller, C. Ryan; Johnson, Gary L.; Anders, Carey K.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1481-1493</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Triple-neg. breast cancer (TNBC), lacking expression of hormone and human epidermal growth factor receptor 2 receptors, is an aggressive subtype that frequently metastasizes to the brain and has no FDA approved systemic therapies.  Previous literature demonstrates mitogen-activated protein kinase kinase (MEK) pathway activation in TNBC brain metastases.  Thus, we aimed to discover rational combinatorial therapies with MEK inhibition, hypothesizing that co-inhibition using clin. available brain-penetrant inhibitors would improve survival in preclin. models of TNBC brain metastases.  Methods: Using human-derived TNBC cell lines, synthetic lethal small interfering RNA kinase screens were evaluated with brain-penetrant inhibitors against MEK1/2 (selumetinib, AZD6244) or phosphatidylinositol-3 kinase (PI3K; buparlisib, BKM120).  Mice bearing intracranial TNBC tumors (SUM149, MDA-MB-231Br, MDA-MB-468, or MDA-MB-436) were treated with MEK, PI3K, or platelet derived growth factor receptor (PDGFR; pazopanib) inhibitors alone or in combination.  Tumors were analyzed by western blot and multiplexed kinase inhibitor beads/mass spectrometry to assess treatment effects.  Results: Screens identified MEK+PI3K and MEK+PDGFR inhibitors as tractable, rational combinations.  Dual treatment of selumetinib with buparlisib or pazopanib was synergistic in TNBC cells in vitro.  Both combinations improved survival in intracranial SUM149 and MDA-MB-231Br, but not MDA-MB-468 or MDA-MB-436.  Treatments decreased mitogen-activated protein kinase (MAPK) and PI3K (Akt) signaling in sensitive (SUM149 and 231Br) but not resistant models (MDA-MB-468).  Exploratory anal. of kinome reprogramming in SUM149 intracranial tumors after MEK ± PI3K inhibition demonstrates extensive kinome changes with treatment, esp. in MAPK pathway members.  Conclusions: Results demonstrate that rational combinations of the clin. available inhibitors selumetinib with buparlisib or pazopanib may prove to be promising therapeutic strategies for the treatment of some TNBC brain metastases.  Addnl., effective combination treatments cause widespread alterations in kinase pathways, including targetable potential resistance drivers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkguj-oYDHd7Vg90H21EOLACvtfcHk0ljAnqHn5Ka0Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2ktbjO&md5=8047401673f6d1cc2f43cd9951a0771d</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnox052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnox052%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BSwearingen%26aufirst%3DA.%2BE.%2BD.%26aulast%3DSambade%26aufirst%3DM.%2BJ.%26aulast%3DSiegel%26aufirst%3DM.%2BB.%26aulast%3DSud%26aufirst%3DS.%26aulast%3DMcNeill%26aufirst%3DR.%2BS.%26aulast%3DBevill%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DBash%26aufirst%3DR.%2BE.%26aulast%3DMounsey%26aufirst%3DL.%26aulast%3DGolitz%26aufirst%3DB.%2BT.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DDeal%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DRashid%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DC.%2BR.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26aulast%3DAnders%26aufirst%3DC.%2BK.%26atitle%3DCombined%2520kinase%2520inhibitors%2520of%2520MEK1%252F2%2520and%2520either%2520PI3K%2520or%2520PDGFR%2520are%2520efficacious%2520in%2520intracranial%2520triple-negative%2520breast%2520cancer%26jtitle%3DNeuro%2520Oncol.%26date%3D2017%26volume%3D19%26issue%3D11%26spage%3D1481%26epage%3D1493%26doi%3D10.1093%2Fneuonc%2Fnox052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandjean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodstal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A.</span></span> <span> </span><span class="NLM_article-title">Comprehensive two- and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1306</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.7150/jca.13266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.7150%2Fjca.13266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26640591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls12lur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1306-1319&issue=12&author=J.+Leeauthor=R.+Gallowayauthor=G.+Grandjeanauthor=J.+Jacobauthor=J.+Humphriesauthor=C.+Bartholomeuszauthor=S.+Goodstalauthor=B.+Limauthor=G.+Bartholomeuszauthor=N.+T.+Uenoauthor=A.+Rao&title=Comprehensive+two-+and+three-dimensional+RNAi+screening+identifies+PI3K+inhibition+as+a+complement+to+MEK+inhibitor+AS703026+for+combination+treatment+of+triple-negative+breast+cancer&doi=10.7150%2Fjca.13266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive two- and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer</span></div><div class="casAuthors">Lee, Jangsoon; Galloway, Rachael; Grandjean, Geoff; Jacob, Justin; Humphries, Juliane; Bartholomeusz, Chandra; Goodstal, Samantha; Lim, Bora; Bartholomeusz, Geoffrey; Ueno, Naoto T.; Rao, Arvind</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer (Wyoming, Australia)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1306-1319</span>CODEN:
                <span class="NLM_cas:coden">JCWAAL</span>;
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher Pty Ltd.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a major cause of death among breast cancer patients that results from intrinsic and acquired resistance to systemic chemotherapies.  To identify novel targets for effective treatment of TNBC through combination strategies with MEK inhibitor (AS703026), we used a novel method of combining high-throughput two- and three-dimensional (2D and 3D) RNAi screening.  TNBC cells were transfected with a kinome siRNA library comprising siRNA targeting 790 kinases under both 2D and 3D culture conditions with or without AS703026.  Mol. activity predictor anal. revealed the PI3K pathway as the major target pathway in our RNAi combination studies in TNBC.  We found that PI3K inhibitor SAR245409 (also called XL765) combined with AS703026 synergistically inhibited proliferation compared with either drug alone (P < 0.001).  Reduced in vitro colony formation (P < 0.001) and migration and invasion ability were also obsd. with the combination treatment (P<0.01).  Our data suggest that SAR245409 combined with AS703026 may be effective in patients with TNBC.  We conclude that a novel powerful high-throughput RNAi assays were able to identify anti-cancer drugs as single or combinational agents.  Integrated and multi-system RNAi screening methods can complement difference between in vitro and in vivo culture conditions, and enriches targets that are close to the in vivo condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohIjAEVc6Ko7Vg90H21EOLACvtfcHk0ljAnqHn5Ka0Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls12lur0%253D&md5=cb45d99fa4aae1fd3f9a65ce745a8efb</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.7150%2Fjca.13266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.13266%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DGalloway%26aufirst%3DR.%26aulast%3DGrandjean%26aufirst%3DG.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DHumphries%26aufirst%3DJ.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DGoodstal%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DBartholomeusz%26aufirst%3DG.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26aulast%3DRao%26aufirst%3DA.%26atitle%3DComprehensive%2520two-%2520and%2520three-dimensional%2520RNAi%2520screening%2520identifies%2520PI3K%2520inhibition%2520as%2520a%2520complement%2520to%2520MEK%2520inhibitor%2520AS703026%2520for%2520combination%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Cancer%26date%3D2015%26volume%3D6%26issue%3D12%26spage%3D1306%26epage%3D1319%26doi%3D10.7150%2Fjca.13266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karhinen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwajda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aittokallio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span> <span> </span><span class="NLM_article-title">Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>, <span class="refDoi"> DOI: 10.1186/s12943-016-0517-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs12943-016-0517-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27165605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivFShtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=34&issue=1&author=P.+Gautamauthor=L.+Karhinenauthor=A.+Szwajdaauthor=S.+K.+Jhaauthor=B.+Yadavauthor=T.+Aittokallioauthor=K.+Wennerberg&title=Identification+of+selective+cytotoxic+and+synthetic+lethal+drug+responses+in+triple+negative+breast+cancer+cells&doi=10.1186%2Fs12943-016-0517-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells</span></div><div class="casAuthors">Gautam, Prson; Karhinen, Leena; Szwajda, Agnieszka; Kumar, Jha Sawan; Yadav, Bhagwan; Aittokallio, Tero; Wennerberg, Krister</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/16</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Triple neg. breast cancer (TNBC) is a highly heterogeneous and aggressive type of cancer that lacks effective targeted therapy.  Despite detailed mol. profiling, no targeted therapy has been established.  Hence, with the aim of gaining deeper understanding of the functional differences of TNBC subtypes and how that may relate to potential novel therapeutic strategies, we studied comprehensive anticancer-agent responses among a panel of TNBC cell lines.  Method: The responses of 301 approved and investigational oncol. compds. were measured in 16 TNBC cell lines applying a functional profiling approach.  To go beyond the std. drug viability effect profiling, which has been used in most chemosensitivity studies, we utilized a multiplexed readout for both cell viability and cytotoxicity, allowing us to differentiate between cytostatic and cytotoxic responses.  Results: Our approach revealed that most single-agent anti-cancer compds. that showed activity for the viability readout had no or little cytotoxic effects.  Major compd. classes that exhibited this type of response included anti-mitotics, mTOR, CDK, and metabolic inhibitors, as well as many agents selectively inhibiting oncogene-activated pathways.  However, within the broad viability-acting classes of compds., there were often subsets of cell lines that responded by cell death, suggesting that these cells are particularly vulnerable to the tested substance.  In those cases we could identify differential levels of protein markers assocd. with cytotoxic responses.  For example, PAI-1, MAPK phosphatase and Notch-3 levels assocd. with cytotoxic responses to mitotic and proteasome inhibitors, suggesting that these might serve as markers of response also in clin. settings.  Furthermore, the cytotoxicity readout highlighted selective synergistic and synthetic lethal drug combinations that were missed by the cell viability readouts.  For instance, the MEK inhibitor trametinib synergized with PARP inhibitors.  Similarly, combination of two non-cytotoxic compds., the rapamycin analog everolimus and an ATP-competitive mTOR inhibitor dactolisib, showed synthetic lethality in several mTOR-addicted cell lines.  Conclusions: Taken together, by studying the combination of cytotoxic and cytostatic drug responses, we identified a deeper spectrum of cellular responses both to single agents and combinations that may be highly relevant for identifying precision medicine approaches in TNBC as well as in other types of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhf9pIYXrFw7Vg90H21EOLACvtfcHk0ljAnqHn5Ka0Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivFShtrs%253D&md5=c4dcfb13defdcac4e1d931eafdc62d20</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1186%2Fs12943-016-0517-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-016-0517-3%26sid%3Dliteratum%253Aachs%26aulast%3DGautam%26aufirst%3DP.%26aulast%3DKarhinen%26aufirst%3DL.%26aulast%3DSzwajda%26aufirst%3DA.%26aulast%3DJha%26aufirst%3DS.%2BK.%26aulast%3DYadav%26aufirst%3DB.%26aulast%3DAittokallio%26aufirst%3DT.%26aulast%3DWennerberg%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520selective%2520cytotoxic%2520and%2520synthetic%2520lethal%2520drug%2520responses%2520in%2520triple%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%26date%3D2016%26volume%3D15%26issue%3D1%26spage%3D34%26doi%3D10.1186%2Fs12943-016-0517-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalimutho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srihari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanayakkara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafique, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raninga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nag, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, K. K.</span></span> <span> </span><span class="NLM_article-title">Blockade of PDGFRbeta circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltration in triple-negative breast cancer</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">85</span>, <span class="refDoi"> DOI: 10.1186/s13046-019-1075-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13046-019-1075-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30777101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3cfkslKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=85&issue=1&author=M.+Kalimuthoauthor=D.+Sinhaauthor=D.+Mittalauthor=S.+Srihariauthor=D.+Nanayakkaraauthor=S.+Shafiqueauthor=P.+Raningaauthor=P.+Nagauthor=K.+Parsonsauthor=K.+K.+Khanna&title=Blockade+of+PDGFRbeta+circumvents+resistance+to+MEK-JAK+inhibition+via+intratumoral+CD8%28%2B%29+T-cells+infiltration+in+triple-negative+breast+cancer&doi=10.1186%2Fs13046-019-1075-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltration in triple-negative breast cancer</span></div><div class="casAuthors">Kalimutho Murugan; Sinha Debottam; Nanayakkara Devathri; Shafique Shagufta; Raninga Prahlad; Nag Purba; Parsons Kate; Khanna Kum Kum; Mittal Deepak; Srihari Sriganesh; Nag Purba</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Despite the increasing progress in targeted and immune based-directed therapies for other solid organ malignancies, currently there is no targeted therapy available for TNBCs.  A number of mechanisms have been reported both in pre-clinical and clinical settings that involve inherent, acquired and adaptive resistance to small molecule inhibitors.  Here, we demonstrated a novel resistance mechanism in TNBC cells mediated by PDGFRβ in response to JAK2 inhibition.  METHODS:  Multiple in vitro (subG1, western blotting, immunofluorescence, RT-PCR, Immunoprecipitation), in vivo and publically available datasets were used.  RESULTS:  We showed that TNBC cells exposed to MEK1/2-JAK2 inhibitors exhibit resistant colonies in anchorage-independent growth assays.  Moreover, cells treated with various small molecule inhibitors including JAK2 promote PDGFRβ upregulation.  Using publically available databases, we showed that patients expressing high PDGFRβ or its ligand PDGFB exhibit poor relapse-free survival upon chemotherapeutic treatment.  Mechanistically we found that JAK2 expression controls steady state levels of PDGFRβ.  Thus, co-blockade of PDGFRβ with JAK2 and MEK1/2 inhibitors completely eradicated resistant colonies in vitro.  We found that triple-combined treatment had a significant impact on CD44(+)/CD24(-) stem-cell-like cells.  Likewise, we found a significant tumor growth inhibition in vivo through intratumoral CD8(+) T cells infiltration in a manner that is reversed by anti-CD8 antibody treatment.  CONCLUSION:  These findings reveal a novel regulatory role of JAK2-mediated PDGFRβ proteolysis and provide an example of a PDGFRβ-mediated resistance mechanism upon specific target inhibition in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKp_mJ5o9m8z0O18WR3iAofW6udTcc2eYloNp6fPiRwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfkslKitA%253D%253D&md5=8b7a0c6c129c7555b2d3d790efd656ee</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1075-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1075-5%26sid%3Dliteratum%253Aachs%26aulast%3DKalimutho%26aufirst%3DM.%26aulast%3DSinha%26aufirst%3DD.%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DSrihari%26aufirst%3DS.%26aulast%3DNanayakkara%26aufirst%3DD.%26aulast%3DShafique%26aufirst%3DS.%26aulast%3DRaninga%26aufirst%3DP.%26aulast%3DNag%26aufirst%3DP.%26aulast%3DParsons%26aufirst%3DK.%26aulast%3DKhanna%26aufirst%3DK.%2BK.%26atitle%3DBlockade%2520of%2520PDGFRbeta%2520circumvents%2520resistance%2520to%2520MEK-JAK%2520inhibition%2520via%2520intratumoral%2520CD8%2528%252B%2529%2520T-cells%2520infiltration%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26issue%3D1%26spage%3D85%26doi%3D10.1186%2Fs13046-019-1075-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zawistowski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevill, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuhlmiller, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivares-Quintero, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciaky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittle, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velarde, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitz, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darr, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span> <span> </span><span class="NLM_article-title">Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F2159-8290.CD-16-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28108460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Klsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=302-321&issue=3&author=J.+S.+Zawistowskiauthor=S.+M.+Bevillauthor=D.+R.+Gouletauthor=T.+J.+Stuhlmillerauthor=A.+S.+Beltranauthor=J.+F.+Olivares-Quinteroauthor=D.+Singhauthor=N.+Sciakyauthor=J.+S.+Parkerauthor=N.+U.+Rashidauthor=X.+Chenauthor=J.+S.+Duncanauthor=M.+C.+Whittleauthor=S.+P.+Angusauthor=S.+H.+Velardeauthor=B.+T.+Golitzauthor=X.+Heauthor=C.+Santosauthor=D.+B.+Darrauthor=K.+Gallagherauthor=L.+M.+Gravesauthor=C.+M.+Perouauthor=L.+A.+Careyauthor=H.+S.+Earpauthor=G.+L.+Johnson&title=Enhancer+remodeling+during+adaptive+bypass+to+MEK+inhibition+is+attenuated+by+pharmacologic+targeting+of+the+P-TEFb+complex&doi=10.1158%2F2159-8290.CD-16-0653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex</span></div><div class="casAuthors">Zawistowski, Jon S.; Bevill, Samantha M.; Goulet, Daniel R.; Stuhlmiller, Timothy J.; Beltran, Adriana S.; Olivares-Quintero, Jose F.; Singh, Darshan; Sciaky, Noah; Parker, Joel S.; Rashid, Naim U.; Chen, Xin; Duncan, James S.; Whittle, Martin C.; Angus, Steven P.; Velarde, Sara Hanna; Golitz, Brian T.; He, Xiaping; Santos, Charlene; Darr, David B.; Gallagher, Kristalyn; Graves, Lee M.; Perou, Charles M.; Carey, Lisa A.; Earp, H. Shelton; Johnson, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">302-321</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clin. trial design.  Despite clin. responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving nongenomic adaptive bypass mechanisms.  Inhibition of MEK1/2 by trametinib in patients with triple-neg. breast cancer (TNBC) induced dramatic transcriptional responses, including upregulation of receptor tyrosine kinases (RTK) comparing tumor samples before and after one week of treatment.  In preclin. models, MEK inhibition induced genome-wide enhancer formation involving the seeding of BRD4, MED1, H3K27 acetylation, and p300 that drives transcriptional adaptation.  Inhibition of the P-TEFb-assocd. proteins BRD4 and CBP/p300 arrested enhancer seeding and RTK upregulation.  BRD4 bromodomain inhibitors overcame trametinib resistance, producing sustained growth inhibition in cells, xenografts, and syngeneic mouse TNBC models.  Pharmacol. targeting of P-TEFb members in conjunction with MEK inhibition by trametinib is an effective strategy to durably inhibit epigenomic remodeling required for adaptive resistance.  Significance: Widespread transcriptional adaptation to pharmacol. MEK inhibition was obsd. in TNBC patient tumors.  In preclin. models, MEK inhibition induces dramatic genome-wide modulation of chromatin, in the form of de novo enhancer formation and enhancer remodeling.  Pharmacol. targeting of P-TEFb complex members at enhancers is an effective strategy to durably inhibit such adaptation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvchkLxcOjcLVg90H21EOLACvtfcHk0ljBEQkPKFYcFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Klsbw%253D&md5=3425c91d4a75b45c55903eeda1928a91</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0653%26sid%3Dliteratum%253Aachs%26aulast%3DZawistowski%26aufirst%3DJ.%2BS.%26aulast%3DBevill%26aufirst%3DS.%2BM.%26aulast%3DGoulet%26aufirst%3DD.%2BR.%26aulast%3DStuhlmiller%26aufirst%3DT.%2BJ.%26aulast%3DBeltran%26aufirst%3DA.%2BS.%26aulast%3DOlivares-Quintero%26aufirst%3DJ.%2BF.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DRashid%26aufirst%3DN.%2BU.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DWhittle%26aufirst%3DM.%2BC.%26aulast%3DAngus%26aufirst%3DS.%2BP.%26aulast%3DVelarde%26aufirst%3DS.%2BH.%26aulast%3DGolitz%26aufirst%3DB.%2BT.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DDarr%26aufirst%3DD.%2BB.%26aulast%3DGallagher%26aufirst%3DK.%26aulast%3DGraves%26aufirst%3DL.%2BM.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26atitle%3DEnhancer%2520remodeling%2520during%2520adaptive%2520bypass%2520to%2520MEK%2520inhibition%2520is%2520attenuated%2520by%2520pharmacologic%2520targeting%2520of%2520the%2520P-TEFb%2520complex%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26issue%3D3%26spage%3D302%26epage%3D321%26doi%3D10.1158%2F2159-8290.CD-16-0653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Adorno, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordentlich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4780</span>– <span class="NLM_lpage">4792</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-16-2622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28465444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4780-4792&issue=16&author=A.+M.+Torres-Adornoauthor=J.+Leeauthor=T.+Kogawaauthor=P.+Ordentlichauthor=D.+Tripathyauthor=B.+Limauthor=N.+T.+Ueno&title=Histone+deacetylase+inhibitor+enhances+the+efficacy+of+MEK+inhibitor+through+NOXA-mediated+MCL1+degradation+in+triple-negative+and+inflammatory+breast+cancer&doi=10.1158%2F1078-0432.CCR-16-2622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer</span></div><div class="casAuthors">Torres-Adorno, Angie M.; Lee, Jangsoon; Kogawa, Takahiro; Ordentlich, Peter; Tripathy, Debu; Lim, Bora; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4780-4792</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Inflammatory breast cancer (IBC), diagnosed clin., and triple-neg. breast cancer (TNBC), diagnosed by mol. receptor status, are the two most aggressive forms of breast cancer, and both lack effective targeted therapies.  We previously demonstrated involvement of histone deacetylase (HDAC) inhibitor entinostat in regulating apoptosis in IBC and TNBC cells; here, we aimed to identify novel combination therapy candidates.  Exptl. Design: Potential therapeutic targets were identified by mRNA expression profiling of TNBC and IBC cells treated with entinostat.  Drug action and synergism were assessed by in vitro proliferation assays, tumor growth in vivo, and proteomic analyses.  Gain/loss-of-expression studies were utilized to functionally validate the role of identified targets in sensitivity of TNBC and IBC cells to combination therapy.  Results: Entinostat induced activity of the oncogenic ERK pathway and expression of proapoptotic NOXA.  These are known to stabilize and degrade, resp., MCL1, an antiapoptotic Bcl-2 protein.  In breast cancer patients, high-MCL1/low-NOXA tumor expression correlated significantly with poor survival outcomes.  Combination treatment of entinostat with MEK inhibitor pimasertib reduced the growth of TNBC and IBC cells in vitro and inhibited tumor growth in vivo.  The synergistic action of combination therapy was obsd. in TNBC and IBC cell lines in which NOXA expression was induced following entinostat treatment.  The therapeutic activity depended on induction of mitochondrial cell death pathways initiated by NOXA-mediated MCL1 degrdn.  Conclusions: Our preclin. findings provide a rationale for the clin. testing of combination HDAC and MEK pathway inhibition for TNBC and IBC that exhibit elevated baseline tumor MCL1 expression.  Clin Cancer Res; 23(16); 4780-92. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVmuZ3LzYmHrVg90H21EOLACvtfcHk0ligelILHA82Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu73J&md5=c8835ce146d5a9ea01161dbaee4f97d9</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2622%26sid%3Dliteratum%253Aachs%26aulast%3DTorres-Adorno%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKogawa%26aufirst%3DT.%26aulast%3DOrdentlich%26aufirst%3DP.%26aulast%3DTripathy%26aufirst%3DD.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520enhances%2520the%2520efficacy%2520of%2520MEK%2520inhibitor%2520through%2520NOXA-mediated%2520MCL1%2520degradation%2520in%2520triple-negative%2520and%2520inflammatory%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D16%26spage%3D4780%26epage%3D4792%26doi%3D10.1158%2F1078-0432.CCR-16-2622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seow, H. F.</span></span> <span> </span><span class="NLM_article-title">Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2015.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.biopha.2015.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26463630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=40-50&author=A.+Ayubauthor=W.+K.+Yipauthor=H.+F.+Seow&title=Dual+treatments+targeting+IGF-1R%2C+PI3K%2C+mTORC+or+MEK+synergize+to+inhibit+cell+growth%2C+induce+apoptosis%2C+and+arrest+cell+cycle+at+G1+phase+in+MDA-MB-231+cell+line&doi=10.1016%2Fj.biopha.2015.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line</span></div><div class="casAuthors">Ayub, Ayunadirah; Yip, Wai Kien; Seow, Heng Fong</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-50</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBCs) are aggressive cancers that do not benefit from hormonal therapy or therapies that target HER2 receptors.  Insulin-like growth factor 1 receptor (IGF-1R), which has been shown to be overexpressed in breast cancer, activates numerous downstream kinases that assoc. with cell proliferation and survival.  This study compared the effects caused by dual treatments targeting IGF-1R, PI3K, mTORC, or MEK with those by single treatments in a TNBC cell line, MDA-MB-231.  We used small-mol. kinase inhibitors, namely, NVP-AEW541, NVP-BKM120, KU0063794, and PD0325901 to target IGF-1R, PI3K, mTORC, and MEK, resp.  Combination treatments of PD0325901 with NVP-AEW541, NVP-BKM120 or KU0063794 and NVP-AEW541 with KU0063794 demonstrated a significant synergistic growth inhibition.  These dual treatments increased apoptosis and/or cell cycle arrest at G0/G1 phase and enhanced the inhibition of phosphorylation of Akt or downstream mols. of mTORC1, as compared to the single treatments.  Our study suggests that targeting multiple kinases in IGF-1R signaling may be a promising therapeutic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkmrJHYBqsrbVg90H21EOLACvtfcHk0ligelILHA82Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtLnK&md5=521bffcb4111aa0aa7225772f2201262</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2015.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2015.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DAyub%26aufirst%3DA.%26aulast%3DYip%26aufirst%3DW.%2BK.%26aulast%3DSeow%26aufirst%3DH.%2BF.%26atitle%3DDual%2520treatments%2520targeting%2520IGF-1R%252C%2520PI3K%252C%2520mTORC%2520or%2520MEK%2520synergize%2520to%2520inhibit%2520cell%2520growth%252C%2520induce%2520apoptosis%252C%2520and%2520arrest%2520cell%2520cycle%2520at%2520G1%2520phase%2520in%2520MDA-MB-231%2520cell%2520line%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2015%26volume%3D75%26spage%3D40%26epage%3D50%26doi%3D10.1016%2Fj.biopha.2015.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noord, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Westen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Water, B.</span></span> <span> </span><span class="NLM_article-title">Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1007/s10549-019-05380-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-019-05380-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31388935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOjur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=263-274&issue=2&author=J.+Heauthor=R.+P.+McLaughlinauthor=V.+van+der+Noordauthor=J.+A.+Foekensauthor=J.+W.+M.+Martensauthor=G.+van%0AWestenauthor=Y.+Zhangauthor=B.+van+de+Water&title=Multi-targeted+kinase+inhibition+alleviates+mTOR+inhibitor+resistance+in+triple-negative+breast+cancer&doi=10.1007%2Fs10549-019-05380-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer</span></div><div class="casAuthors">He, Jichao; McLaughlin, Ronan P.; van der Noord, Vera; Foekens, John A.; Martens, John W. M.; van Westen, Gerard; Zhang, Yinghui; van de Water, Bob</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Owing to its genetic heterogeneity and acquired resistance, triple-neg. breast cancer (TNBC) is not responsive to single-targeted therapy, causing disproportional cancer-related death worldwide.  Combined targeted therapy strategies to block interactive oncogenic signaling networks are being explored for effective treatment of the refractory TNBC subtype.  Methods: A broad kinase inhibitor screen was applied to profile the proliferative responses of TNBC cells, revealing resistance of TNBC cells to inhibition of the mammalian target of rapamycin (mTOR).  A systematic drug combination screen was subsequently performed to identify that AEE788, an inhibitor targeting multiple receptor tyrosine kinases (RTKs) EGFR/HER2 and VEGFR, synergizes with selective mTOR inhibitor rapamycin as well as its analogs (rapalogs) temsirolimus and everolimus to inhibit TNBC cell proliferation.  Results: The combination treatment with AEE788 and rapalog effectively inhibits phosphorylation of mTOR and 4EBP1, relieves mTOR inhibition-mediated upregulation of cyclin D1, and maintains suppression of AKT and ERK signaling, thereby sensitizing TNBC cells to the rapalogs. siRNA validation of cheminformatics-based predicted AEE788 targets has further revealed the mTOR interactive RPS6K members (RPS6KA3, RPS6KA6, RPS6KB1, and RPS6KL1) as synthetic lethal targets for rapalog combination treatment.  Conclusions: mTOR signaling is highly activated in TNBC tumors.  As single rapalog treatment is insufficient to block mTOR signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy to overcome mTOR-targeted therapy resistance in TNBC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAoDwulqfxKbVg90H21EOLACvtfcHk0ligelILHA82Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOjur%252FL&md5=6ac32d78271119524f0936907ad7c58a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1007%2Fs10549-019-05380-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-019-05380-z%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BP.%26aulast%3Dvan%2Bder%2BNoord%26aufirst%3DV.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DMartens%26aufirst%3DJ.%2BW.%2BM.%26aulast%3Dvan%2BWesten%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3Dvan%2Bde%2BWater%26aufirst%3DB.%26atitle%3DMulti-targeted%2520kinase%2520inhibition%2520alleviates%2520mTOR%2520inhibitor%2520resistance%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2019%26volume%3D178%26issue%3D2%26spage%3D263%26epage%3D274%26doi%3D10.1007%2Fs10549-019-05380-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1699</span>– <span class="NLM_lpage">1712</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-15-1772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26546619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Kjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1699-1712&issue=7&author=W.+Moauthor=Q.+Liuauthor=C.+C.+J.+Linauthor=H.+Daiauthor=Y.+Pengauthor=Y.+Liangauthor=G.+Pengauthor=F.+Meric-Bernstamauthor=G.+B.+Millsauthor=K.+Liauthor=S.+Y.+Lin&title=mTOR+inhibitors+suppress+homologous+recombination+repair+and+synergize+with+PARP+inhibitors+via+regulating+SUV39H1+in+BRCA-proficient+triple-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-15-1772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer</span></div><div class="casAuthors">Mo, Wei; Liu, Qingxin; Lin, Curtis Chun-Jen; Dai, Hui; Peng, Yang; Liang, Yulong; Peng, Guang; Meric-Bernstam, Funda; Mills, Gordon B.; Li, Kaiyi; Lin, Shiaw-Yih</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1699-1712</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Triple-neg. breast cancer (TNBC) is a highly heterogeneous disease and has the worst outcome among all subtypes of breast cancers.  Although PARP inhibitors represent a promising treatment in TNBC with BRCA1/BRCA2 mutations, there is great interest in identifying drug combinations that can extend the use of PARP inhibitors to a majority of TNBC patients with wild-type BRCA1/BRCA2.  Here we explored whether mTOR inhibitors, through modulating homologous recombination (HR) repair, would provide therapeutic benefit in combination with PARP inhibitors in preclin. models of BRCA-proficient TNBC.  Exptl. Design: We have studied the effects of mTOR inhibitors on HR repair following DNA double-strand breaks (DSB).  We further demonstrated the in vitro and in vivo activities of combined treatment of mTOR inhibitors with PARP inhibitors in BRCA-proficient TNBC.  Moreover, microarray anal. and rescue expts. were used to investigate the mol. mechanisms of action.  Results: We found that mTOR inhibitors significantly suppressed HR repair in two BRCA-proficient TNBC cell lines. mTOR inhibitors and PARP inhibitors in combination exhibited strong synergism against these TNBC cell lines.  In TNBC xenografts, we obsd. enhanced efficacy of everolimus in combination with talazoparib (BMN673) compared with either drug alone.  We further identified through microarray anal. and by rescue assays that mTOR inhibitors suppressed HR repair and synergized with PARP inhibitors through regulating the expression of SUV39H1 in BRCA-proficient TNBCs.  Conclusions: Collectively, these findings strongly suggest that combining mTOR inhibitors and PARP inhibitors would be an effective therapeutic approach to treat BRCA-proficient TNBC patients.  Clin Cancer Res; 22(7); 1699-712. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5IDshRv03LVg90H21EOLACvtfcHk0lj-OmayloDHFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Kjt7k%253D&md5=dc39d84a3e6b334f1ec8a10b7c264e7d</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1772%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DC.%2BC.%2BJ.%26aulast%3DDai%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DG.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DS.%2BY.%26atitle%3DmTOR%2520inhibitors%2520suppress%2520homologous%2520recombination%2520repair%2520and%2520synergize%2520with%2520PARP%2520inhibitors%2520via%2520regulating%2520SUV39H1%2520in%2520BRCA-proficient%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D7%26spage%3D1699%26epage%3D1712%26doi%3D10.1158%2F1078-0432.CCR-15-1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/s13058-015-0534-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-015-0534-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25888415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2MjltlWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=33&issue=1&author=A.+Minauthor=S.+A.+Imauthor=D.+K.+Kimauthor=S.+H.+Songauthor=H.+J.+Kimauthor=K.+H.+Leeauthor=T.+Y.+Kimauthor=S.+W.+Hanauthor=D.+Y.+Ohauthor=T.+Y.+Kimauthor=M.+J.+O%E2%80%99Connorauthor=Y.+J.+Bang&title=Histone+deacetylase+inhibitor%2C+suberoylanilide+hydroxamic+acid+%28SAHA%29%2C+enhances+anti-tumor+effects+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+olaparib+in+triple-negative+breast+cancer+cells&doi=10.1186%2Fs13058-015-0534-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells</span></div><div class="casAuthors">Min Ahrum; Im Seock-Ah; Song Sang-Hyun; Kim Hee-Jun; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Min Ahrum; Im Seock-Ah; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Im Seock-Ah; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Kim Debora Keunyoung; Kim Hee-Jun; O'Connor Mark J</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies in the homologous recombination repair (HRR) pathway.  Histone deacetylases (HDACs) are important for enabling functional HRR of DNA by regulating the expression of HRR-related genes and promoting the accurate assembly of HRR-directed sub-nuclear foci.  Thus, HDAC inhibitors have recently emerged as a therapeutic agent for treating cancer by inhibiting DNA repair.  Based on this, HDAC inhibition could be predicted to enhance the anti-tumor effect of PARP inhibitors in cancer cells by blocking the HRR pathway.  METHODS:  We determined whether suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor, could enhance the anti-tumor effects of olaparib on breast cancer cell lines using a cytotoxic assay, cell cycle analysis, and Western blotting.  We evaluated how exposure to SAHA affects the expression of HRR-associated genes.  The accumulation of DNA double strand breaks (DSBs) induced by combination treatment was assessed.  Induction of autophagy was monitored by imaging green fluorescent protein-tagged microtubule-associated protein 1A/1B-light chain 3 (LC3) expression following co-treatment with olaparib and SAHA.  These in vitro data were validated in vivo using a human breast cancer xenograft model.  RESULTS:  Triple-negative breast cancer cell (TNBC) lines showed heterogeneous responses to the PARP and HDAC inhibitors.  Co-administration of olaparib and SAHA synergistically inhibited the growth of TNBC cells that expressed functional Phosphatase and tensin homolog (PTEN).  This effect was associated with down-regulation of the proliferative signaling pathway, increased apoptotic and autophagic cell death, and accumulation of DNA damage.  The combined anti-tumor effect of olaparib and SAHA was also observed in a xenograft model.  These data suggest that PTEN expression in TNBC cells can sensitize the cell response to simultaneous inhibition of PARP and HDAC both in vitro and in vivo.  CONCLUSION:  Our findings suggest that expression of functional PTEN may serve as a biomarker for selecting TNBC patients that would favorably respond to a combination of olaparib with SAHA.  This provides a strong rationale for treating TNBC patients with PTEN expression with a combination therapy consisting of olaparib and SAHA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcCnK6c-02m0bxh97K6Vt6fW6udTcc2ebo0HmGhAUJ9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjltlWguw%253D%253D&md5=4d900b24ef95ff4fca352dc27cdc2865</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1186%2Fs13058-015-0534-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-015-0534-y%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DA.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DSong%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26atitle%3DHistone%2520deacetylase%2520inhibitor%252C%2520suberoylanilide%2520hydroxamic%2520acid%2520%2528SAHA%2529%252C%2520enhances%2520anti-tumor%2520effects%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520olaparib%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2015%26volume%3D17%26issue%3D1%26spage%3D33%26doi%3D10.1186%2Fs13058-015-0534-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greifenberg, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dust, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaro, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochupurakkal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarosiek, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmaña, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2367</span>– <span class="NLM_lpage">2381</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.10.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.celrep.2016.10.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27880910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGqt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=2367-2381&issue=9&author=S.+F.+Johnsonauthor=C.+Cruzauthor=A.+K.+Greifenbergauthor=S.+Dustauthor=D.+G.+Stoverauthor=D.+Chiauthor=B.+Primackauthor=S.+Caoauthor=A.+J.+Bernhardyauthor=R.+Coulsonauthor=J.+B.+Lazaroauthor=B.+Kochupurakkalauthor=H.+Sunauthor=C.+Unittauthor=L.+A.+Moreauauthor=K.+A.+Sarosiekauthor=M.+Scaltritiauthor=D.+Juricauthor=J.+Baselgaauthor=A.+L.+Richardsonauthor=S.+J.+Rodigauthor=A.+D.+D%E2%80%99Andreaauthor=J.+Balma%C3%B1aauthor=N.+Johnsonauthor=M.+Geyerauthor=V.+Serraauthor=E.+Limauthor=G.+I.+Shapiro&title=CDK12+inhibition+reverses+de+novo+and+acquired+PARP+inhibitor+resistance+in+BRCA+wild-type+and+mutated+models+of+triple-negative+breast+cancer&doi=10.1016%2Fj.celrep.2016.10.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Johnson, Shawn F.; Cruz, Cristina; Greifenberg, Ann Katrin; Dust, Sofia; Stover, Daniel G.; Chi, David; Primack, Benjamin; Cao, Shiliang; Bernhardy, Andrea J.; Coulson, Rhiannon; Lazaro, Jean-Bernard; Kochupurakkal, Bose; Sun, Heather; Unitt, Christine; Moreau, Lisa A.; Sarosiek, Kristopher A.; Scaltriti, Maurizio; Juric, Dejan; Baselga, Jose; Richardson, Andrea L.; Rodig, Scott J.; D'Andrea, Alan D.; Balmana, Judith; Johnson, Neil; Geyer, Matthias; Serra, Violeta; Lim, Elgene; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2367-2381</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR.  Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, addnl. has potent activity against CDK12, a transcriptional regulator of HR.  In BRCA-mutated triple-neg. breast cancer (TNBC) cells and patient-derived xenografts (PDXs), dinaciclib ablates restored HR and reverses PARP inhibitor resistance.  Addnl., we show that de novo resistance to PARP inhibition in BRCA1-mutated cell lines and a PDX derived from a PARP-inhibitor-naive BRCA1 carrier is mediated by residual HR and is reversed by CDK12 inhibition.  Finally, dinaciclib augments the degree of response in a PARP-inhibitor-sensitive model, converting tumor growth inhibition to durable regression.  These results highlight the significance of HR disruption as a therapeutic strategy and support the broad use of combined CDK12 and PARP inhibition in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyVKyKNc3G1bVg90H21EOLACvtfcHk0lj-OmayloDHFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGqt7%252FL&md5=ae666e75b7a49d0c348789e2d59643fa</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.10.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.10.077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DS.%2BF.%26aulast%3DCruz%26aufirst%3DC.%26aulast%3DGreifenberg%26aufirst%3DA.%2BK.%26aulast%3DDust%26aufirst%3DS.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DChi%26aufirst%3DD.%26aulast%3DPrimack%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DBernhardy%26aufirst%3DA.%2BJ.%26aulast%3DCoulson%26aufirst%3DR.%26aulast%3DLazaro%26aufirst%3DJ.%2BB.%26aulast%3DKochupurakkal%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DUnitt%26aufirst%3DC.%26aulast%3DMoreau%26aufirst%3DL.%2BA.%26aulast%3DSarosiek%26aufirst%3DK.%2BA.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DA.%2BL.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26aulast%3DBalma%25C3%25B1a%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DLim%26aufirst%3DE.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCDK12%2520inhibition%2520reverses%2520de%2520novo%2520and%2520acquired%2520PARP%2520inhibitor%2520resistance%2520in%2520BRCA%2520wild-type%2520and%2520mutated%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D17%26issue%3D9%26spage%3D2367%26epage%3D2381%26doi%3D10.1016%2Fj.celrep.2016.10.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonnalagadda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingareddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palle, K.</span></span> <span> </span><span class="NLM_article-title">Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">104</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1192-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-019-1192-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31492187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MrlvV2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=104&issue=1&author=C.+Maniauthor=S.+Jonnalagaddaauthor=J.+Lingareddyauthor=S.+Awasthiauthor=W.+H.+Gmeinerauthor=K.+Palle&title=Prexasertib+treatment+induces+homologous+recombination+deficiency+and+synergizes+with+olaparib+in+triple-negative+breast+cancer+cells&doi=10.1186%2Fs13058-019-1192-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells</span></div><div class="casAuthors">Mani Chinnadurai; Jonnalagadda Shirisha; Lingareddy Jojireddy; Palle Komaraiah; Lingareddy Jojireddy; Awasthi Sanjay; Gmeiner William H</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Breast cancer remains as one of the most lethal types of cancer in women.  Among various subtypes, triple-negative breast cancer (TNBC) is the most aggressive and hard to treat type of breast cancer.  Mechanistically, increased DNA repair and cell cycle checkpoint activation remain as the foremost reasons behind TNBC tumor resistance to chemotherapy and disease recurrence.  METHODS:  We evaluated the mechanism of prexasertib-induced regulation of homologous recombination (HR) proteins using 20S proteasome inhibitors and RT-PCR.  HR efficiency and DNA damages were evaluated using Dr-GFP and comet assays.  DNA morphology and DNA repair focus studies were analyzed using immunofluorescence.  UALCAN portal was used to evaluate the expression of RAD51 and survival probability based on tumor stage, subtype, and race in breast cancer patients.  RESULTS:  Our results show that prexasertib treatment promotes both post-translational and transcriptional mediated regulation of BRCA1 and RAD51 proteins.  Additionally, prexasertib-treated TNBC cells revealed over 55% reduction in HR efficiency compared to control cells.  Based on these results, we hypothesized that prexasertib treatment induced homologous recombination deficiency (HRD) and thus should synergize with PARP inhibitors (PARPi) in TNBC cells.  As predicted, combined treatment of prexasertib and PARPi olaparib increased DNA strand breaks, γH2AX foci, and nuclear disintegration relative to single-agent treatment.  Further, the prexasertib and olaparib combination was synergistic in multiple TNBC cell lines, as indicated by combination index (CI) values.  Analysis of TCGA data revealed elevated RAD51 expression in breast tumors compared to normal breast tissues, especially in TNBC subtype.  Interestingly, there was a discrepancy in RAD51 expression in racial groups, with African-American and Asian breast cancer patients showing elevated RAD51 expression compared to Caucasian breast cancer patients.  Consistent with these observations, African-American and Asian TNBC patients show decreased survival.  CONCLUSIONS:  Based on these data, RAD51 could be a biomarker for aggressive TNBC and for racial disparity in breast cancer.  As positive correlation exists between RAD51 and CHEK1 expression in breast cancer, the in vitro preclinical data presented here provides additional mechanistic insights for further evaluation of the rational combination of prexasertib and olaparib for improved outcomes and reduced racial disparity in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnQU9kfkdBxi6Ufuk_1xoTfW6udTcc2eZlUpJh9F5MDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrlvV2hug%253D%253D&md5=70eddce7eaa4e071b5b5ad39b7f1a2d6</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1192-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1192-2%26sid%3Dliteratum%253Aachs%26aulast%3DMani%26aufirst%3DC.%26aulast%3DJonnalagadda%26aufirst%3DS.%26aulast%3DLingareddy%26aufirst%3DJ.%26aulast%3DAwasthi%26aufirst%3DS.%26aulast%3DGmeiner%26aufirst%3DW.%2BH.%26aulast%3DPalle%26aufirst%3DK.%26atitle%3DPrexasertib%2520treatment%2520induces%2520homologous%2520recombination%2520deficiency%2520and%2520synergizes%2520with%2520olaparib%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D104%26doi%3D10.1186%2Fs13058-019-1192-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowsheen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span> <span> </span><span class="NLM_article-title">A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">398</span>, <span class="refDoi"> DOI: 10.1038/s41419-019-1628-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41419-019-1628-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31113933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ot1Ogtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=398&issue=6&author=Z.+Songauthor=X.+Tuauthor=Q.+Zhouauthor=J.+Huangauthor=Y.+Chenauthor=J.+Liuauthor=S.+Leeauthor=W.+Kimauthor=S.+Nowsheenauthor=K.+Luoauthor=J.+Yuanauthor=Z.+Lou&title=A+novel+UCHL3+inhibitor%2C+perifosine%2C+enhances+PARP+inhibitor+cytotoxicity+through+inhibition+of+homologous+recombination-mediated+DNA+double+strand+break+repair&doi=10.1038%2Fs41419-019-1628-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair</span></div><div class="casAuthors">Song Zhiwang; Tu Xinyi; Zhou Qin; Huang Jinzhou; Chen Yuping; Liu Jiaqi; Lee SeungBaek; Kim Wootae; Luo Kuntian; Yuan Jian; Lou Zhenkun; Nowsheen Somaira; Luo Kuntian; Yuan Jian; Lou Zhenkun</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">398</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) treatment remains a great challenge for clinical practice and novel therapeutic strategies are urgently needed.  UCHL3 is a deubiquitinase that is overexpressed in TNBC and correlates with poor prognosis.  UCHL3 deubiquitinates RAD51 thereby promoting the recruitment of RAD51 to DNA damage sites and augmenting DNA repair.  Therefore, UCHL3 overexpression can render cancer cells resistant to DNA damage inducing chemo and radiotherapy, and targeting UCHL3 can sensitize TNBC to radiation and chemotherapy.  However, small molecule inhibitors of UCHL3 are yet to be identified.  Here we report that perifosine, a previously reported Akt inhibitor, can inhibit UCHL3 in vitro and in vivo.  We found low dose (50 nM) perifosine inhibited UCHL3 deubiquitination activity without affecting Akt activity.  Furthermore, perifosine enhanced Olaparib-induced growth inhibition in TNBC cells.  Mechanistically, perifosine induced RAD51 ubiquitination and blocked the RAD51-BRCA2 interaction, which in turn decreased ionizing radiation-induced foci (IRIF) of Rad51 and, thereby, homologous recombination (HR)-mediated DNA double strand break repair.  In addition, combination of perifosine and Olaparib showed synergistic antitumor activity in vivo in TNBC xenograft model.  Thus, our present study provides a novel therapeutic approach to optimize PARP inhibitor treatment efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT436YtiSqWi7jnyZkbE8yXfW6udTcc2eZlUpJh9F5MDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ot1Ogtg%253D%253D&md5=e93c3688c9eafd6fe98a1360d71b330d</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1038%2Fs41419-019-1628-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-019-1628-8%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DLou%26aufirst%3DZ.%26atitle%3DA%2520novel%2520UCHL3%2520inhibitor%252C%2520perifosine%252C%2520enhances%2520PARP%2520inhibitor%2520cytotoxicity%2520through%2520inhibition%2520of%2520homologous%2520recombination-mediated%2520DNA%2520double%2520strand%2520break%2520repair%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2019%26volume%3D10%26issue%3D6%26spage%3D398%26doi%3D10.1038%2Fs41419-019-1628-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teo, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versaci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dushyanthen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintoff, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zethoven, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virassamy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luen, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span> <span> </span><span class="NLM_article-title">Combined CDK4/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6340</span>– <span class="NLM_lpage">6352</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-2210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-17-2210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28947417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSnur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6340-6352&issue=22&author=Z.+L.+Teoauthor=S.+Versaciauthor=S.+Dushyanthenauthor=F.+Caramiaauthor=P.+Savasauthor=C.+P.+Mintoffauthor=M.+Zethovenauthor=B.+Virassamyauthor=S.+J.+Luenauthor=G.+A.+McArthurauthor=W.+A.+Phillipsauthor=P.+K.+Darcyauthor=S.+Loi&title=Combined+CDK4%2F6+and+PI3Kalpha+inhibition+is+synergistic+and+immunogenic+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-17-2210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Teo, Zhi Ling; Versaci, Stephanie; Dushyanthen, Sathana; Caramia, Franco; Savas, Peter; Mintoff, Chris P.; Zethoven, Magnus; Virassamy, Balaji; Luen, Stephen J.; McArthur, Grant A.; Phillips, Wayne A.; Darcy, Phillip K.; Loi, Sherene</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6340-6352</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">New treatments for triple-neg. breast cancer (TNBC) are urgently needed.  Despite there being little evidence of clin. activity as single-agent therapies, we show that dual blockade of PI3Kα and CDK4/6 is synergistically effective against multiple RB1-wild-type TNBC models.  Combined PI3Kα and CDK4/6 inhibition significantly increased apoptosis, cell-cycle arrest, and tumor immunogenicity and generated immunogenic cell death in human TNBC cell lines.  Combination treatment also significantly improved disease control in human xenograft models compared with either monotherapy.  Combined PI3Kα and CDK4/6 inhibition significantly increased tumor-infiltrating T-cell activation and cytotoxicity and decreased the frequency of immunosuppressive myeloid-derived suppressor cells in a syngeneic TNBC mouse model.  Notably, combined PI3Kα and CDK4/6 inhibition, along with inhibition of immune checkpoints PD-1 and CTLA-4, induced complete and durable regressions (>1 yr) of established TNBC tumors in vivo.  Overall, our results illustrate convergent mechanisms of PI3Kα and CDK4/6 blockade on cell-cycle progression, DNA damage response, and immune-modulation and may provide a novel therapeutic approach for TNBC.  Cancer Res; 77(22); 6340-52. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSFx4Sw8aPzrVg90H21EOLACvtfcHk0lhmxqaVSoaa5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSnur7M&md5=20b287a3f4e16b6eef46984dd7809d4f</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-2210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-2210%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DZ.%2BL.%26aulast%3DVersaci%26aufirst%3DS.%26aulast%3DDushyanthen%26aufirst%3DS.%26aulast%3DCaramia%26aufirst%3DF.%26aulast%3DSavas%26aufirst%3DP.%26aulast%3DMintoff%26aufirst%3DC.%2BP.%26aulast%3DZethoven%26aufirst%3DM.%26aulast%3DVirassamy%26aufirst%3DB.%26aulast%3DLuen%26aufirst%3DS.%2BJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DPhillips%26aufirst%3DW.%2BA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DLoi%26aufirst%3DS.%26atitle%3DCombined%2520CDK4%252F6%2520and%2520PI3Kalpha%2520inhibition%2520is%2520synergistic%2520and%2520immunogenic%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D22%26spage%3D6340%26epage%3D6352%26doi%3D10.1158%2F0008-5472.CAN-17-2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coussy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Botty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chateau-Joubert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montaudon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leboucher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisset, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painsec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sourd, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servely, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rosa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucotte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foidart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sounni, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaudin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ter Brugge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieche, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, E.</span></span> <span> </span><span class="NLM_article-title">BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">531</span>),  <span class="NLM_fpage">eaax2625</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aax2625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1126%2Fscitranslmed.aax2625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32075943" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eaax2625&issue=531&author=F.+Coussyauthor=R.+El-Bottyauthor=S.+Chateau-Joubertauthor=A.+Dahmaniauthor=E.+Montaudonauthor=S.+Leboucherauthor=L.+Morissetauthor=P.+Painsecauthor=L.+Sourdauthor=L.+Huguetauthor=F.+Nematiauthor=J.+L.+Servelyauthor=T.+Larcherauthor=S.+Vacherauthor=A.+Briauxauthor=C.+Reyesauthor=P.+La+Rosaauthor=G.+Lucotteauthor=T.+Popovaauthor=P.+Foidartauthor=N.+E.+Sounniauthor=A.+Noelauthor=D.+Decaudinauthor=L.+Fuhrmannauthor=A.+Salomonauthor=F.+Reyalauthor=C.+Muellerauthor=P.+Ter+Bruggeauthor=J.+Jonkersauthor=M.+F.+Pouponauthor=M.+H.+Sternauthor=I.+Biecheauthor=Y.+Pommierauthor=E.+Marangoni&title=BRCAness%2C+SLFN11%2C+and+RB1+loss+predict+response+to+topoisomerase+I+inhibitors+in+triple-negative+breast+cancers&doi=10.1126%2Fscitranslmed.aax2625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aax2625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aax2625%26sid%3Dliteratum%253Aachs%26aulast%3DCoussy%26aufirst%3DF.%26aulast%3DEl-Botty%26aufirst%3DR.%26aulast%3DChateau-Joubert%26aufirst%3DS.%26aulast%3DDahmani%26aufirst%3DA.%26aulast%3DMontaudon%26aufirst%3DE.%26aulast%3DLeboucher%26aufirst%3DS.%26aulast%3DMorisset%26aufirst%3DL.%26aulast%3DPainsec%26aufirst%3DP.%26aulast%3DSourd%26aufirst%3DL.%26aulast%3DHuguet%26aufirst%3DL.%26aulast%3DNemati%26aufirst%3DF.%26aulast%3DServely%26aufirst%3DJ.%2BL.%26aulast%3DLarcher%26aufirst%3DT.%26aulast%3DVacher%26aufirst%3DS.%26aulast%3DBriaux%26aufirst%3DA.%26aulast%3DReyes%26aufirst%3DC.%26aulast%3DLa%2BRosa%26aufirst%3DP.%26aulast%3DLucotte%26aufirst%3DG.%26aulast%3DPopova%26aufirst%3DT.%26aulast%3DFoidart%26aufirst%3DP.%26aulast%3DSounni%26aufirst%3DN.%2BE.%26aulast%3DNoel%26aufirst%3DA.%26aulast%3DDecaudin%26aufirst%3DD.%26aulast%3DFuhrmann%26aufirst%3DL.%26aulast%3DSalomon%26aufirst%3DA.%26aulast%3DReyal%26aufirst%3DF.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DTer%2BBrugge%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DPoupon%26aufirst%3DM.%2BF.%26aulast%3DStern%26aufirst%3DM.%2BH.%26aulast%3DBieche%26aufirst%3DI.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DMarangoni%26aufirst%3DE.%26atitle%3DBRCAness%252C%2520SLFN11%252C%2520and%2520RB1%2520loss%2520predict%2520response%2520to%2520topoisomerase%2520I%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26issue%3D531%26spage%3Deaax2625%26doi%3D10.1126%2Fscitranslmed.aax2625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerratana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponnetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Loreto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garattini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damante, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi, F.</span></span> <span> </span><span class="NLM_article-title">BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>144</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1002/ijc.31898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fijc.31898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30259975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlylu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2019&pages=755-766&issue=4&author=C.+Mioauthor=L.+Gerratanaauthor=M.+Bolisauthor=F.+Caponnettoauthor=A.+Zanelloauthor=M.+Barbinaauthor=C.+Di+Loretoauthor=E.+Garattiniauthor=G.+Damanteauthor=F.+Puglisi&title=BET+proteins+regulate+homologous+recombination-mediated+DNA+repair%3A+BRCAness+and+implications+for+cancer+therapy&doi=10.1002%2Fijc.31898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy</span></div><div class="casAuthors">Mio, Catia; Gerratana, Lorenzo; Bolis, Marco; Caponnetto, Federica; Zanello, Andrea; Barbina, Mattia; Di Loreto, Carla; Garattini, Enrico; Damante, Giuseppe; Puglisi, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">755-766</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Bromodomain and Extra-Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage regulation.  Aims of our study were to assess BRD4 regulation in homologous recombination-mediated DNA repair and to explore novel clin. strategies through the combinations of the pharmacol. induction of epigenetic BRCAness in BRCA1 wild-type triple neg. breast cancer (TNBC) cells by means of BET inhibitors and compds. already available in clinic.  Performing a dual approach (chromatin immunopptn. and RNA interference), the direct relationship between BRD4 and BRCA1/RAD51 expression was confirmed in TNBC cells.  Moreover, BRD4 pharmacol. inhibition using two BET inhibitors (JQ1 and GSK525762A) induced a dose-dependent redn. in BRCA1 and RAD51 levels and is able to hinder homologous recombination-mediated DNA damage repair, generating a BRCAness phenotype in TNBC cells.  Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage after platinum salts (i.e., CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e., AZD2281).  Altogether, the present study confirms that BET proteins directly regulate the homologous recombination pathway and their inhibition induced a BRCAness phenotype in BRCA1 wild-type TNBC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru1lYhArJSOLVg90H21EOLACvtfcHk0lhrj7RjxmIJDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlylu7vP&md5=8ff945e7f264b99721c855d122412cd7</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1002%2Fijc.31898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.31898%26sid%3Dliteratum%253Aachs%26aulast%3DMio%26aufirst%3DC.%26aulast%3DGerratana%26aufirst%3DL.%26aulast%3DBolis%26aufirst%3DM.%26aulast%3DCaponnetto%26aufirst%3DF.%26aulast%3DZanello%26aufirst%3DA.%26aulast%3DBarbina%26aufirst%3DM.%26aulast%3DDi%2BLoreto%26aufirst%3DC.%26aulast%3DGarattini%26aufirst%3DE.%26aulast%3DDamante%26aufirst%3DG.%26aulast%3DPuglisi%26aufirst%3DF.%26atitle%3DBET%2520proteins%2520regulate%2520homologous%2520recombination-mediated%2520DNA%2520repair%253A%2520BRCAness%2520and%2520implications%2520for%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D144%26issue%3D4%26spage%3D755%26epage%3D766%26doi%3D10.1002%2Fijc.31898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bevill, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivares-Quintero, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciaky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitz, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuhlmiller, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistowski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span> <span> </span><span class="NLM_article-title">GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-18-1121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1541-7786.MCR-18-1121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31000582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=1503-1518&issue=7&author=S.+M.+Bevillauthor=J.+F.+Olivares-Quinteroauthor=N.+Sciakyauthor=B.+T.+Golitzauthor=D.+Singhauthor=A.+S.+Beltranauthor=N.+U.+Rashidauthor=T.+J.+Stuhlmillerauthor=A.+Haleauthor=N.+J.+Moormanauthor=C.+M.+Santosauthor=S.+P.+Angusauthor=J.+S.+Zawistowskiauthor=G.+L.+Johnson&title=GSK2801%2C+a+BAZ2%2FBRD9+bromodomain+inhibitor%2C+synergizes+with+BET+inhibitors+to+induce+apoptosis+in+triple-negative+breast+cancer&doi=10.1158%2F1541-7786.MCR-18-1121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer</span></div><div class="casAuthors">Bevill, Samantha M.; Olivares-Quintero, Jose F.; Sciaky, Noah; Golitz, Brian T.; Singh, Darshan; Beltran, Adriana S.; Rashid, Naim U.; Stuhlmiller, Timothy J.; Hale, Andrew; Moorman, Nathaniel J.; Santos, Charlene M.; Angus, Steven P.; Zawistowski, Jon S.; Johnson, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1503-1518</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Screening of an inhibitor library targeting kinases and epigenetic regulators identified several mols. having antiproliferative synergy with extraterminal domain (BET) bromodomain (BD) inhibitors (JQ1, OTX015) in triple-neg. breast cancer (TNBC).  GSK2801, an inhibitor of BAZ2A/B BDs, of the imitation switch chromatin remodeling complexes, and BRD9, of the SWI/SNF complex, demonstrated synergy independent of BRD4 control of P-TEFb-mediated pause-release of RNA polymerase II.  GSK2801 or RNAi knockdown of BAZ2A/B with JQ1 selectively displaced BRD2 at promoters/enhancers of ETS-regulated genes.  Addnl. displacement of BRD2 from rDNA in the nucleolus coincided with decreased 45S rRNA, revealing a function of BRD2 in regulating RNA polymerase I transcription.  In 2D cultures, enhanced displacement of BRD2 from chromatin by combination drug treatment induced senescence.  In spheroid cultures, combination treatment induced cleaved caspase-3 and cleaved PARP characteristic of apoptosis in tumor cells.  Thus, GSK2801 blocks BRD2-driven transcription in combination with BET inhibitor and induces apoptosis of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8LuqCVf4RdrVg90H21EOLACvtfcHk0lhrj7RjxmIJDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsL3K&md5=b3304c5c41820df4070bf24ea1000e37</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-18-1121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-18-1121%26sid%3Dliteratum%253Aachs%26aulast%3DBevill%26aufirst%3DS.%2BM.%26aulast%3DOlivares-Quintero%26aufirst%3DJ.%2BF.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DGolitz%26aufirst%3DB.%2BT.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DBeltran%26aufirst%3DA.%2BS.%26aulast%3DRashid%26aufirst%3DN.%2BU.%26aulast%3DStuhlmiller%26aufirst%3DT.%2BJ.%26aulast%3DHale%26aufirst%3DA.%26aulast%3DMoorman%26aufirst%3DN.%2BJ.%26aulast%3DSantos%26aufirst%3DC.%2BM.%26aulast%3DAngus%26aufirst%3DS.%2BP.%26aulast%3DZawistowski%26aufirst%3DJ.%2BS.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26atitle%3DGSK2801%252C%2520a%2520BAZ2%252FBRD9%2520bromodomain%2520inhibitor%252C%2520synergizes%2520with%2520BET%2520inhibitors%2520to%2520induce%2520apoptosis%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D7%26spage%3D1503%26epage%3D1518%26doi%3D10.1158%2F1541-7786.MCR-18-1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y.</span></span> <span> </span><span class="NLM_article-title">Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2</span>. <i>Pathol., Res. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>215</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">152422</span>, <span class="refDoi"> DOI: 10.1016/j.prp.2019.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.prp.2019.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31079851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXps1Wjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2019&pages=152422&issue=7&author=Z.+Gaoauthor=M.+Shiauthor=Y.+Wangauthor=J.+Chenauthor=Y.+Ou&title=Apatinib+enhanced+anti-tumor+activity+of+cisplatin+on+triple-negative+breast+cancer+through+inhibition+of+VEGFR-2&doi=10.1016%2Fj.prp.2019.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2</span></div><div class="casAuthors">Gao, Zhenyuan; Shi, Mohan; Wang, Yaping; Chen, Juan; Ou, Yimei</div><div class="citationInfo"><span class="NLM_cas:title">Pathology, Research and Practice</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">152422</span>CODEN:
                <span class="NLM_cas:coden">PARPDS</span>;
        ISSN:<span class="NLM_cas:issn">0344-0338</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) was known as a fast-growing and an aggressive tumor.  Cisplatin is the effective cytotoxic drug used for the treatment of TNBC.  In addn., apatinib, a VEGFR2 inhibitor, exhibits antitumor activity in patients with TNBC.  However, the effects of combination of apatinib with cisplatin on TNBC remain unclear.  Thus, this study aimed to investigate the effects of apatinib in combination with cisplatin on MDA-MB-231 cells.  Immunohistochem. was used to detect the expression of VEGFR2.  In addn., CCK-8, flow cytometric, transwell assays were used to measure the cell proliferation, apoptosis, migration and invasion, resp.  Moreover, western blotting was used to detect the expressions of Bax, active caspase 3, p-VEGFR2, p-Akt and p-mTOR.  VEGFR2 was significantly upreguated in patients with TNBC.  In addn., the inhibitory effects of cisplatin on the proliferation, migration and invasion of MDA-MB-231 cells were enhanced by apatinib.  Moreover, apatinib increased cisplatin-induced apoptosis on MDA-MB-231 cells via increasing the level of Bax and active caspase 3 and decreasing the expression of Bcl-2.  Importantly, apatinib enhanced anti-tumor effect of cisplatin on MDA-MB-231 cells via inhibiting the levels of p-VEGFR2, p-Akt and p-mTOR.  Our findings indicated that apatinib enhanced the anti-tumor effects of cisplatin on MDA-MB-231 cells via inhibition of VEGFR2.  Thus, the combination of apatinib with cisplatin may serve as a potential approach in the treatment of patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWorp1QdfezbVg90H21EOLACvtfcHk0lhBVkoZqrS1VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXps1Wjt78%253D&md5=57db6debfe0930649b02ec01123c12ef</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.prp.2019.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prp.2019.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DOu%26aufirst%3DY.%26atitle%3DApatinib%2520enhanced%2520anti-tumor%2520activity%2520of%2520cisplatin%2520on%2520triple-negative%2520breast%2520cancer%2520through%2520inhibition%2520of%2520VEGFR-2%26jtitle%3DPathol.%252C%2520Res.%2520Pract.%26date%3D2019%26volume%3D215%26issue%3D7%26spage%3D152422%26doi%3D10.1016%2Fj.prp.2019.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheatley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemsadze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conibear, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foxley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin-Callan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartwright, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span> <span> </span><span class="NLM_article-title">Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1200/JCO.19.00368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.19.00368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31841354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGmurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=423-433&issue=5&author=P.+Schmidauthor=J.+Abrahamauthor=S.+Chanauthor=D.+Wheatleyauthor=A.+M.+Bruntauthor=G.+Nemsadzeauthor=R.+D.+Bairdauthor=Y.+H.+Parkauthor=P.+S.+Hallauthor=T.+Perrenauthor=R.+C.+Steinauthor=L.+Mangelauthor=J.+M.+Ferreroauthor=M.+Phillipsauthor=J.+Conibearauthor=J.+Cortesauthor=A.+Foxleyauthor=E.+C.+de+Bruinauthor=R.+McEwenauthor=D.+Stetsonauthor=B.+Doughertyauthor=S.+J.+Sarkerauthor=A.+Prendergastauthor=M.+McLaughlin-Callanauthor=M.+Burgessauthor=C.+Lawrenceauthor=H.+Cartwrightauthor=K.+Mousaauthor=N.+C.+Turner&title=Capivasertib+plus+paclitaxel+versus+placebo+plus+paclitaxel+as+first-line+therapy+for+metastatic+triple-negative+breast+cancer%3A+The+PAKT+trial&doi=10.1200%2FJCO.19.00368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic 1triple-negative breast cancer: the PAKT trial</span></div><div class="casAuthors">Schmid, Peter; Abraham, Jacinta; Chan, Stephen; Wheatley, Duncan; Brunt, Adrian Murray; Nemsadze, Gia; Baird, Richard D.; Park, Yeon Hee; Hall, Peter S.; Perren, Timothy; Stein, Robert C.; Mangel, Laszlo; Ferrero, Jean-Marc; Phillips, Melissa; Conibear, John; Cortes, Javier; Foxley, Andrew; Bruin, Elza C. de; McEwen, Robert; Stetson, Daniel; Dougherty, Brian; Sarker, Shah-Jalal; Prendergast, Aaron; McLaughlin-Callan, Max; Burgess, Matthew; Lawrence, Cheryl; Cartwright, Hayley; Mousa, Kelly; Turner, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">423-437</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in tripleneg. breast cancer (TNBC).  The AKT inhibitor capivasertib has shown preclin. activity in TNBC models, and drug sensitivity has been assocd. with activation of PI3K or AKT and/or deletions of PTEN.  The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC.  PATIENTS AND METHODS This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC.  A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity.  The primary end point was progression-free survival (PFS).  Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/AKT1/PTEN alterations, tumor response, and safety.  RESULTS Median PFS was 5.9 mo with capivasertib plus paclitaxel and 4.2 mo with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]).  Median OS was 19.1 mo with capivasertib plus paclitaxel and 12.6 mo with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04).  In patients with PIK3CA/AKT1/PTEN-altered tumors (n = 28), median PFS was 9.3 mo with capivasertib plus paclitaxel and 3.7 mo with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01).  The most common grade $ 3 adverse events in those treated with capivasertib plus paclitaxel vs. placebo plus paclitaxel, resp., were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%).  CONCLUSION Addn. of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS.  Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors.  Capivasertib warrants further investigation for treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_uNGmJRJlk7Vg90H21EOLACvtfcHk0lhBVkoZqrS1VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGmurrF&md5=079c77790ce5973be64ec4b93d28280d</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1200%2FJCO.19.00368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.19.00368%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DAbraham%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DWheatley%26aufirst%3DD.%26aulast%3DBrunt%26aufirst%3DA.%2BM.%26aulast%3DNemsadze%26aufirst%3DG.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DHall%26aufirst%3DP.%2BS.%26aulast%3DPerren%26aufirst%3DT.%26aulast%3DStein%26aufirst%3DR.%2BC.%26aulast%3DMangel%26aufirst%3DL.%26aulast%3DFerrero%26aufirst%3DJ.%2BM.%26aulast%3DPhillips%26aufirst%3DM.%26aulast%3DConibear%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DFoxley%26aufirst%3DA.%26aulast%3Dde%2BBruin%26aufirst%3DE.%2BC.%26aulast%3DMcEwen%26aufirst%3DR.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DSarker%26aufirst%3DS.%2BJ.%26aulast%3DPrendergast%26aufirst%3DA.%26aulast%3DMcLaughlin-Callan%26aufirst%3DM.%26aulast%3DBurgess%26aufirst%3DM.%26aulast%3DLawrence%26aufirst%3DC.%26aulast%3DCartwright%26aufirst%3DH.%26aulast%3DMousa%26aufirst%3DK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DCapivasertib%2520plus%2520paclitaxel%2520versus%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%253A%2520The%2520PAKT%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26issue%3D5%26spage%3D423%26epage%3D433%26doi%3D10.1200%2FJCO.19.00368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapp, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslyar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1360</span>– <span class="NLM_lpage">1372</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30450-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2FS1470-2045%2817%2930450-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28800861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSrtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1360-1372&issue=10&author=S.+B.+Kimauthor=R.+Dentauthor=S.+A.+Imauthor=M.+Espieauthor=S.+Blauauthor=A.+R.+Tanauthor=S.+J.+Isakoffauthor=M.+Oliveiraauthor=C.+Sauraauthor=M.+J.+Wongchenkoauthor=A.+V.+Kappauthor=W.+Y.+Chanauthor=S.+M.+Singelauthor=D.+J.+Maslyarauthor=J.+Baselga&title=Ipatasertib+plus+paclitaxel+versus+placebo+plus+paclitaxel+as+first-line+therapy+for+metastatic+triple-negative+breast+cancer+%28LOTUS%29%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2+trial&doi=10.1016%2FS1470-2045%2817%2930450-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial</span></div><div class="casAuthors">Kim, Sung-Bae; Dent, Rebecca; Im, Seock-Ah; Espie, Marc; Blau, Sibel; Tan, Antoinette R.; Isakoff, Steven J.; Oliveira, Mafalda; Saura, Cristina; Wongchenko, Matthew J.; Kapp, Amy V.; Chan, Wai Y.; Singel, Stina M.; Maslyar, Daniel J.; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1360-1372</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-neg. breast cancer.  The LOTUS trial investigated the addn. of ipatasertib to paclitaxel as first-line therapy for triple-neg. breast cancer.  In this randomized, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-neg. breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium.  Enrolled patients were randomly assigned (1:1) to receive i.v. paclitaxel 80 mg/m2 (days 1, 8, 15) with either ipatasertib 400 mg or placebo once per day (days 1-21) every 28 days until disease progression or unacceptable toxicity.  Randomisation was by stratified permuted blocks (block size of four) using an interactive web-response system with three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumor PTEN status.  The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohistochem.) population.  This ongoing trial is registered with ClinicalTrials.gov (NCT02162719).  Between Sept 2, 2014, and Feb 4, 2016, 166 patients were assessed for eligibility and 124 patients were enrolled and randomly assigned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus placebo (n=62).  Median follow-up was 10·4 mo (IQR 6·5-14·1) in the ipatasertib group and 10·2 mo (6·0-13·6) in the placebo group.  Median progression-free survival in the intention-to-treat population was 6·2 mo (95% CI 3·8-9·0) with ipatasertib vs. 4·9 mo (3·6-5·4) with placebo (stratified hazard ratio [HR] 0·60, 95% CI 0·37-0·98; p=0·037) and in the 48 patients with PTEN-low tumors, median progression-free survival was 6·2 mo (95% CI 3·6-9·1) with ipatasertib vs. 3·7 mo (1·9-7·3) with placebo (stratified HR 0·59, 95% CI 0·26-1·32, p=0·18).  The most common grade 3 or worse adverse events were diarrhea (14 [23%] of 61 ipatasertib-treated patients vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]).  No colitis, grade 4 diarrhea, or treatment-related deaths were reported with ipatasertib.  One treatment-related death occurred in the placebo group.  Serious adverse events were reported in 17 (28%) of 61 patients in the ipatasertib group and nine (15%) of 62 patients in the placebo group.  Progression-free survival was longer in patients who received ipatasertib than in those who received placebo.  To our knowledge, these are the first results supporting AKT-targeted therapy for triple-neg. breast cancer.  Ipatasertib warrants further investigation for the treatment of triple-neg. breast cancer.F Hoffmann-La Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUHDoupzZvn7Vg90H21EOLACvtfcHk0livneRp9_CR1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSrtbjO&md5=411d3aeae55045b4241c617922b711d5</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930450-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930450-3%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DDent%26aufirst%3DR.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DEspie%26aufirst%3DM.%26aulast%3DBlau%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DA.%2BR.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DOliveira%26aufirst%3DM.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DWongchenko%26aufirst%3DM.%2BJ.%26aulast%3DKapp%26aufirst%3DA.%2BV.%26aulast%3DChan%26aufirst%3DW.%2BY.%26aulast%3DSingel%26aufirst%3DS.%2BM.%26aulast%3DMaslyar%26aufirst%3DD.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DIpatasertib%2520plus%2520paclitaxel%2520versus%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528LOTUS%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D10%26spage%3D1360%26epage%3D1372%26doi%3D10.1016%2FS1470-2045%2817%2930450-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akcakanat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palla, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewster, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder-Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryden, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symmans, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span> <span> </span><span class="NLM_article-title">Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancerdagger</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdu124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdu124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24669015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2crnslCnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1122-1127&issue=6&author=A.+M.+Gonzalez-Anguloauthor=A.+Akcakanatauthor=S.+Liuauthor=M.+C.+Greenauthor=J.+L.+Murrayauthor=H.+Chenauthor=S.+L.+Pallaauthor=K.+B.+Koenigauthor=A.+M.+Brewsterauthor=V.+Valeroauthor=N.+K.+Ibrahimauthor=S.+Moulder-Thompsonauthor=J.+K.+Littonauthor=E.+Tarcoauthor=J.+Mooreauthor=P.+Floresauthor=D.+Crawfordauthor=M.+J.+Drydenauthor=W.+F.+Symmansauthor=A.+Sahinauthor=S.+H.+Giordanoauthor=L.+Pusztaiauthor=K.+A.+Doauthor=G.+B.+Millsauthor=G.+N.+Hortobagyiauthor=F.+Meric-Bernstam&title=Open-label+randomized+clinical+trial+of+standard+neoadjuvant+chemotherapy+with+paclitaxel+followed+by+FEC+versus+the+combination+of+paclitaxel+and+everolimus+followed+by+FEC+in+women+with+triple+receptor-negative+breast+cancerdagger&doi=10.1093%2Fannonc%2Fmdu124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†</span></div><div class="casAuthors">Gonzalez-Angulo A M; Akcakanat A; Liu S; Murray J L; Chen H; Koenig K B; Valero V; Ibrahim N K; Moulder-Thompson S; Litton J K; Tarco E; Moore J; Flores P; Crawford D; Giordano S H; Hortobagyi G N; Green M C; Palla S L; Do K-A; Brewster A M; Dryden M J; Symmans W F; Sahin A; Pusztai L; Mills G B; Meric-Bernstam F</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1122-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Everolimus synergistically enhances taxane-induced cytotoxicity in breast cancer cells in vitro and in vivo in addition to demonstrating a direct antiproliferative activity.  We aim to determine pharmacodynamics changes and response of adding everolimus to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC).  PATIENTS AND METHODS:  Phase II study in patients with primary TNBC randomized to T-FEC (paclitaxel 80 mg/m(2) i.v. weekly for 12 weeks, followed by 5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2) every 3 weeks for four cycles) versus TR-FEC (paclitaxel 80 mg/m(2) i.v. and everolimus 30 mg PO weekly for 12 weeks, followed by FEC).  Tumor samples were collected to assess molecular changes in the PI3K/AKT/mTOR pathway, at baseline, 48 h, 12 weeks, and at surgery by reverse phase protein arrays (RPPA).  Clinical end points included 12-week clinical response rate (12-week RR), pathological complete response (pCR), and toxicity.  RESULTS:  Sixty-two patients were registered, and 50 were randomized, 27 received T-FEC, and 23 received TR-FEC.  Median age was 48 (range 31-75).  There was downregulation of the mTOR pathway at 48 h in the TR-FEC arm.  Twelve-week RR by ultrasound were 29.6% versus 47.8%, (P = 0.075), and pCR were 25.9% versus 30.4% (P = 0.76) for T-FEC and TR-FEC, respectively. mTOR downregulation at 48 h did not correlate with 12-week RR in the TR-FEC group (P = 0.58).  Main NCI grade 3/4 toxicities included anemia, neutropenia, rash/desquamation, and vomiting in both arms.  There was one case of grade 3 pneumonitis in the TR-FEC arm.  No grade 3/4 stomatitis occurred.  CONCLUSION:  The addition of everolimus to paclitaxel was well tolerated.  Everolimus downregulated mTOR signaling but downregulation of mTOR at 48 h did not correlate with 12-week RR in the TR-FEC group.  CLINICAL TRIAL NUMBER:  NCT00499603.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIm9medsz0NG52AMpI4GK2fW6udTcc2eb3E4fp5pPkiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crnslCnsQ%253D%253D&md5=4777f3c79c797d21b00bc3c2de5279e8</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu124%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DAkcakanat%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DM.%2BC.%26aulast%3DMurray%26aufirst%3DJ.%2BL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DPalla%26aufirst%3DS.%2BL.%26aulast%3DKoenig%26aufirst%3DK.%2BB.%26aulast%3DBrewster%26aufirst%3DA.%2BM.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DIbrahim%26aufirst%3DN.%2BK.%26aulast%3DMoulder-Thompson%26aufirst%3DS.%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DTarco%26aufirst%3DE.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DFlores%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DD.%26aulast%3DDryden%26aufirst%3DM.%2BJ.%26aulast%3DSymmans%26aufirst%3DW.%2BF.%26aulast%3DSahin%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DS.%2BH.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DDo%26aufirst%3DK.%2BA.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26atitle%3DOpen-label%2520randomized%2520clinical%2520trial%2520of%2520standard%2520neoadjuvant%2520chemotherapy%2520with%2520paclitaxel%2520followed%2520by%2520FEC%2520versus%2520the%2520combination%2520of%2520paclitaxel%2520and%2520everolimus%2520followed%2520by%2520FEC%2520in%2520women%2520with%2520triple%2520receptor-negative%2520breast%2520cancerdagger%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26issue%3D6%26spage%3D1122%26epage%3D1127%26doi%3D10.1093%2Fannonc%2Fmdu124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khadang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachim, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakdounes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrun, J.-J.</span></span> <span> </span><span class="NLM_article-title">Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0287-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41416-018-0287-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30482914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVaksL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=1495-1507&issue=12&author=J.+Tianauthor=F.+A.+Raffaauthor=M.+Daiauthor=A.+Moamerauthor=B.+Khadangauthor=I.+Y.+Hachimauthor=K.+Bakdounesauthor=S.+Aliauthor=B.+Jean-Claudeauthor=J.-J.+Lebrun&title=Dasatinib+sensitises+triple+negative+breast+cancer+cells+to+chemotherapy+by+targeting+breast+cancer+stem+cells&doi=10.1038%2Fs41416-018-0287-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells</span></div><div class="casAuthors">Tian, Jun; Raffa, Fatmah Al; Dai, Meiou; Moamer, Alaa; Khadang, Baharak; Hachim, Ibrahim Y.; Bakdounes, Khldoun; Ali, Suhad; Jean-Claude, Bertrand; Lebrun, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Patients with triple neg. breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumor relapse, due to the resistance to chemotherapy.  These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs).  Therefore, targeting BCSCs is a priority to overcoming chemotherapy failure in TNBCs.  Methods: We generated paclitaxel (pac)-resistant TNBC cells which displayed higher sphere forming potential and percentage of BCSC subpopulations compared to the parental cells.  A screen with various kinase inhibitors revealed dasatinib, a Src kinase family inhibitor, as a potent suppressor of BCSC expansion/sphere formation in pac-resistant TNBC cells.  Results: We found dasatinib to block pac-induced BCSC enrichment and Src activation in both parental and pac-resistant TNBC cells.  Interestingly, dasatinib induced an epithelial differentiation of the pac-resistant mesenchymal cells, resulting in their enhanced sensitivity to paclitaxel.  The combination treatment of dasatinib and paclitaxel not only decreased the BCSCs nos. and their sphere forming capacity but also synergistically reduced cell viability of pac-resistant cells.  Preclin. models of breast cancer further demonstrated the efficiency of the dasatinib/paclitaxel combination treatment in inhibiting tumor growth.  Conclusions: Dasatinib is a promising anti-BCSC drug that could be used in combination with paclitaxel to overcome chemoresistance in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooLMaSt2TkzbVg90H21EOLACvtfcHk0ljfQjYkIxDkaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVaksL7N&md5=c5248d79468d37a906fcd473da99dde6</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0287-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0287-3%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DRaffa%26aufirst%3DF.%2BA.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DMoamer%26aufirst%3DA.%26aulast%3DKhadang%26aufirst%3DB.%26aulast%3DHachim%26aufirst%3DI.%2BY.%26aulast%3DBakdounes%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DJean-Claude%26aufirst%3DB.%26aulast%3DLebrun%26aufirst%3DJ.-J.%26atitle%3DDasatinib%2520sensitises%2520triple%2520negative%2520breast%2520cancer%2520cells%2520to%2520chemotherapy%2520by%2520targeting%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D119%26issue%3D12%26spage%3D1495%26epage%3D1507%26doi%3D10.1038%2Fs41416-018-0287-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speyer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhsh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, D. H.</span></span> <span> </span><span class="NLM_article-title">Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>166</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1007/s10549-017-4435-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-017-4435-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28780701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yhsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2017&pages=407-419&issue=2&author=C.+L.+Speyerauthor=M.+A.+Bukhshauthor=W.+S.+Jafryauthor=R.+E.+Sextonauthor=S.+Bandyopadhyayauthor=D.+H.+Gorski&title=Riluzole+synergizes+with+paclitaxel+to+inhibit+cell+growth+and+induce+apoptosis+in+triple-negative+breast+cancer&doi=10.1007%2Fs10549-017-4435-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer</span></div><div class="casAuthors">Speyer, Cecilia L.; Bukhsh, Miriam A.; Jafry, Waris S.; Sexton, Rachael E.; Bandyopadhyay, Sudeshna; Gorski, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">407-419</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: One in eight women will develop breast cancer, 15-20% of whom will have triple-neg. breast cancer (TNBC), an aggressive breast cancer with no current targeted therapy.  We have demonstrated that riluzole, an FDA-approved drug for treating amyotrophic lateral sclerosis, inhibits growth of TNBC.  In this study, we explore potential synergism between riluzole and paclitaxel, a chemotherapeutic agent commonly used to treat TNBC, in regulating TNBC proliferation, cell cycle arrest, and apoptosis.  Methods: TNBC cells were treated with paclitaxel and/or riluzole and synergistic effects on cell proliferation were quantified via MTT assay and CompuSyn anal.  Apoptosis was obsd. morphol. and by measuring cleaved PARP/caspase three products.  Microarray anal. was performed using MDA-MB-231 cells to examine cell cycle genes regulated by riluzole and any enhanced effects on paclitaxel-mediated cell cycle arrest, detd. by FACS anal.  These results were confirmed in vivo using a MDA-MB-231 xenograft model.  Results: Strong enhanced or synergistic effects of riluzole on paclitaxel regulation of cell cycle progression and apoptosis was demonstrated in all TNBC cells tested as well as in the xenograft model.  The MDA-MB-231, SUM149, and SUM229 cells, which are resistant to paclitaxel treatment, demonstrated the strongest synergistic or enhanced effect.  Key protein kinases were shown to be upregulated in this study by riluzole as well as downstream cell cycle genes regulated by these kinases.  Conclusions: All TNBC cells tested responded synergistically to riluzole and paclitaxel strongly suggesting the usefulness of this combinatorial treatment strategy in TNBC, esp. for patients whose tumors are relatively resistant to paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Au2QHDuFELVg90H21EOLACvtfcHk0ljfQjYkIxDkaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yhsrfJ&md5=155ac53ac9ec244d63c1fe0b28cfd44f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1007%2Fs10549-017-4435-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-017-4435-x%26sid%3Dliteratum%253Aachs%26aulast%3DSpeyer%26aufirst%3DC.%2BL.%26aulast%3DBukhsh%26aufirst%3DM.%2BA.%26aulast%3DJafry%26aufirst%3DW.%2BS.%26aulast%3DSexton%26aufirst%3DR.%2BE.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26aulast%3DGorski%26aufirst%3DD.%2BH.%26atitle%3DRiluzole%2520synergizes%2520with%2520paclitaxel%2520to%2520inhibit%2520cell%2520growth%2520and%2520induce%2520apoptosis%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2017%26volume%3D166%26issue%3D2%26spage%3D407%26epage%3D419%26doi%3D10.1007%2Fs10549-017-4435-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Borrego, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Martorell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail-Khan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3126</span>– <span class="NLM_lpage">3133</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.74.8392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2017.74.8392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFylsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=3126-3133&author=A.+Bardiaauthor=M.+Partonauthor=S.+Kummelauthor=L.+G.+Estevezauthor=C.+S.+Huangauthor=J.+Cortesauthor=M.+Ruiz-Borregoauthor=M.+L.+Telliauthor=P.+Martin-Martorellauthor=R.+Lopezauthor=J.+T.+Beckauthor=R.+Ismail-Khanauthor=S.+C.+Chenauthor=S.+A.+Hurvitzauthor=I.+A.+Mayerauthor=D.+Carreonauthor=S.+Cameronauthor=S.+Liaoauthor=J.+Baselgaauthor=S.+B.+Kim&title=Paclitaxel+With+Inhibitor+of+Apoptosis+Antagonist%2C+LCL161%2C+for+Localized+Triple-Negative+Breast+Cancer%2C+Prospectively+Stratified+by+Gene+Signature+in+a+Biomarker-Driven+Neoadjuvant+Trial&doi=10.1200%2FJCO.2017.74.8392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial</span></div><div class="casAuthors">Bardia, Aditya; Parton, Marina; Kummel, Sherko; Estevez, Laura G.; Huang, Chiun-Sheng; Cortes, Javier; Ruiz-Borrego, Manuel; Telli, Melinda L.; Martin-Martorell, Paloma; Lopez, Rafael; Beck, J. Thaddeus; Ismail-Khan, Roohi; Chen, Shin-Cheh; Hurvitz, Sara A.; Mayer, Ingrid A.; Carreon, Daniel; Cameron, Scott; Liao, Serena; Baselga, Jose; Kim, Sung-Bae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3126-3133</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The primary objective was to det. whether neoadjuvant LCL161 enhances efficacy of paclitaxel, defined by > 7.5% increase in the pathol. complete response (pCR, breast) rate, stratified by GS.  Results Of 209 patients enrolled (207 with valid GS scores), 30.4% had GS-pos. TNBC.  In the GS-pos. group, pCR was higher in the combination vs. the control arm (38.2% v 17.2%), with 88.8% posterior probability of > 7.5% increase in pCR.  However, in the GS-neg. group, the pCR was lower in the combination group (5.6% v 16.4%), with 0% posterior probability of > 7.5% increase in pCR.  A higher incidence of grade 3 or 4 adverse events in the combination arm included neutropenia (24.5%) and diarrhea (5.7%).  Overall, 19 patients (18.1%) in the combination arm discontinued treatment because of adverse events, including pyrexia (n = 5), pneumonia (n = 4), and pneumonitis (n = 4), vs. five patients (4.9%) in the control arm.  Conclusion This neoadjuvant trial provides evidence supporting a biomarker-driven targeted therapy approach for selected patients with GS-pos. TNBC and demonstrates the utility of a neoadjuvant trial for biomarker validation and drug development, but also highlights toxicity risk.  Future neoadjuvant clin. trials should carefully weigh these considerations for targeted therapy development in biomarker-defined TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyUury2yHivbVg90H21EOLACvtfcHk0ljfQjYkIxDkaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFylsLc%253D&md5=8d1753e09efbe33bbc03cf2c264a9af5</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.74.8392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.74.8392%26sid%3Dliteratum%253Aachs%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DParton%26aufirst%3DM.%26aulast%3DKummel%26aufirst%3DS.%26aulast%3DEstevez%26aufirst%3DL.%2BG.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRuiz-Borrego%26aufirst%3DM.%26aulast%3DTelli%26aufirst%3DM.%2BL.%26aulast%3DMartin-Martorell%26aufirst%3DP.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DIsmail-Khan%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DCarreon%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BB.%26atitle%3DPaclitaxel%2520With%2520Inhibitor%2520of%2520Apoptosis%2520Antagonist%252C%2520LCL161%252C%2520for%2520Localized%2520Triple-Negative%2520Breast%2520Cancer%252C%2520Prospectively%2520Stratified%2520by%2520Gene%2520Signature%2520in%2520a%2520Biomarker-Driven%2520Neoadjuvant%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D3126%26epage%3D3133%26doi%3D10.1200%2FJCO.2017.74.8392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleer, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. C.</span></span> <span> </span><span class="NLM_article-title">CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5114</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-13105-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41467-019-13105-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31704972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGisbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=5114&issue=1&author=L.+Nieauthor=Y.+Weiauthor=F.+Zhangauthor=Y.+H.+Hsuauthor=L.+C.+Chanauthor=W.+Xiaauthor=B.+Keauthor=C.+Zhuauthor=R.+Dengauthor=J.+Tangauthor=J.+Yaoauthor=Y.+Y.+Chuauthor=X.+Zhaoauthor=Y.+Hanauthor=J.+Houauthor=L.+Huoauthor=H.+W.+Koauthor=W.+C.+Linauthor=H.+Yamaguchiauthor=J.+M.+Hsuauthor=Y.+Yangauthor=D.+N.+Panauthor=J.+L.+Hsuauthor=C.+G.+Kleerauthor=N.+E.+Davidsonauthor=G.+N.+Hortobagyiauthor=M.+C.+Hung&title=CDK2-mediated+site-specific+phosphorylation+of+EZH2+drives+and+maintains+triple-negative+breast+cancer&doi=10.1038%2Fs41467-019-13105-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer</span></div><div class="casAuthors">Nie, Lei; Wei, Yongkun; Zhang, Fei; Hsu, Yi-Hsin; Chan, Li-Chuan; Xia, Weiya; Ke, Baozhen; Zhu, Cihui; Deng, Rong; Tang, Jun; Yao, Jun; Chu, Yu-Yi; Zhao, Xixi; Han, Ye; Hou, Junwei; Huo, Longfei; Ko, How-Wen; Lin, Wan-Chi; Yamaguchi, Hirohito; Hsu, Jung-Mao; Yang, Yi; Pan, Dean N.; Hsu, Jennifer L.; Kleer, Celina G.; Davidson, Nancy E.; Hortobagyi, Gabriel N.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5114</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC), which lacks estrogen receptor α (ERα), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression, is closely related to basal-like breast cancer.  Previously, we and others report that cyclin E/cyclin-dependent kinase 2 (CDK2) phosphorylates enhancer of zeste homolog 2 (EZH2) at T416 (pT416-EZH2).  Here, we show that transgenic expression of phospho-mimicking EZH2 mutant EZH2T416D in mammary glands leads to tumors with TNBC phenotype.  Coexpression of EZH2T416D in mammary epithelia of HER2/Neu transgenic mice reprograms HER2-driven luminal tumors into basal-like tumors.  Pharmacol. inhibition of CDK2 or EZH2 allows re-expression of ER α and converts TNBC to luminal ERa-pos., rendering TNBC cells targetable by tamoxifen.  Furthermore, the combination of either CDK2 or EZH2 inhibitor with tamoxifen effectively suppresses tumor growth and markedly improves the survival of the mice bearing TNBC tumors, suggesting that the mechanism-based combination therapy may be an alternative approach to treat TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9u1jJqRVHrrVg90H21EOLACvtfcHk0li1n6wZRpkjwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGisbrJ&md5=433954dbc62ebd60333dd83b9e05b378</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-13105-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-13105-5%26sid%3Dliteratum%253Aachs%26aulast%3DNie%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DHsu%26aufirst%3DY.%2BH.%26aulast%3DChan%26aufirst%3DL.%2BC.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DKe%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DChu%26aufirst%3DY.%2BY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DHuo%26aufirst%3DL.%26aulast%3DKo%26aufirst%3DH.%2BW.%26aulast%3DLin%26aufirst%3DW.%2BC.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DHsu%26aufirst%3DJ.%2BM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DD.%2BN.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DKleer%26aufirst%3DC.%2BG.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DCDK2-mediated%2520site-specific%2520phosphorylation%2520of%2520EZH2%2520drives%2520and%2520maintains%2520triple-negative%2520breast%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D5114%26doi%3D10.1038%2Fs41467-019-13105-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhola, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuba, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1348</span>– <span class="NLM_lpage">1358</span>, <span class="refDoi"> DOI: 10.1172/JCI65416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1172%2FJCI65416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23391723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVyhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=1348-1358&issue=3&author=N.+E.+Bholaauthor=J.+M.+Balkoauthor=T.+C.+Duggerauthor=M.+G.+Kubaauthor=V.+Sanchezauthor=M.+Sandersauthor=J.+Stanfordauthor=R.+S.+Cookauthor=C.+L.+Arteaga&title=TGF-beta+inhibition+enhances+chemotherapy+action+against+triple-negative+breast+cancer&doi=10.1172%2FJCI65416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer</span></div><div class="casAuthors">Bhola, Neil E.; Balko, Justin M.; Dugger, Teresa C.; Kuba, Maria Gabriela; Sanchez, Violeta; Sanders, Melinda; Stanford, Jamie; Cook, Rebecca S.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1348-1358</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">After an initial response to chemotherapy, many patients with triple-neg. breast cancer (TNBC) have recurrence of drug-resistant metastatic disease.  Studies with TNBC cells suggest that chemotherapy-resistant populations of cancer stem-like cells (CSCs) with self-renewing and tumor-initiating capacities are responsible for these relapses.  TGF-β has been shown to increase stem-like properties in human breast cancer cells.  We analyzed RNA expression in matched pairs of primary breast cancer biopsies before and after chemotherapy.  Biopsies after chemotherapy displayed increased RNA transcripts of genes assocd. with CSCs and TGF-β signaling.  In TNBC cell lines and mouse xenografts, the chemotherapeutic drug paclitaxel increased autocrine TGF-β signaling and IL-8 expression and enriched for CSCs, as indicated by mammosphere formation and CSC markers.  The TGF-β type I receptor kinase inhibitor LY2157299, a neutralizing TGF-β type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion.  Moreover, treatment of TNBC xenografts with LY2157299 prevented reestablishment of tumors after paclitaxel treatment.  These data suggest that chemotherapy-induced TGF-β signaling enhances tumor recurrence through IL-8-dependent expansion of CSCs and that TGF-β pathway inhibitors prevent the development of drug-resistant CSCs.  These findings support testing a combination of TGF-β inhibitors and anticancer chemotherapy in patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrlaIE6QLBw7Vg90H21EOLACvtfcHk0li1n6wZRpkjwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVyhtL4%253D&md5=1e93f3ccf6ab2fa173fc00c400a7e19c</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1172%2FJCI65416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI65416%26sid%3Dliteratum%253Aachs%26aulast%3DBhola%26aufirst%3DN.%2BE.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DDugger%26aufirst%3DT.%2BC.%26aulast%3DKuba%26aufirst%3DM.%2BG.%26aulast%3DSanchez%26aufirst%3DV.%26aulast%3DSanders%26aufirst%3DM.%26aulast%3DStanford%26aufirst%3DJ.%26aulast%3DCook%26aufirst%3DR.%2BS.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DTGF-beta%2520inhibition%2520enhances%2520chemotherapy%2520action%2520against%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26issue%3D3%26spage%3D1348%26epage%3D1358%26doi%3D10.1172%2FJCI65416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Mauro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciciola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Formisano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Falco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicatiello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bonito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantile, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veneziani, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Placido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianco, R.</span></span> <span> </span><span class="NLM_article-title">Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1435</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fbjc.2017.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28441382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVahtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=1425-1435&issue=11&author=C.+Di+Mauroauthor=R.+Rosaauthor=V.+D%E2%80%99Amatoauthor=P.+Ciciolaauthor=A.+Servettoauthor=R.+Marcianoauthor=R.+C.+Orsiniauthor=L.+Formisanoauthor=S.+De+Falcoauthor=V.+Cicatielloauthor=M.+Di+Bonitoauthor=M.+Cantileauthor=F.+Collinaauthor=A.+Chamberyauthor=B.+M.+Venezianiauthor=S.+De+Placidoauthor=R.+Bianco&title=Hedgehog+signalling+pathway+orchestrates+angiogenesis+in+triple-negative+breast+cancers&doi=10.1038%2Fbjc.2017.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers</span></div><div class="casAuthors">Di Mauro, Concetta; Rosa, Roberta; D'Amato, Valentina; Ciciola, Paola; Servetto, Alberto; Marciano, Roberta; Orsini, Roberta Clara; Formisano, Luigi; De Falco, Sandro; Cicatiello, Valeria; Di Bonito, Maurizio; Cantile, Monica; Collina, Francesca; Chambery, Angela; Veneziani, Bianca Maria; De Placido, Sabino; Bianco, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1425-1435</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Several evidences suggest a marked angiogenic dependency in triple-neg. breast cancer (TNBC) tumorigenesis and a potential sensitivity to anti-angiogenic agents.  Herein, the putative role of Hedgehog (Hh) pathway in regulating TNBC-dependent angiogenesis was investigated.  Methods: Expression and regulation of the Hh pathway transcription factor glioma-assocd. oncogene homolog1 protein (GLI1) were studied on the endothelial compartment and on TNBC-initiated angiogenesis.  To evaluate the translational relevance of our findings, the combination of paclitaxel with the Smo inhibitor NVP-LDE225 was tested in TNBC xenografted mice.  Results: Tissue microarray anal. on 200 TNBC patients showed GLI1 overexpression paired with vascular endothelial growth factor receptor 2 (VEGFR2) expression.  In vitro, Hh pathway promotes TNBC progression in an autocrine manner, regulating the VEGF/VEGFR2 loop on cancer cell surface, and in a paracrine manner, orchestrating tumor vascularisation.  These effects were counteracted by Smo pharmacol. inhibition.  In TNBC xenografted mice, scheduling NVP-LDE225 rather than bevacizumab provided a better sustained inhibition of TNBC cells proliferation and endothelial cells organization.  Conclusions: This study identifies the Hh pathway as one of the main regulators of tumor angiogenesis in TNBC, thus suggesting Hh inhibition as a potential new anti-angiogenic therapeutic option to be clin. investigated in GLI1 overexpressing TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDD9hWgGbLELVg90H21EOLACvtfcHk0li1n6wZRpkjwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVahtr0%253D&md5=8bd9ca1d0dfa04d01ffe4fd649f12efa</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.116%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMauro%26aufirst%3DC.%26aulast%3DRosa%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DV.%26aulast%3DCiciola%26aufirst%3DP.%26aulast%3DServetto%26aufirst%3DA.%26aulast%3DMarciano%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DR.%2BC.%26aulast%3DFormisano%26aufirst%3DL.%26aulast%3DDe%2BFalco%26aufirst%3DS.%26aulast%3DCicatiello%26aufirst%3DV.%26aulast%3DDi%2BBonito%26aufirst%3DM.%26aulast%3DCantile%26aufirst%3DM.%26aulast%3DCollina%26aufirst%3DF.%26aulast%3DChambery%26aufirst%3DA.%26aulast%3DVeneziani%26aufirst%3DB.%2BM.%26aulast%3DDe%2BPlacido%26aufirst%3DS.%26aulast%3DBianco%26aufirst%3DR.%26atitle%3DHedgehog%2520signalling%2520pathway%2520orchestrates%2520angiogenesis%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26issue%3D11%26spage%3D1425%26epage%3D1435%26doi%3D10.1038%2Fbjc.2017.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">In Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span> <span> </span><span class="NLM_article-title">Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">115</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1204-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-019-1204-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31640742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjgs1yjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=115&issue=1&author=J.+O.+Leeauthor=M.+J.+Kangauthor=W.+S.+Byunauthor=S.+A.+Kimauthor=I.+H.+Seoauthor=J.+A.+Hanauthor=J.+W.+Moonauthor=J.+H.+Kimauthor=S.+J.+Kimauthor=E.+J.+Leeauthor=S.+In+Parkauthor=S.+H.+Parkauthor=H.+S.+Kim&title=Metformin+overcomes+resistance+to+cisplatin+in+triple-negative+breast+cancer+%28TNBC%29+cells+by+targeting+RAD51&doi=10.1186%2Fs13058-019-1204-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51</span></div><div class="casAuthors">Lee Jung Ok; Kang Min Ju; Byun Won Seok; Kim Shin Ae; Seo Il Hyeok; Han Jeong Ah; Moon Ji Wook; Kim Ji Hae; Kim Su Jin; Park Sun Hwa; Kim Hyeon Soo; Lee Eun Jung; In Park Serk; In Park Serk</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patients.  In contrast, combination therapy has proven to be an effective strategy for TNBC treatment.  Whether metformin enhances the anticancer effects of cisplatin and prevents cisplatin resistance in TNBC cells has not been reported.  METHODS:  Cell viability, wounding healing, and invasion assays were performed on Hs 578T and MDA-MB-231 human TNBC cell lines to demonstrate the anticancer effects of combined cisplatin and metformin treatment compared to treatment with cisplatin alone.  Western blotting and immunofluorescence were used to determine the expression of RAD51 and gamma-H2AX.  In an in vivo 4T1 murine breast cancer model, a synergistic anticancer effect of metformin and cisplatin was observed.  RESULTS:  Cisplatin combined with metformin decreased cell viability and metastatic effect more than cisplatin alone.  Metformin suppressed cisplatin-mediated RAD51 upregulation by decreasing RAD51 protein stability and increasing its ubiquitination.  In contrast, cisplatin increased RAD51 expression in an ERK-dependent manner.  In addition, metformin also increased cisplatin-induced phosphorylation of γ-H2AX.  Overexpression of RAD51 blocked the metformin-induced inhibition of cell migration and invasion, while RAD51 knockdown enhanced cisplatin activity.  Moreover, the combination of metformin and cisplatin exhibited a synergistic anticancer effect in an orthotopic murine model of 4T1 breast cancer in vivo.  CONCLUSIONS:  Metformin enhances anticancer effect of cisplatin by downregulating RAD51 expression, which represents a novel therapeutic target in TNBC management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgKwoA5GWgiSM8MEzWGjS9fW6udTcc2ebNbpHgh3EkVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjgs1yjtA%253D%253D&md5=753fe0794e7ffd0f090a0aebb59d577d</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1204-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1204-2%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BO.%26aulast%3DKang%26aufirst%3DM.%2BJ.%26aulast%3DByun%26aufirst%3DW.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BA.%26aulast%3DSeo%26aufirst%3DI.%2BH.%26aulast%3DHan%26aufirst%3DJ.%2BA.%26aulast%3DMoon%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DE.%2BJ.%26aulast%3DIn%2BPark%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26atitle%3DMetformin%2520overcomes%2520resistance%2520to%2520cisplatin%2520in%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%2520cells%2520by%2520targeting%2520RAD51%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D115%26doi%3D10.1186%2Fs13058-019-1204-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semenza, G. L.</span></span> <span> </span><span class="NLM_article-title">Reciprocal regulation of DUSP9 and DUSP16 expression by HIF1 controls ERK and p38 MAP Kinase activity and mediates chemotherapy-induced breast cancer stem cell enrichment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4191</span>– <span class="NLM_lpage">4202</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-0270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-18-0270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29880481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=4191-4202&issue=15&author=H.+Luauthor=L.+Tranauthor=Y.+Parkauthor=I.+Chenauthor=J.+Lanauthor=Y.+Xieauthor=G.+L.+Semenza&title=Reciprocal+regulation+of+DUSP9+and+DUSP16+expression+by+HIF1+controls+ERK+and+p38+MAP+Kinase+activity+and+mediates+chemotherapy-induced+breast+cancer+stem+cell+enrichment&doi=10.1158%2F0008-5472.CAN-18-0270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment</span></div><div class="casAuthors">Lu, Haiquan; Tran, Linh; Park, Youngrok; Chen, Ivan; Lan, Jie; Xie, Yangyiran; Semenza, Gregg L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4191-4202</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) has a poor prognosis due to its aggressive characteristics and lack of targeted therapies.  Cytotoxic chemotherapy may reduce tumor bulk, but leaves residual disease due to the persistence of chemotherapy-resistant breast cancer stem cells (BCSC), which are crit. for tumor recurrence and metastasis.  Here, we demonstrate that hypoxia-inducible factor (HIF)-1-dependent regulation of mitogen-activated protein kinase (MAPK) signaling pathways contributes to chemotherapy-induced BCSC enrichment.  Chemotherapy increased DUSP9 expression and decreased DUSP16 expression in a HIF1-dependent manner, leading to inhibition of ERK and activation of p38 signaling pathways, resp.  Inhibition of ERK caused transcriptional induction of the pluripotency factor Nanog through decreased inactivating phosphorylation of FoxO3, while activation of p38 stabilized Nanog and Klf4 mRNA through increased inactivating phosphorylation of RNA-binding protein ZFP36L1, both of which promoted specification of the BCSC phenotype.  Inhibition of HIF1 or p38 signaling blocked chemotherapy-induced pluripotency factor expression and BCSC enrichment.  These surprising results delineate a mechanism by which a transcription factor switches cells from ERK to p38 signaling in response to chemotherapy and suggest that therapeutic targeting of HIF1 or the p38 pathway in combination with chemotherapy will block BCSC enrichment and improve outcome in TNBC.  Significance: These findings provide a mol. mechanism that may account for the increased relapse rate of women with TNBC who are treated with cytotoxic chemotherapy and suggest that combining chemotherapy with an inhibitor of HIF1 or p38 activity may increase patient survival.  Cancer Res; 78(15); 4191-202. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXaH5s4lcDzbVg90H21EOLACvtfcHk0liSCViMVTWsdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsbrJ&md5=4f4bf6a96fc22e68c92a260e1cf9669b</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-0270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-0270%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DSemenza%26aufirst%3DG.%2BL.%26atitle%3DReciprocal%2520regulation%2520of%2520DUSP9%2520and%2520DUSP16%2520expression%2520by%2520HIF1%2520controls%2520ERK%2520and%2520p38%2520MAP%2520Kinase%2520activity%2520and%2520mediates%2520chemotherapy-induced%2520breast%2520cancer%2520stem%2520cell%2520enrichment%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D15%26spage%3D4191%26epage%3D4202%26doi%3D10.1158%2F0008-5472.CAN-18-0270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. F.</span></span> <span> </span><span class="NLM_article-title">Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2F1878-0261.12033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28084011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2isbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=266-279&issue=3&author=C.+Y.+Liuauthor=J.+C.+Suauthor=T.+T.+Huangauthor=P.+Y.+Chuauthor=C.+T.+Huangauthor=W.+L.+Wangauthor=C.+H.+Leeauthor=K.+Y.+Lauauthor=W.+C.+Tsaiauthor=H.+P.+Yangauthor=C.+W.+Shiauauthor=L.+M.+Tsengauthor=K.+F.+Chen&title=Sorafenib+analogue+SC-60+induces+apoptosis+through+the+SHP-1%2FSTAT3+pathway+and+enhances+docetaxel+cytotoxicity+in+triple-negative+breast+cancer+cells&doi=10.1002%2F1878-0261.12033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells</span></div><div class="casAuthors">Liu, Chun-Yu; Su, Jung-Chen; Huang, Tzu-Ting; Chu, Pei-Yi; Huang, Chun-Teng; Wang, Wan-Lun; Lee, Chia-Han; Lau, Ka-Yi; Tsai, Wen-Chun; Yang, Hsiu-Ping; Shiau, Chung-Wai; Tseng, Ling-Ming; Chen, Kuen-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">266-279</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Recurrent triple-neg. breast cancer (TNBC) needs new therapeutic targets.  Src homol. region 2 domain-contg. phosphatase-1 (SHP-1) can act as a tumor suppressor by dephosphorylating oncogenic kinases.  One major target of SHP-1 is STAT3, which is highly activated in TNBC.  In this study, we tested a sorafenib analog SC-60, which lacks angiokinase inhibition activity, but acts as a SHP-1 agonist, in TNBC cells.  SC-60 inhibited proliferation and induced apoptosis by dephosphorylating STAT3 in both a dose- and time-dependent manner in TNBC cells (MDA-MB-231, MDA-MB-468, and HCC1937).  By contrast, ectopic expression of STAT3 rescued the anticancer effect induced by SC-60.  SC-60 also increased the SHP-1 activity, but this effect was inhibited when the N-SH2 domain (DN1) was deleted or with SHP-1 point mutation (D61A), implying that SHP-1 is the major target of SC-60 in TNBC.  The use of SC-60 in combination with docetaxel synergized the anticancer effect induced by SC-60 through the SHP-1/STAT3 pathway in TNBC cells.  Importantly, SC-60 also displayed a significant antitumor effect in an MDA-MB-468 xenograft model by modulating the SHP-1/STAT3 axis, indicating the anticancer potential of SC-60 in TNBC treatment.  Targeting SHP-1/p-STAT3 and the potential combination of SHP-1 agonist with chemotherapeutic docetaxel is a feasible therapeutic strategy for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLp-rPisFSQLVg90H21EOLACvtfcHk0lhfZBJhjwV3Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2isbg%253D&md5=3acdff657f976e6cfb3d41f707bbad47</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12033%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DSu%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DLau%26aufirst%3DK.%2BY.%26aulast%3DTsai%26aufirst%3DW.%2BC.%26aulast%3DYang%26aufirst%3DH.%2BP.%26aulast%3DShiau%26aufirst%3DC.%2BW.%26aulast%3DTseng%26aufirst%3DL.%2BM.%26aulast%3DChen%26aufirst%3DK.%2BF.%26atitle%3DSorafenib%2520analogue%2520SC-60%2520induces%2520apoptosis%2520through%2520the%2520SHP-1%252FSTAT3%2520pathway%2520and%2520enhances%2520docetaxel%2520cytotoxicity%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Oncol.%26date%3D2017%26volume%3D11%26issue%3D3%26spage%3D266%26epage%3D279%26doi%3D10.1002%2F1878-0261.12033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dushyanthen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denkert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimm, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilkinton, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doimi, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryzhov, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span> <span> </span><span class="NLM_article-title">RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1509</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-15-1125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26515496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlajsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1499-1509&issue=6&author=S.+Loiauthor=S.+Dushyanthenauthor=P.+A.+Beavisauthor=R.+Salgadoauthor=C.+Denkertauthor=P.+Savasauthor=S.+Combsauthor=D.+L.+Rimmauthor=J.+M.+Giltnaneauthor=M.+V.+Estradaauthor=V.+Sanchezauthor=M.+E.+Sandersauthor=R.+S.+Cookauthor=M.+A.+Pilkintonauthor=S.+A.+Mallalauthor=K.+Wangauthor=V.+A.+Millerauthor=P.+J.+Stephensauthor=R.+Yelenskyauthor=F.+D.+Doimiauthor=H.+Gomezauthor=S.+V.+Ryzhovauthor=P.+K.+Darcyauthor=C.+L.+Arteagaauthor=J.+M.+Balko&title=RAS%2FMAPK+activation+is+associated+with+reduced+tumor-infiltrating+lymphocytes+in+triple-negative+breast+cancer%3A+Therapeutic+cooperation+between+MEK+and+PD-1%2FPD-L1+immune+checkpoint+inhibitors&doi=10.1158%2F1078-0432.CCR-15-1125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors</span></div><div class="casAuthors">Loi, Sherene; Dushyanthen, Sathana; Beavis, Paul A.; Salgado, Roberto; Denkert, Carsten; Savas, Peter; Combs, Susan; Rimm, David L.; Giltnane, Jennifer M.; Estrada, Monica V.; Sanchez, Violeta; Sanders, Melinda E.; Cook, Rebecca S.; Pilkinton, Mark A.; Mallal, Simon A.; Wang, Kai; Miller, Vincent A.; Stephens, Phil J.; Yelensky, Roman; Doimi, Franco D.; Gomez, Henry; Ryzhov, Sergey V.; Darcy, Phillip K.; Arteaga, Carlos L.; Balko, Justin M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1499-1509</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-neg. breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are assocd. with improved survival, but insight into tumor cell-autonomous mol. pathways affecting these features are lacking.  Exptl. Design: We analyzed TILs in the RD of clin. and molecularly characterized TNBCs after NAC and explored therapeutic strategies targeting combinations of MEK inhibitors with PD-1/PD-L1-targeted immunotherapy in mouse models of breast cancer.  Results: Presence of TILs in the RD was significantly assocd. with improved prognosis.  Genetic or transcriptomic alterations in Ras-MAPK signaling were significantly correlated with lower TILs.  MEK inhibition upregulated cell surface MHC expression and PD-L1 in TNBC cells both in vivo and in vitro.  Moreover, combined MEK and PD-L1/PD-1 inhibition enhanced antitumor immune responses in mouse models of breast cancer.  Conclusions: These data suggest the possibility that Ras-MAPK pathway activation promotes immune-evasion in TNBC, and support clin. trials combining MEK- and PD-L1-targeted therapies.  Furthermore, Ras/MAPK activation and MHC expression may be predictive biomarkers of response to immune checkpoint inhibitors.  Clin Cancer Res; 22(6); 1499-509. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVZ44YLo5HKrVg90H21EOLACvtfcHk0lhfZBJhjwV3Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlajsLY%253D&md5=8d7b47ebef865d4e12db7a9a56396029</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1125%26sid%3Dliteratum%253Aachs%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DDushyanthen%26aufirst%3DS.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DSalgado%26aufirst%3DR.%26aulast%3DDenkert%26aufirst%3DC.%26aulast%3DSavas%26aufirst%3DP.%26aulast%3DCombs%26aufirst%3DS.%26aulast%3DRimm%26aufirst%3DD.%2BL.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DEstrada%26aufirst%3DM.%2BV.%26aulast%3DSanchez%26aufirst%3DV.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DCook%26aufirst%3DR.%2BS.%26aulast%3DPilkinton%26aufirst%3DM.%2BA.%26aulast%3DMallal%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DDoimi%26aufirst%3DF.%2BD.%26aulast%3DGomez%26aufirst%3DH.%26aulast%3DRyzhov%26aufirst%3DS.%2BV.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26atitle%3DRAS%252FMAPK%2520activation%2520is%2520associated%2520with%2520reduced%2520tumor-infiltrating%2520lymphocytes%2520in%2520triple-negative%2520breast%2520cancer%253A%2520Therapeutic%2520cooperation%2520between%2520MEK%2520and%2520PD-1%252FPD-L1%2520immune%2520checkpoint%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D6%26spage%3D1499%26epage%3D1509%26doi%3D10.1158%2F1078-0432.CCR-15-1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrojo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostafa, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3405</span>– <span class="NLM_lpage">3415</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-16-2401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28069724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3405-3415&issue=13&author=T.+M.+Cardilloauthor=R.+M.+Sharkeyauthor=D.+L.+Rossiauthor=R.+Arrojoauthor=A.+A.+Mostafaauthor=D.+M.+Goldenberg&title=Synthetic+lethality+exploitation+by+an+anti-Trop-2-SN-38+antibody-drug+conjugate%2C+IMMU-132%2C+plus+PARP+inhibitors+in+BRCA1%2F2-wild-type+triple-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-16-2401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer</span></div><div class="casAuthors">Cardillo, Thomas M.; Sharkey, Robert M.; Rossi, Diane L.; Arrojo, Roberto; Mostafa, Ali A.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3405-3415</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Both PARP inhibitors (PARPi) and sacituzumab govitecan (IMMU-132) are currently under clin. evaluation in triple-neg. breast cancer (TNBC).  We sought to investigate the combined DNA-damaging effects of the topoisomerase I (Topo I)-inhibitory activity of IMMU-132 with PARPi disruption of DNA repair in TNBC.  In vitro, human TNBC cell lines were incubated with IMMU-132 and various PARPi (olaparib, rucaparib, or talazoparib) to det. the effect on growth, double-stranded DNA (dsDNA) breaks, and cell-cycle arrest.  Mice bearing BRCA1/2-mutated or -wild-type human TNBC tumor xenografts were treated with the combination of IMMU-132 and PARPi (olaparib or talazoparib).  Study survival endpoint was tumor progression to >1.0 cm3 and tolerability assessed by hematol. changes.  Combining IMMU-132 in TNBC with all three different PARPi results in synergistic growth inhibition, increased dsDNA breaks, and accumulation of cells in the S-phase of the cell cycle, regardless of BRCA1/2 status.  A combination of IMMU-132 plus olaparib or talazoparib produces significantly improved antitumor effects and delay in time-to-tumor progression compared with monotherapy in mice bearing BRCA1/2-mutated HCC1806 TNBC tumors.  Furthermore, in mice bearing BRCA1/2-wild-type tumors (MDA-MB-468 or MDA-MB-231), the combination of IMMU-132 plus olaparib imparts a significant antitumor effect and survival benefit above that achieved with monotherapy.  Most importantly, this combination was well tolerated, with no substantial changes in hematol. parameters.  These data demonstrate the added benefit of combining Topo I inhibition mediated by IMMU-132 with synthetic lethality provided by PARPi in TNBC, regardless of BRCA1/2 status, thus supporting the rationale for such a combination clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNc78oBM-XaLVg90H21EOLACvtfcHk0lhfZBJhjwV3Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurjJ&md5=6c6d6657c8c64344ce52271736de42fd</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2401%26sid%3Dliteratum%253Aachs%26aulast%3DCardillo%26aufirst%3DT.%2BM.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DRossi%26aufirst%3DD.%2BL.%26aulast%3DArrojo%26aufirst%3DR.%26aulast%3DMostafa%26aufirst%3DA.%2BA.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DSynthetic%2520lethality%2520exploitation%2520by%2520an%2520anti-Trop-2-SN-38%2520antibody-drug%2520conjugate%252C%2520IMMU-132%252C%2520plus%2520PARP%2520inhibitors%2520in%2520BRCA1%252F2-wild-type%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D13%26spage%3D3405%26epage%3D3415%26doi%3D10.1158%2F1078-0432.CCR-16-2401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opzoomer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilieva, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazinska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesch-Domenech, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fittall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez Rodriguez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellizzari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bax, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescioli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petranyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larcombe-Young, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephs, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canevari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestle, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A. N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, S. N.</span></span> <span> </span><span class="NLM_article-title">Anti-folate receptor alpha–directed antibody therapies restrict the growth of triple-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5098</span>– <span class="NLM_lpage">5111</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-0652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-18-0652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30068707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsl2gs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=5098-5111&issue=20&author=A.+Cheungauthor=J.+Opzoomerauthor=K.+M.+Ilievaauthor=P.+Gazinskaauthor=R.+M.+Hoffmannauthor=H.+Mirzaauthor=R.+Marlowauthor=E.+Francesch-Domenechauthor=M.+Fittallauthor=D.+Dominguez+Rodriguezauthor=A.+Cliffordauthor=L.+Badderauthor=N.+Patelauthor=S.+Meleauthor=G.+Pellizzariauthor=H.+J.+Baxauthor=S.+Crescioliauthor=G.+Petranyiauthor=D.+Larcombe-Youngauthor=D.+H.+Josephsauthor=S.+Canevariauthor=M.+Figiniauthor=S.+Pinderauthor=F.+O.+Nestleauthor=C.+Gillettauthor=J.+F.+Spicerauthor=A.+Grigoriadisauthor=A.+N.+J.+Tuttauthor=S.+N.+Karagiannis&title=Anti-folate+receptor+alpha%E2%80%93directed+antibody+therapies+restrict+the+growth+of+triple-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-18-0652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer</span></div><div class="casAuthors">Cheung, Anthony; Opzoomer, James W.; Ilieva, Kristina M.; Gazinska, Patrycja; Hoffmann, Ricarda M.; Mirza, Hasan; Marlow, Rebecca; Francesch-Domenech, Erika; Fittall, Matthew W.; Rodriguez, Diana Dominguez; Clifford, Angela; Badder, Luned; Patel, Nirmesh; Mele, Silvia; Pellizzari, Giulia; Bax, Heather J.; Crescioli, Silvia; Petranyi, Gyula; Larcombe-Young, Daniel; Josephs, Debra H.; Canevari, Silvana; Figini, Mariangela; Pinder, Sarah E.; Nestle, Frank O.; Gillett, Cheryl; Spicer, James; Grigoriadis, Anita; Tutt, Andrew; Karagiannis, Sophia N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5098-5111</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Highly-aggressive triple neg. breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease.  Folate Receptor alpha (FRα) is a central mediator of cell growth regulation that could serve as an important target for cancer therapy.  Exptl. Design: We evaluated FRα expression in breast cancers by genomic (n = 3414) and immunohistochem. (n = 323) analyses and its assocn. with clin. parameters and outcomes.  We measured the functional contributions of FRα in TNBC biol. by RNA interference and the antitumor functions of an antibody recognizing FRα (MOv18-IgG1), in vitro and in human TNBC xenograft models.  Results: FRα is overexpressed in significant proportions of aggressive basal like/TNBC tumors, and in post-neoadjuvant chemotherapy-residual disease assocd. with a high risk of relapse.  Expression is assocd. with worse overall survival.  TNBCs show dysregulated expression of thymidylate synthase, folate hydrolase 1 and methylenetetrahydrofolate reductase, involved in folate metab.  RNA interference to deplete FRα decreased Src and ERK signaling and resulted in redn. of cell growth.  An anti-FRα antibody (MOv18-IgG1) conjugated with a Src inhibitor significantly restricted TNBC xenograft growth.  Moreover, MOv18-IgG1 triggered immune-dependent cancer cell death in vitro by human volunteer and breast cancer patient immune cells, and significantly restricted orthotopic and patient-derived xenograft growth.  Conclusions: FRα is overexpressed in high-grade TNBC and post-chemotherapy residual tumors.  It participates in cancer cell signaling and presents a promising target for therapeutic strategies such as antibody-drug conjugates, or passive immunotherapy priming Fc-mediated anti-tumor immune cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmRa3oT29QpLVg90H21EOLACvtfcHk0lgF9jrOJrrobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsl2gs7Y%253D&md5=7afc4c01fc09eb2d5892ca973817ccc3</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-0652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-0652%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DA.%26aulast%3DOpzoomer%26aufirst%3DJ.%26aulast%3DIlieva%26aufirst%3DK.%2BM.%26aulast%3DGazinska%26aufirst%3DP.%26aulast%3DHoffmann%26aufirst%3DR.%2BM.%26aulast%3DMirza%26aufirst%3DH.%26aulast%3DMarlow%26aufirst%3DR.%26aulast%3DFrancesch-Domenech%26aufirst%3DE.%26aulast%3DFittall%26aufirst%3DM.%26aulast%3DDominguez%2BRodriguez%26aufirst%3DD.%26aulast%3DClifford%26aufirst%3DA.%26aulast%3DBadder%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DMele%26aufirst%3DS.%26aulast%3DPellizzari%26aufirst%3DG.%26aulast%3DBax%26aufirst%3DH.%2BJ.%26aulast%3DCrescioli%26aufirst%3DS.%26aulast%3DPetranyi%26aufirst%3DG.%26aulast%3DLarcombe-Young%26aufirst%3DD.%26aulast%3DJosephs%26aufirst%3DD.%2BH.%26aulast%3DCanevari%26aufirst%3DS.%26aulast%3DFigini%26aufirst%3DM.%26aulast%3DPinder%26aufirst%3DS.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26aulast%3DGillett%26aufirst%3DC.%26aulast%3DSpicer%26aufirst%3DJ.%2BF.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%2BN.%2BJ.%26aulast%3DKaragiannis%26aufirst%3DS.%2BN.%26atitle%3DAnti-folate%2520receptor%2520alpha%25E2%2580%2593directed%2520antibody%2520therapies%2520restrict%2520the%2520growth%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D20%26spage%3D5098%26epage%3D5111%26doi%3D10.1158%2F1078-0432.CCR-18-0652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulaiman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sahli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cron, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alain, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figeys, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1755</span>– <span class="NLM_lpage">1764</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-18-0873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31308079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1755-1764&issue=10&author=A.+Sulaimanauthor=S.+McGarryauthor=S.+El-Sahliauthor=L.+Liauthor=J.+Chambersauthor=A.+Phanauthor=M.+Coteauthor=G.+O.+Cronauthor=T.+Alainauthor=Y.+Leauthor=S.+H.+Leeauthor=S.+Liuauthor=D.+Figeysauthor=S.+Gaddeauthor=L.+Wang&title=Co-targeting+bulk+tumor+and+CSCs+in+clinically+translatable+TNBC+patient-derived+xenografts+via+combination+nanotherapy&doi=10.1158%2F1535-7163.MCT-18-0873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting bulk tumor and cscs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy</span></div><div class="casAuthors">Sulaiman, Andrew; McGarry, Sarah; El-Sahli, Sara; Li, Li; Chambers, Jason; Phan, Alexandra; Cote, Marceline; Cron, Greg O.; Alain, Tommy; Le, Yevgeniya; Lee, Seung-Hwan; Liu, Sheng; Figeys, Daniel; Gadde, Suresh; Wang, Lisheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1755-1764</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) accounts disproportionally for the majority of breast cancer-related deaths throughout the world.  This is largely attributed to lack of a specific therapy capable of targeting both bulk tumor mass and cancer stem cells (CSC), as well as appropriate animal models to accurately evaluate treatment efficacy for clin. translation.  Thus, development of effective and clin. translatable targeted therapies for TNBC is an unmet medical need.  We developed a hybrid nanoparticles-based co-delivery platform contg. both paclitaxel and verteporfin (PV-NP) to target TNBC patient-derived xenograft (PDX) tumor and CSCs.  MRI and IVIS imaging were performed on mice contg. PDX tumors to assess tumor vascularity and accumulation of NPs.  Mice bearing TNBC PDX tumor were treated with PV-NPs and controls, and tumors progression and CSC subpopulations were analyzed.  IVIS imaging showed accumulation of NPs in PDX tumors.  In comparison with control-NPs and free-drug combination, PV-NPs significantly retarded tumor growth of TNBC PDX.  PV-NPs simultaneously repressed NF-κB, Wnt, and YAP that have been shown to be crucial for cancer growth, CSC development, and tumorigenesis.  In conclusion, NPs contg. two clin. used drugs concurrently inhibited NF-κB, Wnt, and YAP pathways and exhibited synergic effects on killing TNBC bulk tumor and CSCs.  This combination nanotherapy evaluated with a PDX model may lead to an effective treatment of patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQArsHcx0yg7Vg90H21EOLACvtfcHk0lgF9jrOJrrobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFKkug%253D%253D&md5=4ea7f5bd6036b04a2b0978ef06e198d0</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0873%26sid%3Dliteratum%253Aachs%26aulast%3DSulaiman%26aufirst%3DA.%26aulast%3DMcGarry%26aufirst%3DS.%26aulast%3DEl-Sahli%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChambers%26aufirst%3DJ.%26aulast%3DPhan%26aufirst%3DA.%26aulast%3DCote%26aufirst%3DM.%26aulast%3DCron%26aufirst%3DG.%2BO.%26aulast%3DAlain%26aufirst%3DT.%26aulast%3DLe%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DFigeys%26aufirst%3DD.%26aulast%3DGadde%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DCo-targeting%2520bulk%2520tumor%2520and%2520CSCs%2520in%2520clinically%2520translatable%2520TNBC%2520patient-derived%2520xenografts%2520via%2520combination%2520nanotherapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26issue%3D10%26spage%3D1755%26epage%3D1764%26doi%3D10.1158%2F1535-7163.MCT-18-0873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span> <span> </span><span class="NLM_article-title">JQ1-loaded polydopamine nanoplatform inhibits c-MYC/programmed cell death ligand 1 to enhance photothermal therapy for triple-negative breast cancer</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">50</span>),  <span class="NLM_fpage">46626</span>– <span class="NLM_lpage">46636</span>, <span class="refDoi"> DOI: 10.1021/acsami.9b18730</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.9b18730" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Wkt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=46626-46636&issue=50&author=Y.+Tianauthor=X.+Wangauthor=S.+Zhaoauthor=X.+Liaoauthor=M.+R.+Younisauthor=S.+Wangauthor=C.+Zhangauthor=G.+Lu&title=JQ1-loaded+polydopamine+nanoplatform+inhibits+c-MYC%2Fprogrammed+cell+death+ligand+1+to+enhance+photothermal+therapy+for+triple-negative+breast+cancer&doi=10.1021%2Facsami.9b18730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer</span></div><div class="casAuthors">Tian, Ying; Wang, Xiaofen; Zhao, Shuang; Liao, Xiang; Younis, Muhammad Rizwan; Wang, Shouju; Zhang, Chunni; Lu, Guangming</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">46626-46636</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Programmed cell death ligand 1 (PD-L1) blockade has achieved great success in cancer immunotherapy; however, the response of triple-neg. breast cancer (TNBC) to PD-L1 antibodies is limited.  To address this challenge, we use the bromodomain and extra-terminal inhibitor JQ1 to down-regulate the expression of PD-L1 and thus elicit the immune response to TNBC instead of using antibodies to block PD-L1.  JQ1 also inhibits the growth of TNBC as a targeted therapeutic agent by inhibiting the BRD4-c-MYC axis.  The polydopamine nanoparticles (PDMNs) are introduced as a biodegradable and adaptable platform to load JQ1 and induce photothermal therapy (PTT) as another synergistic therapeutic modality.  Because the JQ1-loaded PDMNs (PDMN-JQ1) are self-degradable and release JQ1 continuously, this synergistic treatment can lead to remarkable activation of cytotoxic T lymphocytes and induce a strong immune-memory effect to protect mice from tumor re-challenge.  Taken together, our study demonstrates a compact and simple nanoplatform for triple therapy, including targeted therapy, PTT, and immunotherapy, for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTOuiO3HnYrbVg90H21EOLACvtfcHk0lhhNsq0R_4CxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Wkt7bM&md5=d9431a3469c4a1e48006c376f40ee31a</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Facsami.9b18730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.9b18730%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DX.%26aulast%3DYounis%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DG.%26atitle%3DJQ1-loaded%2520polydopamine%2520nanoplatform%2520inhibits%2520c-MYC%252Fprogrammed%2520cell%2520death%2520ligand%25201%2520to%2520enhance%2520photothermal%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2019%26volume%3D11%26issue%3D50%26spage%3D46626%26epage%3D46636%26doi%3D10.1021%2Facsami.9b18730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span> <span> </span><span class="NLM_article-title">Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">105864</span>, <span class="refDoi"> DOI: 10.1016/j.intimp.2019.105864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.intimp.2019.105864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31480004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWgurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2019&pages=105864&author=Q.+Zhangauthor=K.+Leauthor=M.+Xuauthor=J.+Zhouauthor=Y.+Xiaoauthor=W.+Yangauthor=Y.+Jiangauthor=Z.+Xiauthor=T.+Huang&title=Combined+MEK+inhibition+and+tumor-associated+macrophages+depletion+suppresses+tumor+growth+in+a+triple-negative+breast+cancer+mouse+model&doi=10.1016%2Fj.intimp.2019.105864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model</span></div><div class="casAuthors">Zhang, Qiulei; Le, Kehao; Xu, Ming; Zhou, Jun; Xiao, Yunxiao; Yang, Wen; Jiang, Yujia; Xi, Zihan; Huang, Tao</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105864</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tumor-assocd. macrophages (TAMs) are closely related to poor prognosis in triple-neg. breast cancer (TNBC).  Thus, gaining insight into how TAMs support cancer progression could contribute to effective therapies.  We utilized the 4 T1 murine TNBC cell line and murine bone marrow-derived macrophages to assess TAM-mediated pro-proliferative effects in vivo and in vitro.  Moreover, RNA sequencing anal. showed that TAMs could enhance mitogen-activated protein kinase (MAPK) pathway activation in 4 T1 cells compared to that in control cells.  Further, the depletion of TAMs by clodronate liposomes significantly reduced MAPK pathway activation in vivo.  In addn., the blockade of MAPK signaling by a MEK inhibitor repressed TAM-mediated cancer cell proliferation.  Most importantly, MEK inhibition combined with macrophage depletion significantly suppressed tumor growth and increased T lymphocyte infiltration in a TNBC model.  Our study suggests the possibility that TAM-induced MAPK pathway activation promotes cancer cell proliferation.  Thus, MEK inhibition combined with macrophage depletion might represent an effective treatment for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM2jPETHJVQ7Vg90H21EOLACvtfcHk0lhhNsq0R_4CxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWgurrO&md5=0717103be8bf84dbd035fb989d70c0a5</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2019.105864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2019.105864%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DXi%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DT.%26atitle%3DCombined%2520MEK%2520inhibition%2520and%2520tumor-associated%2520macrophages%2520depletion%2520suppresses%2520tumor%2520growth%2520in%2520a%2520triple-negative%2520breast%2520cancer%2520mouse%2520model%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2019%26volume%3D76%26spage%3D105864%26doi%3D10.1016%2Fj.intimp.2019.105864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">46</span>, <span class="refDoi"> DOI: 10.1186/s12943-016-0531-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs12943-016-0531-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27286975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVWrtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=46&issue=1&author=H.+W.+Chiuauthor=Y.+L.+Yehauthor=Y.+C.+Wangauthor=W.+J.+Huangauthor=S.+Y.+Hoauthor=P.+Linauthor=Y.+J.+Wang&title=Combination+of+the+novel+histone+deacetylase+inhibitor+YCW1+and+radiation+induces+autophagic+cell+death+through+the+downregulation+of+BNIP3+in+triple-negative+breast+cancer+cells+in+vitro+and+in+an+orthotopic+mouse+model&doi=10.1186%2Fs12943-016-0531-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model</span></div><div class="casAuthors">Chiu, Hui-Wen; Yeh, Ya-Ling; Wang, Yi-Ching; Huang, Wei-Jan; Ho, Sheng-Yow; Lin, Pinpin; Wang, Ying-Jan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46/1-46/12</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Triple-neg. breast cancer (TNBC) is the most aggressive and invasive of the breast cancer subtypes.  TNBC is a challenging disease that lacks targets for treatment.  Histone deacetylase inhibitors (HDACi) are a group of targeted anticancer agents that enhance radiosensitivity.  Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a member of the Bcl-2 subfamily.  BNIP3 is not found in normal breast tissue but is up-regulated in breast cancer.  In the present study, we investigated the anti-cancer effects of a newly developed HDACi, YCW1, combined with ionizing radiation (IR) in TNBC in vitro and in an orthotopic mouse model.  Furthermore, we examd. the relationship between autophagy and BNIP3.  Methods: Trypan blue exclusion was used to investigate the viability of 4 T1 (a mouse TNBC cell line) and MDA-MB-231 cells (a human TNBC cell line) following combined YCW1 and IR treatment.  Flow cytometry was used to det. apoptosis and autophagy.  The expression levels of BNIP3, endoplasmic reticulum (ER) stress- and autophagic-related proteins were measured using western blot anal.  An orthotopic mouse model was used to investigate the in vivo effects of YCW1 and IR alone and in combination.  Tumor vols. were monitored using a bioluminescence-based IVIS Imaging System 200.  Results: We found that YCW1 significantly enhanced toxicity in 4 T1 cells compared with suberoylanilide hydroxamic acid (SAHA), which was the first HDACi approved by the Food and Drug Administration for clin. use in cancer patients.  The combined treatment of YCW1 and IR enhanced cytotoxicity by inducing ER stress and increasing autophagy induction.  Addnl., the combined treatment caused autophagic flux and autophagic cell death.  Furthermore, the expression level of BNIP3 was significantly decreased in cells following combined treatment.  The downregulation of BNIP3 led to a significant increase in autophagy and cytotoxicity.  The combined anti-tumor effects of YCW1 and IR were also obsd. in an orthotopic mouse model; combination therapy resulted in a significant increase in autophagy and decreased tumor tissue expression of BNIP3 in the tumor tissue.  Conclusions: These data support the possibility of using a combination of HDACi and IR in the treatment of TNBC.  Moreover, BNIP3 may be a potential target protein for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwkW_2WhIzZLVg90H21EOLACvtfcHk0lhhNsq0R_4CxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVWrtrfP&md5=ddc4274a3c924d9175af63dad5d9a472</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1186%2Fs12943-016-0531-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-016-0531-5%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DH.%2BW.%26aulast%3DYeh%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26aulast%3DHo%26aufirst%3DS.%2BY.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26atitle%3DCombination%2520of%2520the%2520novel%2520histone%2520deacetylase%2520inhibitor%2520YCW1%2520and%2520radiation%2520induces%2520autophagic%2520cell%2520death%2520through%2520the%2520downregulation%2520of%2520BNIP3%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520an%2520orthotopic%2520mouse%2520model%26jtitle%3DMol.%2520Cancer%26date%3D2016%26volume%3D15%26issue%3D1%26spage%3D46%26doi%3D10.1186%2Fs12943-016-0531-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panneerselvam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, A.</span></span> <span> </span><span class="NLM_article-title">Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage</span>. <i>Int. J. Radiat. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1080/09553002.2020.1730012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1080%2F09553002.2020.1730012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32052681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB387hsFOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-12&author=M.+Mehtaauthor=J.+Griffithauthor=J.+Panneerselvamauthor=A.+Babuauthor=J.+Maniauthor=T.+Hermanauthor=R.+Rameshauthor=A.+Munshi&title=Regorafenib+sensitizes+human+breast+cancer+cells+to+radiation+by+inhibiting+multiple+kinases+and+inducing+DNA+damage&doi=10.1080%2F09553002.2020.1730012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage</span></div><div class="casAuthors">Mehta Meghna; Griffith James; Babu Anish; Mani Jonathan; Herman Terence; Munshi Anupama; Panneerselvam Janani; Babu Anish; Ramesh Rajagopal; Panneerselvam Janani; Babu Anish; Mani Jonathan; Herman Terence; Ramesh Rajagopal; Munshi Anupama</div><div class="citationInfo"><span class="NLM_cas:title">International journal of radiation biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purpose: Triple-negative breast cancer (TNBC) is the most challenging and aggressive subtype of breast cancer with limited treatment options because of tumor heterogeneity, lack of druggable targets and therapy resistance.  TNBCs are characterized by overexpression of growth factor receptors such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and platelet derived growth factor receptor (PDGFR) making them promising therapeutic targets.  Regorafenib is an FDA approved oral multi-kinase inhibitor that blocks the activity of multiple protein kinases including those involved in the regulation of tumor angiogenesis [VEGFR1-3, TIE2], tumor microenvironment [PDGFR-β, FGFR] and oncogenesis (KIT, RET, RAF-1, BRAF).  In the current study, we examined the radiosensitizing effects of Regorafenib on TNBC cell lines and explored the mechanism by which Regorafenib enhances radiosensitivity.Methods: MDA-MB-231 and SUM159PT (human TNBC cell lines) and MCF 10a (human mammary epithelial cell line) were treated with Regorafenib, ionizing radiation or a combination of both.  Following treatment with Regorafenib and radiation we conducted clonogenic assay to determine radiosensitivity, immunoblot analysis to assess the effect on key signaling targets, tube formation to evaluate effect on angiogenesis and comet assay as well as western blot for γH2AX to assess DNA damage response (DDR).Results: Regorafenib reduced cell proliferation and enhanced radiosensitivity of MDA-MB-231 and SUM159PT cell lines but had no effect on the MCF 10a cells.  Clonogenic survival assays showed that the surviving fraction at 2 Gy for both MDA-MB-231 and SUM159PT was reduced from 66.4 ± 8.9 and 88.2 ± 1.7 in controls to 38.1 ± 4.9 and 75.1 ± 1.1 following a 24 hr pretreatment with 10 μM and 5 μM Regorafenib, respectively.  A marked reduction in the expression of VEGFR, PDGFR, EGFR and the downstream target, ERK, was observed with Regorafenib treatment alone or in combination with radiation.  We also observed a significant inhibition of VEGF-A production in the TNBC cell lines following treatment with Regorafenib.  Further, the addition of conditioned medium from Regorafenib-treated tumor cells onto human umbilical vein endothelial cells (HUVEC) suppressed tube formation, indicating an inhibition of tumor angiogenesis.  Regorafenib also decreased migration of TNBC cells and suppressed radiation-induced DNA damage repair in a time-dependent manner.Conclusions: Our findings demonstrate that Regorafenib enhanced radiosensitivity of breast cancer cells by inhibiting the expression of multiple receptor tyrosine kinases, VEGF-mediated angiogenesis and DNA damage response in TNBC.  Therefore, combining Regorafenib with radiation and antiangiogenic agents will be beneficial and effective in controlling TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStQPHrKG6p7ZagfuraLLzSfW6udTcc2eb_5IQO9utAGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387hsFOhsw%253D%253D&md5=2be15305f8151342b419e37f65ae62a8</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1080%2F09553002.2020.1730012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09553002.2020.1730012%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DM.%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DPanneerselvam%26aufirst%3DJ.%26aulast%3DBabu%26aufirst%3DA.%26aulast%3DMani%26aufirst%3DJ.%26aulast%3DHerman%26aufirst%3DT.%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DMunshi%26aufirst%3DA.%26atitle%3DRegorafenib%2520sensitizes%2520human%2520breast%2520cancer%2520cells%2520to%2520radiation%2520by%2520inhibiting%2520multiple%2520kinases%2520and%2520inducing%2520DNA%2520damage%26jtitle%3DInt.%2520J.%2520Radiat.%2520Biol.%26date%3D2020%26spage%3D1%26epage%3D12%26doi%3D10.1080%2F09553002.2020.1730012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koledova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streuli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span> <span> </span><span class="NLM_article-title">SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">E5731</span>– <span class="NLM_lpage">5740</span>, <span class="refDoi"> DOI: 10.1073/pnas.1611532113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1611532113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27621461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2kurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E5731-5740&issue=39&author=Z.+Koledovaauthor=X.+Zhangauthor=C.+Streuliauthor=R.+Clarkeauthor=O.+Kleinauthor=Z.+Werbauthor=P.+Lu&title=SPRY1+regulates+mammary+epithelial+morphogenesis+by+modulating+EGFR-dependent+stromal+paracrine+signaling+and+ECM+remodeling&doi=10.1073%2Fpnas.1611532113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling</span></div><div class="casAuthors">Koledova, Zuzana; Zhang, Xiaohong; Streuli, Charles; Clarke, Robert B.; Klein, Ophir D.; Werb, Zena; Lu, Pengfei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">E5731-E5740</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The role of the local microenvironment in influencing cell behavior is central to both normal development and cancer formation.  Here, we show that sprouty 1 (SPRY1) modulates the microenvironment to enable proper mammary branching morphogenesis.  This process occurs through neg. regulation of epidermal growth factor receptor (EGFR) signaling in mammary stroma.  Loss of SPRY1 resulted in up-regulation of EGFR-extracellular signal-regulated kinase (ERK) signaling in response to amphiregulin and transforming growth factor alpha stimulation.  Consequently, stromal paracrine signaling and ECM remodeling is augmented, leading to increased epithelial branching in the mutant gland.  By contrast, down-regulation of EGFR-ERK signaling due to gain of Sprouty function in the stroma led to stunted epithelial branching.  Taken together, our results show that modulation of stromal paracrine signaling and ECM remodeling by SPRY1 regulates mammary epithelial morphogenesis during postnatal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI9ec2Pybl1bVg90H21EOLACvtfcHk0lhOvtWEEwXG4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2kurrO&md5=87059e5692bd21cdb6b9462435d38fc7</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1611532113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1611532113%26sid%3Dliteratum%253Aachs%26aulast%3DKoledova%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DStreuli%26aufirst%3DC.%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DKlein%26aufirst%3DO.%26aulast%3DWerb%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DP.%26atitle%3DSPRY1%2520regulates%2520mammary%2520epithelial%2520morphogenesis%2520by%2520modulating%2520EGFR-dependent%2520stromal%2520paracrine%2520signaling%2520and%2520ECM%2520remodeling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D39%26spage%3DE5731%26epage%3D5740%26doi%3D10.1073%2Fpnas.1611532113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, B.</span></span> <span> </span><span class="NLM_article-title">SGCE promotes breast cancer stem cells by stabilizing EGFR</span>. <i>Adv. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1903700</span>, <span class="refDoi"> DOI: 10.1002/advs.201903700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fadvs.201903700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Kqs7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=1903700&issue=14&author=L.+Zhaoauthor=T.+Qiuauthor=D.+Jiangauthor=H.+Xuauthor=L.+Zouauthor=Q.+Yangauthor=C.+Chenauthor=B.+Jiao&title=SGCE+promotes+breast+cancer+stem+cells+by+stabilizing+EGFR&doi=10.1002%2Fadvs.201903700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR</span></div><div class="casAuthors">Zhao, Lina; Qiu, Ting; Jiang, Dewei; Xu, Haibo; Zou, Li; Yang, Qin; Chen, Ceshi; Jiao, Baowei</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Science (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1903700</span>CODEN:
                <span class="NLM_cas:coden">ASDCCF</span>;
        ISSN:<span class="NLM_cas:issn">2198-3844</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Breast cancer stem cells (BCSCs) are responsible for resistance to chemotherapy, high degree of metastasis, and poor prognosis, esp. in triple-neg. breast cancer (TNBC).  The CD24lowCD44high and high aldehyde dehydrogenase 1 (ALDH1) cell subpopulation (CD24lowCD44high ALDH1+) exhibit very high tumor initiating capacity.  In the current study, the upregulated genes are analyzed in both CD24lowCD44high and ALDH1+ cell populations at single-cell resoln., and a highly expressed membrane protein, SGCE, is identified in both BCSC populations.  Further results show that SGCE depletion reduces BCSC self-renewal, chemoresistance, and metastasis both in vitro and in vivo, partially through affecting the accumulation of extracellular matrix (ECM).  For the underlying mechanism, SGCE functions as a sponge mol. for the interaction between epidermal growth factor receptor (EGFR) and its E3 ubiquitination ligase (c-Cbl), and thus inhibits EGFR lysosomal degrdn. to stabilize the EGFR protein.  SGCE knockdown promotes sensitivity to EGFR tyrosine kinase inhibitors (TKIs), providing new clues for deciphering the current failure of targeting EGFR in clin. trials and highlighting a novel candidate for BCSC stemness regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDKF0blsekTbVg90H21EOLACvtfcHk0lhOvtWEEwXG4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Kqs7bL&md5=3639ee51ba9698e16b10bff580cfa3e5</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1002%2Fadvs.201903700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadvs.201903700%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DJiao%26aufirst%3DB.%26atitle%3DSGCE%2520promotes%2520breast%2520cancer%2520stem%2520cells%2520by%2520stabilizing%2520EGFR%26jtitle%3DAdv.%2520Sci.%26date%3D2020%26volume%3D7%26issue%3D14%26spage%3D1903700%26doi%3D10.1002%2Fadvs.201903700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaborit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Dvashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porat, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareja, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindzen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Chetrit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1815</span>– <span class="NLM_lpage">1820</span>, <span class="refDoi"> DOI: 10.1073/pnas.1220763110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1220763110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23319610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisl2ns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=1815-1820&issue=5&author=D.+Ferraroauthor=N.+Gaboritauthor=R.+Maronauthor=H.+Cohen-Dvashiauthor=Z.+Poratauthor=F.+Parejaauthor=S.+Laviauthor=M.+Lindzenauthor=N.+Ben-Chetritauthor=M.+Selaauthor=Y.+Yarden&title=Inhibition+of+triple-negative+breast+cancer+models+by+combinations+of+antibodies+to+EGFR&doi=10.1073%2Fpnas.1220763110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR</span></div><div class="casAuthors">Ferraro, Daniela A.; Gaborit, Nadege; Maron, Ruth; Cohen-Dvashi, Hadas; Porat, Ziv; Pareja, Fresia; Lavi, Sara; Lindzen, Moshit; Ben-Chetrit, Nir; Sela, Michaei; Yarden, Yosef</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1815-1829, S1815/1-S1815/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Breast tumors lacking expression of human epidermal growth factor receptor 2 (HER2) and the estrogen and the progesterone receptors (triple neg.; TNBC) are more aggressive than other disease subtypes, and no mol. targeted agents are currently available for their treatment.  Because TNBC commonly displays EGF receptor (EGFR) expression, and combinations of monoclonal antibodies to EGFR effectively inhibit other tumor models, we addressed the relevance of this strategy to treatment of TNBC.  Unlike a combination of the clin. approved monoclonal antibodies, cetuximab and panitumumab, which displaced each other and displayed no cooperative effects, several other combinations resulted in enhanced inhibition of TNBCs cell growth both in vitro and in animals.  The ability of certain antibody mixts. to remove EGFR from the cell surface and to promote its intracellular degrdn. correlated with the inhibitory potential.  However, unlike EGF-induced sorting of EGFR to lysosomal degrdn., the antibody-induced pathway displayed independence from the intrinsic kinase activity and dimer formation ability of EGFR, and it largely avoided the recycling route.  In conclusion, although TNBC clin. trials testing EGFR inhibitors reported lack of benefit, our results offer an alternative strategy that combines noncompetitive antibodies to achieve robust degrdn. of EGFR and tumor inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFFswJHVwaOLVg90H21EOLACvtfcHk0lhk20wJiRMtlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisl2ns78%253D&md5=82665ac7d67657aeb9efa7b9633241ed</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1220763110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1220763110%26sid%3Dliteratum%253Aachs%26aulast%3DFerraro%26aufirst%3DD.%26aulast%3DGaborit%26aufirst%3DN.%26aulast%3DMaron%26aufirst%3DR.%26aulast%3DCohen-Dvashi%26aufirst%3DH.%26aulast%3DPorat%26aufirst%3DZ.%26aulast%3DPareja%26aufirst%3DF.%26aulast%3DLavi%26aufirst%3DS.%26aulast%3DLindzen%26aufirst%3DM.%26aulast%3DBen-Chetrit%26aufirst%3DN.%26aulast%3DSela%26aufirst%3DM.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520triple-negative%2520breast%2520cancer%2520models%2520by%2520combinations%2520of%2520antibodies%2520to%2520EGFR%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D5%26spage%3D1815%26epage%3D1820%26doi%3D10.1073%2Fpnas.1220763110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Audeh, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-McGuinn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzel, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oaknin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmutzler, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span> <span> </span><span class="NLM_article-title">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">9737</span>),  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)60893-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2FS0140-6736%2810%2960893-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=20609468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=245-251&issue=9737&author=M.+W.+Audehauthor=J.+Carmichaelauthor=R.+T.+Pensonauthor=M.+Friedlanderauthor=B.+Powellauthor=K.+M.+Bell-McGuinnauthor=C.+Scottauthor=J.+N.+Weitzelauthor=A.+Oakninauthor=N.+Lomanauthor=K.+Luauthor=R.+K.+Schmutzlerauthor=U.+Matulonisauthor=M.+Wickensauthor=A.+Tutt&title=Oral+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+in+patients+with+BRCA1+or+BRCA2+mutations+and+recurrent+ovarian+cancer%3A+a+proof-of-concept+trial&doi=10.1016%2FS0140-6736%2810%2960893-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span></div><div class="casAuthors">Audeh, M. William; Carmichael, James; Penson, Richard T.; Friedlander, Michael; Powell, Bethan; Bell-McGuinn, Katherine M.; Scott, Clare; Weitzel, Jeffrey N.; Oaknin, Ana; Loman, Niklas; Lu, Karen; Schmutzler, Rita K.; Matulonis, Ursula; Wickens, Mark; Tutt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9737</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells.  We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations.  In this international, multicentre, phase 2 study, we enrolled two sequential cohorts of women (aged ≥18 years) with confirmed genetic BRCA1 or BRCA2 mutations, and recurrent, measurable disease.  The study was undertaken in 12 centers in Australia, Germany, Spain, Sweden, and the USA.  The first cohort (n=33) was given continuous oral olaparib at the max. tolerated dose of 400 mg twice daily, and the second cohort (n=24) was given continuous oral olaparib at 100 mg twice daily.  The primary efficacy endpoint was objective response rate (ORR).  This study is registered with ClinicalTrials.gov, no. NCT00494442.  Patients had been given a median of three (range 1-16) previous chemotherapy regimens.  ORR was 11 (33%) of 33 patients (95% CI 20-51) in the cohort assigned to olaparib 400 mg twice daily, and three (13%) of 24 (4-31) in the cohort assigned to 100 mg twice daily.  In patients given olaparib 400 mg twice daily, the most frequent causally related adverse events were nausea (grade 1 or 2, 14 [42%]; grade 3 or 4, 2 [6%]), fatigue (grade 1 or 2, 10 [30%]; grade 3 or 4, one [3%]), and anemia (grade 1 or 2, 5 [15%]; grade 3 or 4, 1 [3%]).  The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 7 [29%]; grade 3 or 4, 2 [8%]) and fatigue (grade 1 or 2, 9 [38%]; none grade 3 or 4).  Findings from this phase 2 study provide pos. proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfC3epcFKsLrVg90H21EOLACvtfcHk0lhk20wJiRMtlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D&md5=e74985d2c7ae53462d48277fbc36bb6a</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960893-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960893-8%26sid%3Dliteratum%253Aachs%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DWeitzel%26aufirst%3DJ.%2BN.%26aulast%3DOaknin%26aufirst%3DA.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DTutt%26aufirst%3DA.%26atitle%3DOral%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520recurrent%2520ovarian%2520cancer%253A%2520a%2520proof-of-concept%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26issue%3D9737%26spage%3D245%26epage%3D251%26doi%3D10.1016%2FS0140-6736%2810%2960893-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carey, J. P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayaraghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikule, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyomarsi, K.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-1494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-17-1494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29180466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=742-757&issue=3&author=J.+P.+W.+Careyauthor=C.+Karakasauthor=T.+Buiauthor=X.+Chenauthor=S.+Vijayaraghavanauthor=Y.+Zhaoauthor=J.+Wangauthor=K.+Mikuleauthor=J.+K.+Littonauthor=K.+K.+Huntauthor=K.+Keyomarsi&title=Synthetic+lethality+of+PARP+inhibitors+in+combination+with+MYC+blockade+is+independent+of+BRCA+status+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-17-1494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Carey, Jason. P. W.; Karakas, Cansu; Bui, Tuyen; Chen, Xian; Vijayaraghavan, Smruthi; Zhao, Yang; Wang, Jing; Mikule, Keith; Litton, Jennifer K.; Hunt, Kelly K.; Keyomarsi, Khandan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-757</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients.  Several of those patients exhibit intrinsic/acquired resistance mechanisms that limit efficacy of PARPi monotherapy.  Here we show how the efficacy of PARPi in triple-neg. breast cancers (TNBC) can be expanded by targeting MYC-induced oncogenic addiction.41673032X.  In BRCA-mutant/sporadic TNBC patients, amplification of the MYC gene is correlated with increased expression of the homologous DNA recombination enzyme RAD51 and tumors overexpressing both genes are assocd. with worse overall survival.  Combining MYC blockade with PARPi yielded synthetic lethality in MYC-driven TNBC cells.  Using the cyclin-dependent kinase inhibitor dinaciclib, which downregulates MYC expression, we found that combination with the PARPi niraparib increased DNA damage and downregulated homologous recombination, leading to subsequent downregulation of the epithelial-mesenchymal transition and cancer stem-like cell phenotypes.  Notably, dinaciclib resensitized TBNC cells, which had acquired resistance to niraparib.  We found that the synthetic lethal strategy employing dinaciclib and niraparib was also highly efficacious in ovarian, prostate, pancreatic, colon, and lung cancer cells.  Taken together, our results show how blunting MYC oncogene addiction can leverage cancer cell sensitivity to PARPi, facilitating the clin. use of c-myc as a predictive biomarker for this treatment.  Significance: Dual targeting of MYC-regulated homologous recombination and PARP-mediated DNA repair yields potent synthetic lethality in triple-neg. breast tumors and other aggressive tumors characterized by MYC overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_g3mYyl4rcbVg90H21EOLACvtfcHk0lhk20wJiRMtlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWntr4%253D&md5=1426c788233422558dc98856fa404b0e</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-1494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-1494%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DJ.%2BP.%2BW.%26aulast%3DKarakas%26aufirst%3DC.%26aulast%3DBui%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DVijayaraghavan%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMikule%26aufirst%3DK.%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DHunt%26aufirst%3DK.%2BK.%26aulast%3DKeyomarsi%26aufirst%3DK.%26atitle%3DSynthetic%2520lethality%2520of%2520PARP%2520inhibitors%2520in%2520combination%2520with%2520MYC%2520blockade%2520is%2520independent%2520of%2520BRCA%2520status%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D3%26spage%3D742%26epage%3D757%26doi%3D10.1158%2F0008-5472.CAN-17-1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yusoh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, H.</span></span> <span> </span><span class="NLM_article-title">Metallointercalator [Ru(dppz)(PIP)] renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00843</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00843" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1ansg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=378-387&issue=2&author=N.+Yusohauthor=S.+Leongauthor=S.+Chiaauthor=S.+Harunauthor=M.+Rahmanauthor=K.+Vallisauthor=M.+Gillauthor=H.+Ahmad&title=Metallointercalator+%5BRu%28dppz%29%28PIP%29%5D+renders+BRCA+wild-type+triple-negative+breast+cancer+cells+hypersensitive+to+PARP+inhibition&doi=10.1021%2Facschembio.9b00843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition</span></div><div class="casAuthors">Yusoh, Nur Aininie; Leong, Sze Wei; Chia, Suet Lin; Harun, Siti Norain; Rahman, Mohd Basyaruddin Abdul; Vallis, Katherine A.; Gill, Martin R.; Ahmad, Haslina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">378-387</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a need to improve and extend the use of clin. approved poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), including for BRCA wild-type triple-neg. breast cancer (TNBC).  The demonstration that ruthenium(II) polypyridyl complex (RPC) metallointercalators can rapidly stall DNA replication fork progression provides the rationale for their combination alongside DNA damage response (DDR) inhibitors to achieve synergism in cancer cells.  The aim of the present study was to evaluate use of the multi-intercalator [Ru(dppz)2(PIP)]2+ (dppz = dipyrido[3,2-a:2',3'-c]phenazine, PIP = (2-(phenyl)imidazo[4,5-f][1,10]phenanthroline, Ru-PIP) alongside the PARPi olaparib and NU1025.  Cell proliferation and clonogenic survival assays indicated a synergistic relationship between Ru-PIP and olaparib in MDA-MB-231 TNBC and MCF7 human breast cancer cells.  Strikingly, low dose Ru-PIP renders both cell lines hypersensitive to olaparib, with a >300-fold increase in olaparib potency in TNBC, the largest nongenetic PARPi enhancement effect described to date.  A negligible impact on the viability of normal human fibroblasts was obsd. for any combination tested.  Increased levels of DNA double-strand break (DSB) damage and olaparib abrogation of Ru-PIP-activated pChk1 signaling are consistent with PARPi-facilitated collapse of Ru-PIP-assocd. stalled replication forks.  This results in enhanced G2/M cell-cycle arrest, apoptosis, and decreased cell motility for the combination treatment compared to single-agent conditions.  This work establishes that an RPC metallointercalator can be combined with PARPi for potent synergy in BRCA-proficient breast cancer cells, including TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmxLYg5111gLVg90H21EOLACvtfcHk0ljGQ0DIvHJ2zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1ansg%253D%253D&md5=e251b3f4fdcd36618d5a3e47afd8fe1b</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00843%26sid%3Dliteratum%253Aachs%26aulast%3DYusoh%26aufirst%3DN.%26aulast%3DLeong%26aufirst%3DS.%26aulast%3DChia%26aufirst%3DS.%26aulast%3DHarun%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DM.%26aulast%3DVallis%26aufirst%3DK.%26aulast%3DGill%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DH.%26atitle%3DMetallointercalator%2520%255BRu%2528dppz%2529%2528PIP%2529%255D%2520renders%2520BRCA%2520wild-type%2520triple-negative%2520breast%2520cancer%2520cells%2520hypersensitive%2520to%2520PARP%2520inhibition%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2020%26volume%3D15%26issue%3D2%26spage%3D378%26epage%3D387%26doi%3D10.1021%2Facschembio.9b00843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basudhar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somasundaram, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridnour, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVicar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, D.</span></span> <span> </span><span class="NLM_article-title">Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">49</span>),  <span class="NLM_fpage">13030</span>– <span class="NLM_lpage">13035</span>, <span class="refDoi"> DOI: 10.1073/pnas.1709119114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1709119114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29087320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslalt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=13030-13035&issue=49&author=D.+Basudharauthor=S.+Glynnauthor=M.+Greerauthor=V.+Somasundaramauthor=J.+Noauthor=D.+Scheiblinauthor=P.+Garridoauthor=W.+Heinzauthor=A.+Ryanauthor=J.+Weissauthor=R.+Chengauthor=L.+Ridnourauthor=S.+Lockettauthor=D.+McVicarauthor=S.+Ambsauthor=D.+Wink&title=Coexpression+of+NOS2+and+COX2+accelerates+tumor+growth+and+reduces+survival+in+estrogen+receptor-negative+breast+cancer&doi=10.1073%2Fpnas.1709119114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer</span></div><div class="casAuthors">Basudhar, Debashree; Glynn, Sharon A.; Greer, Madison; Somasundaram, Veena; No, Jae Hong; Scheiblin, David A.; Garrido, Pablo; Heinz, William F.; Ryan, Aideen E.; Weiss, Jonathan M.; Cheng, Robert Y. S.; Ridnour, Lisa A.; Lockett, Stephen J.; McVicar, Daniel W.; Ambs, Stefan; Wink, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">13030-13035</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Proinflammatory signaling pathways are commonly up-regulated in breast cancer.  In estrogen receptor-neg. (ER-) and triple-neg. breast cancer (TNBC), nitric oxide synthase-2 (NOS2) and cyclooxygenase-2 (COX2) have been described as independent predictors of disease outcome.  We further explore these findings by investigating the impact of their coexpression on breast cancer survival.  Elevated coexpression of NOS2/COX2 proteins is a strong predictor of poor survival among ER- patients (hazard ratio: 21).  Furthermore, we found that the key products of NOS2 and COX2, NO and prostaglandin E2 (PGE2), resp., promote feed-forward NOS2/COX2 crosstalk in both MDA-MB-468 (basal-like) and MDA-MB-231 (mesenchymal-like) TNBC cell lines in which NO induced COX2 and PGE2 induced NOS2 proteins.  COX2 induction by NO involved TRAF2 activation that occurred in a TNFα-dependent manner in MDA-MB-468 cells.  In contrast, NO-mediated TRAF2 activation in the more aggressive MDA-MB-231 cells was TNFα independent but involved the endoplasmic reticulum stress response.  Inhibition of NOS2 and COX2 using amino-guanidine and aspirin/indomethacin yielded an additive redn. in the growth of MDA-MB-231 tumor xenografts.  These findings support a role of NOS2/COX2 crosstalk during disease progression of aggressive cancer phenotypes and offer insight into therapeutic applications for better survival of patients with ER- and TNBC disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvJ3zjZ_IIsLVg90H21EOLACvtfcHk0ljGQ0DIvHJ2zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslalt7zO&md5=5226533a29f4bd0ec459517b0e4c93cb</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1709119114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1709119114%26sid%3Dliteratum%253Aachs%26aulast%3DBasudhar%26aufirst%3DD.%26aulast%3DGlynn%26aufirst%3DS.%26aulast%3DGreer%26aufirst%3DM.%26aulast%3DSomasundaram%26aufirst%3DV.%26aulast%3DNo%26aufirst%3DJ.%26aulast%3DScheiblin%26aufirst%3DD.%26aulast%3DGarrido%26aufirst%3DP.%26aulast%3DHeinz%26aufirst%3DW.%26aulast%3DRyan%26aufirst%3DA.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DRidnour%26aufirst%3DL.%26aulast%3DLockett%26aufirst%3DS.%26aulast%3DMcVicar%26aufirst%3DD.%26aulast%3DAmbs%26aufirst%3DS.%26aulast%3DWink%26aufirst%3DD.%26atitle%3DCoexpression%2520of%2520NOS2%2520and%2520COX2%2520accelerates%2520tumor%2520growth%2520and%2520reduces%2520survival%2520in%2520estrogen%2520receptor-negative%2520breast%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D49%26spage%3D13030%26epage%3D13035%26doi%3D10.1073%2Fpnas.1709119114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safe, S.</span></span> <span> </span><span class="NLM_article-title">The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">498</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-14-498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2F1471-2407-14-498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25011475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyqu7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=498&author=U.+Jinauthor=S.+Leeauthor=C.+Pfentauthor=S.+Safe&title=The+aryl+hydrocarbon+receptor+ligand+omeprazole+inhibits+breast+cancer+cell+invasion+and+metastasis&doi=10.1186%2F1471-2407-14-498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis</span></div><div class="casAuthors">Jin, Un-Ho; Lee, Syng-Ook; Pfent, Catherine; Safe, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">498/1-498/14</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Patients with ER-neg. breast tumors are among the most difficult to treat and exhibit low survival rates due, in part, to metastasis from the breast to various distal sites.  Aryl hydrocarbon receptor (AHR) ligands show promise as antimetastatic drugs for estrogen receptor (ER)-neg. breast cancer.  Methods: Triple neg. MDA-MB-231 breast cancer cells were treated with eight AHR-active pharmaceuticals including 4-hydroxtamoxifen, flutamide leflunomide, mexiletine, nimodipine, omeprazole, sulindac and tranilast, and the effects of these compds. on cell proliferation (MTT assay) and cell migration (Boyden chamber assay) were examd.  The role of the AHR in mediating inhibition of MDA-MB-231 cell invasion was investigated by RNA interference (RNAi) and knockdown of AHR or cotreatment with AHR agonists.  Lung metastasis of MDA-MB-231 cells was evaluated in mice administered cells by tail vein injection and prometastatic gene expression was examd. by immunohistochem.  Results: We showed that only the proton pump inhibitor omeprazole decreased MDA-MB-231 breast cancer cell invasion in vitro.  Omeprazole also significantly decreased MDA-MB-231 cancer cell metastasis to the lung in a mouse model (tail vein injection), and in vitro studies showed that omeprazole decreased expression of at least two prometastatic genes, namely matrix metalloproteinase-9 (MMP-9) and C-X-C chemokine receptor 4 (CXCR4).  Results of RNA interference studies confirmed that omeprazole-mediated downregulation of CXCR4 (but not MMP-9) was AHR-dependent.  Chromatin immunopptn. assays demonstrated that omeprazole recruited the AHR to regions in the CXCR4 promoter that contain dioxin response elements (DREs) and this was accompanied by the loss of pol II on the promoter and decreased expression of CXCR4.  Conclusions: AHR-active pharmaceuticals such as omeprazole that decrease breast cancer cell invasion and metastasis may have important clin. applications for late stage breast cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsBXF02GSTmLVg90H21EOLACvtfcHk0ljuY1UU3dwzYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyqu7%252FO&md5=b2475e91df2f61ecbc6f8bb8a868779e</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-14-498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-14-498%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DU.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPfent%26aufirst%3DC.%26aulast%3DSafe%26aufirst%3DS.%26atitle%3DThe%2520aryl%2520hydrocarbon%2520receptor%2520ligand%2520omeprazole%2520inhibits%2520breast%2520cancer%2520cell%2520invasion%2520and%2520metastasis%26jtitle%3DBMC%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D498%26doi%3D10.1186%2F1471-2407-14-498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, N.</span></span> <span> </span><span class="NLM_article-title">Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e0143643</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0143643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0143643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26633806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOhsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0143643&issue=12&author=Y.+Hasegawaauthor=H.+Taninoauthor=J.+Horiguchiauthor=D.+Miuraauthor=T.+Ishikawaauthor=M.+Hayashiauthor=S.+Takaoauthor=S.+Kimauthor=K.+Yamagamiauthor=M.+Miyashitaauthor=M.+Konishiauthor=Y.+Shigeokaauthor=M.+Suzukiauthor=T.+Taguchiauthor=T.+Kubotaauthor=K.+Akazawaauthor=N.+Kohno&title=Randomized+controlled+trial+of+zoledronic+acid+plus+chemotherapy+versus+chemotherapy+alone+as+neoadjuvant+treatment+of+HER2-negative+primary+breast+cancer+%28JONIE+study%29&doi=10.1371%2Fjournal.pone.0143643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study)</span></div><div class="casAuthors">Hasegawa, Yoshie; Tanino, Hirokazu; Horiguchi, Jun; Miura, Daishu; Ishikawa, Takashi; Hayashi, Mitsuhiro; Takao, Shintaro; Kim, Seung Jin; Yamagami, Kazuhiko; Miyashita, Masaru; Konishi, Muneharu; Shigeoka, Yasushi; Suzuki, Masato; Taguchi, Tetsuya; Kubota, Tomoyuki; Akazawa, Kouhei; Kohno, Norio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0143643/1-e0143643/10</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Purpose: Zoledronic acid (ZOL) is a nitrogen-contg. bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway.  Its benefit for the prevention of skeletal complications due to bone metastases has been established.  However, the antitumor efficacy of ZOL, although suggested by multiple preclin. and clin. studies, has not yet been clin. proven.  We performed the present randomized Phase 2 trial to investigate the antitumor effect of ZOL with chemotherapy (CT).  Methods: Asian patients with HER2-neg. invasive breast cancer were randomly assigned to either the CT or CT + ZOL (CTZ) group.  One hundred and eighty-eight patients were randomized to either the CT group (n = 95) or the CTZ group (n = 93) from March 2010 to Apr. 2012, and 180 patients were assessed.  All patients received four cycles of FEC100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2), followed by 12 cycles of paclitaxel at 80 mg/m2 weekly.  ZOL (4 mg) was administered three to four times weekly for 7 wk to the patients in the CTZ group.  The primary endpoint was the pathol. complete response (pCR) rate, which was defined as no invasive cancer in the breast tissue specimen.  Safety was assessed in all patients who received at least one dose of the study drug.  Results: This randomized controlled trial indicated that the rates of pCR in CTZ group (14.8%) was doubled to CT group (7.7%), resp. (one-sided chi-square test, p = 0.068), though the addnl. efficacy of zoledronic acid was not demonstrated statistically.  The pCR rate in postmenopausal patients was 18.4% and 5.1% in the CTZ and CT groups, resp. (one-sided Fisher's exact test, p = 0.071), and that in patients with triple-neg. breast cancer was 35.3% and 11.8% in the CTZ and CT groups, resp. (one-sided Fisher's exact test, p = 0.112).  Thus the addn. of ZOL to neoadjuvant CT has potential anticancer benefits in postmenopausal patients and patients with triple-neg. breast cancer.  Further investigation is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWhR4lzWhdMbVg90H21EOLACvtfcHk0ljuY1UU3dwzYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOhsLjE&md5=9c4012e7ebb1fc6b938416a8a702a8a2</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0143643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0143643%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DTanino%26aufirst%3DH.%26aulast%3DHoriguchi%26aufirst%3DJ.%26aulast%3DMiura%26aufirst%3DD.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DTakao%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DYamagami%26aufirst%3DK.%26aulast%3DMiyashita%26aufirst%3DM.%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DShigeoka%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DKubota%26aufirst%3DT.%26aulast%3DAkazawa%26aufirst%3DK.%26aulast%3DKohno%26aufirst%3DN.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520zoledronic%2520acid%2520plus%2520chemotherapy%2520versus%2520chemotherapy%2520alone%2520as%2520neoadjuvant%2520treatment%2520of%2520HER2-negative%2520primary%2520breast%2520cancer%2520%2528JONIE%2520study%2529%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3De0143643%26doi%3D10.1371%2Fjournal.pone.0143643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, N.</span></span> <span> </span><span class="NLM_article-title">Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer</span>. <i>J. Surg. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>220</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.jss.2017.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.jss.2017.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29180210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCht7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=2017&pages=46-51&author=T.+Ishikawaauthor=K.+Akazawaauthor=Y.+Hasegawaauthor=H.+Taninoauthor=J.+Horiguchiauthor=D.+Miuraauthor=M.+Hayashiauthor=N.+Kohno&title=Survival+outcomes+of+neoadjuvant+chemotherapy+with+zoledronic+acid+for+HER2-negative+breast+cancer&doi=10.1016%2Fj.jss.2017.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer</span></div><div class="casAuthors">Ishikawa, Takashi; Akazawa, Kouhei; Hasegawa, Yoshie; Tanino, Hirokazu; Horiguchi, Jun; Miura, Daishu; Hayashi, Mitsuhiro; Kohno, Norio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-51</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A randomized phase 2 trial in women with HER2-neg. breast cancer has shown that adding zoledronic acid (ZOL) to neoadjuvant chemotherapy (CT) has potential anticancer benefits in postmenopausal and triple-neg. (TN) breast cancer patients.  We report the data for the secondary end point of disease-free survival (DFS).  Patients were randomly assigned to receive CT or CT + ZOL (CT-Z).  All patients received four cycles of FEC100 followed by 12 cycles of paclitaxel weekly.  ZOL (4 mg) was administered 3-4 times weekly for 7 wk to the CT-Z group patients.  The primary end point was pathol. complete response (pCR).  The secondary end points were the clin. response rates, rate of breast-conserving surgery, safety, and DFS.Of the 188 patients enrolled, 95 were assigned to the CT group and 93 to the CT-Z group.  DFS and overall survival were analyzed in 92 and 88 patients with the mean times of 5.15 y and 5.38 y, resp.  The 3-y DFS rate was 84.6% in the CT group and 90.8% in the CT-Z group (P = 0.188).  The particular benefit from ZOL for the neoadjuvant CT seen as improvement of the pCR rate was indicated in the 3-y DFS period for TN cancer cases (CT vs. CT-Z: 70.6% vs. 94.1%) but not for postmenopausal cases.  ZOL did not improve DFS when combined with CT.  However, the improvement of the pCR rate translated to survival outcomes in TN breast cancer.  The short-term application of ZOL may not be sufficient to improve the outcome in postmenopausal patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKZwmFVD_Mu7Vg90H21EOLACvtfcHk0ljuY1UU3dwzYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCht7bN&md5=734137f117e4b7b45b493fd8388236ea</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1016%2Fj.jss.2017.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jss.2017.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DAkazawa%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DTanino%26aufirst%3DH.%26aulast%3DHoriguchi%26aufirst%3DJ.%26aulast%3DMiura%26aufirst%3DD.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DKohno%26aufirst%3DN.%26atitle%3DSurvival%2520outcomes%2520of%2520neoadjuvant%2520chemotherapy%2520with%2520zoledronic%2520acid%2520for%2520HER2-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2017%26volume%3D220%26spage%3D46%26epage%3D51%26doi%3D10.1016%2Fj.jss.2017.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Messiha, F. S.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine: adverse effects and drug-drug interactions</span>. <i>J. Toxicol., Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.3109/15563659309025765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3109%2F15563659309025765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=8254702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADyaK2cXis1Sgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1993&pages=603-630&issue=4&author=F.+S.+Messiha&title=Fluoxetine%3A+adverse+effects+and+drug-drug+interactions&doi=10.3109%2F15563659309025765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine: adverse effects and drug-drug interactions</span></div><div class="casAuthors">Messiha, F.S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicology, Clinical Toxicology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">603-30</span>CODEN:
                <span class="NLM_cas:coden">JTCTDW</span>;
        ISSN:<span class="NLM_cas:issn">0731-3810</span>.
    </div><div class="casAbstract">A review with 251 refs.  This overview summarizes the major and minor side effects and drug interactions of fluoxetine.  The adverse reactions include the "serotonin syndrome", cardiovascular complications, extrapyramidal side effects such as akathisia, dyskinesias, and parkinsonian-like syndromes and an apparently increased risk of suicidality.  Fluoxetine-induced mania and hypomania, seizures and sexual disorders are evaluated along with minor symptoms of allergic reactions, stuttering, hematol. changes, psoriasis, and inappropriate secretion of the antidiuretic hormone.  The major fluoxetine-drug interactions involve the amino acids L-dopa and L-tryptophan, anorexiants, anticonvulsants, antidepressants, anxiolytics, calcium channel blockers, cyproheptadine, lithium salts, and drugs of abuse.  The underlying mechanism and the paradoxical effects of fluoxetine are addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVq2eeqBCWBrVg90H21EOLACvtfcHk0lgWk3od5dKUew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1Sgt74%253D&md5=4403e6c5e2b8087a8cca452a2cb50814</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.3109%2F15563659309025765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15563659309025765%26sid%3Dliteratum%253Aachs%26aulast%3DMessiha%26aufirst%3DF.%2BS.%26atitle%3DFluoxetine%253A%2520adverse%2520effects%2520and%2520drug-drug%2520interactions%26jtitle%3DJ.%2520Toxicol.%252C%2520Clin.%2520Toxicol.%26date%3D1993%26volume%3D31%26issue%3D4%26spage%3D603%26epage%3D630%26doi%3D10.3109%2F15563659309025765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulfkuhle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petricoin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seewaldt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibarra Drendall, C.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer</span>. <i>World J. Clin Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.5306/wjco.v6.i6.299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.5306%2Fwjco.v6.i6.299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26677444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC28risFyjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=299-311&issue=6&author=M.+Bowieauthor=P.+Pilieauthor=J.+Wulfkuhleauthor=S.+Lemauthor=A.+Hoffmanauthor=S.+Desaiauthor=E.+Petricoinauthor=A.+Carterauthor=A.+Ambroseauthor=V.+Seewaldtauthor=D.+Yuauthor=C.+Ibarra+Drendall&title=Fluoxetine+induces+cytotoxic+endoplasmic+reticulum+stress+and+autophagy+in+triple+negative+breast+cancer&doi=10.5306%2Fwjco.v6.i6.299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer</span></div><div class="casAuthors">Bowie Michelle; Pilie Patrick; Wulfkuhle Julia; Lem Siya; Hoffman Abigail; Desai Shraddha; Petricoin Emanuel; Carter Amira; Ambrose Adrian; Seewaldt Victoria; Yu Dihua; Ibarra Drendall Catherine</div><div class="citationInfo"><span class="NLM_cas:title">World journal of clinical oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">299-311</span>
        ISSN:<span class="NLM_cas:issn">2218-4333</span>.
    </div><div class="casAbstract">AIM:  To investigate the mechanism of action of lipophilic antidepressant fluoxetine (FLX) in representative molecular subtypes of breast cancer.  METHODS:  The anti-proliferative effects and mechanistic action of FLX in triple-negative (SUM149PT) and luminal (T47D and Au565) cancer cells and non-transformed MCF10A were investigated.  Reverse phase protein microarray (RPPM) was performed with and without 10 μmol/L FLX for 24 and 48 h to determine which proteins are significantly changed.  Viability and cell cycle analysis were also performed to determine drug effects on cell growth.  Western blotting was used to confirm the change in protein expression examined by RPPM or pursue other signaling proteins.  RESULTS:  The FLX-induced cell growth inhibition in all cell lines was concentration- and time-dependent but less pronounced in early passage MCF10A.  In comparison to the other lines, cell growth reduction in SUM149PT coincided with significant induction of endoplasmic reticulum (ER) stress and autophagy after 24 and 48 h of 10 μmol/L FLX, resulting in decreased translation of proteins along the receptor tyrosine kinase/Akt/mammalian target of rapamycin pathways.  The increase in autophagy marker, cleaved microtubule-associated protein 1 light chain 3, in SUM149PT after 24 h of FLX was likely due to increased metabolic demands of rapidly dividing cells and ER stress.  Consequently, the unfolded protein response mediated by double-stranded RNA-dependent protein kinase-like ER kinase resulted in inhibition of protein synthesis, growth arrest at the G1 phase, autophagy, and caspase-7-mediated cell death.  CONCLUSION:  Our study suggests a new role for FLX as an inducer of ER stress and autophagy, resulting in death of aggressive triple negative breast cancer SUM149PT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQW0ZJxbj5qqlHFYivNCdPRfW6udTcc2eZ9vASrYuUutrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28risFyjtg%253D%253D&md5=2d313d7146729302df3215c91c75bc2b</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.5306%2Fwjco.v6.i6.299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5306%252Fwjco.v6.i6.299%26sid%3Dliteratum%253Aachs%26aulast%3DBowie%26aufirst%3DM.%26aulast%3DPilie%26aufirst%3DP.%26aulast%3DWulfkuhle%26aufirst%3DJ.%26aulast%3DLem%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DPetricoin%26aufirst%3DE.%26aulast%3DCarter%26aufirst%3DA.%26aulast%3DAmbrose%26aufirst%3DA.%26aulast%3DSeewaldt%26aufirst%3DV.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DIbarra%2BDrendall%26aufirst%3DC.%26atitle%3DFluoxetine%2520induces%2520cytotoxic%2520endoplasmic%2520reticulum%2520stress%2520and%2520autophagy%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DWorld%2520J.%2520Clin%2520Oncol.%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D299%26epage%3D311%26doi%3D10.5306%2Fwjco.v6.i6.299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span> <span> </span><span class="NLM_article-title">Phenothiazine antipsychotics exhibit dual properties in pseudo-allergic reactions: Activating MRGPRX2 and inhibiting the H1 receptor</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2019.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.molimm.2019.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31051313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2019&pages=118-127&author=Y.+Houauthor=D.+Cheauthor=D.+Weiauthor=C.+Wangauthor=Y.+Xieauthor=K.+Zhangauthor=J.+Caoauthor=J.+Fuauthor=N.+Zhouauthor=H.+He&title=Phenothiazine+antipsychotics+exhibit+dual+properties+in+pseudo-allergic+reactions%3A+Activating+MRGPRX2+and+inhibiting+the+H1+receptor&doi=10.1016%2Fj.molimm.2019.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Phenothiazine antipsychotics exhibit dual properties in pseudo-allergic reactions: Activating MRGPRX2 and inhibiting the H1 receptor</span></div><div class="casAuthors">Hou, Yajing; Che, Delu; Wei, Di; Wang, Cheng; Xie, Yitong; Zhang, Kaining; Cao, Jiao; Fu, Jia; Zhou, Nan; He, Huaizhen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118-127</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Phenothiazines are a class of antipsychotics that share the same tricyclic structure and are widely used in clin. settings.  Adverse reactions from these drugs, however, have been regularly reported, with allergic skin reactions noted in some cases.  Nevertheless, the mechanisms underlying anaphylaxis by these drugs have not been described.  In the present study, we found that phenothiazine antipsychotics increased calcium mobilization and activated mast cells to release β-hexosaminidase, histamine, and tumor necrosis factor-α via Mas-related G-protein-coupled receptor member X2 (MRGPRX2) in vitro.  In addn., they induced histamine release in serum via Mrgprb2 in C57BL/6 mice without Evans blue extravasation or paw swell.  Further expts. indicated these drugs had good interaction with the histamine H1 receptor (H1R) and show an anti-calcium mobilization effect on H1R-HEK293 cells, which confirmed a potential antagonist effect of these drugs on the H1R.  The mol. docking and activity expts. indicated that the N-Me substitution on the side chain of these drugs played a significant role in activating MRGPRX2, while the phenothiazine tricyclic ring was assocd. with the inhibiting effect on the H1R.  Therefore, due to their dual properties of increasing histamine levels without obvious allergic symptoms, clinicians should be highly vigilant for damage from histamine accumulation and long-term inflammatory reactions during the clin. use of phenothiazine antipsychotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJG4l8VEtLkbVg90H21EOLACvtfcHk0lgWk3od5dKUew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12qsrY%253D&md5=6eedf9e8037101b02b75996d43824ada</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2019.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2019.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DY.%26aulast%3DChe%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DH.%26atitle%3DPhenothiazine%2520antipsychotics%2520exhibit%2520dual%2520properties%2520in%2520pseudo-allergic%2520reactions%253A%2520Activating%2520MRGPRX2%2520and%2520inhibiting%2520the%2520H1%2520receptor%26jtitle%3DMol.%2520Immunol.%26date%3D2019%26volume%3D111%26spage%3D118%26epage%3D127%26doi%3D10.1016%2Fj.molimm.2019.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henao, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peperzak, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichvar, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orebaugh, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skledar, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. A.</span></span> <span> </span><span class="NLM_article-title">Extrapyramidal symptoms following administration of oral perphenazine 4 or 8mg: An 11-year retrospective analysis</span>. <i>Eur. J. Anaesthesiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1097/EJA.0000000000000048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1097%2FEJA.0000000000000048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24503705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFektrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=231-235&issue=4&author=J.+P.+Henaoauthor=K.+A.+Peperzakauthor=A.+B.+Lichvarauthor=S.+L.+Orebaughauthor=S.+J.+Skledarauthor=M.+A.+Pippiauthor=B.+A.+Williams&title=Extrapyramidal+symptoms+following+administration+of+oral+perphenazine+4+or+8mg%3A+An+11-year+retrospective+analysis&doi=10.1097%2FEJA.0000000000000048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Extrapyramidal symptoms following administration of oral perphenazine 4 or 8mg: An 11-year retrospective analysis</span></div><div class="casAuthors">Henao, John P.; Peperzak, Katherin A.; Lichvar, Alicia B.; Orebaugh, Steven L.; Skledar, Susan J.; Pippi, Michael A.; Williams, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Anaesthesiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">231-235</span>CODEN:
                <span class="NLM_cas:coden">EJANEG</span>;
        ISSN:<span class="NLM_cas:issn">0265-0215</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Perphenazine is a treatment option in postoperative nausea and vomiting (PONV) prophylaxis.  Chronic administration and high dose are known to cause extrapyramidal system (EPS) dysfunction at a frequency of 8%, but the incidence of acute EPS after a single 4 or 8mg dose is unknown.  Objective: A retrospective anal. of patient medication billing data and departmental quality records was performed (Jan. 2001 to 10 July 2012) to identify patients who experienced EPS dysfunction after oral perphenazine.  Design: A retrospective anal.  Setting: Surgical outpatients presenting to any one of 10 hospitals in the area of Pittsburgh, Pennsylvania, USA.  Patients: Overall, 45766 patients received 4 or 8mg of perphenazine before same-day surgery.  Main outcome measures: EPS dysfunction was defined as acute dystonia, akathisia or pseudoparkinsonism.  Records were reviewed to det. the likely no. of reactions to perphenazine, the nature of these reactions and impact on patient care.  Results: There were four 'likely' cases of EPS dysfunction, and two 'possible' cases.  Five reported events were consistent with akathisia, with the sixth being a dystonic reaction.  All six patients had resoln. of symptoms, with five receiving i.v. diphenhydramine for treatment.  The incidence of EPS dysfunction was 1.3 events per 10000 patients (95% confidence interval (CI) 0.4 to 3.0, based on six events).  All patients who experienced reactions pre-operatively were able to proceed to surgery without complications or delay.  One patient required unplanned admission and 3-h observation owing to sedation from diphenhydramine.  The incidence of EPS dysfunction after oral perphenazine is low.  Reactions that did occur were mild and easily treated.  Conclusion: Given the infrequent side effects, this single, low dose of perphenazine should be encouraged as a low-risk adjunct to any multimodal PONV prophylaxis regimen, based on the selection criteria described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQMCjfqCBTLVg90H21EOLACvtfcHk0likWIr6uMrPmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFektrs%253D&md5=55baf8908c2105c6350f70adcaadcdfb</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1097%2FEJA.0000000000000048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FEJA.0000000000000048%26sid%3Dliteratum%253Aachs%26aulast%3DHenao%26aufirst%3DJ.%2BP.%26aulast%3DPeperzak%26aufirst%3DK.%2BA.%26aulast%3DLichvar%26aufirst%3DA.%2BB.%26aulast%3DOrebaugh%26aufirst%3DS.%2BL.%26aulast%3DSkledar%26aufirst%3DS.%2BJ.%26aulast%3DPippi%26aufirst%3DM.%2BA.%26aulast%3DWilliams%26aufirst%3DB.%2BA.%26atitle%3DExtrapyramidal%2520symptoms%2520following%2520administration%2520of%2520oral%2520perphenazine%25204%2520or%25208mg%253A%2520An%252011-year%2520retrospective%2520analysis%26jtitle%3DEur.%2520J.%2520Anaesthesiol.%26date%3D2014%26volume%3D31%26issue%3D4%26spage%3D231%26epage%3D235%26doi%3D10.1097%2FEJA.0000000000000048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barajas-Martinez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span> <span> </span><span class="NLM_article-title">Acquired short QT syndrome in a cancer patient treated with Toad</span>. <i>Pace.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1275</span>, <span class="refDoi"> DOI: 10.1111/pace.13708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1111%2Fpace.13708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3M7gs1yrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=1273-1275&issue=9&author=Y.+Huangauthor=Y.+Xuauthor=H.+Barajas-Martinezauthor=D.+Hu&title=Acquired+short+QT+syndrome+in+a+cancer+patient+treated+with+Toad&doi=10.1111%2Fpace.13708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired short QT syndrome in a cancer patient treated with Toad</span></div><div class="casAuthors">Huang Yan; Hu Dan; Huang Yan; Hu Dan; Xu Yong; Barajas-Martinez Hector</div><div class="citationInfo"><span class="NLM_cas:title">Pacing and clinical electrophysiology : PACE</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1273-1275</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although drug-induced short QT syndrome (SQTS) has been recognized, we currently report the first acquired SQTS case induced by bufotalinin (toad, an antineoplastic drug), which is a traditional Chinese folk prescription.  It has cross reaction with digoxin and affects the Na(+) -K(+) -ATPase, the SR Ca(2+) release from ryanodine receptor-2 (RyR2), the reactive oxygen species (ROS) production from the mitochondria.  The case presented with bradycardia, extreme QT shortening, and sinoatrial block that were resolved after gastric lavage, rehydration, electrolyte (hyperkalemia, hyponatremia, hypocalcemia) correction, and atropine injection.  Clinicians should recognize a potential association between toad poisoning and SQTS from this case.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBt3xiNPRhrlw2ofyr07jXfW6udTcc2ebY5vWLlw2sX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7gs1yrtw%253D%253D&md5=a1a307844cca8d1be51013b31fdf62ce</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1111%2Fpace.13708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpace.13708%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBarajas-Martinez%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DD.%26atitle%3DAcquired%2520short%2520QT%2520syndrome%2520in%2520a%2520cancer%2520patient%2520treated%2520with%2520Toad%26jtitle%3DPace.%26date%3D2019%26volume%3D42%26issue%3D9%26spage%3D1273%26epage%3D1275%26doi%3D10.1111%2Fpace.13708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Botteri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotmensz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipolla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanelotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colleoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandini, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1007/s10549-013-2654-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-013-2654-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23912960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wrsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=567-575&issue=3&author=E.+Botteriauthor=E.+Munzoneauthor=N.+Rotmenszauthor=C.+Cipollaauthor=V.+De+Giorgiauthor=B.+Santilloauthor=A.+Zanelottiauthor=L.+Adamoliauthor=M.+Colleoniauthor=G.+Vialeauthor=A.+Goldhirschauthor=S.+Gandini&title=Therapeutic+effect+of+%CE%B2-blockers+in+triple-negative+breast+cancer+postmenopausal+women&doi=10.1007%2Fs10549-013-2654-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women</span></div><div class="casAuthors">Botteri, Edoardo; Munzone, Elisabetta; Rotmensz, Nicole; Cipolla, Carlo; De Giorgi, Vincenzo; Santillo, Barbara; Zanelotti, Arnaldo; Adamoli, Laura; Colleoni, Marco; Viale, Giuseppe; Goldhirsch, Aron; Gandini, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-575</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Beta-blockers (BB) drugs have been used for decades worldwide, mainly to treat hypertension.  However, in recent epidemiol. studies, BBs were suggested to improve cancer prognosis.  In the wake of this evidence, we evaluated the possible therapeutic effect of BBs in triple-neg. breast cancer (TNBC) patients.  We identified 800 postmenopausal women operated between 1997 and 2008 for early primary TNBC.  The effect of BB intake on the risk of breast cancer (BC) recurrence and death was evaluated through competing risk and Cox regression survival models.  At cancer diagnosis, 74 (9.3 %) women out of 800 were BBs users.  Median age was 62 years in BB users and 59 years in non-users (P = 0.02).  BB users and non-users were similarly distributed by all tumor characteristics.  The 5-yr cumulative incidence of BC-related events was 13.6 % in BB users and 27.9 % in non-users (P = 0.02).  The beneficial impact of BBs remained statistically significant at multivariable anal. (HR, 0.52; 95 % CI 0.28-0.97), after the adjustment for age, tumor stage, and treatment, peritumoral vascular invasion and use of other antihypertensive drugs, antithrombotics, and statins.  Adjusted HRs for metastases and for BC deaths were 0.32 (95 % CI 0.12-0.90) and 0.42 (95 % CI 0.18-0.97), resp., in favor of BBs.  Hypertension, other antihypertensive drugs, antithrombotics, and statins did not impact prognosis.  In this series of postmenopausal TNBC patients, BB intake was assocd. with a significantly decreased risk of BC-related recurrence, metastasis, and BC death.  Innovative therapeutic strategies including BBs should be urgently explored in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHfmyF95Zvg7Vg90H21EOLACvtfcHk0likWIr6uMrPmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wrsr3E&md5=0dac95baf551245b5b0a27cbd62218a0</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2654-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2654-3%26sid%3Dliteratum%253Aachs%26aulast%3DBotteri%26aufirst%3DE.%26aulast%3DMunzone%26aufirst%3DE.%26aulast%3DRotmensz%26aufirst%3DN.%26aulast%3DCipolla%26aufirst%3DC.%26aulast%3DDe%2BGiorgi%26aufirst%3DV.%26aulast%3DSantillo%26aufirst%3DB.%26aulast%3DZanelotti%26aufirst%3DA.%26aulast%3DAdamoli%26aufirst%3DL.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DGandini%26aufirst%3DS.%26atitle%3DTherapeutic%2520effect%2520of%2520%25CE%25B2-blockers%2520in%2520triple-negative%2520breast%2520cancer%2520postmenopausal%2520women%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D140%26issue%3D3%26spage%3D567%26epage%3D575%26doi%3D10.1007%2Fs10549-013-2654-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melhem-Bertrandt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-Macgregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conzen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span> <span> </span><span class="NLM_article-title">Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">2645</span>– <span class="NLM_lpage">2652</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.33.4441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2010.33.4441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21632501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2645-2652&issue=19&author=A.+Melhem-Bertrandtauthor=M.+Chavez-Macgregorauthor=X.+Leiauthor=E.+Brownauthor=R.+Leeauthor=F.+Meric-Bernstamauthor=A.+Soodauthor=S.+Conzenauthor=G.+Hortobagyiauthor=A.+Gonzalez-Angulo&title=Beta-blocker+use+is+associated+with+improved+relapse-free+survival+in+patients+with+triple-negative+breast+cancer&doi=10.1200%2FJCO.2010.33.4441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer</span></div><div class="casAuthors">Melhem-Bertrandt, Amal; Chavez-MacGregor, Mariana; Lei, Xiudong; Brown, Erika N.; Lee, Richard T.; Meric-Bernstam, Funda; Sood, Anil K.; Conzen, Suzanne D.; Hortobagyi, Gabriel N.; Gonzalez-Angulo, Ana-Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2645-2652</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To examine the assocn. between beta-blocker (BB) intake, pathol. complete response (pCR) rates, and survival outcomes in patients with breast cancer treated with neoadjuvant chemotherapy.  Patients and Methods: We retrospectively reviewed 1,413 patients with breast cancer who received neoadjuvant chemotherapy between 1995 and 2007.  Patients taking BBs at the start of neoadjuvant therapy were compared with patients with no BB intake.  Rates of pCR between the groups were compared using a χ2 test.  Cox proportional hazards models were fitted to det. the assocn. between BB intake, relapse-free survival (RFS), and overall survival (OS).  Results: Patients who used BBs (n = 102) were compared with patients (n = 1,311) who did not.  Patients receiving BBs tended to be older and obese (P < .001).  The proportion of pCR was not significantly different between the groups (P = .48).  After adjustment for age, race, stage, grade, receptor status, lymphovascular invasion, body mass index, diabetes, hypertension, and angiotensin-converting enzyme inhibitor use, BB intake was assocd. with a significantly better RFS (hazard ratio HR), 0.52; 95% CI, 0.31 to 0.88 but not OS (P = .09).  Among patients with triple-neg. breast cancer (TNBC; n = 377), BB intake was assocd. with improved RFS (HR, 0.30; 95% CI, 0.10 to 0.87; P = .027) but not OS (HR, 0.35; 95% CI, 0.12 to 1.00; P = .05).  Conclusion: In this study, BB intake was assocd. with improved RFS in all patients with breast cancer and in patients with TNBC.  Addnl. studies evaluating the potential benefits of beta-adrenergic blockade on breast cancer recurrence with a focus on TNBC are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6hmqxs7-yM7Vg90H21EOLACvtfcHk0ljf1WBc3zvFmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWltbo%253D&md5=c7681c52976af8156daf3dbb02941280</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.4441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.4441%26sid%3Dliteratum%253Aachs%26aulast%3DMelhem-Bertrandt%26aufirst%3DA.%26aulast%3DChavez-Macgregor%26aufirst%3DM.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DSood%26aufirst%3DA.%26aulast%3DConzen%26aufirst%3DS.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26atitle%3DBeta-blocker%2520use%2520is%2520associated%2520with%2520improved%2520relapse-free%2520survival%2520in%2520patients%2520with%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3D19%26spage%3D2645%26epage%3D2652%26doi%3D10.1200%2FJCO.2010.33.4441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pituskin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J.</span></span> <span> </span><span class="NLM_article-title">Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: A retrospective analysis of the ROSE/TRIO-012 study</span>. <i>Annals of oncology.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1836</span>– <span class="NLM_lpage">1841</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdx264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28520849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1crovFehtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=1836-1841&issue=8&author=G.+Speraauthor=R.+Frescoauthor=H.+Fungauthor=J.+Dyckauthor=E.+Pituskinauthor=I.+Patersonauthor=J.+Mackey&title=Beta+blockers+and+improved+progression-free+survival+in+patients+with+advanced+HER2+negative+breast+cancer%3A+A+retrospective+analysis+of+the+ROSE%2FTRIO-012+study&doi=10.1093%2Fannonc%2Fmdx264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study</span></div><div class="casAuthors">Spera G; Fresco R; Fung H; Dyck J R B; Pituskin E; Pituskin E; Mackey J R; Paterson I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1836-1841</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Recent retrospective studies suggest that beta-adrenergic blocking drugs (BB) are associated with improved outcomes in patients with a range of cancers.  Although limited and discordant data suggest that BB may increase overall survival (OS) in localized breast cancer (BC), there is no information on the effects of BB in women with advanced BC.  Patients and methods:  To explore the association between BB use and BC outcomes, we retrospectively reviewed ROSE/TRIO-012, a double-blinded, multinational phase III trial that randomized 1144 patients with HER2-negative advanced BC to first-line docetaxel in combination with ramucirumab or placebo.  We compared progression-free survival (PFS), OS, overall response rate, and clinical benefit rate in patients who received BB to those who did not.  Results:  153/1144 (13%) patients received BB; 62% prior to enrolment and 38% began after enrolment.  Median PFS in BB treated patients was longer than in patients who did not receive them (10.3 versus 8.3 months; HR 0.81; 95% CI 0.66-0.99; P = 0.038).  Patients treated with BB only after enrolment had even higher median PFS (15.5 versus 8.3 months, P < 0.001).  In the TNBC subset, median PFS was 13.0 months with BB, compared to 5.2 months without BB (HR 0.52; 95% CI 0.34-0.79; P = 0.002).  The benefit of BB intake in PFS was independent of treatment-emergent hypertension (P = 0.476) but associated with treatment arm (P = 0.037).  The test for interactions between BB and treatment arm was not significant (P = 0.276).  No differences were seen in OS, overall response rate, or clinical benefit rate.  A validation dataset analysis had consistent but less substantial improved outcomes for women with node positive operable breast cancer receiving BB in the BCIRG-005 trial.  Conclusions:  In this exploratory analysis, BB intake was associated with significant improvement in PFS, particularly in patients with TNBC and patients not previously exposed to BB.  Clinical trial number:  NCT00703326.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFuk9Z6vWG3-98rul4nhSdfW6udTcc2eZ6FW9n2z1dAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crovFehtA%253D%253D&md5=a4058d0907ce3cde1613776fc3f9f748</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx264%26sid%3Dliteratum%253Aachs%26aulast%3DSpera%26aufirst%3DG.%26aulast%3DFresco%26aufirst%3DR.%26aulast%3DFung%26aufirst%3DH.%26aulast%3DDyck%26aufirst%3DJ.%26aulast%3DPituskin%26aufirst%3DE.%26aulast%3DPaterson%26aufirst%3DI.%26aulast%3DMackey%26aufirst%3DJ.%26atitle%3DBeta%2520blockers%2520and%2520improved%2520progression-free%2520survival%2520in%2520patients%2520with%2520advanced%2520HER2%2520negative%2520breast%2520cancer%253A%2520A%2520retrospective%2520analysis%2520of%2520the%2520ROSE%252FTRIO-012%2520study%26jtitle%3DAnnals%2520of%2520oncology.%26date%3D2017%26volume%3D28%26issue%3D8%26spage%3D1836%26epage%3D1841%26doi%3D10.1093%2Fannonc%2Fmdx264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sardesai, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviano, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinger, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storniolo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauchle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althouse, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span> <span> </span><span class="NLM_article-title">Inhibiting fatty acid synthase in operable triple negative breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">584</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1200/JCO.2020.38.15_suppl.584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2020.38.15_suppl.584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31821065" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=584-584&author=S.+D.+Sardesaiauthor=A.+Thomasauthor=C.+Gallagherauthor=F.+Lynceauthor=Y.+L.+Ottavianoauthor=T.+J.+Ballingerauthor=B.+P.+Schneiderauthor=A.+M.+Stornioloauthor=A.+Bauchleauthor=S.+K.+Althouseauthor=S.+Perkinsauthor=J.+T.+Zhangauthor=K.+Miller&title=Inhibiting+fatty+acid+synthase+in+operable+triple+negative+breast+cancer&doi=10.1200%2FJCO.2020.38.15_suppl.584"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.584%26sid%3Dliteratum%253Aachs%26aulast%3DSardesai%26aufirst%3DS.%2BD.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DGallagher%26aufirst%3DC.%26aulast%3DLynce%26aufirst%3DF.%26aulast%3DOttaviano%26aufirst%3DY.%2BL.%26aulast%3DBallinger%26aufirst%3DT.%2BJ.%26aulast%3DSchneider%26aufirst%3DB.%2BP.%26aulast%3DStorniolo%26aufirst%3DA.%2BM.%26aulast%3DBauchle%26aufirst%3DA.%26aulast%3DAlthouse%26aufirst%3DS.%2BK.%26aulast%3DPerkins%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DK.%26atitle%3DInhibiting%2520fatty%2520acid%2520synthase%2520in%2520operable%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D584%26epage%3D584%26doi%3D10.1200%2FJCO.2020.38.15_suppl.584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernadez-Aya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span> <span> </span><span class="NLM_article-title">Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1211</span>, <span class="refDoi"> DOI: 10.1002/cncr.26439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fcncr.26439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21800293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVyhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=1202-1211&issue=5&author=S.+Bayraktarauthor=L.+Hernadez-Ayaauthor=X.+Leiauthor=F.+Meric-Bernstamauthor=J.+Littonauthor=L.+Hsuauthor=G.+Hortobagyiauthor=A.+Gonzalez-Angulo&title=Effect+of+metformin+on+survival+outcomes+in+diabetic+patients+with+triple+receptor-negative+breast+cancer&doi=10.1002%2Fcncr.26439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer</span></div><div class="casAuthors">Bayraktar, Soley; Hernadez-Aya, Leonel F.; Lei, Xiudong; Meric-Bernstam, Funda; Litton, Jennifer K.; Hsu, Limin; Hortobagyi, Gabriel N.; Gonzalez-Angulo, Ana M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1202-1211</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND: : Recent observational studies have shown that metformin use in diabetic patients decreases both cancer incidence and mortality.  Metformin use is also independently predictive of pathol. complete response.  In the current study, the authors explored the assocn. between metformin use and survival outcomes in patients with triple receptor-neg. breast cancer (TNBC) who were receiving adjuvant chemotherapy.  METHODS: : The Breast Cancer Management System database of The University of Texas MD Anderson Cancer Center identified 1448 women who received adjuvant chemotherapy for TNBC between 1995 and 2007.  Patients were categorized by diabetes status and metformin use.  The Kaplan-Meier product-limit method was used to calc. distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS).  Cox proportional hazards models were fit to det. the assocn. between metformin use and survival outcomes.  RESULTS: : The study cohort was comprised of 63 diabetic patients receiving treatment with metformin, 67 diabetic patients not receiving metformin, and 1318 nondiabetic patients.  Patients in the diabetic groups tended to be older (P = .005); more diabetic patients were postmenopausal (P = .0007), black (P = .0001), and obese (P < .0001).  At a median follow-up of 62 mo, there were no significant differences with regard to 5-yr DMFS (P = .23), RFS (P = .38), and OS (P = .58) between the 3 groups.  Compared with the metformin group, patients who did not receive metformin (hazard ratio [HR], 1.63; 95% confidence interval [95% CI], 0.87-3.06 [P = .13]) and nondiabetic patients (HR, 1.62; 95% CI, 0.97-2.71 [P = .06]) tended to have a higher risk of distant metastases.  CONCLUSIONS: : The findings of the current study suggest that metformin use during adjuvant chemotherapy does not significantly impact survival outcomes in diabetic patients with TNBC.  Cancer 2012;.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPYRGpl2FyFrVg90H21EOLACvtfcHk0ljf1WBc3zvFmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVyhsrg%253D&md5=34a0f257025123fdb9a6555423ccabb2</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1002%2Fcncr.26439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.26439%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DS.%26aulast%3DHernadez-Aya%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DHsu%26aufirst%3DL.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26atitle%3DEffect%2520of%2520metformin%2520on%2520survival%2520outcomes%2520in%2520diabetic%2520patients%2520with%2520triple%2520receptor-negative%2520breast%2520cancer%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26issue%3D5%26spage%3D1202%26epage%3D1211%26doi%3D10.1002%2Fcncr.26439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaloge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espié, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigal-Zafrani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertheau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinebretière, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spielmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savignoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, M.</span></span> <span> </span><span class="NLM_article-title">A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1007/s10549-010-0939-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-010-0939-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=20480225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFymu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2010&pages=429-437&issue=2&author=J.+Piergaauthor=S.+Delalogeauthor=M.+Espi%C3%A9author=E.+Brainauthor=B.+Sigal-Zafraniauthor=M.+Mathieuauthor=P.+Bertheauauthor=J.+Guinebreti%C3%A8reauthor=M.+Spielmannauthor=A.+Savignoniauthor=M.+Marty&title=A+multicenter+randomized+phase+II+study+of+sequential+epirubicin%2Fcyclophosphamide+followed+by+docetaxel+with+or+without+celecoxib+or+trastuzumab+according+to+HER2+status%2C+as+primary+chemotherapy+for+localized+invasive+breast+cancer+patients&doi=10.1007%2Fs10549-010-0939-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients</span></div><div class="casAuthors">Pierga, Jean-Yves; Delaloge, Suzette; Espie, Marc; Brain, Etienne; Sigal-Zafrani, Brigitte; Mathieu, Marie-Christine; Bertheau, Philippe; Guinebretiere, Jean Marc; Spielmann, Marc; Savignoni, Alexia; Marty, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">429-437</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by docetaxel with the randomized addn. of celecoxib in HER2 neg. patients or trastuzumab in HER2 pos. patients.  From May 2004 till Oct. 2007, 340 patients with stage II and III breast adenocarcinoma, ineligible for breast conserving surgery, received eight sequential three weekly cycles of EC-D [epirubicin (75 mg/m2)-cyclophosphamide (750 mg/m2) for four cycles followed by docetaxel (100 mg/m2) for four cycles].  HER2-neg. patients (N = 220) were randomized to receive concomitantly with docetaxel celecoxib 800 mg/day during cycles 5-8 or no addnl. treatment, while HER2-pos. patients confirmed by FISH (N = 120) were randomized to trastuzumab concomitant to docetaxel (8 mg/kg then 6 mg/kg IV every 3 wk) or no addnl. preoperative treatment.  In the HER2 neg. group, pCR (grade 1 and 2 of Chevallier's classification) was obsd. in 11.5 and 13% of patients treated without and with neoadjuvant Celecoxib, resp.  In the HER2 pos. group, pCR rate reached 26% in those who received neoadjuvant trastuzumab vs. 19% in the others.  There was no unexpected toxicity, no cardiac toxicity, and no toxic death.  Triple neg. breast cancers experience the highest pCR rate of 30%.  Celecoxib is not likely to improve pCR rates in addn. to EC-D in patients with HER2-neg. tumor.  In HER2-pos. tumor patients, trastuzumab added to ECD leads to increased pCR rates.  It was the only combination to deserve further study according to the two-stage Fleming's design used in this trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIwG7zqlwaxrVg90H21EOLACvtfcHk0ljh3XDPoq9KRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFymu7s%253D&md5=98b67e9dcf885acca4ce6b5b8beb3ec2</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1007%2Fs10549-010-0939-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-010-0939-3%26sid%3Dliteratum%253Aachs%26aulast%3DPierga%26aufirst%3DJ.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DEspi%25C3%25A9%26aufirst%3DM.%26aulast%3DBrain%26aufirst%3DE.%26aulast%3DSigal-Zafrani%26aufirst%3DB.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DBertheau%26aufirst%3DP.%26aulast%3DGuinebreti%25C3%25A8re%26aufirst%3DJ.%26aulast%3DSpielmann%26aufirst%3DM.%26aulast%3DSavignoni%26aufirst%3DA.%26aulast%3DMarty%26aufirst%3DM.%26atitle%3DA%2520multicenter%2520randomized%2520phase%2520II%2520study%2520of%2520sequential%2520epirubicin%252Fcyclophosphamide%2520followed%2520by%2520docetaxel%2520with%2520or%2520without%2520celecoxib%2520or%2520trastuzumab%2520according%2520to%2520HER2%2520status%252C%2520as%2520primary%2520chemotherapy%2520for%2520localized%2520invasive%2520breast%2520cancer%2520patients%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2010%26volume%3D122%26issue%3D2%26spage%3D429%26epage%3D437%26doi%3D10.1007%2Fs10549-010-0939-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debeb, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobágyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, W.</span></span> <span> </span><span class="NLM_article-title">Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation</span>. <i>Stem Cells Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.5966/sctm.2013-0204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.5966%2Fsctm.2013-0204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24833589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyisb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=849-856&issue=7&author=L.+Lacerdaauthor=J.+Reddyauthor=D.+Liuauthor=R.+Larsonauthor=L.+Liauthor=H.+Masudaauthor=T.+Brewerauthor=B.+Debebauthor=W.+Xuauthor=G.+Hortob%C3%A1gyiauthor=T.+Buchholzauthor=N.+Uenoauthor=W.+Woodward&title=Simvastatin+radiosensitizes+differentiated+and+stem-like+breast+cancer+cell+lines+and+is+associated+with+improved+local+control+in+inflammatory+breast+cancer+patients+treated+with+postmastectomy+radiation&doi=10.5966%2Fsctm.2013-0204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation</span></div><div class="casAuthors">Lacerda, Lara; Reddy, Jay P.; Liu, Diane; Larson, Richard; Li, Li; Masuda, Hiroko; Brewer, Takae; Debeb, Bisrat G.; Xu, Wei; Hortobagyi, Gabriel N.; Buchholz, Thomas A.; Ueno, Naoto T.; Woodward, Wendy A.</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">849-856</span>CODEN:
                <span class="NLM_cas:coden">SCTMC7</span>;
        ISSN:<span class="NLM_cas:issn">2157-6564</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Reported rates of local failure after adjuvant radiation for women with inflammatory breast cancer (IBC) and triple-neg. non-IBC are higher than those of women with receptor-expressing non-IBC.  These high rates of locoregional recurrence are potentially influenced by the contribution of radio-resistant cancer stem cells to these cancers.  Statins have been shown to target stem cells and improve disease-free survival among IBC patients.  We examd. simvastatin radiosensitization of multiple subtypes of breast cancer cell lines in vitro in monolayer and mammosphere-based clonogenic assays and examd. the therapeutic benefit of statin use on local control after postmastectomy radiation (PMRT) among IBC patients.  We found that simvastatin radiosensitizes mammosphere-initiating cells (MICs) of IBC cell lines (MDA-IBC3, SUM149, SUM190) and of the metaplastic, non-IBC triple-neg. receptor cell line (SUM159).  However, simvastatin radioprotects MICs of non-IBC cell lines MCF-7 and SKBR3.  In a retrospective clin. study of 519 IBC patients treated with PMRT, 53 patients used a statin.  On univariate anal., actuarial 3-yr local recurrence-free survival (LRFS) was higher among statin users, and on multivariate anal., triple neg. breast cancer, absence of lymphatic invasion, neoadjuvant pathol. tumor response to preoperative chemotherapy, and statin use were independently assocd. with higher LRFS.  In conclusion, patients with IBC and triple-neg. non-IBC breast cancer have the highest rates of local failure, and there are no available known radiosensitizers.  We report significant improvement in local control after PMRT among statin users with IBC and significant radiosensitization across triple-neg. and IBC cell lines of multiple subtypes using simvastatin.  These data suggest that simvastatin should be justified as a radiosensitizing agent by a prospective clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa5ttgSESxMrVg90H21EOLACvtfcHk0ljh3XDPoq9KRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyisb%252FL&md5=c494bd8a05e3831cc400c6f2f1531a3f</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.5966%2Fsctm.2013-0204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5966%252Fsctm.2013-0204%26sid%3Dliteratum%253Aachs%26aulast%3DLacerda%26aufirst%3DL.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLarson%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DBrewer%26aufirst%3DT.%26aulast%3DDebeb%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHortob%25C3%25A1gyi%26aufirst%3DG.%26aulast%3DBuchholz%26aufirst%3DT.%26aulast%3DUeno%26aufirst%3DN.%26aulast%3DWoodward%26aufirst%3DW.%26atitle%3DSimvastatin%2520radiosensitizes%2520differentiated%2520and%2520stem-like%2520breast%2520cancer%2520cell%2520lines%2520and%2520is%2520associated%2520with%2520improved%2520local%2520control%2520in%2520inflammatory%2520breast%2520cancer%2520patients%2520treated%2520with%2520postmastectomy%2520radiation%26jtitle%3DStem%2520Cells%2520Transl.%2520Med.%26date%3D2014%26volume%3D3%26issue%3D7%26spage%3D849%26epage%3D856%26doi%3D10.5966%2Fsctm.2013-0204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantziarka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziche, M.</span></span> <span> </span><span class="NLM_article-title">Repurposing of drugs for triple negative breast cancer: an overview</span>. <i>ecancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1071</span>, <span class="refDoi"> DOI: 10.3332/ecancer.2020.1071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3332%2Fecancer.2020.1071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32728387" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=1071&author=A.+Spiniauthor=S.+Donniniauthor=P.+Pantziarkaauthor=S.+Crispinoauthor=M.+Ziche&title=Repurposing+of+drugs+for+triple+negative+breast+cancer%3A+an+overview&doi=10.3332%2Fecancer.2020.1071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.3332%2Fecancer.2020.1071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3332%252Fecancer.2020.1071%26sid%3Dliteratum%253Aachs%26aulast%3DSpini%26aufirst%3DA.%26aulast%3DDonnini%26aufirst%3DS.%26aulast%3DPantziarka%26aufirst%3DP.%26aulast%3DCrispino%26aufirst%3DS.%26aulast%3DZiche%26aufirst%3DM.%26atitle%3DRepurposing%2520of%2520drugs%2520for%2520triple%2520negative%2520breast%2520cancer%253A%2520an%2520overview%26jtitle%3Decancer%26date%3D2020%26volume%3D14%26spage%3D1071%26doi%3D10.3332%2Fecancer.2020.1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truica, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.drup.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29145974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1M3itVaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=1-15&author=H.+Jiaauthor=C.+I.+Truicaauthor=B.+Wangauthor=Y.+Wangauthor=X.+Renauthor=H.+A.+Harveyauthor=J.+Songauthor=J.+M.+Yang&title=Immunotherapy+for+triple-negative+breast+cancer%3A+Existing+challenges+and+exciting+prospects&doi=10.1016%2Fj.drup.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects</span></div><div class="casAuthors">Jia Hongyan; Truica Cristina I; Harvey Harold A; Wang Bin; Wang Yanhong; Ren Xingcong; Song Jianxun; Yang Jin-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with breast tumors that do not express the estrogen receptor, the progesterone receptor, nor Her-2/neu are hence termed "triple negatives", and generally have a poor prognosis, with high rates of systemic recurrence and refractoriness to conventional therapy regardless of the choice of adjuvant treatment.  Thus, more effective therapeutic options are sorely needed for triple-negative breast cancer (TNBC), which occurs in approximately 20% of diagnosed breast cancers.  In recent years, exploiting intrinsic mechanisms of the host immune system to eradicate cancer cells has achieved impressive success, and the advances in immunotherapy have yielded potential new therapeutic strategies for the treatment of this devastating subtype of breast cancer.  It is anticipated that the responses initiated by immunotherapeutic interventions will explicitly target and annihilate tumor cells, while at the same time spare normal cells.  Various immunotherapeutic approaches have been already developed and tested, which include the blockade of immune checkpoints using neutralizing or blocking antibodies, induction of cytotoxic T lymphocytes (CTLs), adoptive cell transfer-based therapy, and modulation of the tumor microenvironment to enhance the activity of CTLs.  One of the most important areas of breast cancer research today is understanding the immune features and profiles of TNBC and devising novel immune-modulatory strategies to tackling TNBC, a subtype of breast cancer notorious for its poor prognosis and its imperviousness to conventional treatments.  On the optimal side, one can anticipate that novel, effective, and personalized immunotherapy for TNBC will soon achieve more success and impact clinical treatment of this disease which afflicts approximately 20% of patients with breast cancer.  In the present review, we highlight the current progress and encouraging developments in cancer immunotherapy, with a goal to discuss the challenges and to provide future perspectives on how to exploit a variety of new immunotherapeutic approaches including checkpoint inhibitors and neoadjuvant immunotherapy for the treatment of patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlGWXKBPOQGhKDYG3bNImrfW6udTcc2ebpj_jAwqv9dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3itVaqtw%253D%253D&md5=266b2920bffa364cefd3ccc5e5a599e6</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DH.%26aulast%3DTruica%26aufirst%3DC.%2BI.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DHarvey%26aufirst%3DH.%2BA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26atitle%3DImmunotherapy%2520for%2520triple-negative%2520breast%2520cancer%253A%2520Existing%2520challenges%2520and%2520exciting%2520prospects%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2017%26volume%3D32%26spage%3D1%26epage%3D15%26doi%3D10.1016%2Fj.drup.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, N.</span></span> <span> </span><span class="NLM_article-title">Cowpea mosaic virus immunotherapy combined with cyclophosphamide reduces breast cancer tumor burden and inhibits lung metastasis</span>. <i>Adv. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1802281</span>, <span class="refDoi"> DOI: 10.1002/advs.201802281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fadvs.201802281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MrhvF2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1802281&issue=16&author=H.+Caiauthor=C.+Wangauthor=S.+Shuklaauthor=N.+Steinmetz&title=Cowpea+mosaic+virus+immunotherapy+combined+with+cyclophosphamide+reduces+breast+cancer+tumor+burden+and+inhibits+lung+metastasis&doi=10.1002%2Fadvs.201802281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis</span></div><div class="casAuthors">Cai Hui; Wang Chao; Shukla Sourabh; Steinmetz Nicole F; Cai Hui; Wang Chao; Shukla Sourabh; Steinmetz Nicole F</div><div class="citationInfo"><span class="NLM_cas:title">Advanced science (Weinheim, Baden-Wurttemberg, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1802281</span>
        ISSN:<span class="NLM_cas:issn">2198-3844</span>.
    </div><div class="casAbstract">Patients with metastatic triple-negative breast cancer (TNBC) have a poor prognosis, so new therapies or drug combinations that achieve more effective and durable responses are urgently needed.  Here, a combination therapy using cowpea mosaic virus (CPMV) and low doses of cyclophosphamide (CPA) is developed with remarkable synergistic efficacy against 4T1 mouse tumors in vivo.  The combination therapy not only attenuates the growth of primary tumor and increases survival, but also suppresses distant tumor growth and reduces lung metastasis.  Mechanistic analysis indicates that the combination of CPMV and CPA increases the secretion of several cytokines, activates antigen-presenting cells, increases the abundance of tumor infiltrating T cells, and systematically reverses the immunosuppression.  These results show that the combination of CPMV in situ vaccination with chemotherapy may become a potent new strategy for the treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJQMguY9jFRDdblLE_E9PWfW6udTcc2ebpj_jAwqv9dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrhvF2isQ%253D%253D&md5=d06efad47cbd6539b37ec92b47170efa</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1002%2Fadvs.201802281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadvs.201802281%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DSteinmetz%26aufirst%3DN.%26atitle%3DCowpea%2520mosaic%2520virus%2520immunotherapy%2520combined%2520with%2520cyclophosphamide%2520reduces%2520breast%2520cancer%2520tumor%2520burden%2520and%2520inhibits%2520lung%2520metastasis%26jtitle%3DAdv.%2520Sci.%26date%3D2019%26volume%3D6%26issue%3D16%26spage%3D1802281%26doi%3D10.1002%2Fadvs.201802281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sperlich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teusch, N.</span></span> <span> </span><span class="NLM_article-title">Pseudopterosin inhibits proliferation and 3D invasion in triple-negative breast cancer by agonizing glucocorticoid receptor alpha</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1992</span>, <span class="refDoi"> DOI: 10.3390/molecules23081992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fmolecules23081992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWksLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=1992&issue=8&author=J.+Sperlichauthor=N.+Teusch&title=Pseudopterosin+inhibits+proliferation+and+3D+invasion+in+triple-negative+breast+cancer+by+agonizing+glucocorticoid+receptor+alpha&doi=10.3390%2Fmolecules23081992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudopterosin inhibits proliferation and 3D invasion in triple-negative breast cancer by agonizing glucocorticoid receptor alpha</span></div><div class="casAuthors">Sperlich, Julia; Teusch, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1992/1-1992/14</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pseudopterosin, produced by the sea whip of the genus Antillogorgia, possesses a variety of promising biol. activities, including potent anti-inflammatory effects.  However, few studies examd. pseudopterosin in the treatment of cancer cells and, to our knowledge, the ability to inhibit triple-neg. breast cancer (TNBC) proliferation or invasion has not been explored.  Thus, we evaluated the as-yet unknown mechanism of action of pseudopterosin: Pseudopterosin was able to inhibit proliferation of TNBC.  Interestingly, analyzing breast cancer cell proliferation after knocking down glucocorticoid receptor a(GRa) revealed that the antiproliferative effects of pseudopterosin were significantly inhibited when GRa expression was reduced.  Furthermore, pseudopterosin inhibited the invasion of MDA-MB-231 3D tumor spheroids embedded in an extracellular-like matrix.  Remarkably, the knockdown of GRa in 3D tumor spheroids revealed increased ability of cells to invade the surrounding matrix.  In a coculture, encompassing peripheral blood mononuclear cells (PBMC) and MDA-MB-231 cells, and the prodn. of interleukin 6 (IL-6) and interleukin 8 (IL-8) significantly increased compared to a monoculture.  Notably, pseudopterosin indicated to block cytokine elevation, representing key players in tumor progression in the coculture.  Thus, our results reveal pseudopterosin treatment as a potential novel approach in TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf4IE2zDC62bVg90H21EOLACvtfcHk0ljZ4vFtOFQttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWksLnM&md5=37aef8ce542260bc82870eacac0e266a</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23081992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23081992%26sid%3Dliteratum%253Aachs%26aulast%3DSperlich%26aufirst%3DJ.%26aulast%3DTeusch%26aufirst%3DN.%26atitle%3DPseudopterosin%2520inhibits%2520proliferation%2520and%25203D%2520invasion%2520in%2520triple-negative%2520breast%2520cancer%2520by%2520agonizing%2520glucocorticoid%2520receptor%2520alpha%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D1992%26doi%3D10.3390%2Fmolecules23081992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vikas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borcherding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">The clinical promise of immunotherapy in triple-negative breast cancer</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">6823</span>– <span class="NLM_lpage">6833</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S185176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.2147%2FCMAR.S185176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30573992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOgtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=6823-6833&author=P.+Vikasauthor=N.+Borcherdingauthor=W.+Zhang&title=The+clinical+promise+of+immunotherapy+in+triple-negative+breast+cancer&doi=10.2147%2FCMAR.S185176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical promise of immunotherapy in triple-negative breast cancer</span></div><div class="casAuthors">Vikas, Praveen; Borcherding, Nicholas; Zhang, Weizhou</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6823-6833</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a heterogeneous disease with poorer outcomes compared to other breast cancer subtypes.  Contributing to the worse prognosis in TNBC is the higher rates of relapse and rapid progression after relapse.  Advances in targeted therapeutics and conventional chemotherapy for TNBC have been stymied due to the lack of specific targets.  Moreover, the responses to chemotherapy in TNBC lack durability, partially accounting for the higher rates of relapse.  Immunotherapy, notably immune-checkpoint blockade, has shown to improve survival and maintain robust antitumor responses in both hematol. and solid malignancies.  Unlike lung cancer, melanoma, and bladder cancer, most breast cancers are not inherently immunogenic and typically have low T cell infiltration.  However, among breast cancer subtypes, TNBC is characterized by greater tumor immune infiltrate and higher degree of stromal and intratumoral tumor-infiltrating lymphocytes (TILs), a predictive marker for responses to immunotherapy.  Moreover, in TNBC, the high no. of stromal TILs is predictive of more favorable survival outcomes and response to chemotherapy.  Immunotherapy is being extensively explored in TNBC and clin. trials are showing some promising results.  This article focuses on the rationale for immunotherapy in TNBC, to explore and discuss preclin. data, results from early clin. trials, and to summarize some ongoing trials.  We will also discuss the potential application of immunotherapy in TNBC from a clinician's perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxCHe7L9bI5bVg90H21EOLACvtfcHk0lg8ji2hyrLV3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOgtLfO&md5=2668b7aeaf1269897ccc55604dfb7b24</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S185176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S185176%26sid%3Dliteratum%253Aachs%26aulast%3DVikas%26aufirst%3DP.%26aulast%3DBorcherding%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DThe%2520clinical%2520promise%2520of%2520immunotherapy%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2018%26volume%3D10%26spage%3D6823%26epage%3D6833%26doi%3D10.2147%2FCMAR.S185176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Philipovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydarian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaur, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy of neoadjuvant adjuvant chemotherapy in hispanic/latino (H/L) women with local or locally advanced triple-negative breast cancer (TNBC)</span>. <i>In Vivo</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.21873/invivo.11594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.21873%2Finvivo.11594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31280213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWltL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=1227-1234&issue=4&author=A.+Philipovskiyauthor=J.+Corralauthor=K.+Dwivediauthor=R.+Heydarianauthor=S.+Gaur&title=Efficacy+of+neoadjuvant+adjuvant+chemotherapy+in+hispanic%2Flatino+%28H%2FL%29+women+with+local+or+locally+advanced+triple-negative+breast+cancer+%28TNBC%29&doi=10.21873%2Finvivo.11594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of neoadjuvant versus adjuvant chemotherapy in hispanic/latino (H/L) women with local or locally advanced triple-negative breast cancer (TNBC)</span></div><div class="casAuthors">Philipovskiy, Alexander; Corral, Javier; Dwivedi, Kumar Alok; Heydarian, Rosalinda; Gaur, Sumit</div><div class="citationInfo"><span class="NLM_cas:title">In Vivo</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1227-1234</span>CODEN:
                <span class="NLM_cas:coden">IVIVE4</span>;
        ISSN:<span class="NLM_cas:issn">1791-7549</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background/Aim: The aim of the study was to investigate the efficacy of neoadjuvant and chemotherapy (NACT) and adjuvant chemotherapy (ACT) in Hispanic/Latino (H/L) women with TNBC.  Patients and Methods: We reviewed the charts of patients with TNBC, stages I-III, treated at TTUHSC from 2006 to 2016.  Overall survival (OS) and recurrence-free survival (RFS) were estd. and compared between the treatment groups.  Kaplan-Meier curve and Cox proportional hazards regression analyses were conducted to est. unadjusted and adjusted effects of NACT compared to ACT.  Results: A total of 104 patients with TNBC, 30 (29%) received NACT and 74 (71%) ACT.  Women undergoing NACT were younger, with a mean age of 50.8 years.  Of the 30 patients who received NACT, 12 (40%) had pathol. complete response (pCR).  Women who achieved pCR had an excellent RFS (HR=0.5, p=0.001).  Women with residual cancer after NACT had worse outcome compared to patients who received ACT (HR=1.7, p=0.005).  Conclusion: pCR to NACT is a powerful surrogate for OS in H/L women with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDky7JcY7zg7Vg90H21EOLACvtfcHk0lg8ji2hyrLV3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWltL7O&md5=37602b386a1cb4e452f206ba5efa8046</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.21873%2Finvivo.11594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21873%252Finvivo.11594%26sid%3Dliteratum%253Aachs%26aulast%3DPhilipovskiy%26aufirst%3DA.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DDwivedi%26aufirst%3DK.%26aulast%3DHeydarian%26aufirst%3DR.%26aulast%3DGaur%26aufirst%3DS.%26atitle%3DEfficacy%2520of%2520neoadjuvant%2520adjuvant%2520chemotherapy%2520in%2520hispanic%252Flatino%2520%2528H%252FL%2529%2520women%2520with%2520local%2520or%2520locally%2520advanced%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DIn%2520Vivo%26date%3D2019%26volume%3D33%26issue%3D4%26spage%3D1227%26epage%3D1234%26doi%3D10.21873%2Finvivo.11594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tian  Xu</span>, <span class="hlFld-ContribAuthor ">Jifa  Zhang</span>, <span class="hlFld-ContribAuthor ">Chengcan  Yang</span>, <span class="hlFld-ContribAuthor ">Ryszard  Pluta</span>, <span class="hlFld-ContribAuthor ">Guan  Wang</span>, <span class="hlFld-ContribAuthor ">Tinghong  Ye</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>219 </em>, 113424. <a href="https://doi.org/10.1016/j.ejmech.2021.113424" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113424%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252Boptimization%252Bof%252B3-bromo-N%2525E2%252580%252599-%2525284-hydroxybenzylidene%252529-4-methylbenzohydrazide%252Bderivatives%252Bas%252BmTOR%252Binhibitors%252Bthat%252Binduce%252Bautophagic%252Bcell%252Bdeath%252Band%252Bapoptosis%252Bin%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DXu%26aufirst%3DTian%26date%3D2021%26volume%3D219%26spage%3D113424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0023.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. TNBC subtypes, characteristics, and potential targeted drugs. Based on the gene-expression signatures and biological functions, TNBCs are classified as basal-like 1 TNBC (BL1), basal-like 2 TNBC (BL2), immunomodulatory TNBC (IM), mesenchymal-like TNBC (M), mesenchymal-stem-like TNBC (MSL), the luminal androgen receptor TNBC (LAR), and others. BL1 TNBCs are sensitive to PARP inhibitors; BL2 TNBCs are sensitive to MET and EGFR inhibitors; M TNBCs and MSL TNBCs are sensitive to PI3K/AKT inhibitors; IM TNBCs are sensitive to immunotherapy; LAR TNBCs are sensitive to AR antagonists and CDK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Potential targeted small-molecule drugs and relevant signaling pathways in TNBC therapies. TNBCs are often characterized by excessive activation of growth factor pathways, such as EGFR, c-MET and VEGFR regulated PI3K-AKT-mTOR, Ras-Raf-MEK-ERK, SRC-STAT pathways and JAK-STATS signaling. These pathways play an important role in the proliferation and progression of TNBCs. In addition, PARP is overactivated and involved in DNA repair in response to environmental stress. Overexpression of CDKs and BRD4 also contributes to the progression of TNBC. Moreover, mTOR-related overexpression of eEF2K inhibits the extension of the polypeptide chain during protein synthesis to help the cell adapt to the adverse conditions of nutrition or energy deficiency. Of note, autophagy is also inhibited in TNBC. Thus, the corresponding small-molecule compounds are applied in targeted therapies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of <b>1</b>–<b>5</b> as EGFR inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of <b>6</b>–<b>9</b> as MEK/ERK inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of <b>10</b>–<b>13</b> as PI3K/AKT/mTOR inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of <b>14</b>–<b>18</b> as PARP inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of <b>20</b>–<b>31</b> as JAK/STAT3 inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of <b>32</b>–<b>34</b> as SRC inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of <b>35</b> and <b>36</b> as ULK1 inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of <b>37</b>–<b>41</b> as eEF2K inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of <b>42</b>–<b>44</b> as BRD4 inhibitors in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of <b>85</b>–<b>99</b> as double/multiple targeted small-molecule drugs in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of <b>100</b>–<b>102</b> related to EGFR inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of <b>103</b>–<b>118</b> related to MEK/ERK inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of <b>119</b>–<b>132</b> related to PI3K/Akt/mTOR inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of <b>133</b>–<b>135</b> related to PARP inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of <b>136</b> related to CDK4/6 inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structures of <b>137</b>–<b>144</b> related to some other target inhibitors or activators in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Chemical structures of <b>145</b>–<b>155</b> related to chemotherapy in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of <b>156</b> and <b>157</b> related to other treatment methods in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structures of <b>158</b>–<b>160</b> related to EGFR inhibitors in combination strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/medium/jm0c01180_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures of <b>161</b>–<b>165</b> for drug repurposing in TNBC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01180/20210305/images/large/jm0c01180_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01180&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30106" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30106" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 217 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2019</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.3322/caac.21551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3322%2Fcaac.21551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30620402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3cnptFCntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=7-34&issue=1&author=R.+Siegelauthor=K.+Millerauthor=A.+Jemal&title=Cancer+statistics%2C+2019&doi=10.3322%2Fcaac.21551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2019</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data, available through 2016, were collected by the National Center for Health Statistics.  In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States.  Over the past decade of data, the cancer incidence rate (2006-2015) was stable in women and declined by approximately 2% per year in men, whereas the cancer death rate (2007-2016) declined annually by 1.4% and 1.8%, respectively.  The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.  Although the racial gap in cancer mortality is slowly narrowing, socioeconomic inequalities are widening, with the most notable gaps for the most preventable cancers.  For example, compared with the most affluent counties, mortality rates in the poorest counties were 2-fold higher for cervical cancer and 40% higher for male lung and liver cancers during 2012-2016.  Some states are home to both the wealthiest and the poorest counties, suggesting the opportunity for more equitable dissemination of effective cancer prevention, early detection, and treatment strategies.  A broader application of existing cancer control knowledge with an emphasis on disadvantaged groups would undoubtedly accelerate progress against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBHJFurk9wJJp6t8nS6Nc3fW6udTcc2ebwZkAQRqPYrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnptFCntA%253D%253D&md5=02ba708e57d7573ebe0649182325b52c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21551%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202019%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2019%26volume%3D69%26issue%3D1%26spage%3D7%26epage%3D34%26doi%3D10.3322%2Fcaac.21551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, J. S.</span></span> <span> </span><span class="NLM_article-title">Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers</span>. <i>Histol Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.14670/HH-27.1481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.14670%2FHH-27.1481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23018247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FgslertA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=1481-1493&issue=11&author=J.+Choiauthor=W.+H.+Jungauthor=J.+S.+Koo&title=Clinicopathologic+features+of+molecular+subtypes+of+triple+negative+breast+cancer+based+on+immunohistochemical+markers&doi=10.14670%2FHH-27.1481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers</span></div><div class="casAuthors">Choi Junjeong; Jung Woo-Hee; Koo Ja Seung</div><div class="citationInfo"><span class="NLM_cas:title">Histology and histopathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1481-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This study was performed to identify molecular subtypes of triple negative breast carcinoma (TNBC) based on immunohistochemical markers.  We prepared a tissue microarray from TNBC specimens of 122 patients and performed immunohistochemical staining for cytokeratin (CK) 5/6, epidermal growth factor receptor (EGFR), claudin 3, claudin 4, claudin 7, E-cadherin, androgen receptor (AR), and gammma-glutamyltransferase (GGT1).  Based on immunoreactivity, tumors were classified into basal-like (CK5/6 positive and/or EGFR positive), molecular apocrine (AR positive and/or GGT1 positive), claudin low (claudin 3, claudin 4, claudin 7 negative and/or E-cadherin negative), mixed (tumors belonging to two or more subtypes), and null (tumors not matching any other subtypes).  The TNBC specimens of 122 patients included 27 basal-like (22.1%), 28 claudin low (23.0%), 12 molecular apocrine (9.8%), 23 mixed (18.9%) and 32 null (26.2%) subtype tumors.  The molecular apocrine subtype showed the highest percentage of apocrine differentiation and the lowest Ki-67 labeling index (p<0.001 and p=0.040, respectively).  In univariate analysis, tumor cell discohesiveness was related with shorter disease free survival (DFS) and overall survival (OS) (p=0.005, and 0.002, respectively).  In multivariate analysis, tumor cell discohesiveness was related with shorter OS and CK5/6 positivity (p=0.018), and claudin 7 positivity (p=0.019) was related with shorter DFS.  In conclusion, using immunohistochemical staining for CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, AR, and GGT1, we categorized TNBC into a basal-like subtype, a claudin low subtype, a molecular apocrine subtype, a mixed subtype showing characteristics of two different subtypes, and a null subtype not belonging to any of the subtypes identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPkKQj8k6B0V1C8OJBvdfbfW6udTcc2ebwZkAQRqPYrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FgslertA%253D%253D&md5=45e4fea9e43fe6c32d993994f2c76034</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.14670%2FHH-27.1481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-27.1481%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DW.%2BH.%26aulast%3DKoo%26aufirst%3DJ.%2BS.%26atitle%3DClinicopathologic%2520features%2520of%2520molecular%2520subtypes%2520of%2520triple%2520negative%2520breast%2520cancer%2520based%2520on%2520immunohistochemical%2520markers%26jtitle%3DHistol%2520Histopathol.%26date%3D2012%26volume%3D27%26issue%3D11%26spage%3D1481%26epage%3D1493%26doi%3D10.14670%2FHH-27.1481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coussy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavigne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botty, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bataillon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montaudon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painsec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chateau-Joubert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laetitia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemlali, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melaabi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinebretiere, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieche, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, E.</span></span> <span> </span><span class="NLM_article-title">Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1531</span>– <span class="NLM_lpage">1543</span>, <span class="refDoi"> DOI: 10.7150/thno.36182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.7150%2Fthno.36182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32042320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslalurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1531-1543&issue=4&author=F.+Coussyauthor=M.+Lavigneauthor=L.+de+Koningauthor=R.+E.+Bottyauthor=F.+Nematiauthor=A.+Naguezauthor=G.+Bataillonauthor=B.+Ouineauthor=A.+Dahmaniauthor=E.+Montaudonauthor=P.+Painsecauthor=S.+Chateau-Joubertauthor=F.+Laetitiaauthor=T.+Larcherauthor=S.+Vacherauthor=W.+Chemlaliauthor=A.+Briauxauthor=S.+Melaabiauthor=A.+V.+Salomonauthor=J.+M.+Guinebretiereauthor=I.+Biecheauthor=E.+Marangoni&title=Response+to+mTOR+and+PI3K+inhibitors+in+enzalutamide-resistant+luminal+androgen+receptor+triple-negative+breast+cancer+patient-derived+xenografts&doi=10.7150%2Fthno.36182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts</span></div><div class="casAuthors">Coussy, Florence; Lavigne, Marion; de Koning, Leanne; El Botty, Rania; Nemati, Fariba; Naguez, Adnan; Bataillon, Guillaume; Ouine, Berengere; Dahmani, Ahmed; Montaudon, Elodie; Painsec, Pierre; Chateau-Joubert, Sophie; Laetitia, Fuhrmann; Larcher, Thibaut; Vacher, Sophie; Chemlali, Walid; Briaux, Adrien; Melaabi, Samia; Salomon, Anne Vincent; Guinebretiere, Jean Marc; Bieche, Ivan; Marangoni, Elisabetta</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1531-1543</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Luminal androgen receptor (LAR) breast cancer accounts for 10% of all triple-neg. breast cancers (TNBC).  Anti-androgen therapy for this subtype is in development, but yields only partial clin. benefits.  In this study, we aimed to characterize the genomic alterations of LAR TNBC, to analyze activation of the PI3K signaling pathway and to compare the response to PI3K pathway inhibitors with that to anti-androgen therapy in patient-derived xenografts (PDX) of LAR TNBC.  Four LAR PDX models were identified, on the basis of their transcriptomic profiles, in a cohort of 57 PDX models of TNBC.  The expression of AR-related genes, basal and luminal cytokeratins and EMT genes was analyzed by RT-PCR and IHC.  AKT1 and PIK3CA mutations were identified by targeted NGS, and activation of the PI3K pathway was analyzed with a reverse-phase protein array.  Three LAR PDXs with a PIK3CA or AKT1 mutation were treated with the AR inhibitor enzalutamide, a PI3K inhibitor, a dual PI3K-mTOR inhibitor and a mTORC1-mTORC2 inhibitor.  Finally, we screened a clin. cohort of 329 TNBC for PIK3CA and AKT1 hotspot mutations.  LAR TNBC PDXs were significantly enriched in PIK3CA and AKT1 mutations, and had higher levels of luminal-androgen-like gene expression and a higher PI3K pathway protein activation score than other TNBC subtypes.  Immunohistochem. anal. revealed strong expression of the luminal cytokeratin CK18 and AR in three LAR PDX models.  We found that mTOR and PI3K inhibitors had marked antitumor activity in vivo in PDX harboring genomic alterations of PIK3CA and AKT1 genes that did not respond to the AR antagonist enzalutamide.  PIK3CA mutations were detected in more than one third of AR+TNBC from patients (38%), and only 10% of AR-neg. TNBC.  Our results for Patient derived xenografts models of LAR TNBC resistant to enzalutamide indicate that Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha and AKT1 are potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrV3HvZF6NXLVg90H21EOLACvtfcHk0lgJzB5-uh0Nsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslalurrJ&md5=7f3198d25ee7a8bd95bab1b85bb95651</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.7150%2Fthno.36182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.36182%26sid%3Dliteratum%253Aachs%26aulast%3DCoussy%26aufirst%3DF.%26aulast%3DLavigne%26aufirst%3DM.%26aulast%3Dde%2BKoning%26aufirst%3DL.%26aulast%3DBotty%26aufirst%3DR.%2BE.%26aulast%3DNemati%26aufirst%3DF.%26aulast%3DNaguez%26aufirst%3DA.%26aulast%3DBataillon%26aufirst%3DG.%26aulast%3DOuine%26aufirst%3DB.%26aulast%3DDahmani%26aufirst%3DA.%26aulast%3DMontaudon%26aufirst%3DE.%26aulast%3DPainsec%26aufirst%3DP.%26aulast%3DChateau-Joubert%26aufirst%3DS.%26aulast%3DLaetitia%26aufirst%3DF.%26aulast%3DLarcher%26aufirst%3DT.%26aulast%3DVacher%26aufirst%3DS.%26aulast%3DChemlali%26aufirst%3DW.%26aulast%3DBriaux%26aufirst%3DA.%26aulast%3DMelaabi%26aufirst%3DS.%26aulast%3DSalomon%26aufirst%3DA.%2BV.%26aulast%3DGuinebretiere%26aufirst%3DJ.%2BM.%26aulast%3DBieche%26aufirst%3DI.%26aulast%3DMarangoni%26aufirst%3DE.%26atitle%3DResponse%2520to%2520mTOR%2520and%2520PI3K%2520inhibitors%2520in%2520enzalutamide-resistant%2520luminal%2520androgen%2520receptor%2520triple-negative%2520breast%2520cancer%2520patient-derived%2520xenografts%26jtitle%3DTheranostics%26date%3D2020%26volume%3D10%26issue%3D4%26spage%3D1531%26epage%3D1543%26doi%3D10.7150%2Fthno.36182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamidi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, C.</span></span> <span> </span><span class="NLM_article-title">Unraveling the genomic-epigenomic interaction landscape in triple negative and non-triple negative breast cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1559</span>, <span class="refDoi"> DOI: 10.3390/cancers12061559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers12061559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVehtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1559&issue=6&author=J.+Wuauthor=T.+Mamidiauthor=L.+Zhangauthor=C.+Hicks&title=Unraveling+the+genomic-epigenomic+interaction+landscape+in+triple+negative+and+non-triple+negative+breast+cancer&doi=10.3390%2Fcancers12061559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling the genomic-epigenomic interaction landscape in triple negative and non-triple negative breast cancer</span></div><div class="casAuthors">Wu, Jiande; Mamidi, Tarun Karthik Kumar; Zhang, Lu; Hicks, Chindo</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1559</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Background: The recent surge of next generation sequencing of breast cancer genomes has enabled development of comprehensive catalogues of somatic mutations and expanded the mol. classification of subtypes of breast cancer.  However, somatic mutations and gene expression data have not been leveraged and integrated with epigenomic data to unravel the genomic-epigenomic interaction landscape of triple neg. breast cancer (TNBC) and non-triple neg. breast cancer (non-TNBC).  Methods: We performed integrative data anal. combining somatic mutation, epigenomic and gene expression data from The Cancer Genome Atlas (TCGA) to unravel the possible oncogenic interactions between genomic and epigenomic variation in TNBC and non-TNBC.  We hypothesized that within breast cancers, there are differences in somatic mutation, DNA methylation and gene expression signatures between TNBC and non-TNBC.  We further hypothesized that genomic and epigenomic alterations affect gene regulatory networks and signaling pathways driving the two types of breast cancer.  Results: The investigation revealed somatic mutated, epigenomic and gene expression signatures unique to TNBC and non-TNBC and signatures distinguishing the two types of breast cancer.  In addn., the investigation revealed mol. networks and signaling pathways enriched for somatic mutations and epigenomic changes unique to each type of breast cancer.  The most significant pathways for TNBC were: retinal biosynthesis, BAG2, LXR/RXR, EIF2 and P2Y purigenic receptor signaling pathways.  The most significant pathways for non-TNBC were: UVB-induced MAPK, PCP, Apelin endothelial, Endoplasmatic reticulum stress and mechanisms of viral exit from host signaling Pathways.  Conclusion: The investigation revealed integrated genomic, epigenomic and gene expression signatures and signing pathways unique to TNBC and non-TNBC, and a gene signature distinguishing the two types of breast cancer.  The study demonstrates that integrative anal. of multi-omics data is a powerful approach for unravelling the genomic-epigenomic interaction landscape in TNBC and non-TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4luZIYXkCjbVg90H21EOLACvtfcHk0lgJzB5-uh0Nsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVehtb7M&md5=14b8bfa51f35b3d29feb8d8d47fa534b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fcancers12061559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12061559%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DMamidi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHicks%26aufirst%3DC.%26atitle%3DUnraveling%2520the%2520genomic-epigenomic%2520interaction%2520landscape%2520in%2520triple%2520negative%2520and%2520non-triple%2520negative%2520breast%2520cancer%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D1559%26doi%3D10.3390%2Fcancers12061559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschraegen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaklamani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span> <span> </span><span class="NLM_article-title">Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1038/s41422-020-0375-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41422-020-0375-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32719455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsV2mtbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=178-186&author=Y.+Jiangauthor=Y.+Liuauthor=Y.+Xiaoauthor=X.+Huauthor=L.+Jiangauthor=W.+Zuoauthor=D.+Maauthor=J.+Dingauthor=X.+Zhuauthor=J.+Zouauthor=C.+Verschraegenauthor=D.+Stoverauthor=V.+Kaklamaniauthor=Z.+Wangauthor=Z.+Shao&title=Molecular+subtyping+and+genomic+profiling+expand+precision+medicine+in+refractory+metastatic+triple-negative+breast+cancer%3A+the+FUTURE+trial&doi=10.1038%2Fs41422-020-0375-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer</span></div><div class="casAuthors">Jiang, Yi-Zhou; Liu, Yin; Xiao, Yi; Hu, Xin; Jiang, Lin; Zuo, Wen-Jia; Ma, Ding; Ding, Jiahan; Zhu, Xiaoyu; Zou, Jianjun; Verschraegen, Claire; Stover, Daniel G.; Kaklamani, Virginia; Wang, Zhong-Hua; Shao, Zhi-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-186</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Here, we conducted the FUTURE trial (ClinicalTrials.gov identifier: NCT03805399), a phase Ib/II subtyping-based and genomic biomarker-guided umbrella trial, to evaluate the efficacy of these targets.  Patients with refractory metastatic TNBC were enrolled and stratified by TNBC subtypes and genomic biomarkers, and assigned to one of these seven arms: (A) pyrotinib with capecitabine, (B) androgen receptor inhibitor with CDK4/6 inhibitor, (C) anti PD-1 with nab-paclitaxel, (D) PARP inhibitor included, (E) and (F) anti-VEGFR included, or (G) mTOR inhibitor with nab-paclitaxel.  The primary end point was the objective response rate (ORR).  We enrolled 69 refractory metastatic TNBC patients with a median of three previous lines of therapy (range, 1-8).  Objective response was achieved in 20 (29.0%, 95% confidence interval (CI): 18.7%-41.2%) of the 69 intention-to-treat (ITT) patients.  Our results showed that immunotherapy (arm C), in particular, achieved the highest ORR (52.6%, 95% CI: 28.9%-75.6%) in the ITT population.  Somatic mutations of TOP2A and CD8 immunohistochem. score may have the potential to predict immunotherapy response in the immunomodulatory subtype of TNBC.  In conclusion, the phase Ib/II FUTURE trial suggested a new concept for TNBC treatment, demonstrating the clin. benefit of subtyping-based targeted therapy for refractory metastatic TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2XujAnABJsLVg90H21EOLACvtfcHk0lgQ3mr0itPXWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsV2mtbjM&md5=2421cb15b37f5747f032543589dddb1b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-0375-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-0375-9%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZuo%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DVerschraegen%26aufirst%3DC.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DKaklamani%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DShao%26aufirst%3DZ.%26atitle%3DMolecular%2520subtyping%2520and%2520genomic%2520profiling%2520expand%2520precision%2520medicine%2520in%2520refractory%2520metastatic%2520triple-negative%2520breast%2520cancer%253A%2520the%2520FUTURE%2520trial%26jtitle%3DCell%2520Res.%26date%3D2021%26volume%3D31%26spage%3D178%26epage%3D186%26doi%3D10.1038%2Fs41422-020-0375-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarthy, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span> <span> </span><span class="NLM_article-title">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2750</span>– <span class="NLM_lpage">2767</span>, <span class="refDoi"> DOI: 10.1172/JCI45014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1172%2FJCI45014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21633166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2750-2767&issue=7&author=B.+D.+Lehmannauthor=J.+A.+Bauerauthor=X.+Chenauthor=M.+E.+Sandersauthor=A.+B.+Chakravarthyauthor=Y.+Shyrauthor=J.+A.+Pietenpol&title=Identification+of+human+triple-negative+breast+cancer+subtypes+and+preclinical+models+for+selection+of+targeted+therapies&doi=10.1172%2FJCI45014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</span></div><div class="casAuthors">Lehmann, Brian D.; Bauer, Joshua A.; Chen, Xi; Sanders, Melinda E.; Chakravarthy, A. Bapsi; Shyr, Yu; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2750-2767</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify mol.-based therapies.  In this study, we analyzed gene expression (GE) profiles from 21 breast cancer data sets and identified 587 TNBC cases.  Cluster anal. identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype.  Further, GE anal. allowed us to identify TNBC cell line models representative of these subtypes.  Predicted "driver" signaling pathways were pharmacol. targeted in these cell line models as proof of concept that anal. of distinct GE signatures can inform therapy selection.  BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin.  M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor).  The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling.  LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist).  These data may be useful in biomarker selection, drug discovery, and clin. trial design that will enable alignment of TNBC patients to appropriate targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhoQQUFogW7Vg90H21EOLACvtfcHk0lgQ3mr0itPXWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgu78%253D&md5=c3681c79e0b972f16f6d5a5ecdc99fec</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2FJCI45014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45014%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DBauer%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DChakravarthy%26aufirst%3DA.%2BB.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520of%2520human%2520triple-negative%2520breast%2520cancer%2520subtypes%2520and%2520preclinical%2520models%2520for%2520selection%2520of%2520targeted%2520therapies%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26issue%3D7%26spage%3D2750%26epage%3D2767%26doi%3D10.1172%2FJCI45014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bareche, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatiadis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftimos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotiriou, C.</span></span> <span> </span><span class="NLM_article-title">Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">902</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdy024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29365031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1MvjvVWltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=895-902&issue=4&author=Y.+Barecheauthor=D.+Venetauthor=M.+Ignatiadisauthor=P.+Aftimosauthor=M.+Piccartauthor=F.+Rotheauthor=C.+Sotiriou&title=Unravelling+triple-negative+breast+cancer+molecular+heterogeneity+using+an+integrative+multiomic+analysis&doi=10.1093%2Fannonc%2Fmdy024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis</span></div><div class="casAuthors">Bareche Y; Venet D; Rothe F; Ignatiadis M; Aftimos P; Piccart M; Sotiriou C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-902</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple-negative breast cancers (TNBCs) reporting, at least six different molecular subtypes of TNBC namely Basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL) and luminal androgen receptor (LAR).  However, little is known regarding the potential driving molecular events within each subtype, their difference in survival and response to therapy.  Further insight into the underlying genomic alterations is therefore needed.  Patients and methods:  This study was carried out using copy-number aberrations, somatic mutations and gene expression data derived from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas.  TNBC samples (n = 550) were classified according to Lehmann's molecular subtypes using the TNBCtype online subtyping tool (http://cbc.mc.vanderbilt.edu/tnbc/).  Results:  Each subtype showed significant clinic-pathological characteristic differences.  Using a multivariate model, IM subtype showed to be associated with a better prognosis (HR = 0.68; CI = 0.46-0.99; P = 0.043) whereas LAR subtype was associated with a worst prognosis (HR = 1.47; CI = 1.0-2.14; P = 0.046).  BL1 subtype was found to be most genomically instable subtype with high TP53 mutation (92%) and copy-number deletion in genes involved in DNA repair mechanism (BRCA2, MDM2, PTEN, RB1 and TP53).  LAR tumours were associated with higher mutational burden with significantly enriched mutations in PI3KCA (55%), AKT1 (13%) and CDH1 (13%) genes.  M and MSL subtypes were associated with higher signature score for angiogenesis.  Finally, IM showed high expression levels of immune signatures and check-point inhibitor genes such as PD1, PDL1 and CTLA4.  Conclusion:  Our findings highlight for the first time the substantial genomic heterogeneity that characterize TNBC molecular subtypes, allowing for a better understanding of the disease biology as well as the identification of several candidate targets paving novel approaches for the development of anticancer therapeutics for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFAwKX5MVwZa_dlEzl_fBafW6udTcc2eY6qM7pGjpcHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvjvVWltA%253D%253D&md5=b9932f82899e488739ab272e989b9e32</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy024%26sid%3Dliteratum%253Aachs%26aulast%3DBareche%26aufirst%3DY.%26aulast%3DVenet%26aufirst%3DD.%26aulast%3DIgnatiadis%26aufirst%3DM.%26aulast%3DAftimos%26aufirst%3DP.%26aulast%3DPiccart%26aufirst%3DM.%26aulast%3DRothe%26aufirst%3DF.%26aulast%3DSotiriou%26aufirst%3DC.%26atitle%3DUnravelling%2520triple-negative%2520breast%2520cancer%2520molecular%2520heterogeneity%2520using%2520an%2520integrative%2520multiomic%2520analysis%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26issue%3D4%26spage%3D895%26epage%3D902%26doi%3D10.1093%2Fannonc%2Fmdy024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovanovic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span> <span> </span><span class="NLM_article-title">Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e0157368</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0157368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0157368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27310713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOqtr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0157368&issue=6&author=B.+D.+Lehmannauthor=B.+Jovanovicauthor=X.+Chenauthor=M.+V.+Estradaauthor=K.+N.+Johnsonauthor=Y.+Shyrauthor=H.+L.+Mosesauthor=M.+E.+Sandersauthor=J.+A.+Pietenpol&title=Refinement+of+triple-negative+breast+cancer+molecular+subtypes%3A+implications+for+neoadjuvant+chemotherapy+selection&doi=10.1371%2Fjournal.pone.0157368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection</span></div><div class="casAuthors">Lehmann, Brian D.; Jovanovic, Bojana; Chen, Xi; Estrada, Monica V.; Johnson, Kimberly N.; Shyr, Yu; Moses, Harold L.; Sanders, Melinda E.; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0157368/1-e0157368/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct mol. subtypes by gene expression profiling.  Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival.  Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients.  Previously, we developed an approach to identify six mol. subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to std.-of-care chemotherapy.  Given the complexity of the varying histol. landscape of tumor specimens, we used histopathol. quantification and laser-capture microdissection to det. that transcripts in the previously described immunomodulatory (IM) and mesenchymal stem-like (MSL) subtypes were contributed from infiltrating lymphocytes and tumor-assocd. stromal cells, resp.  Therefore, we refined TNBC mol. subtypes from six (TNBCtype) into four (TNBCtype-4) tumor-specific subtypes (BL1, BL2, M and LAR) and demonstrate differences in diagnosis age, grade, local and distant disease progression and histopathol.  Using five publicly available, neoadjuvant chemotherapy breast cancer gene expression datasets, we retrospectively evaluated chemotherapy response of over 300 TNBC patients from pretreatment biopsies subtyped using either the intrinsic (PAM50) or TNBCtype approaches.  Combined anal. of TNBC patients demonstrated that TNBC subtypes significantly differ in response to similar neoadjuvant chemotherapy with 41% of BL1 patients achieving a pathol. complete response compared to 18% for BL2 and 29% for LAR with 95% confidence intervals (CIs; [33, 51], [9, 28], [17, 41], resp.).  Collectively, we provide pre-clin. data that could inform clin. trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of mol. TNBC subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjbtsOOP5UtLVg90H21EOLACvtfcHk0lirDAp8Fzs_Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOqtr3P&md5=62dddc464beb0b81b34c325e787c698d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0157368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0157368%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DJovanovic%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DEstrada%26aufirst%3DM.%2BV.%26aulast%3DJohnson%26aufirst%3DK.%2BN.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DMoses%26aufirst%3DH.%2BL.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DRefinement%2520of%2520triple-negative%2520breast%2520cancer%2520molecular%2520subtypes%253A%2520implications%2520for%2520neoadjuvant%2520chemotherapy%2520selection%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26issue%3D6%26spage%3De0157368%26doi%3D10.1371%2Fjournal.pone.0157368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells</span>. <i>Acta Bioch Bioph Sin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1093/abbs/gmy117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fabbs%2Fgmy117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30289427" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=1141-1149&issue=11&author=J.+Huoauthor=X.+Chenauthor=H.+Zhangauthor=Y.+Huauthor=Y.+Jiangauthor=S.+Liuauthor=X.+Zhang&title=Bcl-3+promotes+proliferation+and+chemosensitivity+in+BL1+subtype+of+TNBC+cells&doi=10.1093%2Fabbs%2Fgmy117"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fabbs%2Fgmy117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fabbs%252Fgmy117%26sid%3Dliteratum%253Aachs%26aulast%3DHuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DBcl-3%2520promotes%2520proliferation%2520and%2520chemosensitivity%2520in%2520BL1%2520subtype%2520of%2520TNBC%2520cells%26jtitle%3DActa%2520Bioch%2520Bioph%2520Sin.%26date%3D2018%26volume%3D50%26issue%3D11%26spage%3D1141%26epage%3D1149%26doi%3D10.1093%2Fabbs%2Fgmy117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charafe-Jauffret, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamessier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelaide, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houvenaeghel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maraninchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span> <span> </span><span class="NLM_article-title">Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4644</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-06-0031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=16651414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvF2ksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4636-4644&issue=9&author=F.+Bertucciauthor=P.+Finettiauthor=N.+Cerveraauthor=E.+Charafe-Jauffretauthor=E.+Mamessierauthor=J.+Adelaideauthor=S.+Debonoauthor=G.+Houvenaeghelauthor=D.+Maraninchiauthor=P.+Viensauthor=C.+Charpinauthor=J.+Jacquemierauthor=D.+Birnbaum&title=Gene+expression+profiling+shows+medullary+breast+cancer+is+a+subgroup+of+basal+breast+cancers&doi=10.1158%2F0008-5472.CAN-06-0031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers</span></div><div class="casAuthors">Bertucci, Francois; Finetti, Pascal; Cervera, Nathalie; Charafe-Jauffret, Emmanuelle; Mamessier, Emilie; Adelaide, Jose; Debono, Stephane; Houvenaeghel, Gilles; Maraninchi, Dominique; Viens, Patrice; Charpin, Colette; Jacquemier, Jocelyne; Birnbaum, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4636-4644</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Medullary breast cancer (MBC) is a rare but enigmatic pathol. type of breast cancer.  Despite features of aggressiveness, MBC is assocd. with a favorable prognosis.  Morphol. diagnosis remains difficult in many cases.  Very little is known about the mol. alterations involved in MBC.  Notably, it is not clear whether MBC and ductal breast cancer (DBC) represent molecularly distinct entities and what genes/proteins might account for their differences.  Using whole-genome oligonucleotide microarrays, we compared gene expression profiles of 22 MBCs and 44 grade III DBCs.  We show that MBCs are less heterogeneous than DBCs.  Whereas different mol. subtypes (luminal A, luminal B, basal, ERBB2-overexpressing, and normal-like) exist in DBCs, 95% MBCs display a basal profile, similar to that of basal DBCs.  Supervised anal. identified gene expression signatures that discriminated MBCs from DBCs.  Discriminator genes are assocd. with various cellular processes related to MBC features, in particular immune reaction and apoptosis.  As compared with MBCs, basal DBCs overexpress genes involved in smooth muscle cell differentiation, suggesting that MBCs are a distinct subgroup of basal breast cancer with limited myoepithelial differentiation.  Finally, MBCs overexpress a series of genes located on the 12p13 and 6p21 chromosomal regions known to contain pluripotency genes.  Our results contribute to a better understanding of MBC and of mammary oncogenesis in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgy5b76s3ICrVg90H21EOLACvtfcHk0lirDAp8Fzs_Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvF2ksb4%253D&md5=6db0341b38ea8bf331849e6d3eb5fbd2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0031%26sid%3Dliteratum%253Aachs%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DFinetti%26aufirst%3DP.%26aulast%3DCervera%26aufirst%3DN.%26aulast%3DCharafe-Jauffret%26aufirst%3DE.%26aulast%3DMamessier%26aufirst%3DE.%26aulast%3DAdelaide%26aufirst%3DJ.%26aulast%3DDebono%26aufirst%3DS.%26aulast%3DHouvenaeghel%26aufirst%3DG.%26aulast%3DMaraninchi%26aufirst%3DD.%26aulast%3DViens%26aufirst%3DP.%26aulast%3DCharpin%26aufirst%3DC.%26aulast%3DJacquemier%26aufirst%3DJ.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DGene%2520expression%2520profiling%2520shows%2520medullary%2520breast%2520cancer%2520is%2520a%2520subgroup%2520of%2520basal%2520breast%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D9%26spage%3D4636%26epage%3D4644%26doi%3D10.1158%2F0008-5472.CAN-06-0031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A.</span></span> <span> </span><span class="NLM_article-title">Robust enumeration of cell subsets from tissue expression profiles</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1038/nmeth.3337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fnmeth.3337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25822800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVOgu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=453-457&issue=5&author=A.+Newmanauthor=C.+Liuauthor=M.+Greenauthor=A.+Gentlesauthor=W.+Fengauthor=Y.+Xuauthor=C.+Hoangauthor=M.+Diehnauthor=A.+Alizadeh&title=Robust+enumeration+of+cell+subsets+from+tissue+expression+profiles&doi=10.1038%2Fnmeth.3337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Robust enumeration of cell subsets from tissue expression profiles</span></div><div class="casAuthors">Newman, Aaron M.; Liu, Chih Long; Green, Michael R.; Gentles, Andrew J.; Feng, Weiguo; Xu, Yue; Hoang, Chuong D.; Diehn, Maximilian; Alizadeh, Ash A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">453-457</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We introduce CIBERSORT, a method for characterizing cell compn. of complex tissues from their gene expression profiles.  When applied to enumeration of hematopoietic subsets in RNA mixts. from fresh, frozen and fixed tissues, including solid tumors, CIBERSORT outperformed other methods with respect to noise, unknown mixt. content and closely related cell types.  CIBERSORT should enable large-scale anal. of RNA mixts. for cellular biomarkers and therapeutic targets (http://cibersort.stanford.edu/).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE-GiX_cz7kbVg90H21EOLACvtfcHk0lirDAp8Fzs_Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVOgu7Y%253D&md5=8824a5271d4dfdd8b2aaee5210cb14f6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.3337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.3337%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DGentles%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DHoang%26aufirst%3DC.%26aulast%3DDiehn%26aufirst%3DM.%26aulast%3DAlizadeh%26aufirst%3DA.%26atitle%3DRobust%2520enumeration%2520of%2520cell%2520subsets%2520from%2520tissue%2520expression%2520profiles%26jtitle%3DNat.%2520Methods%26date%3D2015%26volume%3D12%26issue%3D5%26spage%3D453%26epage%3D457%26doi%3D10.1038%2Fnmeth.3337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2405</span>– <span class="NLM_lpage">2421</span>, <span class="refDoi"> DOI: 10.7150/thno.38875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.7150%2Fthno.38875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32104513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKltrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=2405-2421&issue=5&author=L.+Zhouauthor=D.+Wangauthor=D.+Shengauthor=J.+Xuauthor=W.+Chenauthor=Y.+Qinauthor=R.+Duauthor=X.+Yangauthor=X.+Heauthor=N.+Xieauthor=S.+Liuauthor=L.+Zhang&title=NOTCH4+maintains+quiescent+mesenchymal-like+breast+cancer+stem+cells+via+transcriptionally+activating+SLUG+and+GAS1+in+triple-negative+breast+cancer&doi=10.7150%2Fthno.38875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer</span></div><div class="casAuthors">Zhou, Lei; Wang, Dong; Sheng, Dandan; Xu, Jiahui; Chen, Weilong; Qin, Yuanyuan; Du, Ruikai; Yang, Xiaoli; He, Xueyan; Xie, Ni; Liu, Suling; Zhang, Lixing</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2405-2421</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A NOTCH4 receptor has been implicated in triple-neg. breast cancer (TNBC) development and breast cancer stem cell (BCSC) regulation.  However, the potential of NOTCH4 as a BCSC marker and the underlying mechanisms remain unclear.  In this study, we detd. the expression and activation of NOTCH4 in breast cancer cell lines and tumor samples by qRT-PCR, western blotting and immunohistochem.  Subsequently, in vitro and in vivo serial diln. expts. were performed to demonstrate the application of NOTCH4 as an efficient mesenchymal-like (ML)-BCSC marker in TNBC.  Stable overexpression of activated NOTCH4 and knockdown cell lines were established using lentivirus.  The RNA-seq and qRT-PCR were employed to reveal the downstream effectors of NOTCH4, followed by dual-luciferase reporter and chromatin immunopptn. assays to identify the genuine binding sites of NOTCH4 on SLUG and GAS1 promoters.  Transwell assay, mammosphere formation and chemoresistance expts. were performed to det. the effects of SLUG, GAS1 and NOTCH4 on the mesenchymal-like characteristics of TNBC cells.  Survival anal. was used to study the relation of NOTCH4, SLUG and GAS1 with prognosis of breast cancer.  The NOTCH4 is aberrantly highly expressed and activated in TNBC, which contributes to the maintenance of ML-BCSCs.  Furthermore, NOTCH4 shows significantly higher efficiency in labeling ML-BCSCs than the currently commonly used CD24-CD44+ marker.  Mechanistically, NOTCH4 transcriptionally upregulates SLUG and GAS1 to promote EMT and quiescence in TNBC, resp.  The effects of NOTCH4 can be mimicked by simultaneous overexpression of SLUG and GAS1.  Moreover, SLUG is also involved in harnessing GAS1, a known tumor suppressor gene, via its anti-apoptotic function.  Our findings reveal that the NOTCH4-SLUG-GAS1 circuit serves as a potential target for tumor intervention by overcoming stemness of ML-BCSCs and by conquering the lethal chemoresistance and metastasis of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdUU_Aj5mbp7Vg90H21EOLACvtfcHk0lg8BRkVGbQn2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKltrjI&md5=809ffcfe31621b13f6111a55bb8f98f1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.7150%2Fthno.38875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.38875%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DNOTCH4%2520maintains%2520quiescent%2520mesenchymal-like%2520breast%2520cancer%2520stem%2520cells%2520via%2520transcriptionally%2520activating%2520SLUG%2520and%2520GAS1%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DTheranostics%26date%3D2020%26volume%3D10%26issue%3D5%26spage%3D2405%26epage%3D2421%26doi%3D10.7150%2Fthno.38875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basho, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbrich, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarracin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-MacGregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. L.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S. L.</span></span> <span> </span><span class="NLM_article-title">Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2016.5281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1001%2Fjamaoncol.2016.5281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27893038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhtVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=509-515&issue=4&author=R.+K.+Bashoauthor=M.+Gilcreaseauthor=R.+K.+Murthyauthor=T.+Helgasonauthor=D.+D.+Karpauthor=F.+Meric-Bernstamauthor=K.+R.+Hessauthor=S.+M.+Herbrichauthor=V.+Valeroauthor=C.+Albarracinauthor=J.+K.+Littonauthor=M.+Chavez-MacGregorauthor=N.+K.+Ibrahimauthor=J.+L.+Murrayauthor=K.+B.+Koenigauthor=D.+Hongauthor=V.+Subbiahauthor=R.+Kurzrockauthor=F.+Jankuauthor=S.+L.+Moulder&title=Targeting+the+PI3K%2FAKT%2FmTOR+pathway+for+the+treatment+of+mesenchymal+triple-negative+breast+cancer%3A+evidence+from+a+phase+1+trial+of+mTOR+inhibition+in+combination+with+liposomal+doxorubicin+and+bevacizumab&doi=10.1001%2Fjamaoncol.2016.5281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab</span></div><div class="casAuthors">Basho Reva K; Gilcrease Michael; Albarracin Constance; Murthy Rashmi K; Valero Vicente; Litton Jennifer K; Ibrahim Nuhad K; Murray James L 3rd; Koenig Kimberly B; Helgason Thorunn; Karp Daniel D; Hong David; Subbiah Vivek; Janku Filip; Meric-Bernstam Funda; Hess Kenneth R; Herbrich Shelley M; Chavez-MacGregor Mariana; Kurzrock Razelle; Moulder Stacy L</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-515</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response.  Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy.  While assays to identify mesenchymal TNBC are under development, metaplastic breast cancer serves as a clinically identifiable surrogate to evaluate potential regimens for mesenchymal TNBC.  Objective:  To assess safety and efficacy of mammalian target of rapamycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with advanced metaplastic TNBC.  Design, Setting, and Participants:  Phase 1 study with dose escalation and dose expansion at the University of Texas MD Anderson Cancer Center of patients with advanced metaplastic TNBC.  Patients were enrolled from April 16, 2009, to November 4, 2014, and followed for outcomes with a cutoff date of November 1, 2015, for data analysis.  Interventions:  Liposomal doxorubicin, bevacizumab, and the mTOR inhibitors temsirolimus or everolimus using 21-day cycles.  Main Outcomes and Measures:  Safety and response.  When available, archived tissue was evaluated for aberrations in the PI3K pathway.  Results:  Fifty-two women with metaplastic TNBC (median age, 58 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE) (N = 13).  The objective response rate was 21% (complete response = 4 [8%]; partial response = 7 [13%]) and 10 (19%) patients had stable disease for at least 6 months, for a clinical benefit rate of 40%.  Tissue was available for testing in 43 patients, and 32 (74%) had a PI3K pathway aberration.  Presence of PI3K pathway aberration was associated with a significant improvement in objective response rate (31% vs 0%; P = .04) but not clinical benefit rate (44% vs 45%; P > .99).  Conclusions and Relevance:  Using metaplastic TNBC as a surrogate for mesenchymal TNBC, DAT and DAE had notable activity in mesenchymal TNBC.  Objective response was limited to patients with PI3K pathway aberration.  A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTatjZ_QtxszUbxh97K6Vt6fW6udTcc2eZLTPL0yeHaELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhtVSjsQ%253D%253D&md5=10ca11d3bfc1e167136b282120d58a7b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2016.5281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2016.5281%26sid%3Dliteratum%253Aachs%26aulast%3DBasho%26aufirst%3DR.%2BK.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DMurthy%26aufirst%3DR.%2BK.%26aulast%3DHelgason%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DD.%2BD.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHess%26aufirst%3DK.%2BR.%26aulast%3DHerbrich%26aufirst%3DS.%2BM.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DAlbarracin%26aufirst%3DC.%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DChavez-MacGregor%26aufirst%3DM.%26aulast%3DIbrahim%26aufirst%3DN.%2BK.%26aulast%3DMurray%26aufirst%3DJ.%2BL.%26aulast%3DKoenig%26aufirst%3DK.%2BB.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DMoulder%26aufirst%3DS.%2BL.%26atitle%3DTargeting%2520the%2520PI3K%252FAKT%252FmTOR%2520pathway%2520for%2520the%2520treatment%2520of%2520mesenchymal%2520triple-negative%2520breast%2520cancer%253A%2520evidence%2520from%2520a%2520phase%25201%2520trial%2520of%2520mTOR%2520inhibition%2520in%2520combination%2520with%2520liposomal%2520doxorubicin%2520and%2520bevacizumab%26jtitle%3DJAMA%2520Oncol.%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D509%26epage%3D515%26doi%3D10.1001%2Fjamaoncol.2016.5281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">e74525</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0074525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0074525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24058584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSqs7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e74525&issue=9&author=K.+Starkauthor=A.+Burgerauthor=J.+Wuauthor=P.+Sheltonauthor=L.+Polinauthor=J.+Li&title=Reactivation+of+estrogen+receptor+%CE%B1+by+vorinostat+sensitizes+mesenchymal-like+triple-negative+breast+cancer+to+aminoflavone%2C+a+ligand+of+the+aryl+hydrocarbon+receptor&doi=10.1371%2Fjournal.pone.0074525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor</span></div><div class="casAuthors">Stark, Karri; Burger, Angelika; Wu, Jianmei; Shelton, Phillip; Polin, Lisa; Li, Jing</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e74525</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Objective: Aminoflavone (AF) acts as a ligand of the aryl hydrocarbon receptor (AhR).  Expression of estrogen receptor α (ERα) and AhR-mediated transcriptional induction of CYP1A1 can sensitize breast cancer cells to AF.  The objective of this study was to investigate the combined antitumor effect of AF and the histone deacetylase inhibitor vorinostat for treating mesenchymal-like triple-neg. breast cancer (TNBC) as well as the underlying mechanisms of such treatment.  Methods: In vitro antiproliferative activity of AFP464 (AF prodrug) in breast cancer cell lines was evaluated by MTS assay.  In vitro, the combined effect of AFP464 and vorinostat on cell proliferation was assessed by the Chou-Talalay method.  In vivo, antitumor activity of AFP464, given alone and in combination with vorinostat, was studied using TNBC xenograft models.  Knockdown of ERα was performed using specific, small-interfering RNA.  Western blot, quant. RT-PCR, immunofluorescence, and immunohistochem. staining were performed to study the mechanisms underlying the combined antitumor effect.  Results: Luminal and basal A subtype breast cancer cell lines were sensitive to AFP464, whereas basal B subtype or mesenchymal-like TNBC cells were resistant.  Vorinostat sensitized mesenchymal-like TNBC MDA-MB-231 and Hs578T cells to AFP464.  It also potentiated the antitumor activity of AFP464 in a xenograft model using MDA-MB-231 cells.  In vitro and in vivo mechanistic studies suggested that vorinostat reactivated ERα expression and restored AhR-mediated transcriptional induction of CYP1A1.  Conclusion: The response of breast cancer cells to AF or AFP464 was assocd. with their gene expression profile.  Vorinostat sensitized mesenchymal-like TNBC to AF, at least in part, by reactivating ERα expression and restoring the responsiveness of AhR to AF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRTL2W5a8iS7Vg90H21EOLACvtfcHk0lhOm5SS774l3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSqs7bO&md5=fdb6e31997a867828b56f8496d639bdc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0074525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0074525%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DK.%26aulast%3DBurger%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DP.%26aulast%3DPolin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DReactivation%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520by%2520vorinostat%2520sensitizes%2520mesenchymal-like%2520triple-negative%2520breast%2520cancer%2520to%2520aminoflavone%252C%2520a%2520ligand%2520of%2520the%2520aryl%2520hydrocarbon%2520receptor%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26issue%3D9%26spage%3De74525%26doi%3D10.1371%2Fjournal.pone.0074525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, T.</span></span> <span> </span><span class="NLM_article-title">Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">406</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1007/s12032-011-9832-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs12032-011-9832-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21264529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2jurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=406-410&issue=2&author=J.+Heauthor=R.+Pengauthor=Z.+Yuanauthor=S.+Wangauthor=J.+Pengauthor=G.+Linauthor=X.+Jiangauthor=T.+Qin&title=Prognostic+value+of+androgen+receptor+expression+in+operable+triple-negative+breast+cancer%3A+a+retrospective+analysis+based+on+a+tissue+microarray&doi=10.1007%2Fs12032-011-9832-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray</span></div><div class="casAuthors">He, Jiehua; Peng, Roujun; Yuan, Zhongyu; Wang, Shusen; Peng, Jiewen; Lin, Guinan; Jiang, Xiaomei; Qin, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Medical Oncology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">406-410</span>CODEN:
                <span class="NLM_cas:coden">MONCEZ</span>;
        ISSN:<span class="NLM_cas:issn">1357-0560</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The aim of this study is to analyze the prognostic value of androgen receptor (AR) expression for patients with triple-neg. breast cancer (TNBC).  Clin. data of these patients were collected and analyzed, and immunohistochem. staining for AR was performed on tissue microarrays of operable breast cancer from 287 patients with TNBC, who were treated at Sun Yat-sen University Cancer Center from Jan. 1995 to Dec. 2008.  AR expression was found in 25.8% of the cases with TNBC.  TNBC patients with AR neg. have a higher proportion of pos. lymph node.  A significant correlation was found between AR expression and disease-free survival (DFS) and overall survival (OS).  Univariated anal. indicated that AR expression had a significant prognostic value in TNBC patients, whereas multivariate anal. indicated that AR was a significant independent prognostic factor of DFS (P = 0.032) in all patients.  Our results suggested that AR was a favorable prognostic factor of DFS and OS in patients with TNBC.  Therefore, TNBC may be further divided into two subtypes according to AR status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2OlUt8Go-5bVg90H21EOLACvtfcHk0lhOm5SS774l3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2jurs%253D&md5=62b1ffd49245aa6f3983b3fb319e4f72</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs12032-011-9832-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-011-9832-0%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DQin%26aufirst%3DT.%26atitle%3DPrognostic%2520value%2520of%2520androgen%2520receptor%2520expression%2520in%2520operable%2520triple-negative%2520breast%2520cancer%253A%2520a%2520retrospective%2520analysis%2520based%2520on%2520a%2520tissue%2520microarray%26jtitle%3DMed.%2520Oncol.%26date%3D2012%26volume%3D29%26issue%3D2%26spage%3D406%26epage%3D410%26doi%3D10.1007%2Fs12032-011-9832-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z. M.</span></span> <span> </span><span class="NLM_article-title">Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2106</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">27</span>),  <span class="NLM_fpage">41285</span>– <span class="NLM_lpage">41293</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.9778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.9778" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2106&pages=41285-41293&issue=27&author=H.+S.+Jiangauthor=X.+Y.+Kuangauthor=W.+L.+Sunauthor=Y.+Xuauthor=Y.+Z.+Zhengauthor=Y.+R.+Liuauthor=G.+T.+Langauthor=F.+Qiaoauthor=X.+Huauthor=Z.+M.+Shao&title=Androgen+receptor+expression+predicts+different+clinical+outcomes+for+breast+cancer+patients+stratified+by+hormone+receptor+status&doi=10.18632%2Foncotarget.9778"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.9778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.9778%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DH.%2BS.%26aulast%3DKuang%26aufirst%3DX.%2BY.%26aulast%3DSun%26aufirst%3DW.%2BL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%2BZ.%26aulast%3DLiu%26aufirst%3DY.%2BR.%26aulast%3DLang%26aufirst%3DG.%2BT.%26aulast%3DQiao%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DZ.%2BM.%26atitle%3DAndrogen%2520receptor%2520expression%2520predicts%2520different%2520clinical%2520outcomes%2520for%2520breast%2520cancer%2520patients%2520stratified%2520by%2520hormone%2520receptor%2520status%26jtitle%3DOncotarget%26date%3D2106%26volume%3D7%26issue%3D27%26spage%3D41285%26epage%3D41293%26doi%3D10.18632%2Foncotarget.9778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colomb, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grizzle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, C.</span></span> <span> </span><span class="NLM_article-title">AR negative triple negative or ″quadruple negative″ breast cancers in African American women have an enriched basal and immune signature</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e0196909</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0196909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0196909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29912871" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=e0196909&issue=6&author=M.+Davisauthor=S.+Tripathiauthor=R.+Hughleyauthor=Q.+Heauthor=S.+Baeauthor=B.+Karanamauthor=R.+Martiniauthor=L.+Newmanauthor=W.+Colombauthor=W.+Grizzleauthor=C.+Yates&title=AR+negative+triple+negative+or+%E2%80%B3quadruple+negative%E2%80%B3+breast+cancers+in+African+American+women+have+an+enriched+basal+and+immune+signature&doi=10.1371%2Fjournal.pone.0196909"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0196909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0196909%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%26aulast%3DTripathi%26aufirst%3DS.%26aulast%3DHughley%26aufirst%3DR.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DBae%26aufirst%3DS.%26aulast%3DKaranam%26aufirst%3DB.%26aulast%3DMartini%26aufirst%3DR.%26aulast%3DNewman%26aufirst%3DL.%26aulast%3DColomb%26aufirst%3DW.%26aulast%3DGrizzle%26aufirst%3DW.%26aulast%3DYates%26aufirst%3DC.%26atitle%3DAR%2520negative%2520triple%2520negative%2520or%2520%25E2%2580%25B3quadruple%2520negative%25E2%2580%25B3%2520breast%2520cancers%2520in%2520African%2520American%2520women%2520have%2520an%2520enriched%2520basal%2520and%2520immune%2520signature%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3De0196909%26doi%3D10.1371%2Fjournal.pone.0196909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burden, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. J.</span></span> <span> </span><span class="NLM_article-title">A novel role for cathepsin s as a potential biomarker in triple negative breast cancer</span>. <i>J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span>,  <span class="NLM_fpage">3980273</span>, <span class="refDoi"> DOI: 10.1155/2019/3980273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1155%2F2019%2F3980273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31346333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MvhtlOrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=3980273&author=R.+D.+A.+Wilkinsonauthor=R.+E.+Burdenauthor=S.+H.+McDowellauthor=D.+G.+McArtauthor=S.+McQuaidauthor=V.+Binghamauthor=R.+Williamsauthor=O.+T.+Coxauthor=R.+O%E2%80%99Connorauthor=N.+McCabeauthor=R.+D.+Kennedyauthor=N.+E.+Buckleyauthor=C.+J.+Scott&title=A+novel+role+for+cathepsin+s+as+a+potential+biomarker+in+triple+negative+breast+cancer&doi=10.1155%2F2019%2F3980273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer</span></div><div class="casAuthors">Wilkinson Richard D A; McDowell Sara H; McArt Darragh G; Williams Rich; McCabe Nuala; Kennedy Richard D; Scott Christopher J; Burden Roberta E; Buckley Niamh E; McQuaid Stephen; Bingham Victoria; Cox Orla T; O'Connor Rosemary; McCabe Nuala; Kennedy Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3980273</span>
        ISSN:<span class="NLM_cas:issn">1687-8450</span>.
    </div><div class="casAbstract">Cathepsin S (CTSS) has previously been implicated in a number of cancer types, where it is associated with poor clinical features and outcome.  To date, patient outcome in breast cancer has not been examined with respect to this protease.  Here, we carried out immunohistochemical (IHC) staining of CTSS using a breast cancer tissue microarray in patients who received adjuvant therapy.  We scored CTSS expression in the epithelial and stromal compartments and evaluated the association of CTSS expression with matched clinical outcome data.  We observed differences in outcome based on CTSS expression, with stromal-derived CTSS expression correlating with a poor outcome and epithelial CTSS expression associated with an improved outcome.  Further subtype characterisation revealed high epithelial CTSS expression in TNBC patients with improved outcome, which remained consistent across two independent TMA cohorts.  Further in silico gene expression analysis, using both in-house and publicly available datasets, confirmed these observations and suggested high CTSS expression may also be beneficial to outcome in ER-/HER2+ cancer.  Furthermore, high CTSS expression was associated with the BL1 Lehmann subgroup, which is characterised by defects in DNA damage repair pathways and correlates with improved outcome.  Finally, analysis of matching IHC analysis reveals an increased M1 (tumour destructive) polarisation in macrophage in patients exhibiting high epithelial CTSS expression.  In conclusion, our observations suggest epithelial CTSS expression may be prognostic of improved outcome in TNBC.  Improved outcome observed with HER2+ at the gene expression level furthermore suggests CTSS may be prognostic of improved outcome in ER- cancers as a whole.  Lastly, from the context of these patients receiving adjuvant therapy and as a result of its association with BL1 subgroup CTSS may be elevated in patients with defects in DNA damage repair pathways, indicating it may be predictive of tumour sensitivity to DNA damaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqORQ4PrRF0BFwe7cAcrfPfW6udTcc2eYpCBUkN_ekM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvhtlOrsw%253D%253D&md5=12ed5d8a82e0fecb9a369c5989aae711</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1155%2F2019%2F3980273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2019%252F3980273%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DR.%2BD.%2BA.%26aulast%3DBurden%26aufirst%3DR.%2BE.%26aulast%3DMcDowell%26aufirst%3DS.%2BH.%26aulast%3DMcArt%26aufirst%3DD.%2BG.%26aulast%3DMcQuaid%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DV.%26aulast%3DWilliams%26aufirst%3DR.%26aulast%3DCox%26aufirst%3DO.%2BT.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DKennedy%26aufirst%3DR.%2BD.%26aulast%3DBuckley%26aufirst%3DN.%2BE.%26aulast%3DScott%26aufirst%3DC.%2BJ.%26atitle%3DA%2520novel%2520role%2520for%2520cathepsin%2520s%2520as%2520a%2520potential%2520biomarker%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Oncol.%26date%3D2019%26volume%3D2019%26spage%3D3980273%26doi%3D10.1155%2F2019%2F3980273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traina, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yardley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eakle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradishar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gucalp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Estevez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudeau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uppal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudor, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span> <span> </span><span class="NLM_article-title">Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">884</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.71.3495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2016.71.3495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29373071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1amtr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=884-890&issue=9&author=T.+A.+Trainaauthor=K.+Millerauthor=D.+A.+Yardleyauthor=J.+Eakleauthor=L.+S.+Schwartzbergauthor=J.+O%E2%80%99Shaughnessyauthor=W.+Gradisharauthor=P.+Schmidauthor=E.+Winerauthor=C.+Kellyauthor=R.+Nandaauthor=A.+Gucalpauthor=A.+Awadaauthor=L.+Garcia-Estevezauthor=M.+E.+Trudeauauthor=J.+Steinbergauthor=H.+Uppalauthor=I.+C.+Tudorauthor=A.+Petersonauthor=J.+Cortes&title=Enzalutamide+for+the+treatment+of+androgen+receptor-expressing+triple-negative+breast+cancer&doi=10.1200%2FJCO.2016.71.3495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer</span></div><div class="casAuthors">Traina, Tiffany A.; Miller, Kathy; Yardley, Denise A.; Eakle, Janice; Schwartzberg, Lee S.; O'Shaughnessy, Joyce; Gradishar, William; Schmid, Peter; Winer, Eric; Kelly, Catherine; Nanda, Rita; Gucalp, Ayca; Awada, Ahmad; Garcia-Estevez, Laura; Trudeau, Maureen E.; Steinberg, Joyce; Uppal, Hirdesh; Tudor, Iulia Cristina; Peterson, Amy; Cortes, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">884-890</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Studies suggest that a subset of patients with triple-neg. breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor.  This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-pos. TNBC.  Patients and Methods Tumors were tested for AR with an immunohistochem. assay optimized for breast cancer; nuclear AR staining > 0% was considered pos.  Patients received enzalutamide 160 mg once per day until disease progression.  The primary end point was clin. benefit rate (CBR) at 16 wk.  Secondary end points included CBR at 24wk, progression-free survival, and safety.  End points were analyzed in all enrolled patients (the intent-to-treat [ITT] population) and in patients with one or more postbaseline assessment whose tumor expressed ≥ 10% nuclear AR (the evaluable subgroup).  Results Of 118 patients enrolled, 78 were evaluable.  CBR at 16 wk was 25% (95% CI, 17% to 33%) in the ITT population and 33% (95% CI, 23% to 45%) in the evaluable subgroup.  Median progression-free survival was 2.9 mo (95% CI, 1.9 to 3.7 mo) in the ITT population and 3.3 mo (95% CI, 1.9 to 4.1 mo) in the evaluable subgroup.  Median overall survival was 12.7 mo (95% CI, 8.5 mo to not yet reached) in the ITT population and 17.6 mo (95% CI, 11.6 mo to not yet reached) in the evaluable subgroup.  Fatigue was the only treatment-related grade 3 or higher adverse event with an incidence of > 2%.  Conclusion Enzalutamide demonstrated clin. activity and was well tolerated in patients with advanced AR-pos. TNBC.  Adverse events related to enzalutamide were consistent with its known safety profile.  This study supports addnl. development of enzalutamide in advanced TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXhl3xaKaC4LVg90H21EOLACvtfcHk0lhse7ly9hEkFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1amtr%252FP&md5=5ac1d1563e9ffcadb63644dab880f9bd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.71.3495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.71.3495%26sid%3Dliteratum%253Aachs%26aulast%3DTraina%26aufirst%3DT.%2BA.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DEakle%26aufirst%3DJ.%26aulast%3DSchwartzberg%26aufirst%3DL.%2BS.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DGradishar%26aufirst%3DW.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DKelly%26aufirst%3DC.%26aulast%3DNanda%26aufirst%3DR.%26aulast%3DGucalp%26aufirst%3DA.%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DGarcia-Estevez%26aufirst%3DL.%26aulast%3DTrudeau%26aufirst%3DM.%2BE.%26aulast%3DSteinberg%26aufirst%3DJ.%26aulast%3DUppal%26aufirst%3DH.%26aulast%3DTudor%26aufirst%3DI.%2BC.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DEnzalutamide%2520for%2520the%2520treatment%2520of%2520androgen%2520receptor-expressing%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D9%26spage%3D884%26epage%3D890%26doi%3D10.1200%2FJCO.2016.71.3495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebied, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper-DeHoff, R.</span></span> <span> </span><span class="NLM_article-title">New drug approvals in 2018 - another record year!</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1016/j.amjmed.2019.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.amjmed.2019.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30853471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3cbitlOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2019&pages=1038-1043&issue=9&author=A.+Ebiedauthor=J.+Naauthor=R.+Cooper-DeHoff&title=New+drug+approvals+in+2018+-+another+record+year%21&doi=10.1016%2Fj.amjmed.2019.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">New Drug Approvals in 2018 - Another Record Year!</span></div><div class="casAuthors">Ebied Alex M; Na Juri; Cooper-DeHoff Rhonda M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1038-1043</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In 2018, the US Food and Drug Administration approved 59 novel drugs.  This all-time record was due primarily to the expedited review pathways; 43 of the 59 (73%) novel drug approvals were designated in an expedited review pathway, and 34 of the 59 (58%) were approved for treatment of rare diseases.  A review of these novel drugs is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtcAMHF8dFLKe0F5ixvZgXfW6udTcc2eYpCBUkN_ekM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbitlOitw%253D%253D&md5=3bacfd49accb4dbe5ce0769f3c83d142</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2019.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2019.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DEbied%26aufirst%3DA.%26aulast%3DNa%26aufirst%3DJ.%26aulast%3DCooper-DeHoff%26aufirst%3DR.%26atitle%3DNew%2520drug%2520approvals%2520in%25202018%2520-%2520another%2520record%2520year%2521%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2019%26volume%3D132%26issue%3D9%26spage%3D1038%26epage%3D1043%26doi%3D10.1016%2Fj.amjmed.2019.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. M.</span></span> <span> </span><span class="NLM_article-title">Varlitinib downregulates HER/ERK signaling and induces apoptosis in triple negative breast cancer cells</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.3390/cancers11010105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers11010105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKgsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=105&issue=1&author=C.+Y.+Liuauthor=P.+Y.+Chuauthor=C.+T.+Huangauthor=J.+L.+Chenauthor=H.+P.+Yangauthor=W.+L.+Wangauthor=K.+Y.+Lauauthor=C.+H.+Leeauthor=T.+Y.+Lanauthor=T.+T.+Huangauthor=P.+H.+Linauthor=M.+S.+Daiauthor=L.+M.+Tseng&title=Varlitinib+downregulates+HER%2FERK+signaling+and+induces+apoptosis+in+triple+negative+breast+cancer+cells&doi=10.3390%2Fcancers11010105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Varlitinib downregulates HER/ERK signaling and induces apoptosis in triple negative breast cancer cells</span></div><div class="casAuthors">Liu, Chun-Yu; Chu, Pei-Yi; Huang, Chun-Teng; Chen, Ji-Lin; Yang, Hsiu-Ping; Wang, Wan-Lun; Lau, Ka-Yi; Lee, Chia-Han; Lan, Tien-Yun; Huang, Tzu-Ting; Lin, Po-Han; Dai, Ming-Shen; Tseng, Ling-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a complex disease assocd. with the aggressive phenotype and poor prognosis.  TNBC harbors heterogeneous mol. subtypes with no approved specific targeted therapy.  It has been reported that HER receptors are overexpressed in breast cancer including TNBC.  In this study, we evaluated the efficacy of varlitinib, a reversible small mol. pan-HER inhibitor in TNBC.  Our results showed that varlitinib reduced cell viability and induced cell apoptosis in most TNBC cell lines but not in MDA-MB-231 cells.  MEK and ERK inhibition overcame resistance to varlitinib in MDA-MB-231 cells.  Varlitinib inhibited HER signaling which led to inhibition of migration, invasion and mammosphere formation of TNBC cells as well as significant suppression of tumor growth of MDA-MB-468 xenograft mouse model.  In summary, these results suggest that HER signaling plays an important role in TNBC progression and that pan-HER inhibition is potentially an effective treatment for TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou9HLm9WN94bVg90H21EOLACvtfcHk0ljCKfsGC1gNTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKgsL7K&md5=0019c6f1f80f329bd3b2c62c3839646a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fcancers11010105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11010105%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DJ.%2BL.%26aulast%3DYang%26aufirst%3DH.%2BP.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DLau%26aufirst%3DK.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DLan%26aufirst%3DT.%2BY.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DLin%26aufirst%3DP.%2BH.%26aulast%3DDai%26aufirst%3DM.%2BS.%26aulast%3DTseng%26aufirst%3DL.%2BM.%26atitle%3DVarlitinib%2520downregulates%2520HER%252FERK%2520signaling%2520and%2520induces%2520apoptosis%2520in%2520triple%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D1%26spage%3D105%26doi%3D10.3390%2Fcancers11010105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. M.</span></span> <span> </span><span class="NLM_article-title">Salidroside inhibits migration, invasion and angiogenesis of MDAMB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.3892/ijo.2018.4430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3892%2Fijo.2018.4430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29901185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=877-885&issue=2&author=D.+Y.+Kangauthor=N.+Spauthor=D.+H.+Kimauthor=Y.+H.+Joungauthor=H.+G.+Leeauthor=Y.+M.+Parkauthor=Y.+M.+Yang&title=Salidroside+inhibits+migration%2C+invasion+and+angiogenesis+of+MDAMB+231+TNBC+cells+by+regulating+EGFR%2FJak2%2FSTAT3+signaling+via+MMP2&doi=10.3892%2Fijo.2018.4430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Salidroside inhibits migration, invasion and angiogenesis of MDA-MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2</span></div><div class="casAuthors">Kang, Dong Young; Sp, Nipin; Kim, Doh Hoon; Joung, Youn Hee; Lee, Hyo Gun; Park, Young Min; Yang, Young Mok</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">877-885</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The major hallmarks of tumor progression are angiogenesis, migration and metastasis.  Among the components of Rhodiola rosea, salidroside (p-hydroxyphenethyl-β-dglucoside) is one of the most potent, and is present in all Rhodiola species.  The present study aimed to analyze how salidroside affects major factors involved in breast cancer, and to elucidate its ability to inhibit angiogenesis and invasion.  Signal transducer and activator of transcription 3 (STAT3) is a marker for tumor angiogenesis and migration, which interacts with matrix metalloproteinases (MMPs).  Specifically, MMPs act as a downstream target for STAT3.  Using western blotting and reverse transcription-quant. polymerase chain reaction anal., the present study demonstrated that treatment of MDA-MB 231 triple-neg. breast cancer (TNBC) cells with salidroside led to inhibition of invasion and migration markers, and of STAT3 signaling.  Furthermore, in vitro angiogenesis analyses in human umbilical vein endothelial cells confirmed the anti-angiogenic activity of salidroside.  An electrophoretic mobility shift assay also demonstrated that salidroside may inhibit the DNA-binding activity of STAT3, preventing STAT3 from binding to a novel binding site of the MMP2 gene promoter.  In conclusion, the present results demonstrated that salidroside may downregulate the STAT3 signaling pathway, and inhibit cell viability, migration and invasion through MMPs in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK7dsZ9hKGhbVg90H21EOLACvtfcHk0ljCKfsGC1gNTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCrtrs%253D&md5=674c95b736f01112367f4e5605781945</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3892%2Fijo.2018.4430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2018.4430%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DD.%2BY.%26aulast%3DSp%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DJoung%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BG.%26aulast%3DPark%26aufirst%3DY.%2BM.%26aulast%3DYang%26aufirst%3DY.%2BM.%26atitle%3DSalidroside%2520inhibits%2520migration%252C%2520invasion%2520and%2520angiogenesis%2520of%2520MDAMB%2520231%2520TNBC%2520cells%2520by%2520regulating%2520EGFR%252FJak2%252FSTAT3%2520signaling%2520via%2520MMP2%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2018%26volume%3D53%26issue%3D2%26spage%3D877%26epage%3D885%26doi%3D10.3892%2Fijo.2018.4430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elbaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasser, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahirwar, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oghumu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoskar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shilo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, W. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganju, R. K.</span></span> <span> </span><span class="NLM_article-title">Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">906</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2014.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.molonc.2014.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25660577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVaktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=906-919&issue=4&author=M.+Elbazauthor=M.+W.+Nasserauthor=J.+Raviauthor=N.+A.+Waniauthor=D.+K.+Ahirwarauthor=H.+Zhaoauthor=S.+Oghumuauthor=A.+R.+Satoskarauthor=K.+Shiloauthor=W.+E.+Carsonauthor=R.+K.+Ganju&title=Modulation+of+the+tumor+microenvironment+and+inhibition+of+EGF%2FEGFR+pathway%3A+novel+anti-tumor+mechanisms+of+Cannabidiol+in+breast+cancer&doi=10.1016%2Fj.molonc.2014.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer</span></div><div class="casAuthors">Elbaz, Mohamad; Nasser, Mohd W.; Ravi, Janani; Wani, Nissar A.; Ahirwar, Dinesh K.; Zhao, Helong; Oghumu, Steve; Satoskar, Abhay R.; Shilo, Konstantin; Carson, Wiliam E., III; Ganju, Ramesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">906-919</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The anti-tumor role and mechanisms of Cannabidiol (CBD), a non-psychotropic cannabinoid compd., are not well studied esp. in triple-neg. breast cancer (TNBC).  In the present study, we analyzed CBD's anti-tumorigenic activity against highly aggressive breast cancer cell lines including TNBC subtype.  We show here -for the first time-that CBD significantly inhibits epidermal growth factor (EGF)-induced proliferation and chemotaxis of breast cancer cells.  Further studies revealed that CBD inhibits EGF-induced activation of EGFR, ERK, AKT and NF-kB signaling pathways as well as MMP2 and MMP9 secretion.  In addn., we demonstrated that CBD inhibits tumor growth and metastasis in different mouse model systems.  Anal. of mol. mechanisms revealed that CBD significantly inhibits the recruitment of tumor-assocd. macrophages in primary tumor stroma and secondary lung metastases.  Similarly, our in vitro studies showed a significant redn. in the no. of migrated RAW 264.7 cells towards the conditioned medium of CBD-treated cancer cells.  The conditioned medium of CBD-treated cancer cells also showed lower levels of GM-CSF and CCL3 cytokines which are important for macrophage recruitment and activation.  In summary, our study shows -for the first time-that CBD inhibits breast cancer growth and metastasis through novel mechanisms by inhibiting EGF/EGFR signaling and modulating the tumor microenvironment.  These results also indicate that CBD can be used as a novel therapeutic option to inhibit growth and metastasis of highly aggressive breast cancer subtypes including TNBC, which currently have limited therapeutic options and are assocd. with poor prognosis and low survival rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0OvPnACYBYrVg90H21EOLACvtfcHk0ljCKfsGC1gNTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVaktbg%253D&md5=20fc63b1ce328066e37db731b7998cbe</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DElbaz%26aufirst%3DM.%26aulast%3DNasser%26aufirst%3DM.%2BW.%26aulast%3DRavi%26aufirst%3DJ.%26aulast%3DWani%26aufirst%3DN.%2BA.%26aulast%3DAhirwar%26aufirst%3DD.%2BK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DOghumu%26aufirst%3DS.%26aulast%3DSatoskar%26aufirst%3DA.%2BR.%26aulast%3DShilo%26aufirst%3DK.%26aulast%3DCarson%26aufirst%3DW.%2BE.%26aulast%3DGanju%26aufirst%3DR.%2BK.%26atitle%3DModulation%2520of%2520the%2520tumor%2520microenvironment%2520and%2520inhibition%2520of%2520EGF%252FEGFR%2520pathway%253A%2520novel%2520anti-tumor%2520mechanisms%2520of%2520Cannabidiol%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26issue%3D4%26spage%3D906%26epage%3D919%26doi%3D10.1016%2Fj.molonc.2014.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kgk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">G, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malla, R. R.</span></span> <span> </span><span class="NLM_article-title">Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">108872</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2019.108872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.cbi.2019.108872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31669320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVyht7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2020&pages=108872&author=D.+Kgkauthor=S.+Kumariauthor=S.+Gauthor=R.+R.+Malla&title=Marine+natural+compound+cyclo%28L-leucyl-L-prolyl%29+peptide+inhibits+migration+of+triple+negative+breast+cancer+cells+by+disrupting+interaction+of+CD151+and+EGFR+signaling&doi=10.1016%2Fj.cbi.2019.108872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling</span></div><div class="casAuthors">Kgk, Deepak; Kumari, Seema; G, Shailender; Malla, Rama Rao</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108872</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Cyclo (L-Leucyl-L-Prolyl) peptide/CLP is a marine natural metabolite and well recognized as an antimicrobial and antioxidant agent with limited studies on anticancer activity.  The current study aims to det. the effect of CLP on migration and growth of triple neg. breast cancer cell lines.  The anti-growth potential was evaluated by MTT, BrdU and TUNEL assays; DNA damage by γH2AX and Dead green assays; antimigration activity by Boyden chamber invasion and wound healing assays.  Interaction of CLP with CD151 was resolved by PatchDock.  Effect of CLP on the expression of transmembrane CD151 was evaluated by cell-based ELISA assay.  The interaction between CD151 and EGFR was predicted by using FireDoc Web server.  Impact of CLP on the interaction of CD151 with EGFR was evaluated by co-immunopptn. assay.  The effect of CLP on the cell cycle and its controlling proteins was detd. by Western blotting.  CLP reduced the viability of MDA-MB-231 and MDA-MB-468 TNBC cell lines but not human breast healthy epithelial cell line (MCF-12A) similar to eribulin, std.  CLP also inhibited proliferation; cell cycle and migration.  It induced DNA strand breaks, DNA damage, and cell death.  It showed the most favorable interactions with CD151 in in silico docking and significantly reduced the expression of membrane-bound CD151 proteins.  FireDoc Web study predicted the assocn. between CD151 and EGFR with -29.13 kcal/mol of binding energy.  CLP reduced the interaction of CD151 with EGFR along with the expression of cyclin D, CDK4, PAK, RAC1, and P27kiP1.  This study concludes that CLP suppresses growth and migration by attenuating cell cycle of TNBC cell lines via EGFR and CD151 signaling.  Thus, exploring the EGFR and CD151 signaling pathway targeted by CLP may provide a new approach in the treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpygt4HuDzKWLVg90H21EOLACvtfcHk0lgoLq14rREpiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVyht7jL&md5=77ea188a2cf955c11807dbad924f4c4c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2019.108872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2019.108872%26sid%3Dliteratum%253Aachs%26aulast%3DKgk%26aufirst%3DD.%26aulast%3DKumari%26aufirst%3DS.%26aulast%3DG%26aufirst%3DS.%26aulast%3DMalla%26aufirst%3DR.%2BR.%26atitle%3DMarine%2520natural%2520compound%2520cyclo%2528L-leucyl-L-prolyl%2529%2520peptide%2520inhibits%2520migration%2520of%2520triple%2520negative%2520breast%2520cancer%2520cells%2520by%2520disrupting%2520interaction%2520of%2520CD151%2520and%2520EGFR%2520signaling%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2020%26volume%3D315%26spage%3D108872%26doi%3D10.1016%2Fj.cbi.2019.108872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatem, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labiod, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chateau-Joubert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Plater, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Botty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servely, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieche, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, E.</span></span> <span> </span><span class="NLM_article-title">Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2510</span>– <span class="NLM_lpage">2521</span>, <span class="refDoi"> DOI: 10.1002/ijc.29974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fijc.29974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26686064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFyksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=2510-2521&issue=10&author=R.+Hatemauthor=D.+Labiodauthor=S.+Chateau-Joubertauthor=L.+de+Platerauthor=R.+El+Bottyauthor=S.+Vacherauthor=F.+Boninauthor=J.+L.+Servelyauthor=V.+Dierasauthor=I.+Biecheauthor=E.+Marangoni&title=Vandetanib+as+a+potential+new+treatment+for+estrogen+receptor-negative+breast+cancers&doi=10.1002%2Fijc.29974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers</span></div><div class="casAuthors">Hatem, Rana; Labiod, Dalila; Chateau-Joubert, Sophie; de Plater, Ludmilla; El Botty, Rania; Vacher, Sophie; Bonin, Florian; Servely, Jean-Luc; Dieras, Veronique; Bieche, Ivan; Marangoni, Elisabetta</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2510-2521</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase RET is implicated in the progression of luminal breast cancers (BC) but its role in estrogen receptor (ER) neg. tumors is unknown.  Here we investigated the expression of RET in breast cancer patients tumors and patient-derived xenografts (PDX) and evaluated the therapeutic potential of Vandetanib, a tyrosin kinase inhibitor with strong activity against RET, EGFR and VEGFR2, in ER neg. breast cancer PDX.  The RT-PCR anal. of RET expression in breast tumors of 446 patients and 57 PDX, showed elevated levels of RET in ER+ and HER2+ subtypes and in a small subgroup of triple-neg. breast cancers (TNBC).  The activity of Vandetanib was tested in vivo in three PDX models of TNBC and one model of HER2+ BC with different expression levels of RET and EGFR.  Vandetanib induced tumor regression in PDX models with high expression of RET or EGFR.  The effect was assocd. with inhibition of RET/EGFR phosphorylation and MAP kinase pathway and increased necrosis.  In a PDX model with no expression of RET nor EGFR, Vandetanib slowed tumor growth without inducing tumor regression.  In addn., treatment by Vandetanib decreased expression of murine Vegf receptors and the endothelial marker Cd31 in the four PDX models tested, suggesting inhibition of tumor vascularization.  In summary, these preclin. results suggest that Vandetanib treatment could be useful for patients with ER neg. breast cancers overexpressing Vandetanib's main targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIK0aqhEtPYLVg90H21EOLACvtfcHk0lgoLq14rREpiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFyksQ%253D%253D&md5=c6c68e2f13043046f24ce9b23314230d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fijc.29974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29974%26sid%3Dliteratum%253Aachs%26aulast%3DHatem%26aufirst%3DR.%26aulast%3DLabiod%26aufirst%3DD.%26aulast%3DChateau-Joubert%26aufirst%3DS.%26aulast%3Dde%2BPlater%26aufirst%3DL.%26aulast%3DEl%2BBotty%26aufirst%3DR.%26aulast%3DVacher%26aufirst%3DS.%26aulast%3DBonin%26aufirst%3DF.%26aulast%3DServely%26aufirst%3DJ.%2BL.%26aulast%3DDieras%26aufirst%3DV.%26aulast%3DBieche%26aufirst%3DI.%26aulast%3DMarangoni%26aufirst%3DE.%26atitle%3DVandetanib%2520as%2520a%2520potential%2520new%2520treatment%2520for%2520estrogen%2520receptor-negative%2520breast%2520cancers%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2016%26volume%3D138%26issue%3D10%26spage%3D2510%26epage%3D2521%26doi%3D10.1002%2Fijc.29974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>175</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1007/s10549-019-05166-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-019-05166-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30826934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWnt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2019&pages=339-351&issue=2&author=J.+Leeauthor=B.+Limauthor=T.+Pearsonauthor=K.+Choiauthor=J.+A.+Fusonauthor=C.+Bartholomeuszauthor=L.+J.+Paradisoauthor=T.+Myersauthor=D.+Tripathyauthor=N.+T.+Ueno&title=Anti-tumor+and+anti-metastasis+efficacy+of+E6201%2C+a+MEK1+inhibitor%2C+in+preclinical+models+of+triple-negative+breast+cancer&doi=10.1007%2Fs10549-019-05166-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer</span></div><div class="casAuthors">Lee, Jangsoon; Lim, Bora; Pearson, Troy; Choi, Kuicheon; Fuson, Jon A.; Bartholomeusz, Chandra; Paradiso, Linda J.; Myers, Thomas; Tripathy, Debu; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-351</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Triple-neg. breast cancer (TNBC) lacks the receptor targets estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, and thus, it does not respond to receptor-targeted treatments.  TNBC has higher recurrence, metastasis, and mortality rates than other subtypes of breast cancer.  Mounting data suggest that the MAPK (also known as RAS-RAF-MEK-ERK) pathway is an important therapeutic target in TNBC.  Methods: To evaluate anti-tumor and anti-metastasis efficacy of E6201, we used cell proliferation assay, soft agar assay, cell cycle assay, Annexin V staining assay, immunoblotting anal., immunohistochem., migration assay, invasion assay, mammary fat pad xenograft, and exptl. and spontaneous metastasis xenograft models.  We also evaluated the anti-tumor efficacy of E6201 plus CDK4/6 inhibitor, mTOR inhibitor, or ATR inhibitor.  Results: E6201 inhibited TNBC cell colony formation, migration, and invasion in a dose-dependent manner.  E6201 induced G1 cell cycle arrest and apoptosis.  E6201 inhibited TNBC xenograft growth and inhibited TNBC lung metastasis and improved mouse survival in exptl. metastasis and spontaneous metastasis assays.  Immunohistochem. staining demonstrated that E6201 decreased the metastatic burden in the lung and decreased phosphorylated ERK expression in a dose-dependent manner.  Combination of E6201 with CDK4/6 inhibitor or mTOR inhibitor enhanced E6201's in vitro anti-tumor efficacy.  Conclusion: These results indicate that E6201 exhibits anti-tumor efficacy against TNBC in vitro and anti-metastasis efficacy against TNBC in vivo.  These results provide a rationale for further clin. development of E6201 as a MAPK-pathway-targeted therapy for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM2oQkV2aX27Vg90H21EOLACvtfcHk0lgoLq14rREpiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWnt7vK&md5=f667ee90f0b3dbcf62a76ab138b90c8f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs10549-019-05166-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-019-05166-3%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DPearson%26aufirst%3DT.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DFuson%26aufirst%3DJ.%2BA.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DParadiso%26aufirst%3DL.%2BJ.%26aulast%3DMyers%26aufirst%3DT.%26aulast%3DTripathy%26aufirst%3DD.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DAnti-tumor%2520and%2520anti-metastasis%2520efficacy%2520of%2520E6201%252C%2520a%2520MEK1%2520inhibitor%252C%2520in%2520preclinical%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2019%26volume%3D175%26issue%3D2%26spage%3D339%26epage%3D351%26doi%3D10.1007%2Fs10549-019-05166-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putatunda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, P. C.</span></span> <span> </span><span class="NLM_article-title">Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3936</span>– <span class="NLM_lpage">3949</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.594028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1074%2Fjbc.M114.594028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25527500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=3936-3949&issue=7&author=S.+Ghoshauthor=A.+Adhikaryauthor=S.+Chakrabortyauthor=P.+Bhattacharjeeauthor=M.+Mazumderauthor=S.+Putatundaauthor=M.+Gorainauthor=A.+Chakrabortyauthor=G.+C.+Kunduauthor=T.+Dasauthor=P.+C.+Sen&title=Cross-talk+between+endoplasmic+reticulum+%28ER%29+stress+and+the+MEK%2FERK+pathway+potentiates+apoptosis+in+human+triple+negative+breast+carcinoma+cells%3A+role+of+a+dihydropyrimidone%2C+nifetepimine&doi=10.1074%2Fjbc.M114.594028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK Pathway Potentiates Apoptosis in Human Triple Negative Breast Carcinoma Cells</span></div><div class="casAuthors">Ghosh, Swatilekha; Adhikary, Arghya; Chakraborty, Supriya; Bhattacharjee, Pushpak; Mazumder, Minakshi; Putatunda, Salil; Gorain, Mahadeo; Chakraborty, Arijit; Kundu, Gopal C.; Das, Tanya; Sen, Parimal C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3936-3949</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Triple neg. breast cancers (TNBC) are among the most aggressive and therapy-resistant breast tumors and currently possess almost no mol. targets for therapeutic options in this horizon.  In the present study we discerned the mol. mechanisms of potential interaction between the endoplasmic reticulum (ER) stress response and the MEK/ERK pathway in inducing apoptosis in TNBC cells.  Here we obsd. that induction of ER stress alone was not sufficient to trigger significant apoptosis but simultaneous inhibition of the MEK/ERK pathway enhanced ER stress-induced apoptosis via a caspase-dependent mechanism.  Our study also demonstrated nifetepimine, a dihydropyrimidone deriv. as a potent anti-cancer agent in TNBC cells.  Nifetepimine down-regulated the MEK/ERK pathway in MDAMB-231 and MDAMB-468 cells and resulted in blockage of ER stress-mediated GRP78 up-regulation.  Detailed mechanistic studies also revealed that nifetepimine by down-regulating pERK expression also declined the promoter binding activity of TFII-I to the GRP78 promoter and in turn regulated GRP78 transcription.  Studies further extended to in vivo Swiss albino and SCID mice models also revalidated the anti-carcinogenic property of nifetepimine.  Thus our findings cumulatively suggest that nifetepimine couples two distinct signaling pathways to induce the apoptotic death cascade in TNBC cells and raises the possibility for the use of nifetepimine as a potent anti-cancer agent with strong immune-restoring properties for therapeutic intervention for this group of cancer bearers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiuRnGB-DU-LVg90H21EOLACvtfcHk0lihC7Aa2Hz62A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGqt70%253D&md5=d88a156eae32d9e35128a2334efab4db</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.594028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.594028%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DAdhikary%26aufirst%3DA.%26aulast%3DChakraborty%26aufirst%3DS.%26aulast%3DBhattacharjee%26aufirst%3DP.%26aulast%3DMazumder%26aufirst%3DM.%26aulast%3DPutatunda%26aufirst%3DS.%26aulast%3DGorain%26aufirst%3DM.%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DKundu%26aufirst%3DG.%2BC.%26aulast%3DDas%26aufirst%3DT.%26aulast%3DSen%26aufirst%3DP.%2BC.%26atitle%3DCross-talk%2520between%2520endoplasmic%2520reticulum%2520%2528ER%2529%2520stress%2520and%2520the%2520MEK%252FERK%2520pathway%2520potentiates%2520apoptosis%2520in%2520human%2520triple%2520negative%2520breast%2520carcinoma%2520cells%253A%2520role%2520of%2520a%2520dihydropyrimidone%252C%2520nifetepimine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26issue%3D7%26spage%3D3936%26epage%3D3949%26doi%3D10.1074%2Fjbc.M114.594028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">6762</span>– <span class="NLM_lpage">6775</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.3105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25742792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnht1Skug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6762-6775&issue=9&author=B.+Liuauthor=L.+Fuauthor=C.+Zhangauthor=L.+Zhangauthor=Y.+Zhangauthor=L.+Ouyangauthor=G.+Heauthor=J.+Huang&title=Computational+design%2C+chemical+synthesis%2C+and+biological+evaluation+of+a+novel+ERK+inhibitor+%28BL-EI001%29+with+apoptosis-inducing+mechanisms+in+breast+cancer&doi=10.18632%2Foncotarget.3105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer</span></div><div class="casAuthors">Liu Bo; Fu Leilei; Zhang Yonghui; Ouyang Liang; He Gu; Zhang Cui; Zhang Lan; Huang Jian; Zhang Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6762-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Extracellular signal-regulated kinase1/2 (ERK1/2) plays a crucial role in the resistance of apoptosis in carcinogenesis; however, its targeted small-molecule inhibitors still remain to be discovered.  Thus, in this study, we computationally and experimentally screened a series of small-molecule inhibitors targeting ERK toward different types of human breast cancer cells.  Subsequently, we synthesized some candidate ERK inhibitors, identified a novel ERK inhibitor (BL-EI001) with anti-proliferative activities, and analyzed the BL-EI001/ERK complex.  Moreover, we found that BL-EI001 induced breast cancer cell apoptosis via mitochondrial pathway but independent on Ras/Raf/MEK pathway.  In addition, we carried out proteomics analyses for exploring some possible BL-EI001-induced apoptotic pathways, and further found that BL-EI001-induced apoptosis affected ERK phosphorylation in breast cancer.  Further, we found that BL-EI001 bear anti-tumor activities without remarkable toxicities, and also induced mitochondrial apoptosis by targeting ERK in vivo.  Taken together, these results demonstrate that in silico design and experimental discovery of a synthesized small-molecule ERK inhibitor (BL-EI001)as a potential novel apoptosis-inducing drug in the treatment of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAcldmGJtbSv9pSBfyDvp7fW6udTcc2ebECxtZueg6mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnht1Skug%253D%253D&md5=f2431958417d2dd62c77664ec3e88604</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3105%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DComputational%2520design%252C%2520chemical%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520%2528BL-EI001%2529%2520with%2520apoptosis-inducing%2520mechanisms%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26issue%3D9%26spage%3D6762%26epage%3D6775%26doi%3D10.18632%2Foncotarget.3105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karreth, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdal, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elemento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Identifying and targeting sporadic oncogenic genetic aberrations in mouse models of triple-negative breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F2159-8290.CD-17-0679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29203461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVCitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=354-369&issue=3&author=H.+Liuauthor=C.+J.+Murphyauthor=F.+A.+Karrethauthor=K.+B.+Emdalauthor=F.+M.+Whiteauthor=O.+Elementoauthor=A.+Tokerauthor=G.+M.+Wulfauthor=L.+C.+Cantley&title=Identifying+and+targeting+sporadic+oncogenic+genetic+aberrations+in+mouse+models+of+triple-negative+breast+cancer&doi=10.1158%2F2159-8290.CD-17-0679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Liu, Hui; Murphy, Charles J.; Karreth, Florian A.; Emdal, Kristina B.; White, Forest M.; Elemento, Olivier; Toker, Alex; Wulf, Gerburg M.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">354-369</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBC) are genetically characterized by aberrations in TP53 and a low rate of activating point mutations in common oncogenes, rendering it challenging in applying targeted therapies.  We performed whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to identify somatic genetic alterations in mouse models of TNBCs driven by loss of Trp53 alone or in combination with Brca1.  Amplifications or translocations that resulted in elevated oncoprotein expression or oncoprotein-contg. fusions, resp., as well as frameshift mutations of tumor suppressors were identified in approx. 50% of the tumors evaluated.  Although the spectrum of sporadic genetic alterations was diverse, the majority had in common the ability to activate the MAPK/PI3K pathways.  Importantly, we demonstrated that approved or exptl. drugs efficiently induce tumor regression specifically in tumors harboring somatic aberrations of the drug target.  Our study suggests that the combination of WES and RNA-seq on human TNBC will lead to the identification of actionable therapeutic targets for precision medicine-guided TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO61D4LP9UArVg90H21EOLACvtfcHk0lihC7Aa2Hz62A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVCitrw%253D&md5=1d0157d39a71c84293034decc0ea1a7b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0679%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMurphy%26aufirst%3DC.%2BJ.%26aulast%3DKarreth%26aufirst%3DF.%2BA.%26aulast%3DEmdal%26aufirst%3DK.%2BB.%26aulast%3DWhite%26aufirst%3DF.%2BM.%26aulast%3DElemento%26aufirst%3DO.%26aulast%3DToker%26aufirst%3DA.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DIdentifying%2520and%2520targeting%2520sporadic%2520oncogenic%2520genetic%2520aberrations%2520in%2520mouse%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D3%26spage%3D354%26epage%3D369%26doi%3D10.1158%2F2159-8290.CD-17-0679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scoggins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrada, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcenas, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damodaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSnyder, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewster, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz-Gomez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arun, B.</span></span> <span> </span><span class="NLM_article-title">Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">508</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2018.36.15_suppl.508" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=508&issue=15_suppl&author=J.+K.+Littonauthor=M.+Scogginsauthor=K.+R.+Hessauthor=B.+Adradaauthor=C.+H.+Barcenasauthor=R.+K.+Murthyauthor=S.+Damodaranauthor=S.+M.+DeSnyderauthor=A.+M.+Brewsterauthor=A.+M.+Thompsonauthor=G.+J.+Whitmanauthor=N.+K.+Ibrahimauthor=S.+L.+Moulderauthor=J.+Schwartz-Gomezauthor=E.+A.+Mittendorfauthor=B.+Arun&title=Neoadjuvant+talazoparib+%28TALA%29+for+operable+breast+cancer+patients+with+a+BRCA+mutation+%28BRCA%2B%29&doi=10.1200%2FJCO.2018.36.15_suppl.508"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.508%26sid%3Dliteratum%253Aachs%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DScoggins%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DK.%2BR.%26aulast%3DAdrada%26aufirst%3DB.%26aulast%3DBarcenas%26aufirst%3DC.%2BH.%26aulast%3DMurthy%26aufirst%3DR.%2BK.%26aulast%3DDamodaran%26aufirst%3DS.%26aulast%3DDeSnyder%26aufirst%3DS.%2BM.%26aulast%3DBrewster%26aufirst%3DA.%2BM.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DWhitman%26aufirst%3DG.%2BJ.%26aulast%3DIbrahim%26aufirst%3DN.%2BK.%26aulast%3DMoulder%26aufirst%3DS.%2BL.%26aulast%3DSchwartz-Gomez%26aufirst%3DJ.%26aulast%3DMittendorf%26aufirst%3DE.%2BA.%26aulast%3DArun%26aufirst%3DB.%26atitle%3DNeoadjuvant%2520talazoparib%2520%2528TALA%2529%2520for%2520operable%2520breast%2520cancer%2520patients%2520with%2520a%2520BRCA%2520mutation%2520%2528BRCA%252B%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D15_suppl%26spage%3D508%26doi%3D10.1200%2FJCO.2018.36.15_suppl.508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pantelidou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonzogni, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Oliveria
Taveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrillon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheney, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulf, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitor efficacy depends on CD8 T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-1218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F2159-8290.CD-18-1218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31015319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FosVGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=722-737&issue=6&author=C.+Pantelidouauthor=O.+Sonzogniauthor=M.+De+Oliveria%0ATaveiraauthor=A.+K.+Mehtaauthor=A.+Kothariauthor=D.+Wangauthor=T.+Visalauthor=M.+K.+Liauthor=J.+Pintoauthor=J.+A.+Castrillonauthor=E.+M.+Cheneyauthor=P.+Bouwmanauthor=J.+Jonkersauthor=S.+Rottenbergauthor=J.+L.+Guerrieroauthor=G.+M.+Wulfauthor=G.+I.+Shapiro&title=PARP+inhibitor+efficacy+depends+on+CD8+T-cell+recruitment+via+intratumoral+STING+pathway+activation+in+BRCA-deficient+models+of+triple-negative+breast+cancer&doi=10.1158%2F2159-8290.CD-18-1218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Pantelidou Constantia; Kothari Aditi; Visal Tanvi; Shapiro Geoffrey I; Sonzogni Olmo; De Oliveria Taveira Mateus; Wang Dan; Li Michelle K; Pinto Jocelin; Wulf Gerburg M; De Oliveria Taveira Mateus; Mehta Anita K; Castrillon Jessica A; Cheney Emily M; Guerriero Jennifer L; Wang Dan; Bouwman Peter; Jonkers Jos; Rottenberg Sven; Rottenberg Sven; Shapiro Geoffrey I</div><div class="citationInfo"><span class="NLM_cas:title">Cancer discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-737</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied.  Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC).  We demonstrate that the PARP inhibitor olaparib induces CD8(+) T-cell infiltration and activation in vivo, and that CD8(+) T-cell depletion severely compromises antitumor efficacy.  Olaparib-induced T-cell recruitment is mediated through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-deficient compared with HR-proficient TNBC cells and in vivo models.  CRISPR-mediated knockout of STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish olaparib-induced T-cell infiltration in vivo.  These findings elucidate an additional mechanism of action of PARP inhibitors and provide a rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC.  SIGNIFICANCE: This work demonstrates cross-talk between PARP inhibition and the tumor microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that governs CD8(+) T-cell recruitment and antitumor efficacy.  The data provide insight into the mechanism of action of PARP inhibitors in BRCA-associated breast cancer.This article is highlighted in the In This Issue feature, p. 681.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxbdzw73c18b0AGQpJZWpJfW6udTcc2ebYea19bKjlRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FosVGhsw%253D%253D&md5=d8487d03a3349df3daf16105de1e4ff9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-1218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-1218%26sid%3Dliteratum%253Aachs%26aulast%3DPantelidou%26aufirst%3DC.%26aulast%3DSonzogni%26aufirst%3DO.%26aulast%3DDe%2BOliveria%2BTaveira%26aufirst%3DM.%26aulast%3DMehta%26aufirst%3DA.%2BK.%26aulast%3DKothari%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DVisal%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DM.%2BK.%26aulast%3DPinto%26aufirst%3DJ.%26aulast%3DCastrillon%26aufirst%3DJ.%2BA.%26aulast%3DCheney%26aufirst%3DE.%2BM.%26aulast%3DBouwman%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DRottenberg%26aufirst%3DS.%26aulast%3DGuerriero%26aufirst%3DJ.%2BL.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DPARP%2520inhibitor%2520efficacy%2520depends%2520on%2520CD8%2520T-cell%2520recruitment%2520via%2520intratumoral%2520STING%2520pathway%2520activation%2520in%2520BRCA-deficient%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D6%26spage%3D722%26epage%3D737%26doi%3D10.1158%2F2159-8290.CD-18-1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1038/s41598-016-0007-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41598-016-0007-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28442756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1crhtFChsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=3&issue=1&author=L.+Fuauthor=S.+Wangauthor=X.+Wangauthor=P.+Wangauthor=Y.+Zhengauthor=D.+Yaoauthor=M.+Guoauthor=L.+Zhangauthor=L.+Ouyang&title=Crystal+structure-based+discovery+of+a+novel+synthesized+PARP1+inhibitor+%28OL-1%29+with+apoptosis-inducing+mechanisms+in+triple-negative+breast+cancer&doi=10.1038%2Fs41598-016-0007-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer</span></div><div class="casAuthors">Fu Leilei; Wang Shuya; Wang Xuan; Wang Peiqi; Zheng Yaxin; Yao Dahong; Guo Mingrui; Zhang Lan; Ouyang Liang; Wang Shuya; Wang Peiqi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conserved enzyme focused on the self-repair of cellular DNA damage.  Until now, numbers of PARP inhibitors have been reported and used for breast cancer therapy in recent years, especially in TNBC.  However, developing a new type PARP inhibitor with distinctive skeleton is alternatively promising strategy for TNBC therapy.  In this study, based on co-crystallization studies and pharmacophore-docking-based virtual screening, we discovered a series of dihydrodibenzo[b,e]-oxepin compounds as PARP1 inhibitors.  Lead optimization result in the identification of compound OL-1 (2-(11-(3-(dimethylamino)propylidene)-6,11- dihydrodibenzo[b,e]oxepin )-2-yl)acetohydrazide), which has a novel chemical scaffold and unique binding interaction with PARP1 protein.  OL-1 demonstrated excellent potency (inhibiting PARP1 enzyme activity with IC50 = 0.079 μM), as well as inhibiting PARP-modulated PARylation and cell proliferation in MDA-MB-436 cells (BRAC1 mutation).  In addition, OL-1 also inhibited cell migration that closely related to cancer metastasis and displayed remarkable anti-tumor efficacy in MDA-MB-436 xenograft model without apparent toxicities.  These findings highlight a new small-molecule PAPR1 inhibitor (OL-1) that has the potential to impact future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCGXnCF2P3vK91pGlMMoT5fW6udTcc2ebYea19bKjlRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhtFChsw%253D%253D&md5=b84954d1577a0b753255501f3e26408a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fs41598-016-0007-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-016-0007-2%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DCrystal%2520structure-based%2520discovery%2520of%2520a%2520novel%2520synthesized%2520PARP1%2520inhibitor%2520%2528OL-1%2529%2520with%2520apoptosis-inducing%2520mechanisms%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D1%26spage%3D3%26doi%3D10.1038%2Fs41598-016-0007-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span> <span> </span><span class="NLM_article-title">A sesquiterpenoid from Farfarae Flos induces apoptosis of MDA-MB-231 human breast cancer cells through inhibition of JAK–STAT3 signaling</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">278</span>, <span class="refDoi"> DOI: 10.3390/biom9070278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fbiom9070278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1eitLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=278&issue=7&author=H.+Jangauthor=H.+Koauthor=K.+Songauthor=S.+Y.+Kim&title=A+sesquiterpenoid+from+Farfarae+Flos+induces+apoptosis+of+MDA-MB-231+human+breast+cancer+cells+through+inhibition+of+JAK%E2%80%93STAT3+signaling&doi=10.3390%2Fbiom9070278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A sesquiterpenoid from farfarae flos induces apoptosis of MDA-MB-231 human breast cancer cells through inhibition of JAK-STAT3 signaling</span></div><div class="casAuthors">Jang, Hyeri; Ko, Hyejin; Song, Kwangho; Kim, Yeong Shik</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">278pp.</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBCs) are hard-to-treat breast tumors with poor prognosis, which need to be treated by chemotherapy.  Signal transducer and activator of transcription 3 (STAT3) is a transcription factor involved in proliferation, metastasis, and invasion of cancer cells.  Therefore, research on searching for promising compds. with metab. that suppress phosphorylation or transcription of STAT3 in TNBC cells is important.  Farfarae Flos is well known as a traditional medicine for treating inflammation.  However, few studies have shown that sesquiterpenoids from Farfarae Flos have an anticancer effect.  In this study, efficient sepn. methods and an MTT assay were conducted to isolate an anticancer compd. from Farfarae Flos against TNBC MDA-MB-231 cells.  Here, 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone (ECN), a compd. isolated from Farfarae Flos showed a potent cytotoxic effect on MDA-MB-231 cells.  ECN inhibited JAK-STAT3 signaling and suppressed the expression of STAT3 target genes.  In addn., ECN induced apoptosis through both extrinsic and intrinsic pathways.  Furthermore, we investigated that ECN inhibited the growth of tumors by i.p. administration in mice injected with MDA-MB-231 cells.  Therefore, ECN can be an effective chemotherapeutic agent for breast cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsry_6SkgatLVg90H21EOLACvtfcHk0liuFFk5sF4PvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1eitLvL&md5=806f6a1964b0e031747f3b5072c945a2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3390%2Fbiom9070278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom9070278%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DH.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BY.%26atitle%3DA%2520sesquiterpenoid%2520from%2520Farfarae%2520Flos%2520induces%2520apoptosis%2520of%2520MDA-MB-231%2520human%2520breast%2520cancer%2520cells%2520through%2520inhibition%2520of%2520JAK%25E2%2580%2593STAT3%2520signaling%26jtitle%3DBiomolecules%26date%3D2019%26volume%3D9%26issue%3D7%26spage%3D278%26doi%3D10.3390%2Fbiom9070278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. J.</span></span> <span> </span><span class="NLM_article-title">Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer</span>. <i>Nat. Prod. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1080/14786419.2017.1396596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1080%2F14786419.2017.1396596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29086600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCmtL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=477-485&issue=4&author=B.+Yangauthor=J.+W.+Shenauthor=D.+H.+Zhouauthor=Y.+P.+Zhaoauthor=W.+Q.+Wangauthor=Y.+Zhuauthor=H.+J.+Zhao&title=Precise+discovery+of+a+STAT3+inhibitor+from+Eupatorium+lindleyanum+and+evaluation+of+its+activity+of+anti-triple-negative+breast+cancer&doi=10.1080%2F14786419.2017.1396596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer</span></div><div class="casAuthors">Yang, Bo; Shen, Jia Wei; Zhou, Dong Heng; Zhao, Ya Ping; Wang, Wei Qian; Zhu, Ying; Zhao, Hua Jun</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">NPRAAT</span>;
        ISSN:<span class="NLM_cas:issn">1478-6419</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Michael reaction acceptors (MRAs) are a class of active compds.  There is a great prospect to screen STAT3 inhibitors from Eupatorium lindleyanum, furthermore, to discover lead compds. for anti-triple-neg. breast cancer (TNBC).  In this study, glutathione (GSH) was employed, and a UPLC-MS screening method was developed to discover MRAs.  We screened MRAs which can inhibit STAT3 using a STAT3-dependent reporter system.  Six sesquiterpene lactones, including a new compd. Eupalinolide O, together with five known compds., Eupalinolide I, Eupalinolide K, Eupalinolide H, Eupalinolide J and Eupalinolide G were isolated.  Eupalinolide J was identified as MRA that decreased luciferase activity of STAT3.  Preliminary activity assessment showed that Eupalinolide J could inhibit the viability of TNBC cell lines.  We demonstrated that Eupalinolide J, which is a natural typical MRA, has a notable inhibition of STAT3 activity and a potential cytotoxic activity against TNBC cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_5-tBUv0LNbVg90H21EOLACvtfcHk0liuFFk5sF4PvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCmtL7P&md5=29d3f06881a4ce1259778e6d1dbd188c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F14786419.2017.1396596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14786419.2017.1396596%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DJ.%2BW.%26aulast%3DZhou%26aufirst%3DD.%2BH.%26aulast%3DZhao%26aufirst%3DY.%2BP.%26aulast%3DWang%26aufirst%3DW.%2BQ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DH.%2BJ.%26atitle%3DPrecise%2520discovery%2520of%2520a%2520STAT3%2520inhibitor%2520from%2520Eupatorium%2520lindleyanum%2520and%2520evaluation%2520of%2520its%2520activity%2520of%2520anti-triple-negative%2520breast%2520cancer%26jtitle%3DNat.%2520Prod.%2520Res.%26date%3D2019%26volume%3D33%26issue%3D4%26spage%3D477%26epage%3D485%26doi%3D10.1080%2F14786419.2017.1396596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, A.</span></span> <span> </span><span class="NLM_article-title">Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.3892/or.2018.6805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3892%2For.2018.6805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30365081" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=437-446&issue=1&author=W.+Liauthor=H.+Yangauthor=X.+Liauthor=L.+Hanauthor=N.+Xuauthor=A.+Shi&title=Signaling+pathway+inhibitors+target+breast+cancer+stem+cells+in+triple-negative+breast+cancer&doi=10.3892%2For.2018.6805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3892%2For.2018.6805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2018.6805%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DN.%26aulast%3DShi%26aufirst%3DA.%26atitle%3DSignaling%2520pathway%2520inhibitors%2520target%2520breast%2520cancer%2520stem%2520cells%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncol.%2520Rep.%26date%3D2018%26volume%3D41%26issue%3D1%26spage%3D437%26epage%3D446%26doi%3D10.3892%2For.2018.6805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span> <span> </span><span class="NLM_article-title">1,3-Dicaffeoylquinic acid targeting 14–3-3 tau suppresses human breast cancer cell proliferation and metastasis through IL6/JAK2/PI3K pathway</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">113752</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.113752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.bcp.2019.113752" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31836387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKrs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2020&pages=113752&author=Y.+Zhouauthor=X.+Fuauthor=Y.+Guanauthor=M.+Gongauthor=K.+Heauthor=B.+Huang&title=1%2C3-Dicaffeoylquinic+acid+targeting+14%E2%80%933-3+tau+suppresses+human+breast+cancer+cell+proliferation+and+metastasis+through+IL6%2FJAK2%2FPI3K+pathway&doi=10.1016%2Fj.bcp.2019.113752"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">1,3-Dicaffeoylquinic acid targeting 14-3-3 tau suppresses human breast cancer cell proliferation and metastasis through IL6/JAK2/PI3K pathway</span></div><div class="casAuthors">Zhou, Yuhang; Fu, Xiang; Guan, Yanqing; Gong, Mengting; He, Kan; Huang, Bei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113752</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">14-3-3τ Plays a crit. role in tumorigenesis and metastasis of breast cancer and can be used as new drug target protein.  Dicaffeoylquinic acids (DCQAs), natural products, have antioxidant, antimicrobial, and anti-inflammatory activities.  In this study, the anticancer effects of DCQAs on breast cancer cells MCF-7, MDA-MB-231 cell lines and mechanism in triple neg. breast cancer (TNBC) were investigated.  First, we screened for DCQAs that could bind to 14-3-3τ and had a significant inhibitory effect on breast cancer cells.  MTT, colony formation, transwell migration, and flow cytometric assays revealed that 1,3-DCQA was the best one of 14-3-3τ binding protein from DCQAs against breast cancer cell proliferation and metastasis but safe for normal cells.  Through mol. docking simulation, overexpression and knockdown assays, we confirmed that 14-3-3τ was one of 1,3-DCQA target protein.  Eukaryotic transcriptome sequencing and western blot anal. demonstrated that 1,3-DCQA binds to 14-3-3τ to prevent breast cancer proliferation and metastasis via Jak/PI3K/Akt and Raf/ERK pathway, which promote IL6 and CSF3 expression raised by CREB (CREBBP, CREB5) and induced cell apoptosis via Bad/Bax/caspase 9 signaling pathway.  Our results provided evidence that 1,3-DCQA can be used as a novel lead compd. against breast cancer by inhibition of 14-3-3 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPvK3pKH9A87Vg90H21EOLACvtfcHk0liuFFk5sF4PvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKrs7zN&md5=0db5cc960c92a4a78cc616cb5a5ef1c0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.113752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.113752%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DB.%26atitle%3D1%252C3-Dicaffeoylquinic%2520acid%2520targeting%252014%25E2%2580%25933-3%2520tau%2520suppresses%2520human%2520breast%2520cancer%2520cell%2520proliferation%2520and%2520metastasis%2520through%2520IL6%252FJAK2%252FPI3K%2520pathway%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2020%26volume%3D172%26spage%3D113752%26doi%3D10.1016%2Fj.bcp.2019.113752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span> <span> </span><span class="NLM_article-title">Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>357</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2014.11.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2014.11.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25434800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVeis7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2015&pages=393-403&issue=1&author=J.+Chunauthor=R.+J.+Liauthor=M.+S.+Chengauthor=Y.+S.+Kim&title=Alantolactone+selectively+suppresses+STAT3+activation+and+exhibits+potent+anticancer+activity+in+MDA-MB-231+cells&doi=10.1016%2Fj.canlet.2014.11.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells</span></div><div class="casAuthors">Chun, Jaemoo; Li, Rui-Juan; Cheng, Mao-Sheng; Kim, Yeong Shik</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">393-403</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The important goal of cancer drug discovery is to develop therapeutic agents that are effective, safe, and affordable.  In the present study, we demonstrated that alantolactone, which is a sesquiterpene lactone, has potential activity against triple-neg. breast cancer MDA-MB-231 cells by suppressing the signal transducer and activator of transcription 3 (STAT3) signaling pathway.  Alantolactone effectively suppressed both constitutive and inducible STAT3 activation at tyrosine 705.  Alantolactone decreased STAT3 translocation to the nucleus, its DNA-binding, and STAT3 target gene expression.  Alantolactone significantly inhibits STAT3 activation with a marginal effect on MAPKs and on NF-κB transcription; however, this effect is not mediated by inhibiting STAT3 upstream kinases.  Although SHP-1, SHP-2, and PTEN, which are protein tyrosine phosphatases (PTPs), were not affected by alantolactone, the treatment with a PTP inhibitor reversed the alantolactone-induced suppression of STAT3 activation, indicating that PTP plays an important role in the action of alantolactone.  Finally, alantolactone treatment resulted in the inhibition of migration, invasion, adhesion, and colony formation.  The in vivo administration of alantolactone inhibited the growth of human breast xenograft tumors.  These results provide preclin. evidence to continue the development of alantolactone as a STAT3 inhibitor and as a potential therapeutic agent against breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNY-D5XCgfH7Vg90H21EOLACvtfcHk0lh0V0wxWa9rYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVeis7%252FK&md5=c904bccd5ba1ec5ae07b8e2941903e8a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.11.049%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DR.%2BJ.%26aulast%3DCheng%26aufirst%3DM.%2BS.%26aulast%3DKim%26aufirst%3DY.%2BS.%26atitle%3DAlantolactone%2520selectively%2520suppresses%2520STAT3%2520activation%2520and%2520exhibits%2520potent%2520anticancer%2520activity%2520in%2520MDA-MB-231%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2015%26volume%3D357%26issue%3D1%26spage%3D393%26epage%3D403%26doi%3D10.1016%2Fj.canlet.2014.11.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, Y. G.</span></span> <span> </span><span class="NLM_article-title">Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5032</span>– <span class="NLM_lpage">5040</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.bmc.2017.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28705432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5032-5040&issue=19&author=H.+S.+Kimauthor=T.+Kimauthor=H.+Koauthor=J.+Leeauthor=Y.+S.+Kimauthor=Y.+G.+Suh&title=Identification+of+galiellalactone-based+novel+STAT3-selective+inhibitors+with+cytotoxic+activities+against+triple-negative+breast+cancer+cell+lines&doi=10.1016%2Fj.bmc.2017.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines</span></div><div class="casAuthors">Kim, Hyun Su; Kim, Taewoo; Ko, Hyejin; Lee, Jeeyeon; Kim, Yeong Shik; Suh, Young-Ger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5032-5040</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is phosphorylated in breast cancer cells, particularly triple-neg. breast cancers (TNBCs).  Therefore, the inhibition of constitutive phosphorylated STAT3 is a promising therapeutic for TNBC treatment.  Recently, a series of novel STAT3 inhibitors based on natural (-)-galiellalactone have been identified to inhibit STAT3 phosphorylation at the Tyr705 residue.  Interestingly, the truncation of the cyclohexene moiety of (-)-galiellalactone to [3.3] bicyclic lactone as a pharmacophoric core produced improved cytotoxic effects against TNBCs.  The potent analogs 16 and 17, identified from a STAT3-mediated luciferase reporter assay, selectively inhibited the STAT3 signaling pathway without affecting STAT1 or STAT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBskRR7L612rVg90H21EOLACvtfcHk0lh0V0wxWa9rYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtbbE&md5=ddb78941b45c15c1a33bd7e6ded6269b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DKo%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%2BS.%26aulast%3DSuh%26aufirst%3DY.%2BG.%26atitle%3DIdentification%2520of%2520galiellalactone-based%2520novel%2520STAT3-selective%2520inhibitors%2520with%2520cytotoxic%2520activities%2520against%2520triple-negative%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D19%26spage%3D5032%26epage%3D5040%26doi%3D10.1016%2Fj.bmc.2017.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span> <span> </span><span class="NLM_article-title">Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells</span>. <i>Acta Biochim. Biophys. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1093/abbs/gmx012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fabbs%2Fgmx012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28338932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2hsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=367-373&issue=4&author=W.+Liauthor=H.+Zhangauthor=M.+Nieauthor=Y.+Tianauthor=X.+Chenauthor=C.+Chenauthor=H.+Chenauthor=R.+Liu&title=Ursolic+acid+derivative+FZU-03%2C010+inhibits+STAT3+and+induces+cell+cycle+arrest+and+apoptosis+in+renal+and+breast+cancer+cells&doi=10.1093%2Fabbs%2Fgmx012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells</span></div><div class="casAuthors">Li, Wei; Zhang, Hongxiu; Nie, Mingxiu; Tian, Yanlei; Chen, Xu; Chen, Ceshi; Chen, Haijun; Liu, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Acta Biochimica et Biophysica Sinica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-373</span>CODEN:
                <span class="NLM_cas:coden">ABBSC2</span>;
        ISSN:<span class="NLM_cas:issn">1672-9145</span>.
    
            (<span class="NLM_cas:orgname">ABBS Editorial Office</span>)
        </div><div class="casAbstract">Advanced renal cell carcinoma and triple neg. breast cancer (TNBC) are malignancies without effective therapeutics currently.  Ursolic acid (UA) has been previously reported to have anti-cancer effects in multiple solid tumors.  In order to develop more potent anti-cancer reagents, FZU-03,010 based on the chem. structure of UA were synthesized.  The results demonstrated that, compared with UA, FZU-03,010 could suppress renal cancer cell 786-0 and TNBC cell HCC1806 cell viability more potently.  Furthermore, FZU-03,010 could induce G1 cell cycle arrest and cell apoptosis more efficiently than UA.  FZU-03,010 could also inhibit signal transducer and activator of transcription 3 activation, induce the expression of cell cycle-dependent kinase inhibitors (p21 and p27) and promote cell apoptosis.  In conclusion, our results suggest that the UA deriv. FZU-03,010 is more potent in inhibiting cancer cell survival, and FZU-03,010 has the potential to be developed as a therapeutic for renal cell cancers and TNBCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKG__Y3r8G7Vg90H21EOLACvtfcHk0lh0V0wxWa9rYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2hsLnK&md5=a0b88e8e5612763db5c44dd6db89e1ce</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fabbs%2Fgmx012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fabbs%252Fgmx012%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DNie%26aufirst%3DM.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26atitle%3DUrsolic%2520acid%2520derivative%2520FZU-03%252C010%2520inhibits%2520STAT3%2520and%2520induces%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%2520in%2520renal%2520and%2520breast%2520cancer%2520cells%26jtitle%3DActa%2520Biochim.%2520Biophys.%2520Sin.%26date%3D2017%26volume%3D49%26issue%3D4%26spage%3D367%26epage%3D373%26doi%3D10.1093%2Fabbs%2Fgmx012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span> <span> </span><span class="NLM_article-title">Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">5292</span>– <span class="NLM_lpage">5304</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0340-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41388-018-0340-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29855616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKqsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=5292-5304&issue=39&author=L.+Luauthor=J.+Dongauthor=L.+Wangauthor=Q.+Xiaauthor=D.+Zhangauthor=H.+Kimauthor=T.+Yinauthor=S.+Fanauthor=Q.+Shen&title=Activation+of+STAT3+and+Bcl-2+and+reduction+of+reactive+oxygen+species+%28ROS%29+promote+radioresistance+in+breast+cancer+and+overcome+of+radioresistance+with+niclosamide&doi=10.1038%2Fs41388-018-0340-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide</span></div><div class="casAuthors">Lu, Lu; Dong, Jiali; Wang, Lili; Xia, Qing; Zhang, Dan; Kim, Hyejin; Yin, Tao; Fan, Saijun; Shen, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5292-5304</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Radiotherapy significantly improves the therapeutic outcomes and survival of breast cancer patients.  However, the acquired resistance to this therapeutic modality is a major clin. challenge.  Here we show that ionizing irradn. (IR)-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) at the Tyr705 residue and the induction of reactive oxygen species (ROS) in wild-type and radioresistant MDA-MB-231 and MDA-MB-468 triple-neg. breast cancer (TNBC) cell lines.  Comparing with radiosensitive parental TNBC cells, significantly low levels of ROS and higher protein levels of phospho-STAT3 and Bcl-2 were obsd. in TNBC cells with acquired radioresistance.  Moreover, knockdown of STAT3 by shRNA sensitized the TNBC cells to IR.  Niclosamide, a potent inhibitor of STAT3, overcame the radioresistance in TNBC cells via inhibition of STAT3 and Bcl-2 and induction of ROS.  In combination with radiation, niclosamide treatment resulted in significant increase of ROS generation and induction of apoptosis in parental and radioresistant TNBC cells in vitro and TNBC xenograft tumors in vivo.  These findings demonstrate that activation of STAT3 and Bcl-2 and redn. of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors.  Our findings suggest that niclosamide in combination with irradn. may offer an effective alternative approach for restoring the sensitivity of radioresistant TNBC cells to IR for improved therapeutic efficacy and outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-x7437dw8-bVg90H21EOLACvtfcHk0ljmse6KvVeGgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKqsr%252FP&md5=e56a599ccdc45378434c4af1d8d3a9e7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0340-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0340-y%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DQ.%26atitle%3DActivation%2520of%2520STAT3%2520and%2520Bcl-2%2520and%2520reduction%2520of%2520reactive%2520oxygen%2520species%2520%2528ROS%2529%2520promote%2520radioresistance%2520in%2520breast%2520cancer%2520and%2520overcome%2520of%2520radioresistance%2520with%2520niclosamide%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26issue%3D39%26spage%3D5292%26epage%3D5304%26doi%3D10.1038%2Fs41388-018-0340-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span> <span> </span><span class="NLM_article-title">Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1993</span>, <span class="refDoi"> DOI: 10.1002/ijc.31585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fijc.31585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29744876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1978-1993&issue=8&author=E.+Ohauthor=Y.+J.+Kimauthor=H.+Anauthor=D.+Sungauthor=T.+M.+Choauthor=L.+Farrandauthor=S.+Jangauthor=J.+H.+Seoauthor=J.+Y.+Kim&title=Flubendazole+elicits+anti-metastatic+effects+in+triple-negative+breast+cancer+via+STAT3+inhibition&doi=10.1002%2Fijc.31585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition</span></div><div class="casAuthors">Oh, Eunhye; Kim, Yoon-Jae; An, Hyunsook; Sung, Daeil; Cho, Tae-Min; Farrand, Lee; Jang, Seojin; Seo, Jae Hong; Kim, Ji Young</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1978-1993</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Tumor metastasis remains the cause of 90% of cancer-related deaths.  Cancer stem cells (CSC) are thought to be responsible for the aggressive and metastatic nature of triple-neg. breast cancers (TNBC), and new therapeutic strategies are being devised to target them.  Flubendazole (FLU) is a widely used anthelmintic agent that also exhibits anticancer activity in several cancer types.  The aim of this study was to characterize the mechanism of action of FLU on breast cancer stem cell (BCSC)-like properties and metastasis in TNBC.  FLU treatment caused a significant induction of apoptosis, accompanied by G2/M phase accumulation, caspase-3/-7 activation and the dysregulation of STAT3 activation in TNBC cells.  The latter phenomenon was assocd. with impairment of cancer stem-like traits, concomitant with a redn. in the CD24low/CD44high, CD24high/CD49fhigh subpopulation, ALDH1 activity and mammosphere formation.  The BCSC-enriched populations exhibited enhanced metastasis with higher STAT3 activation, while FLU administration inhibited tumor growth, angiogenesis and lung and liver metastasis, coinciding with decreased MMP-2 and MMP-9 levels in circulating blood.  FLU kills not only rapid proliferating tumor cells but also effectively eradicates BCSC-like cells in vitro and in vivo.  Our findings warrant further investigation of FLU as a treatment for metastatic TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcep7SDrwIbVg90H21EOLACvtfcHk0ljmse6KvVeGgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrs7zO&md5=0c3d558e8a902a9b9c1063d614c66924</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fijc.31585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.31585%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DAn%26aufirst%3DH.%26aulast%3DSung%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DT.%2BM.%26aulast%3DFarrand%26aufirst%3DL.%26aulast%3DJang%26aufirst%3DS.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26atitle%3DFlubendazole%2520elicits%2520anti-metastatic%2520effects%2520in%2520triple-negative%2520breast%2520cancer%2520via%2520STAT3%2520inhibition%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2018%26volume%3D143%26issue%3D8%26spage%3D1978%26epage%3D1993%26doi%3D10.1002%2Fijc.31585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span> <span> </span><span class="NLM_article-title">Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>486</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1076</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.03.164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.bbrc.2017.03.164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28373070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Wiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2017&pages=1069-1076&issue=4&author=Y.+J.+Kimauthor=J.+Y.+Kimauthor=N.+Leeauthor=E.+Ohauthor=D.+Sungauthor=T.+M.+Choauthor=J.+H.+Seo&title=Disulfiram+suppresses+cancer+stem-like+properties+and+STAT3+signaling+in+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.bbrc.2017.03.164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells</span></div><div class="casAuthors">Kim, Yoon-Jae; Kim, Ji Young; Lee, Nahyun; Oh, Eunhye; Sung, Daeil; Cho, Tae-Min; Seo, Jae Hong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1069-1076</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the presence of copper (Cu), disulfiram (DSF) suppresses properties assocd. with cancer stem cells (CSCs) in breast cancer, but the mechanism of action is poorly understood.  In the present study, we obsd. that DSF/Cu treatment induced apoptosis, mediated by caspase-3 activation in triple-neg. breast cancer (TNBC) cells.  DSF/Cu treatment also specifically targeted CSC-like cell populations, marked by the inhibition of ALDH1 activity, the suppression of CD44+/CD24-and CD49f+/CD24 + subpopulations, and the subsequent impairment of mammosphere formation.  These effects were functionally assocd. with a significant impact on the STAT3 signaling pathway, characterized by the downregulation of phospho-STAT3, cyclin D1 and survivin.  In an MDA-MB-231-derived xenograft model, DSF administration significantly downregulated ALDH1A1, CD44 and phospho-STAT3 levels.  These findings show for the first time that DSF suppresses stem-like properties in TNBC by targeting the STAT3 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopLNEFRU2reLVg90H21EOLACvtfcHk0ljmse6KvVeGgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Wiu7o%253D&md5=46e45ab442b22d2d821773ef2457394f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.03.164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.03.164%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DOh%26aufirst%3DE.%26aulast%3DSung%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DT.%2BM.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26atitle%3DDisulfiram%2520suppresses%2520cancer%2520stem-like%2520properties%2520and%2520STAT3%2520signaling%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D486%26issue%3D4%26spage%3D1069%26epage%3D1076%26doi%3D10.1016%2Fj.bbrc.2017.03.164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span> <span> </span><span class="NLM_article-title">Salinomycin promotes anoikis and decreases the CD44+/CD24-stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e0141919</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0141919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0141919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26528725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWnsbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0141919&issue=11&author=H.+Anauthor=J.+Y.+Kimauthor=E.+Ohauthor=N.+Leeauthor=Y.+Choauthor=J.+H.+Seo&title=Salinomycin+promotes+anoikis+and+decreases+the+CD44%2B%2FCD24-stem-like+population+via+inhibition+of+STAT3+activation+in+MDA-MB-231+cells&doi=10.1371%2Fjournal.pone.0141919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Salinomycin promotes anoikis and decreases the CD44+/CD24- stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells</span></div><div class="casAuthors">An, Hyunsook; Kim, Ji Young; Oh, Eunhye; Lee, Nahyun; Cho, Youngkwan; Seo, Jae Hong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0141919/1-e0141919/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is an aggressive tumor subtype with an enriched CD44+/CD24- stem-like population.  Salinomycin is an antibiotic that has been shown to target cancer stem cells (CSC); however, the mechanisms of action involved have not been well characterized.  The objective of the present study was to investigate the effect of salinomycin on cell death, migration, and invasion, as well as CSC-like properties in MDA-MB-231 breast cancer cells.  Salinomycin significantly induced anoikis-sensitivity, accompanied by caspase-3 and caspase-8 activation and PARP cleavage, during anchorage-independent growth.  Salinomycin treatment also caused a marked suppression of cell migration and invasion with concomitant downregulation of MMP-9 and MMP-2 mRNA levels.  Notably, salinomycin inhibited the formation of mammospheres and effectively reduced the CD44+/CD24- stem-like population during anchorage-independent growth.  These observations were assocd. with the inhibition of STAT3 phosphorylation (Tyr705).  Furthermore, interleukin-6 (IL-6)-induced STAT3 activation was strongly suppressed by salinomycin challenge.  These findings support the notion that salinomycin may be potentially efficacious for targeting breast cancer stem-like cells through the inhibition of STAT3 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhzRJ-nQx-Y7Vg90H21EOLACvtfcHk0ljqgv6D5lZp6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWnsbrP&md5=1c540cc74031a0f2a56c008aa6667587</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0141919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0141919%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DOh%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DCho%26aufirst%3DY.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26atitle%3DSalinomycin%2520promotes%2520anoikis%2520and%2520decreases%2520the%2520CD44%252B%252FCD24-stem-like%2520population%2520via%2520inhibition%2520of%2520STAT3%2520activation%2520in%2520MDA-MB-231%2520cells%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D11%26spage%3De0141919%26doi%3D10.1371%2Fjournal.pone.0141919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, B.</span></span> <span> </span><span class="NLM_article-title">Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2018.04.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.biopha.2018.04.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29679903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosFOqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=435-442&author=W.+Chenauthor=H.+Wangauthor=M.+Chengauthor=L.+Niauthor=L.+Zouauthor=Q.+Yangauthor=X.+Caiauthor=B.+Jiao&title=Isoharringtonine+inhibits+breast+cancer+stem-like+properties+and+STAT3+signaling&doi=10.1016%2Fj.biopha.2018.04.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling</span></div><div class="casAuthors">Chen, Wei; Wang, Hui; Cheng, Mei; Ni, Ling; Zou, Li; Yang, Qin; Cai, Xianghai; Jiao, Baowei</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">435-442</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Breast cancer stem cells (BCSCs) contribute to breast cancer progression, relapse, and treatment resistance.  Identification of the natural inhibitory components of BCSCs is therefore crit. for clin. treatment.  Here, we investigated whether isoharringtonine (IHT) had inhibitory effects on BCSCs in breast cancer cell lines.  HCC1806, HCC1937, and MCF7 cells were treated with IHT.  The proliferation and the migration of cells were detected by MTS assay and wound healing migration assay, resp.  The proportions of BCSCs were detd. by flow cytometry and tumor sphere formation assay.  Using real-time quant. polymerase chain reaction (qRT-PCR) and Western blotting, the expression of Nanog and activation of STAT3 were detected, resp.  Results showed that IHT inhibited the proliferation of HCC1806, HCC1937, and MCF-7 cells, and suppressed the migration of HCC1806 and HCC1937 cells in a dose-dependent manner.  IHT treatment decreased the proportion of BCSCs in MCF-7, HCC1806, and HCC1937 cells.  In addn., the mRNA level of Nanong was significantly downregulated after IHT treatment.  We also found an inhibitory effect of IHT on STAT3 activation.  IHT inhibited the proliferation, migration, and BCSC proportion of breast cancer cell lines via inhibition of the STAT3/Nanong pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7IX4O_m5MbVg90H21EOLACvtfcHk0ljqgv6D5lZp6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosFOqsro%253D&md5=f667b28c35cf51cda6a52095a2c90c0f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.04.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.04.076%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DJiao%26aufirst%3DB.%26atitle%3DIsoharringtonine%2520inhibits%2520breast%2520cancer%2520stem-like%2520properties%2520and%2520STAT3%2520signaling%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2018%26volume%3D103%26spage%3D435%26epage%3D442%26doi%3D10.1016%2Fj.biopha.2018.04.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and structure–activity relationship studies of 3-(phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as a new class of Src inhibitors with potent activities in models of triple negative breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3957</span>– <span class="NLM_lpage">3974</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVaksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3957-3974&issue=9&author=C.+H.+Zhangauthor=M.+W.+Zhengauthor=Y.+P.+Liauthor=X.+D.+Linauthor=M.+Huangauthor=L.+Zhongauthor=G.+B.+Liauthor=R.+J.+Zhangauthor=W.+T.+Linauthor=Y.+Jiaoauthor=X.+A.+Wuauthor=J.+Yangauthor=R.+Xiangauthor=L.+J.+Chenauthor=Y.+L.+Zhaoauthor=W.+Chengauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Design%2C+Synthesis%2C+and+structure%E2%80%93activity+relationship+studies+of+3-%28phenylethynyl%29-1h-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-amine+derivatives+as+a+new+class+of+Src+inhibitors+with+potent+activities+in+models+of+triple+negative+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer</span></div><div class="casAuthors">Zhang, Chun-Hui; Zheng, Ming-Wu; Li, Ya-Ping; Lin, Xing-Dong; Huang, Mei; Zhong, Lei; Li, Guo-Bo; Zhang, Rong-Jie; Lin, Wan-Ting; Jiao, Yan; Wu, Xiao-Ai; Yang, Jiao; Xiang, Rong; Chen, Li-Juan; Zhao, Ying-Lan; Cheng, Wei; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3957-3974</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivs. were designed and synthesized.  Structure-activity relationship (SAR) anal. of these compds. led to the discovery of compd. 1j (I), which showed the highest inhibitory potency against the Src kinase and the most potent antiviability activity against the typical TNBC cell line MDA-MB-231 among all the synthesized compds.  Further kinase inhibition assays showed that compd. 1j was a multikinase inhibitor and potently inhibited Src (IC50 = 0.0009 μM) and MAPK signaling protein kinases B-RAF and C-RAF.  In an MDA-MB-231 xenograft mouse model, a once-daily dose of compd. 1j at 30 mg/kg for 18 days completely suppressed the tumor growth with a tumor inhibition rate larger than 100% without obvious toxicity.  It also displayed good pharmacokinetic properties in a preliminary pharmacokinetic assay.  Western blot and immunohistochem. assays revealed that compd. 1j significantly inhibited Src and MAPK signaling and markedly induced apoptosis in tumor tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvXJluk6Zz57Vg90H21EOLACvtfcHk0ljqgv6D5lZp6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVaksbg%253D&md5=a15a90d306d54efac683cc373940cde4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00270%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DZheng%26aufirst%3DM.%2BW.%26aulast%3DLi%26aufirst%3DY.%2BP.%26aulast%3DLin%26aufirst%3DX.%2BD.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DZhang%26aufirst%3DR.%2BJ.%26aulast%3DLin%26aufirst%3DW.%2BT.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%2BJ.%26aulast%3DZhao%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520studies%2520of%25203-%2528phenylethynyl%2529-1h-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2520derivatives%2520as%2520a%2520new%2520class%2520of%2520Src%2520inhibitors%2520with%2520potent%2520activities%2520in%2520models%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D9%26spage%3D3957%26epage%3D3974%26doi%3D10.1021%2Facs.jmedchem.5b00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banskota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, B. S.</span></span> <span> </span><span class="NLM_article-title">Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">118</span>, <span class="refDoi"> DOI: 10.1038/s12276-018-0135-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs12276-018-0135-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=118&issue=9&author=J.+Gautamauthor=S.+Banskotaauthor=H.+Leeauthor=Y.+J.+Leeauthor=Y.+H.+Jeonauthor=J.+A.+Kimauthor=B.+S.+Jeong&title=Down-regulation+of+cathepsin+S+and+matrix+metalloproteinase-9+via+Src%2C+a+non-receptor+tyrosine+kinase%2C+suppresses+triple-negative+breast+cancer+growth+and+metastasis&doi=10.1038%2Fs12276-018-0135-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs12276-018-0135-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-018-0135-9%26sid%3Dliteratum%253Aachs%26aulast%3DGautam%26aufirst%3DJ.%26aulast%3DBanskota%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DJeon%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BA.%26aulast%3DJeong%26aufirst%3DB.%2BS.%26atitle%3DDown-regulation%2520of%2520cathepsin%2520S%2520and%2520matrix%2520metalloproteinase-9%2520via%2520Src%252C%2520a%2520non-receptor%2520tyrosine%2520kinase%252C%2520suppresses%2520triple-negative%2520breast%2520cancer%2520growth%2520and%2520metastasis%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2018%26volume%3D50%26issue%3D9%26spage%3D118%26doi%3D10.1038%2Fs12276-018-0135-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e0171169</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0171169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0171169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28141839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslSgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0171169&issue=1&author=X.+L.+Qianauthor=J.+Zhangauthor=P.+Z.+Liauthor=R.+G.+Langauthor=W.+D.+Liauthor=H.+Sunauthor=F.+F.+Liuauthor=X.+J.+Guoauthor=F.+Guauthor=L.+Fu&title=Dasatinib+inhibits+c-src+phosphorylation+and+prevents+the+proliferation+of+Triple-Negative+Breast+Cancer+%28TNBC%29+cells+which+overexpress+Syndecan-Binding+Protein+%28SDCBP%29&doi=10.1371%2Fjournal.pone.0171169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-negative breast cancer (TNBC) cells which overexpress syndecan-binding protein (SDCBP)</span></div><div class="casAuthors">Qian, Xiao-Long; Zhang, Jun; Li, Pei-Ze; Lang, Rong-Gang; Li, Wei-Dong; Sun, Hui; Liu, Fang-Fang; Guo, Xiao-Jing; Gu, Feng; Fu, Li</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0171169/1-e0171169/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Triple neg. breast cancer (TNBC) progresses rapidly but lacks effective targeted therapies.  Our previous study showed that downregulating syndecan-binding protein (SDCBP) in TNBC inhibits the proliferation of TNBC cells.  Dasatinib is a new small-mol. inhibitor of c-src phosphorylation.  The aim of this study was to investigate if SDCBP is a potential marker to indicate whether a TNBC is suitable for dasatinib therapy.  This study applied coimmunopptn. to identify the interaction between SDCBP and c-src in TNBC cell lines.  In addn., immunohistochem. was used to investigate SDCBP and tyrosine-419 phosphorylated c-src (p-c-src-Y419) expression in TNBC tissues.  SDCBP-overexpressing MDAMB-231 cells were then constructed to evaluate the effects of dasatinib on SDCBP-induced TNBC progression in vitro and tumor formation in nude mice.  We found wild-type SDCBP interacted with c-src and promoted the phosphorylation of c-src; this phosphorylation was completely blocked by dasatinib.  SDCBP lacking the PDZ domain had no such effect.  Among the 52 consecutive random TNBC cases examd., the expression of SDCBP was consistent with that of p-c-src-Y419, and pos. correlated with histol. grading or Ki-67 levels.  SDCBP overexpression significantly accelerated the proliferation and cell cycle progression of the TNBC cell line MDA-MB-231; these effects were prevented by dasatinib treatment.  However, the subsequent inhibition of p27 expression partially restored the proliferation and viability of the TNBC cells.  The results of this study suggest that SDCBP interacts with c-src, regulates G1/S in TNBC cells, and enhances tumor cell proliferation by promoting the tyrosine phosphorylation of c-src at residue 419.  Dasatinib inhibits such phosphorylation and blocks SDCBP-induced cell cycle progression.  Therefore, SDCBP might be an important marker for identifying TNBC cases that are suitable for dasatinib therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsa7ofiHy617Vg90H21EOLACvtfcHk0ljEeEg2pg1HYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslSgtL0%253D&md5=d2b76d94744be08f00e3454973961363</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0171169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0171169%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DX.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%2BZ.%26aulast%3DLang%26aufirst%3DR.%2BG.%26aulast%3DLi%26aufirst%3DW.%2BD.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%2BF.%26aulast%3DGuo%26aufirst%3DX.%2BJ.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DDasatinib%2520inhibits%2520c-src%2520phosphorylation%2520and%2520prevents%2520the%2520proliferation%2520of%2520Triple-Negative%2520Breast%2520Cancer%2520%2528TNBC%2529%2520cells%2520which%2520overexpress%2520Syndecan-Binding%2520Protein%2520%2528SDCBP%2529%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3De0171169%26doi%3D10.1371%2Fjournal.pone.0171169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2687</span>– <span class="NLM_lpage">2701</span>, <span class="refDoi"> DOI: 10.1039/C6SC05368H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC6SC05368H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28553505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlChtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2687-2701&issue=4&author=L.+Zhangauthor=L.+Fuauthor=S.+Zhangauthor=J.+Zhangauthor=Y.+Zhaoauthor=Y.+Zhengauthor=G.+Heauthor=S.+Yangauthor=L.+Ouyangauthor=B.+Liu&title=Discovery+of+a+small+molecule+targeting+ULK1-modulated+cell+death+of+triple+negative+breast+cancer+in+vitro+and+in+vivo&doi=10.1039%2FC6SC05368H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo</span></div><div class="casAuthors">Zhang, Lan; Fu, Leilei; Zhang, Shouyue; Zhang, Jin; Zhao, Yuqian; Zheng, Yaxin; He, Gu; Yang, Shengyong; Ouyang, Liang; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2687-2701</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">UNC-51-like kinase 1 (ULK1) is well-known to initiate autophagy, and the downregulation of ULK1 has been found in most breast cancer tissues.  Thus, the activation of ULK1-modulated autophagy could be a promising strategy for breast cancer therapy.  In this study, we found that ULK1 was remarkably downregulated in breast cancer tissue samples by The Cancer Genome Atlas (TCGA) anal. and tissue microarray (TMA) anal., esp. in triple neg. breast cancer (TNBC).  To design a ULK1 agonist, we integrated in silico screening and chem. synthesis to acquire a series of small mol. candidates.  After rounds of kinase and anti-proliferative activity screening, we discovered the small mol., LYN-1604, to be the best candidate for a ULK1 agonist.  Addnl., we identified that three amino acid residues (LYS50, LEU53, and TYR89) were key to the activation site of LYN-1604 and ULK1 by site-directed mutagenesis and biochem. assays.  Subsequently, we demonstrated that LYN-1604 could induce cell death, assocd. with autophagy by the ULK complex (ULK1-mATG13-FIP200-ATG101) in MDA-MB-231 cells.  To further explore LYN-1604-induced autophagic mechanisms, we found some potential ULK1 interactors, such as ATF3, RAD21, and caspase3, by performing comparative microarray anal.  Intriguingly, we found that LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.  Moreover, we demonstrated that LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo; thus making this ULK1 agonist a novel potential small-mol. drug candidate for future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqilhZpiddfcbVg90H21EOLACvtfcHk0ljEeEg2pg1HYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlChtg%253D%253D&md5=6c40089843a8fbcdbb5ee60e0547dc7c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1039%2FC6SC05368H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6SC05368H%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520a%2520small%2520molecule%2520targeting%2520ULK1-modulated%2520cell%2520death%2520of%2520triple%2520negative%2520breast%2520cancer%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DChem.%2520Sci.%26date%3D2017%26volume%3D8%26issue%3D4%26spage%3D2687%26epage%3D2701%26doi%3D10.1039%2FC6SC05368H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span> <span> </span><span class="NLM_article-title">Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e12518</span>, <span class="refDoi"> DOI: 10.1111/cpr.12518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1111%2Fcpr.12518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30152053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSrtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=e12518&issue=6&author=C.+Caoauthor=W.+Huangauthor=N.+Zhangauthor=F.+Wuauthor=T.+Xuauthor=X.+Panauthor=C.+Pengauthor=B.+Han&title=Narciclasine+induces+autophagy-dependent+apoptosis+in+triple-negative+breast+cancer+cells+by+regulating+the+AMPK-ULK1+axis&doi=10.1111%2Fcpr.12518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis</span></div><div class="casAuthors">Cao, Chuan; Huang, Wei; Zhang, Nan; Wu, Fengbo; Xu, Ting; Pan, Xiaoli; Peng, Cheng; Han, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Proliferation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e12518/1-e12518/11</span>CODEN:
                <span class="NLM_cas:coden">CPROEM</span>;
        ISSN:<span class="NLM_cas:issn">0960-7722</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : Autophagy and apoptosis are major types of eukaryotic programmed cell death, and regulating these processes holds promise for treating cancers.  In this study, we explored the regulation mechanisms of narciclasine to autophagy and apoptosis processes in triple-neg. breast cancer.  Materials and Methods : Effects of narciclasine on proliferation, apoptosis, and autophagy of HCC-1937 and MDA-MB-231 triple-neg. breast cancer (TNBC) cells were assessed using transmission electronic microscopy, flow cytometry following staining with Annexin V-FITC and propidium iodide, RNA sequencing, real-time PCR, and Western blotting.  The ability of narciclasine to inhibit growth of human HCC1937 TNBC xenografts in mice was assessed, and potential mechanisms of inhibition were explored using immunohistochem.  Results : Narciclasine inhibited TNBC cell proliferation and induced autophagy-dependent apoptosis in a dose-dependent manner.  These apoptotic effects could be reversed using autophagy inhibitors, including an AMPK inhibitor and ULK1 siRNA.  Consistent with these in vitro results, narciclasine significantly inhibited TNBC tumor growth in mice by upregulating autophagy-dependent apoptosis.  Conclusions : Our findings suggest that narciclasine regulates the AMPK-ULK1 signalling axis to promote autophagy-dependent apoptosis, demonstrating therapeutic potential against TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozM94BFEehS7Vg90H21EOLACvtfcHk0lg0hEavnHtzZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSrtLbM&md5=0b59dbfd4b6f5394f107d40915cb372f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fcpr.12518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcpr.12518%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DB.%26atitle%3DNarciclasine%2520induces%2520autophagy-dependent%2520apoptosis%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520by%2520regulating%2520the%2520AMPK-ULK1%2520axis%26jtitle%3DCell%2520Proliferation%26date%3D2018%26volume%3D51%26issue%3D6%26spage%3De12518%26doi%3D10.1111%2Fcpr.12518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voisin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacksenhaus, E.</span></span> <span> </span><span class="NLM_article-title">Combined deletion of PTEN and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1542</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.15252/emmm.201404402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.15252%2Femmm.201404402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25330770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVamur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1542-1560&issue=12&author=J.+C.+Liuauthor=V.+Voisinauthor=S.+Wangauthor=D.+Y.+Wangauthor=R.+A.+Jonesauthor=A.+Dattiauthor=D.+Uehlingauthor=R.+Al-awarauthor=S.+E.+Eganauthor=G.+D.+Baderauthor=M.+Tsaoauthor=T.+W.+Makauthor=E.+Zacksenhaus&title=Combined+deletion+of+PTEN+and+p53+in+mammary+epithelium+accelerates+triple-negative+breast+cancer+with+dependency+on+eEF2K&doi=10.15252%2Femmm.201404402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K</span></div><div class="casAuthors">Liu, Jeff C.; Voisin, Veronique; Wang, Sharon; Wang, Dong-Yu; Jones, Robert A.; Datti, Alessandro; Uehling, David; Al-Awar, Rima; Egan, Sean E.; Bader, Gary D.; Tsao, Ming; Mak, Tak W.; Zacksenhaus, Eldad</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1542-1560</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The tumor suppressors Pten and p53 are frequently lost in breast cancer, yet the consequences of their combined inactivation are poorly understood.  Here, we show that mammary-specific deletion of Pten via WAP-Cre, which targets alveolar progenitors, induced tumors with shortened latency compared to those induced by MMTV-Cre, which targets basal/luminal progenitors.  Combined Pten-p53 mutations accelerated formation of claudin-low, triple-neg.-like breast cancer (TNBC) that exhibited hyper-activated AKT signaling and more mesenchymal features relative to Pten or p53 single-mutant tumors.  Twenty-four genes that were significantly and differentially expressed between WAP-Cre:Pten/p53 and MMTV-Cre:Pten/p53 tumors predicted poor survival for claudin-low patients.  Kinome screens identified eukaryotic elongation factor-2 kinase (eEF2K) inhibitors as more potent than PI3K/AKT/mTOR inhibitors on both mouse and human Pten/p53-deficient TNBC cells.  Sensitivity to eEF2K inhibition correlated with AKT pathway activity. eEF2K monotherapy suppressed growth of Pten/p53-deficient TNBC xenografts in vivo and cooperated with doxorubicin to efficiently kill tumor cells in vitro.  Our results identify a prognostic signature for claudin-low patients and provide a rationale for using eEF2K inhibitors for treatment of TNBC with elevated AKT signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTmlzPz8bEO7Vg90H21EOLACvtfcHk0lg0hEavnHtzZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVamur7E&md5=a801dcd1402ccf33157a65d432678ace</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.15252%2Femmm.201404402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201404402%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BC.%26aulast%3DVoisin%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DD.%2BY.%26aulast%3DJones%26aufirst%3DR.%2BA.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DUehling%26aufirst%3DD.%26aulast%3DAl-awar%26aufirst%3DR.%26aulast%3DEgan%26aufirst%3DS.%2BE.%26aulast%3DBader%26aufirst%3DG.%2BD.%26aulast%3DTsao%26aufirst%3DM.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DZacksenhaus%26aufirst%3DE.%26atitle%3DCombined%2520deletion%2520of%2520PTEN%2520and%2520p53%2520in%2520mammary%2520epithelium%2520accelerates%2520triple-negative%2520breast%2520cancer%2520with%2520dependency%2520on%2520eEF2K%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26issue%3D12%26spage%3D1542%26epage%3D1560%26doi%3D10.15252%2Femmm.201404402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhlis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1007/s10549-018-4847-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-018-4847-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29971628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yksLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2018&pages=593-605&issue=3&author=N.+Kabilauthor=R.+Bayraktarauthor=N.+Kahramanauthor=H.+A.+Mokhlisauthor=G.+A.+Calinauthor=G.+Lopez-Beresteinauthor=B.+Ozpolat&title=Thymoquinone+inhibits+cell+proliferation%2C+migration%2C+and+invasion+by+regulating+the+elongation+factor+2+kinase+%28eEF-2K%29+signaling+axis+in+triple-negative+breast+cancer&doi=10.1007%2Fs10549-018-4847-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer</span></div><div class="casAuthors">Kabil, Nashwa; Bayraktar, Recep; Kahraman, Nermin; Mokhlis, Hamada A.; Calin, George A.; Lopez-Berestein, Gabriel; Ozpolat, Bulent</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">593-605</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background/purpose: Triple-neg. breast cancer (TNBC) is the most aggressive and chemoresistant subtype of breast cancer.  Therefore, new mol. targets and treatments need to be developed to improve poor patient prognosis and survival.  We have previously shown that eukaryotic elongation factor 2 kinase (eEF-2K) is highly expressed in TNBC cells, is assocd. with poor patient survival and prognosis, and promotes cell proliferation, migration, and invasion.  In vivo targeting of eEF-2K significantly reduces the tumor growth of orthotopic TNBC xenograft mouse models, suggesting that eEF-2K may serve as a potential novel therapeutic target.  Methods/results: In the current study, we identified thymoquinone (TQ), an active ingredient of Nigella sativa, as a potential safe and effective eEF-2K inhibitor in TNBC.  We demonstrated for the first time that TQ inhibits the protein and mRNA expression of eEF-2K, as well as the clin. relevant downstream targets, including Src/FAK and Akt, and induces the tumor suppressor miR-603, in response to NF-kB inhibition.  This effect was assocd. with a significant decrease in the proliferation, colony formation, migration, and invasion of TNBC cells.  Furthermore, systemic in vivo injection of TQ (20 and 100 mg/kg) significantly reduced the growth of MDA-MB-231 tumors and inhibited the eEF-2K expression in an orthotopic tumor model in mice.  Conclusion: Our study provides first evidence that TQ treatment inhibits cell proliferation, migration/invasion, and tumor growth, in part through the inhibition of eEF-2K signaling in TNBC.  Thus, our findings suggest that systemic TQ treatment may be used as a targeted therapeutic strategy for the inhibition of eEF-2K in TNBC tumor growth and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8kyxIVXtRLVg90H21EOLACvtfcHk0lg0hEavnHtzZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yksLbL&md5=0bbf638cfefa85c33f9c4bc4f8c492c8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs10549-018-4847-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-018-4847-2%26sid%3Dliteratum%253Aachs%26aulast%3DKabil%26aufirst%3DN.%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DMokhlis%26aufirst%3DH.%2BA.%26aulast%3DCalin%26aufirst%3DG.%2BA.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DThymoquinone%2520inhibits%2520cell%2520proliferation%252C%2520migration%252C%2520and%2520invasion%2520by%2520regulating%2520the%2520elongation%2520factor%25202%2520kinase%2520%2528eEF-2K%2529%2520signaling%2520axis%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2018%26volume%3D171%26issue%3D3%26spage%3D593%26epage%3D605%26doi%3D10.1007%2Fs10549-018-4847-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ejmech.2017.11.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29202403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=402-418&author=Y.+Guoauthor=Y.+Zhaoauthor=G.+Wangauthor=Y.+Chenauthor=Y.+Jiangauthor=L.+Ouyangauthor=B.+Liu&title=Design%2C+synthesis+and+structure-activity+relationship+of+a+focused+library+of+%CE%B2-phenylalanine+derivatives+as+novel+eEF2K+inhibitors+with+apoptosis-inducing+mechanisms+in+breast+cancer&doi=10.1016%2Fj.ejmech.2017.11.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer</span></div><div class="casAuthors">Guo, Yongzhi; Zhao, Yuqian; Wang, Guan; Chen, Yi; Jiang, Yingnan; Ouyang, Liang; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">402-418</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase.  EEF2K has been recently reported to be highly activated or over-expressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target.  In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivs. with assessment of inhibition activity against eEF2K and cytotoxicity.  After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (I) with best eEF2K enzymic activity (IC50 of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC50 of 12.6 μM, MDA-MB-436 cells, IC50 of 19.8 μM).  Moreover, we found that I could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells.  Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo.  These results suggested that I inhibited tumor growth by apoptosis in the xenograft mouse model of breast cancer (MDA-MB-231 and MDA-MB-436).  Collectively, our results demonstrate a novel small-mol. inhibitor targeting eEF2K with mechanism of apoptosis and a therapeutic potential in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHKgIUg85n1LVg90H21EOLACvtfcHk0lgKkBm2xktVRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FM&md5=d5017cf0b61bbd2cc2962d3ded11dda3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.065%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DDesign%252C%2520synthesis%2520and%2520structure-activity%2520relationship%2520of%2520a%2520focused%2520library%2520of%2520%25CE%25B2-phenylalanine%2520derivatives%2520as%2520novel%2520eEF2K%2520inhibitors%2520with%2520apoptosis-inducing%2520mechanisms%2520in%2520breast%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D402%26epage%3D418%26doi%3D10.1016%2Fj.ejmech.2017.11.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span> <span> </span><span class="NLM_article-title">Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1039/C5MB00848D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC5MB00848D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26776155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=729-736&issue=3&author=Z.+Yaoauthor=J.+Liauthor=Z.+Liuauthor=L.+Zhengauthor=N.+Fanauthor=Y.+Zhangauthor=N.+Jiaauthor=J.+Lvauthor=N.+Liuauthor=X.+Zhuauthor=J.+Duauthor=C.+Lvauthor=F.+Xieauthor=Y.+Liuauthor=X.+Wangauthor=Z.+Feiauthor=C.+Gao&title=Integrative+bioinformatics+and+proteomics-based+discovery+of+an+eEF2K+inhibitor+%28cefatrizine%29+with+ER+stress+modulation+in+breast+cancer+cells&doi=10.1039%2FC5MB00848D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells</span></div><div class="casAuthors">Yao, Zhiqiang; Li, Juntang; Liu, Zhongyu; Zheng, Lu; Fan, Naijun; Zhang, Ying; Jia, Nan; Lv, Jingjing; Liu, Ningning; Zhu, Xiaoshan; Du, Jiangbo; Lv, Ci; Xie, Feng; Liu, Yigang; Wang, Xingke; Fei, Zhou; Gao, Chunfang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">729-736</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Eukaryotic elongation factor-2 kinase (eEF2K), a unique calcium/calmodulin-dependent protein kinase, is well known to regulate apoptosis, autophagy and ER stress in many types of human cancers.  Therefore, eEF2K would be regarded as a promising therapeutic target; however, the eEF2K-regulated mechanism and its targeted inhibitor still remain to be discovered in cancer.  Herein, we constructed a protein-protein interaction (PPI) network of eEF2K and achieved an eEF2K-regulated ER stress subnetwork by bioinformatics prediction.  Then, we found that the differential protein expressions involved in ER stress in the context of si-eEF2K-treated MCF-7 and MDA-MB-436 cells by iTRAQ-based analyses, resp.  Integrated into these aforementioned results, we constructed a core eEF2K-regulated ER stress subnetwork in breast cancer cells.  Subsequently, we screened a series of candidate compds. targeting eEF2K and discovered a novel eEF2K inhibitor (cefatrizine) with an anti-proliferative activity toward breast cancer cells.  Moreover, we found that cefatrizine induced ER stress in both MCF-7 and MDA-MB-436 cells.  Interestingly, we demonstrated that the mechanism of cefatrizine-induced ER stress was in good agreement with our bioinformatics and proteomics-based results.  In conclusion, these results demonstrate that a novel eEF2K inhibitor (cefatrizine) induces ER stress in breast cancer cells by integrating bioinformatics prediction, proteomics analyses and exptl. validation, which would provide a clue for exploring more mechanisms of eEF2K and its targeted inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDQPIGrQ6947Vg90H21EOLACvtfcHk0lgKkBm2xktVRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGhuw%253D%253D&md5=84c2bbd60d8c71479e98f426db5fbb5b</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1039%2FC5MB00848D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MB00848D%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DN.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFei%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DC.%26atitle%3DIntegrative%2520bioinformatics%2520and%2520proteomics-based%2520discovery%2520of%2520an%2520eEF2K%2520inhibitor%2520%2528cefatrizine%2529%2520with%2520ER%2520stress%2520modulation%2520in%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520BioSyst.%26date%3D2016%26volume%3D12%26issue%3D3%26spage%3D729%26epage%3D736%26doi%3D10.1039%2FC5MB00848D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer</span>. <i>Cell Proliferation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">e12402</span>, <span class="refDoi"> DOI: 10.1111/cpr.12402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1111%2Fcpr.12402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29094413" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=e12402&issue=2&author=D.+Sunauthor=L.+Zhuauthor=Y.+Zhaoauthor=Y.+Jiangauthor=L.+Chenauthor=Y.+Yuauthor=L.+Ouyang&title=Fluoxetine+induces+autophagic+cell+death+via+eEF2K-AMPK-mTOR-ULK+complex+axis+in+triple+negative+breast+cancer&doi=10.1111%2Fcpr.12402"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1111%2Fcpr.12402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcpr.12402%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DFluoxetine%2520induces%2520autophagic%2520cell%2520death%2520via%2520eEF2K-AMPK-mTOR-ULK%2520complex%2520axis%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DCell%2520Proliferation%26date%3D2018%26volume%3D51%26issue%3D2%26spage%3De12402%26doi%3D10.1111%2Fcpr.12402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeted degradation of BET proteins in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2476</span>– <span class="NLM_lpage">2487</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-2622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-16-2622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28209615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFakurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2476-2487&issue=9&author=L.+Baiauthor=B.+Zhouauthor=C.+Y.+Yangauthor=J.+Jiauthor=D.+McEachernauthor=S.+Przybranowskiauthor=H.+Jiangauthor=J.+Huauthor=F.+Xuauthor=Y.+Zhaoauthor=L.+Liuauthor=E.+Fernandez-Salasauthor=J.+Xuauthor=Y.+Douauthor=B.+Wenauthor=D.+Sunauthor=J.+Meagherauthor=J.+Stuckeyauthor=D.+F.+Hayesauthor=S.+Liauthor=M.+J.+Ellisauthor=S.+Wang&title=Targeted+degradation+of+BET+proteins+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-16-2622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Bai, Longchuan; Zhou, Bing; Yang, Chao-Yie; Ji, Jiao; McEachern, Donna; Przybranowski, Sally; Jiang, Hui; Hu, Jiantao; Xu, Fuming; Zhao, Yujun; Liu, Liu; Fernandez-Salas, Ester; Xu, Jing; Dou, Yali; Wen, Bo; Sun, Duxin; Meagher, Jennifer; Stuckey, Jeanne; Hayes, Daniel F.; Li, Shunqiang; Ellis, Matthew J.; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2476-2487</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBC) remain clin. challenging with a lack of options for targeted therapy.  In this study, we report the development of a second-generation BET protein degrader, BETd-246, which exhibits superior selectivity, potency, and antitumor activity.  In human TNBC cells, BETd-246 induced degrdn. of BET proteins at low nanomolar concns. within 1 h of exposure, resulting in robust growth inhibition and apoptosis.  BETd-246 was more potent and effective in TNBC cells than its parental BET inhibitor compd. BETi-211.  RNA-seq anal. revealed predominant downregulation of a large no. of genes involved in proliferation and apoptosis in cells treated with BETd-246, as compared with BETi-211 treatment that upregulated and downregulated a similar no. of genes.  Functional investigations identified the MCL1 gene as a crit. downstream effector for BET degraders, which synergized with small-mol. inhibitors of BCL-xL in triggering apoptosis.  In multiple murine xenograft models of human breast cancer, BETd-246 and a further optimized analog BETd-260 effectively depleted BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules.  Overall, our findings show that targeting BET proteins for degrdn. represents an effective therapeutic strategy for TNBC treatment.  Cancer Res; 77(9); 2476-87. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8M1VaSNIBCLVg90H21EOLACvtfcHk0lj15PyyoSxlWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFakurg%253D&md5=84c0e0b23e61a5503f8d88385cc88ae5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-2622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-2622%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDou%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DMeagher%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeted%2520degradation%2520of%2520BET%2520proteins%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D9%26spage%3D2476%26epage%3D2487%26doi%3D10.1158%2F0008-5472.CAN-16-2622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small-molecule bromodomain-containing protein 4 (BRD4) inhibitor that induces AMP-Activated protein kinase-modulated autophagy-associated cell death in breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">9990</span>– <span class="NLM_lpage">10012</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00275</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00275" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOitrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9990-10012&issue=24&author=L.+Ouyangauthor=L.+Zhangauthor=J.+Liuauthor=L.+Fuauthor=D.+Yaoauthor=Y.+Zhaoauthor=S.+Zhangauthor=G.+Wangauthor=G.+Heauthor=B.+Liu&title=Discovery+of+a+small-molecule+bromodomain-containing+protein+4+%28BRD4%29+inhibitor+that+induces+AMP-Activated+protein+kinase-modulated+autophagy-associated+cell+death+in+breast+cancer&doi=10.1021%2Facs.jmedchem.7b00275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer</span></div><div class="casAuthors">Ouyang, Liang; Zhang, Lan; Liu, Jie; Fu, Leilei; Yao, Dahong; Zhao, Yuqian; Zhang, Shouyue; Wang, Guan; He, Gu; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9990-10012</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Upon the basis of The Cancer Genome Atlas (TCGA) data set, the authors identified that several autophagy-related proteins such as AMP-activated protein kinase (AMPK) were remarkably downregulated in breast cancer.  Combined with coimmunopptn. assay, the authors demonstrated that BRD4 might interact with AMPK.  After analyses of the pharmacophore and WPF interaction optimization, the authors designed a small-mol. inhibitor of BRD4, 9f (FL-411 (2-(4-hydroxy-3,5-dimethylphenyl)-7-methyl-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one)) which was validated by cocrystal structure with BD1 of BRD4.  Subsequently, 9f was discovered to induce ATG5-dependent autophagy-assocd. cell death (ACD) by blocking BRD4-AMPK interaction and thus activating AMPK-mTOR-ULK1-modulated autophagic pathway in breast cancer cells.  Interestingly, the iTRAQ-based proteomics analyses revealed that 9f induced ACD pathways involved in HMGB1, VDAC1/2, and eEF2.  Moreover, 9f displayed a therapeutic potential on both breast cancer xenograft mouse and zebrafish models.  Together, these results demonstrate that a novel small-mol. inhibitor of BRD4 induces BRD4-AMPK-modulated ACD in breast cancer, which may provide a candidate drug for future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Ocrq2wyy6bVg90H21EOLACvtfcHk0lj15PyyoSxlWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOitrvF&md5=ac15f7e108511ea207f2c2fcd299b4e5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00275%26sid%3Dliteratum%253Aachs%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520a%2520small-molecule%2520bromodomain-containing%2520protein%25204%2520%2528BRD4%2529%2520inhibitor%2520that%2520induces%2520AMP-Activated%2520protein%2520kinase-modulated%2520autophagy-associated%2520cell%2520death%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D24%26spage%3D9990%26epage%3D10012%26doi%3D10.1021%2Facs.jmedchem.7b00275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13305</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-49366-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41598-019-49366-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31527644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MrpsVejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=13305&issue=1&author=I.+H.+Parkauthor=H.+N.+Yangauthor=S.+Y.+Jeonauthor=J.+A.+Hwangauthor=M.+K.+Kimauthor=S.+Y.+Kongauthor=S.+H.+Shimauthor=K.+S.+Lee&title=Anti-tumor+activity+of+BET+inhibitors+in+androgen-receptor-expressing+triple-negative+breast+cancer&doi=10.1038%2Fs41598-019-49366-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer</span></div><div class="casAuthors">Park In Hae; Yang Han Na; Jeon Su Yeon; Kim Min Kyeong; Kong Sun-Young; Shim Sung Hoon; Park In Hae; Shim Sung Hoon; Lee Keun Seok; Hwang Jung-Ah; Kong Sun-Young; Kong Sun-Young</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is a heterogeneous disease comprising several subtypes.  Androgen-receptor (AR) signaling has been targeted by several investigational agents in luminal AR subtype TNBCs.  Bromodomain (BRD) and extra-terminal motif (BET) protein inhibitors have been shown to attenuate AR signaling in metastatic castration-resistant prostate cancer and to overcome enzalutamide resistance.  We demonstrated potent anti-tumor effects of the BET inhibitor JQ1 against AR-positive TNBC cell lines using cell viability and cell cycle analysis.  To reveal the mechanisms of JQ1 effects, multiplex gene expression analysis and immunoblotting assays were used.  We examined in vivo effects of JQ1 in a xenograft model of AR expressing TNBC.  JQ1 exhibited its anti-proliferative activity by inducing apoptosis and cell cycle arrest.  JQ1 activity was not mediated by MYC downregulation.  Instead, JQ1 blocked the interactions among the ATPase-family AAA-domain-containing 2 protein (ATAD2), BRD2, BRD4, and AR; effectively suppressing the expression of AR associated targets.  In addition, JQ1 showed significant anti-tumor activity in vivo in TNBC xenograft mouse models as a monotherapy and in combination with anti-AR therapy.  Taken together, our results showed that the BET inhibitor JQ1 is a promising therapeutic agent for the treatment of AR-positive TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4GG7aPDCwMhBrI9DTGjC0fW6udTcc2eb9vfsoIGbI8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrpsVejtg%253D%253D&md5=f2786099b09c8d89ca85bcf79a2a9239</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-49366-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-49366-9%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BH.%26aulast%3DYang%26aufirst%3DH.%2BN.%26aulast%3DJeon%26aufirst%3DS.%2BY.%26aulast%3DHwang%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DKong%26aufirst%3DS.%2BY.%26aulast%3DShim%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DAnti-tumor%2520activity%2520of%2520BET%2520inhibitors%2520in%2520androgen-receptor-expressing%2520triple-negative%2520breast%2520cancer%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D13305%26doi%3D10.1038%2Fs41598-019-49366-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span> <span> </span><span class="NLM_article-title">C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2019.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30703411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFWmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2019&pages=141-153&author=T.+M.+Choauthor=J.+Y.+Kimauthor=Y.+J.+Kimauthor=D.+Sungauthor=E.+Ohauthor=S.+Jangauthor=L.+Farrandauthor=V.+H.+Hoangauthor=C.+T.+Nguyenauthor=J.+Annauthor=J.+Leeauthor=J.+H.+Seo&title=C-terminal+HSP90+inhibitor+L80+elicits+anti-metastatic+effects+in+triple-negative+breast+cancer+via+STAT3+inhibition&doi=10.1016%2Fj.canlet.2019.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition</span></div><div class="casAuthors">Cho, Tae-Min; Kim, Ji Young; Kim, Yoon-Jae; Sung, Daeil; Oh, Eunhye; Jang, Seojin; Farrand, Lee; Hoang, Van-Hai; Nguyen, Cong-Truong; Ann, Jihyae; Lee, Jeewoo; Seo, Jae Hong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">141-153</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is an aggressive heterogeneous disease with a divergent profile.  It has an earlier tendency to form metastases and is assocd. with poor clin. outcomes due to the limited treatment options available.  Heat-shock protein (HSP90) represents a potential treatment target as it promotes tumor progression and metastasis by modulating the maturation and stabilization of signal transduction proteins.  We sought to investigate the efficacy of the C-terminal HSP90 inhibitor L80 on cell proliferation, breast cancer stem cell (BCSC)-like properties, tumor growth and metastasis.  L80 suppressed cell viability and concomitantly inhibited AKT/MEK/ERK/JAK2/STAT3 signaling in TNBC cells but did not induce cytotoxicity in normal cells.  L80 effectively targeted BCSC-like traits, together with significant redns. in the CD44high/CD24low-population, ALDH1 activity and mammosphere forming-ability.  In support of the in vitro observations, L80 administration caused significant impairment in tumor growth, angiogenesis and distant metastases in an orthotopic allograft model with BCSC-enriched cells in vivo.  These phenomena were assocd. with the suppression of BCSC-like characteristics and STAT3 dysfunction.  Our findings highlight properties of the L80 compd. that may be useful in suppressing metastatic TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrybhXQe-U6ubVg90H21EOLACvtfcHk0lgxYndW-pwXnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFWmsrk%253D&md5=e966bb533d6bf4d9fe583dd6a8cd0dd8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DSung%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DE.%26aulast%3DJang%26aufirst%3DS.%26aulast%3DFarrand%26aufirst%3DL.%26aulast%3DHoang%26aufirst%3DV.%2BH.%26aulast%3DNguyen%26aufirst%3DC.%2BT.%26aulast%3DAnn%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26atitle%3DC-terminal%2520HSP90%2520inhibitor%2520L80%2520elicits%2520anti-metastatic%2520effects%2520in%2520triple-negative%2520breast%2520cancer%2520via%2520STAT3%2520inhibition%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D447%26spage%3D141%26epage%3D153%26doi%3D10.1016%2Fj.canlet.2019.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells</span>. <i>J. Microbiol. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">914</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.4014/jmb.1311.11052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.4014%2Fjmb.1311.11052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24705874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKrsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=914-920&issue=7&author=Q.+Zhaoauthor=C.+Z.+Wuauthor=J.+K.+Leeauthor=S.+R.+Zhaoauthor=H.+M.+Liauthor=Q.+Huoauthor=T.+Maauthor=J.+Zhangauthor=Y.+S.+Hongauthor=H.+Liu&title=Anticancer+effects+of+the+Hsp90+inhibitor+17-demethoxy-reblastatin+in+human+breast+cancer+MDA-MB-231+cells&doi=10.4014%2Fjmb.1311.11052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells</span></div><div class="casAuthors">Zhao, Qing; Wu, Cheng-Zhu; Lee, Jae Kyoung; Zhao, Su-Rong; Li, Hong-Mei; Huo, Qiang; Ma, Tao; Zhang, Jin; Hong, Young-Soo; Liu, Hao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology and Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">914-920</span>CODEN:
                <span class="NLM_cas:coden">JOMBES</span>;
        ISSN:<span class="NLM_cas:issn">1017-7825</span>.
    
            (<span class="NLM_cas:orgname">Korean Society for Microbiology and Biotechnology</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) possesses a higher rate of distant recurrence and a poorer prognosis than other breast cancer subtypes.  Interestingly, most of the heat shock protein 90 (Hsp90) client proteins are oncoproteins, and some are closely related to unfavorable factors of TNBC patients.  17-Demethoxy-reblastatin (17-DR), a novel non-benzoquinone-type geldanamycin analog, exhibited potent Hsp90 ATPase inhibition activity.  In this study, the anticancer effects of 17-DR on TNBC MDA-MB-231 cells were investigated.  These results showed that 17-DR inhibited cell proliferation, induced apoptosis, and suppressed cell invasion and migration in the MDA-MB-231 cells.  Down-regulation of the key Hsp90-dependent tumor-driving mols., such as RIP1 and MMP-9, by 17-DR may be related to these effects.  Taken together, our results suggest that 17-DR has potential as a therapeutic agent for the treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ2qsHTUpUM7Vg90H21EOLACvtfcHk0lgxYndW-pwXnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKrsLjN&md5=6cf2c55bc6f53572cefbf855380ceb08</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.4014%2Fjmb.1311.11052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4014%252Fjmb.1311.11052%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DC.%2BZ.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DZhao%26aufirst%3DS.%2BR.%26aulast%3DLi%26aufirst%3DH.%2BM.%26aulast%3DHuo%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DAnticancer%2520effects%2520of%2520the%2520Hsp90%2520inhibitor%252017-demethoxy-reblastatin%2520in%2520human%2520breast%2520cancer%2520MDA-MB-231%2520cells%26jtitle%3DJ.%2520Microbiol.%2520Biotechnol.%26date%3D2014%26volume%3D24%26issue%3D7%26spage%3D914%26epage%3D920%26doi%3D10.4014%2Fjmb.1311.11052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiery, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Targeting HSP90-HDAC6 regulating network implicates precision treatment of breast cancer</span>. <i>Int. J. Biol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.7150/ijbs.18834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.7150%2Fijbs.18834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28529458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1crpsl2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=505-517&issue=4&author=S.+Yuauthor=X.+Caiauthor=C.+Wuauthor=Y.+Liuauthor=J.+Zhangauthor=X.+Gongauthor=X.+Wangauthor=X.+Wuauthor=T.+Zhuauthor=L.+Moauthor=J.+Guauthor=Z.+Yuauthor=J.+Chenauthor=J.+P.+Thieryauthor=R.+Chaiauthor=L.+Chen&title=Targeting+HSP90-HDAC6+regulating+network+implicates+precision+treatment+of+breast+cancer&doi=10.7150%2Fijbs.18834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer</span></div><div class="casAuthors">Yu Shiyi; Cai Xiuxiu; Wu Chenxi; Liu Yan; Zhang Jun; Gong Xue; Wang Xin; Chen Liming; Yu Shiyi; Cai Xiuxiu; Wu Chenxi; Liu Yan; Zhang Jun; Gong Xue; Wang Xin; Chai Renjie; Chen Liming; Wu Xiaoli; Zhu Tao; Mo Lin; Gu Jun; Yu Zhenghong; Chen Jinfei; Chen Jinfei; Thiery Jean Paul; Thiery Jean Paul; Thiery Jean Paul; Chai Renjie; Chai Renjie</div><div class="citationInfo"><span class="NLM_cas:title">International journal of biological sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-517</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Breast cancer is the leading cause of women death.  Heat shock protein 90 (HSP90) and Histone deacetylase 6 (HDAC6) are promising anti-cancer drug targets.  However, it's still unclear the applicability of anti-HSP90 and anti-HDAC6 strategies in precision treatment of breast cancer.  In current study, we found that triple negative breast cancer (TNBC) cells, compared to T47D, an ERα+ breast cancer cell line, exhibited 7~40 times lower IC50 values, stronger cell cycle perturbation, increased cell apoptosis and stronger inhibition of cell migration upon 17-DMAG treatment, while T47D, compared to TNBC cells, expressed higher HDAC6 and showed stronger anti-cancer response upon treatment of Tubacin.  Mechanically, 17-DMAG treatment inhibited a complex network consists at least ERK, AKT, and Hippo pathway in TNBC cells, and higher expression of HDAC6 inhibited HSP90 activity via deacetylating HSP90.  Furthermore, we found higher HDAC6 expression level in tamoxifen-resistance T47D than that in T47D, and Tubacin treatment suppressed the growth of tamoxifen-resistant cells in vivo.  Our data suggested that anti-HSP90 and anti-HDAC6 are promising strategies to treat TNBC and ERα+ breast cancers respectively, and anti-HDAC6 can be considered during treatment of tamoxifen-resistance breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSX8r12aXIDwoxhnOQkIHOxfW6udTcc2ea_Bn-PzO6LRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crpsl2htQ%253D%253D&md5=9911639d19fd6bb643944844cdacdf33</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.7150%2Fijbs.18834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijbs.18834%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMo%26aufirst%3DL.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DThiery%26aufirst%3DJ.%2BP.%26aulast%3DChai%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DTargeting%2520HSP90-HDAC6%2520regulating%2520network%2520implicates%2520precision%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Biol.%2520Sci.%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D505%26epage%3D517%26doi%3D10.7150%2Fijbs.18834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omerzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterrenburg, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Roos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doornmalen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kops, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, R. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2180</span>– <span class="NLM_lpage">2192</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdv293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26153498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhsVCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2180-2192&issue=10&author=A.+R.+Maiaauthor=J.+de+Manauthor=U.+Boonauthor=A.+Janssenauthor=J.+Y.+Songauthor=M.+Omerzuauthor=J.+G.+Sterrenburgauthor=M.+B.+Prinsenauthor=N.+Willemsen-Seegersauthor=J.+A.+de+Roosauthor=A.+M.+van+Doornmalenauthor=J.+C.+Uitdehaagauthor=G.+J.+Kopsauthor=J.+Jonkersauthor=R.+C.+Buijsmanauthor=G.+J.+Zamanauthor=R.+H.+Medema&title=Inhibition+of+the+spindle+assembly+checkpoint+kinase+TTK+enhances+the+efficacy+of+docetaxel+in+a+triple-negative+breast+cancer+model&doi=10.1093%2Fannonc%2Fmdv293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model</span></div><div class="casAuthors">Maia A R R; Janssen A; de Man J; Sterrenburg J G; Prinsen M B W; Willemsen-Seegers N; de Roos J A D M; van Doornmalen A M; Uitdehaag J C M; Buijsman R C; Zaman G J R; Boon U; Song J-Y; Omerzu M; Kops G J P L; Jonkers J; Medema R H</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2180-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancers (TNBC) are considered the most aggressive type of breast cancer, for which no targeted therapy exists at the moment.  These tumors are characterized by having a high degree of chromosome instability and often overexpress the spindle assembly checkpoint kinase TTK.  To explore the potential of TTK inhibition as a targeted therapy in TNBC, we developed a highly potent and selective small molecule inhibitor of TTK, NTRC 0066-0.  RESULTS AND CONCLUSIONS:  The compound is characterized by long residence time on the target and inhibits the proliferation of a wide variety of human cancer cell lines with potency in the same range as marketed cytotoxic agents.  In cell lines and in mice, NTRC 0066-0 inhibits the phosphorylation of a TTK substrate and induces chromosome missegregation.  NTRC 0066-0 inhibits tumor growth in MDA-MB-231 xenografts as a single agent after oral application.  To address the effect of the inhibitor in breast cancer, we used a well-defined mouse model that spontaneously develops breast tumors that share key morphologic and molecular features with human TNBC.  Our studies show that combination of NTRC 0066-0 with a therapeutic dose of docetaxel resulted in doubling of mouse survival and extended tumor remission, without toxicity.  Furthermore, we observed that treatment efficacy is only achieved upon co-administration of the two compounds, which suggests a synergistic in vivo effect.  Therefore, we propose TTK inhibition as a novel therapeutic target for neoadjuvant therapy in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQW4bdSIlyWFQ8IxFYvehhofW6udTcc2ea-b0GzUJMSsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhsVCrtg%253D%253D&md5=579aa33d6fd0de70b6c68ae86d8316c0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv293%26sid%3Dliteratum%253Aachs%26aulast%3DMaia%26aufirst%3DA.%2BR.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DBoon%26aufirst%3DU.%26aulast%3DJanssen%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DOmerzu%26aufirst%3DM.%26aulast%3DSterrenburg%26aufirst%3DJ.%2BG.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%2BA.%26aulast%3Dvan%2BDoornmalen%26aufirst%3DA.%2BM.%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%26aulast%3DKops%26aufirst%3DG.%2BJ.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26aulast%3DMedema%26aufirst%3DR.%2BH.%26atitle%3DInhibition%2520of%2520the%2520spindle%2520assembly%2520checkpoint%2520kinase%2520TTK%2520enhances%2520the%2520efficacy%2520of%2520docetaxel%2520in%2520a%2520triple-negative%2520breast%2520cancer%2520model%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26issue%3D10%26spage%3D2180%26epage%3D2192%26doi%3D10.1093%2Fannonc%2Fmdv293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kümmel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes
Castan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Borrego, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín
Martorell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail-Khan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I.</span></span> <span> </span><span class="NLM_article-title">1977 Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC)</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">S326</span>, <span class="refDoi"> DOI: 10.1016/S0959-8049(16)30925-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2FS0959-8049%2816%2930925-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=S326&author=A.+Bardiaauthor=J.+S.+Cameronauthor=K.+Venkatesanauthor=D.+Robinsonauthor=D.+Porterauthor=S.+B.+Kimauthor=M.+Partonauthor=S.+K%C3%BCmmelauthor=L.+G.+Estevezauthor=C.+S.+Huangauthor=J.+Cortes%0ACastanauthor=M.+Ruiz-Borregoauthor=M.+Telliauthor=P.+Mart%C3%ADn%0AMartorellauthor=R.+Lopezauthor=J.+T.+Beckauthor=R.+Ismail-Khanauthor=S.+C.+Chenauthor=S.+Hurvitzauthor=I.+Mayer&title=1977+Synergy+of+LCL161%2C+an+antagonist+of+inhibitor+of+apoptosis+proteins+%28IAPs%29%2C+with+paclitaxel+in+a+gene+expression+signature-enriched+cohort+of+triple-negative+breast+cancer+%28TNBC%29&doi=10.1016%2FS0959-8049%2816%2930925-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2816%2930925-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252816%252930925-X%26sid%3Dliteratum%253Aachs%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DJ.%2BS.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DD.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DParton%26aufirst%3DM.%26aulast%3DK%25C3%25BCmmel%26aufirst%3DS.%26aulast%3DEstevez%26aufirst%3DL.%2BG.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DCortes%2BCastan%26aufirst%3DJ.%26aulast%3DRuiz-Borrego%26aufirst%3DM.%26aulast%3DTelli%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn%2BMartorell%26aufirst%3DP.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DIsmail-Khan%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DHurvitz%26aufirst%3DS.%26aulast%3DMayer%26aufirst%3DI.%26atitle%3D1977%2520Synergy%2520of%2520LCL161%252C%2520an%2520antagonist%2520of%2520inhibitor%2520of%2520apoptosis%2520proteins%2520%2528IAPs%2529%252C%2520with%2520paclitaxel%2520in%2520a%2520gene%2520expression%2520signature-enriched%2520cohort%2520of%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2015%26volume%3D51%26spage%3DS326%26doi%3D10.1016%2FS0959-8049%2816%2930925-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span> <span> </span><span class="NLM_article-title">Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells</span>. <i>Phytomedicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.phymed.2018.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.phymed.2018.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30466991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKrs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=43-49&author=S.+Kimauthor=D.+Youauthor=Y.+Jeongauthor=J.+Yuauthor=S.+W.+Kimauthor=S.+J.+Namauthor=J.+E.+Lee&title=Berberine+down-regulates+IL-8+expression+through+inhibition+of+the+EGFR%2FMEK%2FERK+pathway+in+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.phymed.2018.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells</span></div><div class="casAuthors">Kim, Sangmin; You, Daeun; Jeong, Yisun; Yu, Jonghan; Kim, Seok Won; Nam, Seok Jin; Lee, Jeong Eon</div><div class="citationInfo"><span class="NLM_cas:title">Phytomedicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-49</span>CODEN:
                <span class="NLM_cas:coden">PYTOEY</span>;
        ISSN:<span class="NLM_cas:issn">0944-7113</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Interleukin-8 (IL-8) expression is assocd. with metastasis in a variety of cancer cells.  Here, we investigated the regulatory mechanism of IL-8 expression as well as the pharmacol. effect of berberine (BBR) on IL-8 expression in triple-neg. breast cancer (TNBC) cells.  The clin. value of IL-8 was analyzed by from a public database [Kaplan-Meier plotter database.  IL-8 mRNA and protein expression was analyzed by real-time PCR and ELISA, resp.  Cell invasion was analyzed by Boyden chamber assay.  Tumor cell growth was analyzed by colony forming assay.  Clin., we obsd. that breast cancer patients with highly expressed IL-8 are assocd. with poor outcomes in areas such as relapse-free, overall, and distant metastasis-free survival.  We showed that IL-8 expression is higher in TNBC cells than in non-TNBC cells.  In addn., the rates of cell invasion were significantly increased by IL-8 treatment.  These IL-8 levels were decreased by EGFR (Neratinib and Afatinib) and MEK (PD98059) inhibitors in TNBC cells.  Finally, we obsd. that BBR dramatically suppresses IL-8 expression.  In addn., BBR also inhibited cell invasiveness and anchorage-independent growth.  Interestingly, our results showed that BBR down-regulates EGFR protein expression and dose-dependently inhibits MEK and ERK phosphorylation.  Here, we demonstrate that BBR may be a promising drug to suppress cell invasiveness and growth of TNBC through IL-8-related mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6d3y0KdS15LVg90H21EOLACvtfcHk0liWLYwmAAdzHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKrs7vP&md5=5c682d102500aaa5210aa0cccb57a349</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.phymed.2018.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phymed.2018.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DNam%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26atitle%3DBerberine%2520down-regulates%2520IL-8%2520expression%2520through%2520inhibition%2520of%2520the%2520EGFR%252FMEK%252FERK%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DPhytomedicine%26date%3D2018%26volume%3D50%26spage%3D43%26epage%3D49%26doi%3D10.1016%2Fj.phymed.2018.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cretella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumarola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Monica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digiacomo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazzoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Generali, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronini, P. G.</span></span> <span> </span><span class="NLM_article-title">The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">72</span>, <span class="refDoi"> DOI: 10.1186/s13046-018-0741-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13046-018-0741-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29587820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1egtL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=72&issue=1&author=D.+Cretellaauthor=A.+Ravelliauthor=C.+Fumarolaauthor=S.+La+Monicaauthor=G.+Digiacomoauthor=A.+Cavazzoniauthor=R.+Alfieriauthor=A.+Biondiauthor=D.+Generaliauthor=M.+Bonelliauthor=P.+G.+Petronini&title=The+anti-tumor+efficacy+of+CDK4%2F6+inhibition+is+enhanced+by+the+combination+with+PI3K%2FAKT%2FmTOR+inhibitors+through+impairment+of+glucose+metabolism+in+TNBC+cells&doi=10.1186%2Fs13046-018-0741-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells</span></div><div class="casAuthors">Cretella, Daniele; Ravelli, Andrea; Fumarola, Claudia; Monica, Silvia La; Digiacomo, Graziana; Cavazzoni, Andrea; Alfieri, Roberta; Biondi, Alessandra; Generali, Daniele; Bonelli, Mara; Petronini, Pier Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72/1-72/12</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Cell cycle regulators have gain attention as potential targets for anticancer therapy.  Palbociclib is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), which coordinate the G1-S transition.  Palbociclib is currently approved for the treatment of hormone receptor pos., HER2-neg. advanced breast cancer (BC) in assocn. with letrozole or fulvestrant.  In contrast, its efficacy in triple neg. BC (TNBC), either alone or in combined therapies, has not been fully investigated to date.  Methods: Here we evaluated the potential of combining palbociclib with PI3K/mTOR inhibitors in Rb-proficient TNBC cells comparing different schedules of treatment: simultaneous, sequential, or sequential combined treatment (pre-incubation with palbociclib followed by exposure to both palbociclib and PI3K/mTOR inhibitors).  We assessed the effects on cell proliferation, cell death, and cell cycle distribution, and looked at the impact of such treatments on glucose metab.  Results: Palbociclib exerted cytostatic effects in Rb-pos. TNBC cells, inducing a reversible blockade in G0/G1 cell cycle phase assocd. with down-regulation of CDK6, Rb, and c-myc expression and/or activity.  Palbociclib treatment induced AKT signaling, providing a rationale for its combination with PI3K/mTOR inhibitors.  The simultaneous or sequential treatment resulted in an additive inhibition of cell proliferation.  On the other hand, the sequential combined treatment in which palbociclib was maintained also during exposure to PI3K/mTOR inhibitors gave rise to synergistic anti-proliferative and pro-apoptotic effects, by inhibiting both CDK4/6/Rb/myc and PI3K/ mTOR signaling.  Interestingly, the inhibition of the Rb/E2F/myc axis mediated by palbociclib resulted in a significant down-regulation of glucose metab.; most importantly, these inhibitory effects were enhanced by the combination of palbociclib with BYL719 (specific inhibitor of the p110α PI3K-subunit), which promoted a stronger inhibition of GLUT-1 glucose transporter expression, glucose uptake and consumption in comparison with individual treatments, under both normoxic and hypoxic conditions.  Conclusions: Combination of palbociclib with PI3K/mTOR inhibitors may represent a promising therapeutic option for the treatment of Rb-proficient TNBC, with the sequential combined schedule showing a superior efficacy over the other schedules.  In addn. our results demonstrate that the impairment of glucose metab. may contribute to the anti-tumor activity of such drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry9YJWakzPCbVg90H21EOLACvtfcHk0liWLYwmAAdzHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1egtL3M&md5=a957f93b7ae278b8017d16d8042885de</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-0741-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-0741-3%26sid%3Dliteratum%253Aachs%26aulast%3DCretella%26aufirst%3DD.%26aulast%3DRavelli%26aufirst%3DA.%26aulast%3DFumarola%26aufirst%3DC.%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DDigiacomo%26aufirst%3DG.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DBiondi%26aufirst%3DA.%26aulast%3DGenerali%26aufirst%3DD.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26atitle%3DThe%2520anti-tumor%2520efficacy%2520of%2520CDK4%252F6%2520inhibition%2520is%2520enhanced%2520by%2520the%2520combination%2520with%2520PI3K%252FAKT%252FmTOR%2520inhibitors%2520through%2520impairment%2520of%2520glucose%2520metabolism%2520in%2520TNBC%2520cells%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D37%26issue%3D1%26spage%3D72%26doi%3D10.1186%2Fs13046-018-0741-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwik, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowder, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannigan, D. A.</span></span> <span> </span><span class="NLM_article-title">Development of a RSK inhibitor as a novel therapy for triple-negative breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2598</span>– <span class="NLM_lpage">2608</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-16-0106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27528706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVOqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2598-2608&issue=11&author=K.+A.+Ludwikauthor=J.+P.+Campbellauthor=M.+Liauthor=Y.+Liauthor=Z.+M.+Sanduskyauthor=L.+Pasicauthor=M.+E.+Sowderauthor=D.+R.+Breninauthor=J.+A.+Pietenpolauthor=G.+A.+Dohertyauthor=D.+A.+Lannigan&title=Development+of+a+RSK+inhibitor+as+a+novel+therapy+for+triple-negative+breast+cancer&doi=10.1158%2F1535-7163.MCT-16-0106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a RSK inhibitor as a novel therapy for triple-negative breast cancer</span></div><div class="casAuthors">Ludwik, Katarzyna A.; Campbell, J. Preston; Li, Mingzong; Li, Yu; Sandusky, Zachary M.; Pasic, Lejla; Sowder, Miranda E.; Brenin, David R.; Pietenpol, Jennifer A.; O'Doherty, George A.; Lannigan, Deborah A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2598-2608</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metastatic breast cancer is an incurable disease and identification of novel therapeutic opportunities is vital.  Triple-neg. breast cancer (TNBC) frequently metastasizes and high levels of activated p90RSK (RSK), a downstream MEK-ERK1/2 effector, are found in TNBC.  We demonstrate, using direct pharmacol. and genetic inhibition of RSK1/2, that these kinases contribute to the TNBC metastatic process in vivo.  Kinase profiling showed that RSK1 and RSK2 are the predominant kinases targeted by the new inhibitor, which is based on the natural product SL0101.  Further evidence for selectivity was provided by the observations that silencing RSK1 and RSK2 eliminated the ability of the analog to further inhibit survival or proliferation of a TNBC cell line.  In vivo, the new deriv. was as effective as the FDA-approved MEK inhibitor trametinib in reducing the establishment of metastatic foci.  Importantly, inhibition of RSK1/2 did not result in activation of AKT, which is known to limit the efficacy of MEK inhibitors in the clinic.  Our results demonstrate that RSK is a major contributor to the TNBC metastatic program and provide preclin. proof-of-concept for the efficacy of the novel SL0101 analog in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm1jJkBc1CfrVg90H21EOLACvtfcHk0liWLYwmAAdzHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVOqsL8%253D&md5=3f4020911c09d843ecbfbdae4fe61bb9</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0106%26sid%3Dliteratum%253Aachs%26aulast%3DLudwik%26aufirst%3DK.%2BA.%26aulast%3DCampbell%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSandusky%26aufirst%3DZ.%2BM.%26aulast%3DPasic%26aufirst%3DL.%26aulast%3DSowder%26aufirst%3DM.%2BE.%26aulast%3DBrenin%26aufirst%3DD.%2BR.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26aulast%3DDoherty%26aufirst%3DG.%2BA.%26aulast%3DLannigan%26aufirst%3DD.%2BA.%26atitle%3DDevelopment%2520of%2520a%2520RSK%2520inhibitor%2520as%2520a%2520novel%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D2598%26epage%3D2608%26doi%3D10.1158%2F1535-7163.MCT-16-0106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coonrod, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2017.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28844713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVSlsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2017&pages=30-41&author=H.+Qinauthor=X.+Liuauthor=F.+Liauthor=L.+Miaoauthor=T.+Liauthor=B.+Xuauthor=X.+Anauthor=A.+Muthauthor=P.+R.+Thompsonauthor=S.+A.+Coonrodauthor=X.+Zhang&title=PAD1+promotes+epithelial-mesenchymal+transition+and+metastasis+in+triple-negative+breast+cancer+cells+by+regulating+MEK1-ERK1%2F2-MMP2+signaling&doi=10.1016%2Fj.canlet.2017.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling</span></div><div class="casAuthors">Qin, Hao; Liu, Xiaoqiu; Li, Fujun; Miao, Lixia; Li, Tingting; Xu, Boqun; An, Xiaofei; Muth, Aaron; Thompson, Paul R.; Coonrod, Scott A.; Zhang, Xuesen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-41</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Peptidylargininedeiminase 1 (PAD1) catalyzes protein for citrullination, and this activity has been linked to the epidermal cornification.  However, a role for PAD1 in tumorigenesis, including breast cancers has not been previously explored.  Here we first showed that PAD1 is overexpressed in human triple neg. breast cancer (TNBC).  In cultured cells and xenograft mouse models, PAD1 depletion or inhibition reduced cell proliferation, suppressed epithelial-mesenchymal transition, and prevented metastasis of MDA-MB-231 cells.  These changes were correlated with a dramatic decrease in MMP2/9 expression.  Furthermore, ERK1/2 and P38 MAPK signaling pathways are activated upon PAD1 silencing.  Treatment with MEK1/2 inhibitor in PAD1 knockdown cells significantly recovered MMP2 expression, while inhibiting P38 activation only slightly elevated MMP9 levels.  We then showed that PAD1 interacts with and citrullinates MEK1 thereby disrupting MEK1-catalyzed ERK1/2 phosphorylation, thus leading to the MMP2 overexpression.  Collectively, our data indicate that PAD1 appears to promote tumorigenesis by regulating MEK1-ERK1/2-MMP2 signaling in TNBC.  These results also raise the possibility that PAD1 may function as an important new biomarker for TNBC tumors and suggest that PAD1-specific inhibitors could potentially be utilized to treat metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF9YlUyw_CZ7Vg90H21EOLACvtfcHk0lgz23RUWo1HBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVSlsb7N&md5=c3366e717e7496f57bffabb8d23475b1</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DAn%26aufirst%3DX.%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DP.%2BR.%26aulast%3DCoonrod%26aufirst%3DS.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DPAD1%2520promotes%2520epithelial-mesenchymal%2520transition%2520and%2520metastasis%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520by%2520regulating%2520MEK1-ERK1%252F2-MMP2%2520signaling%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D409%26spage%3D30%26epage%3D41%26doi%3D10.1016%2Fj.canlet.2017.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Souid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsayed, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohyeldin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddique, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Sayed, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essafi-Benkhadir, K.</span></span> <span> </span><span class="NLM_article-title">131-Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal-epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1002/mc.22874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fmc.22874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29978911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1507-1524&issue=11&author=S.+Souidauthor=H.+E.+Elsayedauthor=H.+Y.+Ebrahimauthor=M.+M.+Mohyeldinauthor=A.+B.+Siddiqueauthor=H.+Karouiauthor=K.+A.+El+Sayedauthor=K.+Essafi-Benkhadir&title=131-Oxophorbine+protopheophorbide+A+from+Ziziphus+lotus+as+a+novel+mesenchymal-epithelial+transition+factor+receptor+inhibitory+lead+for+the+control+of+breast+tumor+growth+in+vitro+and+in+vivo&doi=10.1002%2Fmc.22874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">131-Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal-epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo</span></div><div class="casAuthors">Souid, Soumaya; Elsayed, Heba E.; Ebrahim, Hassan Y.; Mohyeldin, Mohamed M.; Siddique, Abu Bakar; Karoui, Habib; El Sayed, Khalid A.; Essafi-Benkhadir, Khadija</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1507-1524</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The failure of chemotherapy esp. in triple neg. breast cancer (TNBC) patients has been correlated with the overexpression of the mesenchymal-epithelial transition factor (c-Met) receptor.  Thus, the hepatocyte growth factor (HGF)/c-Met signaling axis has gained considerable attention as a valid mol. target for breast cancer therapy.  This study reports for the first time the discovery of the 131-oxophorbines pheophorbide A and protopheophorbide A along with chlorophyllide A from Ziziphus lotus, an edible typical Tunisian plant, as the potent antiproliferative compds. against the human breast cancer cells MDA-MB-231 and MCF-7.  In silico, this compd. targeted the kinase domain of multiple c-Met crystal structures.  It potently inhibited the kinase domain phosphorylation of wild and mutant c-Met in Z-LYTE kinase assay.  Protopheophorbide A inhibited HGF-induced downstream c-Met-dependent cell proliferation, survival, adhesion and migration through RAF/MEK/ERK and PI3K/PTEN/AKT signaling pathways modulation, ROS generation and activation of JNK and p38 pathways.  Importantly, treatment with protopheophorbide A significantly inhibited the MDA-MB-231 tumor growth in vivo.  Our results suggest that protopheophorbide A could be a novel c-Met inhibitory lead with promise to control c-Met/HGF-dependent breast malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOzfJbfSHQTbVg90H21EOLACvtfcHk0lgz23RUWo1HBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsrnI&md5=9dc0761a41bd3fd958748124cdaa758e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fmc.22874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.22874%26sid%3Dliteratum%253Aachs%26aulast%3DSouid%26aufirst%3DS.%26aulast%3DElsayed%26aufirst%3DH.%2BE.%26aulast%3DEbrahim%26aufirst%3DH.%2BY.%26aulast%3DMohyeldin%26aufirst%3DM.%2BM.%26aulast%3DSiddique%26aufirst%3DA.%2BB.%26aulast%3DKaroui%26aufirst%3DH.%26aulast%3DEl%2BSayed%26aufirst%3DK.%2BA.%26aulast%3DEssafi-Benkhadir%26aufirst%3DK.%26atitle%3D131-Oxophorbine%2520protopheophorbide%2520A%2520from%2520Ziziphus%2520lotus%2520as%2520a%2520novel%2520mesenchymal-epithelial%2520transition%2520factor%2520receptor%2520inhibitory%2520lead%2520for%2520the%2520control%2520of%2520breast%2520tumor%2520growth%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Carcinog.%26date%3D2018%26volume%3D57%26issue%3D11%26spage%3D1507%26epage%3D1524%26doi%3D10.1002%2Fmc.22874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byerly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halstead-Nussloch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsyv, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, H. Y.</span></span> <span> </span><span class="NLM_article-title">PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>, <span class="refDoi"> DOI: 10.1186/s13058-016-0749-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-016-0749-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27663795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGks7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=95&issue=1&author=J.+Byerlyauthor=G.+Halstead-Nusslochauthor=K.+Itoauthor=I.+Katsyvauthor=H.+Y.+Irie&title=PRKCQ+promotes+oncogenic+growth+and+anoikis+resistance+of+a+subset+of+triple-negative+breast+cancer+cells&doi=10.1186%2Fs13058-016-0749-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells</span></div><div class="casAuthors">Byerly, Jessica; Halstead-Nussloch, Gwyneth; Ito, Koichi; Katsyv, Igor; Irie, Hanna Y.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95/1-95/11</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The protein kinase C (PKC) family comprises distinct classes of proteins, many of which are implicated in diverse cellular functions.  Protein tyrosine kinase C theta isoform (PRKCQ)/PKCθ, a member of the novel PKC family, may have a distinct isoform-specific role in breast cancer.  PKCθ is preferentially expressed in triple-neg. breast cancer (TNBC) compared to other breast tumor subtypes.  We hypothesized that PRKCQ/PKCθ critically regulates growth and survival of a subset of TNBC cells.  Methods: To elucidate the role of PRKCQ/PKCθ in regulating growth and anoikis resistance, we used both gain and loss of function to modulate expression of PRKCQ.  We enhanced expression of PKCθ (kinase-active or inactive) in non-transformed breast epithelial cells (MCF-10A) and assessed effects on epidermal growth factor (EGF)-independent growth, anoikis, and migration.  We downregulated expression of PKCθ in TNBC cells, and detd. effects on in vitro and in vivo growth and survival.  TNBC cells were also treated with a small mol. inhibitor to assess requirement for PKCθ kinase activity in the growth of TNBC cells.  Results: PRKCQ/PKCθ can promote oncogenic phenotypes when expressed in non-transformed MCF-10A mammary epithelial cells; PRKCQ/PKCθ enhances anchorage-independent survival, growth-factor-independent proliferation, and migration.  PKCθ expression promotes retinoblastoma (Rb) phosphorylation and cell-cycle progression under growth factor-deprived conditions that typically induce cell-cycle arrest of MCF-10A breast epithelial cells.  Proliferation and Rb phosphorylation are dependent on PKCθ-stimulated extracellular signal-related kinase (Erk)/mitogen-activated protein kinase (MAPK) activity.  Enhanced Erk/MAPK activity is dependent on the kinase activity of PKCθ, as overexpression of kinase-inactive PKCθ does not stimulate Erk/MAPK or Rb phosphorylation or promote growth-factor-independent proliferation.  Downregulation of PRKCQ/PKCθ in TNBC cells enhances anoikis, inhibits growth in 3-D Matrigel cultures, and impairs triple-neg. tumor xenograft growth.  AEB071, an inhibitor of PKCθ kinase activity, also inhibits growth and invasive branching of TNBC cells in 3-D cultures, further supporting a role for PKCθ kinase activity in triple-neg. cancer cell growth.  Conclusions: Enhanced PRKCQ/PKCθ expression can promote growth-factor-independent growth, anoikis resistance, and migration.  PRKCQ critically regulates growth and survival of a subset of TNBC.  Inhibition of PKCθ kinase activity may be an attractive therapeutic approach for TNBC, a subtype in need of improved targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotMxHI_ruRt7Vg90H21EOLACvtfcHk0lgz23RUWo1HBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGks7vP&md5=9bf31c044b4b8aedb311dcf9da49ea20</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1186%2Fs13058-016-0749-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-016-0749-6%26sid%3Dliteratum%253Aachs%26aulast%3DByerly%26aufirst%3DJ.%26aulast%3DHalstead-Nussloch%26aufirst%3DG.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DKatsyv%26aufirst%3DI.%26aulast%3DIrie%26aufirst%3DH.%2BY.%26atitle%3DPRKCQ%2520promotes%2520oncogenic%2520growth%2520and%2520anoikis%2520resistance%2520of%2520a%2520subset%2520of%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26issue%3D1%26spage%3D95%26doi%3D10.1186%2Fs13058-016-0749-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschhaus, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qyli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajendran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinosa, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luker, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luker, G. D.</span></span> <span> </span><span class="NLM_article-title">Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1142</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-18-0836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1541-7786.MCR-18-0836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30718260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVeks77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=1142-1154&issue=5&author=B.+A.+Humphriesauthor=J.+M.+Buschhausauthor=Y.-C.+Chenauthor=H.+R.+Haleyauthor=T.+Qyliauthor=B.+Chiangauthor=N.+Shenauthor=S.+Rajendranauthor=A.+Cutterauthor=Y.-H.+Chengauthor=Y.-T.+Chenauthor=J.+Congauthor=P.+C.+Spinosaauthor=E.+Yoonauthor=K.+E.+Lukerauthor=G.+D.+Luker&title=Plasminogen+activator+inhibitor+1+%28PAI1%29+promotes+actin+cytoskeleton+reorganization+and+glycolytic+metabolism+in+triple-negative+breast+cancer&doi=10.1158%2F1541-7786.MCR-18-0836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer</span></div><div class="casAuthors">Humphries, Brock A.; Buschhaus, Johanna M.; Chen, Yu-Chih; Haley, Henry R.; Qyli, Tonela; Chiang, Benjamin; Shen, Nathan; Rajendran, Shrila; Cutter, Alyssa; Cheng, Yu-Heng; Chen, Yu-Ting; Cong, Jason; Spinosa, Phillip C.; Yoon, Euisik; Luker, Kathryn E.; Luker, Gary D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1142-1154</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here we show that increased PAI1 drives rearrangement of the actin cytoskeleton, mitochondrial fragmentation, and glycolytic metab. in triple-neg. breast cancer (TNBC) cells.  In two-dimensional environments, both stable expression of PAI1 and treatment with recombinant PAI1 increased migration, which could be blocked with the specific inhibitor tiplaxtinin.  PAI1 also promoted invasion into the extracellular matrix from coculture spheroids with human mammary fibroblasts in fibrin gels.  Elevated cellular PAI1 enhanced cytoskeletal features assocd. with migration, actin-rich migratory structures, and reduced actin stress fibers.  In orthotopic tumor xenografts, we discovered that TNBC cells with elevated PAI1 show collagen fibers aligned perpendicular to the tumor margin, an established marker of invasive breast tumors.  Further studies revealed that PAI1 activates ERK signaling, a central regulator of motility, and promotes mitochondrial fragmentation.  Consistent with known effects of mitochondrial fragmentation on metab., fluorescence lifetime imaging microscopy of endogenous NADH showed that PAI1 promotes glycolysis in cell-based assays, orthotopic tumor xenografts, and lung metastases.  Together, these data demonstrate for the first time that PAI1 regulates cancer cell metab. and suggest targeting metab. to block motility and tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQKupxh_tLoLVg90H21EOLACvtfcHk0li1YZ1bqlFL_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVeks77E&md5=3af3739f0e48e693246a54500d56cae6</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-18-0836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-18-0836%26sid%3Dliteratum%253Aachs%26aulast%3DHumphries%26aufirst%3DB.%2BA.%26aulast%3DBuschhaus%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DY.-C.%26aulast%3DHaley%26aufirst%3DH.%2BR.%26aulast%3DQyli%26aufirst%3DT.%26aulast%3DChiang%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DN.%26aulast%3DRajendran%26aufirst%3DS.%26aulast%3DCutter%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DY.-H.%26aulast%3DChen%26aufirst%3DY.-T.%26aulast%3DCong%26aufirst%3DJ.%26aulast%3DSpinosa%26aufirst%3DP.%2BC.%26aulast%3DYoon%26aufirst%3DE.%26aulast%3DLuker%26aufirst%3DK.%2BE.%26aulast%3DLuker%26aufirst%3DG.%2BD.%26atitle%3DPlasminogen%2520activator%2520inhibitor%25201%2520%2528PAI1%2529%2520promotes%2520actin%2520cytoskeleton%2520reorganization%2520and%2520glycolytic%2520metabolism%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D5%26spage%3D1142%26epage%3D1154%26doi%3D10.1158%2F1541-7786.MCR-18-0836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2018.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ebiom.2018.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30651219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3cjit1Wksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=263-275&author=C.+Y.+Liuauthor=T.+T.+Huangauthor=Y.+T.+Chenauthor=J.+L.+Chenauthor=P.+Y.+Chuauthor=C.+T.+Huangauthor=W.+L.+Wangauthor=K.+Y.+Lauauthor=M.+S.+Daiauthor=C.+W.+Shiauauthor=L.+M.+Tseng&title=Targeting+SET+to+restore+PP2A+activity+disrupts+an+oncogenic+CIP2A-feedforward+loop+and+impairs+triple+negative+breast+cancer+progression&doi=10.1016%2Fj.ebiom.2018.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression</span></div><div class="casAuthors">Liu Chun-Yu; Huang Tzu-Ting; Chen Ji-Lin; Chen Yi-Ting; Lau Ka-Yi; Chu Pei-Yi; Huang Chun-Teng; Wang Wan-Lun; Dai Ming-Shen; Shiau Chung-Wai; Tseng Ling-Ming</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263-275</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancer (TNBC) remains difficult to be targeted.  SET and cancerous inhibitor of protein phosphatase 2A (CIP2A) are intrinsic protein-interacting inhibitors of protein phosphatase 2A (PP2A) and frequently overexpressed in cancers, whereas reactivating PP2A activity has been postulated as an anti-cancer strategy.  Here we explored this strategy in TNBC.  METHODS:  Data from The Cancer Genome Atlas (TCGA) database was analyzed.  TNBC cell lines were used for in vitro studies.  Cell viability was examined by MTT assay.  The apoptotic cells were examined by flow cytometry and Western blot.  A SET-PP2A protein-protein interaction antagonist TD19 was used to disrupt signal transduction.  In vivo efficacy of TD19 was tested in MDA-MB-468-xenografted animal model.  FINDINGS:  TCGA data revealed upregulation of SET and CIP2A and positive correlation of these two gene expressions in TNBC tumors.  Ectopic SET or CIP2A increased cell viability, migration, and invasion of TNBC cells.  Notably ERK inhibition increased PP2A activity.  ERK activation is known crucial for Elk-1 activity, a transcriptional factor regulating CIP2A expression, we hypothesized an oncogenic feedforward loop consisting of pERK/pElk-1/CIP2A/PP2A.  This loop was validated by knockdown of PP2A and ectopic expression of Elk-1, showing reciprocal changes in loop members.  In addition, ectopic expression of SET increased pAkt, pERK, pElk-1 and CIP2A expressions, suggesting a positive linkage between SET and CIP2A signaling.  Moreover, TD19 disrupted this CIP2A-feedforward loop by restoring PP2A activity, demonstrating in vitro and in vivo anti-cancer activity.  Mechanistically, TD19 downregulated CIP2A mRNA via inhibiting pERK-mediated Elk-1 nuclear translocation thereby decreased Elk-1 binding to the CIP2A promoter.  INTERPRETATION:  These findings suggested that a novel oncogenic CIP2A-feedforward loop contributes to TNBC progression and targeting SET to disrupt this oncogenic CIP2A loop showed therapeutic potential in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxAmj6DAngMZNiNltV31zlfW6udTcc2eZVEy_2RDTQfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjit1Wksg%253D%253D&md5=03b080b2050c976220e2466b807398a5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2018.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2018.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DChen%26aufirst%3DJ.%2BL.%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DLau%26aufirst%3DK.%2BY.%26aulast%3DDai%26aufirst%3DM.%2BS.%26aulast%3DShiau%26aufirst%3DC.%2BW.%26aulast%3DTseng%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520SET%2520to%2520restore%2520PP2A%2520activity%2520disrupts%2520an%2520oncogenic%2520CIP2A-feedforward%2520loop%2520and%2520impairs%2520triple%2520negative%2520breast%2520cancer%2520progression%26jtitle%3DEBioMedicine%26date%3D2019%26volume%3D40%26spage%3D263%26epage%3D275%26doi%3D10.1016%2Fj.ebiom.2018.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, R. J.</span></span> <span> </span><span class="NLM_article-title">FGFR3 signaling and function in triple negative breast cancer</span>. <i>Cell Commun. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.1186/s12964-019-0486-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs12964-019-0486-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31987043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVGiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=13&issue=1&author=N.+J.+Chewauthor=E.+V.+Nguyenauthor=S.-P.+Suauthor=K.+Novyauthor=H.+C.+Chanauthor=L.+K.+Nguyenauthor=J.+Luuauthor=K.+J.+Simpsonauthor=R.+S.+Leeauthor=R.+J.+Daly&title=FGFR3+signaling+and+function+in+triple+negative+breast+cancer&doi=10.1186%2Fs12964-019-0486-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">FGFR3 signaling and function in triple negative breast cancer</span></div><div class="casAuthors">Chew, Nicole J.; Nguyen, Elizabeth V.; Su, Shih-Ping; Novy, Karel; Chan, Howard C.; Nguyen, Lan K.; Luu, Jennii; Simpson, Kaylene J.; Lee, Rachel S.; Daly, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Communication and Signaling</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13</span>CODEN:
                <span class="NLM_cas:coden">CCSEC6</span>;
        ISSN:<span class="NLM_cas:issn">1478-811X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">High FGFR3 expression and phosphorylation were detected in SUM185PE cells, which harbor a FGFR3-TACC3 gene fusion.  Low FGFR3 phosphorylation was detected in CAL51, MFM-223 and MDA-MB-231 cells.  In SUM185PE cells, the FGFR3-TACC3 fusion protein contributed the majority of phosphorylated FGFR3, and largely localized to the cytoplasm and plasma membrane, with staining at the mitotic spindle in a small subset of cells.  Knockdown of the FGFR3-TACC3 fusion and wildtype FGFR3 in SUM185PE cells decreased FRS2, AKT and ERK phosphorylation, and induced cell death.  Knockdown of wildtype FGFR3 resulted in only a trend for decreased proliferation.  PD173074 significantly decreased FRS2, AKT and ERK activation, and reduced SUM185PE cell proliferation.  Cyclin A and pRb were also decreased in the presence of PD173074, while cleaved PARP was increased, indicating cell cycle arrest in G1 phase and apoptosis.  Knockdown of FGFR3 in CAL51, MFM-223 and MDA-MB-231 cells had no significant effect on cell proliferation.  Interrogation of public datasets revealed that increased FGFR3 expression in breast cancer was significantly assocd. with reduced overall survival, and that potentially oncogenic FGFR3 alterations (eg mutation and amplification) occur in the TNBC/basal, luminal A and luminal B subtypes, but are rare.  These results indicate that targeting FGFR3 may represent a therapeutic option for TNBC, but only for patients with oncogenic FGFR3 alterations, such as the FGFR3-TACC3 fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTYd7FrDSY2LVg90H21EOLACvtfcHk0li4AJfMkDWDnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVGiuro%253D&md5=772fa1a7760de1c2227b6f30092491cf</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1186%2Fs12964-019-0486-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12964-019-0486-4%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DN.%2BJ.%26aulast%3DNguyen%26aufirst%3DE.%2BV.%26aulast%3DSu%26aufirst%3DS.-P.%26aulast%3DNovy%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DH.%2BC.%26aulast%3DNguyen%26aufirst%3DL.%2BK.%26aulast%3DLuu%26aufirst%3DJ.%26aulast%3DSimpson%26aufirst%3DK.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BS.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26atitle%3DFGFR3%2520signaling%2520and%2520function%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DCell%2520Commun.%2520Signaling%26date%3D2020%26volume%3D18%26issue%3D1%26spage%3D13%26doi%3D10.1186%2Fs12964-019-0486-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gari, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGala, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucia, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. R.</span></span> <span> </span><span class="NLM_article-title">PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.07.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2016.07.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27452906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eju7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2016&pages=505-512&issue=2&author=H.+H.+Gariauthor=G.+D.+DeGalaauthor=R.+Rayauthor=M.+S.+Luciaauthor=J.+R.+Lambert&title=PRL-3+engages+the+focal+adhesion+pathway+in+triple-negative+breast+cancer+cells+to+alter+actin+structure+and+substrate+adhesion+properties+critical+for+cell+migration+and+invasion&doi=10.1016%2Fj.canlet.2016.07.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion</span></div><div class="casAuthors">Gari, Hamid H.; DeGala, Gregory D.; Ray, Rahul; Lucia, M. Scott; Lambert, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">505-512</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBCs) are among the most aggressive cancers characterized by a high propensity to invade, metastasize and relapse.  We previously reported that the TNBC-specific inhibitor, AMPI-109, significantly impairs the ability of TNBC cells to migrate and invade by reducing levels of the metastasis-promoting phosphatase, PRL-3.  Here, we examd. the mechanisms by which AMPI-109 and loss of PRL-3 impede cell migration and invasion.  AMPI-109 treatment or knock down of PRL-3 expression were assocd. with deactivation of Src and ERK signaling and concomitant downregulation of RhoA and Rac1/2/3 GTPase protein levels.  These cellular changes led to rearranged filamentous actin networks necessary for cell migration and invasion.  Conversely, overexpression of PRL-3 promoted TNBC cell invasion by upregulating matrix metalloproteinase 10, which resulted in increased TNBC cell adherence to, and degrdn. of, the major basement membrane component laminin.  Our data demonstrate that PRL-3 engages the focal adhesion pathway in TNBC cells as a key mechanism for promoting TNBC cell migration and invasion.  Collectively, these data suggest that blocking PRL-3 activity may be an effective method for reducing the metastatic potential of TNBC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGookcrOakjR7LVg90H21EOLACvtfcHk0li4AJfMkDWDnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eju7%252FK&md5=33ecc31aad335837607772f742dc5ce9</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.07.017%26sid%3Dliteratum%253Aachs%26aulast%3DGari%26aufirst%3DH.%2BH.%26aulast%3DDeGala%26aufirst%3DG.%2BD.%26aulast%3DRay%26aufirst%3DR.%26aulast%3DLucia%26aufirst%3DM.%2BS.%26aulast%3DLambert%26aufirst%3DJ.%2BR.%26atitle%3DPRL-3%2520engages%2520the%2520focal%2520adhesion%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520to%2520alter%2520actin%2520structure%2520and%2520substrate%2520adhesion%2520properties%2520critical%2520for%2520cell%2520migration%2520and%2520invasion%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D380%26issue%3D2%26spage%3D505%26epage%3D512%26doi%3D10.1016%2Fj.canlet.2016.07.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.01.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2019.01.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30707920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisl2qur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2019&pages=11-19&author=S.+Fuauthor=X.+Chenauthor=H.+W.+Loauthor=J.+Lin&title=Combined+bazedoxifene+and+paclitaxel+treatments+inhibit+cell+viability%2C+cell+migration%2C+colony+formation%2C+and+tumor+growth+and+induce+apoptosis+in+breast+cancer&doi=10.1016%2Fj.canlet.2019.01.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer</span></div><div class="casAuthors">Fu, Shengling; Chen, Xiang; Lo, Hui-Wen; Lin, Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Breast cancer, esp. triple-neg. breast cancer (TNBC), has limited treatment options.  We repurposed the FDA-approved drug bazedoxifene as a novel inhibitor of interleukin 6/glycoprotein 130 signaling.  In this study, we investigated the inhibitory effects of bazedoxifene alone or in combination with paclitaxel on several estrogen receptor pos. and TNBC cells.  Bazedoxifene inhibited the cell viability of these cells, as well as tumor growth of TNBC cells in a xenograft tumor model.  Furthermore, bazedoxifene combined with paclitaxel exhibited more potent inhibition of cell viability, colony formation, and cell migration and induced more apoptosis in vitro, and generated stronger inhibition of tumor growth of TNBC in vivo than either drug alone.  Western blotting showed that bazedoxifene inhibited estrogen receptor pos. breast cancer cells by suppressing the expression of estrogen receptor, Cyclin D1, p-P70S6K, Survivin, c-Myc, and Bcl-2, and bazedoxifene inhibited TNBC cells by inhibiting the expression of phosphorylated STAT3 (Tyr705), Cyclin D1, p-P70S6K, c-Myc, p-AKT (Ser473) and p-ERK 1/2 (T202/Y204) without changing the expression of total STAT3.  When combined with paclitaxel, bazedoxifene may be a potential small mol. for the treatment of both estrogen receptor pos. and triple-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrxFrVJz_HPLVg90H21EOLACvtfcHk0lhv9H9ZGjM3Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisl2qur8%253D&md5=94beee09dca36656ea9b922b0aba0d16</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.01.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.01.026%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLo%26aufirst%3DH.%2BW.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DCombined%2520bazedoxifene%2520and%2520paclitaxel%2520treatments%2520inhibit%2520cell%2520viability%252C%2520cell%2520migration%252C%2520colony%2520formation%252C%2520and%2520tumor%2520growth%2520and%2520induce%2520apoptosis%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D448%26spage%3D11%26epage%3D19%26doi%3D10.1016%2Fj.canlet.2019.01.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvet, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godwin, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">326</span>, <span class="refDoi"> DOI: 10.1038/s41419-018-0347-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41419-018-0347-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29487338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1MrlvF2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=326&issue=3&author=L.+X.+Liauthor=J.+X.+Zhouauthor=J.+P.+Calvetauthor=A.+K.+Godwinauthor=R.+A.+Jensenauthor=X.+Li&title=Lysine+methyltransferase+SMYD2+promotes+triple+negative+breast+cancer+progression&doi=10.1038%2Fs41419-018-0347-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression</span></div><div class="casAuthors">Li Linda Xiaoyan; Zhou Julie Xia; Li Xiaogang; Calvet James P; Li Xiaogang; Calvet James P; Li Xiaogang; Godwin Andrew K; Jensen Roy A</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">326</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We identified SMYD2, a SMYD (SET and MYND domain) family protein with lysine methyltransferase activity, as a novel breast cancer oncogene.  SMYD2 was expressed at significantly higher levels in breast cancer cell lines and in breast tumor tissues.  Silencing of SMYD2 by RNAi in triple-negative breast cancer (TNBC) cell lines or inhibition of SMYD2 with its specific inhibitor, AZ505, significantly reduced tumor growth in vivo.  SMYD2 executes this activity via methylation and activation of its novel non-histone substrates, including STAT3 and the p65 subunit of NF-κB, leading to increased TNBC cell proliferation and survival.  There are cross-talk and synergistic effects among SMYD2, STAT3, and NF-κB in TNBC cells, in that STAT3 can contribute to the modification of NF-κB p65 subunit post-translationally by recruitment of SMYD2, whereas the p65 subunit of NF-κB can also contribute to the modification of STAT3 post-translationally by recruitment of SMYD2, leading to methylation and activation of STAT3 and p65 in these cells.  The expression of SMYD2 can be upregulated by IL-6-STAT3 and TNFα-NF-κB signaling, which integrates epigenetic regulation to inflammation in TNBC development.  In addition, we have identified a novel SMYD2 transcriptional target gene, PTPN13, which links SMYD2 to other known breast cancer associated signaling pathways, including ERK, mTOR, and Akt signaling via PTPN13 mediated phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3Ul-MwFVF_Wx8TEN9K18QfW6udTcc2eYqezchO-rLNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrlvF2rtg%253D%253D&md5=fc4f3435b5090f2631b9e595ad319d45</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-0347-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-0347-x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%2BX.%26aulast%3DZhou%26aufirst%3DJ.%2BX.%26aulast%3DCalvet%26aufirst%3DJ.%2BP.%26aulast%3DGodwin%26aufirst%3DA.%2BK.%26aulast%3DJensen%26aufirst%3DR.%2BA.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DLysine%2520methyltransferase%2520SMYD2%2520promotes%2520triple%2520negative%2520breast%2520cancer%2520progression%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D326%26doi%3D10.1038%2Fs41419-018-0347-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ejmech.2017.08.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28923383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=155-171&author=D.+Yaoauthor=Y.+Zhouauthor=L.+Zhuauthor=L.+Ouyangauthor=J.+Zhangauthor=Y.+Jiangauthor=Y.+Zhaoauthor=D.+Sunauthor=S.+Yangauthor=Y.+Yuauthor=J.+Wang&title=Design%2C+synthesis+and+structure-activity+relationship+studies+of+a+focused+library+of+pyrimidine+moiety+with+anti-proliferative+and+anti-metastasis+activities+in+triple+negative+breast+cancer&doi=10.1016%2Fj.ejmech.2017.08.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer</span></div><div class="casAuthors">Yao, Dahong; Zhou, Yuxin; Zhu, Lingjuan; Ouyang, Liang; Zhang, Jin; Jiang, Yingnan; Zhao, Yuqian; Sun, Dejuan; Yang, Shilin; Yu, Yang; Wang, Jinhui</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-171</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this study, based on the structural features of type II kinase inhibitors, a focused library of 41 pyrimidine derivs. possessing potent anti-proliferative activity was designed and synthesized, Y29 showed the most potent activity against MDA-MB-231 cells.  Subsequently, target prediction, homol. modeling, mol. docking, dynamics simulation and detn. of enzymic activity was carried out.  The results suggested that PDGFR-β was its potential target.  In vitro expts. revealed that Y29 attenuated metastasis by PDGFR-β inhibition-induced autophagy and could enhance autophagy-related cell death through AKT-MAPK feedback loop in MDA-MB-231 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQIVq8UJHpX7Vg90H21EOLACvtfcHk0lhv9H9ZGjM3Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsLvI&md5=50571d1957b99e2de04fa9d747c20276</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.067%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520a%2520focused%2520library%2520of%2520pyrimidine%2520moiety%2520with%2520anti-proliferative%2520and%2520anti-metastasis%2520activities%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D140%26spage%3D155%26epage%3D171%26doi%3D10.1016%2Fj.ejmech.2017.08.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. H.</span></span> <span> </span><span class="NLM_article-title">Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1250</span>, <span class="refDoi"> DOI: 10.1038/aps.2016.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Faps.2016.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27397540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCgsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1237-1250&issue=9&author=Y.+Q.+Zhaoauthor=Y.+Q.+Yinauthor=J.+Liuauthor=G.+H.+Wangauthor=J.+Huangauthor=L.+J.+Zhuauthor=J.+H.+Wang&title=Characterization+of+HJ-PI01+as+a+novel+Pim-2+inhibitor+that+induces+apoptosis+and+autophagic+cell+death+in+triple-negative+human+breast+cancer&doi=10.1038%2Faps.2016.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer</span></div><div class="casAuthors">Zhao, Yu-qian; Yin, Yi-qiong; Liu, Jie; Wang, Gui-hua; Huang, Jian; Zhu, Ling-juan; Wang, Jin-hui</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1237-1250</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: Pim-2 is a short-lived serine/threonine kinase, which plays a key role in metastasis of breast cancer through persistent activation of STAT3.  Although the crystal structure of Pim-2 has been reported, but thus far no specific Pim-2-targeted compds. have been reported.  In this study, we identified a novel Pim-2 inhibitor, HJ-PI01, by in silico anal. and exptl. validation.  Methods: The protein-protein interaction (PPI) network, chem. synthesis, mol. docking, and mol. dynamics (MD) simulations were used to design and discover the new Pim-2 inhibitor HJ-PI01.  The anti-tumor effects of HJ-PI01 were evaluated in human breast MDA-MB-231, MDA-MB-468, MDA-MB-436, MCF-7 cells in vitro and in MDA-MB-231 xenograft mice, which were treated with HJ-PI01 (40 mg·kg-1·d-1, ig) with or without lienal polypeptide (50 mg·kg-1·d-1, i.p.) for 10 d.  The apoptosis/autophage-inducing mechanisms of HJ-PI01 were elucidated using Western blots, immunoblots, flow cytometry, transmission electron microscopy and fluorescence microscopy.  Results: Based on the PrePPI network, the potential partners interacting with Pim-2 in regulating apoptosis (160 protein pairs) and autophagy (47 protein pairs) were identified.  Based on the structural characteristics of Pim-2, a total of 15 compds. (HJ-PI01 to HJ-P015) were synthesized, which showed moderate or remarkable anti-proliferative potency in the human breast cancer cell lines tested.  The most effective compd. HJ-PI01 exerted a robust inhibition on MDA-MB-231 cells compared with chlorpromazine and the pan-Pim inhibitor PI003.  Mol. dynamics (MD) simulation revealed that HJ-PI01 had a good binding score with Pim-2.  Moreover, HJ-PI01 (300 nmol/L) induced death receptor-dependent and mitochondrial apoptosis as well as autophagic death in MDA-MB-231 cells.  In MDA-MB-231 xenograft mice, administration of HJ-PI01 remarkably inhibited the tumor growth and induced tumor cell apoptosis in vivo.  Co-administration of HJ-PI01 with lienal polypeptide could improve the anti-tumor activity of HJ-PI01 and reduce its toxicity.  Conclusion: The newly synthesized compd., HJ-PI01, can induce death receptor/mitochondrial apoptosis and autophagic cell death by targeting Pim-2 in human breast cancer cells in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdehhYe3J3SLVg90H21EOLACvtfcHk0lhk4a_G61plZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCgsbrF&md5=033fe94bf83b0cf1bf72edd7ade9ed72</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Faps.2016.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2016.60%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BQ.%26aulast%3DYin%26aufirst%3DY.%2BQ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%2BH.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26atitle%3DCharacterization%2520of%2520HJ-PI01%2520as%2520a%2520novel%2520Pim-2%2520inhibitor%2520that%2520induces%2520apoptosis%2520and%2520autophagic%2520cell%2520death%2520in%2520triple-negative%2520human%2520breast%2520cancer%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2016%26volume%3D37%26issue%3D9%26spage%3D1237%26epage%3D1250%26doi%3D10.1038%2Faps.2016.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Systematic network-based discovery of a Fam20C inhibitor (FL-1607) with apoptosis modulation in triple-negative breast cancer</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2108</span>– <span class="NLM_lpage">2118</span>, <span class="refDoi"> DOI: 10.1039/C6MB00111D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC6MB00111D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27113542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=2108-2118&issue=7&author=Z.+Qinauthor=P.+Wangauthor=X.+Liauthor=S.+Zhangauthor=M.+Tianauthor=Y.+Daiauthor=L.+Fu&title=Systematic+network-based+discovery+of+a+Fam20C+inhibitor+%28FL-1607%29+with+apoptosis+modulation+in+triple-negative+breast+cancer&doi=10.1039%2FC6MB00111D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic network-based discovery of a Fam20C inhibitor (FL-1607) with apoptosis modulation in triple-negative breast cancer</span></div><div class="casAuthors">Qin, Ziyi; Wang, Peiqi; Li, Xinyi; Zhang, Shouyue; Tian, Mao; Dai, Yi; Fu, Leilei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2108-2118</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Family with sequence similarity 20, member C (Fam20C) is a physiol. Golgi casein kinase that phosphorylates multiple secreted proteins.  Recently, it has been reported that Fam20C can be identified as a novel kinase target for therapeutic development.  Thus, inhibition of Fam20C will be a potential therapeutic strategy to prevent tumor cell progression and metastasis.  In our study, based upon the systems-biol. network, mol. modeling and mol. dynamics (MD) simulations, we discovered a novel Fam20C inhibitor (FL-1607) with potent anti-proliferative effects on triple-neg. breast cancer (TNBC) cells.  Subsequently, we found that this Fam20C inhibitor could induce apoptosis and inhibit cell migration in MDA-MB-468 cells.  Together, these findings would provide a new clue to the exploration of more novel Fam20C inhibitors for future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoKtN51oN0lbVg90H21EOLACvtfcHk0lhk4a_G61plZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKqu70%253D&md5=96dfd65f2ea8eda5af05a329639249ed</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1039%2FC6MB00111D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MB00111D%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DSystematic%2520network-based%2520discovery%2520of%2520a%2520Fam20C%2520inhibitor%2520%2528FL-1607%2529%2520with%2520apoptosis%2520modulation%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520BioSyst.%26date%3D2016%26volume%3D12%26issue%3D7%26spage%3D2108%26epage%3D2118%26doi%3D10.1039%2FC6MB00111D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2860</span>– <span class="NLM_lpage">2866</span>, <span class="refDoi"> DOI: 10.1039/C5MB00466G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC5MB00466G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26299935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWlt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=2860-2866&issue=11&author=L.+Zhangauthor=M.+Guoauthor=J.+Liauthor=Y.+Zhengauthor=S.+Zhangauthor=T.+Xieauthor=B.+Liu&title=Systems+biology-based+discovery+of+a+potential+Atg4B+agonist+%28Flubendazole%29+that+induces+autophagy+in+breast+cancer&doi=10.1039%2FC5MB00466G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer</span></div><div class="casAuthors">Zhang, Lan; Guo, Mingrui; Li, Jing; Zheng, Yaxin; Zhang, Shouyue; Xie, Tao; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2860-2866</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The aim of this study was to explore the autophagy-related protein 4B(ATG4B) and its targeted candidate agonist in triple-neg. breast cancer (TNBC) therapy.  In this study, the identification of Atg4B as a novel breast cancer target for screening candidate small mol. agonists was performed by phylogenetic anal., network construction, mol. modeling, mol. docking and mol. dynamics (MD) simulation.  In vitro, MTT assay, electron microscopy, western blot and ROS measurement were used for validating the efficacy of the candidate compds.  We used the phylogenetic anal. of Atg4B and constructed their protein-protein interaction (PPI) network.  Also, we screened target compds. of Atg4 proteins from Drugbank and ZINC.  Flubendazole was validated for its anti-proliferative efficacy in MDA-MB-231 cells.  Further MD simulation results supported the stable interaction between Flubendazole and Atg4B.  Moreover, Flubendazole induced autophagy and increased ROS prodn.  In conclusion, in silico anal. and exptl. validation together demonstrate that Flubendazole can target Atg4B in MDA-MB-231 cells and induce autophagy, which may shed light on the exploration of this compd. as a potential new Atg4B targeted drug for future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4pY16N3ASc7Vg90H21EOLACvtfcHk0lhk4a_G61plZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWlt73O&md5=f1e946be8d60619445e25a70fde2f7b8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1039%2FC5MB00466G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MB00466G%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DSystems%2520biology-based%2520discovery%2520of%2520a%2520potential%2520Atg4B%2520agonist%2520%2528Flubendazole%2529%2520that%2520induces%2520autophagy%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520BioSyst.%26date%3D2015%26volume%3D11%26issue%3D11%26spage%3D2860%26epage%3D2866%26doi%3D10.1039%2FC5MB00466G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vinet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maire, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monchecourt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Némati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesage, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescure, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meseure, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigaill, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Nery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman-Roman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, T.</span></span> <span> </span><span class="NLM_article-title">Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2414</span>– <span class="NLM_lpage">2428</span>, <span class="refDoi"> DOI: 10.1002/cam4.2114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fcam4.2114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30957988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVygsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=2414-2428&issue=5&author=M.+Vinetauthor=S.+Sureshauthor=V.+Maireauthor=C.+Monchecourtauthor=F.+N%C3%A9matiauthor=L.+Lesageauthor=F.+Pierreauthor=M.+Yeauthor=A.+Lescureauthor=A.+Brissonauthor=D.+Meseureauthor=A.+Nicolasauthor=G.+Rigaillauthor=E.+Marangoniauthor=E.+Del+Neryauthor=S.+Roman-Romanauthor=T.+Dubois&title=Protein+arginine+methyltransferase+5%3A+A+novel+therapeutic+target+for+triple-negative+breast+cancers&doi=10.1002%2Fcam4.2114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers</span></div><div class="casAuthors">Vinet, Mathilde; Suresh, Samyuktha; Maire, Virginie; Monchecourt, Clarisse; Nemati, Fariba; Lesage, Laetitia; Pierre, Fabienne; Ye, Mengliang; Lescure, Auriane; Brisson, Amelie; Meseure, Didier; Nicolas, Andre; Rigaill, Guillem; Marangoni, Elisabetta; Del Nery, Elaine; Roman-Roman, Sergio; Dubois, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2414-2428</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">TNBC is a highly heterogeneous and aggressive breast cancer subtype assocd. with high relapse rates, and for which no targeted therapy yet exists.  Protein arginine methyltransferase 5 (PRMT5), an enzyme which catalyzes the methylation of arginines on histone and non-histone proteins, has recently emerged as a putative target for cancer therapy.  Potent and specific PRMT5 inhibitors have been developed, but the therapeutic efficacy of PRMT5 targeting in TNBC has not yet been demonstrated.  Here, we examine the expression of PRMT5 in a human breast cancer cohort obtained from the Institut Curie, and evaluate the therapeutic potential of pharmacol. inhibition of PRMT5 in TNBC.  We find that PRMT5 mRNA and protein are expressed at comparable levels in TNBC, luminal breast tumors, and healthy mammary tissues.  However, immunohistochem. analyzes reveal that PRMT5 is differentially localized in TNBC compared to other breast cancer subtypes and to normal breast tissues.  PRMT5 is heterogeneously expressed in TNBC and high PRMT5 expression correlates with poor prognosis within this breast cancer subtype.  Using the small-mol. inhibitor EPZ015666, we show that PRMT5 inhibition impairs cell proliferation in a subset of TNBC cell lines.  PRMT5 inhibition triggers apoptosis, regulates cell cycle progression and decreases mammosphere formation.  Furthermore, EPZ015666 administration to a patient-derived xenograft model of TNBC significantly deters tumor progression.  Finally, we reveal potentiation between EGFR and PRMT5 targeting, suggestive of a beneficial combination therapy.  Our findings highlight a distinctive subcellular localization of PRMT5 in TNBC, and uphold PRMT5 targeting, alone or in combination, as a relevant treatment strategy for a subset of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDMfM3UVd7aLVg90H21EOLACvtfcHk0lhk4a_G61plZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVygsbbN&md5=4a0496027be8d085828ba4bfa98531f6</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1002%2Fcam4.2114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.2114%26sid%3Dliteratum%253Aachs%26aulast%3DVinet%26aufirst%3DM.%26aulast%3DSuresh%26aufirst%3DS.%26aulast%3DMaire%26aufirst%3DV.%26aulast%3DMonchecourt%26aufirst%3DC.%26aulast%3DN%25C3%25A9mati%26aufirst%3DF.%26aulast%3DLesage%26aufirst%3DL.%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DLescure%26aufirst%3DA.%26aulast%3DBrisson%26aufirst%3DA.%26aulast%3DMeseure%26aufirst%3DD.%26aulast%3DNicolas%26aufirst%3DA.%26aulast%3DRigaill%26aufirst%3DG.%26aulast%3DMarangoni%26aufirst%3DE.%26aulast%3DDel%2BNery%26aufirst%3DE.%26aulast%3DRoman-Roman%26aufirst%3DS.%26aulast%3DDubois%26aufirst%3DT.%26atitle%3DProtein%2520arginine%2520methyltransferase%25205%253A%2520A%2520novel%2520therapeutic%2520target%2520for%2520triple-negative%2520breast%2520cancers%26jtitle%3DCancer%2520Med.%26date%3D2019%26volume%3D8%26issue%3D5%26spage%3D2414%26epage%3D2428%26doi%3D10.1002%2Fcam4.2114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, S. Y.</span></span> <span> </span><span class="NLM_article-title">TRPC3 regulates the proliferation and apoptosis resistance of triple negative breast cancer cells through the TRPC3/RASA4/MAPK pathway</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">558</span>, <span class="refDoi"> DOI: 10.3390/cancers11040558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers11040558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlKk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=558&issue=4&author=Y.+Wangauthor=Y.+X.+Qiauthor=Z.+Qiauthor=S.+Y.+Tsang&title=TRPC3+regulates+the+proliferation+and+apoptosis+resistance+of+triple+negative+breast+cancer+cells+through+the+TRPC3%2FRASA4%2FMAPK+pathway&doi=10.3390%2Fcancers11040558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">TRPC3 regulates the proliferation and apoptosis resistance of triple negative breast cancer cells through the TRPC3/RASA4/MAPK pathway</span></div><div class="casAuthors">Wang, Yan; Qi, Yan-Xiang; Qi, Zenghua; Tsang, Suk-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">558</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Currently, there is no effective mol.-based therapy for triple-neg. breast cancer (TNBC).  Canonical transient receptor potential isoform 3 (TRPC3) was previously shown to be upregulated in breast cancer biopsy tissues when compared to normal breast tissues.  However, the biol. role of TRPC3 in breast cancer still remains to be elucidated.  In this study, subcellular fractionation followed byWestern blot and immunocytochem. showed that TRPC3 was over-expressed on the plasma membrane of TNBC line MDA-MB-231 when compared to an estrogen receptor-pos. cell line MCF-7.  TRPC3 blocker Pyr3 and dominant neg. of TRPC3 attenuated proliferation, induced apoptosis and sensitized cell death to chemotherapeutic agents in MDA-MB-231 as measured by proliferation assays.  Interestingly, Ras GTPase-activating protein 4 (RASA4), a Ca2+-promoted Ras-MAPK pathway suppressor, was found to be located on the plasma membrane of MDA-MB-231.  Blocking TRPC3 decreased the amt. of RASA4 located on the plasma membrane, with concomitant activation of MAPK pathways.  Our results suggest that, in TNBC MDA-MB-231 cells, Ca2+ influx through TRPC3 channel sustains the presence of RASA4 on the plasma membrane where it inhibits the Ras-MAPK pathway, leading to proliferation and apoptosis resistance.  Our study reveals the novel TRPC3-RASA4-MAPK signaling cascade in TNBC cells and suggests that TRPC3 may be exploited as a potential therapeutic target for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg5SkGYp4s7rVg90H21EOLACvtfcHk0lhR5gZZt-6FwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlKk&md5=eb4e31ee71c1287f1429e9eb94f1bb7e</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.3390%2Fcancers11040558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11040558%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%2BX.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DTsang%26aufirst%3DS.%2BY.%26atitle%3DTRPC3%2520regulates%2520the%2520proliferation%2520and%2520apoptosis%2520resistance%2520of%2520triple%2520negative%2520breast%2520cancer%2520cells%2520through%2520the%2520TRPC3%252FRASA4%252FMAPK%2520pathway%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D4%26spage%3D558%26doi%3D10.3390%2Fcancers11040558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">PIM1: a promising target in patients with triple-negative breast cancer</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">142</span>, <span class="refDoi"> DOI: 10.1007/s12032-017-0998-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs12032-017-0998-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28721678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1cjovFKgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=142&issue=8&author=W.+Zhaoauthor=R.+Qiuauthor=P.+Liauthor=J.+Yang&title=PIM1%3A+a+promising+target+in+patients+with+triple-negative+breast+cancer&doi=10.1007%2Fs12032-017-0998-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">PIM1: a promising target in patients with triple-negative breast cancer</span></div><div class="casAuthors">Zhao Wen; Qiu RuiYue; Li Pan; Yang Jin</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">142</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancers (TNBCs) have poor prognosis, and chemotherapy remains the mainstay of therapy because of lack of discovered possible target.  MYC were found overexpressed in TNBCs compared with other subtypes and especially in those resistant to chemotherapy, but the inhibition has been challenging to achieve.  Recently, the cooperation of PIM1 and MYC was identified involved in cell proliferation, migration and apoptosis of TNBCs, which has been reported in hematological malignancy and prostatic cancer.  Inhibition of PIM1 can promote the apoptosis of tumor cells and enhance sensitivity to chemotherapy.  Notably, PIM1-null mice develop normally and are fertile, suggesting the side effects can be tolerated.  Thus, PIM1 may be a promising target in TNBCs and further investigation, both in vivo and in vitro, needs to be carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrLLHJPYqPm9bHMBt0mMIXfW6udTcc2ebdgASydF-O97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjovFKgsw%253D%253D&md5=f6943a0de1f0b867bc16dc99abf70c48</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs12032-017-0998-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-017-0998-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DPIM1%253A%2520a%2520promising%2520target%2520in%2520patients%2520with%2520triple-negative%2520breast%2520cancer%26jtitle%3DMed.%2520Oncol.%26date%3D2017%26volume%3D34%26issue%3D8%26spage%3D142%26doi%3D10.1007%2Fs12032-017-0998-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schech, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1857</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-14-0778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26037781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1yrs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1848-1857&issue=8&author=A.+Schechauthor=A.+Kaziauthor=S.+Yuauthor=P.+Shahauthor=G.+Sabnis&title=Histone+deacetylase+inhibitor+entinostat+inhibits+tumor-initiating+cells+in+triple-negative+breast+cancer+cells&doi=10.1158%2F1535-7163.MCT-14-0778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells</span></div><div class="casAuthors">Schech, Amanda; Kazi, Armina; Yu, Stephen; Shah, Preeti; Sabnis, Gauri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1848-1857</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mortality following breast cancer diagnosis is mainly due to the development of distant metastasis.  To escape from the primary site, tumor cells undergo the epithelial-to-mesenchymal transition (EMT), which helps them acquire a more motile and invasive phenotype.  In our previous study, we showed that class I selective HDAC inhibitor entinostat reverses the EMT phenotype through reversal of epigenetic repression of E-cadherin.  Recent evidence suggests that a subset of cells within a breast tumor may drive the metastatic outgrowth following escape from the primary site.  These cells, termed tumor-initiating cells (TIC), represent a great threat to overall prognosis.  They are crit. in terms of drug resistance and tumor initiation at metastatic sites.  Acquisition of EMT traits has also been shown to impart TIC phenotype to the cells, making EMT a "dual-threat" for prognosis.  In the current study, we show that entinostat treatment can reduce the percentage of TIC cells from triple-neg. breast cancer (TNBC) cells.  Entinostat treatment was able to reduce the CD44high/CD24low cell population, ALDH-1 activity, as well as protein and mRNA expression of known TIC markers such as Bmi-1, Nanog, and Oct-4.  Next, we inoculated MDA-MB-231 cells transfected with firefly luciferase (231/Luc) in mammary fat pad of NSG mice.  The mice were then treated with entinostat (2.5 mg/kg/d), and tumor development and formation of metastasis were assessed by bioluminescence imaging.  Treatment with entinostat significantly reduced tumor formation at the primary site as well as lung metastasis.  As such, entinostat may help prevent development of distant metastasis.  Mol Cancer Ther; 14(8); 1848-57. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRu0jMR4ckFrVg90H21EOLACvtfcHk0lhR5gZZt-6FwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1yrs7vF&md5=0a68c2c5bdfd03939c216a59987fc8bd</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0778%26sid%3Dliteratum%253Aachs%26aulast%3DSchech%26aufirst%3DA.%26aulast%3DKazi%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DSabnis%26aufirst%3DG.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520entinostat%2520inhibits%2520tumor-initiating%2520cells%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D8%26spage%3D1848%26epage%3D1857%26doi%3D10.1158%2F1535-7163.MCT-14-0778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ralff, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, C. L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küçükkase, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicker, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oster, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Deiry, W. S.</span></span> <span> </span><span class="NLM_article-title">ONC201 demonstrates antitumor effects in both triple-negative and non–triple-negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1290</span>– <span class="NLM_lpage">1298</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-17-0121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28424227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSms7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1290-1298&issue=7&author=M.+D.+Ralffauthor=C.+L.+B.+Klineauthor=O.+C.+K%C3%BC%C3%A7%C3%BCkkaseauthor=J.+Wagnerauthor=B.+Limauthor=D.+T.+Dickerauthor=V.+V.+Prabhuauthor=W.+Osterauthor=W.+S.+El-Deiry&title=ONC201+demonstrates+antitumor+effects+in+both+triple-negative+and+non%E2%80%93triple-negative+breast+cancers+through+TRAIL-dependent+and+TRAIL-independent+mechanisms&doi=10.1158%2F1535-7163.MCT-17-0121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms</span></div><div class="casAuthors">Ralff, Marie D.; Kline, Christina L. B.; Kucukkase, Ozan C.; Wagner, Jessica; Lim, Bora; Dicker, David T.; Prabhu, Varun V.; Oster, Wolfgang; El-Deiry, Wafik S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1290-1298</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Breast cancer is a major cause of cancer-related death.  TNF-related apoptosis-inducing ligand (TRAIL) has been of interest as a cancer therapeutic, but only a subset of triple-neg. breast cancers (TNBC) is sensitive to TRAIL.  The small-mol. ONC201 induces expression of TRAIL and its receptor DR5.  ONC201 has entered clin. trials in advanced cancers.  Here, we show that ONC201 is efficacious against both TNBC and non-TNBC cells (n = 13).  A subset of TNBC and non-TNBC cells succumbs to ONC201-induced cell death.  In 2 of 8 TNBC cell lines, ONC201 treatment induces caspase-8 cleavage and cell death that is blocked by TRAIL-neutralizing antibody RIK2.  The proapoptotic effect of ONC201 translates to in vivo efficacy in the MDA-MB-468 xenograft model.  In most TNBC lines tested (6/8), ONC201 has an antiproliferative effect but does not induce apoptosis.  ONC201 decreases cyclin D1 expression and causes an accumulation of cells in the G1 phase of the cell cycle. pRb expression is assocd. with sensitivity to the antiproliferative effects of ONC201, and the compd. synergizes with taxanes in less sensitive cells.  All non-TNBC cells (n = 5) are growth inhibited following ONC201 treatment, and unlike what has been obsd. with TRAIL, a subset (n = 2) shows PARP cleavage.  In these cells, cell death induced by ONC201 is TRAIL independent.  Our data demonstrate that ONC201 has potent antiproliferative and proapoptotic effects in a broad range of breast cancer subtypes, through TRAIL-dependent and TRAIL-independent mechanisms.  These findings develop a preclin. rationale for developing ONC201 as a single agent and/or in combination with approved therapies in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp033TAP6-qX7Vg90H21EOLACvtfcHk0lj7Z7sxGrrLQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSms7rI&md5=551c67303e5d5066e20424f04c329cfc</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0121%26sid%3Dliteratum%253Aachs%26aulast%3DRalff%26aufirst%3DM.%2BD.%26aulast%3DKline%26aufirst%3DC.%2BL.%2BB.%26aulast%3DK%25C3%25BC%25C3%25A7%25C3%25BCkkase%26aufirst%3DO.%2BC.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DDicker%26aufirst%3DD.%2BT.%26aulast%3DPrabhu%26aufirst%3DV.%2BV.%26aulast%3DOster%26aufirst%3DW.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26atitle%3DONC201%2520demonstrates%2520antitumor%2520effects%2520in%2520both%2520triple-negative%2520and%2520non%25E2%2580%2593triple-negative%2520breast%2520cancers%2520through%2520TRAIL-dependent%2520and%2520TRAIL-independent%2520mechanisms%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26issue%3D7%26spage%3D1290%26epage%3D1298%26doi%3D10.1158%2F1535-7163.MCT-17-0121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Adorno, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2687</span>– <span class="NLM_lpage">2699</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-15-0096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26443806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2687-2699&issue=12&author=K.+Kaiauthor=K.+Kondoauthor=X.+Wangauthor=X.+Xieauthor=M.+K.+Pitnerauthor=M.+E.+Reyesauthor=A.+M.+Torres-Adornoauthor=H.+Masudaauthor=G.+N.+Hortobagyiauthor=C.+Bartholomeuszauthor=H.+Sayaauthor=D.+Tripathyauthor=S.+Senauthor=N.+T.+Ueno&title=Antitumor+activity+of+KW-2450+against+triple-negative+breast+cancer+by+inhibiting+Aurora+A+and+B+kinases&doi=10.1158%2F1535-7163.MCT-15-0096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases</span></div><div class="casAuthors">Kai, Kazuharu; Kondo, Kimie; Wang, Xiaoping; Xie, Xuemei; Pitner, Mary K.; Reyes, Monica E.; Torres-Adorno, Angie M.; Masuda, Hiroko; Hortobagyi, Gabriel N.; Bartholomeusz, Chandra; Saya, Hideyuki; Tripathy, Debu; Sen, Subrata; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2687-2699</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Currently, no targeted drug is available for triple-neg. breast cancer (TNBC), an aggressive breast cancer that does not express estrogen receptor, progesterone receptor, or HER2.  TNBC has high mitotic activity, and, because Aurora A and B mitotic kinases drive cell division and are overexpressed in tumors with a high mitotic index, we hypothesized that inhibiting Aurora A and B produces a significant antitumor effect in TNBC.  We tested this hypothesis by detg. the antitumor effects of KW-2450, a multikinase inhibitor of both Aurora A and B kinases.  We obsd. significant inhibitory activities of KW-2450 on cell viability, apoptosis, colony formation in agar, and mammosphere formation in TNBC cells.  The growth of TNBC xenografts was significantly inhibited with KW-2450.  In cell-cycle anal., KW-2450 induced tetraploid accumulation followed by apoptosis or surviving octaploid (8N) cells, depending on dose.  These phenotypes resembled those of Aurora B knockdown and complete pharmaceutical inhibition of Aurora A.  We demonstrated that 8N cells resulting from KW-2450 treatment depended on the activation of mitogen-activated protein kinase kinase (MEK) for their survival.  When treated with the MEK inhibitor selumetinib combined with KW-2450, compared with KW-2450 alone, the 8N cell population was significantly reduced and apoptosis was increased.  Indeed, this combination showed synergistic antitumor effect in SUM149 TNBC xenografts.  Collectively, Aurora A and B inhibition had a significant antitumor effect against TNBC, and this antitumor effect was maximized by the combination of selumetinib with Aurora A and B inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKPTT0DmSbt7Vg90H21EOLACvtfcHk0lj7Z7sxGrrLQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKlu7zO&md5=238da6cf846e04783c879008c719af38</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0096%26sid%3Dliteratum%253Aachs%26aulast%3DKai%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DPitner%26aufirst%3DM.%2BK.%26aulast%3DReyes%26aufirst%3DM.%2BE.%26aulast%3DTorres-Adorno%26aufirst%3DA.%2BM.%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DSaya%26aufirst%3DH.%26aulast%3DTripathy%26aufirst%3DD.%26aulast%3DSen%26aufirst%3DS.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DAntitumor%2520activity%2520of%2520KW-2450%2520against%2520triple-negative%2520breast%2520cancer%2520by%2520inhibiting%2520Aurora%2520A%2520and%2520B%2520kinases%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D12%26spage%3D2687%26epage%3D2699%26doi%3D10.1158%2F1535-7163.MCT-15-0096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. M.</span></span> <span> </span><span class="NLM_article-title">The role and mechanism of CRT0066101 as an effective drug for treatment of triple-negative breast cancer</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.33594/000000027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.33594%2F000000027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30845378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2019&pages=382-396&issue=3&author=Y.+Liuauthor=Y.+Z.+Wangauthor=S.+Y.+Yuauthor=Y.+H.+Zhouauthor=X.+X.+Maauthor=Q.+Suauthor=L.+Anauthor=F.+F.+Wangauthor=A.+H.+Shiauthor=J.+Z.+Zhangauthor=L.+M.+Chen&title=The+role+and+mechanism+of+CRT0066101+as+an+effective+drug+for+treatment+of+triple-negative+breast+cancer&doi=10.33594%2F000000027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The role and mechanism of CRT0066101 as an effective drug for treatment of triple-negative breast cancer</span></div><div class="casAuthors">Liu, Yan; Wang, Yuzhi; Yu, Shiyi; Zhou, Yehui; Ma, Xinxing; Su, Qian; An, Li; Wang, Feifei; Shi, Aihua; Zhang, Jingzhong; Chen, Liming</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology & Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-396</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1421-9778</span>.
    
            (<span class="NLM_cas:orgname">Cell Physiol Biochem Press GmbH & Co. KG</span>)
        </div><div class="casAbstract">Breast cancer is clin. classified into three main subtypes: estrogen receptor-pos. (ER+) breast cancer, human epidermal growth factor receptor 2-pos. (HER2+) breast cancer, and triple-neg. breast cancer (TNBC).  Without specific targeted therapies, patients with TNBC have poorer prognosis compared with those with ER+ and HER2+ breast cancer.  Protein kinase D (PRKD) family members play crucial roles in cancer progression.  CRT0066101, a PRKD inhibitor, has been reported to have anticancer activity in many cancer types.  Nevertheless, the role and mechanism of CRT0066101 in TNBC have not been well investigated.  The expression level of PRKDs was analyzed in breast cancer samples and breast cancer cell lines.  The effects of inhibiting PRKD activity with CRT0066101 on TNBC cell proliferation, cell cycle, apoptosis, and tumor growth were studied by Cell Counting Kit-8 assay, cell cycle assay, propidium iodide/annexin-V assay, and a xenograft mouse model, resp.  To uncover the mol. mechanism of CRT0066101 in TNBC, comparative phosphoproteomic anal. using iTRAQ was employed.  We found that PRKD2 and PRKD3 were preferentially expressed in breast cancers.  Immunohistochem. confirmed the overexpression of PRKD2 and PRKD3 in TNBC.  CRT0066101, which inhibited the activity of PRKDs, dramatically inhibited proliferation, increased apoptosis and the G1-phase population of TNBC cells in vitro, and reduced breast tumor vol. in vivo.  Comparative phosphoproteomic anal. between breast cancer cells with and without CRT0066101 treatment revealed that the anti-breast cancer effects involved regulation of a complex network contg. multiple enriched pathways and several hub-nodes contributing to multiple cancer-related processes, thus explaining the described effects of CRT0066101 on TNBC in vitro and in vivo.  Finally, we validated several targets of PRKD inhibition by treatment with CRT0066101 and small interfering RNAs against PRKD2 and PRKD3 (siPRKD2 and siPRKD3), including p-MYC(T58/S62), p-MAPK1/3(T202/Y204), p-AKT(S473), p-YAP(S127), and p-CDC2(T14).  PRKD inhibitor CRT0066101 exhibits anti-TNBC effects via modulating a phosphor-signaling network and inhibiting the phosphorylation of many cancer-driving factors, including MYC, MAPK1/3, AKT, YAP, and CDC2, providing insight into the important roles as well as the mol. mechanism of CRT0066101 as an effective drug for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok-uxzZIbTWLVg90H21EOLACvtfcHk0liU3hRrBRV0Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFyjt7rN&md5=2990f3ec5227f50c68b56d18dd00995f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.33594%2F000000027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.33594%252F000000027%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%2BZ.%26aulast%3DYu%26aufirst%3DS.%2BY.%26aulast%3DZhou%26aufirst%3DY.%2BH.%26aulast%3DMa%26aufirst%3DX.%2BX.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DAn%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%2BF.%26aulast%3DShi%26aufirst%3DA.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BZ.%26aulast%3DChen%26aufirst%3DL.%2BM.%26atitle%3DThe%2520role%2520and%2520mechanism%2520of%2520CRT0066101%2520as%2520an%2520effective%2520drug%2520for%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2019%26volume%3D52%26issue%3D3%26spage%3D382%26epage%3D396%26doi%3D10.33594%2F000000027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sah, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Vega, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span> <span> </span><span class="NLM_article-title">Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">49</span>),  <span class="NLM_fpage">24881</span>– <span class="NLM_lpage">24891</span>, <span class="refDoi"> DOI: 10.1073/pnas.1912033116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1912033116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31754034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlejsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=24881-24891&issue=49&author=S.+Banerjeeauthor=T.+Weiauthor=J.+Wangauthor=J.+J.+Leeauthor=H.+L.+Gutierrezauthor=O.+Chapmanauthor=S.+E.+Wileyauthor=J.+E.+Mayfieldauthor=V.+Tandonauthor=E.+F.+Juarezauthor=L.+Chavezauthor=R.+Liangauthor=R.+L.+Sahauthor=C.+Costelloauthor=J.+P.+Mesirovauthor=L.+de+la+Vegaauthor=K.+L.+Cooperauthor=J.+E.+Dixonauthor=J.+Xiaoauthor=X.+Lei&title=Inhibition+of+dual-specificity+tyrosine+phosphorylation-regulated+kinase+2+perturbs+26S+proteasome-addicted+neoplastic+progression&doi=10.1073%2Fpnas.1912033116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression</span></div><div class="casAuthors">Banerjee, Sourav; Wei, Tiantian; Wang, Jue; Lee, Jenna J.; Gutierrez, Haydee L.; Chapman, Owen; Wiley, Sandra E.; Mayfield, Joshua E.; Tandon, Vasudha; Juarez, Edwin F.; Chavez, Lukas; Liang, Ruqi; Sah, Robert L.; Costello, Caitlin; Mesirov, Jill P.; de la Vega, Laureano; Cooper, Kimberly L.; Dixon, Jack E.; Xiao, Junyu; Lei, Xiaoguang</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">24881-24891</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dependence on the 26S proteasome is an Achilles heel for triple-neg. breast cancer (TNBC) and multiple myeloma (MM).  The therapeutic proteasome inhibitor, bortezomib, successfully targets MM but often leads to drug-resistant disease relapse and fails in breast cancer.  Here we show that a 26S proteasome-regulating kinase, DYRK2, is a therapeutic target for both MM and TNBC.  Genome editing or small-mol. mediated inhibition of DYRK2 significantly reduces 26S proteasome activity, bypasses bortezomib resistance, and dramatically delays in vivo tumor growth in MM and TNBC thereby promoting survival.  We further characterized the ability of LDN192960, a potent and selective DYRK2-inhibitor, to alleviate tumor burden in vivo.  The drug docks into the active site of DYRK2 and partially inhibits all 3 core peptidase activities of the proteasome.  Our results suggest that targeting 26S proteasome regulators will pave the way for therapeutic strategies in MM and TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXwWbK63rK7Vg90H21EOLACvtfcHk0liU3hRrBRV0Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlejsLnM&md5=6d4c0199cf151357dd70279de8044308</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1912033116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1912033116%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DGutierrez%26aufirst%3DH.%2BL.%26aulast%3DChapman%26aufirst%3DO.%26aulast%3DWiley%26aufirst%3DS.%2BE.%26aulast%3DMayfield%26aufirst%3DJ.%2BE.%26aulast%3DTandon%26aufirst%3DV.%26aulast%3DJuarez%26aufirst%3DE.%2BF.%26aulast%3DChavez%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DR.%26aulast%3DSah%26aufirst%3DR.%2BL.%26aulast%3DCostello%26aufirst%3DC.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3Dde%2Bla%2BVega%26aufirst%3DL.%26aulast%3DCooper%26aufirst%3DK.%2BL.%26aulast%3DDixon%26aufirst%3DJ.%2BE.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DLei%26aufirst%3DX.%26atitle%3DInhibition%2520of%2520dual-specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%25202%2520perturbs%252026S%2520proteasome-addicted%2520neoplastic%2520progression%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26issue%3D49%26spage%3D24881%26epage%3D24891%26doi%3D10.1073%2Fpnas.1912033116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillant, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragno, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanrion, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gräsel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalaoui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geneste, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visvader, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, G. J.</span></span> <span> </span><span class="NLM_article-title">Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">401</span>),  <span class="NLM_fpage">eaam7049</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aam7049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1126%2Fscitranslmed.aam7049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28768804" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaam7049&issue=401&author=D.+Merinoauthor=J.+R.+Whittleauthor=F.+Vaillantauthor=A.+Serranoauthor=J.+N.+Gongauthor=G.+Ginerauthor=A.+L.+Maragnoauthor=M.+Chanrionauthor=E.+Schneiderauthor=B.+Palauthor=X.+Liauthor=G.+Dewsonauthor=J.+Gr%C3%A4selauthor=K.+Liuauthor=N.+Lalaouiauthor=D.+Segalauthor=M.+J.+Heroldauthor=D.+C.+S.+Huangauthor=G.+K.+Smythauthor=O.+Genesteauthor=G.+Lesseneauthor=J.+E.+Visvaderauthor=G.+J.+Lindeman&title=Synergistic+action+of+the+MCL-1+inhibitor+S63845+with+current+therapies+in+preclinical+models+of+triple-negative+and+HER2-amplified+breast+cancer&doi=10.1126%2Fscitranslmed.aam7049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aam7049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aam7049%26sid%3Dliteratum%253Aachs%26aulast%3DMerino%26aufirst%3DD.%26aulast%3DWhittle%26aufirst%3DJ.%2BR.%26aulast%3DVaillant%26aufirst%3DF.%26aulast%3DSerrano%26aufirst%3DA.%26aulast%3DGong%26aufirst%3DJ.%2BN.%26aulast%3DGiner%26aufirst%3DG.%26aulast%3DMaragno%26aufirst%3DA.%2BL.%26aulast%3DChanrion%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DE.%26aulast%3DPal%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDewson%26aufirst%3DG.%26aulast%3DGr%25C3%25A4sel%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DLalaoui%26aufirst%3DN.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DSmyth%26aufirst%3DG.%2BK.%26aulast%3DGeneste%26aufirst%3DO.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DVisvader%26aufirst%3DJ.%2BE.%26aulast%3DLindeman%26aufirst%3DG.%2BJ.%26atitle%3DSynergistic%2520action%2520of%2520the%2520MCL-1%2520inhibitor%2520S63845%2520with%2520current%2520therapies%2520in%2520preclinical%2520models%2520of%2520triple-negative%2520and%2520HER2-amplified%2520breast%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26issue%3D401%26spage%3Deaam7049%26doi%3D10.1126%2Fscitranslmed.aam7049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lind, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeruss, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">1453</span>– <span class="NLM_lpage">1464</span>, <span class="refDoi"> DOI: 10.1080/15384101.2017.1338988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1080%2F15384101.2017.1338988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28678584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1SlsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1453-1464&issue=15&author=A.+L.+Thomasauthor=H.+Lindauthor=A.+Hongauthor=D.+Dokicauthor=K.+Oppatauthor=E.+Rosenthalauthor=A.+Guoauthor=A.+Thomasauthor=R.+Hamdenauthor=J.+S.+Jeruss&title=Inhibition+of+CDK-mediated+Smad3+phosphorylation+reduces+the+Pin1-Smad3+interaction+and+aggressiveness+of+triple+negative+breast+cancer+cells&doi=10.1080%2F15384101.2017.1338988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells</span></div><div class="casAuthors">Thomas, Alexandra L.; Lind, Hanne; Hong, Angela; Dokic, Danijela; Oppat, Kailey; Rosenthal, Elana; Guo, Amina; Thomas, Aaron; Hamden, Randala; Jeruss, Jacqueline S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1453-1464</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Triple neg. breast cancer (TNBC) is a highly aggressive breast cancer subtype that lacks effective targeted therapies.  Although TNBC is not defined by specific therapeutic targets, a subset of patients have tumors that overexpress cyclins.  High cyclin D/E expression catalyzes CDK4/2 activity.  In turn, CDK4/2 can non-canonically phosphorylate Smad3, a key TGFβ signaling intermediate, and this phosphorylation has been assocd. with the shift from tumor-suppressive to oncogenic TGFβ pathway action in breast oncogenesis.  Addnl., CDK-mediated Smad3 phosphorylation facilitates an interaction between Smad3 and Pin1, a cis-trans isomerase that is also overexpressed in aggressive breast cancers.  Treatment with CYC065, a CDK2/9 inhibitor, decreased non-canonical Smad3 phosphorylation and inhibited the Pin1-Smad3 interaction.  We hypothesized that the interaction of Pin1 and Smad3, facilitated by CDK-mediated Smad3 phosphorylation, promotes TNBC cell aggressiveness.  Inhibition of the Pin1-Smad3 interaction in TNBC cell lines, through depletion of Pin1 or CYC065 treatment, resulted in decreased cell migration/invasion and impeded the EMT program.  Inhibition of CDK-mediated phosphorylation of Smad3 by mutagenesis also decreased cell migration, underscoring the importance of non-canonical CDK2 phosphorylation of Smad3 to enable cell motility.  Pin1 depletion restored Smad3 protein levels and tumor-suppressive activity, suggesting that the Pin1-Smad3 interaction has a neg. impact on canonical Smad3 action.  Collectively, the data show that the Pin1-Smad3 interaction, facilitated by CDK-mediated Smad3 phosphorylation, is assocd. with oncogenic TGFβ signaling and breast cancer progression.  Inhibition of this interaction with CYC065 treatment may provide an important therapeutic option for TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrohturOI71vrVg90H21EOLACvtfcHk0ljpDxsXCcYI1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1SlsrrF&md5=4bd60987630499ce0b336e33bbd9fdea</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F15384101.2017.1338988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2017.1338988%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BL.%26aulast%3DLind%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DA.%26aulast%3DDokic%26aufirst%3DD.%26aulast%3DOppat%26aufirst%3DK.%26aulast%3DRosenthal%26aufirst%3DE.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DHamden%26aufirst%3DR.%26aulast%3DJeruss%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520CDK-mediated%2520Smad3%2520phosphorylation%2520reduces%2520the%2520Pin1-Smad3%2520interaction%2520and%2520aggressiveness%2520of%2520triple%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DCell%2520Cycle%26date%3D2017%26volume%3D16%26issue%3D15%26spage%3D1453%26epage%3D1464%26doi%3D10.1080%2F15384101.2017.1338988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Noord, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Water, B.</span></span> <span> </span><span class="NLM_article-title">An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13308</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-49809-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41598-019-49809-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31527768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MrpsVChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=13308&issue=1&author=V.+E.+van%0Ader+Noordauthor=R.+P.+McLaughlinauthor=M.+Smidauthor=J.+A.+Foekensauthor=J.+W.+M.+Martensauthor=Y.+Zhangauthor=B.+van+de+Water&title=An+increased+cell+cycle+gene+network+determines+MEK+and+Akt+inhibitor+double+resistance+in+triple-negative+breast+cancer&doi=10.1038%2Fs41598-019-49809-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer</span></div><div class="casAuthors">van der Noord Vera E; McLaughlin Ronan P; Zhang Yinghui; van de Water Bob; Smid Marcel; Foekens John A; Martens John W M</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13308</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor clinical prognosis and limited targeted treatment strategies.  Kinase inhibitor screening of a panel of 20 TNBC cell lines uncovered three critical TNBC subgroups: 1) sensitive to only MEK inhibitors; 2) sensitive to only Akt inhibitors; 3) resistant to both MEK/Akt inhibitors.  Using genomic, transcriptomic and proteomic datasets of these TNBC cell lines we unravelled molecular features associated with the MEK and Akt drug resistance.  MEK inhibitor-resistant TNBC cell lines were discriminated from Akt inhibitor-resistant lines by the presence of PIK3CA/PIK3R1/PTEN mutations, high p-Akt and low p-MEK levels, yet these features could not distinguish double-resistant cells.  Gene set enrichment analyses of transcriptomic and proteomic data of the MEK and Akt inhibitor response groups revealed a set of cell cycle-related genes associated with the double-resistant phenotype; these genes were overexpressed in a subset of breast cancer patients.  CDK inhibitors targeting the cell cycle programme could overcome the Akt and MEK inhibitor double-resistance.  In conclusion, we uncovered molecular features and alternative treatment strategies for TNBC that are double-resistant to Akt and MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEIuE118wd3kBuFdjgVNKSfW6udTcc2eaWUla9GQAt7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrpsVChug%253D%253D&md5=83fe2e7e98acb8e95d3c126ed17bf682</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-49809-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-49809-3%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BNoord%26aufirst%3DV.%2BE.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BP.%26aulast%3DSmid%26aufirst%3DM.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DMartens%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3Dvan%2Bde%2BWater%26aufirst%3DB.%26atitle%3DAn%2520increased%2520cell%2520cycle%2520gene%2520network%2520determines%2520MEK%2520and%2520Akt%2520inhibitor%2520double%2520resistance%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D13308%26doi%3D10.1038%2Fs41598-019-49809-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guldner, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnepp, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Host, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlepage, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakshatri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2860</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-10743-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41467-019-10743-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31253784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MzitF2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2860&issue=1&author=Y.+Niauthor=K.+R.+Schmidtauthor=B.+A.+Wernerauthor=J.+K.+Koenigauthor=I.+H.+Guldnerauthor=P.+M.+Schneppauthor=X.+Tanauthor=L.+Jiangauthor=M.+Hostauthor=L.+Sunauthor=E.+N.+Howeauthor=J.+Wuauthor=L.+E.+Littlepageauthor=H.+Nakshatriauthor=S.+Zhang&title=Death+effector+domain-containing+protein+induces+vulnerability+to+cell+cycle+inhibition+in+triple-negative+breast+cancer&doi=10.1038%2Fs41467-019-10743-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer</span></div><div class="casAuthors">Ni Yingjia; Schmidt Keon R; Werner Barnes A; Koenig Jenna K; Guldner Ian H; Schnepp Patricia M; Tan Xuejuan; Jiang Lan; Host Misha; Sun Longhua; Howe Erin N; Zhang Siyuan; Ni Yingjia; Schmidt Keon R; Werner Barnes A; Koenig Jenna K; Guldner Ian H; Schnepp Patricia M; Tan Xuejuan; Jiang Lan; Host Misha; Sun Longhua; Howe Erin N; Wu Junmin; Littlepage Laurie E; Zhang Siyuan; Wu Junmin; Littlepage Laurie E; Zhang Siyuan; Littlepage Laurie E; Nakshatri Harikrishna; Zhang Siyuan; Nakshatri Harikrishna</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2860</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most clinically challenging subtype of breast cancer.  In this study, we reveal that Death Effector Domain-containing DNA-binding protein (DEDD), which is overexpressed in > 60% of TNBCs, drives a mitogen-independent G1/S cell cycle transition through cytoplasm localization.  The gain of cytosolic DEDD enhances cyclin D1 expression by interacting with heat shock 71 kDa protein 8 (HSC70).  Concurrently, DEDD interacts with Rb family proteins and promotes their proteasome-mediated degradation.  DEDD overexpression renders TNBCs vulnerable to cell cycle inhibition.  Patients with TNBC have been excluded from CDK 4/6 inhibitor clinical trials due to the perceived high frequency of Rb-loss in TNBCs.  Interestingly, our study demonstrated that, irrespective of Rb status, TNBCs with DEDD overexpression exhibit a DEDD-dependent vulnerability to combinatorial treatment with CDK4/6 inhibitor and EGFR inhibitor in vitro and in vivo.  Thus, our study provided a rationale for the clinical application of CDK4/6 inhibitor combinatorial regimens for patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxAinuUQmJ7mLFM_lbR1VmfW6udTcc2eahzD2JqYQ_nrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzitF2gsw%253D%253D&md5=62a15d6691dd464b37c0dc7e04504083</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-10743-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-10743-7%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DY.%26aulast%3DSchmidt%26aufirst%3DK.%2BR.%26aulast%3DWerner%26aufirst%3DB.%2BA.%26aulast%3DKoenig%26aufirst%3DJ.%2BK.%26aulast%3DGuldner%26aufirst%3DI.%2BH.%26aulast%3DSchnepp%26aufirst%3DP.%2BM.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DHost%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DHowe%26aufirst%3DE.%2BN.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLittlepage%26aufirst%3DL.%2BE.%26aulast%3DNakshatri%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DDeath%2520effector%2520domain-containing%2520protein%2520induces%2520vulnerability%2520to%2520cell%2520cycle%2520inhibition%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D2860%26doi%3D10.1038%2Fs41467-019-10743-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethier, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tew, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. Y.</span></span> <span> </span><span class="NLM_article-title">MYC inhibition depletes cancer stem-like cells in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6641</span>– <span class="NLM_lpage">6650</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-3452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-16-3452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28951456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6641-6650&issue=23&author=A.+Yangauthor=S.+Qinauthor=B.+A.+Schulteauthor=S.+P.+Ethierauthor=K.+D.+Tewauthor=G.+Y.+Wang&title=MYC+inhibition+depletes+cancer+stem-like+cells+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-16-3452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Yang, Aimin; Qin, Shenghui; Schulte, Bradley A.; Ethier, Stephen P.; Tew, Kenneth D.; Wang, Gavin Y.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6641-6650</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is mounting evidence that cancer stem-like cells (CSC) are selectively enriched in residual tumors after anticancer therapies, which may account for tumor recurrence and metastasis by regenerating new tumors.  Thus, there is a crit. need to develop new therapeutic agents that can effectively eliminate drug-resistant CSCs and improve the efficacy of cancer therapy.  Here, we report that Triptolide (C1572), a small-mol. natural product, selectively depletes CSCs in a dose-dependent fashion in human triple-neg. breast cancer (TNBC) cell lines.  Nanomolar concns. of C1572 markedly reduced c-MYC (MYC) protein levels via a proteasome-dependent mechanism.  Silencing MYC expression phenocopied the CSC depletion effects of C1572 and induced senescence in TNBC cells.  Limited diln. assays revealed that ex vivo treatment of TNBC cells with C1572 reduced CSC levels by 28-fold.  In mouse xenograft models of human TNBC, administration of C1572 suppressed tumor growth and depleted CSCs in a manner correlated with diminished MYC expression in residual tumor tissues.  Together, these new findings provide a preclin. proof of concept defining C1572 as a promising therapeutic agent to eradicate CSCs for drug-resistant TNBC treatment.  Cancer Res; 77(23); 6641-50. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_SrzHLvV6MLVg90H21EOLACvtfcHk0lgfpyA9MDKaOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsb7J&md5=5cf6cd4c22f30fc6638da4f2a9f10500</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-3452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-3452%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DA.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DSchulte%26aufirst%3DB.%2BA.%26aulast%3DEthier%26aufirst%3DS.%2BP.%26aulast%3DTew%26aufirst%3DK.%2BD.%26aulast%3DWang%26aufirst%3DG.%2BY.%26atitle%3DMYC%2520inhibition%2520depletes%2520cancer%2520stem-like%2520cells%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D23%26spage%3D6641%26epage%3D6650%26doi%3D10.1158%2F0008-5472.CAN-16-3452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzmann, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, D. K.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomics-enabled covalent ligand screening reveals a thioredoxin-caspase 3 interaction disruptor that impairs breast cancer pathogenicity</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2522</span>– <span class="NLM_lpage">2528</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00711</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00711" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKmurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2522-2528&issue=10&author=K.+E.+Andersonauthor=M.+Toauthor=J.+A.+Olzmannauthor=D.+K.+Nomura&title=Chemoproteomics-enabled+covalent+ligand+screening+reveals+a+thioredoxin-caspase+3+interaction+disruptor+that+impairs+breast+cancer+pathogenicity&doi=10.1021%2Facschembio.7b00711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity</span></div><div class="casAuthors">Anderson, Kimberly E.; To, Milton; Olzmann, James A.; Nomura, Daniel K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2522-2528</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Covalent ligand discovery is a promising strategy to develop small-mol. effectors against therapeutic targets.  Recent studies have shown that dichlorotriazines are promising reactive scaffolds that preferentially react with lysines.  Here, we have synthesized a series of dichlorotriazine-based covalent ligands and have screened this library to reveal small mols. that impair triple-neg. breast cancer cell survival.  Upon identifying a lead hit from this screen KEA1-97, we used activity-based protein profiling (ABPP)-based chemoproteomic platforms to identify that this compd. targets lysine 72 of thioredoxin-a site previously shown to be important in protein interactions with caspase 3 to inhibit caspase 3 activity and suppress apoptosis.  We show that KEA1-97 disrupts the interaction of thioredoxin with caspase 3, activates caspases, and induces apoptosis without affecting thioredoxin activity.  Moreover, KEA1-97 impairs in vivo breast tumor xenograft growth.  Our study showcases how the screening of covalent ligands can be coupled with ABPP platforms to identify unique anticancer lead and target pairs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3VpILz2ADVbVg90H21EOLACvtfcHk0liBOECVfQhz1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKmurvF&md5=d428a05bb7d1fc5500fbdbf6ab214326</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00711%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DK.%2BE.%26aulast%3DTo%26aufirst%3DM.%26aulast%3DOlzmann%26aufirst%3DJ.%2BA.%26aulast%3DNomura%26aufirst%3DD.%2BK.%26atitle%3DChemoproteomics-enabled%2520covalent%2520ligand%2520screening%2520reveals%2520a%2520thioredoxin-caspase%25203%2520interaction%2520disruptor%2520that%2520impairs%2520breast%2520cancer%2520pathogenicity%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26issue%3D10%26spage%3D2522%26epage%3D2528%26doi%3D10.1021%2Facschembio.7b00711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradishar, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span> <span> </span><span class="NLM_article-title">A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2019.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ebiom.2019.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31101597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ntVCjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=98-111&author=Z.+Zhouauthor=Z.+Fengauthor=D.+Huauthor=P.+Yangauthor=M.+Gurauthor=I.+Baharauthor=M.+Cristofanilliauthor=W.+J.+Gradisharauthor=X.+Q.+Xieauthor=Y.+Wan&title=A+novel+small-molecule+antagonizes+PRMT5-mediated+KLF4+methylation+for+targeted+therapy&doi=10.1016%2Fj.ebiom.2019.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy</span></div><div class="casAuthors">Zhou Zhuan; Feng Zhiwei; Yang Peng; Hu Dong; Gur Mert; Bahar Ivet; Cristofanilli Massimo; Gradishar William J; Xie Xiang-Qun; Wan Yong</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-111</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple negative breast cancers (TNBCs) have a poor prognosis and are not amenable to endocrine- or HER2-targeted therapies.  The malignant and invasive feature of TNBCs is correlated with its high cancer stem cell population.  Recent results from us and others have unveiled an oncogenic role for the PRMT5-KLF4 axis in regulating tumor progression by orchestrating the stemness in mammary tumor cell as well as genome stability.  Methylation of KLF4 by PRMT5 leads to KLF4 stabilization, resulting in promoting mitogenesis.  METHODS:  We have developed a small molecule inhibitor, WX2-43, that specifically intercepts the interaction between PRMT5 and KLF4, thereby enhancing KLF4 degradation.  FINDINGS:  Results from our characterization demonstrate that WX2-43 binds to the region between amino acids L400-M500 on PRMT5.  Degradation of KLF4 down-regulates KLF4-mediated genes transcription.  We have characterized the potent effect for WX2-43 in inhibiting PRMT5-KLF4 binding that, in turns, suppresses tumor progression and induces tumor cell death in both TNBC cultured-cell and animal models.  INTERPRETATION:  WX2-43-mediated inhibition of KLF4 methylation by PRMT5 could be a potential strategy for anti-TNBC treatment.  FUND: This work was supported, in whole or in part, by National Institutes of Health grants CA202963 and CA202948 (Wan), R21HL109654 (Xie), P30DA035778 (Xie and Bahar) and P41GM103712 (Bahar).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdQsNVpjLaH5Pq5LRczm8ffW6udTcc2ea4SCyWv43LFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ntVCjsQ%253D%253D&md5=71776296f85255c2bd3412bbe9fe2b10</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2019.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2019.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DGur%26aufirst%3DM.%26aulast%3DBahar%26aufirst%3DI.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DGradishar%26aufirst%3DW.%2BJ.%26aulast%3DXie%26aufirst%3DX.%2BQ.%26aulast%3DWan%26aufirst%3DY.%26atitle%3DA%2520novel%2520small-molecule%2520antagonizes%2520PRMT5-mediated%2520KLF4%2520methylation%2520for%2520targeted%2520therapy%26jtitle%3DEBioMedicine%26date%3D2019%26volume%3D44%26spage%3D98%26epage%3D111%26doi%3D10.1016%2Fj.ebiom.2019.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrolecki, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-Vidana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orellana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renwick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsonis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrulle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtarge, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimawi, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, T. F.</span></span> <span> </span><span class="NLM_article-title">Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1038/nm.4507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fnm.4507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29578538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvFKnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=505-511&issue=4&author=A.+Nairauthor=H.+C.+Chungauthor=T.+Sunauthor=S.+Tyagiauthor=L.+E.+Dobroleckiauthor=R.+Dominguez-Vidanaauthor=S.+J.+Kurleyauthor=M.+Orellanaauthor=A.+Renwickauthor=D.+M.+Henkeauthor=P.+Katsonisauthor=E.+Schmittauthor=D.+W.+Chanauthor=H.+Liauthor=S.+Maoauthor=I.+Petrovicauthor=C.+J.+Creightonauthor=C.+Gutierrezauthor=J.+Dubrulleauthor=F.+Stossiauthor=J.+W.+Tynerauthor=O.+Lichtargeauthor=C.+Y.+Linauthor=B.+Zhangauthor=K.+L.+Scottauthor=S.+G.+Hilsenbeckauthor=J.+Sunauthor=X.+Yuauthor=C.+K.+Osborneauthor=R.+Schiffauthor=J.+G.+Christensenauthor=D.+J.+Shieldsauthor=M.+F.+Rimawiauthor=M.+J.+Ellisauthor=C.+A.+Shawauthor=M.+T.+Lewisauthor=T.+F.+Westbrook&title=Combinatorial+inhibition+of+PTPN12-regulated+receptors+leads+to+a+broadly+effective+therapeutic+strategy+in+triple-negative+breast+cancer&doi=10.1038%2Fnm.4507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer</span></div><div class="casAuthors">Nair, Amritha; Chung, Hsiang-Ching; Sun, Tingting; Tyagi, Siddhartha; Dobrolecki, Lacey E.; Dominguez-Vidana, Rocio; Kurley, Sarah J.; Orellana, Mayra; Renwick, Alexander; Henke, David M.; Katsonis, Panagiotis; Schmitt, Earlene; Chan, Doug W.; Li, Hui; Mao, Sufeng; Petrovic, Ivana; Creighton, Chad J.; Gutierrez, Carolina; Dubrulle, Julien; Stossi, Fabio; Tyner, Jeffrey W.; Lichtarge, Olivier; Lin, Charles Y.; Zhang, Bing; Scott, Kenneth L.; Hilsenbeck, Susan G.; Sun, Jinpeng; Yu, Xiao; Osborne, C. Kent; Schiff, Rachel; Christensen, James G.; Shields, David J.; Rimawi, Mothaffar F.; Ellis, Matthew J.; Shaw, Chad A.; Lewis, Michael T.; Westbrook, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-511</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is an aggressive subtype of breast cancer diagnosed in more than 200,000 women each year and is recalcitrant to targeted therapies.  Although TNBCs harbor multiple hyperactive receptor tyrosine kinases (RTKs), RTK inhibitors have been largely ineffective in TNBC patients thus far.  We developed a broadly effective therapeutic strategy for TNBC that is based on combined inhibition of receptors that share the neg. regulator PTPN12.  Previously, we and others identified the tyrosine phosphatase PTPN12 as a tumor suppressor that is frequently inactivated in TNBC.  PTPN12 restrains several RTKs, suggesting that PTPN12 deficiency leads to aberrant activation of multiple RTKs and a co-dependency on these receptors.  This in turn leads to the therapeutic hypothesis that PTPN12-deficient TNBCs may be responsive to combined RTK inhibition.  However, the repertoire of RTKs that are restrained by PTPN12 in human cells has not been systematically explored.  By methodically identifying the suite of RTK substrates (MET, PDGFRβ, EGFR, and others) inhibited by PTPN12, we rationalized a combination RTK-inhibitor therapy that induced potent tumor regression across heterogeneous models of TNBC.  Orthogonal approaches revealed that PTPN12 was recruited to and inhibited these receptors after ligand stimulation, thereby serving as a feedback mechanism to limit receptor signaling.  Cancer-assocd. mutation of PTPN12 or reduced PTPN12 protein levels diminished this feedback mechanism, leading to aberrant activity of these receptors.  Restoring PTPN12 protein levels restrained signaling from RTKs, including PDGFRβ and MET, and impaired TNBC survival.  In contrast with single agents, combined inhibitors targeting the PDGFRβ and MET receptors induced the apoptosis in TNBC cells in vitro and in vivo.  This therapeutic strategy resulted in tumor regressions in chemo-refractory patient-derived TNBC models.  Notably, response correlated with PTPN12 deficiency, suggesting that impaired receptor feedback may establish a combined addiction to these proto-oncogenic receptors.  Taken together, our data provide a rationale for combining RTK inhibitors in TNBC and other malignancies that lack receptor-activating mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE5kB8_e753LVg90H21EOLACvtfcHk0liSujOf7-vqig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvFKnu7k%253D&md5=eff751e8524a226313d512aa4ff63e51</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnm.4507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4507%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DH.%2BC.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DTyagi%26aufirst%3DS.%26aulast%3DDobrolecki%26aufirst%3DL.%2BE.%26aulast%3DDominguez-Vidana%26aufirst%3DR.%26aulast%3DKurley%26aufirst%3DS.%2BJ.%26aulast%3DOrellana%26aufirst%3DM.%26aulast%3DRenwick%26aufirst%3DA.%26aulast%3DHenke%26aufirst%3DD.%2BM.%26aulast%3DKatsonis%26aufirst%3DP.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DD.%2BW.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DPetrovic%26aufirst%3DI.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DGutierrez%26aufirst%3DC.%26aulast%3DDubrulle%26aufirst%3DJ.%26aulast%3DStossi%26aufirst%3DF.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLichtarge%26aufirst%3DO.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DK.%2BL.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DShields%26aufirst%3DD.%2BJ.%26aulast%3DRimawi%26aufirst%3DM.%2BF.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DShaw%26aufirst%3DC.%2BA.%26aulast%3DLewis%26aufirst%3DM.%2BT.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26atitle%3DCombinatorial%2520inhibition%2520of%2520PTPN12-regulated%2520receptors%2520leads%2520to%2520a%2520broadly%2520effective%2520therapeutic%2520strategy%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D4%26spage%3D505%26epage%3D511%26doi%3D10.1038%2Fnm.4507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1007/s11523-013-0300-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs11523-013-0300-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24233638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2c7ms1Cgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=349-357&issue=4&author=M.+Zhangauthor=X.+Zhangauthor=S.+Zhaoauthor=Y.+Wangauthor=W.+Diauthor=G.+Zhaoauthor=M.+Yangauthor=Q.+Zhang&title=Prognostic+value+of+survivin+and+EGFR+protein+expression+in+triple-negative+breast+cancer+%28TNBC%29+patients&doi=10.1007%2Fs11523-013-0300-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic value of survivin and EGFR protein expression  in triple-negative breast cancer (TNBC) patients</span></div><div class="casAuthors">Zhang Minghui; Zhang Xiaosan; Zhao Shu; Wang Yan; Di Wenyu; Zhao Gangling; Yang Maopeng; Zhang Qingyuan</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">349-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is a particular type of breast cancer which is characterized by its biological aggressiveness, worse prognosis, and lack of prognostic markers or therapeutic targets in contrast with hormonal receptor-positive and human epidermal growth factor receptor 2-positive (HER2+) breast cancers.  We aimed to evaluate survivin and epidermal growth factor receptor (EGFR) expression and their prognostic value and determine their relationships with the clinicopathological parameters of TNBC.  A total of 136 patients who had undergone a resection of primary TNBC were enrolled at the Third Affiliated Hospital of Harbin Medical University from March 2003 to September 2005.  Expression of ER, PR, HER2, EGFR, and survivin was assessed by immunohistochemistry.  The association of TNBC and other clinicopathological variables and the prognostic value of survivin and EGFR expression were evaluated.  Survivin was expressed in 62 (45.6 %) cases and EGFR was expressed in 82 (60.3 %) cases.  Survivin expression was associated with menopausal status (P = 0.011), tumor size (P = 0.037), and lymph node status (P = 0.001).  EGFR expression was associated with menopausal status (P = 0.029), lymph node status (P = 0.004), P53 expression (P = 0.001), Ki-67 expression (P = 0.028), and lymphatic vascular invasion (P = 0.037).  A multivariate analysis demonstrated that tumor size (hazard ratio (HR) 1.587, 95 % confidence interval (CI) 1.081-2.330, P = 0.018 for disease-free survival (DFS); HR 1.606, 95%CI 1.096-2.354, P = 0.015 for overall survival (OS)), lymph node status (HR 2.873, 95%CI 1.544-5.344, P = 0.001 for DFS; HR 2.915, 95%CI 1.553-5.471, P = 0.001 for OS), tumor grade (HR 1.914, 95%CI 1.218-3.007, P = 0.005 for DFS; HR 1.983, 95%CI 1.228-3.203, P = 0.005 for OS), EGFR (HR 3.008, 95%CI 1.331-6.792, P = 0.008 for DFS; HR 3.151, 95%CI 1.374-7.226, P = 0.007 for OS), and survivin (HR 1.573, 95%CI 1.087-2.277, P = 0.016 for DFS; HR 1.607, 95%CI 1.088-2.374, P = 0.017 for OS) were of prognostic significance for disease-free and overall survival.  We draw a conclusion from the present study that survivin and EGFR expression are useful prognostic markers of TNBC and might be useful for molecular targeting therapy of TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQllMhUDJ_GNoUSrryheKE6fW6udTcc2eb5m58JqShyS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7ms1Cgug%253D%253D&md5=1cc1119c318e8033b50ee7aa1c88809b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1007%2Fs11523-013-0300-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-013-0300-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDi%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DPrognostic%2520value%2520of%2520survivin%2520and%2520EGFR%2520protein%2520expression%2520in%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%2520patients%26jtitle%3DTarget%2520Oncol.%26date%3D2014%26volume%3D9%26issue%3D4%26spage%3D349%26epage%3D357%26doi%3D10.1007%2Fs11523-013-0300-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antignani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnovsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, D.</span></span> <span> </span><span class="NLM_article-title">Targeting a cancer-specific epitope of the epidermal growth factor receptor in triple-negative breast cancer</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">djw028</span>, <span class="refDoi"> DOI: 10.1093/jnci/djw028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fjnci%2Fdjw028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=djw028&issue=8&author=N.+Simonauthor=A.+Antignaniauthor=R.+Sarnovskyauthor=S.+M.+Hewittauthor=D.+FitzGerald&title=Targeting+a+cancer-specific+epitope+of+the+epidermal+growth+factor+receptor+in+triple-negative+breast+cancer&doi=10.1093%2Fjnci%2Fdjw028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjw028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjw028%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DN.%26aulast%3DAntignani%26aufirst%3DA.%26aulast%3DSarnovsky%26aufirst%3DR.%26aulast%3DHewitt%26aufirst%3DS.%2BM.%26aulast%3DFitzGerald%26aufirst%3DD.%26atitle%3DTargeting%2520a%2520cancer-specific%2520epitope%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2016%26volume%3D108%26issue%3D8%26spage%3Ddjw028%26doi%3D10.1093%2Fjnci%2Fdjw028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span> <span> </span><span class="NLM_article-title">Overexpression of miR-361–5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway</span>. <i>Bosnian J. Basic Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.17305/bjbms.2018.3399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.17305%2Fbjbms.2018.3399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29924958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWmu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=52-59&issue=1&author=J.+Hanauthor=J.+Yuauthor=Y.+Daiauthor=J.+Liauthor=M.+Guoauthor=J.+Songauthor=X.+Zhou&title=Overexpression+of+miR-361%E2%80%935p+in+triple-negative+breast+cancer+%28TNBC%29+inhibits+migration+and+invasion+by+targeting+RQCD1+and+inhibiting+the+EGFR%2FPI3K%2FAkt+pathway&doi=10.17305%2Fbjbms.2018.3399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway</span></div><div class="casAuthors">Han, Jianjun; Yu, Jingjing; Dai, Yu'na; Li, Jumei; Guo, Meiyan; Song, Jingzhen; Zhou, Xuefeng</div><div class="citationInfo"><span class="NLM_cas:title">Bosnian Journal of Basic Medical Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-59</span>CODEN:
                <span class="NLM_cas:coden">BJBMAF</span>;
        ISSN:<span class="NLM_cas:issn">1840-4812</span>.
    
            (<span class="NLM_cas:orgname">Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the leading cause of cancer-related death in women.  Previous studies indicated that miR-361-5p was downregulated in breast cancer, however, the exact effect of miR-361-5p on TNBC requires further investigation.  In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC.  The expression of miR-361-5p and RQCD1 was detd. by quant. reverse transcription PCR (qRT-PCR) and/or western blot in TNBC and the adjacent tissues. miR-361-5p mimics were constructed and transfected to TNBC cell line MDA-MB-231.  Cells were divided into three groups: blank control group, miRNA mimic neg. control (NC) group, and miR-361-5p mimics group.  Expression of miR-361-5p, mRNA and protein expression of PI3K, Akt, EGFR, phosphorylated (p)-EGFR/PI3K/Akt, and protein expression of RQCD1 and matrix metallopeptidase 9 (MMP-9) in MDA-MB-231 were measured by qRT-PCR/western blot after transfection.  Cell viability was detd. by CCK-8 assay.  Cell migration and invasion ability were evaluated by scratch and transwell assay, resp. miR-361-5p target gene was detd. by bioinformatics anal. and luciferase reporter assay.  RQCD1 was identified as a target of miR-361-5p by TargetScan and confirmed by luciferase reporter assay.  Downregulated miR-361-5p and upregulated RQCD1 were obsd. in TNBC tissues.  Expression of EGFR, PI3K, Akt and MMP-9 was inhibited in cells treated with miR-361-5p mimics.  Transfection of miR-361-5p mimics also inhibited the phosphorylation of EGFR, PI3K, and Akt.  Suppressed cell viability, migration, and invasion was found in miR-361-5p mimics groups.  Our results indicated that overexpression of miR-361-5p might act as a suppressor in TNBC by targeting RQCD1 to inhibit the EGFR/PI3K/Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_wKBf3lfEGLVg90H21EOLACvtfcHk0lhujAM1OYoNcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWmu7bJ&md5=ed011a587d7f8afa35cf06f4cd255f08</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.17305%2Fbjbms.2018.3399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17305%252Fbjbms.2018.3399%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DX.%26atitle%3DOverexpression%2520of%2520miR-361%25E2%2580%25935p%2520in%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%2520inhibits%2520migration%2520and%2520invasion%2520by%2520targeting%2520RQCD1%2520and%2520inhibiting%2520the%2520EGFR%252FPI3K%252FAkt%2520pathway%26jtitle%3DBosnian%2520J.%2520Basic%2520Med.%2520Sci.%26date%3D2019%26volume%3D19%26issue%3D1%26spage%3D52%26epage%3D59%26doi%3D10.17305%2Fbjbms.2018.3399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Guerrab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamdad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubel, C.</span></span> <span> </span><span class="NLM_article-title">Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">73618</span>– <span class="NLM_lpage">73637</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.12037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27655662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2svivVyjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=73618-73637&issue=45&author=A.+El%0AGuerrabauthor=M.+Bamdadauthor=F.+Kwiatkowskiauthor=Y.+Bignonauthor=F.+Penault-Llorcaauthor=C.+Aubel&title=Anti-EGFR+monoclonal+antibodies+and+EGFR+tyrosine+kinase+inhibitors+as+combination+therapy+for+triple-negative+breast+cancer&doi=10.18632%2Foncotarget.12037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer</span></div><div class="casAuthors">El Guerrab Abderrahim; Kwiatkowski Fabrice; Bignon Yves-Jean; Penault-Llorca Frederique; Aubel Corinne; El Guerrab Abderrahim; Bamdad Mahchid; Bignon Yves-Jean; Penault-Llorca Frederique; Aubel Corinne; Bamdad Mahchid</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">73618-73637</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is characterized by overexpression of epidermal growth factor receptor (EGFR) and activation of its downstream signaling pathways.  Dual targeting of EGFR using one monoclonal antibody (mAb; cetuximab or panitumumab) and one tyrosine kinase inhibitor (EGFR-TKI; gefitinib or erlotinib) is a potential therapeutic approach.  We investigated the effect of these therapies in EGFR-expressing TNBC cell lines that do or do not harbor the main activating mutations of EGFR pathways.  Cell lines were sensitive to EGFR-TKIs, whereas mAbs were active only in MDA-MB-468 (EGFR amplification) and SUM-1315 (KRAS and PTEN wild-type) cells.  MDA-MB-231 (KRAS mutated) and HCC-1937 (PTEN deletion) cells were resistant to mAbs.  The combined treatment resulted in a synergistic effect on cell proliferation and superior inhibition of the RAS/MAPK signaling pathway in mAb-sensitive cells.  The anti-proliferative effect was associated with G1 cell cycle arrest followed by apoptosis.  Sensitivity to therapies was characterized by induction of positive regulators and inactivation of negative regulators of cell cycle.  These results suggest that dual EGFR inhibition might result in an enhanced antitumor effect in a subgroup of TNBC.  The status of EGFR, KRAS and PTEN could be used as a molecular marker for predicting the response to this therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcxR9XiFsCPFWTCLT8lX9SfW6udTcc2eZKRnAl4TmLDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svivVyjtw%253D%253D&md5=41bc12650451f8b0d57e659dbb4ebe98</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12037%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BGuerrab%26aufirst%3DA.%26aulast%3DBamdad%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DF.%26aulast%3DBignon%26aufirst%3DY.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DAubel%26aufirst%3DC.%26atitle%3DAnti-EGFR%2520monoclonal%2520antibodies%2520and%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%2520as%2520combination%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D45%26spage%3D73618%26epage%3D73637%26doi%3D10.18632%2Foncotarget.12037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H. P.</span></span> <span> </span><span class="NLM_article-title">RON and MET co-overexpression are significant pathological characteristics of poor survival and therapeutic targets of tyrosine kinase inhibitors in triple-negative breast cancer</span>. <i>Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.4143/crt.2019.726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.4143%2Fcrt.2019.726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32324988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2ms73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2020&pages=973-986&issue=3&author=T.+H.+Wengauthor=M.+Y.+Yaoauthor=X.+M.+Xuauthor=C.+Y.+Huauthor=S.+H.+Yaoauthor=Y.+Z.+Liuauthor=Z.+G.+Wuauthor=T.+M.+Tangauthor=P.+F.+Fuauthor=M.+H.+Wangauthor=H.+P.+Yao&title=RON+and+MET+co-overexpression+are+significant+pathological+characteristics+of+poor+survival+and+therapeutic+targets+of+tyrosine+kinase+inhibitors+in+triple-negative+breast+cancer&doi=10.4143%2Fcrt.2019.726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">RON and MET co-overexpression are significant pathological characteristics of poor survival and therapeutic targets of tyrosine kinase inhibitors in triple-negative breast cancer</span></div><div class="casAuthors">Weng, Tian-Hao; Yao, Min-Ya; Xu, Xiang-Ming; Hu, Chen-Yu; Yao, Shu-Hao; Liu, Yi-Zhi; Wu, Zhi-Gang; Tang, Tao-Ming; Fu, Pei-Fen; Wang, Ming-Hai; Yao, Hang-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">973-986</span>CODEN:
                <span class="NLM_cas:coden">CRTAC2</span>;
        ISSN:<span class="NLM_cas:issn">2005-9256</span>.
    
            (<span class="NLM_cas:orgname">Korean Cancer Association</span>)
        </div><div class="casAbstract">Purpose Triple-neg. breast cancer (TNBC) is highly malignant and has poor prognosis and a high mortality rate.  The lack of effective therapy has spurred our investigation of new targets for treating this malignant cancer.  Here,we identified RON (macrophage-stimulating 1 receptor) and MET (MET proto-oncogene, receptor tyrosine kinase) as a prognostic biomarker and therapeutic targets for potential TNBC treatment.  Materials and Methods We analyzed RON and MET expression in 187 primary TNBC clin. samples with immunohistochem.  We validated the targeted therapeutic effects of RON and MET in TNBC using three tyrosine kinase inhibitors (TKIs): BMS-777607, INCB28060, and tivantinib.  The preclin. therapeutic efficacy of the TKIs was mainly estd. using a TNBC xenograft model.  Results Patients with TNBC had widespread, abnormal expression of RON and MET.  There was RON overexpression, MET overexpression, and RON and MET co-overexpression in 63 (33.7%), 63 (33.7%), and 43 cases (23.0%), resp., which had poor prognosis and short survival.  In vivo, the TKI targeting RON ant MET inhibited the activation of the downstream signaling mols., inhibited TNBC cell migration and proliferation, and increased TNBC cell apoptosis; in the xenograft model, they significantly inhibited tumor growth and shrank tumor vols.  The TKI targeting RON and Met, such as BMS-777607 and tivantinib, yielded stronger anti-tumor effects than INCB28060.  Conclusion RON and MET co-overexpression can be significant pathol. characteristics in TNBC for poor prognosis.  TKIs targeting RON and MET have stronger drug development potential for treating TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPJjnYNhm_OLVg90H21EOLACvtfcHk0lhujAM1OYoNcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2ms73E&md5=3e26c76abb461440735bc820771a5ff8</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2019.726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2019.726%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DT.%2BH.%26aulast%3DYao%26aufirst%3DM.%2BY.%26aulast%3DXu%26aufirst%3DX.%2BM.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DYao%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DY.%2BZ.%26aulast%3DWu%26aufirst%3DZ.%2BG.%26aulast%3DTang%26aufirst%3DT.%2BM.%26aulast%3DFu%26aufirst%3DP.%2BF.%26aulast%3DWang%26aufirst%3DM.%2BH.%26aulast%3DYao%26aufirst%3DH.%2BP.%26atitle%3DRON%2520and%2520MET%2520co-overexpression%2520are%2520significant%2520pathological%2520characteristics%2520of%2520poor%2520survival%2520and%2520therapeutic%2520targets%2520of%2520tyrosine%2520kinase%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2020%26volume%3D52%26issue%3D3%26spage%3D973%26epage%3D986%26doi%3D10.4143%2Fcrt.2019.726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrouche, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cure, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuselier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonicelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Daccak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bensussan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giustiniani, J.</span></span> <span> </span><span class="NLM_article-title">IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">33</span>),  <span class="NLM_fpage">53350</span>– <span class="NLM_lpage">53361</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.10804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.10804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27462789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ksl2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=53350-53361&issue=33&author=Y.+Merroucheauthor=J.+Fabreauthor=H.+Cureauthor=C.+Garbarauthor=C.+Fuselierauthor=J.+Bastidauthor=F.+Antonicelliauthor=R.+Al-Daccakauthor=A.+Bensussanauthor=J.+Giustiniani&title=IL-17E+synergizes+with+EGF+and+confers+in+vitro+resistance+to+EGFR-targeted+therapies+in+TNBC+cells&doi=10.18632%2Foncotarget.10804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells</span></div><div class="casAuthors">Merrouche Yacine; Fabre Joseph; Garbar Christian; Fuselier Camille; Giustiniani Jerome; Merrouche Yacine; Fabre Joseph; Garbar Christian; Fuselier Camille; Antonicelli Frank; Giustiniani Jerome; Cure Herve; Cure Herve; Bastid Jeremy; Bensussan Armand; Al-Daccak Reem; Bensussan Armand; Al-Daccak Reem; Bensussan Armand</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">53350-53361</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Estrogen receptor-, progesterone receptor- and HER2-negative breast cancers, also known as triple-negative breast cancers (TNBCs), have poor prognoses and are refractory to current therapeutic agents, including epidermal growth factor receptor (EGFR) inhibitors.  Resistance to anti-EGFR therapeutic agents is often associated with sustained kinase phosphorylation, which promotes EGFR activation and translocation to the nucleus and prevents these agents from acting on their targets.  The mechanisms underlying this resistance have not been fully elucidated.  In addition, the IL-17E receptor is overexpressed in TNBC tumors and is associated with a poor prognosis.  We have previously reported that IL-17E promotes TNBC resistance to anti-mitotic therapies.  Here, we investigated whether IL-17E promotes TNBC resistance to anti-EGFR therapeutic agents by exploring the link between the IL-17E/IL-17E receptor axis and EGF signaling.  We found that IL-17E, similarly to EGF, activates the EGFR in TNBC cells that are resistant to EGFR inhibitors.  It also activates the PYK-2, Src and STAT3 kinases, which are essential for EGFR activation and nuclear translocation.  IL-17E binds its specific receptor, IL-17RA/IL17RB, on these TNBC cells and synergizes with the EGF signaling pathway, thereby inducing Src-dependent EGFR transactivation and pSTAT3 and pEGFR translocation to the nucleus.  Collectively, our data indicate that the IL-17E/IL-17E receptor axis may underlie TNBC resistance to EGFR inhibitors and suggest that inhibiting IL-17E or its receptor in combination with EGFR inhibitor administration may improve TNBC management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRs0_2DtmXYlMGsG_HTXYFfW6udTcc2ebmDqTocRN7Irntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ksl2ktg%253D%253D&md5=31a10425d0c90669ac4e093f27c64e49</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10804%26sid%3Dliteratum%253Aachs%26aulast%3DMerrouche%26aufirst%3DY.%26aulast%3DFabre%26aufirst%3DJ.%26aulast%3DCure%26aufirst%3DH.%26aulast%3DGarbar%26aufirst%3DC.%26aulast%3DFuselier%26aufirst%3DC.%26aulast%3DBastid%26aufirst%3DJ.%26aulast%3DAntonicelli%26aufirst%3DF.%26aulast%3DAl-Daccak%26aufirst%3DR.%26aulast%3DBensussan%26aufirst%3DA.%26aulast%3DGiustiniani%26aufirst%3DJ.%26atitle%3DIL-17E%2520synergizes%2520with%2520EGF%2520and%2520confers%2520in%2520vitro%2520resistance%2520to%2520EGFR-targeted%2520therapies%2520in%2520TNBC%2520cells%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D33%26spage%3D53350%26epage%3D53361%26doi%3D10.18632%2Foncotarget.10804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells</span>. <i>Cell Biol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1007/s10565-018-09458-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10565-018-09458-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30612216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2019&pages=361-371&issue=4&author=F.+Jiangauthor=Y.+Liauthor=L.+Siauthor=Z.+Zhangauthor=Z.+Li&title=Interaction+of+EZH2+and+P65+is+involved+in+the+arsenic+trioxide-induced+anti-angiogenesis+in+human+triple-negative+breast+cancer+cells&doi=10.1007%2Fs10565-018-09458-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells</span></div><div class="casAuthors">Jiang, Fei; Li, Yuan; Si, Lu; Zhang, Zengli; Li, Zhong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology and Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">361-371</span>CODEN:
                <span class="NLM_cas:coden">CBTOE2</span>;
        ISSN:<span class="NLM_cas:issn">0742-2091</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Breast cancer (BC) is the most common female malignancy in the world.  Triple-neg. breast cancer (TNBC) is a subtype of BC characterized by the lack of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor-2 (HER-2), resulting in the limited therapeutic options.  Due to the aggressive behaviors at early stage, TNBC exhibits poorer outcomes compared to other BC subtypes.  Hematogenous metastasis, which spreads cancerous cells to lungs and/or bones, plays a pivotal role in the progression of TNBC.  Therefore, it is of great importance to study the anti-angiogenesis regulation mechanism for finding new treatment options for TNBC.  Arsenic trioxide (ATO) exhibits anti-cancer effect on solid tumors, including TNBC.  However, the roles and the mol. mechanism of ATO in the anti-angiogenesis of TNBC remain less well documented.  Our data showed that ATO restrained the expression and secretion of vascular endothelial growth factor (VEGF) and impaired the angiogenic ability in TNBC cells.  In addn., ATO suppressed the angiogenic ability in TNBC by inhibiting the interaction of the enhancer of zeste homolog 2 (EZH2) with p65, downregulating the nuclear factor-κB (NF-κB) activity, hence contributing to the regulation of IL-6/Stat3 signaling pathway.  All of our findings would help to better understand the mechanism of ATO anti-angiogenesis in TNBC, thus highlighting the therapeutic potential of ATO in TNBC by targeting angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBSVEJ5vAAKLVg90H21EOLACvtfcHk0ljf2jLkQBB4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVCjt7vJ&md5=ab00ede90b610b8036f3df6d7c3cd155</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1007%2Fs10565-018-09458-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10565-018-09458-0%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DInteraction%2520of%2520EZH2%2520and%2520P65%2520is%2520involved%2520in%2520the%2520arsenic%2520trioxide-induced%2520anti-angiogenesis%2520in%2520human%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DCell%2520Biol.%2520Toxicol.%26date%3D2019%26volume%3D35%26issue%3D4%26spage%3D361%26epage%3D371%26doi%3D10.1007%2Fs10565-018-09458-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drews-Elger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzam, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picon-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ashry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, J. M.</span></span> <span> </span><span class="NLM_article-title">VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3107</span>– <span class="NLM_lpage">3119</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fonc.2014.257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25151964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSqtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=3107-3119&issue=24&author=D.+Zhaoauthor=C.+Panauthor=J.+Sunauthor=C.+Gilbertauthor=K.+Drews-Elgerauthor=D.+J.+Azzamauthor=M.+Picon-Ruizauthor=M.+Kimauthor=W.+Ullmerauthor=D.+El-Ashryauthor=C.+J.+Creightonauthor=J.+M.+Slingerland&title=VEGF+drives+cancer-initiating+stem+cells+through+VEGFR-2%2FStat3+signaling+to+upregulate+Myc+and+Sox2&doi=10.1038%2Fonc.2014.257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2</span></div><div class="casAuthors">Zhao, D.; Pan, C.; Sun, J.; Gilbert, C.; Drews-Elger, K.; Azzam, D. J.; Picon-Ruiz, M.; Kim, M.; Ullmer, W.; El-Ashry, D.; Creighton, C. J.; Slingerland, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3107-3119</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Vascular endothelial growth factor-A (VEGF), a potent angiogenic factor, is also implicated in self-renewal in several normal tissue types.  VEGF has been shown to drive malignant stem cells but mechanisms thereof and tumor types affected are not fully characterized.  Here, we show VEGF promotes breast and lung cancer stem cell (CSC) self-renewal via VEGF receptor-2 (VEGFR-2)/STAT3-mediated upregulation of Myc and Sox2.  VEGF increased tumor spheres and aldehyde dehydrogenase activity, both proxies for stem cell function in vitro, in triple-neg. breast cancer (TNBC) lines and dissocd. primary cancers, and in lung cancer lines.  VEGF exposure before injection increased breast cancer-initiating cell abundance in vivo yielding increased orthotopic tumors, and increased metastasis from orthotopic primaries and following tail vein injection without further VEGF treatment.  VEGF rapidly stimulated VEGFR-2/JAK2/STAT3 binding and activated STAT3 to bind MYC and SOX2 promoters and induce their expression.  VEGFR-2 knockdown or inhibition abrogated VEGF-mediated STAT3 activation, MYC and SOX2 induction and sphere formation.  Notably, knockdown of either STAT3, MYC or SOX2 impaired VEGF-upregulation of pSTAT3, MYC and SOX2 expression and sphere formation.  Each transcription factor, once upregulated, appears to promote sustained activation of the others, creating a feed-forward loop to drive self-renewal.  Thus, in addn. to angiogenic effects, VEGF promotes tumor-initiating cell self-renewal through VEGFR-2/STAT3 signaling.  Anal. of primary breast and lung cancers (>1300 each) showed high VEGF expression, was prognostic of poor outcome and strongly assocd. with STAT3 and MYC expression, supporting the link between VEGF and CSC self-renewal.  High-VEGF tumors may be most likely to escape anti-angiogenics by upregulating VEGF, driving CSC self-renewal to re-populate post-treatment.  Our work highlights the need to better define VEGF-driven cancer subsets and supports further investigation of combined therapeutic blockade of VEGF or VEGFR-2 and JAK2/STAT3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJaiaQtHeeBbVg90H21EOLACvtfcHk0ljf2jLkQBB4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSqtb%252FJ&md5=be3d066b7f65a8a7ed1c1d0d9ebc05a1</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.257%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DC.%26aulast%3DDrews-Elger%26aufirst%3DK.%26aulast%3DAzzam%26aufirst%3DD.%2BJ.%26aulast%3DPicon-Ruiz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DUllmer%26aufirst%3DW.%26aulast%3DEl-Ashry%26aufirst%3DD.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DSlingerland%26aufirst%3DJ.%2BM.%26atitle%3DVEGF%2520drives%2520cancer-initiating%2520stem%2520cells%2520through%2520VEGFR-2%252FStat3%2520signaling%2520to%2520upregulate%2520Myc%2520and%2520Sox2%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26issue%3D24%26spage%3D3107%26epage%3D3119%26doi%3D10.1038%2Fonc.2014.257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vance, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gralow, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickler, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobleigh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkier, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vang
Nielsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sledge, G. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparano, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badve, S. S.</span></span> <span> </span><span class="NLM_article-title">Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1289</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-12-3029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23340303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFektLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1281-1289&issue=5&author=B.+P.+Schneiderauthor=R.+J.+Grayauthor=M.+Radovichauthor=F.+Shenauthor=G.+Vanceauthor=L.+Liauthor=G.+Jiangauthor=K.+D.+Millerauthor=J.+R.+Gralowauthor=M.+N.+Dicklerauthor=M.+A.+Cobleighauthor=E.+A.+Perezauthor=T.+N.+Shenkierauthor=K.+Vang%0ANielsenauthor=S.+Mullerauthor=A.+Thorauthor=G.+W.+Sledgeauthor=J.+A.+Sparanoauthor=N.+E.+Davidsonauthor=S.+S.+Badve&title=Prognostic+and+predictive+value+of+tumor+vascular+endothelial+growth+factor+gene+amplification+in+metastatic+breast+cancer+treated+with+paclitaxel+with+and+without+bevacizumab%3B+results+from+ECOG+2100+trial&doi=10.1158%2F1078-0432.CCR-12-3029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial</span></div><div class="casAuthors">Schneider, Bryan P.; Gray, Robert J.; Radovich, Milan; Shen, Fei; Vance, Gail; Li, Lang; Jiang, Guanglong; Miller, Kathy D.; Gralow, Julie R.; Dickler, Maura N.; Cobleigh, Melody A.; Perez, Edith A.; Shenkier, Tamara N.; Vang Nielsen, Kirsten; Mueller, Sven; Thor, Ann; Sledge, George W., Jr.; Sparano, Joseph A.; Davidson, Nancy E.; Badve, Sunil S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1281-1289</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Clin. validated biomarkers for anti-angiogenesis agents are not available.  We have previously reported assocns. between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100.  The assocns. between tumor VEGFA amplification and outcome are evaluated here.  Exptl. Design: E2100 was a phase III trial comparing paclitaxel with or without bevacizumab for patients with metastatic breast cancer.  FISH to assess gene amplification status for VEGFA was conducted on paraffin-embedded tumors from 363 patients in E2100.  Evaluation for assocn. between amplification status and outcomes was conducted.  Results: Estrogen receptor (ER)+ or progesterone receptor (PR)+ tumors were less likely to have VEGFA amplification than ER/PR- tumors (P = 0.020).  VEGFA amplification was assocd. with worse OS (20.2 vs. 25.3 mo; P = 0.013) in univariate anal. with a trend for worse OS in multivariate anal. (P = 0.08).  There was a significant interaction between VEGFA amplification, hormone receptor status, and study arm.  Patients with VEGFA amplification and triple-neg. breast cancers (TNBC) or HER2 amplification had inferior OS (P = 0.047); amplification did not affect OS for those who were ER+ or PR+ and HER2-.  Those who received bevacizumab with VEGFA amplification had inferior progression-free survival (PFS; P = 0.010) and OS (P = 0.042); no assocn. was seen in the control arm.  Test for interaction between study arm and VEGFA amplification with OS was not significant.  Conclusion: VEGFA amplification in univariate anal. was assocd. with poor outcomes; this was particularly prominent in HER2+ or TNBCs.  Addnl. studies are necessary to confirm the trend for poor OS seen on multivariate anal. for patients treated with bevacizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmAv75J8R6PLVg90H21EOLACvtfcHk0liAHm-Ay9POkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFektLY%253D&md5=1e9d79073d36e3e96d900e2f9fe06cba</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3029%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DB.%2BP.%26aulast%3DGray%26aufirst%3DR.%2BJ.%26aulast%3DRadovich%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DVance%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DGralow%26aufirst%3DJ.%2BR.%26aulast%3DDickler%26aufirst%3DM.%2BN.%26aulast%3DCobleigh%26aufirst%3DM.%2BA.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DShenkier%26aufirst%3DT.%2BN.%26aulast%3DVang%2BNielsen%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DThor%26aufirst%3DA.%26aulast%3DSledge%26aufirst%3DG.%2BW.%26aulast%3DSparano%26aufirst%3DJ.%2BA.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DBadve%26aufirst%3DS.%2BS.%26atitle%3DPrognostic%2520and%2520predictive%2520value%2520of%2520tumor%2520vascular%2520endothelial%2520growth%2520factor%2520gene%2520amplification%2520in%2520metastatic%2520breast%2520cancer%2520treated%2520with%2520paclitaxel%2520with%2520and%2520without%2520bevacizumab%253B%2520results%2520from%2520ECOG%25202100%2520trial%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D5%26spage%3D1281%26epage%3D1289%26doi%3D10.1158%2F1078-0432.CCR-12-3029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoforides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aitelli, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izatt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacioru, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakarya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Vega, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billings, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salhia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousses, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J. D.</span></span> <span> </span><span class="NLM_article-title">Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-12-0781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23171949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVamug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=104-116&issue=1&author=D.+W.+Craigauthor=J.+A.+O%E2%80%99Shaughnessyauthor=J.+A.+Kieferauthor=J.+Aldrichauthor=S.+Sinariauthor=T.+M.+Mosesauthor=S.+Wongauthor=J.+Dinhauthor=A.+Christoforidesauthor=J.+L.+Blumauthor=C.+L.+Aitelliauthor=C.+R.+Osborneauthor=T.+Izattauthor=A.+Kurdogluauthor=A.+Bakerauthor=J.+Koemanauthor=C.+Barbacioruauthor=O.+Sakaryaauthor=F.+M.+De+La+Vegaauthor=A.+Siddiquiauthor=L.+Hoangauthor=P.+R.+Billingsauthor=B.+Salhiaauthor=A.+W.+Tolcherauthor=J.+M.+Trentauthor=S.+Moussesauthor=D.+Von+Hoffauthor=J.+D.+Carpten&title=Genome+and+transcriptome+sequencing+in+prospective+metastatic+triple-negative+breast+cancer+uncovers+therapeutic+vulnerabilities&doi=10.1158%2F1535-7163.MCT-12-0781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities</span></div><div class="casAuthors">Craig, David W.; O'Shaughnessy, Joyce A.; Kiefer, Jeffrey A.; Aldrich, Jessica; Sinari, Shripad; Moses, Tracy M.; Wong, Shukmei; Dinh, Jennifer; Christoforides, Alexis; Blum, Joanne L.; Aitelli, Cristi L.; Osborne, Cynthia R.; Izatt, Tyler; Kurdoglu, Ahmet; Baker, Angela; Koeman, Julie; Barbacioru, Catalin; Sakarya, Onur; De La Vega, Francisco M.; Siddiqui, Asim; Hoang, Linh; Billings, Paul R.; Salhia, Bodour; Tolcher, Anthony W.; Trent, Jeffrey M.; Mousses, Spyro; Von Hoff, Daniel; Carpten, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-116</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2.  Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor prognosis with median survival of one year.  Here, we present initial analyses of whole genome and transcriptome sequencing data from 14 prospective mTNBC.  We have cataloged the collection of somatic genomic alterations in these advanced tumors, particularly those that may inform targeted therapies.  Genes mutated in multiple tumors included TP53, LRP1B, HERC1, CDH5, RB1, and NF1.  Notable genes involved in focal structural events were CTNNA1, PTEN, FBXW7, BRCA2, WT1, FGFR1, KRAS, HRAS, ARAF, BRAF, and PGCP.  Homozygous deletion of CTNNA1 was detected in 2 of 6 African Americans.  RNA sequencing revealed consistent overexpression of the FOXM1 gene when tumor gene expression was compared with nonmalignant breast samples.  Using an outlier anal. of gene expression comparing one cancer with all the others, we detected expression patterns unique to each patient's tumor.  Integrative DNA/RNA anal. provided evidence for deregulation of mutated genes, including the monoallelic expression of TP53 mutations.  Finally, mol. alterations in several cancers supported targeted therapeutic intervention on clin. trials with known inhibitors, particularly for alterations in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways.  In conclusion, whole genome and transcriptome profiling of mTNBC have provided insights into somatic events occurring in this difficult to treat cancer.  These genomic data have guided patients to investigational treatment trials and provide hypotheses for future trials in this irremediable cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-JLQZ9xmALVg90H21EOLACvtfcHk0liAHm-Ay9POkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVamug%253D%253D&md5=0cc86f6a13750602c4663ad034e9ff71</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0781%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DD.%2BW.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%2BA.%26aulast%3DKiefer%26aufirst%3DJ.%2BA.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DSinari%26aufirst%3DS.%26aulast%3DMoses%26aufirst%3DT.%2BM.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DDinh%26aufirst%3DJ.%26aulast%3DChristoforides%26aufirst%3DA.%26aulast%3DBlum%26aufirst%3DJ.%2BL.%26aulast%3DAitelli%26aufirst%3DC.%2BL.%26aulast%3DOsborne%26aufirst%3DC.%2BR.%26aulast%3DIzatt%26aufirst%3DT.%26aulast%3DKurdoglu%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DA.%26aulast%3DKoeman%26aufirst%3DJ.%26aulast%3DBarbacioru%26aufirst%3DC.%26aulast%3DSakarya%26aufirst%3DO.%26aulast%3DDe%2BLa%2BVega%26aufirst%3DF.%2BM.%26aulast%3DSiddiqui%26aufirst%3DA.%26aulast%3DHoang%26aufirst%3DL.%26aulast%3DBillings%26aufirst%3DP.%2BR.%26aulast%3DSalhia%26aufirst%3DB.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DTrent%26aufirst%3DJ.%2BM.%26aulast%3DMousses%26aufirst%3DS.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26atitle%3DGenome%2520and%2520transcriptome%2520sequencing%2520in%2520prospective%2520metastatic%2520triple-negative%2520breast%2520cancer%2520uncovers%2520therapeutic%2520vulnerabilities%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26issue%3D1%26spage%3D104%26epage%3D116%26doi%3D10.1158%2F1535-7163.MCT-12-0781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y. Q.</span></span> <span> </span><span class="NLM_article-title">Expression and significance of ERK-1 and p27 in human breast cancer</span>. <i>J. Mod. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>, (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2496</span>– <span class="NLM_lpage">2498</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=2496-2498&issue=11&author=J.+Y.+Qinauthor=L.+Wangauthor=L.+H.+Niuauthor=L.+M.+Liauthor=Y.+Q.+Su&title=Expression+and+significance+of+ERK-1+and+p27+in+human+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNiu%26aufirst%3DL.%2BH.%26aulast%3DLi%26aufirst%3DL.%2BM.%26aulast%3DSu%26aufirst%3DY.%2BQ.%26atitle%3DExpression%2520and%2520significance%2520of%2520ERK-1%2520and%2520p27%2520in%2520human%2520breast%2520cancer%26jtitle%3DJ.%2520Mod.%2520Oncol.%26date%3D2013%26issue%3D11%26spage%3D2496%26epage%3D2498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalezangulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2011-0377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1634%2Ftheoncologist.2011-0377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=22584435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrsLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=766-774&issue=6&author=C.+Bartholomeuszauthor=A.+Gonzalezanguloauthor=L.+Pingauthor=N.+Hayashiauthor=G.+N.+Hortobagyiauthor=N.+T.+Ueno&title=High+ERK+protein+expression+levels+correlate+with+shorter+survival+in+triple-negative+breast+cancer&doi=10.1634%2Ftheoncologist.2011-0377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">High ERK protein expression levels correlate with shorter survival in triple-breast cancer patients</span></div><div class="casAuthors">Bartholomeusz, Chandra; Gonzalez-Angulo, Ana M.; Liu, Ping; Hayashi, Naoki; Lluch, Ana; Ferrer-Lozano, Jaime; Hortobagyi, Gabriel N.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">766-774</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) signaling pathway is known to be activated in triple-neg. breast cancer (TNBC).  Extracellular signal-related kinase (ERK), a member of the MAPK pathway, promotes cell proliferation, angiogenesis, cell differentiation, and cell survival.  To assess the prognostic impact of ERK in TNBC patients, relative quantities of ERK (ERK-2 and pMAPK) and direct targets of the ERK pathway (MAPK/ERK kinase 1, phospho-enriched protein in astrocytes [PEA]-15, phosphorylated (p)PEA-15, tuberous sclerosis protein 2, p70S6 kinase, and p27) were measured using reverse-phase protein arrays in tumor tissue from patients with TNBC (n = 97) and non-TNBC (n = 223).  Protein levels in patients with TNBC were correlated with clin. and tumor characteristics and outcome.  The median age of patients with TNBC was 55 years (range, 27-86 years).  Disease stage was I in 21%, II in 60%, and III in 20% of the patients.  In a multivariate anal., among patients with TNBC, those with ERK-2-overexpressing tumors had a lower overall survival rate than those with low ERK-2-expressing tumors (hazard ratio [HR], 2.76; 95% confidence interval [CI], 1.19-6.41).  However, high pMAPK levels were assocd. with a significantly higher relapse-free survival rate (HR, 0.66; 95% CI, 0.46-0.95).  In conclusion, ERK-2 and pMAPK are valuable prognostic markers in TNBC.  Further studies are justified to elucidate ERK's role in TNBC tumorigenicity and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG-QY4WCoyHLVg90H21EOLACvtfcHk0lipjZAzM25QkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrsLbE&md5=adcaa0a1a5fb7605f88051b531dc2448</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2011-0377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2011-0377%26sid%3Dliteratum%253Aachs%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DGonzalezangulo%26aufirst%3DA.%26aulast%3DPing%26aufirst%3DL.%26aulast%3DHayashi%26aufirst%3DN.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DHigh%2520ERK%2520protein%2520expression%2520levels%2520correlate%2520with%2520shorter%2520survival%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncologist%26date%3D2012%26volume%3D17%26issue%3D6%26spage%3D766%26epage%3D774%26doi%3D10.1634%2Ftheoncologist.2011-0377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor types</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3976</span>– <span class="NLM_lpage">3995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01896</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01896" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFOku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3976-3995&issue=8&author=G.+Wangauthor=Y.+Zhaoauthor=Y.+Liuauthor=D.+Sunauthor=Y.+Zhenauthor=J.+Liuauthor=L.+Fuauthor=L.+Zhangauthor=L.+Ouyang&title=Discovery+of+a+novel+dual-target+inhibitor+of+ERK1+and+ERK5+that+induces+regulated+cell+death+to+overcome+compensatory+mechanism+in+specific+tumor+types&doi=10.1021%2Facs.jmedchem.9b01896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types</span></div><div class="casAuthors">Wang, Guan; Zhao, Yuqian; Liu, Yao; Sun, Dejuan; Zhen, Yongqi; Liu, Jie; Fu, Leilei; Zhang, Lan; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3976-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ERK1 and ERK5 are proposed to have pivotal roles in several types of cancer.  Under some circumstance, ERK5 may provide a common bypass route, which rescues proliferation upon abrogation of ERK1 signaling.  Thus, we accurately classified the tumor types from The Cancer Genome Atlas (TCGA) based on the expression levels of ERK1 and ERK5.  We proposed a novel therapeutic strategy to overcome the above-mentioned compensatory mechanism in specific tumor types by co-targeting both ERK1 and ERK5.  On the basis of the idea of overcoming ERK5 compensation mechanism, 22ac (ADTL-EI1712) as the first selective dual-target inhibitor of ERK1 and ERK5 was discovered to have potent antitumor effects in vitro and in vivo.  Interestingly, this compd. was found to induce regulated cell death accompanied by autophagy in MKN-74 cells.  Taken together, our results warrant the potential of this dual-target inhibitor as a new candidate drug that conquers compensatory mechanism in certain tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlxVBmkLH7mrVg90H21EOLACvtfcHk0lipjZAzM25QkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFOku7c%253D&md5=a39e2b19b4e97ba739e78f2453335714</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01896%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520dual-target%2520inhibitor%2520of%2520ERK1%2520and%2520ERK5%2520that%2520induces%2520regulated%2520cell%2520death%2520to%2520overcome%2520compensatory%2520mechanism%2520in%2520specific%2520tumor%2520types%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26issue%3D8%26spage%3D3976%26epage%3D3995%26doi%3D10.1021%2Facs.jmedchem.9b01896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizwanullah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, K.</span></span> <span> </span><span class="NLM_article-title">PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2181</span>– <span class="NLM_lpage">2191</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.drudis.2019.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31520748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWju7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2181-2191&issue=11&author=M.+Khanauthor=V.+Jainauthor=M.+Rizwanullahauthor=J.+Ahmadauthor=K.+Jain&title=PI3K%2FAKT%2FmTOR+pathway+inhibitors+in+triple-negative+breast+cancer%3A+a+review+on+drug+discovery+and+future+challenges&doi=10.1016%2Fj.drudis.2019.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges</span></div><div class="casAuthors">Khan, Mohammad A.; Jain, Vineet K.; Rizwanullah, Md.; Ahmad, Javed; Jain, Keerti</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2181-2191</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is a highly malignant subtype of breast cancer assocd. with poor prognosis.  Although conventional chemotherapy regimens have shown some effectiveness in early TNBC cases, the outcome in advanced stages is poor.  The PI3K/AKT/mTOR pathway is one of the important and active pathways involved in chemoresistance and survival of TNBC.  This pathway is speculated to play an important part in malignant transformation and has been considered as a potential mol. target for the design of therapeutic agents to treat TNBC.  This review discusses the potentials and drug discovery perspectives of PI3K/AKT/mTOR as a therapeutic target for effective management of TNBC with anticipated challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4h1LPJcV0U7Vg90H21EOLACvtfcHk0liU7aG6IaqZFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWju7rF&md5=dbde097d9af193befbd393d8b62a9136</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DJain%26aufirst%3DV.%26aulast%3DRizwanullah%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DJ.%26aulast%3DJain%26aufirst%3DK.%26atitle%3DPI3K%252FAKT%252FmTOR%2520pathway%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%253A%2520a%2520review%2520on%2520drug%2520discovery%2520and%2520future%2520challenges%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26issue%3D11%26spage%3D2181%26epage%3D2191%26doi%3D10.1016%2Fj.drudis.2019.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarracin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-MacGregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mtor inhibition in combination with liposomal doxorubicin and bevacizumab</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2016.5281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1001%2Fjamaoncol.2016.5281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27893038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhtVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=509-515&issue=4&author=R.+Bashoauthor=M.+Gilcreaseauthor=R.+Murthyauthor=T.+Helgasonauthor=D.+Karpauthor=F.+Meric-Bernstamauthor=K.+Hessauthor=S.+Herbrichauthor=V.+Valeroauthor=C.+Albarracinauthor=J.+Littonauthor=M.+Chavez-MacGregorauthor=N.+Ibrahimauthor=J.+Murrayauthor=K.+Koenigauthor=D.+Hongauthor=V.+Subbiahauthor=R.+Kurzrockauthor=F.+Jankuauthor=S.+Moulder&title=Targeting+the+PI3K%2FAKT%2FmTOR+pathway+for+the+treatment+of+mesenchymal+triple-negative+breast+cancer%3A+evidence+from+a+phase+1+trial+of+mtor+inhibition+in+combination+with+liposomal+doxorubicin+and+bevacizumab&doi=10.1001%2Fjamaoncol.2016.5281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab</span></div><div class="casAuthors">Basho Reva K; Gilcrease Michael; Albarracin Constance; Murthy Rashmi K; Valero Vicente; Litton Jennifer K; Ibrahim Nuhad K; Murray James L 3rd; Koenig Kimberly B; Helgason Thorunn; Karp Daniel D; Hong David; Subbiah Vivek; Janku Filip; Meric-Bernstam Funda; Hess Kenneth R; Herbrich Shelley M; Chavez-MacGregor Mariana; Kurzrock Razelle; Moulder Stacy L</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-515</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response.  Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy.  While assays to identify mesenchymal TNBC are under development, metaplastic breast cancer serves as a clinically identifiable surrogate to evaluate potential regimens for mesenchymal TNBC.  Objective:  To assess safety and efficacy of mammalian target of rapamycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with advanced metaplastic TNBC.  Design, Setting, and Participants:  Phase 1 study with dose escalation and dose expansion at the University of Texas MD Anderson Cancer Center of patients with advanced metaplastic TNBC.  Patients were enrolled from April 16, 2009, to November 4, 2014, and followed for outcomes with a cutoff date of November 1, 2015, for data analysis.  Interventions:  Liposomal doxorubicin, bevacizumab, and the mTOR inhibitors temsirolimus or everolimus using 21-day cycles.  Main Outcomes and Measures:  Safety and response.  When available, archived tissue was evaluated for aberrations in the PI3K pathway.  Results:  Fifty-two women with metaplastic TNBC (median age, 58 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE) (N = 13).  The objective response rate was 21% (complete response = 4 [8%]; partial response = 7 [13%]) and 10 (19%) patients had stable disease for at least 6 months, for a clinical benefit rate of 40%.  Tissue was available for testing in 43 patients, and 32 (74%) had a PI3K pathway aberration.  Presence of PI3K pathway aberration was associated with a significant improvement in objective response rate (31% vs 0%; P = .04) but not clinical benefit rate (44% vs 45%; P > .99).  Conclusions and Relevance:  Using metaplastic TNBC as a surrogate for mesenchymal TNBC, DAT and DAE had notable activity in mesenchymal TNBC.  Objective response was limited to patients with PI3K pathway aberration.  A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTatjZ_QtxszUbxh97K6Vt6fW6udTcc2eaE9EibZuTWObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhtVSjsQ%253D%253D&md5=10ca11d3bfc1e167136b282120d58a7b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2016.5281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2016.5281%26sid%3Dliteratum%253Aachs%26aulast%3DBasho%26aufirst%3DR.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DMurthy%26aufirst%3DR.%26aulast%3DHelgason%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DD.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHess%26aufirst%3DK.%26aulast%3DHerbrich%26aufirst%3DS.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DAlbarracin%26aufirst%3DC.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DChavez-MacGregor%26aufirst%3DM.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DKoenig%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DMoulder%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520PI3K%252FAKT%252FmTOR%2520pathway%2520for%2520the%2520treatment%2520of%2520mesenchymal%2520triple-negative%2520breast%2520cancer%253A%2520evidence%2520from%2520a%2520phase%25201%2520trial%2520of%2520mtor%2520inhibition%2520in%2520combination%2520with%2520liposomal%2520doxorubicin%2520and%2520bevacizumab%26jtitle%3DJAMA%2520Oncol.%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D509%26epage%3D515%26doi%3D10.1001%2Fjamaoncol.2016.5281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">González-Martínez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Mies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero-Barrio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios-Berraquero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-García, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios, J.</span></span> <span> </span><span class="NLM_article-title">Molecular features of metaplastic breast carcinoma: an infrequent subtype of triple negative breast carcinoma</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1832</span>, <span class="refDoi"> DOI: 10.3390/cancers12071832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers12071832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKms7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1832&issue=7&author=S.+Gonz%C3%A1lez-Mart%C3%ADnezauthor=B.+P%C3%A9rez-Miesauthor=I.+Carretero-Barrioauthor=M.+Palacios-Berraqueroauthor=J.+Perez-Garc%C3%ADaauthor=J.+Cort%C3%A9sauthor=J.+Palacios&title=Molecular+features+of+metaplastic+breast+carcinoma%3A+an+infrequent+subtype+of+triple+negative+breast+carcinoma&doi=10.3390%2Fcancers12071832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular features of metaplastic breast carcinoma: An infrequent subtype of triple negative breast carcinoma</span></div><div class="casAuthors">Gonzalez-Martinez, Silvia; Perez-Mies, Belen; Carretero-Barrio, Irene; Palacios-Berraquero, Maria Luisa; Perez-Garcia, Jose; Cortes, Javier; Palacios, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1832</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent invasive carcinomas that display differentiation of the neoplastic epithelium towards squamous cells and/or mesenchymal-type elements.  Most MBC have a triple neg. phenotype and poor prognosis.  Thus, MBC have worse survival rates than other invasive breast carcinomas, including other triple neg. breast carcinomas (TNBC).  In this study, we reviewed the mol. features of MBC, pointing out the differences among subtypes.  The most frequently mutated genes in MBC were TP53 and PIK3CA.  Addnl., mutations in the other genes of the PI3K/AKT pathway indicated its importance in the pathogenesis of MBC.  Regarding copy no. variations (CNVs), MYC was the most frequently amplified gene, and the most frequent gene loss affected the CDKN2A/CDKN2B locus.  Furthermore, the pattern of mutations and CNVs of MBC differed from those reported in other TNBC.  However, the mol. profile of MBC was not homogeneous among histol. subtypes, being the alterations in the PI3K pathway most frequent in spindle cell carcinomas.  Transcriptomic studies have demonstrated an epithelial to mesenchymal program activation and the enrichment of stemness genes in most MBC.  In addn., current studies are attempting to define the immune microenvironment of these tumors.  In conclusion, due to specific mol. features, MBC have a different clin. behavior from other types of TNBC, being more resistant to std. chemotherapy.  For this reason, new therapeutic approaches based on tumor mol. characteristics are needed to treat MBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosthQ8DLljKbVg90H21EOLACvtfcHk0ljwrtINol1KGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKms7rP&md5=9fe24d62bdaa0176f9cf5e95ae4c039b</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.3390%2Fcancers12071832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12071832%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Mart%25C3%25ADnez%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez-Mies%26aufirst%3DB.%26aulast%3DCarretero-Barrio%26aufirst%3DI.%26aulast%3DPalacios-Berraquero%26aufirst%3DM.%26aulast%3DPerez-Garc%25C3%25ADa%26aufirst%3DJ.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26aulast%3DPalacios%26aufirst%3DJ.%26atitle%3DMolecular%2520features%2520of%2520metaplastic%2520breast%2520carcinoma%253A%2520an%2520infrequent%2520subtype%2520of%2520triple%2520negative%2520breast%2520carcinoma%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26issue%3D7%26spage%3D1832%26doi%3D10.3390%2Fcancers12071832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarracin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1346</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdv163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25878190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2MjksVWnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=1346-1352&issue=7&author=S.+Moulderauthor=T.+Helgasonauthor=F.+Jankuauthor=J.+Whelerauthor=J.+Moroneyauthor=D.+Booserauthor=C.+Albarracinauthor=P.+Morrowauthor=J.+Atkinsauthor=K.+Koenigauthor=M.+Gilcreaseauthor=R.+Kurzrock&title=Inhibition+of+the+phosphoinositide+3-kinase+pathway+for+the+treatment+of+patients+with+metastatic+metaplastic+breast+cancer&doi=10.1093%2Fannonc%2Fmdv163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer</span></div><div class="casAuthors">Moulder S; Helgason T; Janku F; Wheler J; Moroney J; Atkins J; Booser D; Morrow P K; Koenig K; Albarracin C; Gilcrease M; Kurzrock R</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1346-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor phosphoinositide 3-kinase (PI3kinase) alterations; thus, therapy with mTor inhibitors may demonstrate activity.  PATIENTS AND METHODS:  Patients with mesenchymal/MpBC treated with temsirolimus-based regimens were evaluated.  Mutational analyses [polymerase chain reaction (PCR)-based DNA sequencing method, mass spectrometric detection (Sequenom MassARRAY), or next-generation sequencing] as well as loss of phosphatase and tensin homolog (PTEN) (immunohistochemistry) were performed (archived tissue when available).  RESULTS:  Twenty-three patients (one of whom was on two separate trials) were treated using temsirolimus-containing regimens: temsirolimus alone (n = 1 patient) or combined with the following: liposomal doxorubicin and bevacizumab (DAT, n = 18); liposomal doxorubicin (DT, n = 1); paclitaxel and bevacizumab (TAT, n = 2); paclitaxel (TT, n = 1); carboplatin and bevacizumab (CAT, n = 1).  Response rate [complete response (CR) + partial response (PR)] was 25% across all regimens; 32% in the anthracycline-based regimens [DAT and DT (CR = 2, PR = 4; N = 19)].  An additional two patients achieved stable disease (SD) ≥6 months [total SD ≥6 months/CR/PR = 8 (33%)].  Molecular aberrations in the PI3K pathway were common: PIK3CA mutation = 6/15 (40%), PTEN mutation = 3/11 (27%), and PTEN loss = 2/11 (18%).  A point mutation in the NF2 gene (K159fs*16; NF2 alterations can activate mTor) was found in one patient who attained CR (3+ years).  Of the eight patients who achieved SD ≥6 months/CR/PR, all 4 patients with available tissue had a molecular aberration that activate the PIK3CA/Akt/mTOR axis: PIK3CA mutation = 2; PTEN loss = 1; NF2 aberration = 1.  CONCLUSIONS:  DAT has activity in MpBCs including complete CRs.  Molecular aberrations that can activate the PI3 K/Akt/mTOR axis are common in MpBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB_xIuv3BuABFwe7cAcrfPfW6udTcc2ebcDl_zZfyTs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjksVWnuw%253D%253D&md5=20467882c60bc34839680e80102bbd47</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv163%26sid%3Dliteratum%253Aachs%26aulast%3DMoulder%26aufirst%3DS.%26aulast%3DHelgason%26aufirst%3DT.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DWheler%26aufirst%3DJ.%26aulast%3DMoroney%26aufirst%3DJ.%26aulast%3DBooser%26aufirst%3DD.%26aulast%3DAlbarracin%26aufirst%3DC.%26aulast%3DMorrow%26aufirst%3DP.%26aulast%3DAtkins%26aufirst%3DJ.%26aulast%3DKoenig%26aufirst%3DK.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520metastatic%2520metaplastic%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26issue%3D7%26spage%3D1346%26epage%3D1352%26doi%3D10.1093%2Fannonc%2Fmdv163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basho, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilcrease, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgason, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albarracin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-MacGregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span> <span> </span><span class="NLM_article-title">Comparative effectiveness of an mTOR-based systemic therapy regimen in advanced, metaplastic and nonmetaplastic triple-negative breast cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1300</span>– <span class="NLM_lpage">1309</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2017-0498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1634%2Ftheoncologist.2017-0498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30139837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=1300-1309&issue=11&author=R.+Bashoauthor=C.+Yamauthor=M.+Gilcreaseauthor=R.+Murthyauthor=T.+Helgasonauthor=D.+Karpauthor=F.+Meric-Bernstamauthor=K.+Hessauthor=V.+Valeroauthor=C.+Albarracinauthor=J.+Littonauthor=M.+Chavez-MacGregorauthor=D.+Hongauthor=R.+Kurzrockauthor=G.+Hortobagyiauthor=F.+Jankuauthor=S.+Moulder&title=Comparative+effectiveness+of+an+mTOR-based+systemic+therapy+regimen+in+advanced%2C+metaplastic+and+nonmetaplastic+triple-negative+breast+cancer&doi=10.1634%2Ftheoncologist.2017-0498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer</span></div><div class="casAuthors">Basho, Reva K.; Yam, Clinton; Gilcrease, Michael; Murthy, Rashmi K.; Helgason, Thorunn; Karp, Daniel D.; Meric-Bernstam, Funda; Hess, Kenneth R.; Valero, Vicente; Albarracin, Constance; Litton, Jennifer K.; Chavez-MacGregor, Mariana; Hong, David; Kurzrock, Razelle; Hortobagyi, Gabriel N.; Janku, Filip; Moulder, Stacy L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1300-1309</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1549-490X</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Background : Triple-neg. breast cancer (TNBC) is a heterogeneous disease with subtypes having different "targetable" mol. aberrations.  To det. if tumor subtype influences prognosis, we compared treatment outcomes of patients with MpBC with those of patients with nonmetaplastic TNBC receiving an mTOR-based systemic therapy regimen.  Patients and Methods : Patients with advanced MpBC and nonmetaplastic TNBC were treated at our institution from Apr. 16, 2009, through Nov. 4, 2014, using mTOR inhibition (temsirolimus or everolimus) with liposomal doxorubicin and bevacizumab (DAT/DAE).  Multivariable models were adjusted for all covariates.  Results : Fourteen patients with nonmetaplastic TNBC and 59 patients with advanced MpBC were treated with DAT/DAE.  Median PFS for the nonmetaplastic TNBC and MpBC patients was 2.5 mo and 4.8 mo, resp.  MpBC remained significantly assocd. with improved OS on multivariable anal. (p < .0001).  Conclusion : In our study, DAT/DAE appeared to be more effective in MpBC compared with nonmetaplastic TNBC.  These data support patient selection for targeted therapy in TNBC.  Patients with advanced MpBC treated with an mTOR-based systemic therapy regimen had better long-term outcomes compared with patients with nonmetaplastic triple-neg. breast cancer treated with the same regimen, suggesting that metaplastic histol. may predict benefit from agents targeting the PI3K/Akt/mTOR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAqAHhPuirGLVg90H21EOLACvtfcHk0ljwrtINol1KGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKnu7s%253D&md5=ec560680485f71f6e46f005922c4c2f8</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2017-0498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2017-0498%26sid%3Dliteratum%253Aachs%26aulast%3DBasho%26aufirst%3DR.%26aulast%3DYam%26aufirst%3DC.%26aulast%3DGilcrease%26aufirst%3DM.%26aulast%3DMurthy%26aufirst%3DR.%26aulast%3DHelgason%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DD.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DHess%26aufirst%3DK.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DAlbarracin%26aufirst%3DC.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DChavez-MacGregor%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DD.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DMoulder%26aufirst%3DS.%26atitle%3DComparative%2520effectiveness%2520of%2520an%2520mTOR-based%2520systemic%2520therapy%2520regimen%2520in%2520advanced%252C%2520metaplastic%2520and%2520nonmetaplastic%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncologist%26date%3D2018%26volume%3D23%26issue%3D11%26spage%3D1300%26epage%3D1309%26doi%3D10.1634%2Ftheoncologist.2017-0498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Couch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godwin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankratz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olswold, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slettedahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidugli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janni, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantopoulou, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fostira, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vratimos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fountzilas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelttari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapper, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durcan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilarski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevanlinna, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yannoukakos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasching, P.</span></span> <span> </span><span class="NLM_article-title">Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.57.1414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2014.57.1414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25452441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Glsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=304-311&issue=4&author=F.+Couchauthor=S.+Hartauthor=P.+Sharmaauthor=A.+Tolandauthor=X.+Wangauthor=P.+Mironauthor=J.+Olsonauthor=A.+Godwinauthor=V.+Pankratzauthor=C.+Olswoldauthor=S.+Slettedahlauthor=E.+Hallbergauthor=L.+Guidugliauthor=J.+Davilaauthor=M.+Beckmannauthor=W.+Janniauthor=B.+Rackauthor=A.+Ekiciauthor=D.+Slamonauthor=I.+Konstantopoulouauthor=F.+Fostiraauthor=A.+Vratimosauthor=G.+Fountzilasauthor=L.+Pelttariauthor=W.+Tapperauthor=L.+Durcanauthor=S.+Crossauthor=R.+Pilarskiauthor=C.+Shapiroauthor=J.+Klempauthor=S.+Yaoauthor=J.+Garberauthor=A.+Coxauthor=H.+Brauchauthor=C.+Ambrosoneauthor=H.+Nevanlinnaauthor=D.+Yannoukakosauthor=S.+Slagerauthor=C.+Vachonauthor=D.+Ecclesauthor=P.+Fasching&title=Inherited+mutations+in+17+breast+cancer+susceptibility+genes+among+a+large+triple-negative+breast+cancer+cohort+unselected+for+family+history+of+breast+cancer&doi=10.1200%2FJCO.2014.57.1414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer</span></div><div class="casAuthors">Couch, Fergus J.; Hart, Steven N.; Sharma, Priyanka; Toland, Amanda Ewart; Wang, Xianshu; Miron, Penelope; Olson, Janet E.; Godwin, Andrew K.; Pankratz, V. Shane; Olswold, Curtis; Slettedahl, Seth; Hallberg, Emily; Guidugli, Lucia; Davila, Jaime I.; Beckmann, Matthias W.; Janni, Wolfgang; Rack, Brigitte; Ekici, Arif B.; Slamon, Dennis J.; Konstantopoulou, Irene; Fostira, Florentia; Vratimos, Athanassios; Fountzilas, George; Pelttari, Liisa M.; Tapper, William J.; Durcan, Lorraine; Cross, Simon S.; Pilarski, Robert; Shapiro, Charles L.; Klemp, Jennifer; Yao, Song; Garber, Judy; Cox, Angela; Brauch, Hiltrud; Ambrosone, Christine; Nevanlinna, Heli; Yannoukakos, Drakoulis; Slager, Susan L.; Vachon, Celine M.; Eccles, Diana M.; Fasching, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-311</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing of patients.  We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-neg. breast cancer (TNBC) unselected for family history of breast or ovarian cancer to det. the utility of germline genetic testing for those with TNBC.  Patients and Methods Patients with TNBC (N = 1,824) unselected for family history of breast or ovarian cancer were recruited through 12 studies, and germline DNA was sequenced to identify mutations.  Results Deleterious mutations were identified in 14.6% of all patients.  Of these, 11.2% had mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes.  Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority obsd. in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%).  Patients with TNBC with mutations were diagnosed at an earlier age (P < .001) and had higher-grade tumors (P = .01) than those without mutations.  Conclusion Deleterious mutations in predisposition genes are present at high frequency in patients with TNBC unselected for family history of cancer.  Mutation prevalence ests. suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2.  Although mutations in other predisposition genes are obsd. among patients with TNBC, better cancer risk ests. are needed before these mutations are used for clin. risk assessment in relatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozoxGL1DDjHLVg90H21EOLACvtfcHk0livxZjXvkHShA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Glsr8%253D&md5=696dff86c2a17d15869cd2729b395cd4</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.57.1414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.57.1414%26sid%3Dliteratum%253Aachs%26aulast%3DCouch%26aufirst%3DF.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DToland%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMiron%26aufirst%3DP.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DGodwin%26aufirst%3DA.%26aulast%3DPankratz%26aufirst%3DV.%26aulast%3DOlswold%26aufirst%3DC.%26aulast%3DSlettedahl%26aufirst%3DS.%26aulast%3DHallberg%26aufirst%3DE.%26aulast%3DGuidugli%26aufirst%3DL.%26aulast%3DDavila%26aufirst%3DJ.%26aulast%3DBeckmann%26aufirst%3DM.%26aulast%3DJanni%26aufirst%3DW.%26aulast%3DRack%26aufirst%3DB.%26aulast%3DEkici%26aufirst%3DA.%26aulast%3DSlamon%26aufirst%3DD.%26aulast%3DKonstantopoulou%26aufirst%3DI.%26aulast%3DFostira%26aufirst%3DF.%26aulast%3DVratimos%26aufirst%3DA.%26aulast%3DFountzilas%26aufirst%3DG.%26aulast%3DPelttari%26aufirst%3DL.%26aulast%3DTapper%26aufirst%3DW.%26aulast%3DDurcan%26aufirst%3DL.%26aulast%3DCross%26aufirst%3DS.%26aulast%3DPilarski%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DC.%26aulast%3DKlemp%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DGarber%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DA.%26aulast%3DBrauch%26aufirst%3DH.%26aulast%3DAmbrosone%26aufirst%3DC.%26aulast%3DNevanlinna%26aufirst%3DH.%26aulast%3DYannoukakos%26aufirst%3DD.%26aulast%3DSlager%26aufirst%3DS.%26aulast%3DVachon%26aufirst%3DC.%26aulast%3DEccles%26aufirst%3DD.%26aulast%3DFasching%26aufirst%3DP.%26atitle%3DInherited%2520mutations%2520in%252017%2520breast%2520cancer%2520susceptibility%2520genes%2520among%2520a%2520large%2520triple-negative%2520breast%2520cancer%2520cohort%2520unselected%2520for%2520family%2520history%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3D4%26spage%3D304%26epage%3D311%26doi%3D10.1200%2FJCO.2014.57.1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senkus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domchek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaloge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goessl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runswick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, P.</span></span> <span> </span><span class="NLM_article-title">Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1056%2FNEJMoa1706450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28578601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=523-533&issue=6&author=M.+Robsonauthor=S.+A.+Imauthor=E.+Senkusauthor=B.+Xuauthor=S.+M.+Domchekauthor=N.+Masudaauthor=S.+Delalogeauthor=W.+Liauthor=N.+Tungauthor=A.+Armstrongauthor=W.+Wuauthor=C.+Goesslauthor=S.+Runswickauthor=P.+Conte&title=Olaparib+for+metastatic+breast+cancer+in+patients+with+a+germline+BRCA+mutation&doi=10.1056%2FNEJMoa1706450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</span></div><div class="casAuthors">Robson, Mark; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Li, Wei; Tung, Nadine; Armstrong, Anne; Wu, Wenting; Goessl, Carsten; Runswick, Sarah; Conte, Pierfranco</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">523-533</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Olaparib is an oral poly(ADP-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.  We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with std. therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (HER2)-neg. metastatic breast cancer who had received no more than two previous chemotherapy regimens for metastatic disease.  Patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets (300 mg twice daily) or std. therapy with single-agent chemotherapy of the physician's choice (capecitabine, eribulin, or vinorelbine in 21-day cycles).  The primary end point was progression-free survival, which was assessed by blinded independent central review and was analyzed on an intention-to-treat basis. results Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive std. therapy.  Median progression-free survival was significantly longer in the olaparib group than in the std.-therapy group (7.0 mo vs. 4.2 mo; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).  The response rate was 59.9% in the olaparib group and 28.8% in the std.-therapy group.  The rate of grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the std.-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, resp.  Among patients with HER2-neg. metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over std. therapy; median progression-free survival was 2.8 mo longer and the risk of disease progression or death was 42% lower with olaparib monotherapy than with std. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMXxR-ZN4IGrVg90H21EOLACvtfcHk0livxZjXvkHShA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyksrbN&md5=7c8c62182a717c16c5762443fb3f6d5d</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706450%26sid%3Dliteratum%253Aachs%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DSenkus%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTung%26aufirst%3DN.%26aulast%3DArmstrong%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DGoessl%26aufirst%3DC.%26aulast%3DRunswick%26aufirst%3DS.%26aulast%3DConte%26aufirst%3DP.%26atitle%3DOlaparib%2520for%2520metastatic%2520breast%2520cancer%2520in%2520patients%2520with%2520a%2520germline%2520BRCA%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26issue%3D6%26spage%3D523%26epage%3D533%26doi%3D10.1056%2FNEJMoa1706450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okuma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonemori, K.</span></span> <span> </span><span class="NLM_article-title">BRCA gene mutations and poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1026</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1007/978-981-10-6020-5_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2F978-981-10-6020-5_13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29282689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCns7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1026&publication_year=2017&pages=271-286&author=H.+Okumaauthor=K.+Yonemori&title=BRCA+gene+mutations+and+poly%28ADP-ribose%29+polymerase+inhibitors+in+triple-negative+breast+cancer&doi=10.1007%2F978-981-10-6020-5_13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">BRCA gene mutations and poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer</span></div><div class="casAuthors">Okuma, Hitomi Sumiyoshi; Yonemori, Kan</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1026</span>
        (<span class="NLM_cas:issue">Translational Research in Breast Cancer</span>),
    <span class="NLM_cas:pages">271-286</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Breast cancer is the most common cancer in women worldwide.  Treatment is chosen according to its hormone receptor status and human epidermal growth factor receptor 2 (HER2) status.  Among the four main clin. set subtypes, hormone receptor-neg./HER2-neg. subtype, also called triple-neg. subtype (TNBC), is the most aggressive type with limited choices of therapy.  However, recent research has provided important new insights into effective treatments for this subtype.  One mol. target that has gained attention is the BRCA gene.  BRCA proteins are involved in the maintenance of genomic integrity, therefore playing an important role as a "caretaker" DNA repair protein.  Approx. 5% of all breast cancer patients are BRCA mutation carriers, and among the patients with BRCA mutations, 57.1% have the clin. TNBC subtype, showing a high assocn. between BRCA mutations and TNBCs.  When cells lack either BRCA1 or BRCA2, all types of homol.-directed repairs are compromised, and poly(ADP-ribose) (PAR) polymerase (PARP) acts as a backup system to maintain the genome, consequently making the cells highly sensitive to PARP1 inhibitors.  PARP inhibitors have shown promising activity in preclin. and early clin. trials, and today, phase III trials are ongoing.  In this chapter, we discuss the mechanism and the role of PARP inhibitors in BRCA-mutated breast cancers and further elaborate the clin. potential of PARP inhibitors as well as their barriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ9T0ZyRJavbVg90H21EOLACvtfcHk0lgOJKDHUnlJJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCns7vO&md5=aa55e62f4f2d0061a97bb425743f12be</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1007%2F978-981-10-6020-5_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-981-10-6020-5_13%26sid%3Dliteratum%253Aachs%26aulast%3DOkuma%26aufirst%3DH.%26aulast%3DYonemori%26aufirst%3DK.%26atitle%3DBRCA%2520gene%2520mutations%2520and%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D1026%26spage%3D271%26epage%3D286%26doi%3D10.1007%2F978-981-10-6020-5_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marotta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almendro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marusyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipitsin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schemme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloushtain-Qimron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessarabova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolskaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, K.</span></span> <span> </span><span class="NLM_article-title">The JAK2/STAT3 signaling pathway is required for growth of CD44<sup>+</sup>CD24<sup>–</sup> stem cell-like breast cancer cells in human tumors</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2723</span>– <span class="NLM_lpage">2735</span>, <span class="refDoi"> DOI: 10.1172/JCI44745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1172%2FJCI44745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21633165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovVKgurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2723-2735&issue=7&author=L.+Marottaauthor=V.+Almendroauthor=A.+Marusykauthor=M.+Shipitsinauthor=J.+Schemmeauthor=S.+Walkerauthor=N.+Bloushtain-Qimronauthor=J.+Kimauthor=S.+Choudhuryauthor=R.+Maruyamaauthor=Z.+Wuauthor=M.+G%C3%B6nenauthor=L.+Mulveyauthor=M.+Bessarabovaauthor=S.+Huhauthor=S.+Silverauthor=S.+Kimauthor=S.+Parkauthor=H.+Leeauthor=K.+Andersonauthor=A.+Richardsonauthor=T.+Nikolskayaauthor=Y.+Nikolskyauthor=X.+Liuauthor=D.+Rootauthor=W.+Hahnauthor=D.+Frankauthor=K.+Polyak&title=The+JAK2%2FSTAT3+signaling+pathway+is+required+for+growth+of+CD44%2BCD24%E2%80%93+stem+cell-like+breast+cancer+cells+in+human+tumors&doi=10.1172%2FJCI44745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors</span></div><div class="casAuthors">Marotta, Lauren L. C.; Almendro, Vanessa; Marusyk, Andriy; Shipitsin, Michail; Schemme, Janina; Walker, Sarah R.; Bloushtain-Qimron, Noga; Kim, Jessica J.; Choudhury, Sibgat A.; Maruyama, Reo; Wu, Zhenhua; Gonen, Mithat; Mulvey, Laura A.; Bessarabova, Marina O.; Huh, Sung Jin; Silver, Serena J.; Kim, So Young; Park, So Yeon; Lee, Hee Eun; Anderson, Karen S.; Richardson, Andrea L.; Nikolskaya, Tatiana; Nikolsky, Yuri; Liu, X. Shirley; Root, David E.; Hahn, William C.; Frank, David A.; Polyak, Kornelia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2723-2735</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Intratumor heterogeneity is a major clin. problem because tumor cell subtypes display variable sensitivity to therapeutics and may play different roles in progression.  We previously characterized 2 cell populations in human breast tumors with distinct properties: CD44+CD24- cells that have stem cell-like characteristics, and CD44-CD24+ cells that resemble more differentiated breast cancer cells.  Here we identified 15 genes required for cell growth or proliferation in CD44+CD24- human breast cancer cells in a large-scale loss-of-function screen and found that inhibition of several of these (IL6, PTGIS, HAS1, CXCL3, and PFKFB3) reduced Stat3 activation.  We found that the IL-6/JAK2/Stat3 pathway was preferentially active in CD44+CD24- breast cancer cells compared with other tumor cell types, and inhibition of JAK2 decreased their no. and blocked growth of xenografts.  Our results highlight the differences between distinct breast cancer cell types and identify targets such as JAK2 and Stat3 that may lead to more specific and effective breast cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQqJMwVplyerVg90H21EOLACvtfcHk0lgOJKDHUnlJJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovVKgurc%253D&md5=572bfdae3d883384eca4888540698458</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1172%2FJCI44745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI44745%26sid%3Dliteratum%253Aachs%26aulast%3DMarotta%26aufirst%3DL.%26aulast%3DAlmendro%26aufirst%3DV.%26aulast%3DMarusyk%26aufirst%3DA.%26aulast%3DShipitsin%26aufirst%3DM.%26aulast%3DSchemme%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DBloushtain-Qimron%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DChoudhury%26aufirst%3DS.%26aulast%3DMaruyama%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DG%25C3%25B6nen%26aufirst%3DM.%26aulast%3DMulvey%26aufirst%3DL.%26aulast%3DBessarabova%26aufirst%3DM.%26aulast%3DHuh%26aufirst%3DS.%26aulast%3DSilver%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DRichardson%26aufirst%3DA.%26aulast%3DNikolskaya%26aufirst%3DT.%26aulast%3DNikolsky%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRoot%26aufirst%3DD.%26aulast%3DHahn%26aufirst%3DW.%26aulast%3DFrank%26aufirst%3DD.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DThe%2520JAK2%252FSTAT3%2520signaling%2520pathway%2520is%2520required%2520for%2520growth%2520of%2520CD44%252BCD24%25E2%2580%2593%2520stem%2520cell-like%2520breast%2520cancer%2520cells%2520in%2520human%2520tumors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26issue%3D7%26spage%3D2723%26epage%3D2735%26doi%3D10.1172%2FJCI44745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweardy, D. J.</span></span> <span> </span><span class="NLM_article-title">Targeting STAT3 in cancer therapy</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1097/00001813-200507000-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1097%2F00001813-200507000-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=15930886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Glurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=601-607&issue=6&author=N.+Jingauthor=D.+J.+Tweardy&title=Targeting+STAT3+in+cancer+therapy&doi=10.1097%2F00001813-200507000-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Stat3 in cancer therapy</span></div><div class="casAuthors">Jing, Naijie; Tweardy, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-607</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Stat3 is constitutively activated in many human cancers where it functions as a crit. mediator of oncogenic signaling through transcriptional activation of genes encoding apoptosis inhibitors (e.g. Bcl-xL, Mcl-1 and survivin), cell-cycle regulators (e.g. cyclin D1 and c-Myc) and inducers of angiogenesis (e.g. vascular endothelial growth factor).  This article reviews several approaches that have been pursued for targeting Stat3 in cancer therapy including antisense strategies, tyrosine kinase inhibition, decoy phosphopeptides, decoy duplex oligonucleotides and G-quartet oligodeoxynucleotides (GQ-ODN).  The GQ-ODN strategy is reviewed in somewhat greater detail than the others because it includes a novel system that effectively delivers drug into cells and tissues, addresses successfully the issue of specificity of targeting Stat3 vs. Stat1, and has demonstrated efficacy in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLZy2Lwe8ObVg90H21EOLACvtfcHk0lgOJKDHUnlJJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Glurg%253D&md5=3d6cc9c9427a6a53a103bfb367457e12</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1097%2F00001813-200507000-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200507000-00002%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DN.%26aulast%3DTweardy%26aufirst%3DD.%2BJ.%26atitle%3DTargeting%2520STAT3%2520in%2520cancer%2520therapy%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2005%26volume%3D16%26issue%3D6%26spage%3D601%26epage%3D607%26doi%3D10.1097%2F00001813-200507000-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aodengqimuge</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span> <span> </span><span class="NLM_article-title">Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1023</span>– <span class="NLM_lpage">1032</span>, <span class="refDoi"> DOI: 10.1111/cas.12712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1111%2Fcas.12712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26041409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKgsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2015&pages=1023-1032&issue=8&author=Q.+Tanauthor=H.+Wangauthor=Y.+Huauthor=M.+Huauthor=X.+Liauthor=+Aodengqimugeauthor=Y.+Maauthor=C.+Weiauthor=L.+Song&title=Src%2FSTAT3-dependent+heme+oxygenase-1+induction+mediates+chemoresistance+of+breast+cancer+cells+to+doxorubicin+by+promoting+autophagy&doi=10.1111%2Fcas.12712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy</span></div><div class="casAuthors">Tan, Qixing; Wang, Hongli; Hu, Yongliang; Hu, Meiru; Li, Xiaoguang; Aodengqimuge; Ma, Yuanfang; Wei, Changyuan; Song, Lun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1023-1032</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Chemotherapeutic resistance in breast cancer, whether acquired or intrinsic, remains a major clin. obstacle.  Thus, increasing tumor cell sensitivity to chemotherapeutic agents will be helpful in improving the clin. management of breast cancer.  In the present study, we found an induction of HO-1 expression in doxorubicin (DOX)-treated MDA-MB-231 human breast adenocarcinoma cells, which showed insensitivity to DOX treatment.  Knockdown HO-1 expression dramatically upregulated the incidence of MDA-MB-231 cell death under DOX treatment, indicating that HO-1 functions as a crit. contributor to drug resistance in MDA-MB-231 cells.  We further obsd. that DOX exposure induced a cytoprotective autophagic flux in MDA-MB-231 cells, which was dependent on HO-1 induction.  Moreover, upregulation of HO-1 expression required the activation of both signal transducer and activator of transcription (STAT)3 and its upstream regulator, protein kinase Src.  Abrogating Src/STAT3 pathway activation attenuated HO-1 and autophagy induction, thus increasing the chemosensitivity of MDA-MB-231 cells.  Therefore, we conclude that Src/STAT3-dependent HO-1 induction protects MDA-MB-231 breast cancer cells from DOX-induced death through promoting autophagy.  In the following study, we further demonstrated the contribution of Src/STAT3/HO-1/autophagy pathway activation to DOX resistance in another breast cancer cell line, MDA-MB-468, which bears a similar phenotype to MDA-MB-231 cells.  Therefore, activation of Src/STAT3/HO-1/autophagy signaling pathway might play a general role in protecting certain subtypes of breast cancer cells from DOX-induced cytotoxicity.  Targeting this signaling event may provide a potential approach for overcoming DOX resistance in breast cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5JMVyHxsU6LVg90H21EOLACvtfcHk0ljJn9jYyTaV2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKgsLjE&md5=fcde40487289be2840e579ce043245a2</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1111%2Fcas.12712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12712%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DAodengqimuge%26aulast%3DMa%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DL.%26atitle%3DSrc%252FSTAT3-dependent%2520heme%2520oxygenase-1%2520induction%2520mediates%2520chemoresistance%2520of%2520breast%2520cancer%2520cells%2520to%2520doxorubicin%2520by%2520promoting%2520autophagy%26jtitle%3DCancer%2520Sci.%26date%3D2015%26volume%3D106%26issue%3D8%26spage%3D1023%26epage%3D1032%26doi%3D10.1111%2Fcas.12712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1080/15548627.2017.1283470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1080%2F15548627.2017.1283470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28165887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFKjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=777-778&issue=4&author=L.+Ouyangauthor=L.+Zhangauthor=L.+Fuauthor=B.+Liu&title=A+small-molecule+activator+induces+ULK1-modulating+autophagy-associated+cell+death+in+triple+negative+breast+cancer&doi=10.1080%2F15548627.2017.1283470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer</span></div><div class="casAuthors">Ouyang, Liang; Zhang, Lan; Fu, Leilei; Liu, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">777-778</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8635</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">ULK1 (unc-51 like autophagy activating kinase 1) is well known to be required to initiate the macroautophagy/autophagy process, and thus activation of ULK1-modulating autophagy/autophagy-assocd. cell death (ACD) may be a possible therapeutic strategy in triple neg. breast cancer (TNBC).  Here, our integrated The Cancer Genome Atlas (TCGA) data set, tissue microarray-based analyses and multiple biol. evaluations together demonstrate a new small-mol. activator of ULK1 for better understanding of how ULK1, the mammalian homolog of yeast Atg1, as a potential drug target can regulate ACD by the ULK complex (ULK1-ATG13-RB1CC1/FIP200-ATG101), as well as other possible ULK1 interactors, including ATF3, RAD21 and CASP3/caspase3 in TNBC.  Moreover, such new inspiring findings may help us discover that this activator of ULK1 (LYN-1604) with its anti-tumor activity and ACD-modulating mechanisms can be further exploited as a small-mol. candidate drug for future TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEYz4amkfwXrVg90H21EOLACvtfcHk0ljJn9jYyTaV2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFKjsbY%253D&md5=011ed979ea170fc6a8f54252ac641de1</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1080%2F15548627.2017.1283470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15548627.2017.1283470%26sid%3Dliteratum%253Aachs%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DA%2520small-molecule%2520activator%2520induces%2520ULK1-modulating%2520autophagy-associated%2520cell%2520death%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DAutophagy%26date%3D2017%26volume%3D13%26issue%3D4%26spage%3D777%26epage%3D778%26doi%3D10.1080%2F15548627.2017.1283470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanlikilicer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguztuzun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulasli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arslan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Berestein, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozpolat, B.</span></span> <span> </span><span class="NLM_article-title">MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">11641</span>– <span class="NLM_lpage">11658</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.14264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28036267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1c7gs1eisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=11641-11658&issue=7&author=R.+Bayraktarauthor=M.+Pichlerauthor=P.+Kanlikilicerauthor=C.+Ivanauthor=E.+Bayraktarauthor=N.+Kahramanauthor=B.+Aslanauthor=S.+Oguztuzunauthor=M.+Ulasliauthor=A.+Arslanauthor=G.+Calinauthor=G.+Lopez-Beresteinauthor=B.+Ozpolat&title=MicroRNA+603+acts+as+a+tumor+suppressor+and+inhibits+triple-negative+breast+cancer+tumorigenesis+by+targeting+elongation+factor+2+kinase&doi=10.18632%2Foncotarget.14264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase</span></div><div class="casAuthors">Bayraktar Recep; Kanlikilicer Pinar; Ivan Cristina; Bayraktar Emine; Kahraman Nermin; Aslan Burcu; Calin George; Lopez-Berestein Gabriel; Ozpolat Bulent; Bayraktar Recep; Bayraktar Emine; Ulasli Mustafa; Arslan Ahmet; Pichler Martin; Ivan Cristina; Calin George; Lopez-Berestein Gabriel; Ozpolat Bulent; Oguztuzun Serpil</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">11641-11658</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by the absence of defined molecular targets, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and is associated with high rates of relapse and distant metastasis despite surgery and adjuvant chemotherapy.  The lack of effective targeted therapies for TNBC represents an unmet therapeutic challenge.  Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical calcium/calmodulin-dependent serine/threonine kinase that promotes TNBC tumorigenesis, progression, and drug resistance, representing a potential novel molecular target.  However, the mechanisms regulating eEF2K expression are unknown.  Here, we report that eEF2K protein expression is highly up-regulated in TNBC cells and patient tumors and it is associated with poor patient survival and clinical outcome.  We found that loss/reduced expression of miR-603 leads to eEF2K overexpression in TNBC cell lines.  Its expression results in inhibition of eEF2K by directly targeting the 3-UTR and the inhibition of tumor cell growth, migration and invasion in TNBC.  In vivo therapeutic gene delivery of miR-603 into TNBC xenograft mouse models by systemic administration of miR-603-nanoparticles led to a significant inhibition of eEF2K expression and tumor growth, which was associated with decreased activity of the downstream targets of eEF2K, including Src, Akt, cyclin D1 and c-myc.  Our findings suggest that miR-603 functions as a tumor suppressor and loss of miR-603 expression leads to increase in eEF2K expression and contributes to the growth, invasion, and progression of TNBC.  Taken together, our data suggest that miR-603-based gene therapy is a potential strategy against TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-_T1YwZchiaNc3HjJRoFAfW6udTcc2eYhnw0dZA5Jxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7gs1eisA%253D%253D&md5=629328be6dd8244a4b8183d7c0b1bf18</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14264%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DR.%26aulast%3DPichler%26aufirst%3DM.%26aulast%3DKanlikilicer%26aufirst%3DP.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DBayraktar%26aufirst%3DE.%26aulast%3DKahraman%26aufirst%3DN.%26aulast%3DAslan%26aufirst%3DB.%26aulast%3DOguztuzun%26aufirst%3DS.%26aulast%3DUlasli%26aufirst%3DM.%26aulast%3DArslan%26aufirst%3DA.%26aulast%3DCalin%26aufirst%3DG.%26aulast%3DLopez-Berestein%26aufirst%3DG.%26aulast%3DOzpolat%26aufirst%3DB.%26atitle%3DMicroRNA%2520603%2520acts%2520as%2520a%2520tumor%2520suppressor%2520and%2520inhibits%2520triple-negative%2520breast%2520cancer%2520tumorigenesis%2520by%2520targeting%2520elongation%2520factor%25202%2520kinase%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D7%26spage%3D11641%26epage%3D11658%26doi%3D10.18632%2Foncotarget.14264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akcakanat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span> <span> </span><span class="NLM_article-title">Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">R138</span>, <span class="refDoi"> DOI: 10.1186/bcr3343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fbcr3343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23102376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslyqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=R138&issue=5&author=F.+Meric-Bernstamauthor=H.+Chenauthor=A.+Akcakanatauthor=K.+A.+Doauthor=A.+Lluchauthor=B.+T.+Hennessyauthor=G.+N.+Hortobagyiauthor=G.+B.+Millsauthor=A.+Gonzalez-Angulo&title=Aberrations+in+translational+regulation+are+associated+with+poor+prognosis+in+hormone+receptor-positive+breast+cancer&doi=10.1186%2Fbcr3343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer</span></div><div class="casAuthors">Meric-Bernstam, Funda; Chen, Huiqin; Akcakanat, Argun; Do, Kim-Anh; Lluch, Ana; Hennessy, Bryan T.; Hortobagyi, Gabriel N.; Mills, Gordon B.; Gonzalez-Angulo, Ana Maria</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">R138</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: Translation initiation is activated in cancer through increase in eukaryotic initiation factor 4E (eIF4E), eIF4G, phosphorylated eIF4E-binding protein (p4E-BP1) and phosphorylated ribosomal protein S6 (pS6), and decreased programmed cell death protein 4 (pdcd4), a translational inhibitor.  Further, translation elongation is deregulated though alterations in eukaryotic elongation factor 2 (eEF2) and eEF2 kinase (eEF2K).  We sought to det. the assocn. of these translational aberrations with clin.-pathol. factors and survival outcomes in hormone receptor-pos. breast cancer.  Methods: Primary tumors were collected from 190 patients with Stage I to III hormone receptor-pos. breast cancer.  Expression of eIF4E, eIF4G, 4E-BP1, p4E-BP1 T37/46, p4E-BP1 S65, p4E-BP1 T70, S6, pS6 S235/236, pS6 S240/244, pdcd4, eEF2 and eEF2K was assessed by reverse phase protein arrays.  Univariable and multivariable analyses for recurrence-free survival (RFS) and overall survival (OS) were performed.  Results: High eEF2, S6, pS6 S240/244, p4E-BP1 T70, and low pdcd4 were significantly assocd. with node positivity.  Median follow-up for living patients was 96 mo.  High p4E-BP1 T36/47, p4E-BP1 S65, p4E-BP1 T70 and 4E-BP1 were assocd. with worse RFS.  High p4E-BP1 T70 and pS6 S235/236, and low pdcd4, were assocd. with worse OS.  In multivariable anal., in addn. to pos. nodes, p4E-BP1 S65 remained a significant predictor of RFS (HR = 1.62, 95% CI = 1.13-2.31; P = 0.008).  In addn. to age, pS6 S235/236 (HR = 1.73, 95% CI = 1.03-2.90, P = 0.039), eEF2K (HR = 2.19, 95% CI = 1.35-3.56, P = 0.002) and pdcd4 (HR = 0.42, 95% CI = 0.25-0.70, P = 0.001) were assocd. with OS.  Conclusions: Increased pS6, p4E-BP1, eEF2K and decreased pdcd4 are assocd. with poor prognosis in hormone receptor-pos. breast cancer, suggesting their role as prognostic markers and therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-rWwQTSYn97Vg90H21EOLACvtfcHk0limVkVk8evPkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslyqs7o%253D&md5=ab7e221e04951266a2bce6a1874c1ae8</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1186%2Fbcr3343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr3343%26sid%3Dliteratum%253Aachs%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DAkcakanat%26aufirst%3DA.%26aulast%3DDo%26aufirst%3DK.%2BA.%26aulast%3DLluch%26aufirst%3DA.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26atitle%3DAberrations%2520in%2520translational%2520regulation%2520are%2520associated%2520with%2520poor%2520prognosis%2520in%2520hormone%2520receptor-positive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2012%26volume%3D14%26issue%3D5%26spage%3DR138%26doi%3D10.1186%2Fbcr3343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span> <span> </span><span class="NLM_article-title">Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells</span>. <i>Cell Stress Chaperones</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1007/s12192-014-0545-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs12192-014-0545-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25248493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Ohsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=217-220&issue=2&author=H.+Zhuauthor=X.+Yangauthor=J.+Liuauthor=L.+Zhouauthor=C.+Zhangauthor=L.+Xuauthor=Q.+Qinauthor=L.+Zhanauthor=J.+Luauthor=H.+Chengauthor=X.+Sun&title=Eukaryotic+elongation+factor+2+kinase+confers+tolerance+to+stress+conditions+in+cancer+cells&doi=10.1007%2Fs12192-014-0545-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells</span></div><div class="casAuthors">Zhu, Hongcheng; Yang, Xi; Liu, Jia; Zhou, Lu; Zhang, Chi; Xu, Liping; Qin, Qin; Zhan, Liangliang; Lu, Jing; Cheng, Hongyan; Sun, Xinchen</div><div class="citationInfo"><span class="NLM_cas:title">Cell Stress & Chaperones</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-220</span>CODEN:
                <span class="NLM_cas:coden">CSCHFG</span>;
        ISSN:<span class="NLM_cas:issn">1355-8145</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Eukaryotic elongation factor 2 (eEF2) is a member of the GTP-binding translation elongation factor family that is essential for protein synthesis.  EEF2 kinase (eEF2K) is a structurally and functionally unique protein kinase in the calmodulin-mediated signaling pathway.  EEF2K phosphorylates eEF2, thereby inhibiting eEF2 function under stressful conditions.  EEF2K regulates numerous processes, such as protein synthesis, cell cycle progression, and induction of autophagy and apoptosis in cancer cells.  This review will demonstrate the mechanisms underlying eEF2K activity in cancer cells under different stresses, such as nutrient deprivation, hypoxia, and DNA damage via eEF2 regulation.  In vivo, in vitro, and clin. studies indicated that eEF2K may be a novel biomarker and therapeutic target for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3kybEFmecs7Vg90H21EOLACvtfcHk0limVkVk8evPkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Ohsr3L&md5=aafe80b35665d94527be0adc7fd3d1c0</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1007%2Fs12192-014-0545-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12192-014-0545-0%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DX.%26atitle%3DEukaryotic%2520elongation%2520factor%25202%2520kinase%2520confers%2520tolerance%2520to%2520stress%2520conditions%2520in%2520cancer%2520cells%26jtitle%3DCell%2520Stress%2520Chaperones%26date%3D2015%26volume%3D20%26issue%3D2%26spage%3D217%26epage%3D220%26doi%3D10.1007%2Fs12192-014-0545-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witwicki, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabassum, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiszewska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekram, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, K.</span></span> <span> </span><span class="NLM_article-title">Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>529</i></span> (<span class="NLM_issue">7586</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1038/nature16508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fnature16508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26735014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1Gmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=413-417&issue=7586&author=S.+Shuauthor=C.+Y.+Linauthor=H.+H.+Heauthor=R.+M.+Witwickiauthor=D.+P.+Tabassumauthor=J.+M.+Robertsauthor=M.+Janiszewskaauthor=S.+J.+Huhauthor=Y.+Liangauthor=J.+Ryanauthor=E.+Dohertyauthor=H.+Mohammedauthor=H.+Guoauthor=D.+G.+Stoverauthor=M.+B.+Ekramauthor=J.+Brownauthor=C.+D%E2%80%99Santosauthor=I.+E.+Kropauthor=D.+Dillonauthor=M.+McKeownauthor=C.+Ottauthor=J.+Qiauthor=M.+Niauthor=P.+K.+Raoauthor=M.+Duarteauthor=S.+Y.+Wuauthor=C.+M.+Chiangauthor=L.+Andersauthor=R.+A.+Youngauthor=E.+Winerauthor=A.+Letaiauthor=W.+T.+Barryauthor=J.+S.+Carrollauthor=H.+Longauthor=M.+Brownauthor=X.+S.+Liuauthor=C.+A.+Meyerauthor=J.+E.+Bradnerauthor=K.+Polyak&title=Response+and+resistance+to+BET+bromodomain+inhibitors+in+triple-negative+breast+cancer&doi=10.1038%2Fnature16508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer</span></div><div class="casAuthors">Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Tabassum, Doris P.; Roberts, Justin M.; Janiszewska, Michalina; Huh, Sung Jin; Liang, Yi; Ryan, Jeremy; Doherty, Ernest; Mohammed, Hisham; Guo, Hao; Stover, Daniel G.; Ekram, Muhammad B.; Peluffo, Guillermo; Brown, Jonathan; D'Santos, Clive; Krop, Ian E.; Dillon, Deborah; McKeown, Michael; Ott, Christopher; Qi, Jun; Ni, Min; Rao, Prakash K.; Duarte, Melissa; Wu, Shwu-Yuan; Chiang, Cheng-Ming; Anders, Lars; Young, Richard A.; Winer, Eric P.; Letai, Antony; Barry, William T.; Carroll, Jason S.; Long, Henry W.; Brown, Myles; Shirley Liu, X.; Meyer, Clifford A.; Bradner, James E.; Polyak, Kornelia</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">413-417</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a heterogeneous and clin. aggressive disease for which there is no targeted therapy.  BET bromodomain inhibitors, which have shown efficacy in several models of cancer, have not been evaluated in TNBC.  These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs.  Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clin. investigation and further motivation to understand mechanisms of resistance.  In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation.  BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner.  Proteomic studies of resistant TNBC identify strong assocn. with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase.  Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clin. drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZu5A85pdQDbVg90H21EOLACvtfcHk0liYq4XtTV1gBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1Gmtw%253D%253D&md5=50a03861d9156ee6e344e95c5f5361b9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnature16508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16508%26sid%3Dliteratum%253Aachs%26aulast%3DShu%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DHe%26aufirst%3DH.%2BH.%26aulast%3DWitwicki%26aufirst%3DR.%2BM.%26aulast%3DTabassum%26aufirst%3DD.%2BP.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DJaniszewska%26aufirst%3DM.%26aulast%3DHuh%26aufirst%3DS.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DRyan%26aufirst%3DJ.%26aulast%3DDoherty%26aufirst%3DE.%26aulast%3DMohammed%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DEkram%26aufirst%3DM.%2BB.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Santos%26aufirst%3DC.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DDillon%26aufirst%3DD.%26aulast%3DMcKeown%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DP.%2BK.%26aulast%3DDuarte%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DChiang%26aufirst%3DC.%2BM.%26aulast%3DAnders%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWiner%26aufirst%3DE.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DBarry%26aufirst%3DW.%2BT.%26aulast%3DCarroll%26aufirst%3DJ.%2BS.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DMeyer%26aufirst%3DC.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DPolyak%26aufirst%3DK.%26atitle%3DResponse%2520and%2520resistance%2520to%2520BET%2520bromodomain%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DNature%26date%3D2016%26volume%3D529%26issue%3D7586%26spage%3D413%26epage%3D417%26doi%3D10.1038%2Fnature16508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrieu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strissel, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, G. V.</span></span> <span> </span><span class="NLM_article-title">BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6555</span>– <span class="NLM_lpage">6567</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-0559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-16-0559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27651315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCjt73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=6555-6567&issue=22&author=G.+Andrieuauthor=A.+H.+Tranauthor=K.+J.+Strisselauthor=G.+V.+Denis&title=BRD4+Regulates+Breast+Cancer+Dissemination+through+Jagged1%2FNotch1+Signaling&doi=10.1158%2F0008-5472.CAN-16-0559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling</span></div><div class="casAuthors">Andrieu, Guillaume; Tran, Anna H.; Strissel, Katherine J.; Denis, Gerald V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6555-6567</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The bromodomain and extraterminal (BET) proteins are epigenetic "readers" of acetylated histones in chromatin and have been identified as promising therapeutic targets in diverse cancers.  However, it remains unclear how individual family members participate in cancer progression and small mol. inhibitors such as JQ1 can target functionally independent BET proteins.  Here, we report a signaling pathway involving BRD4 and the ligand/receptor pair Jagged1/Notch1 that sustains triple-neg. breast cancer migration and invasion.  BRD4, but not BRD2 or BRD3, regulated Jagged1 expression and Notch1 signaling.  BRD4-selective knockdown suppressed Notch1 activity and impeded breast cancer migration and invasion.  BRD4 was required for IL6-stimulated, Notch1-induced migration and invasion, coupling microenvironment inflammation with cancer propagation.  Moreover, in patients, BRD4 and Jagged1 expression pos. correlated with the presence of distant metastases.  These results identify a BRD4/Jagged1/Notch1 signaling pathway that is crit. for dissemination of triple-neg. breast cancer.  Cancer Res; 76(22); 6555-67. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Mrq6xjdRILVg90H21EOLACvtfcHk0liYq4XtTV1gBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCjt73F&md5=319d1cd2436dbf65cc2ef00732aa26f7</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-0559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-0559%26sid%3Dliteratum%253Aachs%26aulast%3DAndrieu%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DA.%2BH.%26aulast%3DStrissel%26aufirst%3DK.%2BJ.%26aulast%3DDenis%26aufirst%3DG.%2BV.%26atitle%3DBRD4%2520Regulates%2520Breast%2520Cancer%2520Dissemination%2520through%2520Jagged1%252FNotch1%2520Signaling%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D22%26spage%3D6555%26epage%3D6567%26doi%3D10.1158%2F0008-5472.CAN-16-0559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span> <span> </span><span class="NLM_article-title">Integrating multiple omics data for the discovery of potential Beclin-1 interactions in breast cancer</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">999</span>, <span class="refDoi"> DOI: 10.1039/C6MB00653A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1039%2FC6MB00653A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28401970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Khsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=991-999&issue=5&author=Y.+Chenauthor=X.+Wangauthor=G.+Wangauthor=Z.+Liauthor=J.+Wangauthor=L.+Huangauthor=Z.+Qinauthor=X.+Yuanauthor=Z.+Chengauthor=S.+Zhangauthor=Y.+Yinauthor=J.+He&title=Integrating+multiple+omics+data+for+the+discovery+of+potential+Beclin-1+interactions+in+breast+cancer&doi=10.1039%2FC6MB00653A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating multiple omics data for the discovery of potential Beclin-1 interactions in breast cancer</span></div><div class="casAuthors">Chen, Yi; Wang, Xuan; Wang, Guan; Li, Zhaozhi; Wang, Jinjin; Huang, Lingyu; Qin, Ziyi; Yuan, Xiang; Cheng, Zhong; Zhang, Shu; Yin, Yiqiong; He, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">991-999</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Breast cancer has been reported as one of the most frequently diagnosed malignant diseases and the leading cause of cancer death in women all around the world.  Furthermore, this complicated cancer is divided into multiple subtypes which present different clin. symptoms and need correspondingly directed therapy.  We took BECN1, a core gene in autophagy performing a tumor inhibitory effect, as a starting point.  The study in this paper aims to identify genes related to breast cancer and its multiple subtypes by integrating multiple omics data using the least abs. shrinkage and selection operator (LASSO), which is a statistical method that can integrate more than two types of omics data.  All the data is obtained from The Cancer Genome Atlas (TCGA) platform which stores clin. and mol. tumor data.  The model constructed is based on three kinds of data including mRNA-gene expression with a dependent variable level, DNA methylation and copy no. alterations as independent variables.  Finally, we propose four subnets of four subtypes of breast cancer, and consider as a result of microarray anal. that AFF3 is assocd. with BECN1 in breast cancer, and may be a potential therapeutic target.  This finding may provide some potential targeted therapeutics for the four different subtypes of breast cancer at the genetic level.  In conclusion, finding out the major role Beclin-1 plays in breast cancer subtypes is of great value.  The results obtained are instructive for further research and may provide excellent results in clin. applications, as well as testing in animal expts., and may also indicate a new method to perform bioinformatics anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGQ8V8nTMe-LVg90H21EOLACvtfcHk0liYq4XtTV1gBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Khsrk%253D&md5=70431f1b7ef1e624bb231a66bf30e532</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2FC6MB00653A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MB00653A%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26atitle%3DIntegrating%2520multiple%2520omics%2520data%2520for%2520the%2520discovery%2520of%2520potential%2520Beclin-1%2520interactions%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520BioSyst.%26date%3D2017%26volume%3D13%26issue%3D5%26spage%3D991%26epage%3D999%26doi%3D10.1039%2FC6MB00653A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of benzimidazole derivatives as the G9a histone methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2017.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.bioorg.2017.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28460359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFCjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2017&pages=168-181&author=J.+Zhangauthor=D.+Yaoauthor=Y.+Jiangauthor=J.+Huangauthor=S.+Yangauthor=J.+Wang&title=Synthesis+and+biological+evaluation+of+benzimidazole+derivatives+as+the+G9a+histone+methyltransferase+inhibitors+that+induce+autophagy+and+apoptosis+of+breast+cancer+cells&doi=10.1016%2Fj.bioorg.2017.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells</span></div><div class="casAuthors">Zhang, Jin; Yao, Dahong; Jiang, Yingnan; Huang, Jian; Yang, Shilin; Wang, Jinhui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">168-181</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G9a (also known as KMT1C or EHMT2) is initially identified as a H3K9 methyltransferase that specifically mono- and dimethylates 'Lys 9' of histone H3 (H3K9me1 and H3K9me2, resp.) in euchromatin.  It is overexpressed in various human cancers and employed as a promising target in cancer therapy.  The authors discovered a benzoxazole scaffold through virtual high-throughput screening, and designed, synthesized 24 derivs. and investigated for inhibition of G9a.  After several rounds of kinase and anti-proliferative activity screening, the authors discovered a potent G9a antagonist (GA001) with an IC50 value of 1.32 μM that could induce autophagy via AMPK in MCF7 cells.  In addn., the authors found high concn. of GA001 could induce apoptosis via p21-Bim signal cascades in MCF7 cells.  The authors' results highlight a new approach for the development of a novel drug targeting G9a with a potential to induce autophagy and apoptosis for future breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvEhWsr0H7QbVg90H21EOLACvtfcHk0lg71-TUamD6xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFCjur4%253D&md5=1a8ffbf3cf110bbee8cc01bf80cb853d</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2017.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2017.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520benzimidazole%2520derivatives%2520as%2520the%2520G9a%2520histone%2520methyltransferase%2520inhibitors%2520that%2520induce%2520autophagy%2520and%2520apoptosis%2520of%2520breast%2520cancer%2520cells%26jtitle%3DBioorg.%2520Chem.%26date%3D2017%26volume%3D72%26spage%3D168%26epage%3D181%26doi%3D10.1016%2Fj.bioorg.2017.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1002/med.21398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fmed.21398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27357603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ltVamsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=983-1035&issue=6&author=B.+Keauthor=M.+Tianauthor=J.+Liauthor=B.+Liuauthor=G.+He&title=Targeting+programmed+cell+death+using+small-molecule+compounds+to+improve+potential+cancer+therapy&doi=10.1002%2Fmed.21398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy</span></div><div class="casAuthors">Ke Bowen; Tian Mao; Li Jingjing; Liu Bo; He Gu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">983-1035</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Evasion of cell death is one of the hallmarks of cancer cells, beginning with long-established apoptosis and extending to other new forms of cell death.  An elaboration of cell death pathways thus will contribute to a better understanding of cancer pathogenesis and therapeutics.  With the recent substantial biochemical and genetic explorations of cell death subroutines, their classification has switched from primarily morphological to more molecular definitions.  According to their measurable biochemical features and intricate mechanisms, cell death subroutines can be divided into apoptosis, autophagic cell death, mitotic catastrophe, necroptosis, parthanatos, ferroptosis, pyroptosis, pyronecrosis, anoikis, cornification, entosis, and NETosis.  Supportive evidence has gradually revealed the prime molecular mechanisms of each subroutine and thus providing series of possible targets in cancer therapy, while the intricate relationships between different cell death subroutines still remain to be clarified.  Over the past decades, cancer drug discovery has significantly benefited from the use of small-molecule compounds to target classical modalities of cell death such as apoptosis, while newly identified cell death subroutines has also emerging their potential for cancer drug discovery in recent years.  In this review, we comprehensively focus on summarizing 12 cell death subroutines and discussing their corresponding small-molecule compounds in potential cancer therapy.  Together, these inspiring findings may provide more evidence to fill in the gaps between cell death subroutines and small-molecule compounds to better develop novel cancer therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhPsvIEAjUsGBAiYWy6n3SfW6udTcc2eaIik-GcepLfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ltVamsA%253D%253D&md5=3fc5de00cb2c9a65b378d0358dfd3f5e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fmed.21398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21398%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DB.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DTargeting%2520programmed%2520cell%2520death%2520using%2520small-molecule%2520compounds%2520to%2520improve%2520potential%2520cancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2016%26volume%3D36%26issue%3D6%26spage%3D983%26epage%3D1035%26doi%3D10.1002%2Fmed.21398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Targeting autophagy-related protein kinases for potential therapeutic purpose</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2019.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.apsb.2019.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32322463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnslWjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=569-581&author=H.+Xiangauthor=J.+Zhangauthor=C.+Linauthor=L.+Zhangauthor=B.+Liuauthor=L.+Ouyang&title=Targeting+autophagy-related+protein+kinases+for+potential+therapeutic+purpose&doi=10.1016%2Fj.apsb.2019.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting autophagy-related protein kinases for potential therapeutic purpose</span></div><div class="casAuthors">Xiang, Honggang; Zhang, Jifa; Lin, Congcong; Zhang, Lan; Liu, Bo; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">569-581</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Autophagy, defined as a scavenging process of protein aggregates and damaged organelles mediated by lysosomes, plays a significant role in the quality control of macromols. and organelles.  Since protein kinases are integral to the autophagy process, it is critically important to understand the role of kinases in autophagic regulation.  At present, intervention of autophagic processes by small-mol. modulators targeting specific kinases has becoming a reasonable and prevalent strategy for treating several varieties of human disease, esp. cancer.  In this review, we describe the role of some autophagy-related kinase targets and kinase-mediated phosphorylation mechanisms in autophagy regulation.  We also summarize the small-mol. kinase inhibitors/activators of these targets, high-lighting the opportunities of these new therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUZ5eGWVZ5RbVg90H21EOLACvtfcHk0lg71-TUamD6xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnslWjug%253D%253D&md5=277da77a9145fb63c521c5babf333e9b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DTargeting%2520autophagy-related%2520protein%2520kinases%2520for%2520potential%2520therapeutic%2520purpose%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D569%26epage%3D581%26doi%3D10.1016%2Fj.apsb.2019.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, G.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2019.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30742942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1Clsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2019&pages=94-104&author=Q.+Heauthor=S.+Xueauthor=Y.+Tanauthor=L.+Zhangauthor=Q.+Shaoauthor=L.+Xingauthor=Y.+Liauthor=T.+Xiangauthor=X.+Luoauthor=G.+Ren&title=Dual+inhibition+of+Akt+and+ERK+signaling+induces+cell+senescence+in+triple-negative+breast+cancer&doi=10.1016%2Fj.canlet.2019.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer</span></div><div class="casAuthors">He, Qiang; Xue, Shuyin; Tan, Yiqing; Zhang, Ling; Shao, Qing; Xing, Lei; Li, Yunhai; Xiang, Tingxiu; Luo, Xinrong; Ren, Guosheng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-104</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activated Akt and ERK signaling pathways are closely related to breast cancer progression, and Akt or ERK inhibition induces cell senescence.  However, the crosstalk between the Akt and ERK signaling pathways in cell senescence and how to simultaneously suppress Akt and ERK signaling in triple-neg. breast cancer (TNBC) are undefined.  In this study, we found that norcantharidin (NCTD) effectively induced cell senescence and cell cycle arrest in TNBC in vitro, which was accompanied by a decline in phosphorylated Akt and ERK1/2 and a rise in p21 and p16.  The inhibitors LY294002 and U0126 imitated the effect of NCTD when these two inhibitors were combined regardless of crosstalk between these two signaling pathways.  In addn., NCTD inhibited the growth of xenografts via downregulation of phosphorylated Akt and ERK1/2 and upregulation of p21 in vivo.  However, NCTD upregulated the level of sol. signaling factors of the senescence-assocd. secretory phenotype (SASP) in a NF-κB-independent manner.  Collectively, these findings demonstrate that NCTD induced cell senescence and cell cycle arrest mainly by simultaneously blocking Akt and ERK signaling in TNBC, suggesting that NCTD may be used as a potential adjuvant therapy in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCyKsXlTOVZLVg90H21EOLACvtfcHk0lg71-TUamD6xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1Clsbo%253D&md5=22793342d13431bd800588b9ec09545c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DXue%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DQ.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DT.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DG.%26atitle%3DDual%2520inhibition%2520of%2520Akt%2520and%2520ERK%2520signaling%2520induces%2520cell%2520senescence%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2019%26volume%3D448%26spage%3D94%26epage%3D104%26doi%3D10.1016%2Fj.canlet.2019.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ejmech.2016.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27839788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=997-1011&author=Y.+Chenauthor=Y.+Zhengauthor=Q.+Jiangauthor=F.+Qinauthor=Y.+Zhangauthor=L.+Fuauthor=G.+He&title=Integrated+bioinformatics%2C+computational+and+experimental+methods+to+discover+novel+Raf%2Fextracellular-signal+regulated+kinase+%28ERK%29+dual+inhibitors+against+breast+cancer+cells&doi=10.1016%2Fj.ejmech.2016.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells</span></div><div class="casAuthors">Chen, Yin; Zheng, Yaxin; Jiang, Qinglin; Qin, Feifei; Zhang, Yonghui; Fu, Leilei; He, Gu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">997-1011</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Beginning with our previously reported ERK inhibitor BL-EI001, we found Raf1 to be an important regulator in the ERK interactive network, and then we designed and synthesized a novel series of Raf1/ERK dual inhibitors against human breast cancers through integrative computational, synthetic and biol. screening methods.  Moreover, we found that compd. 9d suppressed the proliferation of breast cancer cell lines and induced cellular apoptosis via a mitochondrial pathway with only partial dependence on Raf1 and ERK.  Our results suggest that an integrative method including in silico design, chem. synthesis, biol. screening and bioinformatics anal. could be an attractive strategy for the discovery of multi-target inhibitors against breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMI2OafaPJvbVg90H21EOLACvtfcHk0liO97dIP_2poQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCitr3P&md5=23515e24b2f67b319f99fc28ab6c617a</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DQin%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DIntegrated%2520bioinformatics%252C%2520computational%2520and%2520experimental%2520methods%2520to%2520discover%2520novel%2520Raf%252Fextracellular-signal%2520regulated%2520kinase%2520%2528ERK%2529%2520dual%2520inhibitors%2520against%2520breast%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D997%26epage%3D1011%26doi%3D10.1016%2Fj.ejmech.2016.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenney, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niepel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivakumaren, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yapp, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorger, P. K.</span></span> <span> </span><span class="NLM_article-title">Torin2 exploits replication and checkpoint vulnerabilities to cause death of PI3K-activated triple-negative breast cancer cells</span>. <i>Cell Syst.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.cels.2019.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.cels.2019.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31812693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFeiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=66-81&issue=1&author=S.+S.+Chopraauthor=A.+Jenneyauthor=A.+Palmerauthor=M.+Niepelauthor=M.+Chungauthor=C.+Millsauthor=S.+C.+Sivakumarenauthor=Q.+Liuauthor=J.-Y.+Chenauthor=C.+Yappauthor=J.+M.+Asaraauthor=N.+S.+Grayauthor=P.+K.+Sorger&title=Torin2+exploits+replication+and+checkpoint+vulnerabilities+to+cause+death+of+PI3K-activated+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.cels.2019.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells</span></div><div class="casAuthors">Chopra, Sameer S.; Jenney, Anne; Palmer, Adam; Niepel, Mario; Chung, Mirra; Mills, Caitlin; Sivakumaren, Sindhu Carmen; Liu, Qingsong; Chen, Jia-Yun; Yapp, Clarence; Asara, John M.; Gray, Nathanael S.; Sorger, Peter K.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Systems</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-81.e11</span>CODEN:
                <span class="NLM_cas:coden">CSEYA4</span>;
        ISSN:<span class="NLM_cas:issn">2405-4712</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clin. successes are rare.  As a result, many cancers with high PI3K pathway activity, such as triple-neg. breast cancer (TNBC), are treated primarily with chemotherapy.  By systematically analyzing responses of TNBC cells to a diverse collection of PI3K pathway inhibitors, we find that one drug, Torin2, is unusually effective because it inhibits both mTOR and other PI3K-like kinases (PIKKs).  In contrast to mTOR-selective inhibitors, Torin2 exploits dependencies on several kinases for S-phase progression and cell-cycle checkpoints, thereby causing accumulation of single-stranded DNA and death by replication catastrophe or mitotic failure.  Thus, Torin2 and its chem. analogs represent a mechanistically distinct class of PI3K pathway inhibitors that are uniquely cytotoxic to TNBC cells.  This insight could be translated therapeutically by further developing Torin2 analogs or combinations of existing mTOR and PIKK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEVxEZJ8wcgrVg90H21EOLACvtfcHk0liO97dIP_2poQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFeiu78%253D&md5=5137380fdfa6a7c45d531b70de377b42</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.cels.2019.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cels.2019.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DChopra%26aufirst%3DS.%2BS.%26aulast%3DJenney%26aufirst%3DA.%26aulast%3DPalmer%26aufirst%3DA.%26aulast%3DNiepel%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DSivakumaren%26aufirst%3DS.%2BC.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DJ.-Y.%26aulast%3DYapp%26aufirst%3DC.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSorger%26aufirst%3DP.%2BK.%26atitle%3DTorin2%2520exploits%2520replication%2520and%2520checkpoint%2520vulnerabilities%2520to%2520cause%2520death%2520of%2520PI3K-activated%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DCell%2520Syst.%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D66%26epage%3D81%26doi%3D10.1016%2Fj.cels.2019.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, T. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohoon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillanders, W. E.</span></span> <span> </span><span class="NLM_article-title">Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5411</span>– <span class="NLM_lpage">5423</span>, <span class="refDoi"> DOI: 10.1172/JCI75661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1172%2FJCI75661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25365225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2M3lt1artg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=5411-5423&issue=12&author=T.+U.+Barbieauthor=G.+Alexeauthor=A.+R.+Arefauthor=S.+Liauthor=Z.+Zhuauthor=X.+Zhangauthor=Y.+Imamuraauthor=T.+C.+Thaiauthor=Y.+Huangauthor=M.+Bowdenauthor=J.+Herndonauthor=T.+J.+Cohoonauthor=T.+Flemingauthor=P.+Tamayoauthor=J.+P.+Mesirovauthor=S.+Oginoauthor=K.+K.+Wongauthor=M.+J.+Ellisauthor=W.+C.+Hahnauthor=D.+A.+Barbieauthor=W.+E.+Gillanders&title=Targeting+an+IKBKE+cytokine+network+impairs+triple-negative+breast+cancer+growth&doi=10.1172%2FJCI75661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth</span></div><div class="casAuthors">Barbie Thanh U; Alexe Gabriela; Aref Amir R; Li Shunqiang; Zhu Zehua; Zhang Xiuli; Imamura Yu; Thai Tran C; Huang Ying; Bowden Michaela; Herndon John; Cohoon Travis J; Fleming Timothy; Tamayo Pablo; Mesirov Jill P; Ogino Shuji; Wong Kwok-Kin; Ellis Matthew J; Hahn William C; Barbie David A; Gillanders William E</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5411-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancers (TNBCs) are a heterogeneous set of cancers that are defined by the absence of hormone receptor expression and HER2 amplification.  Here, we found that inducible IκB kinase-related (IKK-related) kinase IKBKE expression and JAK/STAT pathway activation compose a cytokine signaling network in the immune-activated subset of TNBC.  We found that treatment of cultured IKBKE-driven breast cancer cells with CYT387, a potent inhibitor of TBK1/IKBKE and JAK signaling, impairs proliferation, while inhibition of JAK alone does not.  CYT387 treatment inhibited activation of both NF-κB and STAT and disrupted expression of the protumorigenic cytokines CCL5 and IL-6 in these IKBKE-driven breast cancer cells.  Moreover, in 3D culture models, the addition of CCL5 and IL-6 to the media not only promoted tumor spheroid dispersal but also stimulated proliferation and migration of endothelial cells.  Interruption of cytokine signaling by CYT387 in vivo impaired the growth of an IKBKE-driven TNBC cell line and patient-derived xenografts (PDXs).  A combination of CYT387 therapy with a MEK inhibitor was particularly effective, abrogating tumor growth and angiogenesis in an aggressive PDX model of TNBC.  Together, these findings reveal that IKBKE-associated cytokine signaling promotes tumorigenicity of immune-driven TNBC and identify a potential therapeutic strategy using clinically available compounds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1IkpC-K_EokBuFdjgVNKSfW6udTcc2eZVSxnXhG-1Ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3lt1artg%253D%253D&md5=064d796c65d142b84f5c72c7330c5ea6</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1172%2FJCI75661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI75661%26sid%3Dliteratum%253Aachs%26aulast%3DBarbie%26aufirst%3DT.%2BU.%26aulast%3DAlexe%26aufirst%3DG.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DImamura%26aufirst%3DY.%26aulast%3DThai%26aufirst%3DT.%2BC.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DBowden%26aufirst%3DM.%26aulast%3DHerndon%26aufirst%3DJ.%26aulast%3DCohoon%26aufirst%3DT.%2BJ.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DMesirov%26aufirst%3DJ.%2BP.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DGillanders%26aufirst%3DW.%2BE.%26atitle%3DTargeting%2520an%2520IKBKE%2520cytokine%2520network%2520impairs%2520triple-negative%2520breast%2520cancer%2520growth%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26issue%3D12%26spage%3D5411%26epage%3D5423%26doi%3D10.1172%2FJCI75661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of a novel orally available SRC/Raf/VEGFR2 inhibitor, SKLB646, in the treatment of triple-negative breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-15-0501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26721945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCmsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=366-378&issue=3&author=M.+W.+Zhengauthor=C.+H.+Zhangauthor=K.+Chenauthor=M.+Huangauthor=Y.+P.+Liauthor=W.+T.+Linauthor=R.+J.+Zhangauthor=L.+Zhongauthor=R.+Xiangauthor=L.+L.+Liauthor=X.+Y.+Liuauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Preclinical+evaluation+of+a+novel+orally+available+SRC%2FRaf%2FVEGFR2+inhibitor%2C+SKLB646%2C+in+the+treatment+of+triple-negative+breast+cancer&doi=10.1158%2F1535-7163.MCT-15-0501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Zheng, Ming-Wu; Zhang, Chun-Hui; Chen, Kai; Huang, Mei; Li, Ya-Ping; Lin, Wan-Ting; Zhang, Rong-Jie; Zhong, Lei; Xiang, Rong; Li, Lin-Li; Liu, Xin-Yu; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">366-378</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most aggressive and deadly breast cancer subtype.  To date, chemotherapy is the only systemic therapy and prognosis remains poor.  Herein, we report the preclin. evaluation of SKLB646 in the treatment of TNBC; SKLB646 is a novel multiple kinase inhibitor developed by us recently.  This compd. potently inhibited SRC and VEGFR2 with IC50 values of 0.002 μmol/L and 0.012 μmol/L, resp.  It also considerably inhibited B-Raf and C-Raf with IC50 values of 0.022 and 0.019 μmol/L, resp.  It exhibited significant antiproliferation and antiviability activities against TNBC cell lines.  Studies of mechanism of action indicated that SKLB646 inhibited the activation of SRC signaling and blocked the MAPK signaling through inhibiting the Raf kinases.  Interestingly, SKLB646 dose dependently downregulated the expression of Fra1, a transcriptional factor that plays a crit. role in the epithelial-to-mesenchymal transition.  In addn., SKLB646 could inhibit HUVEC proliferation, migration, and invasion.  It effectively blocked the formation of intersegmental vessels in zebrafish embryos and displayed considerable antiangiogenic effects in the tumor-induced neovascularization zebrafish model.  In TNBC xenograft models, SKLB646 suppressed the tumor growth in a dose-dependent manner.  Moreover, SKLB646 could remarkably inhibit TNBC cell migration and invasion in vitro.  Furthermore, in an exptl. lung metastasis model, the overall survival time of groups treated with SKLB646 was much longer compared with the control-, dasatinib-, and paclitaxel-treated groups.  In a preliminary pharmacokinetic study, SKLB646 showed good pharmacokinetic properties.  Taken together, the preclin. data show that SKLB646 could be a promising lead compd. for the treatment of TNBC.  Mol Cancer Ther; 15(3); 366-78. 2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodSEWSFArBprVg90H21EOLACvtfcHk0lj0npmSG1uTcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCmsL8%253D&md5=5503431d68d044995a94faa8948f27ba</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0501%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DM.%2BW.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%2BP.%26aulast%3DLin%26aufirst%3DW.%2BT.%26aulast%3DZhang%26aufirst%3DR.%2BJ.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DPreclinical%2520evaluation%2520of%2520a%2520novel%2520orally%2520available%2520SRC%252FRaf%252FVEGFR2%2520inhibitor%252C%2520SKLB646%252C%2520in%2520the%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D3%26spage%3D366%26epage%3D378%26doi%3D10.1158%2F1535-7163.MCT-15-0501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phadke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachacz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziubinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwarcinski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidwell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merajver, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M.</span></span> <span> </span><span class="NLM_article-title">In vivoretraction: UM-164: A potent c-Src/p38 kinase inhibitor with activity against triple-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1777</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-20-0653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-20-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32238414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB38zgtVCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=1777&issue=7&author=R.+Gilaniauthor=S.+Phadkeauthor=L.+Baoauthor=E.+Lachaczauthor=M.+Dziubinskiauthor=K.+Brandvoldauthor=M.+Steffeyauthor=F.+Kwarcinskiauthor=C.+Graveelauthor=K.+Kidwellauthor=S.+Merajverauthor=M.+Soellner&title=In+vivoretraction%3A+UM-164%3A+A+potent+c-Src%2Fp38+kinase+inhibitor+with+activity+against+triple-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-20-0653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Retraction: UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer</span></div><div class="casAuthors">Gilani Rabia A; Phadke Sameer; Bao Li Wei; Lachacz Eric J; Dziubinski Michele L; Brandvold Kristoffer R; Steffey Michael E; Kwarcinski Frank E; Graveel Carrie R; Kidwell Kelley M; Merajver Sofia D; Soellner Matthew B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1777</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSV37Rg-SVp0WPgL4LrC-0VfW6udTcc2ebv6rJe3yFIg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zgtVCltQ%253D%253D&md5=86237cdc504a8d60506d61b53bed3dc8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-20-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-20-0653%26sid%3Dliteratum%253Aachs%26aulast%3DGilani%26aufirst%3DR.%26aulast%3DPhadke%26aufirst%3DS.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DLachacz%26aufirst%3DE.%26aulast%3DDziubinski%26aufirst%3DM.%26aulast%3DBrandvold%26aufirst%3DK.%26aulast%3DSteffey%26aufirst%3DM.%26aulast%3DKwarcinski%26aufirst%3DF.%26aulast%3DGraveel%26aufirst%3DC.%26aulast%3DKidwell%26aufirst%3DK.%26aulast%3DMerajver%26aufirst%3DS.%26aulast%3DSoellner%26aufirst%3DM.%26atitle%3DIn%2520vivoretraction%253A%2520UM-164%253A%2520A%2520potent%2520c-Src%252Fp38%2520kinase%2520inhibitor%2520with%2520activity%2520against%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26issue%3D7%26spage%3D1777%26doi%3D10.1158%2F1078-0432.CCR-20-0653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span> <span> </span><span class="NLM_article-title">From lead to drug candidate: optimization of 3-(phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as agents for the treatment of triple negative breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9788</span>– <span class="NLM_lpage">9805</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00943</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00943" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9788-9805&issue=21&author=C.+H.+Zhangauthor=K.+Chenauthor=Y.+Jiaoauthor=L.+L.+Liauthor=Y.+P.+Liauthor=R.+J.+Zhangauthor=M.+W.+Zhengauthor=L.+Zhongauthor=S.+Z.+Huangauthor=C.+L.+Songauthor=W.+T.+Linauthor=J.+Yangauthor=R.+Xiangauthor=B.+Pengauthor=J.+H.+Hanauthor=G.+W.+Luauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=From+lead+to+drug+candidate%3A+optimization+of+3-%28phenylethynyl%29-1h-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-amine+derivatives+as+agents+for+the+treatment+of+triple+negative+breast+cancer&doi=10.1021%2Facs.jmedchem.6b00943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer</span></div><div class="casAuthors">Zhang, Chun-Hui; Chen, Kai; Jiao, Yan; Li, Lin-Li; Li, Ya-Ping; Zhang, Rong-Jie; Zheng, Ming-Wu; Zhong, Lei; Huang, Shen-Zhen; Song, Chun-Li; Lin, Wan-Ting; Yang, Jiao; Xiang, Rong; Peng, Bing; Han, Jun-Hong; Lu, Guang-Wen; Wei, Yu-Quan; Yang, Sheng-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9788-9805</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compd. I, which showed high potency in the treatment of triple neg. breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity.  A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivs. were synthesized.  In vitro cell-based phenotypic screening together with in vivo assays and structure-activity relationship (SAR) studies finally led to the discovery of N-(3-((4-amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (II). II is a multikinase inhibitor, which potently inhibited Src (IC50 = 0.003 μM), KDR (IC50 = 0.032 μM), and several kinases involved in the MAPK signal transduction.  This compd. showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity.  Mechanisms of action of anti-TNBC were also investigated.  Collectively, the data obtained in this study indicate that II could be a promising drug candidate for the treatment of TNBC and hence merits further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGfeoJEAklBLVg90H21EOLACvtfcHk0liYMiUTIO-y_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks7vL&md5=074c0b21b8f61237497d21254cb5e423</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00943%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DY.%2BP.%26aulast%3DZhang%26aufirst%3DR.%2BJ.%26aulast%3DZheng%26aufirst%3DM.%2BW.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DS.%2BZ.%26aulast%3DSong%26aufirst%3DC.%2BL.%26aulast%3DLin%26aufirst%3DW.%2BT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DJ.%2BH.%26aulast%3DLu%26aufirst%3DG.%2BW.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DFrom%2520lead%2520to%2520drug%2520candidate%253A%2520optimization%2520of%25203-%2528phenylethynyl%2529-1h-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2520derivatives%2520as%2520agents%2520for%2520the%2520treatment%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D21%26spage%3D9788%26epage%3D9805%26doi%3D10.1021%2Facs.jmedchem.6b00943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meslamani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K. l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M. M.</span></span> <span> </span><span class="NLM_article-title">Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">31</span>),  <span class="NLM_fpage">7949</span>– <span class="NLM_lpage">7954</span>, <span class="refDoi"> DOI: 10.1073/pnas.1720000115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1720000115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30012592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOmurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=7949-7954&issue=31&author=C.+Renauthor=G.+Zhangauthor=F.+Hanauthor=S.+Fuauthor=Y.+Caoauthor=F.+Zhangauthor=Q.+Zhangauthor=J.+Meslamaniauthor=Y.+Xuauthor=D.+Jiauthor=L.+Caoauthor=Q.+Zhouauthor=K.+l.+Cheungauthor=R.+Sharmaauthor=N.+Babaultauthor=Z.+Yiauthor=W.+Zhangauthor=M.+J.+Walshauthor=L.+Zengauthor=M.+M.+Zhou&title=Spatially+constrained+tandem+bromodomain+inhibition+bolsters+sustained+repression+of+BRD4+transcriptional+activity+for+TNBC+cell+growth&doi=10.1073%2Fpnas.1720000115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth</span></div><div class="casAuthors">Ren, Chunyan; Zhang, Guangtao; Han, Fangbin; Fu, Shibo; Cao, Yingdi; Zhang, Fan; Zhang, Qiang; Meslamani, Jamel; Xub, Yaoyao; Ji, Donglei; Cao, Lingling; Zhou, Qian; Cheung, Ka-Lung; Sharma, Rajal; Babault, Nicolas; Yic, Zhengzi; Zhang, Weijia; Walsh, Martin J.; Zeng, Lei; Zhou, Ming-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">7949-7954</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The importance of BET protein BRD4 in gene transcription is well recognized through the study of chem. modulation of its characteristic tandem bromodomain (BrD) binding to lysine-acetylated histones and transcription factors.  However, while monovalent inhibition of BRD4 by BET BrD inhibitors such as JQ1 blocks growth of hematopoietic cancers, it is much less effective generally in solid tumors.  Here, we report a thienodiazepine-based bivalent BrD inhibitor, MS645, that affords spatially constrained tandem BrD inhibition and consequently sustained repression of BRD4 transcriptional activity in blocking proliferation of solid-tumor cells including a panel of triple-neg. breast cancer (TNBC) cells.  MS645 blocks BRD4 binding to transcription enhancer/mediator proteins MED1 and YY1 with potency superior to monovalent BET inhibitors, resulting in down-regulation of proinflammatory cytokines and genes for cell-cycle control and DNA damage repair that are largely unaffected by monovalent BrD inhibition.  Our study suggests a therapeutic strategy to maximally control BRD4 activity for rapid growth of solid-tumor TNBC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrg_KdQUQCjbVg90H21EOLACvtfcHk0liYMiUTIO-y_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOmurrI&md5=7b0d3b8bc61ff57c100ac2bf875e8586</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1720000115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1720000115%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DMeslamani%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DD.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DCheung%26aufirst%3DK.%2Bl.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DBabault%26aufirst%3DN.%26aulast%3DYi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWalsh%26aufirst%3DM.%2BJ.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DM.%2BM.%26atitle%3DSpatially%2520constrained%2520tandem%2520bromodomain%2520inhibition%2520bolsters%2520sustained%2520repression%2520of%2520BRD4%2520transcriptional%2520activity%2520for%2520TNBC%2520cell%2520growth%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D31%26spage%3D7949%26epage%3D7954%26doi%3D10.1073%2Fpnas.1720000115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasi, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soon, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melcher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreich, M.</span></span> <span> </span><span class="NLM_article-title">The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">e113300</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0113300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0113300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25412417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2htrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e113300&issue=11&author=N.+K.+Sasiauthor=K.+Tiwariauthor=F.+F.+Soonauthor=D.+Bonteauthor=T.+Wangauthor=K.+Melcherauthor=H.+E.+Xuauthor=M.+Weinreich&title=The+potent+Cdc7-Dbf4+%28DDK%29+kinase+inhibitor+XL413+has+limited+activity+in+many+cancer+cell+lines+and+discovery+of+potential+new+DDK+inhibitor+scaffolds&doi=10.1371%2Fjournal.pone.0113300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds</span></div><div class="casAuthors">Sasi, Nanda Kumar; Tiwari, Kanchan; Soon, Fen-Fen; Bonte, Dorine; Wang, Tong; Melcher, Karsten; Xu, H. Eric; Weinreich, Michael</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e113300/1-e113300/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cdc7-Dbf4 kinase or DDK (Dbf4-dependent kinase) is required to initiate DNA replication by phosphorylating and activating the replicative Mcm2-7 DNA helicase.  DDK is overexpressed in many tumor cells and is an emerging chemotherapeutic target since DDK inhibition causes apoptosis of diverse cancer cell types but not of normal cells.  PHA-767491 and XL413 are among a no. of potent DDK inhibitors with low nanomolar IC50 values against the purified kinase.  Although XL413 is highly selective for DDK, its activity has not been extensively characterized on cell lines.  We measured anti-proliferative and apoptotic effects of XL413 on a panel of tumor cell lines compared to PHA-767491, whose activity is well characterized.  Both compds. were effective biochem. DDK inhibitors but surprisingly, their activities in cell lines were highly divergent.  Unlike PHA-767491, XL413 had significant anti-proliferative activity against only one of the ten cell lines tested.  Since XL413 did not effectively inhibit DDK in multiple cell lines, this compd. likely has limited bioavailability.  To identify potential leads for addnl. DDK inhibitors, we also tested the cross-reactivity of ∼400 known kinase inhibitors against DDK using a DDK thermal stability shift assay (TSA).  We identified 11 compds. that significantly stabilized DDK.  Several inhibited DDK with comparable potency to PHA-767491, including Chk1 and PKR kinase inhibitors, but had divergent chem. scaffolds from known DDK inhibitors.  Taken together, these data show that several well-known kinase inhibitors cross-react with DDK and also highlight the opportunity to design addnl. specific, biol. active DDK inhibitors for use as chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPt1UTrCoCKLVg90H21EOLACvtfcHk0liYMiUTIO-y_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2htrnN&md5=3bf109d9e597319c787a9f947667c021</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0113300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0113300%26sid%3Dliteratum%253Aachs%26aulast%3DSasi%26aufirst%3DN.%2BK.%26aulast%3DTiwari%26aufirst%3DK.%26aulast%3DSoon%26aufirst%3DF.%2BF.%26aulast%3DBonte%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DMelcher%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DH.%2BE.%26aulast%3DWeinreich%26aufirst%3DM.%26atitle%3DThe%2520potent%2520Cdc7-Dbf4%2520%2528DDK%2529%2520kinase%2520inhibitor%2520XL413%2520has%2520limited%2520activity%2520in%2520many%2520cancer%2520cell%2520lines%2520and%2520discovery%2520of%2520potential%2520new%2520DDK%2520inhibitor%2520scaffolds%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26issue%3D11%26spage%3De113300%26doi%3D10.1371%2Fjournal.pone.0113300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kothari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panayotopoulou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selitrennik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtrich, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lev, S.</span></span> <span> </span><span class="NLM_article-title">Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-1797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-16-1797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27793840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=86-99&issue=1&author=N.+Vermaauthor=A.+K.+Mullerauthor=C.+Kothariauthor=E.+Panayotopoulouauthor=A.+Kedanauthor=M.+Selitrennikauthor=G.+B.+Millsauthor=L.+K.+Nguyenauthor=S.+Shinauthor=T.+Karnauthor=U.+Holtrichauthor=S.+Lev&title=Targeting+of+PYK2+synergizes+with+EGFR+antagonists+in+basal-like+TNBC+and+circumvents+HER3-associated+resistance+via+the+NEDD4-NDRG1+axis&doi=10.1158%2F0008-5472.CAN-16-1797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis</span></div><div class="casAuthors">Verma, Nandini; Muller, Anna-Katharina; Kothari, Charu; Panayotopoulou, Effrosini; Kedan, Amir; Selitrennik, Michael; Mills, Gordon B.; Nguyen, Lan K.; Shin, Sungyoung; Karn, Thomas; Holtrich, Uwe; Lev, Sima</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-99</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly aggressive, heterogeneous disease with poor prognosis and no effective targeted therapies.  EGFR is highly expressed in basal-like TNBC and is considered as a potential therapeutic target.  However, EGFR targeting exerts only marginal clin. benefits, possibly due to activation of compensatory signaling pathways, which are frequently assocd. with HER3 upregulation.  Here we show that concomitant targeting of EGFR and the nonreceptor tyrosine kinases PYK2/FAK synergistically inhibits the proliferation of basal-like TNBC cells in vitro and attenuates tumor growth in a mouse xenograft model.  Dual targeting of EGFR and PYK2/FAK inhibited complementary key growth and survival pathways mediated by AKT, S6K, STAT3, and ERK1/2 activation.  PYK2 inhibition also abrogated HER3 upregulation in response to EGFR antagonists, thereby circumventing HER3-assocd. drug resistance.  Mechanistically, PYK2 inhibition facilitated the proteasomal degrdn. of HER3 while inducing upregulation of NDRG1 (N-myc downstream regulated 1 gene).  NDRG1 enhanced the interaction of HER3 with the ubiquitin ligase NEDD4, while PYK2, which interacts with NEDD4 and HER3, interfered with NEDD4-HER3 binding, suggesting that the PYK2-NDRG1-NEDD4 circuit has a crit. role in receptor degrdn., drug response, and resistance mechanism.  Our studies offer a preclin. proof of concept for a strategy of cotargeting the EGFR and PYK2/FAK kinases to improve TNBC therapy.  Cancer Res; 77(1); 86-99. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFyqnUMLlVh7Vg90H21EOLACvtfcHk0ljO1BNlgm-hsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSn&md5=aed20fd02e56aad146d254b81fedd96d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-1797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-1797%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DA.%2BK.%26aulast%3DKothari%26aufirst%3DC.%26aulast%3DPanayotopoulou%26aufirst%3DE.%26aulast%3DKedan%26aufirst%3DA.%26aulast%3DSelitrennik%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DNguyen%26aufirst%3DL.%2BK.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DKarn%26aufirst%3DT.%26aulast%3DHoltrich%26aufirst%3DU.%26aulast%3DLev%26aufirst%3DS.%26atitle%3DTargeting%2520of%2520PYK2%2520synergizes%2520with%2520EGFR%2520antagonists%2520in%2520basal-like%2520TNBC%2520and%2520circumvents%2520HER3-associated%2520resistance%2520via%2520the%2520NEDD4-NDRG1%2520axis%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D1%26spage%3D86%26epage%3D99%26doi%3D10.1158%2F0008-5472.CAN-16-1797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rayson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupichuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhesy-Thind, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellard, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prady, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludkovski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonomi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagerman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, P.</span></span> <span> </span><span class="NLM_article-title">Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1007/s10549-016-3812-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-016-3812-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27116183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XotF2lsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=109-116&issue=1&author=D.+Raysonauthor=S.+Lupichukauthor=K.+Potvinauthor=S.+Dentauthor=T.+Shenkierauthor=S.+Dhesy-Thindauthor=S.+L.+Ellardauthor=C.+Pradyauthor=M.+Salimauthor=P.+Farmerauthor=G.+Alloauthor=M.+S.+Tsaoauthor=A.+Allanauthor=O.+Ludkovskiauthor=M.+Bonomiauthor=D.+Tuauthor=L.+Hagermanauthor=R.+Goodwinauthor=E.+Eisenhauerauthor=P.+Bradbury&title=Canadian+Cancer+Trials+Group+IND197%3A+a+phase+II+study+of+foretinib+in+patients+with+estrogen+receptor%2C+progesterone+receptor%2C+and+human+epidermal+growth+factor+receptor+2-negative+recurrent+or+metastatic+breast+cancer&doi=10.1007%2Fs10549-016-3812-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer</span></div><div class="casAuthors">Rayson, Daniel; Lupichuk, Sasha; Potvin, Kylea; Dent, Susan; Shenkier, Tamara; Dhesy-Thind, Sukhbinder; Ellard, Susan L.; Prady, Catherine; Salim, Muhammad; Farmer, Patricia; Allo, Ghasson; Tsao, Ming-Sound; Allan, Alison; Ludkovski, Olga; Bonomi, Maria; Tu, Dongsheng; Hagerman, Linda; Goodwin, Rachel; Eisenhauer, Elizabeth; Bradbury, Penelope</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-116</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In murine models, overexpression of the MET receptor transgene induces tumors with human basal gene expression characteristics supporting MET inhibition as a treatment strategy for triple-neg. breast cancer (TNBC).  Foretinib is an oral multi-kinase inhibitor of MET, RON, AXL, TIE-2, and VEGF receptors with anti-tumor activity in advanced HCC and papillary renal cell cancer.  Patients with centrally reviewed primary TNBC and 0-1 prior regimens for metastatic disease received daily foretinib 60 mg po in a 2-stage single-arm trial.  Primary endpoints were objective response and early progression rates per RECIST 1.1.  In stage 2, correlative studies of MET, PTEN, EGFR, and p53 on archival and fresh tumor specimens were performed along with enumeration of CTCs. 45 patients were enrolled with 37 patients having response evaluable and centrally confirmed primary TNBC (cTNBC).  There were 2 partial responses (ITT 4.7 % response evaluable cTNBC 5.4 %) with a median duration of 4.4 mo (range 3.7-5 m) and 15 patients had stable disease (ITT 33 %, response evaluable cTNBC 40.5 %) with a median duration of 5.4 mo (range 2.3-9.7 m).  The most common toxicities (all grades/grade 3) were nausea (64/4 %), fatigue (60/4 %), hypertension (58/49 %), and diarrhea (40/7 %).  Six serious adverse events were considered possibly related to foretinib and 4 patients went off study due to adverse events.  There was no correlation between MET positivity and response nor between response and PTEN, EGFR, p53, or MET expression in CTCs.  Although CCTG IND 197 did not meet its primary endpoint, the observation of a clin. benefit rate of 46 % in this cTNBC population suggests that foretinib may have clin. activity as a single, non-cytotoxic agent in TNBC (ClinicalTrials.gov no., NCT01147484).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC4vs0yv27lLVg90H21EOLACvtfcHk0ljO1BNlgm-hsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotF2lsb0%253D&md5=011afe463c72f862f27e20f7649787e4</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs10549-016-3812-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-016-3812-1%26sid%3Dliteratum%253Aachs%26aulast%3DRayson%26aufirst%3DD.%26aulast%3DLupichuk%26aufirst%3DS.%26aulast%3DPotvin%26aufirst%3DK.%26aulast%3DDent%26aufirst%3DS.%26aulast%3DShenkier%26aufirst%3DT.%26aulast%3DDhesy-Thind%26aufirst%3DS.%26aulast%3DEllard%26aufirst%3DS.%2BL.%26aulast%3DPrady%26aufirst%3DC.%26aulast%3DSalim%26aufirst%3DM.%26aulast%3DFarmer%26aufirst%3DP.%26aulast%3DAllo%26aufirst%3DG.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26aulast%3DAllan%26aufirst%3DA.%26aulast%3DLudkovski%26aufirst%3DO.%26aulast%3DBonomi%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DHagerman%26aufirst%3DL.%26aulast%3DGoodwin%26aufirst%3DR.%26aulast%3DEisenhauer%26aufirst%3DE.%26aulast%3DBradbury%26aufirst%3DP.%26atitle%3DCanadian%2520Cancer%2520Trials%2520Group%2520IND197%253A%2520a%2520phase%2520II%2520study%2520of%2520foretinib%2520in%2520patients%2520with%2520estrogen%2520receptor%252C%2520progesterone%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-negative%2520recurrent%2520or%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2016%26volume%3D157%26issue%3D1%26spage%3D109%26epage%3D116%26doi%3D10.1007%2Fs10549-016-3812-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, T.</span></span> <span> </span><span class="NLM_article-title">Targeted therapies for triple-negative breast cancer</span>. <i>Curr. Treat Option On.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">82</span>, <span class="refDoi"> DOI: 10.1007/s11864-019-0682-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs11864-019-0682-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31754897" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=82&issue=11&author=T.+Lyons&title=Targeted+therapies+for+triple-negative+breast+cancer&doi=10.1007%2Fs11864-019-0682-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1007%2Fs11864-019-0682-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11864-019-0682-x%26sid%3Dliteratum%253Aachs%26aulast%3DLyons%26aufirst%3DT.%26atitle%3DTargeted%2520therapies%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DCurr.%2520Treat%2520Option%2520On.%26date%3D2019%26volume%3D20%26issue%3D11%26spage%3D82%26doi%3D10.1007%2Fs11864-019-0682-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. S.</span></span> <span> </span><span class="NLM_article-title">Medical uses of mylabris in ancient China and recent studies</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/0378-8741(89)90062-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2F0378-8741%2889%2990062-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=2689797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADyaK3cXptFSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1989&pages=147-162&issue=2&author=G.+S.+Wang&title=Medical+uses+of+mylabris+in+ancient+China+and+recent+studies&doi=10.1016%2F0378-8741%2889%2990062-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Medical uses of Mylabris in ancient China and recent studies</span></div><div class="casAuthors">Wang, Guangsheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-62</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    </div><div class="casAbstract">A review with 56 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtR_mIS1cynLVg90H21EOLACvtfcHk0lg9MbKJ0kbveg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXptFSitg%253D%253D&md5=ac51dbf89c0fbb622bb0939b7d4a9f27</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2F0378-8741%2889%2990062-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-8741%252889%252990062-7%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%2BS.%26atitle%3DMedical%2520uses%2520of%2520mylabris%2520in%2520ancient%2520China%2520and%2520recent%2520studies%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D1989%26volume%3D26%26issue%3D2%26spage%3D147%26epage%3D162%26doi%3D10.1016%2F0378-8741%2889%2990062-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, M.</span></span> <span> </span><span class="NLM_article-title">Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>217</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2004.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.canlet.2004.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=15596295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKksbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2005&pages=43-52&issue=1&author=S.+Kokauthor=S.+Chengauthor=C.+Hongauthor=J.+Leeauthor=S.+Linauthor=Y.+Kuoauthor=C.+Chiangauthor=M.+Kuo&title=Norcantharidin-induced+apoptosis+in+oral+cancer+cells+is+associated+with+an+increase+of+proapoptotic+to+antiapoptotic+protein+ratio&doi=10.1016%2Fj.canlet.2004.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio</span></div><div class="casAuthors">Kok, Sang-Heng; Cheng, Shih-Jung; Hong, Chi-Yuan; Lee, Jang-Jaer; Lin, Sze-Kwan; Kuo, Ying-Shiung; Chiang, Chun-Pin; Kuo, Mark Yen-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-52</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Norcantharidin (NCTD), the demethylated analog of cantharidin, was used to treat human cancers in China since 1984.  It was recently found to be capable of inducing apoptosis in human colon carcinoma, hepatoma and glioblastoma cells by way of an elusive mechanism.  In this study, the authors demonstrated that NCTD also induces apoptosis in human oral cancer cell lines SAS (p53 wild-type phenotype) and Ca9-22 (p53 mutant) as evidenced by nuclear condensation, TUNEL labeling, DNA fragmentation and cleavage of PARP.  Apoptosis induced by NCTD was both dose- and time-dependent.  The authors found NCTD did not induce Fas and FasL, implying that it activated other apoptosis pathways.  The authors' data showed that NCTD caused accumulation of cytosolic cytochrome c and activation of caspase-9, suggesting that apoptosis occurred via the mitochondria mediated pathway.  NCTD enhanced the expression of Bax in SAS cells consistent with their p53 status.  Moreover, the authors showed that NCTD downregulated the expression of Bcl-2 in Ca9-22 and Bcl-XL in SAS.  The authors' results suggest that NCTD-induced apoptosis in oral cancer cells may be mediated by an increase in the ratios of proapoptotic to antiapoptotic proteins.  Since oral cancer cells with mutant p53 or elevated Bcl-XL levels showed resistance to multiple chemotherapeutic agents, NCTD may overcome the chemoresistance of these cells and provide potential new avenues for treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh0t5WMeg_eLVg90H21EOLACvtfcHk0lg9MbKJ0kbveg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKksbfJ&md5=505b03d726bd7a687c2daacc4a0d8dd2</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DKok%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DKuo%26aufirst%3DY.%26aulast%3DChiang%26aufirst%3DC.%26aulast%3DKuo%26aufirst%3DM.%26atitle%3DNorcantharidin-induced%2520apoptosis%2520in%2520oral%2520cancer%2520cells%2520is%2520associated%2520with%2520an%2520increase%2520of%2520proapoptotic%2520to%2520antiapoptotic%2520protein%2520ratio%26jtitle%3DCancer%2520Lett.%26date%3D2005%26volume%3D217%26issue%3D1%26spage%3D43%26epage%3D52%26doi%3D10.1016%2Fj.canlet.2004.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shreeram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blow, J. J.</span></span> <span> </span><span class="NLM_article-title">Cell type-specific responses of human cells to inhibition of replication licensing</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">6624</span>– <span class="NLM_lpage">6632</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fsj.onc.1205910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=12242660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFenu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6624-6632&issue=43&author=S.+Shreeramauthor=A.+Sparksauthor=D.+P.+Laneauthor=J.+J.+Blow&title=Cell+type-specific+responses+of+human+cells+to+inhibition+of+replication+licensing&doi=10.1038%2Fsj.onc.1205910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Cell type-specific responses of human cells to inhibition of replication licensing</span></div><div class="casAuthors">Shreeram, S.; Sparks, Alison; Lane, David P.; Blow, J. Julian</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">6624-6632</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Replication origins are licensed' for a single initiation event by loading Mcm2-7 complexes during late mitosis and G1.  Licensing is blocked at other cell cycle stages by the activity of cyclin-dependent kinases and a small protein called geminin.  Here, we describe the effects of over-expressing a non-degradable form of geminin in various cell lines.  Geminin expression reduced the quantity of Mcm2 bound to chromatin and blocked cell proliferation.  U2OS (p53+/Rb+) cells showed an early S phase arrest with high cyclin E and undetectable cyclin A levels, consistent with the activation of an intra-S checkpoint.  Saos2 (p53-/Rb-) cells showed an accumulation of cells in late S and G2/M with approx. normal levels of cyclin A, consistent with loss of this intra-S phase checkpoint.  Geminin also induced apoptosis in both these cell lines.  In contrast, IMR90 primary fibroblasts over-expressing geminin arrested in G1 with reduced cyclin E levels and no detectable apoptosis.  A licensing checkpoint' may therefore act in primary cells to prevent passage into S phase in the absence of sufficient origin licensing.  These results suggest that inhibition of the licensing system may cause cancer-specific cell killing and therefore represent a novel anti-cancer target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDBIPPuuHsBrVg90H21EOLACvtfcHk0lg9MbKJ0kbveg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFenu7k%253D&md5=ed31520729a8704bcc3b904099b79361</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205910%26sid%3Dliteratum%253Aachs%26aulast%3DShreeram%26aufirst%3DS.%26aulast%3DSparks%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DBlow%26aufirst%3DJ.%2BJ.%26atitle%3DCell%2520type-specific%2520responses%2520of%2520human%2520cells%2520to%2520inhibition%2520of%2520replication%2520licensing%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26issue%3D43%26spage%3D6624%26epage%3D6632%26doi%3D10.1038%2Fsj.onc.1205910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igrejas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodeiro, C.</span></span> <span> </span><span class="NLM_article-title">An overview of the effective combination therapies for the treatment of breast cancer</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2016.04.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.biomaterials.2016.04.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27162073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFyitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2016&pages=34-50&author=C.+N%C3%BA%C3%B1ezauthor=J.+Capeloauthor=G.+Igrejasauthor=A.+Alfonsoauthor=L.+Botanaauthor=C.+Lodeiro&title=An+overview+of+the+effective+combination+therapies+for+the+treatment+of+breast+cancer&doi=10.1016%2Fj.biomaterials.2016.04.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of the effective combination therapies for the treatment of breast cancer</span></div><div class="casAuthors">Nunez, Cristina; Capelo, Jose Luis; Igrejas, Gilberto; Alfonso, Amparo; Botana, Luis M.; Lodeiro, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34-50</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Breast cancer (BC) is generally classified based on the receptors overexpressed on the cell nucleus, which include hormone receptors such as progesterone (PR) and estrogen (ER), and HER2.  Triple-neg. breast cancer (TNBC) is a type of cancer that lacks any of these three types of receptor proteins (ER/PR/HER2).  Tumor cells exhibit drug resistant phenotypes that decrease the efficacy of chemotherapeutic treatments.  Generally, drug resistance has a genetic basis that is caused by an abnormal gene expression, nevertheless, there are several types of drug resistance: efflux pumps reducing the cellular concn. of the drug, alterations in membrane lipids that reduce cellular uptake, increased or altered drug targets, metabolic alteration of the drug, inhibition of apoptosis, repair of the damaged DNA, and alteration of the cell cycle checkpoints.  The use of "combination therapy" is recognized as an efficient soln. to treat human diseases, in particular, breast cancer.  In this review, the authors give examples of different nanocarriers used to co-deliver multiple therapeutics (chemotherapeutic agent and nucleic acid) to drug-resistant tumor cells, and lastly, the authors give the recommendations for the future directions for the co-delivery treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPqDJbJcwJ7bVg90H21EOLACvtfcHk0lg9MbKJ0kbveg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFyitr0%253D&md5=29b20c53e6e5937e67cb8ca892558f42</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2016.04.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2016.04.027%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DC.%26aulast%3DCapelo%26aufirst%3DJ.%26aulast%3DIgrejas%26aufirst%3DG.%26aulast%3DAlfonso%26aufirst%3DA.%26aulast%3DBotana%26aufirst%3DL.%26aulast%3DLodeiro%26aufirst%3DC.%26atitle%3DAn%2520overview%2520of%2520the%2520effective%2520combination%2520therapies%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DBiomaterials%26date%3D2016%26volume%3D97%26spage%3D34%26epage%3D50%26doi%3D10.1016%2Fj.biomaterials.2016.04.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djamgoz, M.</span></span> <span> </span><span class="NLM_article-title">Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">110</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2017.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.ctrv.2017.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29202431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvValtbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=110-122&author=A.+Leeauthor=M.+Djamgoz&title=Triple+negative+breast+cancer%3A+Emerging+therapeutic+modalities+and+novel+combination+therapies&doi=10.1016%2Fj.ctrv.2017.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies</span></div><div class="casAuthors">Lee, Alice; Djamgoz, Mustafa B. A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">110-122</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Triple neg. breast cancer (TNBC) is a complex and aggressive subtype of breast cancer which lacks estrogen receptors, progesterone receptors and HER2 amplification, thereby making it difficult to target therapeutically.  In addn., TNBC has the highest rates of metastatic disease and the poorest overall survival of all breast cancer subtypes.  Resultantly, development of targeted therapies for TNBC is urgently needed.  Recent efforts aimed at mol. characterization of TNBCs have revealed various emerging therapeutic targets including PARP1, receptor and non-receptor tyrosine kinases, immune-checkpoints, androgen receptor and epigenetic proteins.  Key successes include that of the PARP inhibitor, olaparib, which prolonged progression-free survival in a trial of BRCA-mutated breast cancer and for which clin. approval (in this setting) appears imminent.  Nevertheless, the heterogeneity of TNBC has limited the clin. benefits of many trialled therapies in 'unselected' patients.  Further, drug resistance develops following use of many targeted monotherapies due to upregulation of compensatory signalling pathways.  In this review, we evaluate the current status of investigational targeted treatments and present evidence for the role of novel biomarkers and combination therapies in increasing response rates and circumventing drug-induced resistance.  Addnl., we discuss promising novel targets in metastatic TNBC identified through preclin. and/or epidemiol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraUe6qPPRyzbVg90H21EOLACvtfcHk0lhRh4LtxoF_Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvValtbnK&md5=738b63405e3d6c1a3541982a6987a2dd</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2017.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2017.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DA.%26aulast%3DDjamgoz%26aufirst%3DM.%26atitle%3DTriple%2520negative%2520breast%2520cancer%253A%2520Emerging%2520therapeutic%2520modalities%2520and%2520novel%2520combination%2520therapies%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2018%26volume%3D62%26spage%3D110%26epage%3D122%26doi%3D10.1016%2Fj.ctrv.2017.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linklater, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovar, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essenburg, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madaj, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnik, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkaya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maroun, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensma, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graveel, C. R.</span></span> <span> </span><span class="NLM_article-title">Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">69903</span>– <span class="NLM_lpage">69915</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.12065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27655711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2svivVymsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=69903-69915&issue=43&author=E.+S.+Linklaterauthor=E.+A.+Tovarauthor=C.+J.+Essenburgauthor=L.+Turnerauthor=Z.+Madajauthor=M.+E.+Winnauthor=M.+K.+Melnikauthor=H.+Korkayaauthor=C.+R.+Marounauthor=J.+G.+Christensenauthor=M.+R.+Steensmaauthor=J.+L.+Boernerauthor=C.+R.+Graveel&title=Targeting+MET+and+EGFR+crosstalk+signaling+in+triple-negative+breast+cancers&doi=10.18632%2Foncotarget.12065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers</span></div><div class="casAuthors">Linklater Erik S; Tovar Elizabeth A; Essenburg Curt J; Steensma Matthew R; Graveel Carrie R; Turner Lisa; Madaj Zachary; Winn Mary E; Melnik Marianne K; Steensma Matthew R; Melnik Marianne K; Melnik Marianne K; Steensma Matthew R; Korkaya Hasan; Maroun Christiane R; Christensen James G; Maroun Christiane R; Boerner Julie L</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">69903-69915</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is a vital need for improved therapeutic strategies that are effective in both primary and metastatic triple-negative breast cancer (TNBC).  Current treatment options for TNBC patients are restricted to chemotherapy; however tyrosine kinases are promising druggable targets due to their high expression in multiple TNBC subtypes.  Since coexpression of receptor tyrosine kinases (RTKs) can promote signaling crosstalk and cell survival in the presence of kinase inhibitors, it is likely that multiple RTKs will need to be inhibited to enhance therapeutic benefit and prevent resistance.  The MET and EGFR receptors are actionable targets due to their high expression in TNBC; however crosstalk between MET and EGFR has been implicated in therapeutic resistance to single agent use of MET or EGFR inhibitors in several cancer types.  Therefore it is likely that dual inhibition of MET and EGFR is required to prevent crosstalk signaling and acquired resistance.  In this study, we evaluated the heterogeneity of MET and EGFR expression and activation in primary and metastatic TNBC tumorgrafts and determined the efficacy of MET (MGCD265 or crizotinib) and/or EGFR (erlotinib) inhibition against TNBC progression.  Here we demonstrate that combined MET and EGFR inhibition with either MGCD265 and erlotinib treatment or crizotinib and erlotinib treatment were highly effective at abrogating tumor growth and significantly decreased the variability in treatment response compared to monotherapy.  These results advance our understanding of the RTK signaling architecture in TNBC and demonstrate that combined MET and EGFR inhibition may be a promising therapeutic strategy for TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcxR9XiFsCPOdfST00W0BcfW6udTcc2eaqAcdweLQfHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svivVymsg%253D%253D&md5=e2fa57381f2fc7914598ec763f2aa70c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12065%26sid%3Dliteratum%253Aachs%26aulast%3DLinklater%26aufirst%3DE.%2BS.%26aulast%3DTovar%26aufirst%3DE.%2BA.%26aulast%3DEssenburg%26aufirst%3DC.%2BJ.%26aulast%3DTurner%26aufirst%3DL.%26aulast%3DMadaj%26aufirst%3DZ.%26aulast%3DWinn%26aufirst%3DM.%2BE.%26aulast%3DMelnik%26aufirst%3DM.%2BK.%26aulast%3DKorkaya%26aufirst%3DH.%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSteensma%26aufirst%3DM.%2BR.%26aulast%3DBoerner%26aufirst%3DJ.%2BL.%26aulast%3DGraveel%26aufirst%3DC.%2BR.%26atitle%3DTargeting%2520MET%2520and%2520EGFR%2520crosstalk%2520signaling%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26issue%3D43%26spage%3D69903%26epage%3D69915%26doi%3D10.18632%2Foncotarget.12065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stringer-Reasor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caterinicchia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forero-Torres, A.</span></span> <span> </span><span class="NLM_article-title">An open label, pilot study of veliparib (ABT-888) and lapatinib in patients with metastatic, triple negative (ER, PR, and HER-2 negative) breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">1095</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.1095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2018.36.15_suppl.1095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1095-1095&issue=15_suppl&author=E.+M.+Stringer-Reasorauthor=E.+S.+H.+Yangauthor=J.+E.+Mayauthor=V.+Caterinicchiaauthor=Y.+Liauthor=A.+Forero-Torres&title=An+open+label%2C+pilot+study+of+veliparib+%28ABT-888%29+and+lapatinib+in+patients+with+metastatic%2C+triple+negative+%28ER%2C+PR%2C+and+HER-2+negative%29+breast+cancer&doi=10.1200%2FJCO.2018.36.15_suppl.1095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.1095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.1095%26sid%3Dliteratum%253Aachs%26aulast%3DStringer-Reasor%26aufirst%3DE.%2BM.%26aulast%3DYang%26aufirst%3DE.%2BS.%2BH.%26aulast%3DMay%26aufirst%3DJ.%2BE.%26aulast%3DCaterinicchia%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DForero-Torres%26aufirst%3DA.%26atitle%3DAn%2520open%2520label%252C%2520pilot%2520study%2520of%2520veliparib%2520%2528ABT-888%2529%2520and%2520lapatinib%2520in%2520patients%2520with%2520metastatic%252C%2520triple%2520negative%2520%2528ER%252C%2520PR%252C%2520and%2520HER-2%2520negative%2529%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D15_suppl%26spage%3D1095%26epage%3D1095%26doi%3D10.1200%2FJCO.2018.36.15_suppl.1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simiczyjew, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dratkiewicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Troys, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ampe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Styczen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, D.</span></span> <span> </span><span class="NLM_article-title">Combination of EGFR inhibitor lapatinib and MET inhibitor foretinib inhibits migration of triple negative breast cancer cell lines</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">335</span>, <span class="refDoi"> DOI: 10.3390/cancers10090335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fcancers10090335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVyhtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=335&issue=9&author=A.+Simiczyjewauthor=E.+Dratkiewiczauthor=M.+Van+Troysauthor=C.+Ampeauthor=I.+Styczenauthor=D.+Nowak&title=Combination+of+EGFR+inhibitor+lapatinib+and+MET+inhibitor+foretinib+inhibits+migration+of+triple+negative+breast+cancer+cell+lines&doi=10.3390%2Fcancers10090335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of EGFR inhibitor lapatinib and MET inhibitor foretinib inhibits migration of triple negative breast cancer cell lines</span></div><div class="casAuthors">Simiczyjew, Aleksandra; Dratkiewicz, Ewelina; Van Troys, Marleen; Ampe, Christophe; Styczen, Ilona; Nowak, Dorota</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">335/1-335/17</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them.  Promising therapeutic targets are the hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR), which expression is frequently elevated in TNBC.  Inhibitors of these receptors used as monotherapy are often ineffective.  Due to that, we studied the efficacy of combined therapy targeting MET and EGFR simultaneously.  Two TNBC cell lines were treated with lapatinib (a dual EGFR and HER2 inhibitor), foretinib (a MET inhibitor), or a combination of the two.  After the inhibitors treatment, we verified the cell viability (XTT assay), distribution of the cell cycle phases, the activation of signaling pathways (Western blotting), distribution of invadopodia, fluorescent gelatin digestion (immunofluorescence), and the invasion capacity of cells.  A combination of foretinib and lapatinib effectively reduced the viability of examd. cells, led to G2/M arrest and redn. of pAKT.  There was also a decreasein no. of invadopodia formed by cells, their ability to digest gelatin and redn. of cells migration/invasion capacity.  Therapy targeting of both EGFR and MET receptors was much more effective against tested cells than monotherapy.  We selected a combination of drugs that could be successfully used against this breast cancer subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmOczbGv2Zh7Vg90H21EOLACvtfcHk0lhdkslZ41SRQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVyhtrbJ&md5=119835585685be125ad663e0218718c3</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.3390%2Fcancers10090335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers10090335%26sid%3Dliteratum%253Aachs%26aulast%3DSimiczyjew%26aufirst%3DA.%26aulast%3DDratkiewicz%26aufirst%3DE.%26aulast%3DVan%2BTroys%26aufirst%3DM.%26aulast%3DAmpe%26aufirst%3DC.%26aulast%3DStyczen%26aufirst%3DI.%26aulast%3DNowak%26aufirst%3DD.%26atitle%3DCombination%2520of%2520EGFR%2520inhibitor%2520lapatinib%2520and%2520MET%2520inhibitor%2520foretinib%2520inhibits%2520migration%2520of%2520triple%2520negative%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DCancers%26date%3D2018%26volume%3D10%26issue%3D9%26spage%3D335%26doi%3D10.3390%2Fcancers10090335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noord, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Water, B.</span></span> <span> </span><span class="NLM_article-title">A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">77</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1161-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-019-1161-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31262335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MzjtVCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=77&issue=1&author=R.+P.+McLaughlinauthor=J.+Heauthor=V.+E.+van+der+Noordauthor=J.+Redelauthor=J.+A.+Foekensauthor=J.+W.+M.+Martensauthor=M.+Smidauthor=Y.+Zhangauthor=B.+van+de+Water&title=A+kinase+inhibitor+screen+identifies+a+dual+cdc7%2FCDK9+inhibitor+to+sensitise+triple-negative+breast+cancer+to+EGFR-targeted+therapy&doi=10.1186%2Fs13058-019-1161-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy</span></div><div class="casAuthors">McLaughlin Ronan P; He Jichao; van der Noord Vera E; Redel Jevin; Zhang Yinghui; van de Water Bob; Foekens John A; Martens John W M; Smid Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge.  Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signalling pathways in TNBC, resistance to EGFR-tyrosine kinase inhibitors (TKIs) remains endemic.  Therefore, the identification of targeted agents, which synergise with current therapeutic options, is paramount.  METHODS:  Compound-based, high-throughput, proliferation screening was used to profile the response of TNBC cell lines to EGFR-TKIs, western blotting and siRNA transfection being used to examine the effect of inhibitors on EGFR-mediated signal transduction and cellular dependence on such pathways, respectively.  A kinase inhibitor combination screen was used to identify compounds that synergised with EGFR-TKIs in TNBC, utilising sulphorhodamine B (SRB) assay as read-out for proliferation.  The impact of drug combinations on cell cycle arrest, apoptosis and signal transduction was assessed using flow cytometry, automated live-cell imaging and western blotting, respectively.  RNA sequencing was employed to unravel transcriptomic changes elicited by this synergistic combination and to permit identification of the signalling networks most sensitive to co-inhibition.  RESULTS:  We demonstrate that a dual cdc7/CDK9 inhibitor, PHA-767491, synergises with multiple EGFR-TKIs (lapatinib, erlotinib and gefitinib) to overcome resistance to EGFR-targeted therapy in various TNBC cell lines.  Combined inhibition of EGFR and cdc7/CDK9 resulted in reduced cell proliferation, accompanied by induction of apoptosis, G2-M cell cycle arrest, inhibition of DNA replication and abrogation of CDK9-mediated transcriptional elongation, in contrast to mono-inhibition.  Moreover, high expression of cdc7 and RNA polymerase II Subunit A (POLR2A), the direct target of CDK9, is significantly correlated with poor metastasis-free survival in a cohort of breast cancer patients.  RNA sequencing revealed marked downregulation of pathways governing proliferation, transcription and cell survival in TNBC cells treated with the combination of an EGFR-TKI and a dual cdc7/CDK9 inhibitor.  A number of genes enriched in these downregulated pathways are associated with poor metastasis-free survival in TNBC.  CONCLUSIONS:  Our results highlight that dual inhibition of cdc7 and CDK9 by PHA-767491 is a potential strategy for targeting TNBC resistant to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvKxW8FVhTbg20zIbnCCI3fW6udTcc2eYyeiDWajRYxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzjtVCmtg%253D%253D&md5=832bb81fafa9e5645e4b842285e054fc</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1161-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1161-9%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DR.%2BP.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BNoord%26aufirst%3DV.%2BE.%26aulast%3DRedel%26aufirst%3DJ.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DMartens%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DSmid%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3Dvan%2Bde%2BWater%26aufirst%3DB.%26atitle%3DA%2520kinase%2520inhibitor%2520screen%2520identifies%2520a%2520dual%2520cdc7%252FCDK9%2520inhibitor%2520to%2520sensitise%2520triple-negative%2520breast%2520cancer%2520to%2520EGFR-targeted%2520therapy%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D77%26doi%3D10.1186%2Fs13058-019-1161-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canonici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eustace, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crown, J.</span></span> <span> </span><span class="NLM_article-title">Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer</span>. <i>Ther Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1177/1758835919897546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1177%2F1758835919897546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1-16&author=A.+Canoniciauthor=A.+L.+Browneauthor=M.+F.+K.+Ibrahimauthor=K.+P.+Fanningauthor=S.+Rocheauthor=N.+T.+Conlonauthor=F.+O%E2%80%99Neillauthor=J.+Meillerauthor=M.+Cremonaauthor=C.+Morganauthor=B.+T.+Hennessyauthor=A.+J.+Eustaceauthor=F.+Solcaauthor=N.+O%E2%80%99Donovanauthor=J.+Crown&title=Combined+targeting+EGFR+and+SRC+as+a+potential+novel+therapeutic+approach+for+the+treatment+of+triple+negative+breast+cancer&doi=10.1177%2F1758835919897546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1177%2F1758835919897546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758835919897546%26sid%3Dliteratum%253Aachs%26aulast%3DCanonici%26aufirst%3DA.%26aulast%3DBrowne%26aufirst%3DA.%2BL.%26aulast%3DIbrahim%26aufirst%3DM.%2BF.%2BK.%26aulast%3DFanning%26aufirst%3DK.%2BP.%26aulast%3DRoche%26aufirst%3DS.%26aulast%3DConlon%26aufirst%3DN.%2BT.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DF.%26aulast%3DMeiller%26aufirst%3DJ.%26aulast%3DCremona%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DEustace%26aufirst%3DA.%2BJ.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26aulast%3DCrown%26aufirst%3DJ.%26atitle%3DCombined%2520targeting%2520EGFR%2520and%2520SRC%2520as%2520a%2520potential%2520novel%2520therapeutic%2520approach%2520for%2520the%2520treatment%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DTher%2520Adv.%2520Med.%2520Oncol.%26date%3D2020%26volume%3D12%26spage%3D1%26epage%3D16%26doi%3D10.1177%2F1758835919897546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">61</span>),  <span class="NLM_fpage">104193</span>– <span class="NLM_lpage">104205</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.22119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.18632%2Foncotarget.22119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29262632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzjs1egsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=104193-104205&issue=61&author=Y.+Chenauthor=X.+Wangauthor=C.+Caoauthor=X.+Wangauthor=S.+Liangauthor=C.+Pengauthor=L.+Fuauthor=G.+He&title=Inhibition+of+HSP90+sensitizes+a+novel+Raf%2FERK+dual+inhibitor+CY-9d+in+triple-negative+breast+cancer+cells&doi=10.18632%2Foncotarget.22119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells</span></div><div class="casAuthors">Chen Yujuan; Wang Xiaoyun; Wang Xiaodong; Liang Shufang; Fu Leilei; He Gu; Cao Chuan; Peng Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">61</span>),
    <span class="NLM_cas:pages">104193-104205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Raf and extracellular signal-regulated kinases (ERK) are both important therapeutic targets in the mitogen-activated protein kinase (MAPK) pathway, and play crucial roles in the apoptosis resistance of breast cancer cells.  In the present study, cytotoxic and apoptosis-inducing activities of the Raf/ERK dual inhibitor CY-9d were found to be restricted in triple negative breast cancer (TNBC) cells compared with ER/PR-positive cells.  Based on the analysis of differentially expressed proteins using a quantitative proteomic iTRAQ method and bioinformatics analysis, HSP90 was found to identify as a potential mediator between Raf and ERK in TNBC cells.  Western blotting and RNA interference suggested that down-regulated IQGAP1 can attenuate the routine Raf/MEK/ERK cascade and recruit HSP90 as a bypass pathway.  Simultaneous treatment with the HSP90 inhibitor and CY-9d at sub-therapeutic doses was found to produce synergistic therapeutic and apoptosis-inducing effects in TNBC cells.  Moreover, CY-9d was also found to suppress breast cancer growth, inhibit the activation of Raf/ERK, and induce mitochondrial apoptosis in vivo without remarkable toxicity.  These results support the combination of HSP90 and Raf/ERK inhibitors as a potential target therapeutic strategy with enhanced tumor growth suppression, downstream pathway blockade, and greater induction of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ7MGLt-1wSC-bLEOO4dYpfW6udTcc2ebCZ70NteqLd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzjs1egsg%253D%253D&md5=639905f07dc04ba69fada4057d8671fb</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.22119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.22119%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520HSP90%2520sensitizes%2520a%2520novel%2520Raf%252FERK%2520dual%2520inhibitor%2520CY-9d%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D61%26spage%3D104193%26epage%3D104205%26doi%3D10.18632%2Foncotarget.22119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Swearingen, A. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambade, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevill, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bash, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mounsey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitz, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, C. K.</span></span> <span> </span><span class="NLM_article-title">Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer</span>. <i>Neuro Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nox052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fneuonc%2Fnox052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28486691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2ktbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1481-1493&issue=11&author=A.+E.+D.+Van+Swearingenauthor=M.+J.+Sambadeauthor=M.+B.+Siegelauthor=S.+Sudauthor=R.+S.+McNeillauthor=S.+M.+Bevillauthor=X.+Chenauthor=R.+E.+Bashauthor=L.+Mounseyauthor=B.+T.+Golitzauthor=C.+Santosauthor=A.+Dealauthor=J.+S.+Parkerauthor=N.+Rashidauthor=C.+R.+Millerauthor=G.+L.+Johnsonauthor=C.+K.+Anders&title=Combined+kinase+inhibitors+of+MEK1%2F2+and+either+PI3K+or+PDGFR+are+efficacious+in+intracranial+triple-negative+breast+cancer&doi=10.1093%2Fneuonc%2Fnox052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Combined kinase inhibitors of mek1/2 and either pi3k or pdgfr are efficacious in intracranial triple-negative breast cancer</span></div><div class="casAuthors">Van Swearingen, Amanda E. D.; Sambade, Maria J.; Siegel, Marni B.; Sud, Shivani; McNeill, Robert S.; Bevill, Samantha M.; Chen, Xin; Bash, Ryan E.; Mounsey, Louisa; Golitz, Brian T.; Santos, Charlene; Deal, Allison; Parker, Joel S.; Rashid, Naim; Miller, C. Ryan; Johnson, Gary L.; Anders, Carey K.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1481-1493</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1523-5866</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Triple-neg. breast cancer (TNBC), lacking expression of hormone and human epidermal growth factor receptor 2 receptors, is an aggressive subtype that frequently metastasizes to the brain and has no FDA approved systemic therapies.  Previous literature demonstrates mitogen-activated protein kinase kinase (MEK) pathway activation in TNBC brain metastases.  Thus, we aimed to discover rational combinatorial therapies with MEK inhibition, hypothesizing that co-inhibition using clin. available brain-penetrant inhibitors would improve survival in preclin. models of TNBC brain metastases.  Methods: Using human-derived TNBC cell lines, synthetic lethal small interfering RNA kinase screens were evaluated with brain-penetrant inhibitors against MEK1/2 (selumetinib, AZD6244) or phosphatidylinositol-3 kinase (PI3K; buparlisib, BKM120).  Mice bearing intracranial TNBC tumors (SUM149, MDA-MB-231Br, MDA-MB-468, or MDA-MB-436) were treated with MEK, PI3K, or platelet derived growth factor receptor (PDGFR; pazopanib) inhibitors alone or in combination.  Tumors were analyzed by western blot and multiplexed kinase inhibitor beads/mass spectrometry to assess treatment effects.  Results: Screens identified MEK+PI3K and MEK+PDGFR inhibitors as tractable, rational combinations.  Dual treatment of selumetinib with buparlisib or pazopanib was synergistic in TNBC cells in vitro.  Both combinations improved survival in intracranial SUM149 and MDA-MB-231Br, but not MDA-MB-468 or MDA-MB-436.  Treatments decreased mitogen-activated protein kinase (MAPK) and PI3K (Akt) signaling in sensitive (SUM149 and 231Br) but not resistant models (MDA-MB-468).  Exploratory anal. of kinome reprogramming in SUM149 intracranial tumors after MEK ± PI3K inhibition demonstrates extensive kinome changes with treatment, esp. in MAPK pathway members.  Conclusions: Results demonstrate that rational combinations of the clin. available inhibitors selumetinib with buparlisib or pazopanib may prove to be promising therapeutic strategies for the treatment of some TNBC brain metastases.  Addnl., effective combination treatments cause widespread alterations in kinase pathways, including targetable potential resistance drivers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkguj-oYDHd7Vg90H21EOLACvtfcHk0lg6CPx4QpEN1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2ktbjO&md5=8047401673f6d1cc2f43cd9951a0771d</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnox052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnox052%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BSwearingen%26aufirst%3DA.%2BE.%2BD.%26aulast%3DSambade%26aufirst%3DM.%2BJ.%26aulast%3DSiegel%26aufirst%3DM.%2BB.%26aulast%3DSud%26aufirst%3DS.%26aulast%3DMcNeill%26aufirst%3DR.%2BS.%26aulast%3DBevill%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DBash%26aufirst%3DR.%2BE.%26aulast%3DMounsey%26aufirst%3DL.%26aulast%3DGolitz%26aufirst%3DB.%2BT.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DDeal%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DRashid%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DC.%2BR.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26aulast%3DAnders%26aufirst%3DC.%2BK.%26atitle%3DCombined%2520kinase%2520inhibitors%2520of%2520MEK1%252F2%2520and%2520either%2520PI3K%2520or%2520PDGFR%2520are%2520efficacious%2520in%2520intracranial%2520triple-negative%2520breast%2520cancer%26jtitle%3DNeuro%2520Oncol.%26date%3D2017%26volume%3D19%26issue%3D11%26spage%3D1481%26epage%3D1493%26doi%3D10.1093%2Fneuonc%2Fnox052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandjean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodstal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeusz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A.</span></span> <span> </span><span class="NLM_article-title">Comprehensive two- and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1306</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.7150/jca.13266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.7150%2Fjca.13266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26640591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls12lur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1306-1319&issue=12&author=J.+Leeauthor=R.+Gallowayauthor=G.+Grandjeanauthor=J.+Jacobauthor=J.+Humphriesauthor=C.+Bartholomeuszauthor=S.+Goodstalauthor=B.+Limauthor=G.+Bartholomeuszauthor=N.+T.+Uenoauthor=A.+Rao&title=Comprehensive+two-+and+three-dimensional+RNAi+screening+identifies+PI3K+inhibition+as+a+complement+to+MEK+inhibitor+AS703026+for+combination+treatment+of+triple-negative+breast+cancer&doi=10.7150%2Fjca.13266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive two- and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer</span></div><div class="casAuthors">Lee, Jangsoon; Galloway, Rachael; Grandjean, Geoff; Jacob, Justin; Humphries, Juliane; Bartholomeusz, Chandra; Goodstal, Samantha; Lim, Bora; Bartholomeusz, Geoffrey; Ueno, Naoto T.; Rao, Arvind</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer (Wyoming, Australia)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1306-1319</span>CODEN:
                <span class="NLM_cas:coden">JCWAAL</span>;
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher Pty Ltd.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a major cause of death among breast cancer patients that results from intrinsic and acquired resistance to systemic chemotherapies.  To identify novel targets for effective treatment of TNBC through combination strategies with MEK inhibitor (AS703026), we used a novel method of combining high-throughput two- and three-dimensional (2D and 3D) RNAi screening.  TNBC cells were transfected with a kinome siRNA library comprising siRNA targeting 790 kinases under both 2D and 3D culture conditions with or without AS703026.  Mol. activity predictor anal. revealed the PI3K pathway as the major target pathway in our RNAi combination studies in TNBC.  We found that PI3K inhibitor SAR245409 (also called XL765) combined with AS703026 synergistically inhibited proliferation compared with either drug alone (P < 0.001).  Reduced in vitro colony formation (P < 0.001) and migration and invasion ability were also obsd. with the combination treatment (P<0.01).  Our data suggest that SAR245409 combined with AS703026 may be effective in patients with TNBC.  We conclude that a novel powerful high-throughput RNAi assays were able to identify anti-cancer drugs as single or combinational agents.  Integrated and multi-system RNAi screening methods can complement difference between in vitro and in vivo culture conditions, and enriches targets that are close to the in vivo condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohIjAEVc6Ko7Vg90H21EOLACvtfcHk0lg6CPx4QpEN1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls12lur0%253D&md5=cb45d99fa4aae1fd3f9a65ce745a8efb</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.7150%2Fjca.13266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.13266%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DGalloway%26aufirst%3DR.%26aulast%3DGrandjean%26aufirst%3DG.%26aulast%3DJacob%26aufirst%3DJ.%26aulast%3DHumphries%26aufirst%3DJ.%26aulast%3DBartholomeusz%26aufirst%3DC.%26aulast%3DGoodstal%26aufirst%3DS.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DBartholomeusz%26aufirst%3DG.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26aulast%3DRao%26aufirst%3DA.%26atitle%3DComprehensive%2520two-%2520and%2520three-dimensional%2520RNAi%2520screening%2520identifies%2520PI3K%2520inhibition%2520as%2520a%2520complement%2520to%2520MEK%2520inhibitor%2520AS703026%2520for%2520combination%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Cancer%26date%3D2015%26volume%3D6%26issue%3D12%26spage%3D1306%26epage%3D1319%26doi%3D10.7150%2Fjca.13266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karhinen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwajda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aittokallio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span> <span> </span><span class="NLM_article-title">Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>, <span class="refDoi"> DOI: 10.1186/s12943-016-0517-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs12943-016-0517-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27165605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXivFShtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=34&issue=1&author=P.+Gautamauthor=L.+Karhinenauthor=A.+Szwajdaauthor=S.+K.+Jhaauthor=B.+Yadavauthor=T.+Aittokallioauthor=K.+Wennerberg&title=Identification+of+selective+cytotoxic+and+synthetic+lethal+drug+responses+in+triple+negative+breast+cancer+cells&doi=10.1186%2Fs12943-016-0517-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells</span></div><div class="casAuthors">Gautam, Prson; Karhinen, Leena; Szwajda, Agnieszka; Kumar, Jha Sawan; Yadav, Bhagwan; Aittokallio, Tero; Wennerberg, Krister</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/16</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Triple neg. breast cancer (TNBC) is a highly heterogeneous and aggressive type of cancer that lacks effective targeted therapy.  Despite detailed mol. profiling, no targeted therapy has been established.  Hence, with the aim of gaining deeper understanding of the functional differences of TNBC subtypes and how that may relate to potential novel therapeutic strategies, we studied comprehensive anticancer-agent responses among a panel of TNBC cell lines.  Method: The responses of 301 approved and investigational oncol. compds. were measured in 16 TNBC cell lines applying a functional profiling approach.  To go beyond the std. drug viability effect profiling, which has been used in most chemosensitivity studies, we utilized a multiplexed readout for both cell viability and cytotoxicity, allowing us to differentiate between cytostatic and cytotoxic responses.  Results: Our approach revealed that most single-agent anti-cancer compds. that showed activity for the viability readout had no or little cytotoxic effects.  Major compd. classes that exhibited this type of response included anti-mitotics, mTOR, CDK, and metabolic inhibitors, as well as many agents selectively inhibiting oncogene-activated pathways.  However, within the broad viability-acting classes of compds., there were often subsets of cell lines that responded by cell death, suggesting that these cells are particularly vulnerable to the tested substance.  In those cases we could identify differential levels of protein markers assocd. with cytotoxic responses.  For example, PAI-1, MAPK phosphatase and Notch-3 levels assocd. with cytotoxic responses to mitotic and proteasome inhibitors, suggesting that these might serve as markers of response also in clin. settings.  Furthermore, the cytotoxicity readout highlighted selective synergistic and synthetic lethal drug combinations that were missed by the cell viability readouts.  For instance, the MEK inhibitor trametinib synergized with PARP inhibitors.  Similarly, combination of two non-cytotoxic compds., the rapamycin analog everolimus and an ATP-competitive mTOR inhibitor dactolisib, showed synthetic lethality in several mTOR-addicted cell lines.  Conclusions: Taken together, by studying the combination of cytotoxic and cytostatic drug responses, we identified a deeper spectrum of cellular responses both to single agents and combinations that may be highly relevant for identifying precision medicine approaches in TNBC as well as in other types of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhf9pIYXrFw7Vg90H21EOLACvtfcHk0lj_uECmMVUEDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXivFShtrs%253D&md5=c4dcfb13defdcac4e1d931eafdc62d20</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1186%2Fs12943-016-0517-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-016-0517-3%26sid%3Dliteratum%253Aachs%26aulast%3DGautam%26aufirst%3DP.%26aulast%3DKarhinen%26aufirst%3DL.%26aulast%3DSzwajda%26aufirst%3DA.%26aulast%3DJha%26aufirst%3DS.%2BK.%26aulast%3DYadav%26aufirst%3DB.%26aulast%3DAittokallio%26aufirst%3DT.%26aulast%3DWennerberg%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520selective%2520cytotoxic%2520and%2520synthetic%2520lethal%2520drug%2520responses%2520in%2520triple%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Cancer%26date%3D2016%26volume%3D15%26issue%3D1%26spage%3D34%26doi%3D10.1186%2Fs12943-016-0517-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalimutho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srihari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanayakkara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafique, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raninga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nag, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, K. K.</span></span> <span> </span><span class="NLM_article-title">Blockade of PDGFRbeta circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltration in triple-negative breast cancer</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">85</span>, <span class="refDoi"> DOI: 10.1186/s13046-019-1075-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13046-019-1075-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30777101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3cfkslKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=85&issue=1&author=M.+Kalimuthoauthor=D.+Sinhaauthor=D.+Mittalauthor=S.+Srihariauthor=D.+Nanayakkaraauthor=S.+Shafiqueauthor=P.+Raningaauthor=P.+Nagauthor=K.+Parsonsauthor=K.+K.+Khanna&title=Blockade+of+PDGFRbeta+circumvents+resistance+to+MEK-JAK+inhibition+via+intratumoral+CD8%28%2B%29+T-cells+infiltration+in+triple-negative+breast+cancer&doi=10.1186%2Fs13046-019-1075-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltration in triple-negative breast cancer</span></div><div class="casAuthors">Kalimutho Murugan; Sinha Debottam; Nanayakkara Devathri; Shafique Shagufta; Raninga Prahlad; Nag Purba; Parsons Kate; Khanna Kum Kum; Mittal Deepak; Srihari Sriganesh; Nag Purba</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Despite the increasing progress in targeted and immune based-directed therapies for other solid organ malignancies, currently there is no targeted therapy available for TNBCs.  A number of mechanisms have been reported both in pre-clinical and clinical settings that involve inherent, acquired and adaptive resistance to small molecule inhibitors.  Here, we demonstrated a novel resistance mechanism in TNBC cells mediated by PDGFRβ in response to JAK2 inhibition.  METHODS:  Multiple in vitro (subG1, western blotting, immunofluorescence, RT-PCR, Immunoprecipitation), in vivo and publically available datasets were used.  RESULTS:  We showed that TNBC cells exposed to MEK1/2-JAK2 inhibitors exhibit resistant colonies in anchorage-independent growth assays.  Moreover, cells treated with various small molecule inhibitors including JAK2 promote PDGFRβ upregulation.  Using publically available databases, we showed that patients expressing high PDGFRβ or its ligand PDGFB exhibit poor relapse-free survival upon chemotherapeutic treatment.  Mechanistically we found that JAK2 expression controls steady state levels of PDGFRβ.  Thus, co-blockade of PDGFRβ with JAK2 and MEK1/2 inhibitors completely eradicated resistant colonies in vitro.  We found that triple-combined treatment had a significant impact on CD44(+)/CD24(-) stem-cell-like cells.  Likewise, we found a significant tumor growth inhibition in vivo through intratumoral CD8(+) T cells infiltration in a manner that is reversed by anti-CD8 antibody treatment.  CONCLUSION:  These findings reveal a novel regulatory role of JAK2-mediated PDGFRβ proteolysis and provide an example of a PDGFRβ-mediated resistance mechanism upon specific target inhibition in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKp_mJ5o9m8z0O18WR3iAofW6udTcc2eaVBqU4hHYEyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfkslKitA%253D%253D&md5=8b7a0c6c129c7555b2d3d790efd656ee</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1186%2Fs13046-019-1075-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-019-1075-5%26sid%3Dliteratum%253Aachs%26aulast%3DKalimutho%26aufirst%3DM.%26aulast%3DSinha%26aufirst%3DD.%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DSrihari%26aufirst%3DS.%26aulast%3DNanayakkara%26aufirst%3DD.%26aulast%3DShafique%26aufirst%3DS.%26aulast%3DRaninga%26aufirst%3DP.%26aulast%3DNag%26aufirst%3DP.%26aulast%3DParsons%26aufirst%3DK.%26aulast%3DKhanna%26aufirst%3DK.%2BK.%26atitle%3DBlockade%2520of%2520PDGFRbeta%2520circumvents%2520resistance%2520to%2520MEK-JAK%2520inhibition%2520via%2520intratumoral%2520CD8%2528%252B%2529%2520T-cells%2520infiltration%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26issue%3D1%26spage%3D85%26doi%3D10.1186%2Fs13046-019-1075-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zawistowski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevill, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuhlmiller, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivares-Quintero, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciaky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittle, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velarde, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitz, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darr, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span> <span> </span><span class="NLM_article-title">Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F2159-8290.CD-16-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28108460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Klsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=302-321&issue=3&author=J.+S.+Zawistowskiauthor=S.+M.+Bevillauthor=D.+R.+Gouletauthor=T.+J.+Stuhlmillerauthor=A.+S.+Beltranauthor=J.+F.+Olivares-Quinteroauthor=D.+Singhauthor=N.+Sciakyauthor=J.+S.+Parkerauthor=N.+U.+Rashidauthor=X.+Chenauthor=J.+S.+Duncanauthor=M.+C.+Whittleauthor=S.+P.+Angusauthor=S.+H.+Velardeauthor=B.+T.+Golitzauthor=X.+Heauthor=C.+Santosauthor=D.+B.+Darrauthor=K.+Gallagherauthor=L.+M.+Gravesauthor=C.+M.+Perouauthor=L.+A.+Careyauthor=H.+S.+Earpauthor=G.+L.+Johnson&title=Enhancer+remodeling+during+adaptive+bypass+to+MEK+inhibition+is+attenuated+by+pharmacologic+targeting+of+the+P-TEFb+complex&doi=10.1158%2F2159-8290.CD-16-0653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex</span></div><div class="casAuthors">Zawistowski, Jon S.; Bevill, Samantha M.; Goulet, Daniel R.; Stuhlmiller, Timothy J.; Beltran, Adriana S.; Olivares-Quintero, Jose F.; Singh, Darshan; Sciaky, Noah; Parker, Joel S.; Rashid, Naim U.; Chen, Xin; Duncan, James S.; Whittle, Martin C.; Angus, Steven P.; Velarde, Sara Hanna; Golitz, Brian T.; He, Xiaping; Santos, Charlene; Darr, David B.; Gallagher, Kristalyn; Graves, Lee M.; Perou, Charles M.; Carey, Lisa A.; Earp, H. Shelton; Johnson, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">302-321</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clin. trial design.  Despite clin. responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving nongenomic adaptive bypass mechanisms.  Inhibition of MEK1/2 by trametinib in patients with triple-neg. breast cancer (TNBC) induced dramatic transcriptional responses, including upregulation of receptor tyrosine kinases (RTK) comparing tumor samples before and after one week of treatment.  In preclin. models, MEK inhibition induced genome-wide enhancer formation involving the seeding of BRD4, MED1, H3K27 acetylation, and p300 that drives transcriptional adaptation.  Inhibition of the P-TEFb-assocd. proteins BRD4 and CBP/p300 arrested enhancer seeding and RTK upregulation.  BRD4 bromodomain inhibitors overcame trametinib resistance, producing sustained growth inhibition in cells, xenografts, and syngeneic mouse TNBC models.  Pharmacol. targeting of P-TEFb members in conjunction with MEK inhibition by trametinib is an effective strategy to durably inhibit epigenomic remodeling required for adaptive resistance.  Significance: Widespread transcriptional adaptation to pharmacol. MEK inhibition was obsd. in TNBC patient tumors.  In preclin. models, MEK inhibition induces dramatic genome-wide modulation of chromatin, in the form of de novo enhancer formation and enhancer remodeling.  Pharmacol. targeting of P-TEFb complex members at enhancers is an effective strategy to durably inhibit such adaptation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvchkLxcOjcLVg90H21EOLACvtfcHk0lj_uECmMVUEDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Klsbw%253D&md5=3425c91d4a75b45c55903eeda1928a91</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0653%26sid%3Dliteratum%253Aachs%26aulast%3DZawistowski%26aufirst%3DJ.%2BS.%26aulast%3DBevill%26aufirst%3DS.%2BM.%26aulast%3DGoulet%26aufirst%3DD.%2BR.%26aulast%3DStuhlmiller%26aufirst%3DT.%2BJ.%26aulast%3DBeltran%26aufirst%3DA.%2BS.%26aulast%3DOlivares-Quintero%26aufirst%3DJ.%2BF.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DRashid%26aufirst%3DN.%2BU.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DWhittle%26aufirst%3DM.%2BC.%26aulast%3DAngus%26aufirst%3DS.%2BP.%26aulast%3DVelarde%26aufirst%3DS.%2BH.%26aulast%3DGolitz%26aufirst%3DB.%2BT.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DDarr%26aufirst%3DD.%2BB.%26aulast%3DGallagher%26aufirst%3DK.%26aulast%3DGraves%26aufirst%3DL.%2BM.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26atitle%3DEnhancer%2520remodeling%2520during%2520adaptive%2520bypass%2520to%2520MEK%2520inhibition%2520is%2520attenuated%2520by%2520pharmacologic%2520targeting%2520of%2520the%2520P-TEFb%2520complex%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26issue%3D3%26spage%3D302%26epage%3D321%26doi%3D10.1158%2F2159-8290.CD-16-0653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Adorno, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordentlich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4780</span>– <span class="NLM_lpage">4792</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-16-2622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28465444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4780-4792&issue=16&author=A.+M.+Torres-Adornoauthor=J.+Leeauthor=T.+Kogawaauthor=P.+Ordentlichauthor=D.+Tripathyauthor=B.+Limauthor=N.+T.+Ueno&title=Histone+deacetylase+inhibitor+enhances+the+efficacy+of+MEK+inhibitor+through+NOXA-mediated+MCL1+degradation+in+triple-negative+and+inflammatory+breast+cancer&doi=10.1158%2F1078-0432.CCR-16-2622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer</span></div><div class="casAuthors">Torres-Adorno, Angie M.; Lee, Jangsoon; Kogawa, Takahiro; Ordentlich, Peter; Tripathy, Debu; Lim, Bora; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4780-4792</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Inflammatory breast cancer (IBC), diagnosed clin., and triple-neg. breast cancer (TNBC), diagnosed by mol. receptor status, are the two most aggressive forms of breast cancer, and both lack effective targeted therapies.  We previously demonstrated involvement of histone deacetylase (HDAC) inhibitor entinostat in regulating apoptosis in IBC and TNBC cells; here, we aimed to identify novel combination therapy candidates.  Exptl. Design: Potential therapeutic targets were identified by mRNA expression profiling of TNBC and IBC cells treated with entinostat.  Drug action and synergism were assessed by in vitro proliferation assays, tumor growth in vivo, and proteomic analyses.  Gain/loss-of-expression studies were utilized to functionally validate the role of identified targets in sensitivity of TNBC and IBC cells to combination therapy.  Results: Entinostat induced activity of the oncogenic ERK pathway and expression of proapoptotic NOXA.  These are known to stabilize and degrade, resp., MCL1, an antiapoptotic Bcl-2 protein.  In breast cancer patients, high-MCL1/low-NOXA tumor expression correlated significantly with poor survival outcomes.  Combination treatment of entinostat with MEK inhibitor pimasertib reduced the growth of TNBC and IBC cells in vitro and inhibited tumor growth in vivo.  The synergistic action of combination therapy was obsd. in TNBC and IBC cell lines in which NOXA expression was induced following entinostat treatment.  The therapeutic activity depended on induction of mitochondrial cell death pathways initiated by NOXA-mediated MCL1 degrdn.  Conclusions: Our preclin. findings provide a rationale for the clin. testing of combination HDAC and MEK pathway inhibition for TNBC and IBC that exhibit elevated baseline tumor MCL1 expression.  Clin Cancer Res; 23(16); 4780-92. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVmuZ3LzYmHrVg90H21EOLACvtfcHk0lh2r3JSm_EGVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu73J&md5=c8835ce146d5a9ea01161dbaee4f97d9</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2622%26sid%3Dliteratum%253Aachs%26aulast%3DTorres-Adorno%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKogawa%26aufirst%3DT.%26aulast%3DOrdentlich%26aufirst%3DP.%26aulast%3DTripathy%26aufirst%3DD.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520enhances%2520the%2520efficacy%2520of%2520MEK%2520inhibitor%2520through%2520NOXA-mediated%2520MCL1%2520degradation%2520in%2520triple-negative%2520and%2520inflammatory%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D16%26spage%3D4780%26epage%3D4792%26doi%3D10.1158%2F1078-0432.CCR-16-2622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seow, H. F.</span></span> <span> </span><span class="NLM_article-title">Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2015.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.biopha.2015.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26463630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=40-50&author=A.+Ayubauthor=W.+K.+Yipauthor=H.+F.+Seow&title=Dual+treatments+targeting+IGF-1R%2C+PI3K%2C+mTORC+or+MEK+synergize+to+inhibit+cell+growth%2C+induce+apoptosis%2C+and+arrest+cell+cycle+at+G1+phase+in+MDA-MB-231+cell+line&doi=10.1016%2Fj.biopha.2015.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line</span></div><div class="casAuthors">Ayub, Ayunadirah; Yip, Wai Kien; Seow, Heng Fong</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-50</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Triple-neg. breast cancers (TNBCs) are aggressive cancers that do not benefit from hormonal therapy or therapies that target HER2 receptors.  Insulin-like growth factor 1 receptor (IGF-1R), which has been shown to be overexpressed in breast cancer, activates numerous downstream kinases that assoc. with cell proliferation and survival.  This study compared the effects caused by dual treatments targeting IGF-1R, PI3K, mTORC, or MEK with those by single treatments in a TNBC cell line, MDA-MB-231.  We used small-mol. kinase inhibitors, namely, NVP-AEW541, NVP-BKM120, KU0063794, and PD0325901 to target IGF-1R, PI3K, mTORC, and MEK, resp.  Combination treatments of PD0325901 with NVP-AEW541, NVP-BKM120 or KU0063794 and NVP-AEW541 with KU0063794 demonstrated a significant synergistic growth inhibition.  These dual treatments increased apoptosis and/or cell cycle arrest at G0/G1 phase and enhanced the inhibition of phosphorylation of Akt or downstream mols. of mTORC1, as compared to the single treatments.  Our study suggests that targeting multiple kinases in IGF-1R signaling may be a promising therapeutic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkmrJHYBqsrbVg90H21EOLACvtfcHk0lh2r3JSm_EGVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtLnK&md5=521bffcb4111aa0aa7225772f2201262</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2015.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2015.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DAyub%26aufirst%3DA.%26aulast%3DYip%26aufirst%3DW.%2BK.%26aulast%3DSeow%26aufirst%3DH.%2BF.%26atitle%3DDual%2520treatments%2520targeting%2520IGF-1R%252C%2520PI3K%252C%2520mTORC%2520or%2520MEK%2520synergize%2520to%2520inhibit%2520cell%2520growth%252C%2520induce%2520apoptosis%252C%2520and%2520arrest%2520cell%2520cycle%2520at%2520G1%2520phase%2520in%2520MDA-MB-231%2520cell%2520line%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2015%26volume%3D75%26spage%3D40%26epage%3D50%26doi%3D10.1016%2Fj.biopha.2015.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Noord, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foekens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Westen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Water, B.</span></span> <span> </span><span class="NLM_article-title">Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1007/s10549-019-05380-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-019-05380-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31388935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFOjur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=263-274&issue=2&author=J.+Heauthor=R.+P.+McLaughlinauthor=V.+van+der+Noordauthor=J.+A.+Foekensauthor=J.+W.+M.+Martensauthor=G.+van%0AWestenauthor=Y.+Zhangauthor=B.+van+de+Water&title=Multi-targeted+kinase+inhibition+alleviates+mTOR+inhibitor+resistance+in+triple-negative+breast+cancer&doi=10.1007%2Fs10549-019-05380-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer</span></div><div class="casAuthors">He, Jichao; McLaughlin, Ronan P.; van der Noord, Vera; Foekens, John A.; Martens, John W. M.; van Westen, Gerard; Zhang, Yinghui; van de Water, Bob</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Owing to its genetic heterogeneity and acquired resistance, triple-neg. breast cancer (TNBC) is not responsive to single-targeted therapy, causing disproportional cancer-related death worldwide.  Combined targeted therapy strategies to block interactive oncogenic signaling networks are being explored for effective treatment of the refractory TNBC subtype.  Methods: A broad kinase inhibitor screen was applied to profile the proliferative responses of TNBC cells, revealing resistance of TNBC cells to inhibition of the mammalian target of rapamycin (mTOR).  A systematic drug combination screen was subsequently performed to identify that AEE788, an inhibitor targeting multiple receptor tyrosine kinases (RTKs) EGFR/HER2 and VEGFR, synergizes with selective mTOR inhibitor rapamycin as well as its analogs (rapalogs) temsirolimus and everolimus to inhibit TNBC cell proliferation.  Results: The combination treatment with AEE788 and rapalog effectively inhibits phosphorylation of mTOR and 4EBP1, relieves mTOR inhibition-mediated upregulation of cyclin D1, and maintains suppression of AKT and ERK signaling, thereby sensitizing TNBC cells to the rapalogs. siRNA validation of cheminformatics-based predicted AEE788 targets has further revealed the mTOR interactive RPS6K members (RPS6KA3, RPS6KA6, RPS6KB1, and RPS6KL1) as synthetic lethal targets for rapalog combination treatment.  Conclusions: mTOR signaling is highly activated in TNBC tumors.  As single rapalog treatment is insufficient to block mTOR signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy to overcome mTOR-targeted therapy resistance in TNBC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAoDwulqfxKbVg90H21EOLACvtfcHk0lh2r3JSm_EGVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFOjur%252FL&md5=6ac32d78271119524f0936907ad7c58a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1007%2Fs10549-019-05380-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-019-05380-z%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BP.%26aulast%3Dvan%2Bder%2BNoord%26aufirst%3DV.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DMartens%26aufirst%3DJ.%2BW.%2BM.%26aulast%3Dvan%2BWesten%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3Dvan%2Bde%2BWater%26aufirst%3DB.%26atitle%3DMulti-targeted%2520kinase%2520inhibition%2520alleviates%2520mTOR%2520inhibitor%2520resistance%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2019%26volume%3D178%26issue%3D2%26spage%3D263%26epage%3D274%26doi%3D10.1007%2Fs10549-019-05380-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1699</span>– <span class="NLM_lpage">1712</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-15-1772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26546619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Kjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1699-1712&issue=7&author=W.+Moauthor=Q.+Liuauthor=C.+C.+J.+Linauthor=H.+Daiauthor=Y.+Pengauthor=Y.+Liangauthor=G.+Pengauthor=F.+Meric-Bernstamauthor=G.+B.+Millsauthor=K.+Liauthor=S.+Y.+Lin&title=mTOR+inhibitors+suppress+homologous+recombination+repair+and+synergize+with+PARP+inhibitors+via+regulating+SUV39H1+in+BRCA-proficient+triple-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-15-1772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer</span></div><div class="casAuthors">Mo, Wei; Liu, Qingxin; Lin, Curtis Chun-Jen; Dai, Hui; Peng, Yang; Liang, Yulong; Peng, Guang; Meric-Bernstam, Funda; Mills, Gordon B.; Li, Kaiyi; Lin, Shiaw-Yih</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1699-1712</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Triple-neg. breast cancer (TNBC) is a highly heterogeneous disease and has the worst outcome among all subtypes of breast cancers.  Although PARP inhibitors represent a promising treatment in TNBC with BRCA1/BRCA2 mutations, there is great interest in identifying drug combinations that can extend the use of PARP inhibitors to a majority of TNBC patients with wild-type BRCA1/BRCA2.  Here we explored whether mTOR inhibitors, through modulating homologous recombination (HR) repair, would provide therapeutic benefit in combination with PARP inhibitors in preclin. models of BRCA-proficient TNBC.  Exptl. Design: We have studied the effects of mTOR inhibitors on HR repair following DNA double-strand breaks (DSB).  We further demonstrated the in vitro and in vivo activities of combined treatment of mTOR inhibitors with PARP inhibitors in BRCA-proficient TNBC.  Moreover, microarray anal. and rescue expts. were used to investigate the mol. mechanisms of action.  Results: We found that mTOR inhibitors significantly suppressed HR repair in two BRCA-proficient TNBC cell lines. mTOR inhibitors and PARP inhibitors in combination exhibited strong synergism against these TNBC cell lines.  In TNBC xenografts, we obsd. enhanced efficacy of everolimus in combination with talazoparib (BMN673) compared with either drug alone.  We further identified through microarray anal. and by rescue assays that mTOR inhibitors suppressed HR repair and synergized with PARP inhibitors through regulating the expression of SUV39H1 in BRCA-proficient TNBCs.  Conclusions: Collectively, these findings strongly suggest that combining mTOR inhibitors and PARP inhibitors would be an effective therapeutic approach to treat BRCA-proficient TNBC patients.  Clin Cancer Res; 22(7); 1699-712. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5IDshRv03LVg90H21EOLACvtfcHk0ljdJlAOKdzy-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Kjt7k%253D&md5=dc39d84a3e6b334f1ec8a10b7c264e7d</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1772%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DC.%2BC.%2BJ.%26aulast%3DDai%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DG.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DS.%2BY.%26atitle%3DmTOR%2520inhibitors%2520suppress%2520homologous%2520recombination%2520repair%2520and%2520synergize%2520with%2520PARP%2520inhibitors%2520via%2520regulating%2520SUV39H1%2520in%2520BRCA-proficient%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D7%26spage%3D1699%26epage%3D1712%26doi%3D10.1158%2F1078-0432.CCR-15-1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/s13058-015-0534-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-015-0534-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25888415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2MjltlWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=33&issue=1&author=A.+Minauthor=S.+A.+Imauthor=D.+K.+Kimauthor=S.+H.+Songauthor=H.+J.+Kimauthor=K.+H.+Leeauthor=T.+Y.+Kimauthor=S.+W.+Hanauthor=D.+Y.+Ohauthor=T.+Y.+Kimauthor=M.+J.+O%E2%80%99Connorauthor=Y.+J.+Bang&title=Histone+deacetylase+inhibitor%2C+suberoylanilide+hydroxamic+acid+%28SAHA%29%2C+enhances+anti-tumor+effects+of+the+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+olaparib+in+triple-negative+breast+cancer+cells&doi=10.1186%2Fs13058-015-0534-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells</span></div><div class="casAuthors">Min Ahrum; Im Seock-Ah; Song Sang-Hyun; Kim Hee-Jun; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Min Ahrum; Im Seock-Ah; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Im Seock-Ah; Lee Kyung-Hun; Kim Tae-Yong; Han Sae-Won; Oh Do-Youn; Kim Tae-You; Bang Yung-Jue; Kim Debora Keunyoung; Kim Hee-Jun; O'Connor Mark J</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies in the homologous recombination repair (HRR) pathway.  Histone deacetylases (HDACs) are important for enabling functional HRR of DNA by regulating the expression of HRR-related genes and promoting the accurate assembly of HRR-directed sub-nuclear foci.  Thus, HDAC inhibitors have recently emerged as a therapeutic agent for treating cancer by inhibiting DNA repair.  Based on this, HDAC inhibition could be predicted to enhance the anti-tumor effect of PARP inhibitors in cancer cells by blocking the HRR pathway.  METHODS:  We determined whether suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor, could enhance the anti-tumor effects of olaparib on breast cancer cell lines using a cytotoxic assay, cell cycle analysis, and Western blotting.  We evaluated how exposure to SAHA affects the expression of HRR-associated genes.  The accumulation of DNA double strand breaks (DSBs) induced by combination treatment was assessed.  Induction of autophagy was monitored by imaging green fluorescent protein-tagged microtubule-associated protein 1A/1B-light chain 3 (LC3) expression following co-treatment with olaparib and SAHA.  These in vitro data were validated in vivo using a human breast cancer xenograft model.  RESULTS:  Triple-negative breast cancer cell (TNBC) lines showed heterogeneous responses to the PARP and HDAC inhibitors.  Co-administration of olaparib and SAHA synergistically inhibited the growth of TNBC cells that expressed functional Phosphatase and tensin homolog (PTEN).  This effect was associated with down-regulation of the proliferative signaling pathway, increased apoptotic and autophagic cell death, and accumulation of DNA damage.  The combined anti-tumor effect of olaparib and SAHA was also observed in a xenograft model.  These data suggest that PTEN expression in TNBC cells can sensitize the cell response to simultaneous inhibition of PARP and HDAC both in vitro and in vivo.  CONCLUSION:  Our findings suggest that expression of functional PTEN may serve as a biomarker for selecting TNBC patients that would favorably respond to a combination of olaparib with SAHA.  This provides a strong rationale for treating TNBC patients with PTEN expression with a combination therapy consisting of olaparib and SAHA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcCnK6c-02m0bxh97K6Vt6fW6udTcc2eYmLOniP66yDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjltlWguw%253D%253D&md5=4d900b24ef95ff4fca352dc27cdc2865</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1186%2Fs13058-015-0534-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-015-0534-y%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DA.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DD.%2BK.%26aulast%3DSong%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26atitle%3DHistone%2520deacetylase%2520inhibitor%252C%2520suberoylanilide%2520hydroxamic%2520acid%2520%2528SAHA%2529%252C%2520enhances%2520anti-tumor%2520effects%2520of%2520the%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520olaparib%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2015%26volume%3D17%26issue%3D1%26spage%3D33%26doi%3D10.1186%2Fs13058-015-0534-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greifenberg, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dust, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaro, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochupurakkal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarosiek, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmaña, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2367</span>– <span class="NLM_lpage">2381</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.10.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.celrep.2016.10.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27880910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGqt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=2367-2381&issue=9&author=S.+F.+Johnsonauthor=C.+Cruzauthor=A.+K.+Greifenbergauthor=S.+Dustauthor=D.+G.+Stoverauthor=D.+Chiauthor=B.+Primackauthor=S.+Caoauthor=A.+J.+Bernhardyauthor=R.+Coulsonauthor=J.+B.+Lazaroauthor=B.+Kochupurakkalauthor=H.+Sunauthor=C.+Unittauthor=L.+A.+Moreauauthor=K.+A.+Sarosiekauthor=M.+Scaltritiauthor=D.+Juricauthor=J.+Baselgaauthor=A.+L.+Richardsonauthor=S.+J.+Rodigauthor=A.+D.+D%E2%80%99Andreaauthor=J.+Balma%C3%B1aauthor=N.+Johnsonauthor=M.+Geyerauthor=V.+Serraauthor=E.+Limauthor=G.+I.+Shapiro&title=CDK12+inhibition+reverses+de+novo+and+acquired+PARP+inhibitor+resistance+in+BRCA+wild-type+and+mutated+models+of+triple-negative+breast+cancer&doi=10.1016%2Fj.celrep.2016.10.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer</span></div><div class="casAuthors">Johnson, Shawn F.; Cruz, Cristina; Greifenberg, Ann Katrin; Dust, Sofia; Stover, Daniel G.; Chi, David; Primack, Benjamin; Cao, Shiliang; Bernhardy, Andrea J.; Coulson, Rhiannon; Lazaro, Jean-Bernard; Kochupurakkal, Bose; Sun, Heather; Unitt, Christine; Moreau, Lisa A.; Sarosiek, Kristopher A.; Scaltriti, Maurizio; Juric, Dejan; Baselga, Jose; Richardson, Andrea L.; Rodig, Scott J.; D'Andrea, Alan D.; Balmana, Judith; Johnson, Neil; Geyer, Matthias; Serra, Violeta; Lim, Elgene; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2367-2381</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR.  Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, addnl. has potent activity against CDK12, a transcriptional regulator of HR.  In BRCA-mutated triple-neg. breast cancer (TNBC) cells and patient-derived xenografts (PDXs), dinaciclib ablates restored HR and reverses PARP inhibitor resistance.  Addnl., we show that de novo resistance to PARP inhibition in BRCA1-mutated cell lines and a PDX derived from a PARP-inhibitor-naive BRCA1 carrier is mediated by residual HR and is reversed by CDK12 inhibition.  Finally, dinaciclib augments the degree of response in a PARP-inhibitor-sensitive model, converting tumor growth inhibition to durable regression.  These results highlight the significance of HR disruption as a therapeutic strategy and support the broad use of combined CDK12 and PARP inhibition in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyVKyKNc3G1bVg90H21EOLACvtfcHk0ljdJlAOKdzy-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGqt7%252FL&md5=ae666e75b7a49d0c348789e2d59643fa</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.10.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.10.077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DS.%2BF.%26aulast%3DCruz%26aufirst%3DC.%26aulast%3DGreifenberg%26aufirst%3DA.%2BK.%26aulast%3DDust%26aufirst%3DS.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DChi%26aufirst%3DD.%26aulast%3DPrimack%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DS.%26aulast%3DBernhardy%26aufirst%3DA.%2BJ.%26aulast%3DCoulson%26aufirst%3DR.%26aulast%3DLazaro%26aufirst%3DJ.%2BB.%26aulast%3DKochupurakkal%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DUnitt%26aufirst%3DC.%26aulast%3DMoreau%26aufirst%3DL.%2BA.%26aulast%3DSarosiek%26aufirst%3DK.%2BA.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DA.%2BL.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26aulast%3DBalma%25C3%25B1a%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DLim%26aufirst%3DE.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCDK12%2520inhibition%2520reverses%2520de%2520novo%2520and%2520acquired%2520PARP%2520inhibitor%2520resistance%2520in%2520BRCA%2520wild-type%2520and%2520mutated%2520models%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D17%26issue%3D9%26spage%3D2367%26epage%3D2381%26doi%3D10.1016%2Fj.celrep.2016.10.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonnalagadda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingareddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palle, K.</span></span> <span> </span><span class="NLM_article-title">Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">104</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1192-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-019-1192-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31492187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MrlvV2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=104&issue=1&author=C.+Maniauthor=S.+Jonnalagaddaauthor=J.+Lingareddyauthor=S.+Awasthiauthor=W.+H.+Gmeinerauthor=K.+Palle&title=Prexasertib+treatment+induces+homologous+recombination+deficiency+and+synergizes+with+olaparib+in+triple-negative+breast+cancer+cells&doi=10.1186%2Fs13058-019-1192-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells</span></div><div class="casAuthors">Mani Chinnadurai; Jonnalagadda Shirisha; Lingareddy Jojireddy; Palle Komaraiah; Lingareddy Jojireddy; Awasthi Sanjay; Gmeiner William H</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Breast cancer remains as one of the most lethal types of cancer in women.  Among various subtypes, triple-negative breast cancer (TNBC) is the most aggressive and hard to treat type of breast cancer.  Mechanistically, increased DNA repair and cell cycle checkpoint activation remain as the foremost reasons behind TNBC tumor resistance to chemotherapy and disease recurrence.  METHODS:  We evaluated the mechanism of prexasertib-induced regulation of homologous recombination (HR) proteins using 20S proteasome inhibitors and RT-PCR.  HR efficiency and DNA damages were evaluated using Dr-GFP and comet assays.  DNA morphology and DNA repair focus studies were analyzed using immunofluorescence.  UALCAN portal was used to evaluate the expression of RAD51 and survival probability based on tumor stage, subtype, and race in breast cancer patients.  RESULTS:  Our results show that prexasertib treatment promotes both post-translational and transcriptional mediated regulation of BRCA1 and RAD51 proteins.  Additionally, prexasertib-treated TNBC cells revealed over 55% reduction in HR efficiency compared to control cells.  Based on these results, we hypothesized that prexasertib treatment induced homologous recombination deficiency (HRD) and thus should synergize with PARP inhibitors (PARPi) in TNBC cells.  As predicted, combined treatment of prexasertib and PARPi olaparib increased DNA strand breaks, γH2AX foci, and nuclear disintegration relative to single-agent treatment.  Further, the prexasertib and olaparib combination was synergistic in multiple TNBC cell lines, as indicated by combination index (CI) values.  Analysis of TCGA data revealed elevated RAD51 expression in breast tumors compared to normal breast tissues, especially in TNBC subtype.  Interestingly, there was a discrepancy in RAD51 expression in racial groups, with African-American and Asian breast cancer patients showing elevated RAD51 expression compared to Caucasian breast cancer patients.  Consistent with these observations, African-American and Asian TNBC patients show decreased survival.  CONCLUSIONS:  Based on these data, RAD51 could be a biomarker for aggressive TNBC and for racial disparity in breast cancer.  As positive correlation exists between RAD51 and CHEK1 expression in breast cancer, the in vitro preclinical data presented here provides additional mechanistic insights for further evaluation of the rational combination of prexasertib and olaparib for improved outcomes and reduced racial disparity in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnQU9kfkdBxi6Ufuk_1xoTfW6udTcc2eamXFY1tAzgD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrlvV2hug%253D%253D&md5=70eddce7eaa4e071b5b5ad39b7f1a2d6</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1192-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1192-2%26sid%3Dliteratum%253Aachs%26aulast%3DMani%26aufirst%3DC.%26aulast%3DJonnalagadda%26aufirst%3DS.%26aulast%3DLingareddy%26aufirst%3DJ.%26aulast%3DAwasthi%26aufirst%3DS.%26aulast%3DGmeiner%26aufirst%3DW.%2BH.%26aulast%3DPalle%26aufirst%3DK.%26atitle%3DPrexasertib%2520treatment%2520induces%2520homologous%2520recombination%2520deficiency%2520and%2520synergizes%2520with%2520olaparib%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D104%26doi%3D10.1186%2Fs13058-019-1192-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowsheen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span> <span> </span><span class="NLM_article-title">A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">398</span>, <span class="refDoi"> DOI: 10.1038/s41419-019-1628-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41419-019-1628-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31113933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ot1Ogtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=398&issue=6&author=Z.+Songauthor=X.+Tuauthor=Q.+Zhouauthor=J.+Huangauthor=Y.+Chenauthor=J.+Liuauthor=S.+Leeauthor=W.+Kimauthor=S.+Nowsheenauthor=K.+Luoauthor=J.+Yuanauthor=Z.+Lou&title=A+novel+UCHL3+inhibitor%2C+perifosine%2C+enhances+PARP+inhibitor+cytotoxicity+through+inhibition+of+homologous+recombination-mediated+DNA+double+strand+break+repair&doi=10.1038%2Fs41419-019-1628-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair</span></div><div class="casAuthors">Song Zhiwang; Tu Xinyi; Zhou Qin; Huang Jinzhou; Chen Yuping; Liu Jiaqi; Lee SeungBaek; Kim Wootae; Luo Kuntian; Yuan Jian; Lou Zhenkun; Nowsheen Somaira; Luo Kuntian; Yuan Jian; Lou Zhenkun</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">398</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) treatment remains a great challenge for clinical practice and novel therapeutic strategies are urgently needed.  UCHL3 is a deubiquitinase that is overexpressed in TNBC and correlates with poor prognosis.  UCHL3 deubiquitinates RAD51 thereby promoting the recruitment of RAD51 to DNA damage sites and augmenting DNA repair.  Therefore, UCHL3 overexpression can render cancer cells resistant to DNA damage inducing chemo and radiotherapy, and targeting UCHL3 can sensitize TNBC to radiation and chemotherapy.  However, small molecule inhibitors of UCHL3 are yet to be identified.  Here we report that perifosine, a previously reported Akt inhibitor, can inhibit UCHL3 in vitro and in vivo.  We found low dose (50 nM) perifosine inhibited UCHL3 deubiquitination activity without affecting Akt activity.  Furthermore, perifosine enhanced Olaparib-induced growth inhibition in TNBC cells.  Mechanistically, perifosine induced RAD51 ubiquitination and blocked the RAD51-BRCA2 interaction, which in turn decreased ionizing radiation-induced foci (IRIF) of Rad51 and, thereby, homologous recombination (HR)-mediated DNA double strand break repair.  In addition, combination of perifosine and Olaparib showed synergistic antitumor activity in vivo in TNBC xenograft model.  Thus, our present study provides a novel therapeutic approach to optimize PARP inhibitor treatment efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT436YtiSqWi7jnyZkbE8yXfW6udTcc2eamXFY1tAzgD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ot1Ogtg%253D%253D&md5=e93c3688c9eafd6fe98a1360d71b330d</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1038%2Fs41419-019-1628-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-019-1628-8%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DLou%26aufirst%3DZ.%26atitle%3DA%2520novel%2520UCHL3%2520inhibitor%252C%2520perifosine%252C%2520enhances%2520PARP%2520inhibitor%2520cytotoxicity%2520through%2520inhibition%2520of%2520homologous%2520recombination-mediated%2520DNA%2520double%2520strand%2520break%2520repair%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2019%26volume%3D10%26issue%3D6%26spage%3D398%26doi%3D10.1038%2Fs41419-019-1628-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teo, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versaci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dushyanthen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintoff, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zethoven, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virassamy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luen, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span> <span> </span><span class="NLM_article-title">Combined CDK4/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6340</span>– <span class="NLM_lpage">6352</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-2210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-17-2210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28947417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSnur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=6340-6352&issue=22&author=Z.+L.+Teoauthor=S.+Versaciauthor=S.+Dushyanthenauthor=F.+Caramiaauthor=P.+Savasauthor=C.+P.+Mintoffauthor=M.+Zethovenauthor=B.+Virassamyauthor=S.+J.+Luenauthor=G.+A.+McArthurauthor=W.+A.+Phillipsauthor=P.+K.+Darcyauthor=S.+Loi&title=Combined+CDK4%2F6+and+PI3Kalpha+inhibition+is+synergistic+and+immunogenic+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-17-2210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Teo, Zhi Ling; Versaci, Stephanie; Dushyanthen, Sathana; Caramia, Franco; Savas, Peter; Mintoff, Chris P.; Zethoven, Magnus; Virassamy, Balaji; Luen, Stephen J.; McArthur, Grant A.; Phillips, Wayne A.; Darcy, Phillip K.; Loi, Sherene</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6340-6352</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">New treatments for triple-neg. breast cancer (TNBC) are urgently needed.  Despite there being little evidence of clin. activity as single-agent therapies, we show that dual blockade of PI3Kα and CDK4/6 is synergistically effective against multiple RB1-wild-type TNBC models.  Combined PI3Kα and CDK4/6 inhibition significantly increased apoptosis, cell-cycle arrest, and tumor immunogenicity and generated immunogenic cell death in human TNBC cell lines.  Combination treatment also significantly improved disease control in human xenograft models compared with either monotherapy.  Combined PI3Kα and CDK4/6 inhibition significantly increased tumor-infiltrating T-cell activation and cytotoxicity and decreased the frequency of immunosuppressive myeloid-derived suppressor cells in a syngeneic TNBC mouse model.  Notably, combined PI3Kα and CDK4/6 inhibition, along with inhibition of immune checkpoints PD-1 and CTLA-4, induced complete and durable regressions (>1 yr) of established TNBC tumors in vivo.  Overall, our results illustrate convergent mechanisms of PI3Kα and CDK4/6 blockade on cell-cycle progression, DNA damage response, and immune-modulation and may provide a novel therapeutic approach for TNBC.  Cancer Res; 77(22); 6340-52. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSFx4Sw8aPzrVg90H21EOLACvtfcHk0ljOUHnFW5mPKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSnur7M&md5=20b287a3f4e16b6eef46984dd7809d4f</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-2210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-2210%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DZ.%2BL.%26aulast%3DVersaci%26aufirst%3DS.%26aulast%3DDushyanthen%26aufirst%3DS.%26aulast%3DCaramia%26aufirst%3DF.%26aulast%3DSavas%26aufirst%3DP.%26aulast%3DMintoff%26aufirst%3DC.%2BP.%26aulast%3DZethoven%26aufirst%3DM.%26aulast%3DVirassamy%26aufirst%3DB.%26aulast%3DLuen%26aufirst%3DS.%2BJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DPhillips%26aufirst%3DW.%2BA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DLoi%26aufirst%3DS.%26atitle%3DCombined%2520CDK4%252F6%2520and%2520PI3Kalpha%2520inhibition%2520is%2520synergistic%2520and%2520immunogenic%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D22%26spage%3D6340%26epage%3D6352%26doi%3D10.1158%2F0008-5472.CAN-17-2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coussy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Botty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chateau-Joubert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montaudon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leboucher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisset, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painsec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sourd, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servely, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rosa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucotte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foidart, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sounni, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaudin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ter Brugge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonkers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieche, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangoni, E.</span></span> <span> </span><span class="NLM_article-title">BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">531</span>),  <span class="NLM_fpage">eaax2625</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aax2625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1126%2Fscitranslmed.aax2625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32075943" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eaax2625&issue=531&author=F.+Coussyauthor=R.+El-Bottyauthor=S.+Chateau-Joubertauthor=A.+Dahmaniauthor=E.+Montaudonauthor=S.+Leboucherauthor=L.+Morissetauthor=P.+Painsecauthor=L.+Sourdauthor=L.+Huguetauthor=F.+Nematiauthor=J.+L.+Servelyauthor=T.+Larcherauthor=S.+Vacherauthor=A.+Briauxauthor=C.+Reyesauthor=P.+La+Rosaauthor=G.+Lucotteauthor=T.+Popovaauthor=P.+Foidartauthor=N.+E.+Sounniauthor=A.+Noelauthor=D.+Decaudinauthor=L.+Fuhrmannauthor=A.+Salomonauthor=F.+Reyalauthor=C.+Muellerauthor=P.+Ter+Bruggeauthor=J.+Jonkersauthor=M.+F.+Pouponauthor=M.+H.+Sternauthor=I.+Biecheauthor=Y.+Pommierauthor=E.+Marangoni&title=BRCAness%2C+SLFN11%2C+and+RB1+loss+predict+response+to+topoisomerase+I+inhibitors+in+triple-negative+breast+cancers&doi=10.1126%2Fscitranslmed.aax2625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aax2625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aax2625%26sid%3Dliteratum%253Aachs%26aulast%3DCoussy%26aufirst%3DF.%26aulast%3DEl-Botty%26aufirst%3DR.%26aulast%3DChateau-Joubert%26aufirst%3DS.%26aulast%3DDahmani%26aufirst%3DA.%26aulast%3DMontaudon%26aufirst%3DE.%26aulast%3DLeboucher%26aufirst%3DS.%26aulast%3DMorisset%26aufirst%3DL.%26aulast%3DPainsec%26aufirst%3DP.%26aulast%3DSourd%26aufirst%3DL.%26aulast%3DHuguet%26aufirst%3DL.%26aulast%3DNemati%26aufirst%3DF.%26aulast%3DServely%26aufirst%3DJ.%2BL.%26aulast%3DLarcher%26aufirst%3DT.%26aulast%3DVacher%26aufirst%3DS.%26aulast%3DBriaux%26aufirst%3DA.%26aulast%3DReyes%26aufirst%3DC.%26aulast%3DLa%2BRosa%26aufirst%3DP.%26aulast%3DLucotte%26aufirst%3DG.%26aulast%3DPopova%26aufirst%3DT.%26aulast%3DFoidart%26aufirst%3DP.%26aulast%3DSounni%26aufirst%3DN.%2BE.%26aulast%3DNoel%26aufirst%3DA.%26aulast%3DDecaudin%26aufirst%3DD.%26aulast%3DFuhrmann%26aufirst%3DL.%26aulast%3DSalomon%26aufirst%3DA.%26aulast%3DReyal%26aufirst%3DF.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DTer%2BBrugge%26aufirst%3DP.%26aulast%3DJonkers%26aufirst%3DJ.%26aulast%3DPoupon%26aufirst%3DM.%2BF.%26aulast%3DStern%26aufirst%3DM.%2BH.%26aulast%3DBieche%26aufirst%3DI.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DMarangoni%26aufirst%3DE.%26atitle%3DBRCAness%252C%2520SLFN11%252C%2520and%2520RB1%2520loss%2520predict%2520response%2520to%2520topoisomerase%2520I%2520inhibitors%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26issue%3D531%26spage%3Deaax2625%26doi%3D10.1126%2Fscitranslmed.aax2625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerratana, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponnetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Loreto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garattini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damante, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puglisi, F.</span></span> <span> </span><span class="NLM_article-title">BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>144</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">766</span>, <span class="refDoi"> DOI: 10.1002/ijc.31898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fijc.31898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30259975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlylu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2019&pages=755-766&issue=4&author=C.+Mioauthor=L.+Gerratanaauthor=M.+Bolisauthor=F.+Caponnettoauthor=A.+Zanelloauthor=M.+Barbinaauthor=C.+Di+Loretoauthor=E.+Garattiniauthor=G.+Damanteauthor=F.+Puglisi&title=BET+proteins+regulate+homologous+recombination-mediated+DNA+repair%3A+BRCAness+and+implications+for+cancer+therapy&doi=10.1002%2Fijc.31898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy</span></div><div class="casAuthors">Mio, Catia; Gerratana, Lorenzo; Bolis, Marco; Caponnetto, Federica; Zanello, Andrea; Barbina, Mattia; Di Loreto, Carla; Garattini, Enrico; Damante, Giuseppe; Puglisi, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">755-766</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Bromodomain and Extra-Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage regulation.  Aims of our study were to assess BRD4 regulation in homologous recombination-mediated DNA repair and to explore novel clin. strategies through the combinations of the pharmacol. induction of epigenetic BRCAness in BRCA1 wild-type triple neg. breast cancer (TNBC) cells by means of BET inhibitors and compds. already available in clinic.  Performing a dual approach (chromatin immunopptn. and RNA interference), the direct relationship between BRD4 and BRCA1/RAD51 expression was confirmed in TNBC cells.  Moreover, BRD4 pharmacol. inhibition using two BET inhibitors (JQ1 and GSK525762A) induced a dose-dependent redn. in BRCA1 and RAD51 levels and is able to hinder homologous recombination-mediated DNA damage repair, generating a BRCAness phenotype in TNBC cells.  Furthermore, BET inhibition impaired the ability of TNBC cells to overcome the increase in DNA damage after platinum salts (i.e., CDDP) exposure, leading to massive cell death, and triggered synthetic lethality when combined with PARP inhibitors (i.e., AZD2281).  Altogether, the present study confirms that BET proteins directly regulate the homologous recombination pathway and their inhibition induced a BRCAness phenotype in BRCA1 wild-type TNBC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru1lYhArJSOLVg90H21EOLACvtfcHk0ljOUHnFW5mPKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlylu7vP&md5=8ff945e7f264b99721c855d122412cd7</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1002%2Fijc.31898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.31898%26sid%3Dliteratum%253Aachs%26aulast%3DMio%26aufirst%3DC.%26aulast%3DGerratana%26aufirst%3DL.%26aulast%3DBolis%26aufirst%3DM.%26aulast%3DCaponnetto%26aufirst%3DF.%26aulast%3DZanello%26aufirst%3DA.%26aulast%3DBarbina%26aufirst%3DM.%26aulast%3DDi%2BLoreto%26aufirst%3DC.%26aulast%3DGarattini%26aufirst%3DE.%26aulast%3DDamante%26aufirst%3DG.%26aulast%3DPuglisi%26aufirst%3DF.%26atitle%3DBET%2520proteins%2520regulate%2520homologous%2520recombination-mediated%2520DNA%2520repair%253A%2520BRCAness%2520and%2520implications%2520for%2520cancer%2520therapy%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D144%26issue%3D4%26spage%3D755%26epage%3D766%26doi%3D10.1002%2Fijc.31898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bevill, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivares-Quintero, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciaky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitz, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuhlmiller, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistowski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span> <span> </span><span class="NLM_article-title">GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-18-1121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1541-7786.MCR-18-1121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31000582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=1503-1518&issue=7&author=S.+M.+Bevillauthor=J.+F.+Olivares-Quinteroauthor=N.+Sciakyauthor=B.+T.+Golitzauthor=D.+Singhauthor=A.+S.+Beltranauthor=N.+U.+Rashidauthor=T.+J.+Stuhlmillerauthor=A.+Haleauthor=N.+J.+Moormanauthor=C.+M.+Santosauthor=S.+P.+Angusauthor=J.+S.+Zawistowskiauthor=G.+L.+Johnson&title=GSK2801%2C+a+BAZ2%2FBRD9+bromodomain+inhibitor%2C+synergizes+with+BET+inhibitors+to+induce+apoptosis+in+triple-negative+breast+cancer&doi=10.1158%2F1541-7786.MCR-18-1121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer</span></div><div class="casAuthors">Bevill, Samantha M.; Olivares-Quintero, Jose F.; Sciaky, Noah; Golitz, Brian T.; Singh, Darshan; Beltran, Adriana S.; Rashid, Naim U.; Stuhlmiller, Timothy J.; Hale, Andrew; Moorman, Nathaniel J.; Santos, Charlene M.; Angus, Steven P.; Zawistowski, Jon S.; Johnson, Gary L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1503-1518</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Screening of an inhibitor library targeting kinases and epigenetic regulators identified several mols. having antiproliferative synergy with extraterminal domain (BET) bromodomain (BD) inhibitors (JQ1, OTX015) in triple-neg. breast cancer (TNBC).  GSK2801, an inhibitor of BAZ2A/B BDs, of the imitation switch chromatin remodeling complexes, and BRD9, of the SWI/SNF complex, demonstrated synergy independent of BRD4 control of P-TEFb-mediated pause-release of RNA polymerase II.  GSK2801 or RNAi knockdown of BAZ2A/B with JQ1 selectively displaced BRD2 at promoters/enhancers of ETS-regulated genes.  Addnl. displacement of BRD2 from rDNA in the nucleolus coincided with decreased 45S rRNA, revealing a function of BRD2 in regulating RNA polymerase I transcription.  In 2D cultures, enhanced displacement of BRD2 from chromatin by combination drug treatment induced senescence.  In spheroid cultures, combination treatment induced cleaved caspase-3 and cleaved PARP characteristic of apoptosis in tumor cells.  Thus, GSK2801 blocks BRD2-driven transcription in combination with BET inhibitor and induces apoptosis of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8LuqCVf4RdrVg90H21EOLACvtfcHk0lhtO9zY0XDjbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1KjsL3K&md5=b3304c5c41820df4070bf24ea1000e37</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-18-1121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-18-1121%26sid%3Dliteratum%253Aachs%26aulast%3DBevill%26aufirst%3DS.%2BM.%26aulast%3DOlivares-Quintero%26aufirst%3DJ.%2BF.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DGolitz%26aufirst%3DB.%2BT.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DBeltran%26aufirst%3DA.%2BS.%26aulast%3DRashid%26aufirst%3DN.%2BU.%26aulast%3DStuhlmiller%26aufirst%3DT.%2BJ.%26aulast%3DHale%26aufirst%3DA.%26aulast%3DMoorman%26aufirst%3DN.%2BJ.%26aulast%3DSantos%26aufirst%3DC.%2BM.%26aulast%3DAngus%26aufirst%3DS.%2BP.%26aulast%3DZawistowski%26aufirst%3DJ.%2BS.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26atitle%3DGSK2801%252C%2520a%2520BAZ2%252FBRD9%2520bromodomain%2520inhibitor%252C%2520synergizes%2520with%2520BET%2520inhibitors%2520to%2520induce%2520apoptosis%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D7%26spage%3D1503%26epage%3D1518%26doi%3D10.1158%2F1541-7786.MCR-18-1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y.</span></span> <span> </span><span class="NLM_article-title">Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2</span>. <i>Pathol., Res. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>215</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">152422</span>, <span class="refDoi"> DOI: 10.1016/j.prp.2019.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.prp.2019.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31079851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXps1Wjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2019&pages=152422&issue=7&author=Z.+Gaoauthor=M.+Shiauthor=Y.+Wangauthor=J.+Chenauthor=Y.+Ou&title=Apatinib+enhanced+anti-tumor+activity+of+cisplatin+on+triple-negative+breast+cancer+through+inhibition+of+VEGFR-2&doi=10.1016%2Fj.prp.2019.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2</span></div><div class="casAuthors">Gao, Zhenyuan; Shi, Mohan; Wang, Yaping; Chen, Juan; Ou, Yimei</div><div class="citationInfo"><span class="NLM_cas:title">Pathology, Research and Practice</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">152422</span>CODEN:
                <span class="NLM_cas:coden">PARPDS</span>;
        ISSN:<span class="NLM_cas:issn">0344-0338</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) was known as a fast-growing and an aggressive tumor.  Cisplatin is the effective cytotoxic drug used for the treatment of TNBC.  In addn., apatinib, a VEGFR2 inhibitor, exhibits antitumor activity in patients with TNBC.  However, the effects of combination of apatinib with cisplatin on TNBC remain unclear.  Thus, this study aimed to investigate the effects of apatinib in combination with cisplatin on MDA-MB-231 cells.  Immunohistochem. was used to detect the expression of VEGFR2.  In addn., CCK-8, flow cytometric, transwell assays were used to measure the cell proliferation, apoptosis, migration and invasion, resp.  Moreover, western blotting was used to detect the expressions of Bax, active caspase 3, p-VEGFR2, p-Akt and p-mTOR.  VEGFR2 was significantly upreguated in patients with TNBC.  In addn., the inhibitory effects of cisplatin on the proliferation, migration and invasion of MDA-MB-231 cells were enhanced by apatinib.  Moreover, apatinib increased cisplatin-induced apoptosis on MDA-MB-231 cells via increasing the level of Bax and active caspase 3 and decreasing the expression of Bcl-2.  Importantly, apatinib enhanced anti-tumor effect of cisplatin on MDA-MB-231 cells via inhibiting the levels of p-VEGFR2, p-Akt and p-mTOR.  Our findings indicated that apatinib enhanced the anti-tumor effects of cisplatin on MDA-MB-231 cells via inhibition of VEGFR2.  Thus, the combination of apatinib with cisplatin may serve as a potential approach in the treatment of patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWorp1QdfezbVg90H21EOLACvtfcHk0lhtO9zY0XDjbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXps1Wjt78%253D&md5=57db6debfe0930649b02ec01123c12ef</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.prp.2019.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prp.2019.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DOu%26aufirst%3DY.%26atitle%3DApatinib%2520enhanced%2520anti-tumor%2520activity%2520of%2520cisplatin%2520on%2520triple-negative%2520breast%2520cancer%2520through%2520inhibition%2520of%2520VEGFR-2%26jtitle%3DPathol.%252C%2520Res.%2520Pract.%26date%3D2019%26volume%3D215%26issue%3D7%26spage%3D152422%26doi%3D10.1016%2Fj.prp.2019.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheatley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemsadze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conibear, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foxley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEwen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin-Callan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartwright, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span> <span> </span><span class="NLM_article-title">Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1200/JCO.19.00368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.19.00368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31841354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGmurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=423-433&issue=5&author=P.+Schmidauthor=J.+Abrahamauthor=S.+Chanauthor=D.+Wheatleyauthor=A.+M.+Bruntauthor=G.+Nemsadzeauthor=R.+D.+Bairdauthor=Y.+H.+Parkauthor=P.+S.+Hallauthor=T.+Perrenauthor=R.+C.+Steinauthor=L.+Mangelauthor=J.+M.+Ferreroauthor=M.+Phillipsauthor=J.+Conibearauthor=J.+Cortesauthor=A.+Foxleyauthor=E.+C.+de+Bruinauthor=R.+McEwenauthor=D.+Stetsonauthor=B.+Doughertyauthor=S.+J.+Sarkerauthor=A.+Prendergastauthor=M.+McLaughlin-Callanauthor=M.+Burgessauthor=C.+Lawrenceauthor=H.+Cartwrightauthor=K.+Mousaauthor=N.+C.+Turner&title=Capivasertib+plus+paclitaxel+versus+placebo+plus+paclitaxel+as+first-line+therapy+for+metastatic+triple-negative+breast+cancer%3A+The+PAKT+trial&doi=10.1200%2FJCO.19.00368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic 1triple-negative breast cancer: the PAKT trial</span></div><div class="casAuthors">Schmid, Peter; Abraham, Jacinta; Chan, Stephen; Wheatley, Duncan; Brunt, Adrian Murray; Nemsadze, Gia; Baird, Richard D.; Park, Yeon Hee; Hall, Peter S.; Perren, Timothy; Stein, Robert C.; Mangel, Laszlo; Ferrero, Jean-Marc; Phillips, Melissa; Conibear, John; Cortes, Javier; Foxley, Andrew; Bruin, Elza C. de; McEwen, Robert; Stetson, Daniel; Dougherty, Brian; Sarker, Shah-Jalal; Prendergast, Aaron; McLaughlin-Callan, Max; Burgess, Matthew; Lawrence, Cheryl; Cartwright, Hayley; Mousa, Kelly; Turner, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">423-437</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in tripleneg. breast cancer (TNBC).  The AKT inhibitor capivasertib has shown preclin. activity in TNBC models, and drug sensitivity has been assocd. with activation of PI3K or AKT and/or deletions of PTEN.  The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC.  PATIENTS AND METHODS This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC.  A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity.  The primary end point was progression-free survival (PFS).  Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/AKT1/PTEN alterations, tumor response, and safety.  RESULTS Median PFS was 5.9 mo with capivasertib plus paclitaxel and 4.2 mo with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]).  Median OS was 19.1 mo with capivasertib plus paclitaxel and 12.6 mo with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04).  In patients with PIK3CA/AKT1/PTEN-altered tumors (n = 28), median PFS was 9.3 mo with capivasertib plus paclitaxel and 3.7 mo with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01).  The most common grade $ 3 adverse events in those treated with capivasertib plus paclitaxel vs. placebo plus paclitaxel, resp., were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%).  CONCLUSION Addn. of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS.  Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors.  Capivasertib warrants further investigation for treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_uNGmJRJlk7Vg90H21EOLACvtfcHk0lhtO9zY0XDjbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGmurrF&md5=079c77790ce5973be64ec4b93d28280d</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1200%2FJCO.19.00368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.19.00368%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DAbraham%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DWheatley%26aufirst%3DD.%26aulast%3DBrunt%26aufirst%3DA.%2BM.%26aulast%3DNemsadze%26aufirst%3DG.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DHall%26aufirst%3DP.%2BS.%26aulast%3DPerren%26aufirst%3DT.%26aulast%3DStein%26aufirst%3DR.%2BC.%26aulast%3DMangel%26aufirst%3DL.%26aulast%3DFerrero%26aufirst%3DJ.%2BM.%26aulast%3DPhillips%26aufirst%3DM.%26aulast%3DConibear%26aufirst%3DJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DFoxley%26aufirst%3DA.%26aulast%3Dde%2BBruin%26aufirst%3DE.%2BC.%26aulast%3DMcEwen%26aufirst%3DR.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DSarker%26aufirst%3DS.%2BJ.%26aulast%3DPrendergast%26aufirst%3DA.%26aulast%3DMcLaughlin-Callan%26aufirst%3DM.%26aulast%3DBurgess%26aufirst%3DM.%26aulast%3DLawrence%26aufirst%3DC.%26aulast%3DCartwright%26aufirst%3DH.%26aulast%3DMousa%26aufirst%3DK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DCapivasertib%2520plus%2520paclitaxel%2520versus%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%253A%2520The%2520PAKT%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26issue%3D5%26spage%3D423%26epage%3D433%26doi%3D10.1200%2FJCO.19.00368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapp, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslyar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1360</span>– <span class="NLM_lpage">1372</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30450-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2FS1470-2045%2817%2930450-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28800861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSrtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1360-1372&issue=10&author=S.+B.+Kimauthor=R.+Dentauthor=S.+A.+Imauthor=M.+Espieauthor=S.+Blauauthor=A.+R.+Tanauthor=S.+J.+Isakoffauthor=M.+Oliveiraauthor=C.+Sauraauthor=M.+J.+Wongchenkoauthor=A.+V.+Kappauthor=W.+Y.+Chanauthor=S.+M.+Singelauthor=D.+J.+Maslyarauthor=J.+Baselga&title=Ipatasertib+plus+paclitaxel+versus+placebo+plus+paclitaxel+as+first-line+therapy+for+metastatic+triple-negative+breast+cancer+%28LOTUS%29%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2+trial&doi=10.1016%2FS1470-2045%2817%2930450-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial</span></div><div class="casAuthors">Kim, Sung-Bae; Dent, Rebecca; Im, Seock-Ah; Espie, Marc; Blau, Sibel; Tan, Antoinette R.; Isakoff, Steven J.; Oliveira, Mafalda; Saura, Cristina; Wongchenko, Matthew J.; Kapp, Amy V.; Chan, Wai Y.; Singel, Stina M.; Maslyar, Daniel J.; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1360-1372</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-neg. breast cancer.  The LOTUS trial investigated the addn. of ipatasertib to paclitaxel as first-line therapy for triple-neg. breast cancer.  In this randomized, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-neg. breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium.  Enrolled patients were randomly assigned (1:1) to receive i.v. paclitaxel 80 mg/m2 (days 1, 8, 15) with either ipatasertib 400 mg or placebo once per day (days 1-21) every 28 days until disease progression or unacceptable toxicity.  Randomisation was by stratified permuted blocks (block size of four) using an interactive web-response system with three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumor PTEN status.  The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohistochem.) population.  This ongoing trial is registered with ClinicalTrials.gov (NCT02162719).  Between Sept 2, 2014, and Feb 4, 2016, 166 patients were assessed for eligibility and 124 patients were enrolled and randomly assigned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus placebo (n=62).  Median follow-up was 10·4 mo (IQR 6·5-14·1) in the ipatasertib group and 10·2 mo (6·0-13·6) in the placebo group.  Median progression-free survival in the intention-to-treat population was 6·2 mo (95% CI 3·8-9·0) with ipatasertib vs. 4·9 mo (3·6-5·4) with placebo (stratified hazard ratio [HR] 0·60, 95% CI 0·37-0·98; p=0·037) and in the 48 patients with PTEN-low tumors, median progression-free survival was 6·2 mo (95% CI 3·6-9·1) with ipatasertib vs. 3·7 mo (1·9-7·3) with placebo (stratified HR 0·59, 95% CI 0·26-1·32, p=0·18).  The most common grade 3 or worse adverse events were diarrhea (14 [23%] of 61 ipatasertib-treated patients vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]).  No colitis, grade 4 diarrhea, or treatment-related deaths were reported with ipatasertib.  One treatment-related death occurred in the placebo group.  Serious adverse events were reported in 17 (28%) of 61 patients in the ipatasertib group and nine (15%) of 62 patients in the placebo group.  Progression-free survival was longer in patients who received ipatasertib than in those who received placebo.  To our knowledge, these are the first results supporting AKT-targeted therapy for triple-neg. breast cancer.  Ipatasertib warrants further investigation for the treatment of triple-neg. breast cancer.F Hoffmann-La Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUHDoupzZvn7Vg90H21EOLACvtfcHk0lhAOaYORn0AlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSrtbjO&md5=411d3aeae55045b4241c617922b711d5</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930450-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930450-3%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DDent%26aufirst%3DR.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DEspie%26aufirst%3DM.%26aulast%3DBlau%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DA.%2BR.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DOliveira%26aufirst%3DM.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DWongchenko%26aufirst%3DM.%2BJ.%26aulast%3DKapp%26aufirst%3DA.%2BV.%26aulast%3DChan%26aufirst%3DW.%2BY.%26aulast%3DSingel%26aufirst%3DS.%2BM.%26aulast%3DMaslyar%26aufirst%3DD.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DIpatasertib%2520plus%2520paclitaxel%2520versus%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528LOTUS%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D10%26spage%3D1360%26epage%3D1372%26doi%3D10.1016%2FS1470-2045%2817%2930450-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akcakanat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palla, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewster, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valero, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder-Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryden, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symmans, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span> <span> </span><span class="NLM_article-title">Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancerdagger</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdu124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdu124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24669015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC2crnslCnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1122-1127&issue=6&author=A.+M.+Gonzalez-Anguloauthor=A.+Akcakanatauthor=S.+Liuauthor=M.+C.+Greenauthor=J.+L.+Murrayauthor=H.+Chenauthor=S.+L.+Pallaauthor=K.+B.+Koenigauthor=A.+M.+Brewsterauthor=V.+Valeroauthor=N.+K.+Ibrahimauthor=S.+Moulder-Thompsonauthor=J.+K.+Littonauthor=E.+Tarcoauthor=J.+Mooreauthor=P.+Floresauthor=D.+Crawfordauthor=M.+J.+Drydenauthor=W.+F.+Symmansauthor=A.+Sahinauthor=S.+H.+Giordanoauthor=L.+Pusztaiauthor=K.+A.+Doauthor=G.+B.+Millsauthor=G.+N.+Hortobagyiauthor=F.+Meric-Bernstam&title=Open-label+randomized+clinical+trial+of+standard+neoadjuvant+chemotherapy+with+paclitaxel+followed+by+FEC+versus+the+combination+of+paclitaxel+and+everolimus+followed+by+FEC+in+women+with+triple+receptor-negative+breast+cancerdagger&doi=10.1093%2Fannonc%2Fmdu124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†</span></div><div class="casAuthors">Gonzalez-Angulo A M; Akcakanat A; Liu S; Murray J L; Chen H; Koenig K B; Valero V; Ibrahim N K; Moulder-Thompson S; Litton J K; Tarco E; Moore J; Flores P; Crawford D; Giordano S H; Hortobagyi G N; Green M C; Palla S L; Do K-A; Brewster A M; Dryden M J; Symmans W F; Sahin A; Pusztai L; Mills G B; Meric-Bernstam F</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1122-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Everolimus synergistically enhances taxane-induced cytotoxicity in breast cancer cells in vitro and in vivo in addition to demonstrating a direct antiproliferative activity.  We aim to determine pharmacodynamics changes and response of adding everolimus to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC).  PATIENTS AND METHODS:  Phase II study in patients with primary TNBC randomized to T-FEC (paclitaxel 80 mg/m(2) i.v. weekly for 12 weeks, followed by 5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2) every 3 weeks for four cycles) versus TR-FEC (paclitaxel 80 mg/m(2) i.v. and everolimus 30 mg PO weekly for 12 weeks, followed by FEC).  Tumor samples were collected to assess molecular changes in the PI3K/AKT/mTOR pathway, at baseline, 48 h, 12 weeks, and at surgery by reverse phase protein arrays (RPPA).  Clinical end points included 12-week clinical response rate (12-week RR), pathological complete response (pCR), and toxicity.  RESULTS:  Sixty-two patients were registered, and 50 were randomized, 27 received T-FEC, and 23 received TR-FEC.  Median age was 48 (range 31-75).  There was downregulation of the mTOR pathway at 48 h in the TR-FEC arm.  Twelve-week RR by ultrasound were 29.6% versus 47.8%, (P = 0.075), and pCR were 25.9% versus 30.4% (P = 0.76) for T-FEC and TR-FEC, respectively. mTOR downregulation at 48 h did not correlate with 12-week RR in the TR-FEC group (P = 0.58).  Main NCI grade 3/4 toxicities included anemia, neutropenia, rash/desquamation, and vomiting in both arms.  There was one case of grade 3 pneumonitis in the TR-FEC arm.  No grade 3/4 stomatitis occurred.  CONCLUSION:  The addition of everolimus to paclitaxel was well tolerated.  Everolimus downregulated mTOR signaling but downregulation of mTOR at 48 h did not correlate with 12-week RR in the TR-FEC group.  CLINICAL TRIAL NUMBER:  NCT00499603.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIm9medsz0NG52AMpI4GK2fW6udTcc2ebnbX5822Sbdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crnslCnsQ%253D%253D&md5=4777f3c79c797d21b00bc3c2de5279e8</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu124%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DAkcakanat%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DM.%2BC.%26aulast%3DMurray%26aufirst%3DJ.%2BL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DPalla%26aufirst%3DS.%2BL.%26aulast%3DKoenig%26aufirst%3DK.%2BB.%26aulast%3DBrewster%26aufirst%3DA.%2BM.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DIbrahim%26aufirst%3DN.%2BK.%26aulast%3DMoulder-Thompson%26aufirst%3DS.%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DTarco%26aufirst%3DE.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DFlores%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DD.%26aulast%3DDryden%26aufirst%3DM.%2BJ.%26aulast%3DSymmans%26aufirst%3DW.%2BF.%26aulast%3DSahin%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DS.%2BH.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DDo%26aufirst%3DK.%2BA.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26atitle%3DOpen-label%2520randomized%2520clinical%2520trial%2520of%2520standard%2520neoadjuvant%2520chemotherapy%2520with%2520paclitaxel%2520followed%2520by%2520FEC%2520versus%2520the%2520combination%2520of%2520paclitaxel%2520and%2520everolimus%2520followed%2520by%2520FEC%2520in%2520women%2520with%2520triple%2520receptor-negative%2520breast%2520cancerdagger%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26issue%3D6%26spage%3D1122%26epage%3D1127%26doi%3D10.1093%2Fannonc%2Fmdu124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffa, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khadang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachim, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakdounes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrun, J.-J.</span></span> <span> </span><span class="NLM_article-title">Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1495</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0287-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41416-018-0287-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30482914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVaksL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=1495-1507&issue=12&author=J.+Tianauthor=F.+A.+Raffaauthor=M.+Daiauthor=A.+Moamerauthor=B.+Khadangauthor=I.+Y.+Hachimauthor=K.+Bakdounesauthor=S.+Aliauthor=B.+Jean-Claudeauthor=J.-J.+Lebrun&title=Dasatinib+sensitises+triple+negative+breast+cancer+cells+to+chemotherapy+by+targeting+breast+cancer+stem+cells&doi=10.1038%2Fs41416-018-0287-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells</span></div><div class="casAuthors">Tian, Jun; Raffa, Fatmah Al; Dai, Meiou; Moamer, Alaa; Khadang, Baharak; Hachim, Ibrahim Y.; Bakdounes, Khldoun; Ali, Suhad; Jean-Claude, Bertrand; Lebrun, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Patients with triple neg. breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumor relapse, due to the resistance to chemotherapy.  These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs).  Therefore, targeting BCSCs is a priority to overcoming chemotherapy failure in TNBCs.  Methods: We generated paclitaxel (pac)-resistant TNBC cells which displayed higher sphere forming potential and percentage of BCSC subpopulations compared to the parental cells.  A screen with various kinase inhibitors revealed dasatinib, a Src kinase family inhibitor, as a potent suppressor of BCSC expansion/sphere formation in pac-resistant TNBC cells.  Results: We found dasatinib to block pac-induced BCSC enrichment and Src activation in both parental and pac-resistant TNBC cells.  Interestingly, dasatinib induced an epithelial differentiation of the pac-resistant mesenchymal cells, resulting in their enhanced sensitivity to paclitaxel.  The combination treatment of dasatinib and paclitaxel not only decreased the BCSCs nos. and their sphere forming capacity but also synergistically reduced cell viability of pac-resistant cells.  Preclin. models of breast cancer further demonstrated the efficiency of the dasatinib/paclitaxel combination treatment in inhibiting tumor growth.  Conclusions: Dasatinib is a promising anti-BCSC drug that could be used in combination with paclitaxel to overcome chemoresistance in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooLMaSt2TkzbVg90H21EOLACvtfcHk0lg2kdITvJ4PYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVaksL7N&md5=c5248d79468d37a906fcd473da99dde6</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0287-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0287-3%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DRaffa%26aufirst%3DF.%2BA.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DMoamer%26aufirst%3DA.%26aulast%3DKhadang%26aufirst%3DB.%26aulast%3DHachim%26aufirst%3DI.%2BY.%26aulast%3DBakdounes%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DJean-Claude%26aufirst%3DB.%26aulast%3DLebrun%26aufirst%3DJ.-J.%26atitle%3DDasatinib%2520sensitises%2520triple%2520negative%2520breast%2520cancer%2520cells%2520to%2520chemotherapy%2520by%2520targeting%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D119%26issue%3D12%26spage%3D1495%26epage%3D1507%26doi%3D10.1038%2Fs41416-018-0287-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speyer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhsh, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafry, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, D. H.</span></span> <span> </span><span class="NLM_article-title">Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>166</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1007/s10549-017-4435-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-017-4435-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28780701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yhsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2017&pages=407-419&issue=2&author=C.+L.+Speyerauthor=M.+A.+Bukhshauthor=W.+S.+Jafryauthor=R.+E.+Sextonauthor=S.+Bandyopadhyayauthor=D.+H.+Gorski&title=Riluzole+synergizes+with+paclitaxel+to+inhibit+cell+growth+and+induce+apoptosis+in+triple-negative+breast+cancer&doi=10.1007%2Fs10549-017-4435-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer</span></div><div class="casAuthors">Speyer, Cecilia L.; Bukhsh, Miriam A.; Jafry, Waris S.; Sexton, Rachael E.; Bandyopadhyay, Sudeshna; Gorski, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">407-419</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: One in eight women will develop breast cancer, 15-20% of whom will have triple-neg. breast cancer (TNBC), an aggressive breast cancer with no current targeted therapy.  We have demonstrated that riluzole, an FDA-approved drug for treating amyotrophic lateral sclerosis, inhibits growth of TNBC.  In this study, we explore potential synergism between riluzole and paclitaxel, a chemotherapeutic agent commonly used to treat TNBC, in regulating TNBC proliferation, cell cycle arrest, and apoptosis.  Methods: TNBC cells were treated with paclitaxel and/or riluzole and synergistic effects on cell proliferation were quantified via MTT assay and CompuSyn anal.  Apoptosis was obsd. morphol. and by measuring cleaved PARP/caspase three products.  Microarray anal. was performed using MDA-MB-231 cells to examine cell cycle genes regulated by riluzole and any enhanced effects on paclitaxel-mediated cell cycle arrest, detd. by FACS anal.  These results were confirmed in vivo using a MDA-MB-231 xenograft model.  Results: Strong enhanced or synergistic effects of riluzole on paclitaxel regulation of cell cycle progression and apoptosis was demonstrated in all TNBC cells tested as well as in the xenograft model.  The MDA-MB-231, SUM149, and SUM229 cells, which are resistant to paclitaxel treatment, demonstrated the strongest synergistic or enhanced effect.  Key protein kinases were shown to be upregulated in this study by riluzole as well as downstream cell cycle genes regulated by these kinases.  Conclusions: All TNBC cells tested responded synergistically to riluzole and paclitaxel strongly suggesting the usefulness of this combinatorial treatment strategy in TNBC, esp. for patients whose tumors are relatively resistant to paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Au2QHDuFELVg90H21EOLACvtfcHk0lg2kdITvJ4PYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yhsrfJ&md5=155ac53ac9ec244d63c1fe0b28cfd44f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1007%2Fs10549-017-4435-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-017-4435-x%26sid%3Dliteratum%253Aachs%26aulast%3DSpeyer%26aufirst%3DC.%2BL.%26aulast%3DBukhsh%26aufirst%3DM.%2BA.%26aulast%3DJafry%26aufirst%3DW.%2BS.%26aulast%3DSexton%26aufirst%3DR.%2BE.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26aulast%3DGorski%26aufirst%3DD.%2BH.%26atitle%3DRiluzole%2520synergizes%2520with%2520paclitaxel%2520to%2520inhibit%2520cell%2520growth%2520and%2520induce%2520apoptosis%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2017%26volume%3D166%26issue%3D2%26spage%3D407%26epage%3D419%26doi%3D10.1007%2Fs10549-017-4435-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Borrego, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Martorell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail-Khan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3126</span>– <span class="NLM_lpage">3133</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.74.8392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2017.74.8392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFylsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=3126-3133&author=A.+Bardiaauthor=M.+Partonauthor=S.+Kummelauthor=L.+G.+Estevezauthor=C.+S.+Huangauthor=J.+Cortesauthor=M.+Ruiz-Borregoauthor=M.+L.+Telliauthor=P.+Martin-Martorellauthor=R.+Lopezauthor=J.+T.+Beckauthor=R.+Ismail-Khanauthor=S.+C.+Chenauthor=S.+A.+Hurvitzauthor=I.+A.+Mayerauthor=D.+Carreonauthor=S.+Cameronauthor=S.+Liaoauthor=J.+Baselgaauthor=S.+B.+Kim&title=Paclitaxel+With+Inhibitor+of+Apoptosis+Antagonist%2C+LCL161%2C+for+Localized+Triple-Negative+Breast+Cancer%2C+Prospectively+Stratified+by+Gene+Signature+in+a+Biomarker-Driven+Neoadjuvant+Trial&doi=10.1200%2FJCO.2017.74.8392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial</span></div><div class="casAuthors">Bardia, Aditya; Parton, Marina; Kummel, Sherko; Estevez, Laura G.; Huang, Chiun-Sheng; Cortes, Javier; Ruiz-Borrego, Manuel; Telli, Melinda L.; Martin-Martorell, Paloma; Lopez, Rafael; Beck, J. Thaddeus; Ismail-Khan, Roohi; Chen, Shin-Cheh; Hurvitz, Sara A.; Mayer, Ingrid A.; Carreon, Daniel; Cameron, Scott; Liao, Serena; Baselga, Jose; Kim, Sung-Bae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">3126-3133</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The primary objective was to det. whether neoadjuvant LCL161 enhances efficacy of paclitaxel, defined by > 7.5% increase in the pathol. complete response (pCR, breast) rate, stratified by GS.  Results Of 209 patients enrolled (207 with valid GS scores), 30.4% had GS-pos. TNBC.  In the GS-pos. group, pCR was higher in the combination vs. the control arm (38.2% v 17.2%), with 88.8% posterior probability of > 7.5% increase in pCR.  However, in the GS-neg. group, the pCR was lower in the combination group (5.6% v 16.4%), with 0% posterior probability of > 7.5% increase in pCR.  A higher incidence of grade 3 or 4 adverse events in the combination arm included neutropenia (24.5%) and diarrhea (5.7%).  Overall, 19 patients (18.1%) in the combination arm discontinued treatment because of adverse events, including pyrexia (n = 5), pneumonia (n = 4), and pneumonitis (n = 4), vs. five patients (4.9%) in the control arm.  Conclusion This neoadjuvant trial provides evidence supporting a biomarker-driven targeted therapy approach for selected patients with GS-pos. TNBC and demonstrates the utility of a neoadjuvant trial for biomarker validation and drug development, but also highlights toxicity risk.  Future neoadjuvant clin. trials should carefully weigh these considerations for targeted therapy development in biomarker-defined TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyUury2yHivbVg90H21EOLACvtfcHk0lg2kdITvJ4PYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFylsLc%253D&md5=8d1753e09efbe33bbc03cf2c264a9af5</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.74.8392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.74.8392%26sid%3Dliteratum%253Aachs%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DParton%26aufirst%3DM.%26aulast%3DKummel%26aufirst%3DS.%26aulast%3DEstevez%26aufirst%3DL.%2BG.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DRuiz-Borrego%26aufirst%3DM.%26aulast%3DTelli%26aufirst%3DM.%2BL.%26aulast%3DMartin-Martorell%26aufirst%3DP.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DIsmail-Khan%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DS.%2BC.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DCarreon%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BB.%26atitle%3DPaclitaxel%2520With%2520Inhibitor%2520of%2520Apoptosis%2520Antagonist%252C%2520LCL161%252C%2520for%2520Localized%2520Triple-Negative%2520Breast%2520Cancer%252C%2520Prospectively%2520Stratified%2520by%2520Gene%2520Signature%2520in%2520a%2520Biomarker-Driven%2520Neoadjuvant%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D3126%26epage%3D3133%26doi%3D10.1200%2FJCO.2017.74.8392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleer, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. C.</span></span> <span> </span><span class="NLM_article-title">CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5114</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-13105-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fs41467-019-13105-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31704972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGisbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=5114&issue=1&author=L.+Nieauthor=Y.+Weiauthor=F.+Zhangauthor=Y.+H.+Hsuauthor=L.+C.+Chanauthor=W.+Xiaauthor=B.+Keauthor=C.+Zhuauthor=R.+Dengauthor=J.+Tangauthor=J.+Yaoauthor=Y.+Y.+Chuauthor=X.+Zhaoauthor=Y.+Hanauthor=J.+Houauthor=L.+Huoauthor=H.+W.+Koauthor=W.+C.+Linauthor=H.+Yamaguchiauthor=J.+M.+Hsuauthor=Y.+Yangauthor=D.+N.+Panauthor=J.+L.+Hsuauthor=C.+G.+Kleerauthor=N.+E.+Davidsonauthor=G.+N.+Hortobagyiauthor=M.+C.+Hung&title=CDK2-mediated+site-specific+phosphorylation+of+EZH2+drives+and+maintains+triple-negative+breast+cancer&doi=10.1038%2Fs41467-019-13105-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer</span></div><div class="casAuthors">Nie, Lei; Wei, Yongkun; Zhang, Fei; Hsu, Yi-Hsin; Chan, Li-Chuan; Xia, Weiya; Ke, Baozhen; Zhu, Cihui; Deng, Rong; Tang, Jun; Yao, Jun; Chu, Yu-Yi; Zhao, Xixi; Han, Ye; Hou, Junwei; Huo, Longfei; Ko, How-Wen; Lin, Wan-Chi; Yamaguchi, Hirohito; Hsu, Jung-Mao; Yang, Yi; Pan, Dean N.; Hsu, Jennifer L.; Kleer, Celina G.; Davidson, Nancy E.; Hortobagyi, Gabriel N.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5114</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC), which lacks estrogen receptor α (ERα), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression, is closely related to basal-like breast cancer.  Previously, we and others report that cyclin E/cyclin-dependent kinase 2 (CDK2) phosphorylates enhancer of zeste homolog 2 (EZH2) at T416 (pT416-EZH2).  Here, we show that transgenic expression of phospho-mimicking EZH2 mutant EZH2T416D in mammary glands leads to tumors with TNBC phenotype.  Coexpression of EZH2T416D in mammary epithelia of HER2/Neu transgenic mice reprograms HER2-driven luminal tumors into basal-like tumors.  Pharmacol. inhibition of CDK2 or EZH2 allows re-expression of ER α and converts TNBC to luminal ERa-pos., rendering TNBC cells targetable by tamoxifen.  Furthermore, the combination of either CDK2 or EZH2 inhibitor with tamoxifen effectively suppresses tumor growth and markedly improves the survival of the mice bearing TNBC tumors, suggesting that the mechanism-based combination therapy may be an alternative approach to treat TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9u1jJqRVHrrVg90H21EOLACvtfcHk0lgbDzwZJ3Z1zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGisbrJ&md5=433954dbc62ebd60333dd83b9e05b378</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-13105-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-13105-5%26sid%3Dliteratum%253Aachs%26aulast%3DNie%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DHsu%26aufirst%3DY.%2BH.%26aulast%3DChan%26aufirst%3DL.%2BC.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DKe%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DChu%26aufirst%3DY.%2BY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DHuo%26aufirst%3DL.%26aulast%3DKo%26aufirst%3DH.%2BW.%26aulast%3DLin%26aufirst%3DW.%2BC.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DHsu%26aufirst%3DJ.%2BM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DD.%2BN.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DKleer%26aufirst%3DC.%2BG.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DCDK2-mediated%2520site-specific%2520phosphorylation%2520of%2520EZH2%2520drives%2520and%2520maintains%2520triple-negative%2520breast%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D5114%26doi%3D10.1038%2Fs41467-019-13105-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhola, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuba, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span> <span> </span><span class="NLM_article-title">TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1348</span>– <span class="NLM_lpage">1358</span>, <span class="refDoi"> DOI: 10.1172/JCI65416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1172%2FJCI65416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23391723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVyhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=1348-1358&issue=3&author=N.+E.+Bholaauthor=J.+M.+Balkoauthor=T.+C.+Duggerauthor=M.+G.+Kubaauthor=V.+Sanchezauthor=M.+Sandersauthor=J.+Stanfordauthor=R.+S.+Cookauthor=C.+L.+Arteaga&title=TGF-beta+inhibition+enhances+chemotherapy+action+against+triple-negative+breast+cancer&doi=10.1172%2FJCI65416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer</span></div><div class="casAuthors">Bhola, Neil E.; Balko, Justin M.; Dugger, Teresa C.; Kuba, Maria Gabriela; Sanchez, Violeta; Sanders, Melinda; Stanford, Jamie; Cook, Rebecca S.; Arteaga, Carlos L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1348-1358</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">After an initial response to chemotherapy, many patients with triple-neg. breast cancer (TNBC) have recurrence of drug-resistant metastatic disease.  Studies with TNBC cells suggest that chemotherapy-resistant populations of cancer stem-like cells (CSCs) with self-renewing and tumor-initiating capacities are responsible for these relapses.  TGF-β has been shown to increase stem-like properties in human breast cancer cells.  We analyzed RNA expression in matched pairs of primary breast cancer biopsies before and after chemotherapy.  Biopsies after chemotherapy displayed increased RNA transcripts of genes assocd. with CSCs and TGF-β signaling.  In TNBC cell lines and mouse xenografts, the chemotherapeutic drug paclitaxel increased autocrine TGF-β signaling and IL-8 expression and enriched for CSCs, as indicated by mammosphere formation and CSC markers.  The TGF-β type I receptor kinase inhibitor LY2157299, a neutralizing TGF-β type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion.  Moreover, treatment of TNBC xenografts with LY2157299 prevented reestablishment of tumors after paclitaxel treatment.  These data suggest that chemotherapy-induced TGF-β signaling enhances tumor recurrence through IL-8-dependent expansion of CSCs and that TGF-β pathway inhibitors prevent the development of drug-resistant CSCs.  These findings support testing a combination of TGF-β inhibitors and anticancer chemotherapy in patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrlaIE6QLBw7Vg90H21EOLACvtfcHk0lgbDzwZJ3Z1zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVyhtL4%253D&md5=1e93f3ccf6ab2fa173fc00c400a7e19c</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1172%2FJCI65416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI65416%26sid%3Dliteratum%253Aachs%26aulast%3DBhola%26aufirst%3DN.%2BE.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26aulast%3DDugger%26aufirst%3DT.%2BC.%26aulast%3DKuba%26aufirst%3DM.%2BG.%26aulast%3DSanchez%26aufirst%3DV.%26aulast%3DSanders%26aufirst%3DM.%26aulast%3DStanford%26aufirst%3DJ.%26aulast%3DCook%26aufirst%3DR.%2BS.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26atitle%3DTGF-beta%2520inhibition%2520enhances%2520chemotherapy%2520action%2520against%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26issue%3D3%26spage%3D1348%26epage%3D1358%26doi%3D10.1172%2FJCI65416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Mauro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciciola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Formisano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Falco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicatiello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bonito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantile, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collina, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veneziani, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Placido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianco, R.</span></span> <span> </span><span class="NLM_article-title">Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1435</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1038%2Fbjc.2017.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28441382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosVahtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=1425-1435&issue=11&author=C.+Di+Mauroauthor=R.+Rosaauthor=V.+D%E2%80%99Amatoauthor=P.+Ciciolaauthor=A.+Servettoauthor=R.+Marcianoauthor=R.+C.+Orsiniauthor=L.+Formisanoauthor=S.+De+Falcoauthor=V.+Cicatielloauthor=M.+Di+Bonitoauthor=M.+Cantileauthor=F.+Collinaauthor=A.+Chamberyauthor=B.+M.+Venezianiauthor=S.+De+Placidoauthor=R.+Bianco&title=Hedgehog+signalling+pathway+orchestrates+angiogenesis+in+triple-negative+breast+cancers&doi=10.1038%2Fbjc.2017.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers</span></div><div class="casAuthors">Di Mauro, Concetta; Rosa, Roberta; D'Amato, Valentina; Ciciola, Paola; Servetto, Alberto; Marciano, Roberta; Orsini, Roberta Clara; Formisano, Luigi; De Falco, Sandro; Cicatiello, Valeria; Di Bonito, Maurizio; Cantile, Monica; Collina, Francesca; Chambery, Angela; Veneziani, Bianca Maria; De Placido, Sabino; Bianco, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1425-1435</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Several evidences suggest a marked angiogenic dependency in triple-neg. breast cancer (TNBC) tumorigenesis and a potential sensitivity to anti-angiogenic agents.  Herein, the putative role of Hedgehog (Hh) pathway in regulating TNBC-dependent angiogenesis was investigated.  Methods: Expression and regulation of the Hh pathway transcription factor glioma-assocd. oncogene homolog1 protein (GLI1) were studied on the endothelial compartment and on TNBC-initiated angiogenesis.  To evaluate the translational relevance of our findings, the combination of paclitaxel with the Smo inhibitor NVP-LDE225 was tested in TNBC xenografted mice.  Results: Tissue microarray anal. on 200 TNBC patients showed GLI1 overexpression paired with vascular endothelial growth factor receptor 2 (VEGFR2) expression.  In vitro, Hh pathway promotes TNBC progression in an autocrine manner, regulating the VEGF/VEGFR2 loop on cancer cell surface, and in a paracrine manner, orchestrating tumor vascularisation.  These effects were counteracted by Smo pharmacol. inhibition.  In TNBC xenografted mice, scheduling NVP-LDE225 rather than bevacizumab provided a better sustained inhibition of TNBC cells proliferation and endothelial cells organization.  Conclusions: This study identifies the Hh pathway as one of the main regulators of tumor angiogenesis in TNBC, thus suggesting Hh inhibition as a potential new anti-angiogenic therapeutic option to be clin. investigated in GLI1 overexpressing TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDD9hWgGbLELVg90H21EOLACvtfcHk0lje7EHv55AWMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosVahtr0%253D&md5=8bd9ca1d0dfa04d01ffe4fd649f12efa</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.116%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMauro%26aufirst%3DC.%26aulast%3DRosa%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DV.%26aulast%3DCiciola%26aufirst%3DP.%26aulast%3DServetto%26aufirst%3DA.%26aulast%3DMarciano%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DR.%2BC.%26aulast%3DFormisano%26aufirst%3DL.%26aulast%3DDe%2BFalco%26aufirst%3DS.%26aulast%3DCicatiello%26aufirst%3DV.%26aulast%3DDi%2BBonito%26aufirst%3DM.%26aulast%3DCantile%26aufirst%3DM.%26aulast%3DCollina%26aufirst%3DF.%26aulast%3DChambery%26aufirst%3DA.%26aulast%3DVeneziani%26aufirst%3DB.%2BM.%26aulast%3DDe%2BPlacido%26aufirst%3DS.%26aulast%3DBianco%26aufirst%3DR.%26atitle%3DHedgehog%2520signalling%2520pathway%2520orchestrates%2520angiogenesis%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26issue%3D11%26spage%3D1425%26epage%3D1435%26doi%3D10.1038%2Fbjc.2017.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">In Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span> <span> </span><span class="NLM_article-title">Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">115</span>, <span class="refDoi"> DOI: 10.1186/s13058-019-1204-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs13058-019-1204-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31640742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3Mjgs1yjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=115&issue=1&author=J.+O.+Leeauthor=M.+J.+Kangauthor=W.+S.+Byunauthor=S.+A.+Kimauthor=I.+H.+Seoauthor=J.+A.+Hanauthor=J.+W.+Moonauthor=J.+H.+Kimauthor=S.+J.+Kimauthor=E.+J.+Leeauthor=S.+In+Parkauthor=S.+H.+Parkauthor=H.+S.+Kim&title=Metformin+overcomes+resistance+to+cisplatin+in+triple-negative+breast+cancer+%28TNBC%29+cells+by+targeting+RAD51&doi=10.1186%2Fs13058-019-1204-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51</span></div><div class="casAuthors">Lee Jung Ok; Kang Min Ju; Byun Won Seok; Kim Shin Ae; Seo Il Hyeok; Han Jeong Ah; Moon Ji Wook; Kim Ji Hae; Kim Su Jin; Park Sun Hwa; Kim Hyeon Soo; Lee Eun Jung; In Park Serk; In Park Serk</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patients.  In contrast, combination therapy has proven to be an effective strategy for TNBC treatment.  Whether metformin enhances the anticancer effects of cisplatin and prevents cisplatin resistance in TNBC cells has not been reported.  METHODS:  Cell viability, wounding healing, and invasion assays were performed on Hs 578T and MDA-MB-231 human TNBC cell lines to demonstrate the anticancer effects of combined cisplatin and metformin treatment compared to treatment with cisplatin alone.  Western blotting and immunofluorescence were used to determine the expression of RAD51 and gamma-H2AX.  In an in vivo 4T1 murine breast cancer model, a synergistic anticancer effect of metformin and cisplatin was observed.  RESULTS:  Cisplatin combined with metformin decreased cell viability and metastatic effect more than cisplatin alone.  Metformin suppressed cisplatin-mediated RAD51 upregulation by decreasing RAD51 protein stability and increasing its ubiquitination.  In contrast, cisplatin increased RAD51 expression in an ERK-dependent manner.  In addition, metformin also increased cisplatin-induced phosphorylation of γ-H2AX.  Overexpression of RAD51 blocked the metformin-induced inhibition of cell migration and invasion, while RAD51 knockdown enhanced cisplatin activity.  Moreover, the combination of metformin and cisplatin exhibited a synergistic anticancer effect in an orthotopic murine model of 4T1 breast cancer in vivo.  CONCLUSIONS:  Metformin enhances anticancer effect of cisplatin by downregulating RAD51 expression, which represents a novel therapeutic target in TNBC management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgKwoA5GWgiSM8MEzWGjS9fW6udTcc2ea1WoOqr1V7j7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mjgs1yjtA%253D%253D&md5=753fe0794e7ffd0f090a0aebb59d577d</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1186%2Fs13058-019-1204-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-019-1204-2%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BO.%26aulast%3DKang%26aufirst%3DM.%2BJ.%26aulast%3DByun%26aufirst%3DW.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BA.%26aulast%3DSeo%26aufirst%3DI.%2BH.%26aulast%3DHan%26aufirst%3DJ.%2BA.%26aulast%3DMoon%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DE.%2BJ.%26aulast%3DIn%2BPark%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26atitle%3DMetformin%2520overcomes%2520resistance%2520to%2520cisplatin%2520in%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%2520cells%2520by%2520targeting%2520RAD51%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D115%26doi%3D10.1186%2Fs13058-019-1204-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semenza, G. L.</span></span> <span> </span><span class="NLM_article-title">Reciprocal regulation of DUSP9 and DUSP16 expression by HIF1 controls ERK and p38 MAP Kinase activity and mediates chemotherapy-induced breast cancer stem cell enrichment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4191</span>– <span class="NLM_lpage">4202</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-0270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-18-0270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29880481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=4191-4202&issue=15&author=H.+Luauthor=L.+Tranauthor=Y.+Parkauthor=I.+Chenauthor=J.+Lanauthor=Y.+Xieauthor=G.+L.+Semenza&title=Reciprocal+regulation+of+DUSP9+and+DUSP16+expression+by+HIF1+controls+ERK+and+p38+MAP+Kinase+activity+and+mediates+chemotherapy-induced+breast+cancer+stem+cell+enrichment&doi=10.1158%2F0008-5472.CAN-18-0270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment</span></div><div class="casAuthors">Lu, Haiquan; Tran, Linh; Park, Youngrok; Chen, Ivan; Lan, Jie; Xie, Yangyiran; Semenza, Gregg L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4191-4202</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) has a poor prognosis due to its aggressive characteristics and lack of targeted therapies.  Cytotoxic chemotherapy may reduce tumor bulk, but leaves residual disease due to the persistence of chemotherapy-resistant breast cancer stem cells (BCSC), which are crit. for tumor recurrence and metastasis.  Here, we demonstrate that hypoxia-inducible factor (HIF)-1-dependent regulation of mitogen-activated protein kinase (MAPK) signaling pathways contributes to chemotherapy-induced BCSC enrichment.  Chemotherapy increased DUSP9 expression and decreased DUSP16 expression in a HIF1-dependent manner, leading to inhibition of ERK and activation of p38 signaling pathways, resp.  Inhibition of ERK caused transcriptional induction of the pluripotency factor Nanog through decreased inactivating phosphorylation of FoxO3, while activation of p38 stabilized Nanog and Klf4 mRNA through increased inactivating phosphorylation of RNA-binding protein ZFP36L1, both of which promoted specification of the BCSC phenotype.  Inhibition of HIF1 or p38 signaling blocked chemotherapy-induced pluripotency factor expression and BCSC enrichment.  These surprising results delineate a mechanism by which a transcription factor switches cells from ERK to p38 signaling in response to chemotherapy and suggest that therapeutic targeting of HIF1 or the p38 pathway in combination with chemotherapy will block BCSC enrichment and improve outcome in TNBC.  Significance: These findings provide a mol. mechanism that may account for the increased relapse rate of women with TNBC who are treated with cytotoxic chemotherapy and suggest that combining chemotherapy with an inhibitor of HIF1 or p38 activity may increase patient survival.  Cancer Res; 78(15); 4191-202. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXaH5s4lcDzbVg90H21EOLACvtfcHk0lje7EHv55AWMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsbrJ&md5=4f4bf6a96fc22e68c92a260e1cf9669b</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-0270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-0270%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DSemenza%26aufirst%3DG.%2BL.%26atitle%3DReciprocal%2520regulation%2520of%2520DUSP9%2520and%2520DUSP16%2520expression%2520by%2520HIF1%2520controls%2520ERK%2520and%2520p38%2520MAP%2520Kinase%2520activity%2520and%2520mediates%2520chemotherapy-induced%2520breast%2520cancer%2520stem%2520cell%2520enrichment%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D15%26spage%3D4191%26epage%3D4202%26doi%3D10.1158%2F0008-5472.CAN-18-0270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. F.</span></span> <span> </span><span class="NLM_article-title">Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1002/1878-0261.12033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2F1878-0261.12033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28084011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2isbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=266-279&issue=3&author=C.+Y.+Liuauthor=J.+C.+Suauthor=T.+T.+Huangauthor=P.+Y.+Chuauthor=C.+T.+Huangauthor=W.+L.+Wangauthor=C.+H.+Leeauthor=K.+Y.+Lauauthor=W.+C.+Tsaiauthor=H.+P.+Yangauthor=C.+W.+Shiauauthor=L.+M.+Tsengauthor=K.+F.+Chen&title=Sorafenib+analogue+SC-60+induces+apoptosis+through+the+SHP-1%2FSTAT3+pathway+and+enhances+docetaxel+cytotoxicity+in+triple-negative+breast+cancer+cells&doi=10.1002%2F1878-0261.12033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells</span></div><div class="casAuthors">Liu, Chun-Yu; Su, Jung-Chen; Huang, Tzu-Ting; Chu, Pei-Yi; Huang, Chun-Teng; Wang, Wan-Lun; Lee, Chia-Han; Lau, Ka-Yi; Tsai, Wen-Chun; Yang, Hsiu-Ping; Shiau, Chung-Wai; Tseng, Ling-Ming; Chen, Kuen-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">266-279</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1878-0261</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Recurrent triple-neg. breast cancer (TNBC) needs new therapeutic targets.  Src homol. region 2 domain-contg. phosphatase-1 (SHP-1) can act as a tumor suppressor by dephosphorylating oncogenic kinases.  One major target of SHP-1 is STAT3, which is highly activated in TNBC.  In this study, we tested a sorafenib analog SC-60, which lacks angiokinase inhibition activity, but acts as a SHP-1 agonist, in TNBC cells.  SC-60 inhibited proliferation and induced apoptosis by dephosphorylating STAT3 in both a dose- and time-dependent manner in TNBC cells (MDA-MB-231, MDA-MB-468, and HCC1937).  By contrast, ectopic expression of STAT3 rescued the anticancer effect induced by SC-60.  SC-60 also increased the SHP-1 activity, but this effect was inhibited when the N-SH2 domain (DN1) was deleted or with SHP-1 point mutation (D61A), implying that SHP-1 is the major target of SC-60 in TNBC.  The use of SC-60 in combination with docetaxel synergized the anticancer effect induced by SC-60 through the SHP-1/STAT3 pathway in TNBC cells.  Importantly, SC-60 also displayed a significant antitumor effect in an MDA-MB-468 xenograft model by modulating the SHP-1/STAT3 axis, indicating the anticancer potential of SC-60 in TNBC treatment.  Targeting SHP-1/p-STAT3 and the potential combination of SHP-1 agonist with chemotherapeutic docetaxel is a feasible therapeutic strategy for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLp-rPisFSQLVg90H21EOLACvtfcHk0lhxItmqQDnxLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2isbg%253D&md5=3acdff657f976e6cfb3d41f707bbad47</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1002%2F1878-0261.12033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1878-0261.12033%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DSu%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DLau%26aufirst%3DK.%2BY.%26aulast%3DTsai%26aufirst%3DW.%2BC.%26aulast%3DYang%26aufirst%3DH.%2BP.%26aulast%3DShiau%26aufirst%3DC.%2BW.%26aulast%3DTseng%26aufirst%3DL.%2BM.%26aulast%3DChen%26aufirst%3DK.%2BF.%26atitle%3DSorafenib%2520analogue%2520SC-60%2520induces%2520apoptosis%2520through%2520the%2520SHP-1%252FSTAT3%2520pathway%2520and%2520enhances%2520docetaxel%2520cytotoxicity%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DMol.%2520Oncol.%26date%3D2017%26volume%3D11%26issue%3D3%26spage%3D266%26epage%3D279%26doi%3D10.1002%2F1878-0261.12033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dushyanthen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denkert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimm, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilkinton, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallal, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doimi, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryzhov, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arteaga, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balko, J. M.</span></span> <span> </span><span class="NLM_article-title">RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1509</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-15-1125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26515496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlajsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1499-1509&issue=6&author=S.+Loiauthor=S.+Dushyanthenauthor=P.+A.+Beavisauthor=R.+Salgadoauthor=C.+Denkertauthor=P.+Savasauthor=S.+Combsauthor=D.+L.+Rimmauthor=J.+M.+Giltnaneauthor=M.+V.+Estradaauthor=V.+Sanchezauthor=M.+E.+Sandersauthor=R.+S.+Cookauthor=M.+A.+Pilkintonauthor=S.+A.+Mallalauthor=K.+Wangauthor=V.+A.+Millerauthor=P.+J.+Stephensauthor=R.+Yelenskyauthor=F.+D.+Doimiauthor=H.+Gomezauthor=S.+V.+Ryzhovauthor=P.+K.+Darcyauthor=C.+L.+Arteagaauthor=J.+M.+Balko&title=RAS%2FMAPK+activation+is+associated+with+reduced+tumor-infiltrating+lymphocytes+in+triple-negative+breast+cancer%3A+Therapeutic+cooperation+between+MEK+and+PD-1%2FPD-L1+immune+checkpoint+inhibitors&doi=10.1158%2F1078-0432.CCR-15-1125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors</span></div><div class="casAuthors">Loi, Sherene; Dushyanthen, Sathana; Beavis, Paul A.; Salgado, Roberto; Denkert, Carsten; Savas, Peter; Combs, Susan; Rimm, David L.; Giltnane, Jennifer M.; Estrada, Monica V.; Sanchez, Violeta; Sanders, Melinda E.; Cook, Rebecca S.; Pilkinton, Mark A.; Mallal, Simon A.; Wang, Kai; Miller, Vincent A.; Stephens, Phil J.; Yelensky, Roman; Doimi, Franco D.; Gomez, Henry; Ryzhov, Sergey V.; Darcy, Phillip K.; Arteaga, Carlos L.; Balko, Justin M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1499-1509</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-neg. breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are assocd. with improved survival, but insight into tumor cell-autonomous mol. pathways affecting these features are lacking.  Exptl. Design: We analyzed TILs in the RD of clin. and molecularly characterized TNBCs after NAC and explored therapeutic strategies targeting combinations of MEK inhibitors with PD-1/PD-L1-targeted immunotherapy in mouse models of breast cancer.  Results: Presence of TILs in the RD was significantly assocd. with improved prognosis.  Genetic or transcriptomic alterations in Ras-MAPK signaling were significantly correlated with lower TILs.  MEK inhibition upregulated cell surface MHC expression and PD-L1 in TNBC cells both in vivo and in vitro.  Moreover, combined MEK and PD-L1/PD-1 inhibition enhanced antitumor immune responses in mouse models of breast cancer.  Conclusions: These data suggest the possibility that Ras-MAPK pathway activation promotes immune-evasion in TNBC, and support clin. trials combining MEK- and PD-L1-targeted therapies.  Furthermore, Ras/MAPK activation and MHC expression may be predictive biomarkers of response to immune checkpoint inhibitors.  Clin Cancer Res; 22(6); 1499-509. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVZ44YLo5HKrVg90H21EOLACvtfcHk0lhxItmqQDnxLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlajsLY%253D&md5=8d7b47ebef865d4e12db7a9a56396029</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1125%26sid%3Dliteratum%253Aachs%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DDushyanthen%26aufirst%3DS.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DSalgado%26aufirst%3DR.%26aulast%3DDenkert%26aufirst%3DC.%26aulast%3DSavas%26aufirst%3DP.%26aulast%3DCombs%26aufirst%3DS.%26aulast%3DRimm%26aufirst%3DD.%2BL.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DEstrada%26aufirst%3DM.%2BV.%26aulast%3DSanchez%26aufirst%3DV.%26aulast%3DSanders%26aufirst%3DM.%2BE.%26aulast%3DCook%26aufirst%3DR.%2BS.%26aulast%3DPilkinton%26aufirst%3DM.%2BA.%26aulast%3DMallal%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DDoimi%26aufirst%3DF.%2BD.%26aulast%3DGomez%26aufirst%3DH.%26aulast%3DRyzhov%26aufirst%3DS.%2BV.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26atitle%3DRAS%252FMAPK%2520activation%2520is%2520associated%2520with%2520reduced%2520tumor-infiltrating%2520lymphocytes%2520in%2520triple-negative%2520breast%2520cancer%253A%2520Therapeutic%2520cooperation%2520between%2520MEK%2520and%2520PD-1%252FPD-L1%2520immune%2520checkpoint%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D6%26spage%3D1499%26epage%3D1509%26doi%3D10.1158%2F1078-0432.CCR-15-1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrojo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostafa, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3405</span>– <span class="NLM_lpage">3415</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-16-2401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28069724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3405-3415&issue=13&author=T.+M.+Cardilloauthor=R.+M.+Sharkeyauthor=D.+L.+Rossiauthor=R.+Arrojoauthor=A.+A.+Mostafaauthor=D.+M.+Goldenberg&title=Synthetic+lethality+exploitation+by+an+anti-Trop-2-SN-38+antibody-drug+conjugate%2C+IMMU-132%2C+plus+PARP+inhibitors+in+BRCA1%2F2-wild-type+triple-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-16-2401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer</span></div><div class="casAuthors">Cardillo, Thomas M.; Sharkey, Robert M.; Rossi, Diane L.; Arrojo, Roberto; Mostafa, Ali A.; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3405-3415</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Both PARP inhibitors (PARPi) and sacituzumab govitecan (IMMU-132) are currently under clin. evaluation in triple-neg. breast cancer (TNBC).  We sought to investigate the combined DNA-damaging effects of the topoisomerase I (Topo I)-inhibitory activity of IMMU-132 with PARPi disruption of DNA repair in TNBC.  In vitro, human TNBC cell lines were incubated with IMMU-132 and various PARPi (olaparib, rucaparib, or talazoparib) to det. the effect on growth, double-stranded DNA (dsDNA) breaks, and cell-cycle arrest.  Mice bearing BRCA1/2-mutated or -wild-type human TNBC tumor xenografts were treated with the combination of IMMU-132 and PARPi (olaparib or talazoparib).  Study survival endpoint was tumor progression to >1.0 cm3 and tolerability assessed by hematol. changes.  Combining IMMU-132 in TNBC with all three different PARPi results in synergistic growth inhibition, increased dsDNA breaks, and accumulation of cells in the S-phase of the cell cycle, regardless of BRCA1/2 status.  A combination of IMMU-132 plus olaparib or talazoparib produces significantly improved antitumor effects and delay in time-to-tumor progression compared with monotherapy in mice bearing BRCA1/2-mutated HCC1806 TNBC tumors.  Furthermore, in mice bearing BRCA1/2-wild-type tumors (MDA-MB-468 or MDA-MB-231), the combination of IMMU-132 plus olaparib imparts a significant antitumor effect and survival benefit above that achieved with monotherapy.  Most importantly, this combination was well tolerated, with no substantial changes in hematol. parameters.  These data demonstrate the added benefit of combining Topo I inhibition mediated by IMMU-132 with synthetic lethality provided by PARPi in TNBC, regardless of BRCA1/2 status, thus supporting the rationale for such a combination clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNc78oBM-XaLVg90H21EOLACvtfcHk0lhxItmqQDnxLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurjJ&md5=6c6d6657c8c64344ce52271736de42fd</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2401%26sid%3Dliteratum%253Aachs%26aulast%3DCardillo%26aufirst%3DT.%2BM.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DRossi%26aufirst%3DD.%2BL.%26aulast%3DArrojo%26aufirst%3DR.%26aulast%3DMostafa%26aufirst%3DA.%2BA.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DSynthetic%2520lethality%2520exploitation%2520by%2520an%2520anti-Trop-2-SN-38%2520antibody-drug%2520conjugate%252C%2520IMMU-132%252C%2520plus%2520PARP%2520inhibitors%2520in%2520BRCA1%252F2-wild-type%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D13%26spage%3D3405%26epage%3D3415%26doi%3D10.1158%2F1078-0432.CCR-16-2401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opzoomer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilieva, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazinska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesch-Domenech, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fittall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez Rodriguez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellizzari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bax, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescioli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petranyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larcombe-Young, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephs, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canevari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestle, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A. N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, S. N.</span></span> <span> </span><span class="NLM_article-title">Anti-folate receptor alpha–directed antibody therapies restrict the growth of triple-negative breast cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5098</span>– <span class="NLM_lpage">5111</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-0652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1078-0432.CCR-18-0652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30068707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsl2gs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=5098-5111&issue=20&author=A.+Cheungauthor=J.+Opzoomerauthor=K.+M.+Ilievaauthor=P.+Gazinskaauthor=R.+M.+Hoffmannauthor=H.+Mirzaauthor=R.+Marlowauthor=E.+Francesch-Domenechauthor=M.+Fittallauthor=D.+Dominguez+Rodriguezauthor=A.+Cliffordauthor=L.+Badderauthor=N.+Patelauthor=S.+Meleauthor=G.+Pellizzariauthor=H.+J.+Baxauthor=S.+Crescioliauthor=G.+Petranyiauthor=D.+Larcombe-Youngauthor=D.+H.+Josephsauthor=S.+Canevariauthor=M.+Figiniauthor=S.+Pinderauthor=F.+O.+Nestleauthor=C.+Gillettauthor=J.+F.+Spicerauthor=A.+Grigoriadisauthor=A.+N.+J.+Tuttauthor=S.+N.+Karagiannis&title=Anti-folate+receptor+alpha%E2%80%93directed+antibody+therapies+restrict+the+growth+of+triple-negative+breast+cancer&doi=10.1158%2F1078-0432.CCR-18-0652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer</span></div><div class="casAuthors">Cheung, Anthony; Opzoomer, James W.; Ilieva, Kristina M.; Gazinska, Patrycja; Hoffmann, Ricarda M.; Mirza, Hasan; Marlow, Rebecca; Francesch-Domenech, Erika; Fittall, Matthew W.; Rodriguez, Diana Dominguez; Clifford, Angela; Badder, Luned; Patel, Nirmesh; Mele, Silvia; Pellizzari, Giulia; Bax, Heather J.; Crescioli, Silvia; Petranyi, Gyula; Larcombe-Young, Daniel; Josephs, Debra H.; Canevari, Silvana; Figini, Mariangela; Pinder, Sarah E.; Nestle, Frank O.; Gillett, Cheryl; Spicer, James; Grigoriadis, Anita; Tutt, Andrew; Karagiannis, Sophia N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5098-5111</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Highly-aggressive triple neg. breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease.  Folate Receptor alpha (FRα) is a central mediator of cell growth regulation that could serve as an important target for cancer therapy.  Exptl. Design: We evaluated FRα expression in breast cancers by genomic (n = 3414) and immunohistochem. (n = 323) analyses and its assocn. with clin. parameters and outcomes.  We measured the functional contributions of FRα in TNBC biol. by RNA interference and the antitumor functions of an antibody recognizing FRα (MOv18-IgG1), in vitro and in human TNBC xenograft models.  Results: FRα is overexpressed in significant proportions of aggressive basal like/TNBC tumors, and in post-neoadjuvant chemotherapy-residual disease assocd. with a high risk of relapse.  Expression is assocd. with worse overall survival.  TNBCs show dysregulated expression of thymidylate synthase, folate hydrolase 1 and methylenetetrahydrofolate reductase, involved in folate metab.  RNA interference to deplete FRα decreased Src and ERK signaling and resulted in redn. of cell growth.  An anti-FRα antibody (MOv18-IgG1) conjugated with a Src inhibitor significantly restricted TNBC xenograft growth.  Moreover, MOv18-IgG1 triggered immune-dependent cancer cell death in vitro by human volunteer and breast cancer patient immune cells, and significantly restricted orthotopic and patient-derived xenograft growth.  Conclusions: FRα is overexpressed in high-grade TNBC and post-chemotherapy residual tumors.  It participates in cancer cell signaling and presents a promising target for therapeutic strategies such as antibody-drug conjugates, or passive immunotherapy priming Fc-mediated anti-tumor immune cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmRa3oT29QpLVg90H21EOLACvtfcHk0lhXDBybljPniw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsl2gs7Y%253D&md5=7afc4c01fc09eb2d5892ca973817ccc3</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-0652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-0652%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DA.%26aulast%3DOpzoomer%26aufirst%3DJ.%26aulast%3DIlieva%26aufirst%3DK.%2BM.%26aulast%3DGazinska%26aufirst%3DP.%26aulast%3DHoffmann%26aufirst%3DR.%2BM.%26aulast%3DMirza%26aufirst%3DH.%26aulast%3DMarlow%26aufirst%3DR.%26aulast%3DFrancesch-Domenech%26aufirst%3DE.%26aulast%3DFittall%26aufirst%3DM.%26aulast%3DDominguez%2BRodriguez%26aufirst%3DD.%26aulast%3DClifford%26aufirst%3DA.%26aulast%3DBadder%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DMele%26aufirst%3DS.%26aulast%3DPellizzari%26aufirst%3DG.%26aulast%3DBax%26aufirst%3DH.%2BJ.%26aulast%3DCrescioli%26aufirst%3DS.%26aulast%3DPetranyi%26aufirst%3DG.%26aulast%3DLarcombe-Young%26aufirst%3DD.%26aulast%3DJosephs%26aufirst%3DD.%2BH.%26aulast%3DCanevari%26aufirst%3DS.%26aulast%3DFigini%26aufirst%3DM.%26aulast%3DPinder%26aufirst%3DS.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26aulast%3DGillett%26aufirst%3DC.%26aulast%3DSpicer%26aufirst%3DJ.%2BF.%26aulast%3DGrigoriadis%26aufirst%3DA.%26aulast%3DTutt%26aufirst%3DA.%2BN.%2BJ.%26aulast%3DKaragiannis%26aufirst%3DS.%2BN.%26atitle%3DAnti-folate%2520receptor%2520alpha%25E2%2580%2593directed%2520antibody%2520therapies%2520restrict%2520the%2520growth%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D20%26spage%3D5098%26epage%3D5111%26doi%3D10.1158%2F1078-0432.CCR-18-0652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulaiman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Sahli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cron, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alain, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figeys, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Co-targeting bulk tumor and CSCs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1755</span>– <span class="NLM_lpage">1764</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-0873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F1535-7163.MCT-18-0873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31308079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=1755-1764&issue=10&author=A.+Sulaimanauthor=S.+McGarryauthor=S.+El-Sahliauthor=L.+Liauthor=J.+Chambersauthor=A.+Phanauthor=M.+Coteauthor=G.+O.+Cronauthor=T.+Alainauthor=Y.+Leauthor=S.+H.+Leeauthor=S.+Liuauthor=D.+Figeysauthor=S.+Gaddeauthor=L.+Wang&title=Co-targeting+bulk+tumor+and+CSCs+in+clinically+translatable+TNBC+patient-derived+xenografts+via+combination+nanotherapy&doi=10.1158%2F1535-7163.MCT-18-0873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting bulk tumor and cscs in clinically translatable TNBC patient-derived xenografts via combination nanotherapy</span></div><div class="casAuthors">Sulaiman, Andrew; McGarry, Sarah; El-Sahli, Sara; Li, Li; Chambers, Jason; Phan, Alexandra; Cote, Marceline; Cron, Greg O.; Alain, Tommy; Le, Yevgeniya; Lee, Seung-Hwan; Liu, Sheng; Figeys, Daniel; Gadde, Suresh; Wang, Lisheng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1755-1764</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) accounts disproportionally for the majority of breast cancer-related deaths throughout the world.  This is largely attributed to lack of a specific therapy capable of targeting both bulk tumor mass and cancer stem cells (CSC), as well as appropriate animal models to accurately evaluate treatment efficacy for clin. translation.  Thus, development of effective and clin. translatable targeted therapies for TNBC is an unmet medical need.  We developed a hybrid nanoparticles-based co-delivery platform contg. both paclitaxel and verteporfin (PV-NP) to target TNBC patient-derived xenograft (PDX) tumor and CSCs.  MRI and IVIS imaging were performed on mice contg. PDX tumors to assess tumor vascularity and accumulation of NPs.  Mice bearing TNBC PDX tumor were treated with PV-NPs and controls, and tumors progression and CSC subpopulations were analyzed.  IVIS imaging showed accumulation of NPs in PDX tumors.  In comparison with control-NPs and free-drug combination, PV-NPs significantly retarded tumor growth of TNBC PDX.  PV-NPs simultaneously repressed NF-κB, Wnt, and YAP that have been shown to be crucial for cancer growth, CSC development, and tumorigenesis.  In conclusion, NPs contg. two clin. used drugs concurrently inhibited NF-κB, Wnt, and YAP pathways and exhibited synergic effects on killing TNBC bulk tumor and CSCs.  This combination nanotherapy evaluated with a PDX model may lead to an effective treatment of patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQArsHcx0yg7Vg90H21EOLACvtfcHk0lhXDBybljPniw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFKkug%253D%253D&md5=4ea7f5bd6036b04a2b0978ef06e198d0</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-0873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-0873%26sid%3Dliteratum%253Aachs%26aulast%3DSulaiman%26aufirst%3DA.%26aulast%3DMcGarry%26aufirst%3DS.%26aulast%3DEl-Sahli%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChambers%26aufirst%3DJ.%26aulast%3DPhan%26aufirst%3DA.%26aulast%3DCote%26aufirst%3DM.%26aulast%3DCron%26aufirst%3DG.%2BO.%26aulast%3DAlain%26aufirst%3DT.%26aulast%3DLe%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DFigeys%26aufirst%3DD.%26aulast%3DGadde%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DCo-targeting%2520bulk%2520tumor%2520and%2520CSCs%2520in%2520clinically%2520translatable%2520TNBC%2520patient-derived%2520xenografts%2520via%2520combination%2520nanotherapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2019%26volume%3D18%26issue%3D10%26spage%3D1755%26epage%3D1764%26doi%3D10.1158%2F1535-7163.MCT-18-0873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younis, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span> <span> </span><span class="NLM_article-title">JQ1-loaded polydopamine nanoplatform inhibits c-MYC/programmed cell death ligand 1 to enhance photothermal therapy for triple-negative breast cancer</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">50</span>),  <span class="NLM_fpage">46626</span>– <span class="NLM_lpage">46636</span>, <span class="refDoi"> DOI: 10.1021/acsami.9b18730</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.9b18730" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Wkt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=46626-46636&issue=50&author=Y.+Tianauthor=X.+Wangauthor=S.+Zhaoauthor=X.+Liaoauthor=M.+R.+Younisauthor=S.+Wangauthor=C.+Zhangauthor=G.+Lu&title=JQ1-loaded+polydopamine+nanoplatform+inhibits+c-MYC%2Fprogrammed+cell+death+ligand+1+to+enhance+photothermal+therapy+for+triple-negative+breast+cancer&doi=10.1021%2Facsami.9b18730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer</span></div><div class="casAuthors">Tian, Ying; Wang, Xiaofen; Zhao, Shuang; Liao, Xiang; Younis, Muhammad Rizwan; Wang, Shouju; Zhang, Chunni; Lu, Guangming</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">46626-46636</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Programmed cell death ligand 1 (PD-L1) blockade has achieved great success in cancer immunotherapy; however, the response of triple-neg. breast cancer (TNBC) to PD-L1 antibodies is limited.  To address this challenge, we use the bromodomain and extra-terminal inhibitor JQ1 to down-regulate the expression of PD-L1 and thus elicit the immune response to TNBC instead of using antibodies to block PD-L1.  JQ1 also inhibits the growth of TNBC as a targeted therapeutic agent by inhibiting the BRD4-c-MYC axis.  The polydopamine nanoparticles (PDMNs) are introduced as a biodegradable and adaptable platform to load JQ1 and induce photothermal therapy (PTT) as another synergistic therapeutic modality.  Because the JQ1-loaded PDMNs (PDMN-JQ1) are self-degradable and release JQ1 continuously, this synergistic treatment can lead to remarkable activation of cytotoxic T lymphocytes and induce a strong immune-memory effect to protect mice from tumor re-challenge.  Taken together, our study demonstrates a compact and simple nanoplatform for triple therapy, including targeted therapy, PTT, and immunotherapy, for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTOuiO3HnYrbVg90H21EOLACvtfcHk0ljMwJkUMtmrOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Wkt7bM&md5=d9431a3469c4a1e48006c376f40ee31a</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Facsami.9b18730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.9b18730%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DX.%26aulast%3DYounis%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DG.%26atitle%3DJQ1-loaded%2520polydopamine%2520nanoplatform%2520inhibits%2520c-MYC%252Fprogrammed%2520cell%2520death%2520ligand%25201%2520to%2520enhance%2520photothermal%2520therapy%2520for%2520triple-negative%2520breast%2520cancer%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2019%26volume%3D11%26issue%3D50%26spage%3D46626%26epage%3D46636%26doi%3D10.1021%2Facsami.9b18730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span> <span> </span><span class="NLM_article-title">Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">105864</span>, <span class="refDoi"> DOI: 10.1016/j.intimp.2019.105864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.intimp.2019.105864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31480004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWgurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2019&pages=105864&author=Q.+Zhangauthor=K.+Leauthor=M.+Xuauthor=J.+Zhouauthor=Y.+Xiaoauthor=W.+Yangauthor=Y.+Jiangauthor=Z.+Xiauthor=T.+Huang&title=Combined+MEK+inhibition+and+tumor-associated+macrophages+depletion+suppresses+tumor+growth+in+a+triple-negative+breast+cancer+mouse+model&doi=10.1016%2Fj.intimp.2019.105864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model</span></div><div class="casAuthors">Zhang, Qiulei; Le, Kehao; Xu, Ming; Zhou, Jun; Xiao, Yunxiao; Yang, Wen; Jiang, Yujia; Xi, Zihan; Huang, Tao</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105864</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tumor-assocd. macrophages (TAMs) are closely related to poor prognosis in triple-neg. breast cancer (TNBC).  Thus, gaining insight into how TAMs support cancer progression could contribute to effective therapies.  We utilized the 4 T1 murine TNBC cell line and murine bone marrow-derived macrophages to assess TAM-mediated pro-proliferative effects in vivo and in vitro.  Moreover, RNA sequencing anal. showed that TAMs could enhance mitogen-activated protein kinase (MAPK) pathway activation in 4 T1 cells compared to that in control cells.  Further, the depletion of TAMs by clodronate liposomes significantly reduced MAPK pathway activation in vivo.  In addn., the blockade of MAPK signaling by a MEK inhibitor repressed TAM-mediated cancer cell proliferation.  Most importantly, MEK inhibition combined with macrophage depletion significantly suppressed tumor growth and increased T lymphocyte infiltration in a TNBC model.  Our study suggests the possibility that TAM-induced MAPK pathway activation promotes cancer cell proliferation.  Thus, MEK inhibition combined with macrophage depletion might represent an effective treatment for TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM2jPETHJVQ7Vg90H21EOLACvtfcHk0ljMwJkUMtmrOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWgurrO&md5=0717103be8bf84dbd035fb989d70c0a5</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2019.105864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2019.105864%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DXi%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DT.%26atitle%3DCombined%2520MEK%2520inhibition%2520and%2520tumor-associated%2520macrophages%2520depletion%2520suppresses%2520tumor%2520growth%2520in%2520a%2520triple-negative%2520breast%2520cancer%2520mouse%2520model%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2019%26volume%3D76%26spage%3D105864%26doi%3D10.1016%2Fj.intimp.2019.105864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span> <span> </span><span class="NLM_article-title">Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">46</span>, <span class="refDoi"> DOI: 10.1186/s12943-016-0531-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2Fs12943-016-0531-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27286975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVWrtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=46&issue=1&author=H.+W.+Chiuauthor=Y.+L.+Yehauthor=Y.+C.+Wangauthor=W.+J.+Huangauthor=S.+Y.+Hoauthor=P.+Linauthor=Y.+J.+Wang&title=Combination+of+the+novel+histone+deacetylase+inhibitor+YCW1+and+radiation+induces+autophagic+cell+death+through+the+downregulation+of+BNIP3+in+triple-negative+breast+cancer+cells+in+vitro+and+in+an+orthotopic+mouse+model&doi=10.1186%2Fs12943-016-0531-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model</span></div><div class="casAuthors">Chiu, Hui-Wen; Yeh, Ya-Ling; Wang, Yi-Ching; Huang, Wei-Jan; Ho, Sheng-Yow; Lin, Pinpin; Wang, Ying-Jan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46/1-46/12</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Triple-neg. breast cancer (TNBC) is the most aggressive and invasive of the breast cancer subtypes.  TNBC is a challenging disease that lacks targets for treatment.  Histone deacetylase inhibitors (HDACi) are a group of targeted anticancer agents that enhance radiosensitivity.  Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a member of the Bcl-2 subfamily.  BNIP3 is not found in normal breast tissue but is up-regulated in breast cancer.  In the present study, we investigated the anti-cancer effects of a newly developed HDACi, YCW1, combined with ionizing radiation (IR) in TNBC in vitro and in an orthotopic mouse model.  Furthermore, we examd. the relationship between autophagy and BNIP3.  Methods: Trypan blue exclusion was used to investigate the viability of 4 T1 (a mouse TNBC cell line) and MDA-MB-231 cells (a human TNBC cell line) following combined YCW1 and IR treatment.  Flow cytometry was used to det. apoptosis and autophagy.  The expression levels of BNIP3, endoplasmic reticulum (ER) stress- and autophagic-related proteins were measured using western blot anal.  An orthotopic mouse model was used to investigate the in vivo effects of YCW1 and IR alone and in combination.  Tumor vols. were monitored using a bioluminescence-based IVIS Imaging System 200.  Results: We found that YCW1 significantly enhanced toxicity in 4 T1 cells compared with suberoylanilide hydroxamic acid (SAHA), which was the first HDACi approved by the Food and Drug Administration for clin. use in cancer patients.  The combined treatment of YCW1 and IR enhanced cytotoxicity by inducing ER stress and increasing autophagy induction.  Addnl., the combined treatment caused autophagic flux and autophagic cell death.  Furthermore, the expression level of BNIP3 was significantly decreased in cells following combined treatment.  The downregulation of BNIP3 led to a significant increase in autophagy and cytotoxicity.  The combined anti-tumor effects of YCW1 and IR were also obsd. in an orthotopic mouse model; combination therapy resulted in a significant increase in autophagy and decreased tumor tissue expression of BNIP3 in the tumor tissue.  Conclusions: These data support the possibility of using a combination of HDACi and IR in the treatment of TNBC.  Moreover, BNIP3 may be a potential target protein for TNBC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwkW_2WhIzZLVg90H21EOLACvtfcHk0ljMwJkUMtmrOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVWrtrfP&md5=ddc4274a3c924d9175af63dad5d9a472</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1186%2Fs12943-016-0531-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-016-0531-5%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DH.%2BW.%26aulast%3DYeh%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26aulast%3DHo%26aufirst%3DS.%2BY.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26atitle%3DCombination%2520of%2520the%2520novel%2520histone%2520deacetylase%2520inhibitor%2520YCW1%2520and%2520radiation%2520induces%2520autophagic%2520cell%2520death%2520through%2520the%2520downregulation%2520of%2520BNIP3%2520in%2520triple-negative%2520breast%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520an%2520orthotopic%2520mouse%2520model%26jtitle%3DMol.%2520Cancer%26date%3D2016%26volume%3D15%26issue%3D1%26spage%3D46%26doi%3D10.1186%2Fs12943-016-0531-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panneerselvam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, A.</span></span> <span> </span><span class="NLM_article-title">Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage</span>. <i>Int. J. Radiat. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1080/09553002.2020.1730012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1080%2F09553002.2020.1730012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32052681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB387hsFOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-12&author=M.+Mehtaauthor=J.+Griffithauthor=J.+Panneerselvamauthor=A.+Babuauthor=J.+Maniauthor=T.+Hermanauthor=R.+Rameshauthor=A.+Munshi&title=Regorafenib+sensitizes+human+breast+cancer+cells+to+radiation+by+inhibiting+multiple+kinases+and+inducing+DNA+damage&doi=10.1080%2F09553002.2020.1730012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage</span></div><div class="casAuthors">Mehta Meghna; Griffith James; Babu Anish; Mani Jonathan; Herman Terence; Munshi Anupama; Panneerselvam Janani; Babu Anish; Ramesh Rajagopal; Panneerselvam Janani; Babu Anish; Mani Jonathan; Herman Terence; Ramesh Rajagopal; Munshi Anupama</div><div class="citationInfo"><span class="NLM_cas:title">International journal of radiation biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Purpose: Triple-negative breast cancer (TNBC) is the most challenging and aggressive subtype of breast cancer with limited treatment options because of tumor heterogeneity, lack of druggable targets and therapy resistance.  TNBCs are characterized by overexpression of growth factor receptors such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and platelet derived growth factor receptor (PDGFR) making them promising therapeutic targets.  Regorafenib is an FDA approved oral multi-kinase inhibitor that blocks the activity of multiple protein kinases including those involved in the regulation of tumor angiogenesis [VEGFR1-3, TIE2], tumor microenvironment [PDGFR-β, FGFR] and oncogenesis (KIT, RET, RAF-1, BRAF).  In the current study, we examined the radiosensitizing effects of Regorafenib on TNBC cell lines and explored the mechanism by which Regorafenib enhances radiosensitivity.Methods: MDA-MB-231 and SUM159PT (human TNBC cell lines) and MCF 10a (human mammary epithelial cell line) were treated with Regorafenib, ionizing radiation or a combination of both.  Following treatment with Regorafenib and radiation we conducted clonogenic assay to determine radiosensitivity, immunoblot analysis to assess the effect on key signaling targets, tube formation to evaluate effect on angiogenesis and comet assay as well as western blot for γH2AX to assess DNA damage response (DDR).Results: Regorafenib reduced cell proliferation and enhanced radiosensitivity of MDA-MB-231 and SUM159PT cell lines but had no effect on the MCF 10a cells.  Clonogenic survival assays showed that the surviving fraction at 2 Gy for both MDA-MB-231 and SUM159PT was reduced from 66.4 ± 8.9 and 88.2 ± 1.7 in controls to 38.1 ± 4.9 and 75.1 ± 1.1 following a 24 hr pretreatment with 10 μM and 5 μM Regorafenib, respectively.  A marked reduction in the expression of VEGFR, PDGFR, EGFR and the downstream target, ERK, was observed with Regorafenib treatment alone or in combination with radiation.  We also observed a significant inhibition of VEGF-A production in the TNBC cell lines following treatment with Regorafenib.  Further, the addition of conditioned medium from Regorafenib-treated tumor cells onto human umbilical vein endothelial cells (HUVEC) suppressed tube formation, indicating an inhibition of tumor angiogenesis.  Regorafenib also decreased migration of TNBC cells and suppressed radiation-induced DNA damage repair in a time-dependent manner.Conclusions: Our findings demonstrate that Regorafenib enhanced radiosensitivity of breast cancer cells by inhibiting the expression of multiple receptor tyrosine kinases, VEGF-mediated angiogenesis and DNA damage response in TNBC.  Therefore, combining Regorafenib with radiation and antiangiogenic agents will be beneficial and effective in controlling TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStQPHrKG6p7ZagfuraLLzSfW6udTcc2ebqYTMFD1Pm4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387hsFOhsw%253D%253D&md5=2be15305f8151342b419e37f65ae62a8</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1080%2F09553002.2020.1730012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09553002.2020.1730012%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DM.%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DPanneerselvam%26aufirst%3DJ.%26aulast%3DBabu%26aufirst%3DA.%26aulast%3DMani%26aufirst%3DJ.%26aulast%3DHerman%26aufirst%3DT.%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DMunshi%26aufirst%3DA.%26atitle%3DRegorafenib%2520sensitizes%2520human%2520breast%2520cancer%2520cells%2520to%2520radiation%2520by%2520inhibiting%2520multiple%2520kinases%2520and%2520inducing%2520DNA%2520damage%26jtitle%3DInt.%2520J.%2520Radiat.%2520Biol.%26date%3D2020%26spage%3D1%26epage%3D12%26doi%3D10.1080%2F09553002.2020.1730012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koledova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streuli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werb, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span> <span> </span><span class="NLM_article-title">SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">E5731</span>– <span class="NLM_lpage">5740</span>, <span class="refDoi"> DOI: 10.1073/pnas.1611532113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1611532113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=27621461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2kurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E5731-5740&issue=39&author=Z.+Koledovaauthor=X.+Zhangauthor=C.+Streuliauthor=R.+Clarkeauthor=O.+Kleinauthor=Z.+Werbauthor=P.+Lu&title=SPRY1+regulates+mammary+epithelial+morphogenesis+by+modulating+EGFR-dependent+stromal+paracrine+signaling+and+ECM+remodeling&doi=10.1073%2Fpnas.1611532113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling</span></div><div class="casAuthors">Koledova, Zuzana; Zhang, Xiaohong; Streuli, Charles; Clarke, Robert B.; Klein, Ophir D.; Werb, Zena; Lu, Pengfei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">E5731-E5740</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The role of the local microenvironment in influencing cell behavior is central to both normal development and cancer formation.  Here, we show that sprouty 1 (SPRY1) modulates the microenvironment to enable proper mammary branching morphogenesis.  This process occurs through neg. regulation of epidermal growth factor receptor (EGFR) signaling in mammary stroma.  Loss of SPRY1 resulted in up-regulation of EGFR-extracellular signal-regulated kinase (ERK) signaling in response to amphiregulin and transforming growth factor alpha stimulation.  Consequently, stromal paracrine signaling and ECM remodeling is augmented, leading to increased epithelial branching in the mutant gland.  By contrast, down-regulation of EGFR-ERK signaling due to gain of Sprouty function in the stroma led to stunted epithelial branching.  Taken together, our results show that modulation of stromal paracrine signaling and ECM remodeling by SPRY1 regulates mammary epithelial morphogenesis during postnatal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI9ec2Pybl1bVg90H21EOLACvtfcHk0lgKu0zr5N_Btg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2kurrO&md5=87059e5692bd21cdb6b9462435d38fc7</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1611532113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1611532113%26sid%3Dliteratum%253Aachs%26aulast%3DKoledova%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DStreuli%26aufirst%3DC.%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DKlein%26aufirst%3DO.%26aulast%3DWerb%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DP.%26atitle%3DSPRY1%2520regulates%2520mammary%2520epithelial%2520morphogenesis%2520by%2520modulating%2520EGFR-dependent%2520stromal%2520paracrine%2520signaling%2520and%2520ECM%2520remodeling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D39%26spage%3DE5731%26epage%3D5740%26doi%3D10.1073%2Fpnas.1611532113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, B.</span></span> <span> </span><span class="NLM_article-title">SGCE promotes breast cancer stem cells by stabilizing EGFR</span>. <i>Adv. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1903700</span>, <span class="refDoi"> DOI: 10.1002/advs.201903700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fadvs.201903700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Kqs7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=1903700&issue=14&author=L.+Zhaoauthor=T.+Qiuauthor=D.+Jiangauthor=H.+Xuauthor=L.+Zouauthor=Q.+Yangauthor=C.+Chenauthor=B.+Jiao&title=SGCE+promotes+breast+cancer+stem+cells+by+stabilizing+EGFR&doi=10.1002%2Fadvs.201903700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR</span></div><div class="casAuthors">Zhao, Lina; Qiu, Ting; Jiang, Dewei; Xu, Haibo; Zou, Li; Yang, Qin; Chen, Ceshi; Jiao, Baowei</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Science (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1903700</span>CODEN:
                <span class="NLM_cas:coden">ASDCCF</span>;
        ISSN:<span class="NLM_cas:issn">2198-3844</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Breast cancer stem cells (BCSCs) are responsible for resistance to chemotherapy, high degree of metastasis, and poor prognosis, esp. in triple-neg. breast cancer (TNBC).  The CD24lowCD44high and high aldehyde dehydrogenase 1 (ALDH1) cell subpopulation (CD24lowCD44high ALDH1+) exhibit very high tumor initiating capacity.  In the current study, the upregulated genes are analyzed in both CD24lowCD44high and ALDH1+ cell populations at single-cell resoln., and a highly expressed membrane protein, SGCE, is identified in both BCSC populations.  Further results show that SGCE depletion reduces BCSC self-renewal, chemoresistance, and metastasis both in vitro and in vivo, partially through affecting the accumulation of extracellular matrix (ECM).  For the underlying mechanism, SGCE functions as a sponge mol. for the interaction between epidermal growth factor receptor (EGFR) and its E3 ubiquitination ligase (c-Cbl), and thus inhibits EGFR lysosomal degrdn. to stabilize the EGFR protein.  SGCE knockdown promotes sensitivity to EGFR tyrosine kinase inhibitors (TKIs), providing new clues for deciphering the current failure of targeting EGFR in clin. trials and highlighting a novel candidate for BCSC stemness regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDKF0blsekTbVg90H21EOLACvtfcHk0lgKu0zr5N_Btg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Kqs7bL&md5=3639ee51ba9698e16b10bff580cfa3e5</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1002%2Fadvs.201903700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadvs.201903700%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DJiao%26aufirst%3DB.%26atitle%3DSGCE%2520promotes%2520breast%2520cancer%2520stem%2520cells%2520by%2520stabilizing%2520EGFR%26jtitle%3DAdv.%2520Sci.%26date%3D2020%26volume%3D7%26issue%3D14%26spage%3D1903700%26doi%3D10.1002%2Fadvs.201903700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaborit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Dvashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porat, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareja, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindzen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Chetrit, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1815</span>– <span class="NLM_lpage">1820</span>, <span class="refDoi"> DOI: 10.1073/pnas.1220763110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1220763110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23319610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisl2ns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=1815-1820&issue=5&author=D.+Ferraroauthor=N.+Gaboritauthor=R.+Maronauthor=H.+Cohen-Dvashiauthor=Z.+Poratauthor=F.+Parejaauthor=S.+Laviauthor=M.+Lindzenauthor=N.+Ben-Chetritauthor=M.+Selaauthor=Y.+Yarden&title=Inhibition+of+triple-negative+breast+cancer+models+by+combinations+of+antibodies+to+EGFR&doi=10.1073%2Fpnas.1220763110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR</span></div><div class="casAuthors">Ferraro, Daniela A.; Gaborit, Nadege; Maron, Ruth; Cohen-Dvashi, Hadas; Porat, Ziv; Pareja, Fresia; Lavi, Sara; Lindzen, Moshit; Ben-Chetrit, Nir; Sela, Michaei; Yarden, Yosef</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1815-1829, S1815/1-S1815/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Breast tumors lacking expression of human epidermal growth factor receptor 2 (HER2) and the estrogen and the progesterone receptors (triple neg.; TNBC) are more aggressive than other disease subtypes, and no mol. targeted agents are currently available for their treatment.  Because TNBC commonly displays EGF receptor (EGFR) expression, and combinations of monoclonal antibodies to EGFR effectively inhibit other tumor models, we addressed the relevance of this strategy to treatment of TNBC.  Unlike a combination of the clin. approved monoclonal antibodies, cetuximab and panitumumab, which displaced each other and displayed no cooperative effects, several other combinations resulted in enhanced inhibition of TNBCs cell growth both in vitro and in animals.  The ability of certain antibody mixts. to remove EGFR from the cell surface and to promote its intracellular degrdn. correlated with the inhibitory potential.  However, unlike EGF-induced sorting of EGFR to lysosomal degrdn., the antibody-induced pathway displayed independence from the intrinsic kinase activity and dimer formation ability of EGFR, and it largely avoided the recycling route.  In conclusion, although TNBC clin. trials testing EGFR inhibitors reported lack of benefit, our results offer an alternative strategy that combines noncompetitive antibodies to achieve robust degrdn. of EGFR and tumor inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFFswJHVwaOLVg90H21EOLACvtfcHk0lhqE1ucIS7rlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisl2ns78%253D&md5=82665ac7d67657aeb9efa7b9633241ed</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1220763110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1220763110%26sid%3Dliteratum%253Aachs%26aulast%3DFerraro%26aufirst%3DD.%26aulast%3DGaborit%26aufirst%3DN.%26aulast%3DMaron%26aufirst%3DR.%26aulast%3DCohen-Dvashi%26aufirst%3DH.%26aulast%3DPorat%26aufirst%3DZ.%26aulast%3DPareja%26aufirst%3DF.%26aulast%3DLavi%26aufirst%3DS.%26aulast%3DLindzen%26aufirst%3DM.%26aulast%3DBen-Chetrit%26aufirst%3DN.%26aulast%3DSela%26aufirst%3DM.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520triple-negative%2520breast%2520cancer%2520models%2520by%2520combinations%2520of%2520antibodies%2520to%2520EGFR%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D5%26spage%3D1815%26epage%3D1820%26doi%3D10.1073%2Fpnas.1220763110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Audeh, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedlander, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-McGuinn, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitzel, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oaknin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmutzler, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span> <span> </span><span class="NLM_article-title">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">9737</span>),  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)60893-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2FS0140-6736%2810%2960893-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=20609468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=245-251&issue=9737&author=M.+W.+Audehauthor=J.+Carmichaelauthor=R.+T.+Pensonauthor=M.+Friedlanderauthor=B.+Powellauthor=K.+M.+Bell-McGuinnauthor=C.+Scottauthor=J.+N.+Weitzelauthor=A.+Oakninauthor=N.+Lomanauthor=K.+Luauthor=R.+K.+Schmutzlerauthor=U.+Matulonisauthor=M.+Wickensauthor=A.+Tutt&title=Oral+poly%28ADP-ribose%29+polymerase+inhibitor+olaparib+in+patients+with+BRCA1+or+BRCA2+mutations+and+recurrent+ovarian+cancer%3A+a+proof-of-concept+trial&doi=10.1016%2FS0140-6736%2810%2960893-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial</span></div><div class="casAuthors">Audeh, M. William; Carmichael, James; Penson, Richard T.; Friedlander, Michael; Powell, Bethan; Bell-McGuinn, Katherine M.; Scott, Clare; Weitzel, Jeffrey N.; Oaknin, Ana; Loman, Niklas; Lu, Karen; Schmutzler, Rita K.; Matulonis, Ursula; Wickens, Mark; Tutt, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">9737</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells.  We aimed to assess the efficacy and safety of olaparib for treatment of advanced ovarian cancer in patients with BRCA1 or BRCA2 mutations.  In this international, multicentre, phase 2 study, we enrolled two sequential cohorts of women (aged ≥18 years) with confirmed genetic BRCA1 or BRCA2 mutations, and recurrent, measurable disease.  The study was undertaken in 12 centers in Australia, Germany, Spain, Sweden, and the USA.  The first cohort (n=33) was given continuous oral olaparib at the max. tolerated dose of 400 mg twice daily, and the second cohort (n=24) was given continuous oral olaparib at 100 mg twice daily.  The primary efficacy endpoint was objective response rate (ORR).  This study is registered with ClinicalTrials.gov, no. NCT00494442.  Patients had been given a median of three (range 1-16) previous chemotherapy regimens.  ORR was 11 (33%) of 33 patients (95% CI 20-51) in the cohort assigned to olaparib 400 mg twice daily, and three (13%) of 24 (4-31) in the cohort assigned to 100 mg twice daily.  In patients given olaparib 400 mg twice daily, the most frequent causally related adverse events were nausea (grade 1 or 2, 14 [42%]; grade 3 or 4, 2 [6%]), fatigue (grade 1 or 2, 10 [30%]; grade 3 or 4, one [3%]), and anemia (grade 1 or 2, 5 [15%]; grade 3 or 4, 1 [3%]).  The most frequent causally related adverse events in the cohort given 100 mg twice daily were nausea (grade 1 or 2, 7 [29%]; grade 3 or 4, 2 [8%]) and fatigue (grade 1 or 2, 9 [38%]; none grade 3 or 4).  Findings from this phase 2 study provide pos. proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfC3epcFKsLrVg90H21EOLACvtfcHk0lhqE1ucIS7rlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Kktb4%253D&md5=e74985d2c7ae53462d48277fbc36bb6a</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2960893-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252960893-8%26sid%3Dliteratum%253Aachs%26aulast%3DAudeh%26aufirst%3DM.%2BW.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DFriedlander%26aufirst%3DM.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DBell-McGuinn%26aufirst%3DK.%2BM.%26aulast%3DScott%26aufirst%3DC.%26aulast%3DWeitzel%26aufirst%3DJ.%2BN.%26aulast%3DOaknin%26aufirst%3DA.%26aulast%3DLoman%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DSchmutzler%26aufirst%3DR.%2BK.%26aulast%3DMatulonis%26aufirst%3DU.%26aulast%3DWickens%26aufirst%3DM.%26aulast%3DTutt%26aufirst%3DA.%26atitle%3DOral%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520olaparib%2520in%2520patients%2520with%2520BRCA1%2520or%2520BRCA2%2520mutations%2520and%2520recurrent%2520ovarian%2520cancer%253A%2520a%2520proof-of-concept%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26issue%3D9737%26spage%3D245%26epage%3D251%26doi%3D10.1016%2FS0140-6736%2810%2960893-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carey, J. P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayaraghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikule, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyomarsi, K.</span></span> <span> </span><span class="NLM_article-title">Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-1494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1158%2F0008-5472.CAN-17-1494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29180466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=742-757&issue=3&author=J.+P.+W.+Careyauthor=C.+Karakasauthor=T.+Buiauthor=X.+Chenauthor=S.+Vijayaraghavanauthor=Y.+Zhaoauthor=J.+Wangauthor=K.+Mikuleauthor=J.+K.+Littonauthor=K.+K.+Huntauthor=K.+Keyomarsi&title=Synthetic+lethality+of+PARP+inhibitors+in+combination+with+MYC+blockade+is+independent+of+BRCA+status+in+triple-negative+breast+cancer&doi=10.1158%2F0008-5472.CAN-17-1494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Carey, Jason. P. W.; Karakas, Cansu; Bui, Tuyen; Chen, Xian; Vijayaraghavan, Smruthi; Zhao, Yang; Wang, Jing; Mikule, Keith; Litton, Jennifer K.; Hunt, Kelly K.; Keyomarsi, Khandan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-757</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients.  Several of those patients exhibit intrinsic/acquired resistance mechanisms that limit efficacy of PARPi monotherapy.  Here we show how the efficacy of PARPi in triple-neg. breast cancers (TNBC) can be expanded by targeting MYC-induced oncogenic addiction.41673032X.  In BRCA-mutant/sporadic TNBC patients, amplification of the MYC gene is correlated with increased expression of the homologous DNA recombination enzyme RAD51 and tumors overexpressing both genes are assocd. with worse overall survival.  Combining MYC blockade with PARPi yielded synthetic lethality in MYC-driven TNBC cells.  Using the cyclin-dependent kinase inhibitor dinaciclib, which downregulates MYC expression, we found that combination with the PARPi niraparib increased DNA damage and downregulated homologous recombination, leading to subsequent downregulation of the epithelial-mesenchymal transition and cancer stem-like cell phenotypes.  Notably, dinaciclib resensitized TBNC cells, which had acquired resistance to niraparib.  We found that the synthetic lethal strategy employing dinaciclib and niraparib was also highly efficacious in ovarian, prostate, pancreatic, colon, and lung cancer cells.  Taken together, our results show how blunting MYC oncogene addiction can leverage cancer cell sensitivity to PARPi, facilitating the clin. use of c-myc as a predictive biomarker for this treatment.  Significance: Dual targeting of MYC-regulated homologous recombination and PARP-mediated DNA repair yields potent synthetic lethality in triple-neg. breast tumors and other aggressive tumors characterized by MYC overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_g3mYyl4rcbVg90H21EOLACvtfcHk0lhqE1ucIS7rlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWntr4%253D&md5=1426c788233422558dc98856fa404b0e</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-1494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-1494%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DJ.%2BP.%2BW.%26aulast%3DKarakas%26aufirst%3DC.%26aulast%3DBui%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DVijayaraghavan%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMikule%26aufirst%3DK.%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DHunt%26aufirst%3DK.%2BK.%26aulast%3DKeyomarsi%26aufirst%3DK.%26atitle%3DSynthetic%2520lethality%2520of%2520PARP%2520inhibitors%2520in%2520combination%2520with%2520MYC%2520blockade%2520is%2520independent%2520of%2520BRCA%2520status%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D3%26spage%3D742%26epage%3D757%26doi%3D10.1158%2F0008-5472.CAN-17-1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yusoh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, H.</span></span> <span> </span><span class="NLM_article-title">Metallointercalator [Ru(dppz)(PIP)] renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00843</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00843" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjt1ansg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=378-387&issue=2&author=N.+Yusohauthor=S.+Leongauthor=S.+Chiaauthor=S.+Harunauthor=M.+Rahmanauthor=K.+Vallisauthor=M.+Gillauthor=H.+Ahmad&title=Metallointercalator+%5BRu%28dppz%29%28PIP%29%5D+renders+BRCA+wild-type+triple-negative+breast+cancer+cells+hypersensitive+to+PARP+inhibition&doi=10.1021%2Facschembio.9b00843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition</span></div><div class="casAuthors">Yusoh, Nur Aininie; Leong, Sze Wei; Chia, Suet Lin; Harun, Siti Norain; Rahman, Mohd Basyaruddin Abdul; Vallis, Katherine A.; Gill, Martin R.; Ahmad, Haslina</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">378-387</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a need to improve and extend the use of clin. approved poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), including for BRCA wild-type triple-neg. breast cancer (TNBC).  The demonstration that ruthenium(II) polypyridyl complex (RPC) metallointercalators can rapidly stall DNA replication fork progression provides the rationale for their combination alongside DNA damage response (DDR) inhibitors to achieve synergism in cancer cells.  The aim of the present study was to evaluate use of the multi-intercalator [Ru(dppz)2(PIP)]2+ (dppz = dipyrido[3,2-a:2',3'-c]phenazine, PIP = (2-(phenyl)imidazo[4,5-f][1,10]phenanthroline, Ru-PIP) alongside the PARPi olaparib and NU1025.  Cell proliferation and clonogenic survival assays indicated a synergistic relationship between Ru-PIP and olaparib in MDA-MB-231 TNBC and MCF7 human breast cancer cells.  Strikingly, low dose Ru-PIP renders both cell lines hypersensitive to olaparib, with a >300-fold increase in olaparib potency in TNBC, the largest nongenetic PARPi enhancement effect described to date.  A negligible impact on the viability of normal human fibroblasts was obsd. for any combination tested.  Increased levels of DNA double-strand break (DSB) damage and olaparib abrogation of Ru-PIP-activated pChk1 signaling are consistent with PARPi-facilitated collapse of Ru-PIP-assocd. stalled replication forks.  This results in enhanced G2/M cell-cycle arrest, apoptosis, and decreased cell motility for the combination treatment compared to single-agent conditions.  This work establishes that an RPC metallointercalator can be combined with PARPi for potent synergy in BRCA-proficient breast cancer cells, including TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmxLYg5111gLVg90H21EOLACvtfcHk0lgvYJYPUHxccw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjt1ansg%253D%253D&md5=e251b3f4fdcd36618d5a3e47afd8fe1b</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00843%26sid%3Dliteratum%253Aachs%26aulast%3DYusoh%26aufirst%3DN.%26aulast%3DLeong%26aufirst%3DS.%26aulast%3DChia%26aufirst%3DS.%26aulast%3DHarun%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DM.%26aulast%3DVallis%26aufirst%3DK.%26aulast%3DGill%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DH.%26atitle%3DMetallointercalator%2520%255BRu%2528dppz%2529%2528PIP%2529%255D%2520renders%2520BRCA%2520wild-type%2520triple-negative%2520breast%2520cancer%2520cells%2520hypersensitive%2520to%2520PARP%2520inhibition%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2020%26volume%3D15%26issue%3D2%26spage%3D378%26epage%3D387%26doi%3D10.1021%2Facschembio.9b00843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basudhar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somasundaram, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridnour, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVicar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wink, D.</span></span> <span> </span><span class="NLM_article-title">Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">49</span>),  <span class="NLM_fpage">13030</span>– <span class="NLM_lpage">13035</span>, <span class="refDoi"> DOI: 10.1073/pnas.1709119114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1073%2Fpnas.1709119114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29087320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslalt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=13030-13035&issue=49&author=D.+Basudharauthor=S.+Glynnauthor=M.+Greerauthor=V.+Somasundaramauthor=J.+Noauthor=D.+Scheiblinauthor=P.+Garridoauthor=W.+Heinzauthor=A.+Ryanauthor=J.+Weissauthor=R.+Chengauthor=L.+Ridnourauthor=S.+Lockettauthor=D.+McVicarauthor=S.+Ambsauthor=D.+Wink&title=Coexpression+of+NOS2+and+COX2+accelerates+tumor+growth+and+reduces+survival+in+estrogen+receptor-negative+breast+cancer&doi=10.1073%2Fpnas.1709119114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer</span></div><div class="casAuthors">Basudhar, Debashree; Glynn, Sharon A.; Greer, Madison; Somasundaram, Veena; No, Jae Hong; Scheiblin, David A.; Garrido, Pablo; Heinz, William F.; Ryan, Aideen E.; Weiss, Jonathan M.; Cheng, Robert Y. S.; Ridnour, Lisa A.; Lockett, Stephen J.; McVicar, Daniel W.; Ambs, Stefan; Wink, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">13030-13035</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Proinflammatory signaling pathways are commonly up-regulated in breast cancer.  In estrogen receptor-neg. (ER-) and triple-neg. breast cancer (TNBC), nitric oxide synthase-2 (NOS2) and cyclooxygenase-2 (COX2) have been described as independent predictors of disease outcome.  We further explore these findings by investigating the impact of their coexpression on breast cancer survival.  Elevated coexpression of NOS2/COX2 proteins is a strong predictor of poor survival among ER- patients (hazard ratio: 21).  Furthermore, we found that the key products of NOS2 and COX2, NO and prostaglandin E2 (PGE2), resp., promote feed-forward NOS2/COX2 crosstalk in both MDA-MB-468 (basal-like) and MDA-MB-231 (mesenchymal-like) TNBC cell lines in which NO induced COX2 and PGE2 induced NOS2 proteins.  COX2 induction by NO involved TRAF2 activation that occurred in a TNFα-dependent manner in MDA-MB-468 cells.  In contrast, NO-mediated TRAF2 activation in the more aggressive MDA-MB-231 cells was TNFα independent but involved the endoplasmic reticulum stress response.  Inhibition of NOS2 and COX2 using amino-guanidine and aspirin/indomethacin yielded an additive redn. in the growth of MDA-MB-231 tumor xenografts.  These findings support a role of NOS2/COX2 crosstalk during disease progression of aggressive cancer phenotypes and offer insight into therapeutic applications for better survival of patients with ER- and TNBC disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvJ3zjZ_IIsLVg90H21EOLACvtfcHk0lgvYJYPUHxccw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslalt7zO&md5=5226533a29f4bd0ec459517b0e4c93cb</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1709119114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1709119114%26sid%3Dliteratum%253Aachs%26aulast%3DBasudhar%26aufirst%3DD.%26aulast%3DGlynn%26aufirst%3DS.%26aulast%3DGreer%26aufirst%3DM.%26aulast%3DSomasundaram%26aufirst%3DV.%26aulast%3DNo%26aufirst%3DJ.%26aulast%3DScheiblin%26aufirst%3DD.%26aulast%3DGarrido%26aufirst%3DP.%26aulast%3DHeinz%26aufirst%3DW.%26aulast%3DRyan%26aufirst%3DA.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DRidnour%26aufirst%3DL.%26aulast%3DLockett%26aufirst%3DS.%26aulast%3DMcVicar%26aufirst%3DD.%26aulast%3DAmbs%26aufirst%3DS.%26aulast%3DWink%26aufirst%3DD.%26atitle%3DCoexpression%2520of%2520NOS2%2520and%2520COX2%2520accelerates%2520tumor%2520growth%2520and%2520reduces%2520survival%2520in%2520estrogen%2520receptor-negative%2520breast%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D49%26spage%3D13030%26epage%3D13035%26doi%3D10.1073%2Fpnas.1709119114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safe, S.</span></span> <span> </span><span class="NLM_article-title">The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">498</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-14-498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1186%2F1471-2407-14-498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=25011475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyqu7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=498&author=U.+Jinauthor=S.+Leeauthor=C.+Pfentauthor=S.+Safe&title=The+aryl+hydrocarbon+receptor+ligand+omeprazole+inhibits+breast+cancer+cell+invasion+and+metastasis&doi=10.1186%2F1471-2407-14-498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis</span></div><div class="casAuthors">Jin, Un-Ho; Lee, Syng-Ook; Pfent, Catherine; Safe, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">498/1-498/14</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Patients with ER-neg. breast tumors are among the most difficult to treat and exhibit low survival rates due, in part, to metastasis from the breast to various distal sites.  Aryl hydrocarbon receptor (AHR) ligands show promise as antimetastatic drugs for estrogen receptor (ER)-neg. breast cancer.  Methods: Triple neg. MDA-MB-231 breast cancer cells were treated with eight AHR-active pharmaceuticals including 4-hydroxtamoxifen, flutamide leflunomide, mexiletine, nimodipine, omeprazole, sulindac and tranilast, and the effects of these compds. on cell proliferation (MTT assay) and cell migration (Boyden chamber assay) were examd.  The role of the AHR in mediating inhibition of MDA-MB-231 cell invasion was investigated by RNA interference (RNAi) and knockdown of AHR or cotreatment with AHR agonists.  Lung metastasis of MDA-MB-231 cells was evaluated in mice administered cells by tail vein injection and prometastatic gene expression was examd. by immunohistochem.  Results: We showed that only the proton pump inhibitor omeprazole decreased MDA-MB-231 breast cancer cell invasion in vitro.  Omeprazole also significantly decreased MDA-MB-231 cancer cell metastasis to the lung in a mouse model (tail vein injection), and in vitro studies showed that omeprazole decreased expression of at least two prometastatic genes, namely matrix metalloproteinase-9 (MMP-9) and C-X-C chemokine receptor 4 (CXCR4).  Results of RNA interference studies confirmed that omeprazole-mediated downregulation of CXCR4 (but not MMP-9) was AHR-dependent.  Chromatin immunopptn. assays demonstrated that omeprazole recruited the AHR to regions in the CXCR4 promoter that contain dioxin response elements (DREs) and this was accompanied by the loss of pol II on the promoter and decreased expression of CXCR4.  Conclusions: AHR-active pharmaceuticals such as omeprazole that decrease breast cancer cell invasion and metastasis may have important clin. applications for late stage breast cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsBXF02GSTmLVg90H21EOLACvtfcHk0lgvYJYPUHxccw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyqu7%252FO&md5=b2475e91df2f61ecbc6f8bb8a868779e</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-14-498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-14-498%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DU.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPfent%26aufirst%3DC.%26aulast%3DSafe%26aufirst%3DS.%26atitle%3DThe%2520aryl%2520hydrocarbon%2520receptor%2520ligand%2520omeprazole%2520inhibits%2520breast%2520cancer%2520cell%2520invasion%2520and%2520metastasis%26jtitle%3DBMC%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D498%26doi%3D10.1186%2F1471-2407-14-498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, N.</span></span> <span> </span><span class="NLM_article-title">Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e0143643</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0143643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1371%2Fjournal.pone.0143643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26633806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOhsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0143643&issue=12&author=Y.+Hasegawaauthor=H.+Taninoauthor=J.+Horiguchiauthor=D.+Miuraauthor=T.+Ishikawaauthor=M.+Hayashiauthor=S.+Takaoauthor=S.+Kimauthor=K.+Yamagamiauthor=M.+Miyashitaauthor=M.+Konishiauthor=Y.+Shigeokaauthor=M.+Suzukiauthor=T.+Taguchiauthor=T.+Kubotaauthor=K.+Akazawaauthor=N.+Kohno&title=Randomized+controlled+trial+of+zoledronic+acid+plus+chemotherapy+versus+chemotherapy+alone+as+neoadjuvant+treatment+of+HER2-negative+primary+breast+cancer+%28JONIE+study%29&doi=10.1371%2Fjournal.pone.0143643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of zoledronic acid plus chemotherapy versus chemotherapy alone as neoadjuvant treatment of HER2-negative primary breast cancer (JONIE study)</span></div><div class="casAuthors">Hasegawa, Yoshie; Tanino, Hirokazu; Horiguchi, Jun; Miura, Daishu; Ishikawa, Takashi; Hayashi, Mitsuhiro; Takao, Shintaro; Kim, Seung Jin; Yamagami, Kazuhiko; Miyashita, Masaru; Konishi, Muneharu; Shigeoka, Yasushi; Suzuki, Masato; Taguchi, Tetsuya; Kubota, Tomoyuki; Akazawa, Kouhei; Kohno, Norio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0143643/1-e0143643/10</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Purpose: Zoledronic acid (ZOL) is a nitrogen-contg. bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway.  Its benefit for the prevention of skeletal complications due to bone metastases has been established.  However, the antitumor efficacy of ZOL, although suggested by multiple preclin. and clin. studies, has not yet been clin. proven.  We performed the present randomized Phase 2 trial to investigate the antitumor effect of ZOL with chemotherapy (CT).  Methods: Asian patients with HER2-neg. invasive breast cancer were randomly assigned to either the CT or CT + ZOL (CTZ) group.  One hundred and eighty-eight patients were randomized to either the CT group (n = 95) or the CTZ group (n = 93) from March 2010 to Apr. 2012, and 180 patients were assessed.  All patients received four cycles of FEC100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2), followed by 12 cycles of paclitaxel at 80 mg/m2 weekly.  ZOL (4 mg) was administered three to four times weekly for 7 wk to the patients in the CTZ group.  The primary endpoint was the pathol. complete response (pCR) rate, which was defined as no invasive cancer in the breast tissue specimen.  Safety was assessed in all patients who received at least one dose of the study drug.  Results: This randomized controlled trial indicated that the rates of pCR in CTZ group (14.8%) was doubled to CT group (7.7%), resp. (one-sided chi-square test, p = 0.068), though the addnl. efficacy of zoledronic acid was not demonstrated statistically.  The pCR rate in postmenopausal patients was 18.4% and 5.1% in the CTZ and CT groups, resp. (one-sided Fisher's exact test, p = 0.071), and that in patients with triple-neg. breast cancer was 35.3% and 11.8% in the CTZ and CT groups, resp. (one-sided Fisher's exact test, p = 0.112).  Thus the addn. of ZOL to neoadjuvant CT has potential anticancer benefits in postmenopausal patients and patients with triple-neg. breast cancer.  Further investigation is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWhR4lzWhdMbVg90H21EOLACvtfcHk0lizpeVli5KZdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOhsLjE&md5=9c4012e7ebb1fc6b938416a8a702a8a2</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0143643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0143643%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DTanino%26aufirst%3DH.%26aulast%3DHoriguchi%26aufirst%3DJ.%26aulast%3DMiura%26aufirst%3DD.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DTakao%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DYamagami%26aufirst%3DK.%26aulast%3DMiyashita%26aufirst%3DM.%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DShigeoka%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DKubota%26aufirst%3DT.%26aulast%3DAkazawa%26aufirst%3DK.%26aulast%3DKohno%26aufirst%3DN.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520zoledronic%2520acid%2520plus%2520chemotherapy%2520versus%2520chemotherapy%2520alone%2520as%2520neoadjuvant%2520treatment%2520of%2520HER2-negative%2520primary%2520breast%2520cancer%2520%2528JONIE%2520study%2529%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3De0143643%26doi%3D10.1371%2Fjournal.pone.0143643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, N.</span></span> <span> </span><span class="NLM_article-title">Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer</span>. <i>J. Surg. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>220</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.jss.2017.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.jss.2017.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29180210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCht7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=2017&pages=46-51&author=T.+Ishikawaauthor=K.+Akazawaauthor=Y.+Hasegawaauthor=H.+Taninoauthor=J.+Horiguchiauthor=D.+Miuraauthor=M.+Hayashiauthor=N.+Kohno&title=Survival+outcomes+of+neoadjuvant+chemotherapy+with+zoledronic+acid+for+HER2-negative+breast+cancer&doi=10.1016%2Fj.jss.2017.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer</span></div><div class="casAuthors">Ishikawa, Takashi; Akazawa, Kouhei; Hasegawa, Yoshie; Tanino, Hirokazu; Horiguchi, Jun; Miura, Daishu; Hayashi, Mitsuhiro; Kohno, Norio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-51</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A randomized phase 2 trial in women with HER2-neg. breast cancer has shown that adding zoledronic acid (ZOL) to neoadjuvant chemotherapy (CT) has potential anticancer benefits in postmenopausal and triple-neg. (TN) breast cancer patients.  We report the data for the secondary end point of disease-free survival (DFS).  Patients were randomly assigned to receive CT or CT + ZOL (CT-Z).  All patients received four cycles of FEC100 followed by 12 cycles of paclitaxel weekly.  ZOL (4 mg) was administered 3-4 times weekly for 7 wk to the CT-Z group patients.  The primary end point was pathol. complete response (pCR).  The secondary end points were the clin. response rates, rate of breast-conserving surgery, safety, and DFS.Of the 188 patients enrolled, 95 were assigned to the CT group and 93 to the CT-Z group.  DFS and overall survival were analyzed in 92 and 88 patients with the mean times of 5.15 y and 5.38 y, resp.  The 3-y DFS rate was 84.6% in the CT group and 90.8% in the CT-Z group (P = 0.188).  The particular benefit from ZOL for the neoadjuvant CT seen as improvement of the pCR rate was indicated in the 3-y DFS period for TN cancer cases (CT vs. CT-Z: 70.6% vs. 94.1%) but not for postmenopausal cases.  ZOL did not improve DFS when combined with CT.  However, the improvement of the pCR rate translated to survival outcomes in TN breast cancer.  The short-term application of ZOL may not be sufficient to improve the outcome in postmenopausal patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKZwmFVD_Mu7Vg90H21EOLACvtfcHk0lizpeVli5KZdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCht7bN&md5=734137f117e4b7b45b493fd8388236ea</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1016%2Fj.jss.2017.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jss.2017.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DAkazawa%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DTanino%26aufirst%3DH.%26aulast%3DHoriguchi%26aufirst%3DJ.%26aulast%3DMiura%26aufirst%3DD.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DKohno%26aufirst%3DN.%26atitle%3DSurvival%2520outcomes%2520of%2520neoadjuvant%2520chemotherapy%2520with%2520zoledronic%2520acid%2520for%2520HER2-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2017%26volume%3D220%26spage%3D46%26epage%3D51%26doi%3D10.1016%2Fj.jss.2017.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Messiha, F. S.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine: adverse effects and drug-drug interactions</span>. <i>J. Toxicol., Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.3109/15563659309025765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3109%2F15563659309025765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=8254702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADyaK2cXis1Sgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1993&pages=603-630&issue=4&author=F.+S.+Messiha&title=Fluoxetine%3A+adverse+effects+and+drug-drug+interactions&doi=10.3109%2F15563659309025765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine: adverse effects and drug-drug interactions</span></div><div class="casAuthors">Messiha, F.S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicology, Clinical Toxicology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">603-30</span>CODEN:
                <span class="NLM_cas:coden">JTCTDW</span>;
        ISSN:<span class="NLM_cas:issn">0731-3810</span>.
    </div><div class="casAbstract">A review with 251 refs.  This overview summarizes the major and minor side effects and drug interactions of fluoxetine.  The adverse reactions include the "serotonin syndrome", cardiovascular complications, extrapyramidal side effects such as akathisia, dyskinesias, and parkinsonian-like syndromes and an apparently increased risk of suicidality.  Fluoxetine-induced mania and hypomania, seizures and sexual disorders are evaluated along with minor symptoms of allergic reactions, stuttering, hematol. changes, psoriasis, and inappropriate secretion of the antidiuretic hormone.  The major fluoxetine-drug interactions involve the amino acids L-dopa and L-tryptophan, anorexiants, anticonvulsants, antidepressants, anxiolytics, calcium channel blockers, cyproheptadine, lithium salts, and drugs of abuse.  The underlying mechanism and the paradoxical effects of fluoxetine are addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVq2eeqBCWBrVg90H21EOLACvtfcHk0lizpeVli5KZdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1Sgt74%253D&md5=4403e6c5e2b8087a8cca452a2cb50814</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.3109%2F15563659309025765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15563659309025765%26sid%3Dliteratum%253Aachs%26aulast%3DMessiha%26aufirst%3DF.%2BS.%26atitle%3DFluoxetine%253A%2520adverse%2520effects%2520and%2520drug-drug%2520interactions%26jtitle%3DJ.%2520Toxicol.%252C%2520Clin.%2520Toxicol.%26date%3D1993%26volume%3D31%26issue%3D4%26spage%3D603%26epage%3D630%26doi%3D10.3109%2F15563659309025765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulfkuhle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petricoin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seewaldt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibarra Drendall, C.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer</span>. <i>World J. Clin Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.5306/wjco.v6.i6.299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.5306%2Fwjco.v6.i6.299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=26677444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC28risFyjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=299-311&issue=6&author=M.+Bowieauthor=P.+Pilieauthor=J.+Wulfkuhleauthor=S.+Lemauthor=A.+Hoffmanauthor=S.+Desaiauthor=E.+Petricoinauthor=A.+Carterauthor=A.+Ambroseauthor=V.+Seewaldtauthor=D.+Yuauthor=C.+Ibarra+Drendall&title=Fluoxetine+induces+cytotoxic+endoplasmic+reticulum+stress+and+autophagy+in+triple+negative+breast+cancer&doi=10.5306%2Fwjco.v6.i6.299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer</span></div><div class="casAuthors">Bowie Michelle; Pilie Patrick; Wulfkuhle Julia; Lem Siya; Hoffman Abigail; Desai Shraddha; Petricoin Emanuel; Carter Amira; Ambrose Adrian; Seewaldt Victoria; Yu Dihua; Ibarra Drendall Catherine</div><div class="citationInfo"><span class="NLM_cas:title">World journal of clinical oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">299-311</span>
        ISSN:<span class="NLM_cas:issn">2218-4333</span>.
    </div><div class="casAbstract">AIM:  To investigate the mechanism of action of lipophilic antidepressant fluoxetine (FLX) in representative molecular subtypes of breast cancer.  METHODS:  The anti-proliferative effects and mechanistic action of FLX in triple-negative (SUM149PT) and luminal (T47D and Au565) cancer cells and non-transformed MCF10A were investigated.  Reverse phase protein microarray (RPPM) was performed with and without 10 μmol/L FLX for 24 and 48 h to determine which proteins are significantly changed.  Viability and cell cycle analysis were also performed to determine drug effects on cell growth.  Western blotting was used to confirm the change in protein expression examined by RPPM or pursue other signaling proteins.  RESULTS:  The FLX-induced cell growth inhibition in all cell lines was concentration- and time-dependent but less pronounced in early passage MCF10A.  In comparison to the other lines, cell growth reduction in SUM149PT coincided with significant induction of endoplasmic reticulum (ER) stress and autophagy after 24 and 48 h of 10 μmol/L FLX, resulting in decreased translation of proteins along the receptor tyrosine kinase/Akt/mammalian target of rapamycin pathways.  The increase in autophagy marker, cleaved microtubule-associated protein 1 light chain 3, in SUM149PT after 24 h of FLX was likely due to increased metabolic demands of rapidly dividing cells and ER stress.  Consequently, the unfolded protein response mediated by double-stranded RNA-dependent protein kinase-like ER kinase resulted in inhibition of protein synthesis, growth arrest at the G1 phase, autophagy, and caspase-7-mediated cell death.  CONCLUSION:  Our study suggests a new role for FLX as an inducer of ER stress and autophagy, resulting in death of aggressive triple negative breast cancer SUM149PT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQW0ZJxbj5qqlHFYivNCdPRfW6udTcc2ealV5mYyi-yX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28risFyjtg%253D%253D&md5=2d313d7146729302df3215c91c75bc2b</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.5306%2Fwjco.v6.i6.299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5306%252Fwjco.v6.i6.299%26sid%3Dliteratum%253Aachs%26aulast%3DBowie%26aufirst%3DM.%26aulast%3DPilie%26aufirst%3DP.%26aulast%3DWulfkuhle%26aufirst%3DJ.%26aulast%3DLem%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DS.%26aulast%3DPetricoin%26aufirst%3DE.%26aulast%3DCarter%26aufirst%3DA.%26aulast%3DAmbrose%26aufirst%3DA.%26aulast%3DSeewaldt%26aufirst%3DV.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DIbarra%2BDrendall%26aufirst%3DC.%26atitle%3DFluoxetine%2520induces%2520cytotoxic%2520endoplasmic%2520reticulum%2520stress%2520and%2520autophagy%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DWorld%2520J.%2520Clin%2520Oncol.%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D299%26epage%3D311%26doi%3D10.5306%2Fwjco.v6.i6.299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span> <span> </span><span class="NLM_article-title">Phenothiazine antipsychotics exhibit dual properties in pseudo-allergic reactions: Activating MRGPRX2 and inhibiting the H1 receptor</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2019.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.molimm.2019.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31051313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12qsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2019&pages=118-127&author=Y.+Houauthor=D.+Cheauthor=D.+Weiauthor=C.+Wangauthor=Y.+Xieauthor=K.+Zhangauthor=J.+Caoauthor=J.+Fuauthor=N.+Zhouauthor=H.+He&title=Phenothiazine+antipsychotics+exhibit+dual+properties+in+pseudo-allergic+reactions%3A+Activating+MRGPRX2+and+inhibiting+the+H1+receptor&doi=10.1016%2Fj.molimm.2019.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Phenothiazine antipsychotics exhibit dual properties in pseudo-allergic reactions: Activating MRGPRX2 and inhibiting the H1 receptor</span></div><div class="casAuthors">Hou, Yajing; Che, Delu; Wei, Di; Wang, Cheng; Xie, Yitong; Zhang, Kaining; Cao, Jiao; Fu, Jia; Zhou, Nan; He, Huaizhen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118-127</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Phenothiazines are a class of antipsychotics that share the same tricyclic structure and are widely used in clin. settings.  Adverse reactions from these drugs, however, have been regularly reported, with allergic skin reactions noted in some cases.  Nevertheless, the mechanisms underlying anaphylaxis by these drugs have not been described.  In the present study, we found that phenothiazine antipsychotics increased calcium mobilization and activated mast cells to release β-hexosaminidase, histamine, and tumor necrosis factor-α via Mas-related G-protein-coupled receptor member X2 (MRGPRX2) in vitro.  In addn., they induced histamine release in serum via Mrgprb2 in C57BL/6 mice without Evans blue extravasation or paw swell.  Further expts. indicated these drugs had good interaction with the histamine H1 receptor (H1R) and show an anti-calcium mobilization effect on H1R-HEK293 cells, which confirmed a potential antagonist effect of these drugs on the H1R.  The mol. docking and activity expts. indicated that the N-Me substitution on the side chain of these drugs played a significant role in activating MRGPRX2, while the phenothiazine tricyclic ring was assocd. with the inhibiting effect on the H1R.  Therefore, due to their dual properties of increasing histamine levels without obvious allergic symptoms, clinicians should be highly vigilant for damage from histamine accumulation and long-term inflammatory reactions during the clin. use of phenothiazine antipsychotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJG4l8VEtLkbVg90H21EOLACvtfcHk0liDh0VKczshZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12qsrY%253D&md5=6eedf9e8037101b02b75996d43824ada</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2019.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2019.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DY.%26aulast%3DChe%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DH.%26atitle%3DPhenothiazine%2520antipsychotics%2520exhibit%2520dual%2520properties%2520in%2520pseudo-allergic%2520reactions%253A%2520Activating%2520MRGPRX2%2520and%2520inhibiting%2520the%2520H1%2520receptor%26jtitle%3DMol.%2520Immunol.%26date%3D2019%26volume%3D111%26spage%3D118%26epage%3D127%26doi%3D10.1016%2Fj.molimm.2019.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henao, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peperzak, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichvar, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orebaugh, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skledar, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. A.</span></span> <span> </span><span class="NLM_article-title">Extrapyramidal symptoms following administration of oral perphenazine 4 or 8mg: An 11-year retrospective analysis</span>. <i>Eur. J. Anaesthesiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1097/EJA.0000000000000048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1097%2FEJA.0000000000000048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24503705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFektrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=231-235&issue=4&author=J.+P.+Henaoauthor=K.+A.+Peperzakauthor=A.+B.+Lichvarauthor=S.+L.+Orebaughauthor=S.+J.+Skledarauthor=M.+A.+Pippiauthor=B.+A.+Williams&title=Extrapyramidal+symptoms+following+administration+of+oral+perphenazine+4+or+8mg%3A+An+11-year+retrospective+analysis&doi=10.1097%2FEJA.0000000000000048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Extrapyramidal symptoms following administration of oral perphenazine 4 or 8mg: An 11-year retrospective analysis</span></div><div class="casAuthors">Henao, John P.; Peperzak, Katherin A.; Lichvar, Alicia B.; Orebaugh, Steven L.; Skledar, Susan J.; Pippi, Michael A.; Williams, Brian A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Anaesthesiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">231-235</span>CODEN:
                <span class="NLM_cas:coden">EJANEG</span>;
        ISSN:<span class="NLM_cas:issn">0265-0215</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Perphenazine is a treatment option in postoperative nausea and vomiting (PONV) prophylaxis.  Chronic administration and high dose are known to cause extrapyramidal system (EPS) dysfunction at a frequency of 8%, but the incidence of acute EPS after a single 4 or 8mg dose is unknown.  Objective: A retrospective anal. of patient medication billing data and departmental quality records was performed (Jan. 2001 to 10 July 2012) to identify patients who experienced EPS dysfunction after oral perphenazine.  Design: A retrospective anal.  Setting: Surgical outpatients presenting to any one of 10 hospitals in the area of Pittsburgh, Pennsylvania, USA.  Patients: Overall, 45766 patients received 4 or 8mg of perphenazine before same-day surgery.  Main outcome measures: EPS dysfunction was defined as acute dystonia, akathisia or pseudoparkinsonism.  Records were reviewed to det. the likely no. of reactions to perphenazine, the nature of these reactions and impact on patient care.  Results: There were four 'likely' cases of EPS dysfunction, and two 'possible' cases.  Five reported events were consistent with akathisia, with the sixth being a dystonic reaction.  All six patients had resoln. of symptoms, with five receiving i.v. diphenhydramine for treatment.  The incidence of EPS dysfunction was 1.3 events per 10000 patients (95% confidence interval (CI) 0.4 to 3.0, based on six events).  All patients who experienced reactions pre-operatively were able to proceed to surgery without complications or delay.  One patient required unplanned admission and 3-h observation owing to sedation from diphenhydramine.  The incidence of EPS dysfunction after oral perphenazine is low.  Reactions that did occur were mild and easily treated.  Conclusion: Given the infrequent side effects, this single, low dose of perphenazine should be encouraged as a low-risk adjunct to any multimodal PONV prophylaxis regimen, based on the selection criteria described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQMCjfqCBTLVg90H21EOLACvtfcHk0liDh0VKczshZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFektrs%253D&md5=55baf8908c2105c6350f70adcaadcdfb</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1097%2FEJA.0000000000000048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FEJA.0000000000000048%26sid%3Dliteratum%253Aachs%26aulast%3DHenao%26aufirst%3DJ.%2BP.%26aulast%3DPeperzak%26aufirst%3DK.%2BA.%26aulast%3DLichvar%26aufirst%3DA.%2BB.%26aulast%3DOrebaugh%26aufirst%3DS.%2BL.%26aulast%3DSkledar%26aufirst%3DS.%2BJ.%26aulast%3DPippi%26aufirst%3DM.%2BA.%26aulast%3DWilliams%26aufirst%3DB.%2BA.%26atitle%3DExtrapyramidal%2520symptoms%2520following%2520administration%2520of%2520oral%2520perphenazine%25204%2520or%25208mg%253A%2520An%252011-year%2520retrospective%2520analysis%26jtitle%3DEur.%2520J.%2520Anaesthesiol.%26date%3D2014%26volume%3D31%26issue%3D4%26spage%3D231%26epage%3D235%26doi%3D10.1097%2FEJA.0000000000000048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barajas-Martinez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span> <span> </span><span class="NLM_article-title">Acquired short QT syndrome in a cancer patient treated with Toad</span>. <i>Pace.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1275</span>, <span class="refDoi"> DOI: 10.1111/pace.13708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1111%2Fpace.13708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3M7gs1yrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=1273-1275&issue=9&author=Y.+Huangauthor=Y.+Xuauthor=H.+Barajas-Martinezauthor=D.+Hu&title=Acquired+short+QT+syndrome+in+a+cancer+patient+treated+with+Toad&doi=10.1111%2Fpace.13708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired short QT syndrome in a cancer patient treated with Toad</span></div><div class="casAuthors">Huang Yan; Hu Dan; Huang Yan; Hu Dan; Xu Yong; Barajas-Martinez Hector</div><div class="citationInfo"><span class="NLM_cas:title">Pacing and clinical electrophysiology : PACE</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1273-1275</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although drug-induced short QT syndrome (SQTS) has been recognized, we currently report the first acquired SQTS case induced by bufotalinin (toad, an antineoplastic drug), which is a traditional Chinese folk prescription.  It has cross reaction with digoxin and affects the Na(+) -K(+) -ATPase, the SR Ca(2+) release from ryanodine receptor-2 (RyR2), the reactive oxygen species (ROS) production from the mitochondria.  The case presented with bradycardia, extreme QT shortening, and sinoatrial block that were resolved after gastric lavage, rehydration, electrolyte (hyperkalemia, hyponatremia, hypocalcemia) correction, and atropine injection.  Clinicians should recognize a potential association between toad poisoning and SQTS from this case.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBt3xiNPRhrlw2ofyr07jXfW6udTcc2eYw4YpHAA50wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7gs1yrtw%253D%253D&md5=a1a307844cca8d1be51013b31fdf62ce</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1111%2Fpace.13708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpace.13708%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBarajas-Martinez%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DD.%26atitle%3DAcquired%2520short%2520QT%2520syndrome%2520in%2520a%2520cancer%2520patient%2520treated%2520with%2520Toad%26jtitle%3DPace.%26date%3D2019%26volume%3D42%26issue%3D9%26spage%3D1273%26epage%3D1275%26doi%3D10.1111%2Fpace.13708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Botteri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotmensz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipolla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santillo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanelotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colleoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandini, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1007/s10549-013-2654-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-013-2654-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=23912960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Wrsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=567-575&issue=3&author=E.+Botteriauthor=E.+Munzoneauthor=N.+Rotmenszauthor=C.+Cipollaauthor=V.+De+Giorgiauthor=B.+Santilloauthor=A.+Zanelottiauthor=L.+Adamoliauthor=M.+Colleoniauthor=G.+Vialeauthor=A.+Goldhirschauthor=S.+Gandini&title=Therapeutic+effect+of+%CE%B2-blockers+in+triple-negative+breast+cancer+postmenopausal+women&doi=10.1007%2Fs10549-013-2654-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women</span></div><div class="casAuthors">Botteri, Edoardo; Munzone, Elisabetta; Rotmensz, Nicole; Cipolla, Carlo; De Giorgi, Vincenzo; Santillo, Barbara; Zanelotti, Arnaldo; Adamoli, Laura; Colleoni, Marco; Viale, Giuseppe; Goldhirsch, Aron; Gandini, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">567-575</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Beta-blockers (BB) drugs have been used for decades worldwide, mainly to treat hypertension.  However, in recent epidemiol. studies, BBs were suggested to improve cancer prognosis.  In the wake of this evidence, we evaluated the possible therapeutic effect of BBs in triple-neg. breast cancer (TNBC) patients.  We identified 800 postmenopausal women operated between 1997 and 2008 for early primary TNBC.  The effect of BB intake on the risk of breast cancer (BC) recurrence and death was evaluated through competing risk and Cox regression survival models.  At cancer diagnosis, 74 (9.3 %) women out of 800 were BBs users.  Median age was 62 years in BB users and 59 years in non-users (P = 0.02).  BB users and non-users were similarly distributed by all tumor characteristics.  The 5-yr cumulative incidence of BC-related events was 13.6 % in BB users and 27.9 % in non-users (P = 0.02).  The beneficial impact of BBs remained statistically significant at multivariable anal. (HR, 0.52; 95 % CI 0.28-0.97), after the adjustment for age, tumor stage, and treatment, peritumoral vascular invasion and use of other antihypertensive drugs, antithrombotics, and statins.  Adjusted HRs for metastases and for BC deaths were 0.32 (95 % CI 0.12-0.90) and 0.42 (95 % CI 0.18-0.97), resp., in favor of BBs.  Hypertension, other antihypertensive drugs, antithrombotics, and statins did not impact prognosis.  In this series of postmenopausal TNBC patients, BB intake was assocd. with a significantly decreased risk of BC-related recurrence, metastasis, and BC death.  Innovative therapeutic strategies including BBs should be urgently explored in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHfmyF95Zvg7Vg90H21EOLACvtfcHk0lhlczN5FpyNww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Wrsr3E&md5=0dac95baf551245b5b0a27cbd62218a0</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2654-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2654-3%26sid%3Dliteratum%253Aachs%26aulast%3DBotteri%26aufirst%3DE.%26aulast%3DMunzone%26aufirst%3DE.%26aulast%3DRotmensz%26aufirst%3DN.%26aulast%3DCipolla%26aufirst%3DC.%26aulast%3DDe%2BGiorgi%26aufirst%3DV.%26aulast%3DSantillo%26aufirst%3DB.%26aulast%3DZanelotti%26aufirst%3DA.%26aulast%3DAdamoli%26aufirst%3DL.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DGandini%26aufirst%3DS.%26atitle%3DTherapeutic%2520effect%2520of%2520%25CE%25B2-blockers%2520in%2520triple-negative%2520breast%2520cancer%2520postmenopausal%2520women%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D140%26issue%3D3%26spage%3D567%26epage%3D575%26doi%3D10.1007%2Fs10549-013-2654-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melhem-Bertrandt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez-Macgregor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conzen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span> <span> </span><span class="NLM_article-title">Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">2645</span>– <span class="NLM_lpage">2652</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.33.4441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2010.33.4441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21632501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=2645-2652&issue=19&author=A.+Melhem-Bertrandtauthor=M.+Chavez-Macgregorauthor=X.+Leiauthor=E.+Brownauthor=R.+Leeauthor=F.+Meric-Bernstamauthor=A.+Soodauthor=S.+Conzenauthor=G.+Hortobagyiauthor=A.+Gonzalez-Angulo&title=Beta-blocker+use+is+associated+with+improved+relapse-free+survival+in+patients+with+triple-negative+breast+cancer&doi=10.1200%2FJCO.2010.33.4441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer</span></div><div class="casAuthors">Melhem-Bertrandt, Amal; Chavez-MacGregor, Mariana; Lei, Xiudong; Brown, Erika N.; Lee, Richard T.; Meric-Bernstam, Funda; Sood, Anil K.; Conzen, Suzanne D.; Hortobagyi, Gabriel N.; Gonzalez-Angulo, Ana-Maria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2645-2652</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To examine the assocn. between beta-blocker (BB) intake, pathol. complete response (pCR) rates, and survival outcomes in patients with breast cancer treated with neoadjuvant chemotherapy.  Patients and Methods: We retrospectively reviewed 1,413 patients with breast cancer who received neoadjuvant chemotherapy between 1995 and 2007.  Patients taking BBs at the start of neoadjuvant therapy were compared with patients with no BB intake.  Rates of pCR between the groups were compared using a χ2 test.  Cox proportional hazards models were fitted to det. the assocn. between BB intake, relapse-free survival (RFS), and overall survival (OS).  Results: Patients who used BBs (n = 102) were compared with patients (n = 1,311) who did not.  Patients receiving BBs tended to be older and obese (P < .001).  The proportion of pCR was not significantly different between the groups (P = .48).  After adjustment for age, race, stage, grade, receptor status, lymphovascular invasion, body mass index, diabetes, hypertension, and angiotensin-converting enzyme inhibitor use, BB intake was assocd. with a significantly better RFS (hazard ratio HR), 0.52; 95% CI, 0.31 to 0.88 but not OS (P = .09).  Among patients with triple-neg. breast cancer (TNBC; n = 377), BB intake was assocd. with improved RFS (HR, 0.30; 95% CI, 0.10 to 0.87; P = .027) but not OS (HR, 0.35; 95% CI, 0.12 to 1.00; P = .05).  Conclusion: In this study, BB intake was assocd. with improved RFS in all patients with breast cancer and in patients with TNBC.  Addnl. studies evaluating the potential benefits of beta-adrenergic blockade on breast cancer recurrence with a focus on TNBC are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6hmqxs7-yM7Vg90H21EOLACvtfcHk0lhlczN5FpyNww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWltbo%253D&md5=c7681c52976af8156daf3dbb02941280</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.4441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.4441%26sid%3Dliteratum%253Aachs%26aulast%3DMelhem-Bertrandt%26aufirst%3DA.%26aulast%3DChavez-Macgregor%26aufirst%3DM.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DSood%26aufirst%3DA.%26aulast%3DConzen%26aufirst%3DS.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26atitle%3DBeta-blocker%2520use%2520is%2520associated%2520with%2520improved%2520relapse-free%2520survival%2520in%2520patients%2520with%2520triple-negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3D19%26spage%3D2645%26epage%3D2652%26doi%3D10.1200%2FJCO.2010.33.4441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pituskin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J.</span></span> <span> </span><span class="NLM_article-title">Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: A retrospective analysis of the ROSE/TRIO-012 study</span>. <i>Annals of oncology.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1836</span>– <span class="NLM_lpage">1841</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1093%2Fannonc%2Fmdx264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=28520849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1crovFehtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=1836-1841&issue=8&author=G.+Speraauthor=R.+Frescoauthor=H.+Fungauthor=J.+Dyckauthor=E.+Pituskinauthor=I.+Patersonauthor=J.+Mackey&title=Beta+blockers+and+improved+progression-free+survival+in+patients+with+advanced+HER2+negative+breast+cancer%3A+A+retrospective+analysis+of+the+ROSE%2FTRIO-012+study&doi=10.1093%2Fannonc%2Fmdx264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study</span></div><div class="casAuthors">Spera G; Fresco R; Fung H; Dyck J R B; Pituskin E; Pituskin E; Mackey J R; Paterson I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1836-1841</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Recent retrospective studies suggest that beta-adrenergic blocking drugs (BB) are associated with improved outcomes in patients with a range of cancers.  Although limited and discordant data suggest that BB may increase overall survival (OS) in localized breast cancer (BC), there is no information on the effects of BB in women with advanced BC.  Patients and methods:  To explore the association between BB use and BC outcomes, we retrospectively reviewed ROSE/TRIO-012, a double-blinded, multinational phase III trial that randomized 1144 patients with HER2-negative advanced BC to first-line docetaxel in combination with ramucirumab or placebo.  We compared progression-free survival (PFS), OS, overall response rate, and clinical benefit rate in patients who received BB to those who did not.  Results:  153/1144 (13%) patients received BB; 62% prior to enrolment and 38% began after enrolment.  Median PFS in BB treated patients was longer than in patients who did not receive them (10.3 versus 8.3 months; HR 0.81; 95% CI 0.66-0.99; P = 0.038).  Patients treated with BB only after enrolment had even higher median PFS (15.5 versus 8.3 months, P < 0.001).  In the TNBC subset, median PFS was 13.0 months with BB, compared to 5.2 months without BB (HR 0.52; 95% CI 0.34-0.79; P = 0.002).  The benefit of BB intake in PFS was independent of treatment-emergent hypertension (P = 0.476) but associated with treatment arm (P = 0.037).  The test for interactions between BB and treatment arm was not significant (P = 0.276).  No differences were seen in OS, overall response rate, or clinical benefit rate.  A validation dataset analysis had consistent but less substantial improved outcomes for women with node positive operable breast cancer receiving BB in the BCIRG-005 trial.  Conclusions:  In this exploratory analysis, BB intake was associated with significant improvement in PFS, particularly in patients with TNBC and patients not previously exposed to BB.  Clinical trial number:  NCT00703326.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFuk9Z6vWG3-98rul4nhSdfW6udTcc2ebziP9walytDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crovFehtA%253D%253D&md5=a4058d0907ce3cde1613776fc3f9f748</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx264%26sid%3Dliteratum%253Aachs%26aulast%3DSpera%26aufirst%3DG.%26aulast%3DFresco%26aufirst%3DR.%26aulast%3DFung%26aufirst%3DH.%26aulast%3DDyck%26aufirst%3DJ.%26aulast%3DPituskin%26aufirst%3DE.%26aulast%3DPaterson%26aufirst%3DI.%26aulast%3DMackey%26aufirst%3DJ.%26atitle%3DBeta%2520blockers%2520and%2520improved%2520progression-free%2520survival%2520in%2520patients%2520with%2520advanced%2520HER2%2520negative%2520breast%2520cancer%253A%2520A%2520retrospective%2520analysis%2520of%2520the%2520ROSE%252FTRIO-012%2520study%26jtitle%3DAnnals%2520of%2520oncology.%26date%3D2017%26volume%3D28%26issue%3D8%26spage%3D1836%26epage%3D1841%26doi%3D10.1093%2Fannonc%2Fmdx264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sardesai, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynce, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviano, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballinger, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storniolo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauchle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althouse, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span> <span> </span><span class="NLM_article-title">Inhibiting fatty acid synthase in operable triple negative breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">584</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1200/JCO.2020.38.15_suppl.584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1200%2FJCO.2020.38.15_suppl.584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31821065" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=584-584&author=S.+D.+Sardesaiauthor=A.+Thomasauthor=C.+Gallagherauthor=F.+Lynceauthor=Y.+L.+Ottavianoauthor=T.+J.+Ballingerauthor=B.+P.+Schneiderauthor=A.+M.+Stornioloauthor=A.+Bauchleauthor=S.+K.+Althouseauthor=S.+Perkinsauthor=J.+T.+Zhangauthor=K.+Miller&title=Inhibiting+fatty+acid+synthase+in+operable+triple+negative+breast+cancer&doi=10.1200%2FJCO.2020.38.15_suppl.584"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.584%26sid%3Dliteratum%253Aachs%26aulast%3DSardesai%26aufirst%3DS.%2BD.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DGallagher%26aufirst%3DC.%26aulast%3DLynce%26aufirst%3DF.%26aulast%3DOttaviano%26aufirst%3DY.%2BL.%26aulast%3DBallinger%26aufirst%3DT.%2BJ.%26aulast%3DSchneider%26aufirst%3DB.%2BP.%26aulast%3DStorniolo%26aufirst%3DA.%2BM.%26aulast%3DBauchle%26aufirst%3DA.%26aulast%3DAlthouse%26aufirst%3DS.%2BK.%26aulast%3DPerkins%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DK.%26atitle%3DInhibiting%2520fatty%2520acid%2520synthase%2520in%2520operable%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D584%26epage%3D584%26doi%3D10.1200%2FJCO.2020.38.15_suppl.584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayraktar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernadez-Aya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A.</span></span> <span> </span><span class="NLM_article-title">Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1202</span>– <span class="NLM_lpage">1211</span>, <span class="refDoi"> DOI: 10.1002/cncr.26439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fcncr.26439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=21800293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVyhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=1202-1211&issue=5&author=S.+Bayraktarauthor=L.+Hernadez-Ayaauthor=X.+Leiauthor=F.+Meric-Bernstamauthor=J.+Littonauthor=L.+Hsuauthor=G.+Hortobagyiauthor=A.+Gonzalez-Angulo&title=Effect+of+metformin+on+survival+outcomes+in+diabetic+patients+with+triple+receptor-negative+breast+cancer&doi=10.1002%2Fcncr.26439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer</span></div><div class="casAuthors">Bayraktar, Soley; Hernadez-Aya, Leonel F.; Lei, Xiudong; Meric-Bernstam, Funda; Litton, Jennifer K.; Hsu, Limin; Hortobagyi, Gabriel N.; Gonzalez-Angulo, Ana M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1202-1211</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND: : Recent observational studies have shown that metformin use in diabetic patients decreases both cancer incidence and mortality.  Metformin use is also independently predictive of pathol. complete response.  In the current study, the authors explored the assocn. between metformin use and survival outcomes in patients with triple receptor-neg. breast cancer (TNBC) who were receiving adjuvant chemotherapy.  METHODS: : The Breast Cancer Management System database of The University of Texas MD Anderson Cancer Center identified 1448 women who received adjuvant chemotherapy for TNBC between 1995 and 2007.  Patients were categorized by diabetes status and metformin use.  The Kaplan-Meier product-limit method was used to calc. distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS).  Cox proportional hazards models were fit to det. the assocn. between metformin use and survival outcomes.  RESULTS: : The study cohort was comprised of 63 diabetic patients receiving treatment with metformin, 67 diabetic patients not receiving metformin, and 1318 nondiabetic patients.  Patients in the diabetic groups tended to be older (P = .005); more diabetic patients were postmenopausal (P = .0007), black (P = .0001), and obese (P < .0001).  At a median follow-up of 62 mo, there were no significant differences with regard to 5-yr DMFS (P = .23), RFS (P = .38), and OS (P = .58) between the 3 groups.  Compared with the metformin group, patients who did not receive metformin (hazard ratio [HR], 1.63; 95% confidence interval [95% CI], 0.87-3.06 [P = .13]) and nondiabetic patients (HR, 1.62; 95% CI, 0.97-2.71 [P = .06]) tended to have a higher risk of distant metastases.  CONCLUSIONS: : The findings of the current study suggest that metformin use during adjuvant chemotherapy does not significantly impact survival outcomes in diabetic patients with TNBC.  Cancer 2012;.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPYRGpl2FyFrVg90H21EOLACvtfcHk0lh-IoKRBK9G9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVyhsrg%253D&md5=34a0f257025123fdb9a6555423ccabb2</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1002%2Fcncr.26439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.26439%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DS.%26aulast%3DHernadez-Aya%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DLitton%26aufirst%3DJ.%26aulast%3DHsu%26aufirst%3DL.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%26atitle%3DEffect%2520of%2520metformin%2520on%2520survival%2520outcomes%2520in%2520diabetic%2520patients%2520with%2520triple%2520receptor-negative%2520breast%2520cancer%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26issue%3D5%26spage%3D1202%26epage%3D1211%26doi%3D10.1002%2Fcncr.26439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaloge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espié, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigal-Zafrani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertheau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinebretière, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spielmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savignoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, M.</span></span> <span> </span><span class="NLM_article-title">A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1007/s10549-010-0939-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1007%2Fs10549-010-0939-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=20480225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFymu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2010&pages=429-437&issue=2&author=J.+Piergaauthor=S.+Delalogeauthor=M.+Espi%C3%A9author=E.+Brainauthor=B.+Sigal-Zafraniauthor=M.+Mathieuauthor=P.+Bertheauauthor=J.+Guinebreti%C3%A8reauthor=M.+Spielmannauthor=A.+Savignoniauthor=M.+Marty&title=A+multicenter+randomized+phase+II+study+of+sequential+epirubicin%2Fcyclophosphamide+followed+by+docetaxel+with+or+without+celecoxib+or+trastuzumab+according+to+HER2+status%2C+as+primary+chemotherapy+for+localized+invasive+breast+cancer+patients&doi=10.1007%2Fs10549-010-0939-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients</span></div><div class="casAuthors">Pierga, Jean-Yves; Delaloge, Suzette; Espie, Marc; Brain, Etienne; Sigal-Zafrani, Brigitte; Mathieu, Marie-Christine; Bertheau, Philippe; Guinebretiere, Jean Marc; Spielmann, Marc; Savignoni, Alexia; Marty, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">429-437</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by docetaxel with the randomized addn. of celecoxib in HER2 neg. patients or trastuzumab in HER2 pos. patients.  From May 2004 till Oct. 2007, 340 patients with stage II and III breast adenocarcinoma, ineligible for breast conserving surgery, received eight sequential three weekly cycles of EC-D [epirubicin (75 mg/m2)-cyclophosphamide (750 mg/m2) for four cycles followed by docetaxel (100 mg/m2) for four cycles].  HER2-neg. patients (N = 220) were randomized to receive concomitantly with docetaxel celecoxib 800 mg/day during cycles 5-8 or no addnl. treatment, while HER2-pos. patients confirmed by FISH (N = 120) were randomized to trastuzumab concomitant to docetaxel (8 mg/kg then 6 mg/kg IV every 3 wk) or no addnl. preoperative treatment.  In the HER2 neg. group, pCR (grade 1 and 2 of Chevallier's classification) was obsd. in 11.5 and 13% of patients treated without and with neoadjuvant Celecoxib, resp.  In the HER2 pos. group, pCR rate reached 26% in those who received neoadjuvant trastuzumab vs. 19% in the others.  There was no unexpected toxicity, no cardiac toxicity, and no toxic death.  Triple neg. breast cancers experience the highest pCR rate of 30%.  Celecoxib is not likely to improve pCR rates in addn. to EC-D in patients with HER2-neg. tumor.  In HER2-pos. tumor patients, trastuzumab added to ECD leads to increased pCR rates.  It was the only combination to deserve further study according to the two-stage Fleming's design used in this trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIwG7zqlwaxrVg90H21EOLACvtfcHk0lhz5ufHYKTbbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFymu7s%253D&md5=98b67e9dcf885acca4ce6b5b8beb3ec2</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1007%2Fs10549-010-0939-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-010-0939-3%26sid%3Dliteratum%253Aachs%26aulast%3DPierga%26aufirst%3DJ.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DEspi%25C3%25A9%26aufirst%3DM.%26aulast%3DBrain%26aufirst%3DE.%26aulast%3DSigal-Zafrani%26aufirst%3DB.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DBertheau%26aufirst%3DP.%26aulast%3DGuinebreti%25C3%25A8re%26aufirst%3DJ.%26aulast%3DSpielmann%26aufirst%3DM.%26aulast%3DSavignoni%26aufirst%3DA.%26aulast%3DMarty%26aufirst%3DM.%26atitle%3DA%2520multicenter%2520randomized%2520phase%2520II%2520study%2520of%2520sequential%2520epirubicin%252Fcyclophosphamide%2520followed%2520by%2520docetaxel%2520with%2520or%2520without%2520celecoxib%2520or%2520trastuzumab%2520according%2520to%2520HER2%2520status%252C%2520as%2520primary%2520chemotherapy%2520for%2520localized%2520invasive%2520breast%2520cancer%2520patients%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2010%26volume%3D122%26issue%3D2%26spage%3D429%26epage%3D437%26doi%3D10.1007%2Fs10549-010-0939-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debeb, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobágyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchholz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, W.</span></span> <span> </span><span class="NLM_article-title">Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation</span>. <i>Stem Cells Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.5966/sctm.2013-0204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.5966%2Fsctm.2013-0204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=24833589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyisb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=849-856&issue=7&author=L.+Lacerdaauthor=J.+Reddyauthor=D.+Liuauthor=R.+Larsonauthor=L.+Liauthor=H.+Masudaauthor=T.+Brewerauthor=B.+Debebauthor=W.+Xuauthor=G.+Hortob%C3%A1gyiauthor=T.+Buchholzauthor=N.+Uenoauthor=W.+Woodward&title=Simvastatin+radiosensitizes+differentiated+and+stem-like+breast+cancer+cell+lines+and+is+associated+with+improved+local+control+in+inflammatory+breast+cancer+patients+treated+with+postmastectomy+radiation&doi=10.5966%2Fsctm.2013-0204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation</span></div><div class="casAuthors">Lacerda, Lara; Reddy, Jay P.; Liu, Diane; Larson, Richard; Li, Li; Masuda, Hiroko; Brewer, Takae; Debeb, Bisrat G.; Xu, Wei; Hortobagyi, Gabriel N.; Buchholz, Thomas A.; Ueno, Naoto T.; Woodward, Wendy A.</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">849-856</span>CODEN:
                <span class="NLM_cas:coden">SCTMC7</span>;
        ISSN:<span class="NLM_cas:issn">2157-6564</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Reported rates of local failure after adjuvant radiation for women with inflammatory breast cancer (IBC) and triple-neg. non-IBC are higher than those of women with receptor-expressing non-IBC.  These high rates of locoregional recurrence are potentially influenced by the contribution of radio-resistant cancer stem cells to these cancers.  Statins have been shown to target stem cells and improve disease-free survival among IBC patients.  We examd. simvastatin radiosensitization of multiple subtypes of breast cancer cell lines in vitro in monolayer and mammosphere-based clonogenic assays and examd. the therapeutic benefit of statin use on local control after postmastectomy radiation (PMRT) among IBC patients.  We found that simvastatin radiosensitizes mammosphere-initiating cells (MICs) of IBC cell lines (MDA-IBC3, SUM149, SUM190) and of the metaplastic, non-IBC triple-neg. receptor cell line (SUM159).  However, simvastatin radioprotects MICs of non-IBC cell lines MCF-7 and SKBR3.  In a retrospective clin. study of 519 IBC patients treated with PMRT, 53 patients used a statin.  On univariate anal., actuarial 3-yr local recurrence-free survival (LRFS) was higher among statin users, and on multivariate anal., triple neg. breast cancer, absence of lymphatic invasion, neoadjuvant pathol. tumor response to preoperative chemotherapy, and statin use were independently assocd. with higher LRFS.  In conclusion, patients with IBC and triple-neg. non-IBC breast cancer have the highest rates of local failure, and there are no available known radiosensitizers.  We report significant improvement in local control after PMRT among statin users with IBC and significant radiosensitization across triple-neg. and IBC cell lines of multiple subtypes using simvastatin.  These data suggest that simvastatin should be justified as a radiosensitizing agent by a prospective clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa5ttgSESxMrVg90H21EOLACvtfcHk0lhz5ufHYKTbbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyisb%252FL&md5=c494bd8a05e3831cc400c6f2f1531a3f</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.5966%2Fsctm.2013-0204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5966%252Fsctm.2013-0204%26sid%3Dliteratum%253Aachs%26aulast%3DLacerda%26aufirst%3DL.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLarson%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DBrewer%26aufirst%3DT.%26aulast%3DDebeb%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHortob%25C3%25A1gyi%26aufirst%3DG.%26aulast%3DBuchholz%26aufirst%3DT.%26aulast%3DUeno%26aufirst%3DN.%26aulast%3DWoodward%26aufirst%3DW.%26atitle%3DSimvastatin%2520radiosensitizes%2520differentiated%2520and%2520stem-like%2520breast%2520cancer%2520cell%2520lines%2520and%2520is%2520associated%2520with%2520improved%2520local%2520control%2520in%2520inflammatory%2520breast%2520cancer%2520patients%2520treated%2520with%2520postmastectomy%2520radiation%26jtitle%3DStem%2520Cells%2520Transl.%2520Med.%26date%3D2014%26volume%3D3%26issue%3D7%26spage%3D849%26epage%3D856%26doi%3D10.5966%2Fsctm.2013-0204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantziarka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crispino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziche, M.</span></span> <span> </span><span class="NLM_article-title">Repurposing of drugs for triple negative breast cancer: an overview</span>. <i>ecancer</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1071</span>, <span class="refDoi"> DOI: 10.3332/ecancer.2020.1071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3332%2Fecancer.2020.1071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=32728387" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=1071&author=A.+Spiniauthor=S.+Donniniauthor=P.+Pantziarkaauthor=S.+Crispinoauthor=M.+Ziche&title=Repurposing+of+drugs+for+triple+negative+breast+cancer%3A+an+overview&doi=10.3332%2Fecancer.2020.1071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.3332%2Fecancer.2020.1071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3332%252Fecancer.2020.1071%26sid%3Dliteratum%253Aachs%26aulast%3DSpini%26aufirst%3DA.%26aulast%3DDonnini%26aufirst%3DS.%26aulast%3DPantziarka%26aufirst%3DP.%26aulast%3DCrispino%26aufirst%3DS.%26aulast%3DZiche%26aufirst%3DM.%26atitle%3DRepurposing%2520of%2520drugs%2520for%2520triple%2520negative%2520breast%2520cancer%253A%2520an%2520overview%26jtitle%3Decancer%26date%3D2020%26volume%3D14%26spage%3D1071%26doi%3D10.3332%2Fecancer.2020.1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truica, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. M.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1016%2Fj.drup.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=29145974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BC1M3itVaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=1-15&author=H.+Jiaauthor=C.+I.+Truicaauthor=B.+Wangauthor=Y.+Wangauthor=X.+Renauthor=H.+A.+Harveyauthor=J.+Songauthor=J.+M.+Yang&title=Immunotherapy+for+triple-negative+breast+cancer%3A+Existing+challenges+and+exciting+prospects&doi=10.1016%2Fj.drup.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects</span></div><div class="casAuthors">Jia Hongyan; Truica Cristina I; Harvey Harold A; Wang Bin; Wang Yanhong; Ren Xingcong; Song Jianxun; Yang Jin-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with breast tumors that do not express the estrogen receptor, the progesterone receptor, nor Her-2/neu are hence termed "triple negatives", and generally have a poor prognosis, with high rates of systemic recurrence and refractoriness to conventional therapy regardless of the choice of adjuvant treatment.  Thus, more effective therapeutic options are sorely needed for triple-negative breast cancer (TNBC), which occurs in approximately 20% of diagnosed breast cancers.  In recent years, exploiting intrinsic mechanisms of the host immune system to eradicate cancer cells has achieved impressive success, and the advances in immunotherapy have yielded potential new therapeutic strategies for the treatment of this devastating subtype of breast cancer.  It is anticipated that the responses initiated by immunotherapeutic interventions will explicitly target and annihilate tumor cells, while at the same time spare normal cells.  Various immunotherapeutic approaches have been already developed and tested, which include the blockade of immune checkpoints using neutralizing or blocking antibodies, induction of cytotoxic T lymphocytes (CTLs), adoptive cell transfer-based therapy, and modulation of the tumor microenvironment to enhance the activity of CTLs.  One of the most important areas of breast cancer research today is understanding the immune features and profiles of TNBC and devising novel immune-modulatory strategies to tackling TNBC, a subtype of breast cancer notorious for its poor prognosis and its imperviousness to conventional treatments.  On the optimal side, one can anticipate that novel, effective, and personalized immunotherapy for TNBC will soon achieve more success and impact clinical treatment of this disease which afflicts approximately 20% of patients with breast cancer.  In the present review, we highlight the current progress and encouraging developments in cancer immunotherapy, with a goal to discuss the challenges and to provide future perspectives on how to exploit a variety of new immunotherapeutic approaches including checkpoint inhibitors and neoadjuvant immunotherapy for the treatment of patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlGWXKBPOQGhKDYG3bNImrfW6udTcc2eanIyGQPgdGDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3itVaqtw%253D%253D&md5=266b2920bffa364cefd3ccc5e5a599e6</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DH.%26aulast%3DTruica%26aufirst%3DC.%2BI.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DHarvey%26aufirst%3DH.%2BA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%2BM.%26atitle%3DImmunotherapy%2520for%2520triple-negative%2520breast%2520cancer%253A%2520Existing%2520challenges%2520and%2520exciting%2520prospects%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2017%26volume%3D32%26spage%3D1%26epage%3D15%26doi%3D10.1016%2Fj.drup.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, N.</span></span> <span> </span><span class="NLM_article-title">Cowpea mosaic virus immunotherapy combined with cyclophosphamide reduces breast cancer tumor burden and inhibits lung metastasis</span>. <i>Adv. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1802281</span>, <span class="refDoi"> DOI: 10.1002/advs.201802281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.1002%2Fadvs.201802281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A280%3ADC%252BB3MrhvF2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1802281&issue=16&author=H.+Caiauthor=C.+Wangauthor=S.+Shuklaauthor=N.+Steinmetz&title=Cowpea+mosaic+virus+immunotherapy+combined+with+cyclophosphamide+reduces+breast+cancer+tumor+burden+and+inhibits+lung+metastasis&doi=10.1002%2Fadvs.201802281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis</span></div><div class="casAuthors">Cai Hui; Wang Chao; Shukla Sourabh; Steinmetz Nicole F; Cai Hui; Wang Chao; Shukla Sourabh; Steinmetz Nicole F</div><div class="citationInfo"><span class="NLM_cas:title">Advanced science (Weinheim, Baden-Wurttemberg, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1802281</span>
        ISSN:<span class="NLM_cas:issn">2198-3844</span>.
    </div><div class="casAbstract">Patients with metastatic triple-negative breast cancer (TNBC) have a poor prognosis, so new therapies or drug combinations that achieve more effective and durable responses are urgently needed.  Here, a combination therapy using cowpea mosaic virus (CPMV) and low doses of cyclophosphamide (CPA) is developed with remarkable synergistic efficacy against 4T1 mouse tumors in vivo.  The combination therapy not only attenuates the growth of primary tumor and increases survival, but also suppresses distant tumor growth and reduces lung metastasis.  Mechanistic analysis indicates that the combination of CPMV and CPA increases the secretion of several cytokines, activates antigen-presenting cells, increases the abundance of tumor infiltrating T cells, and systematically reverses the immunosuppression.  These results show that the combination of CPMV in situ vaccination with chemotherapy may become a potent new strategy for the treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJQMguY9jFRDdblLE_E9PWfW6udTcc2eanIyGQPgdGDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrhvF2isQ%253D%253D&md5=d06efad47cbd6539b37ec92b47170efa</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1002%2Fadvs.201802281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadvs.201802281%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DSteinmetz%26aufirst%3DN.%26atitle%3DCowpea%2520mosaic%2520virus%2520immunotherapy%2520combined%2520with%2520cyclophosphamide%2520reduces%2520breast%2520cancer%2520tumor%2520burden%2520and%2520inhibits%2520lung%2520metastasis%26jtitle%3DAdv.%2520Sci.%26date%3D2019%26volume%3D6%26issue%3D16%26spage%3D1802281%26doi%3D10.1002%2Fadvs.201802281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sperlich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teusch, N.</span></span> <span> </span><span class="NLM_article-title">Pseudopterosin inhibits proliferation and 3D invasion in triple-negative breast cancer by agonizing glucocorticoid receptor alpha</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1992</span>, <span class="refDoi"> DOI: 10.3390/molecules23081992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.3390%2Fmolecules23081992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWksLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=1992&issue=8&author=J.+Sperlichauthor=N.+Teusch&title=Pseudopterosin+inhibits+proliferation+and+3D+invasion+in+triple-negative+breast+cancer+by+agonizing+glucocorticoid+receptor+alpha&doi=10.3390%2Fmolecules23081992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudopterosin inhibits proliferation and 3D invasion in triple-negative breast cancer by agonizing glucocorticoid receptor alpha</span></div><div class="casAuthors">Sperlich, Julia; Teusch, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1992/1-1992/14</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pseudopterosin, produced by the sea whip of the genus Antillogorgia, possesses a variety of promising biol. activities, including potent anti-inflammatory effects.  However, few studies examd. pseudopterosin in the treatment of cancer cells and, to our knowledge, the ability to inhibit triple-neg. breast cancer (TNBC) proliferation or invasion has not been explored.  Thus, we evaluated the as-yet unknown mechanism of action of pseudopterosin: Pseudopterosin was able to inhibit proliferation of TNBC.  Interestingly, analyzing breast cancer cell proliferation after knocking down glucocorticoid receptor a(GRa) revealed that the antiproliferative effects of pseudopterosin were significantly inhibited when GRa expression was reduced.  Furthermore, pseudopterosin inhibited the invasion of MDA-MB-231 3D tumor spheroids embedded in an extracellular-like matrix.  Remarkably, the knockdown of GRa in 3D tumor spheroids revealed increased ability of cells to invade the surrounding matrix.  In a coculture, encompassing peripheral blood mononuclear cells (PBMC) and MDA-MB-231 cells, and the prodn. of interleukin 6 (IL-6) and interleukin 8 (IL-8) significantly increased compared to a monoculture.  Notably, pseudopterosin indicated to block cytokine elevation, representing key players in tumor progression in the coculture.  Thus, our results reveal pseudopterosin treatment as a potential novel approach in TNBC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf4IE2zDC62bVg90H21EOLACvtfcHk0ljiqbPYyusPDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWksLnM&md5=37aef8ce542260bc82870eacac0e266a</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23081992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23081992%26sid%3Dliteratum%253Aachs%26aulast%3DSperlich%26aufirst%3DJ.%26aulast%3DTeusch%26aufirst%3DN.%26atitle%3DPseudopterosin%2520inhibits%2520proliferation%2520and%25203D%2520invasion%2520in%2520triple-negative%2520breast%2520cancer%2520by%2520agonizing%2520glucocorticoid%2520receptor%2520alpha%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D1992%26doi%3D10.3390%2Fmolecules23081992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vikas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borcherding, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">The clinical promise of immunotherapy in triple-negative breast cancer</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">6823</span>– <span class="NLM_lpage">6833</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S185176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.2147%2FCMAR.S185176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=30573992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOgtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=6823-6833&author=P.+Vikasauthor=N.+Borcherdingauthor=W.+Zhang&title=The+clinical+promise+of+immunotherapy+in+triple-negative+breast+cancer&doi=10.2147%2FCMAR.S185176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical promise of immunotherapy in triple-negative breast cancer</span></div><div class="casAuthors">Vikas, Praveen; Borcherding, Nicholas; Zhang, Weizhou</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6823-6833</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a heterogeneous disease with poorer outcomes compared to other breast cancer subtypes.  Contributing to the worse prognosis in TNBC is the higher rates of relapse and rapid progression after relapse.  Advances in targeted therapeutics and conventional chemotherapy for TNBC have been stymied due to the lack of specific targets.  Moreover, the responses to chemotherapy in TNBC lack durability, partially accounting for the higher rates of relapse.  Immunotherapy, notably immune-checkpoint blockade, has shown to improve survival and maintain robust antitumor responses in both hematol. and solid malignancies.  Unlike lung cancer, melanoma, and bladder cancer, most breast cancers are not inherently immunogenic and typically have low T cell infiltration.  However, among breast cancer subtypes, TNBC is characterized by greater tumor immune infiltrate and higher degree of stromal and intratumoral tumor-infiltrating lymphocytes (TILs), a predictive marker for responses to immunotherapy.  Moreover, in TNBC, the high no. of stromal TILs is predictive of more favorable survival outcomes and response to chemotherapy.  Immunotherapy is being extensively explored in TNBC and clin. trials are showing some promising results.  This article focuses on the rationale for immunotherapy in TNBC, to explore and discuss preclin. data, results from early clin. trials, and to summarize some ongoing trials.  We will also discuss the potential application of immunotherapy in TNBC from a clinician's perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxCHe7L9bI5bVg90H21EOLACvtfcHk0ljiqbPYyusPDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOgtLfO&md5=2668b7aeaf1269897ccc55604dfb7b24</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S185176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S185176%26sid%3Dliteratum%253Aachs%26aulast%3DVikas%26aufirst%3DP.%26aulast%3DBorcherding%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DThe%2520clinical%2520promise%2520of%2520immunotherapy%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2018%26volume%3D10%26spage%3D6823%26epage%3D6833%26doi%3D10.2147%2FCMAR.S185176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Philipovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwivedi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydarian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaur, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy of neoadjuvant adjuvant chemotherapy in hispanic/latino (H/L) women with local or locally advanced triple-negative breast cancer (TNBC)</span>. <i>In Vivo</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.21873/invivo.11594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=10.21873%2Finvivo.11594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=31280213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVWltL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=1227-1234&issue=4&author=A.+Philipovskiyauthor=J.+Corralauthor=K.+Dwivediauthor=R.+Heydarianauthor=S.+Gaur&title=Efficacy+of+neoadjuvant+adjuvant+chemotherapy+in+hispanic%2Flatino+%28H%2FL%29+women+with+local+or+locally+advanced+triple-negative+breast+cancer+%28TNBC%29&doi=10.21873%2Finvivo.11594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of neoadjuvant versus adjuvant chemotherapy in hispanic/latino (H/L) women with local or locally advanced triple-negative breast cancer (TNBC)</span></div><div class="casAuthors">Philipovskiy, Alexander; Corral, Javier; Dwivedi, Kumar Alok; Heydarian, Rosalinda; Gaur, Sumit</div><div class="citationInfo"><span class="NLM_cas:title">In Vivo</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1227-1234</span>CODEN:
                <span class="NLM_cas:coden">IVIVE4</span>;
        ISSN:<span class="NLM_cas:issn">1791-7549</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background/Aim: The aim of the study was to investigate the efficacy of neoadjuvant and chemotherapy (NACT) and adjuvant chemotherapy (ACT) in Hispanic/Latino (H/L) women with TNBC.  Patients and Methods: We reviewed the charts of patients with TNBC, stages I-III, treated at TTUHSC from 2006 to 2016.  Overall survival (OS) and recurrence-free survival (RFS) were estd. and compared between the treatment groups.  Kaplan-Meier curve and Cox proportional hazards regression analyses were conducted to est. unadjusted and adjusted effects of NACT compared to ACT.  Results: A total of 104 patients with TNBC, 30 (29%) received NACT and 74 (71%) ACT.  Women undergoing NACT were younger, with a mean age of 50.8 years.  Of the 30 patients who received NACT, 12 (40%) had pathol. complete response (pCR).  Women who achieved pCR had an excellent RFS (HR=0.5, p=0.001).  Women with residual cancer after NACT had worse outcome compared to patients who received ACT (HR=1.7, p=0.005).  Conclusion: pCR to NACT is a powerful surrogate for OS in H/L women with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDky7JcY7zg7Vg90H21EOLACvtfcHk0lhBhqaPHnJ68g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVWltL7O&md5=37602b386a1cb4e452f206ba5efa8046</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.21873%2Finvivo.11594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21873%252Finvivo.11594%26sid%3Dliteratum%253Aachs%26aulast%3DPhilipovskiy%26aufirst%3DA.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DDwivedi%26aufirst%3DK.%26aulast%3DHeydarian%26aufirst%3DR.%26aulast%3DGaur%26aufirst%3DS.%26atitle%3DEfficacy%2520of%2520neoadjuvant%2520adjuvant%2520chemotherapy%2520in%2520hispanic%252Flatino%2520%2528H%252FL%2529%2520women%2520with%2520local%2520or%2520locally%2520advanced%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DIn%2520Vivo%26date%3D2019%26volume%3D33%26issue%3D4%26spage%3D1227%26epage%3D1234%26doi%3D10.21873%2Finvivo.11594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01180&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01180%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01180" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ab66cec453d2a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
